Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT04118036	Abemaciclib + Pembrolizumab In Glioblastoma		Withdrawn	No Results Available	Glioblastoma	Drug: Pembrolizumab|Drug: Abemaciclib	TIL density in tumor tissue (surgery)|Progression Free Survival 6 months (non surgery)|Radiographic response rate (non surgery)|Median progression free survival|Overall survival|Tumor cell death (Surgery)|tumor cell proliferation (surgery)	Dana-Farber Cancer Institute	All	"18 Months and older   (Child, Adult, Older Adult)"	Phase 2	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-351	1-Dec-21	1-Dec-23	1-Dec-24	7-Oct-19		14-Dec-21	"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT04118036
2	NCT04552977	A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma	Drug: fluzoparil|Drug: temozolomide	6-months PFS rate in all participants by RECIST 1.1|ORR in all paients by RECIST Version 1.1|Disease control rate in all patients by RECIST Version 1.1|Overall survival (OS) in all participants|mPFS in all participants|mOS in all participants|Number of participants experiencing an adverse event (AE)|Number of participants experiencing a serious adverse event (SAE)	Shandong Cancer Hospital and Institute	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM-IIT-SHR3162-TMZ	Sep-20	Aug-21	Aug-22	17-Sep-20		17-Sep-20			https://ClinicalTrials.gov/show/NCT04552977
3	NCT04443010	Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma	GLIOSUN	Not yet recruiting	No Results Available	Glioblastoma	Drug: Onfekafusp alfa|Drug: Temozolomide	For Phase 1: DLT|For Phase 2: Overall Survival|PFS|ORR in CR|ORR in PR|DCR in CR|DCR in PR|DCR in SD|BORR in CR|BORR in PR|BORR in SD|Safety (AE)|Safety (SAE)|Safety (DILI)	Philogen S.p.A.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	226	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PH-L19TNFTMZ-01/20	Dec-20	Oct-26	Dec-26	23-Jun-20		8-Dec-20			https://ClinicalTrials.gov/show/NCT04443010
4	NCT03048240	INtraoperative photoDYnamic Therapy of GliOblastoma	INDYGO	"Active, not recruiting"	No Results Available	Glioblastoma	"Device: ""perPDT""|Drug: GLIOLAN"	"Number of Patients having the full ""PerPDT"" treatment with unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0|Progression Free Survival (PFS)|Overall Survival (OS)|Response to treatment|Incidence of ""per PDT"" treatment-emergent Adverse Events|Quality of Life Questionnaire -C30 ( QLQ-C30)|Quality of Life Questionnaire - Brain Cancer Module (QLQ-BN20)"	"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016_06|2016-002706-39	5-May-17	May-21	May-21	9-Feb-17		20-Nov-20	"Hôpital Roger Salengro, CHRU, Lille, France"		https://ClinicalTrials.gov/show/NCT03048240
5	NCT03661723	Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Pembrolizumab|Drug: Bevacizumab|Radiation: Re-irradiation	Objective response rate|Overall survival rate|Safety & Tolerability: toxicities and grades experienced by participants|Duration of response|Median Progression free survival|6-month Progression free survival|Median Overall Survival	Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	61	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-277|3475-787	28-Sep-18	9-Dec-21	1-Jun-22	7-Sep-18		6-Jul-21	"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University / Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03661723
6	NCT04814329	Glioblastoma Response Prediction to Apatinib		Recruiting	No Results Available	Glioblastoma	Other: genetic characteristic	genetic outcome	Beijing Sanbo Brain Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"		18	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	2021ZZLX03	22-Apr-21	Sep-22	Dec-22	24-Mar-21		24-Jun-21	"Capital Medical University Sanbo Brain Hospital, Beijing, China"		https://ClinicalTrials.gov/show/NCT04814329
7	NCT02977780	INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Temozolomide|Drug: Neratinib	Overall Survival in Experimental Arms Compared with Standard Therapy|Incidence of Treatment-Emergent Adverse Events|Progression Free Survival Among Experimental Arms And Biomarker Groups|Overall Survival Among Experimental Arms And Biomarker Groups|Association Between Progression Free Survival and Overall Survival Effects Of Experimental Agents	"Patrick Y. Wen, MD|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure|Dana-Farber Cancer Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	250	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-443	9-Feb-17	Dec-21	Dec-22	30-Nov-16		11-Aug-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Lifespan / Rhode Island Hospital, Providence, Rhode Island, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02977780
8	NCT04417933	Tumor Electric Fields Treatment System for Glioblastoma		Recruiting	No Results Available	Glioblastoma	Device: Tumor Electric Fields Treatment System	The treatment-related adverse events|Time to Progression|Overall Survival Rate	"Xiangya Hospital of Central South University|Hunan An Tai Kang Cheng Biotechnology Co., Ltd"	All	"18 Years to 65 Years   (Adult, Older Adult)"	Early Phase 1	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	202001012	7-Apr-20	May-21	May-21	5-Jun-20		11-Jun-20	"Xiangya Hospital Central South University, Changsha, Hunan, China"		https://ClinicalTrials.gov/show/NCT04417933
9	NCT03529448	TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma	GEINOCANN	Not yet recruiting	No Results Available	Glioblastoma	Drug: TN-TC11G|Drug: Temozolomide Oral Product|Radiation: Radiotherapy	THC-CBD Maximum tolerated dose|Incidence of Treatment-Emergent Adverse Events|Antitumor activity of THC-CBD combination with temozolamide and radiotherapy|Overall survival|Progression free survival|Expression of Midkine	Grupo Español de Investigación en Neurooncología|Medical Cannabis Bike Tour|Voices Against Brain Cancer|Tilray	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEINO-1601|2016-003216-12	Nov-21	Dec-21	Jun-23	18-May-18		16-Dec-20	"Institut Català d'Oncología L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Mallorca, Spain|Consorcio Hospitalario Provincial de Castellón, Castelló, Valencia, Spain|Hospital del Mar, Barcelona, Spain|Complejo Hospitalario Regional Virgen de las Nieves, Granada, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain"		https://ClinicalTrials.gov/show/NCT03529448
10	NCT03139916	Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Temozolomide|Drug: Bavituximab|Radiation: Radiation	Overall Survival|Radiographic Response|Progression Free Survival	Massachusetts General Hospital|Peregrine Pharmaceuticals|National Comprehensive Cancer Network	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-037	13-Sep-17	31-Aug-22	31-Aug-22	4-May-17		29-Oct-21	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts general Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT03139916
11	NCT04319276	Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma	"Drug: Gallium maltolate (500 mg)|Drug: Gallium maltolate (1,000 mg)|Drug: Gallium maltolate (1,500 mg)|Drug: Gallium maltolate (recommended phase 2 dose)"	Maximum-tolerated dose.|Progression-free survival|Overall survival|Dose-limiting toxicity	Medical College of Wisconsin	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO00041263	Feb-22	Jul-25	Jul-26	24-Mar-20		28-Oct-21			https://ClinicalTrials.gov/show/NCT04319276
12	NCT03243851	Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma	METT	Completed	No Results Available	Glioblastoma	Drug: Temozolomide+Metformin|Drug: Temozolomide+Placebo	Comparison of progression-free survival obtained from progression-free survival curve|Response Rate|Tumor control probability|6 month progression free survival|6 month overall survival|Assessment of the quality of life of cancer patients	"Yong-Kil Hong|Saint Vincent's Hospital, Korea|Incheon St.Mary's Hospital|National Cancer Center, Korea|Konkuk University Hospital|Seoul National University Bundang Hospital|Samsung Medical Center|Seoul National University Hospital|Asan Medical Center|Ajou University School of Medicine|Severance Hospital|Chonnam National University Hospital|Seoul St. Mary's Hospital"	All	"19 Years and older   (Adult, Older Adult)"	Phase 2	81	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	KNOG-1501	21-Nov-16	31-Dec-20	31-Dec-20	9-Aug-17		9-Sep-21	"National Cancer Center Korea, Ilsan, Gyeonggi-Do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-Do, Korea, Republic of|Ajou University Hospital, Suwon-si, Gyeonggi-Do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-Do, Korea, Republic of|Incheon St. Mary's Hospital, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Konkuk University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Saint Vincent's Hospital, Korea, Suwon-si, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT03243851
13	NCT03403803	Prognosis and Therapeutic Biomarkers for Glioblastoma Patients		Terminated	No Results Available	Glioblastoma	Device: Optune	"Primary Outcome - CD44 expression in cerebrospinal fluid (CSF), blood and saliva"	Baylor Research Institute	All	"22 Years and older   (Adult, Older Adult)"		10	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	160280	1-Sep-17	25-Mar-19	25-Mar-19	19-Jan-18		27-Mar-19	"Baylor Scott and White Medical Center, Temple, Texas, United States"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/Prot_000.pdf|""Informed Consent Form: Main Consent"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/ICF_001.pdf|""Informed Consent Form: Control Consent"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/ICF_002.pdf"	https://ClinicalTrials.gov/show/NCT03403803
14	NCT05173623	Trial of Dichloroacetate in Glioblastoma	DCA	Not yet recruiting	No Results Available	Glioblastoma	Drug: Dichloroacetate	Level of phosphorylated PDC protein expression in tumor tissue	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Food and Drug Administration (FDA)	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	40	Other|U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2189	10-Jan-22	30-Dec-26	10-Jan-27	30-Dec-21		30-Dec-21	"Johns Hopkins University, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT05173623
15	NCT04747145	Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma		Recruiting	No Results Available	Glioblastoma	Device: Radiation|Drug: Concurrent Chemotherapy (Temozolomide)|Drug: Adjuvant Chemotherapy (Temozolomide)	Progression-free survival|Death	Medical College of Wisconsin	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	38	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO00039277	3-Jun-21	Jun-25	Jun-26	10-Feb-21		12-Jul-21	"Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT04747145
16	NCT04004975	Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib		Unknown status	No Results Available	Recurrent Glioblastoma	Drug: Anlotinib	Progress free survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Quality of Life score (QoL)	Shandong Cancer Hospital and Institute	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ShandongCHI006	25-Jun-19	25-Jul-20	25-Jul-21	2-Jul-19		2-Jul-19	"Shandong cancer hospital, Jinan, Shandong, China"		https://ClinicalTrials.gov/show/NCT04004975
17	NCT04657146	Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	LAMB-G	Not yet recruiting	No Results Available	Glioblastoma	Other: Biorepository	Variations in blood and bone marrow T cell counts|Variations in Sphingosine-1-phosphate receptor 1 (S1P1) levels	Duke University	All	"18 Years and older   (Adult, Older Adult)"		40	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	Pro00107040	1-Dec-21	31-Aug-23	31-Aug-24	8-Dec-20		20-Sep-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04657146
18	NCT02617745	Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid	GLIOPLAK	Recruiting	No Results Available	Glioblastoma	Other: Platelet level determination	Number of time where platelet level was Under 100 000 per mm3|Overall survival|Therapeutic modifications	Centre Henri Becquerel	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	150	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CHB 15.02	30-Nov-15	Nov-22	Dec-24	1-Dec-15		30-Jul-20	"Centre Henri Becquerel, Rouen, France"		https://ClinicalTrials.gov/show/NCT02617745
19	NCT02254954	"Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma"		Terminated	No Results Available	Glioblastoma	Drug: Macitentan in combination with RT and TMZ	"Number of subjects with dose-limiting toxicities observed during the first 10 weeks of study treatment (i.e., 6 weeks of concurrent therapy with macitentan, RT and TMZ and 4 weeks of monotherapy with macitentan).|Plasma concentrations of endothelin-1|Plasma concentrations of macitentan and its metabolite|Area under the plasma concentration-time curve (AUCτ) for macitentan during one dosing interval for subjects treated with doses of macitentan 150 mg or higher|Peak plasma concentration (Cmax) of macitentan during one dosing interval for subjects treated with doses of macitentan 150 mg or higher|Time to reach peak plasma concentration (Tmax) of macitentan during one dosing interval for subjects treated with doses of macitentan 150 mg or higher|Number of adverse events (per Common Terminology Criteria for Adverse Events [CTCAE] criteria, version 4.03]) leading to premature discontinuation of study treatment|Number of subjects with marked laboratory abnormalities or abnormal electrocardiogram (ECG) findings|Change from baseline in pulse rate, systolic & diastolic blood pressure|Exploratory efficacy endpoint of proportion of subjects with progression free survival (PFS) at 6 and 12 months|Number of adverse events (per CTCAE] criteria, version 4.03]) as a measure of safety and tolerability."	Actelion	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AC-055-118	8-Jan-15	29-Sep-16	29-Sep-16	2-Oct-14		27-Feb-18	"MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02254954
20	NCT03430791	"Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma"		Terminated	No Results Available	Recurrent Glioblastoma	Drug: Nivolumab 240 mg IV|Drug: Nivolumab 3 mg/kg|Drug: Ipilimumab 1 mg/kg|Device: NovoTTF200A (Optune)	Objective response rate according to modified iRANO criteria	Baptist Health South Florida|Bristol-Myers Squibb|NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	5	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-ODI-002	5-Nov-18	10-Mar-21	10-Mar-21	13-Feb-18		1-Nov-21	"Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States"		https://ClinicalTrials.gov/show/NCT03430791
21	NCT02799238	Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma	ALECSAT	Completed	No Results Available	Glioblastoma	Biological: ALECSAT|Radiation: Radiotherapy|Drug: Temozolomide	Progression Free Survival|Proportion of patients alive at 12 and 24 months|Frequency and Severity of treatment related Adverse Events	CytoVac A/S	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	62	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CV-006	Mar-16	14-Nov-19	24-Feb-20	14-Jun-16		30-Apr-20	"Sahlgrenska University Hospital, Göteborg, Sweden|Ryhov hospital, Jönköping, Sweden|Skånes university hospital, Lund, Sweden|Karolinska University hospital, Stockholm, Sweden"		https://ClinicalTrials.gov/show/NCT02799238
22	NCT05108012	Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients		Recruiting	No Results Available	Glioblastoma Multiform|Recurrent Glioblastoma	Biological: NK cell therapy	Toxicity assay|Adverse Events (AEs)|Safety evaluation|MRI and MRS from the tumor region|Patient survival	Royan Institute|Tehran University of Medical Sciences	All	"3 Years to 60 Years   (Child, Adult)"	Phase 1	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GMB1	1-Aug-21	Nov-21	Apr-22	4-Nov-21		22-Nov-21	"Royan institute, Tehran, Iran, Islamic Republic of"		https://ClinicalTrials.gov/show/NCT05108012
23	NCT04677049	Study of Niacin in Glioblastoma		Recruiting	No Results Available	Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype	Drug: Niacin CRT	Determining the Maximum Tolerated Dose|Evaluating if Niacin CRT Improves Glioblastoma Survival Rates|Effect of Niacin CRT in Peripheral Monocytes|Response Rate Associated with Niacin|Overall Survival Rate Associated with Niacin|Quality of Life While on Study using EORTC QLQ-C30 Questionnaires|Quality of Life While on Study using EORTC BN-20 Questionnaires	AHS Cancer Control Alberta|Tom Baker Cancer Centre	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	59	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NiacinCNS2020	18-Mar-21	Jan-26	Jan-26	21-Dec-20		22-Jun-21	"Tom Baker Cancer Centre, Calgary, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT04677049
24	NCT04359745	Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression		Recruiting	No Results Available	Glioblastoma		Accuracy of the artificial intelligence model|Failure rate of the artificial intelligence model	Guy's and St Thomas' NHS Foundation Trust|King's College London	All	"18 Years to 80 Years   (Adult, Older Adult)"		500	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	5.0 15/01/21	21-Mar-19	26-May-22	26-May-23	24-Apr-20		18-Mar-21	"Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom|Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, United Kingdom|Ninewells Hospital and Medical School, NHS Tayside, Dundee, United Kingdom|Hull Royal Infirmary, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Leeds General Infirmary, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|King's College Hospital, King's College Hospital NHS Trust, London, United Kingdom|Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom|National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom|The Christie Hospital, The Christie NHS Foundation Trust, Manchester, United Kingdom|The Freeman Hospital, Newcastle upon Tyne hospitals NHS foundation trust, Newcastle Upon Tyne, United Kingdom|The Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT04359745
25	NCT03557372	Mathematical Model-Adapted Radiation In Glioblastoma		"Active, not recruiting"	Has Results	Recurrent Glioblastoma	Radiation: Mathematical Model-Adapted Radiation Fractionation Schedule	Number of Participants to Complete Model Adapted Radiations Fractionation Scheduled|Quality of Life (MD Anderson Symptom Inventory Brain Tumor)|Incidence of Radiation Necrosis|Time to Development of Radiation Necrosis|Incidence of Seizures|Time to the Development of Seizures|Overall Survival|Karnofsky Performance Status|Incidence of Grade 3+ Acute or Delayed CNS Toxicity|Time to the Development of Grade 3+ Acute or Delayed CNS Toxicity|Progression-free Survival|Local Recurrence|Incidence of Salvage Craniotomy|Time to Salvage Craniotomy|Incidence of Additional Systemic Treatments After Reirradiation|Time to Additional Systemic Treatments After Reirradiation|Tumor Volumes	Dana-Farber Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	14	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-105	12-Nov-18	1-Jun-20	1-Jun-22	15-Jun-18	11-Jun-21	7-Jul-21	"Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/72/NCT03557372/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03557372/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT03557372
26	NCT01345370	Comparison of Different Methods to Test MGMT Status in Glioblastoma Patients	ECOM	Completed	No Results Available	Glioblastoma	Drug: Temozolomide|Radiation: Radiation Therapy	Survival of patients according to their MGMT status.|Progression-Free Survival	Center Eugene Marquis|Rennes University Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"		300	Other	Observational	Time Perspective: Prospective	ECOM-Glioblastome	Mar-09	Apr-15	Jun-15	2-May-11		29-Jan-16	"CHRU Hautepierre, Strasbourg, Alsace, France|CHU de Bordeaux, Bordeaux, Aquitaine, France|CHU Cote de Nacre, Caen, Basse Normandie, France|Center Eugene Marquis, Rennes, Brittany, France|CHU La Salpetriere, Paris, Ile de France, France|CHRU de Lille, Lille, Nord Pas-de-Calais, France|CHU La Timone, Marseille, Paca, France|CHU de Poitiers, Poitiers, Poitou-Charentes, France|CHU de Grenoble, Grenoble, Rhone-Alpes, France|CHU de Lyon, Lyon, Rhone-Alpes, France"		https://ClinicalTrials.gov/show/NCT01345370
27	NCT02076152	FMISO PET Study of Glioblastoma		Completed	Has Results	Recurrent Glioblastoma	Device: FMISO PET|Device: MRI|Drug: Bevacizumab|Drug: CCNU	Change in Tumor Blood Flow/Perfusion|Change in Tumor Hypoxic Volume|Blood Vessel Permeability (Ktrans Change on MRI Scan)|Tumor Blood Flow Measured by MRI Perfusion	Massachusetts General Hospital|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	11	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	13-482|R01CA129371	Feb-14	Apr-19	Apr-19	3-Mar-14	30-Jul-21	30-Jul-21	"Massachusetts General Hospital, Boston, Massachusetts, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/52/NCT02076152/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02076152/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT02076152
28	NCT04385173	Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma|Refractory Glioblastoma	Drug: B7-H3 CAR-T|Drug: Temozolomide	"Incidence and type of adverse events|Maximum tolerated dose (MTD)|Overall survival (OS)|Progression-free survival (PFS)|The pharmacokinetics (PK) of B7-H3 CAR-T|Disease response (ORR, CR, PR, DOR)"	"Second Affiliated Hospital, School of Medicine, Zhejiang University|BoYuan RunSheng Pharma (Hangzhou) Co., Ltd."	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAHZJU-BP102	1-Jun-20	1-May-22	1-Jul-22	12-May-20		12-May-20	"the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04385173
29	NCT04656535	AB154 Combined With AB122 for Recurrent Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: AB122|Drug: AB154|Drug: Placebo	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] associated with the combination AB122 and AB154 in patients with recurrent glioblastoma|Single cell RNA sequencing of tumor and blood after exposure to AB154 with and without AB122|Tregs and CD8 T cells ratio by immunofluorescence	"Yale University|Arcus Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	46	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	2000028799	21-Apr-21	Dec-22	Jul-23	7-Dec-20		16-Jul-21	"Yale University, New Haven, Connecticut, United States"		https://ClinicalTrials.gov/show/NCT04656535
30	NCT01499251	Clinical Study on the Safety and Tolerability of Macitentan in Combination With Dose-dense Temozolomide in Patients With Recurrent Glioblastoma		Terminated	No Results Available	Glioblastoma	Drug: Phase 1 Dose Escalation|Drug: Phase 1b|Drug: Ancillary Study	To determine the maximum tolerated dose of macitentan in combination with dose-dense temozolomide|Number of patients with treatment-emergent adverse events (AEs) and serious AEs|Number of patients with AEs leading to premature discontinuation of study treatment|Incidence of treatment-emergent* marked laboratory abnormalities|Number of patients with treatment-emergent ECG abnormalities|Change from baseline in vital signs|Occurrence of at least grade 2 ALT and/or AST elevation	Actelion	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	75	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AC-055-115	Jan-12	Jan-16	Apr-16	26-Dec-11		5-May-16	"MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01499251
31	NCT05015543	Physical Training in Glioblastoma Patients During Cytotoxic Therapy	MMH	Recruiting	No Results Available	Glioblastoma	Other: Personal Training Program	Increase in Physical Performance according to Physical Work Capacity (PWC) Test|Physical Work Capacity (PWC)|PWC|Spiroergometry - maximal oxygen consumption (VO2max)|Spiroergometry - lactate|EORTC-QLQ-C30 Brain module|Distress Thermometer (DT)|Hospital Anxiety and Depression Scale (HADS)	University Hospital Muenster	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	43	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	MMH_01	23-Jul-20	31-Dec-23	28-Feb-24	20-Aug-21		20-Aug-21	"Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany"		https://ClinicalTrials.gov/show/NCT05015543
32	NCT02770378	A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Temozolomide|Drug: Aprepitant|Drug: Minocycline|Drug: Disulfiram|Drug: Celecoxib|Drug: Sertraline|Drug: Captopril|Drug: Itraconazole|Drug: Ritonavir|Drug: Auranofin	"Endpoint for phase Ib is the number of patients experiencing dose-limiting toxicity defined as:|Endpoint for phase IIa of the trial is objective stable disease or a better tumor response (i.e., partial response, complete response)|Overall survival according to Kaplan-Meier estimates|Progression-free survival according to Kaplan-Meier estimates|Best tumor response according to the Revised Assessment in Neuro-Oncology (RANO) criteria"	"University of Ulm|Reliable Cancer Therapies|Anticancer Fund, Belgium"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CUSP9v3	Nov-16	Oct-18	Dec-20	12-May-16		5-Oct-21	"University of Ulm School of Medicine, Ulm, Baden-Württemberg, Germany"		https://ClinicalTrials.gov/show/NCT02770378
33	NCT05131711	Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)	CSREIG	Recruiting	No Results Available	Recurrent Glioblastoma	Combination Product: Combined stereotactic radiosurgery and enhanced immunotherapy	Incidence of Treatment-related Adverse Events|Progression-free Survival|overall survival	Beijing Tiantan Hospital	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1|Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B0012	16-Nov-21	16-Nov-22	16-Nov-23	23-Nov-21		23-Nov-21	"Beijing Tiantan Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT05131711
34	NCT04952571	Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Camrelizumab and Bevacizumab	Progression-free survival rate at 6 months|OS(overall survival)|PFS(progression free survival)|ORR(objective response rate)|DCR（Disease Control Rate）|The correlation between KPS change and efficacy|Median duration of KPS ≥ 70|Frequency and severity of treatment-related adverse events|Median duration of stable/improved quality of life assessed by EORTC QLQ-C30|Median duration of stable/improved quality of life assessed by EORTC QLQ-BN20	Beijing Sanbo Brain Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	94	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OBU-BJ-GBM-II-007	1-May-21	31-Dec-23	31-Dec-24	7-Jul-21		7-Jul-21	"Beijing Sanbo Brain Hospital, Beijing, China"		https://ClinicalTrials.gov/show/NCT04952571
35	NCT02685605	Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme	INTRAGO-II	Recruiting	No Results Available	Glioblastoma	Procedure: Standard surgery|Radiation: Intraoperative radiotherapy|Radiation: Radiochemotherapy|Drug: Temozolomide	"Median Progression-Free Survival|Median Overall Survival|PFS within a 1-2 cm margin around the cavity|OS with respect to Age|PFS with respect to Age|OS with respect to KPS|PFS with respect to KPS|OS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumor margin|PFS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumor margin|OS with respect to extent of resection|PFS with respect to extent of resection|OS with respect to MGMT promoter methylation status|PFS with respect to MGMT promoter methylation status|Quality of Life (QoL) questionnaire|Activities of daily living (ADL), assessed using the Barthel Index (Mahoney & Barthel, 1965).|Radiation-related (acute / early delayed / late) neurotoxicity"	"Universitätsmedizin Mannheim|Carl Zeiss Meditec AG|University of California, Los Angeles"	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 3	314	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INTRAGO-II|ARO-2016-1|AG-NRO-03	9-Dec-16	Dec-23	Mar-24	19-Feb-16		30-Apr-21	"Barrow Neurological Institute (SJHMC), Phoenix, Arizona, United States|Stritch School of Medicine Loyola University, Maywood, Illinois, United States|Long Island Jewish Medical Center, North Shore University Hospital, Lake Success, New York, United States|Lenox Hill Hospital, Hofstra Northwell School of Medicine, New York, New York, United States|West Virginia University, Morgantown, West Virginia, United States|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada|Klinikum Augsburg, Augsburg, Germany|Charité - Universitätsmedizin, Berlin, Germany|St. Georg, Leipzig, Germany|University Hospital Mannheim, Mannheim, Germany|Technical University of Munich (TUM), Department of Radiation Oncology, Munich, Germany|Klinikum Stuttgart, Stuttgart, Germany|Helios University Hospital Wuppertal, Wuppertal, Germany|Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Clinica Delgado-AUNA, Lima, Peru|Catalan Institute of Oncology (ICO), Barcelona, Spain|Hospital Reina Sofia, Córdoba, Spain|The London Clinic, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT02685605
36	NCT02067156	"Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma"		Completed	No Results Available	Glioblastoma Multiforme	Drug: G-202	"6-month progression-free survival|Safety|Objective tumor response rate, best overall response|Duration of PFS|Overall survival|G-202 pharmacokinetics and pharmacodynamics"	"GenSpera, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	26	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	G-202-004|R01FD005077	Feb-14	Dec-16	Feb-17	20-Feb-14		24-Feb-17	"University of California, San Diego Moores Cancer Center, La Jolla, California, United States"		https://ClinicalTrials.gov/show/NCT02067156
37	NCT04752280	Glioblastoma Radiotherapy Using IMRT or Proton Beams	GRIPS	Recruiting	No Results Available	Glioblastoma	Radiation: Proton irradiation|Radiation: Photon irradiation	Cumulative rate of toxicity|Progression free survival|Overall survival|Acute Toxicity|Late Toxicity|Quality of life according to EORTC QLQ-C30|Quality of life according to EORTC QLQ-BN20|Neurocognition|Measuring number of Lymphocytes count	University Hospital Heidelberg	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	326	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GRIPS	19-Apr-21	19-Aug-25	19-Oct-27	12-Feb-21		20-Apr-21	"Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Gießen und Marburg, Marburg, Germany|Klinikum Stuttgart, Stuttgart, Germany"		https://ClinicalTrials.gov/show/NCT04752280
38	NCT04391062	Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma	DOSINDYGO	Recruiting	No Results Available	Glioblastoma	Drug: Gliolan|Device: Intraoperative PDT	"Maximum Tolerated Dose-Light Level (MTDL) defined as the light dose associated with an acceptable dose-limiting toxicity level (TDL)|Progression Free Survival (PFS)|Global Progression Free Survival (PFS)|Overall Survival (OS)|Response to treatment|Incidence of ""intraoperative PDT"" treatment-emergent Adverse Events|Quality of Life Questionnaire -C30 ( QLQ-C30|Quality of Life Questionnaire - Brain Cancer Module (QLQ-BN20)"	"University Hospital, Lille|Institut National de la Santé Et de la Recherche Médicale, France|Hemerion Therapeutics"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	21	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018_58|2019-004796-40|2019-A03157-50	28-Sep-21	Sep-24	Sep-24	18-May-20		5-Oct-21	"Hôpital Erasme, Clinique Universitaire de Bruxelles, Brussels, Belgium|Hopital Roger Salengro, CHU Lille, Lille, France"		https://ClinicalTrials.gov/show/NCT04391062
39	NCT02060890	Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma	TGEN	Completed	Has Results	Adult Glioblastoma	Other: specialized tumor board recommendation	Number of Participants Who Received Treatment Recommendations Within 35 Days of Surgery|Number of Patients Who Chose to Pursue Treatment	"University of California, San Francisco|Translational Genomics Research Institute|The Ben & Catherine Ivy Foundation"	All	"18 Years and older   (Adult, Older Adult)"		20	Other	Observational	Observational Model: Other|Time Perspective: Prospective	CC14101|NCI-2017-00467	Aug-14	3-Sep-15	10-May-17	12-Feb-14	6-Dec-17	28-Jul-20	"University of California, San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT02060890
40	NCT03714334	DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma		Recruiting	No Results Available	"Glioblastoma|Glioblastoma, Adult"	Drug: DNX-2440 injection	Incidence of Treatment-Emergent Adverse Events after brain administration of DNX-2440.|Overall Survival at 12 months (OS12)|Overall survival|Overall response rate (ORR)	"Clinica Universidad de Navarra, Universidad de Navarra|DNAtrix, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D2440GBM1	16-Oct-18	16-Apr-22	16-Oct-22	22-Oct-18		25-Jun-20	"Clinica Universidad de Navarra, Pamplona, Navarra, Spain"		https://ClinicalTrials.gov/show/NCT03714334
41	NCT04536649	Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.		Not yet recruiting	No Results Available	Glioblastoma	Radiation: Radiotherapy	Overall Survival|Progression-free Survival|Toxicities|Recognitive Function|Life Quality	Shanghai Proton and Heavy Ion Center|RenJi Hospital|Ruijin Hospital|Fudan University	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 3	369	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SPHIC-TR-HNCNS-2020-45	1-Oct-20	30-Sep-23	30-Sep-25	2-Sep-20		2-Sep-20	"Shanghai Proton and Heavy Ion Center, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT04536649
42	NCT04772846	Chloroquine for Glioblastoma.		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Oral tablet|Drug: Placebo	"Survival duration after surgery|End-point evaluation, survival at three years"	Egyptian Medical Syndicate	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	CQGBM	1-Mar-18	1-Dec-20	Mar-21	26-Feb-21		26-Feb-21	"Private clinics, Cairo, Egypt"		https://ClinicalTrials.gov/show/NCT04772846
43	NCT04588454	18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme	PSMA-GBM	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Other: 18F-PSMA-1007 PET tracer	The uptake of 18F-PSMA PET/CT in suspected GBM lesions|The correlation between PSMA protein and RNA expression with 18F-PSMA PET/CT uptake|Correlation between 18F-PSMA PET/CT and T1Gd MRI	Radboud University	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NL64616.091.18	17-Jan-20	31-Oct-20	1-Jun-21	19-Oct-20		27-Jan-21	"Radboud University Medical Center, Nijmegen, Gelderland, Netherlands"		https://ClinicalTrials.gov/show/NCT04588454
44	NCT04959500	Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: Anlotinib Hydrochloride|Drug: Placebo|Radiation: Radiation Therapy|Drug: Temozolomide	Progression Free Survival (PFS) assessed by IRC|The progression free survival (PFS)|Overall survival (OS)	Sun Yat-sen University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	150	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	ALTN-Ⅱ-01	10-Jun-21	31-Oct-23	31-Oct-23	13-Jul-21		13-Jul-21	"The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Beijing TianTan Hospital,Capital Medical University, Beijing, Beijing Province, China|The Sixth Madical Center of PLA General Hospital, Beijing, Beijing, China|The General Hospital of the People's Liberation Army (PLAGH), Beijing, Beijing, China|Chongqing University Cancer Hospital, Chongqing, Chongqing Province, China|Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China|Lanzhou University Second Hospital, Lanzhou, Gansu, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, Guangdong, China|The affiliated hospital of xuzhou medical university, Xuzhou, Jiangsu, China|The First Affiliated Hospital of NanChang University, Nanchang, Jiangxi, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, China|Gansu Provincial Hospital, Gansu, Lanzhou Province, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Fudan University shabghai cancer center, Shanghai, Shanghai, China|The Second Affiliated Hospital of PLA Air Force Medical University, Xian, Shanxi, China|West China Hospital，Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University General Hospital, Tianjin, Tianjin, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04959500
45	NCT03466450	Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma	GEINOGLAS	Recruiting	No Results Available	Glioblastoma	Drug: PF-04449913|Drug: Temozolomide Oral Capsule	Glasdegib Dose|Overall survival|Progression Free Survival|Adverse events (safety)|Response to treatment	Grupo Español de Investigación en Neurooncología	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1|Phase 2	75	Other	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEINO-1602|2017-002410-31	15-Mar-18	Oct-21	Dec-21	15-Mar-18		4-Feb-21	"Institut Catalá de Oncología Badalona/Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Institut Catalá de Oncología Girona/Hospital Universitari Dr. Josep Trueta, Girona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario y Politécnico La Fe, Valencia, Spain"		https://ClinicalTrials.gov/show/NCT03466450
46	NCT04450160	Trial of AEO in New Glioblastoma (GBM)	AEO	Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: Anhydrous Enol-Oxaloacetate (AEO)|Other: Standard of Care	Overall Survival|Progression Free Survival-6|Seizures|Chalfont-National Hospital Seizure Severity|PROMIS-Cancer - Fatigue	"MetVital, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Terra-001-201	Dec-20	Jul-22	Sep-22	29-Jun-20		29-Jun-20			https://ClinicalTrials.gov/show/NCT04450160
47	NCT02394665	Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma		Terminated	Has Results	Glioblastoma	Radiation: Intensity Modulated Radiation Therapy|Drug: Temozolomide|Behavioral: Functional Assessment of Cancer Therapy-Brain (FACT-Br)|Radiation: Stereotactic Radiosurgery Boost|Radiation: Simultaneous Integrated Boost|Device: 3D MRSI	Rate of Overall Survival (OS) in Study Patients|Rate of Progression-Free Survival (PFS) in Study Patients|Rate of Grade 3 or Higher Toxicity as a a Consequence of Study Therapy.|Change in Quality of Life From Baseline in Study Participants|Patterns of Failure in Study Participants Post-Protocol Therapy	University of Miami	All	"19 Years and older   (Adult, Older Adult)"	Phase 2	1	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20140540	Mar-15	Sep-16	Sep-16	20-Mar-15	5-Jan-17	5-Jan-17	"University of Miami, Miami, Florida, United States"		https://ClinicalTrials.gov/show/NCT02394665
48	NCT02945826	uPAR-PET/MRI in Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: One injection of 68Ga-NOTA-AE105|Device: PET/MRI	uPAR PET/MRI imaging of uPAR expression|uPAR PET/MRI prognostic factor for overall survival|uPAR PET/MRI prognostic factor for progression free survival	"Rigshospitalet, Denmark"	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 2	35	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AK2016-2|2016-002417-21	Jan-17	Dec-20	Dec-20	26-Oct-16		10-Apr-18	"Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT02945826
49	NCT01403285	Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma		Terminated	No Results Available	Glioblastoma	Drug: Cyclophosphamide|Biological: IMA950 plus GM-CSF|Biological: IMA950|Drug: Imiquimod	"Safety and tolerability of IMA950 administered with granulocyte macrophage colony stimulating factor (GM-CSF) and topical imiquimod together following a single low-dose application of cyclophosphamide.|Immunogenicity of IMA950|Immune status parameters|Biomarker assessment and correlation to clinical and immunological response|Clinical anti-tumor activity (response rate, 6-month progression-free survival)|Influence of corticosteroids on immunogenicity of IMA950|Health-related quality of life"	Immatics Biotechnologies GmbH|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	6	Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IMA950-102|11C0192	Aug-11	Apr-14	Apr-14	27-Jul-11		19-May-14	"Neuro-Oncology Branch of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01403285
50	NCT04277221	ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)		Recruiting	No Results Available	Glioblastoma Multiforme	"Biological: Autologous Dendritic Cell/Tumor Antigen, ADCTA"	Overall Survival (OS)|Progression-free Survival (PFS)|Progression-free Survival at 6 months (PFS6)|1 and 2-year Survival Rate	"Safe Save Medical Cell Sciences & Technology Co.,Ltd."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADCTA-SSI-G1	19-Sep-19	31-Dec-22	31-Dec-22	20-Feb-20		17-Mar-20	"Chang Gung Memorial Hospital, Chiayi branch, Chiayi City, Taiwan|Chang Gung Memorial Hospital, Kaohsiung branch, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital, Keelung branch, Keelung, Taiwan|Taichung Veterans General Hospital, Taichung City, Taiwan|National Cheng Kung University Hospital, Tainan City, Taiwan|Chi Mei Medical Center, Tainan City, Taiwan|Chang Gung Memorial Hospital, Linkou branch, Taoyuan City, Taiwan"		https://ClinicalTrials.gov/show/NCT04277221
51	NCT03395587	Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma	GlioVax	Recruiting	No Results Available	Glioblastoma	"Biological: Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Drug: standard therapy"	"Overall survival (OS)|Progression free survival (PFS)|OS rates|PFS rates|Frequency and severity of adverse events|Karnofsky Performance Status|MMSE-2|Quality of life of cancer patients|Quality of life in patients with brain cancer|Psychological distress in oncology patients|Psychological distress, anxiety and depression"	"Heinrich-Heine University, Duesseldorf|German Federal Ministry of Education and Research"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	136	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GlioVax	6-Mar-18	6-Sep-22	6-Jun-23	10-Jan-18		27-May-20	"Klinik für Neurologie, Knappschaftskrankenhaus Bochum, Bochum, Northrhine Westphalia, Germany|Klinik für Neurochirurgie, Sana Kliniken Duisburg, Duisburg, Northrhine Westphalia, Germany|Neurochirurgische Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Northrhine Westphalia, Germany|Klinik für Allgemeine Neurologie, Universitätsklinikum Münster, Münster, Northrhine Westphalia, Germany|Helios Klinikum Krefeld, Klinik für Neurochirurgie, Krefeld, Germany"		https://ClinicalTrials.gov/show/NCT03395587
52	NCT02880410	Feasibility Study on LITT for Newly Diagnosed Glioblastoma	FLAG	Terminated	No Results Available	Glioblastoma	Device: NeuroBlate System|Drug: Radiation therapy and temozolomide	Adverse Events|Progression-Free Survival Rate|Overall Survival|Changes in Quality of Life	Monteris Medical	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	3	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FLAG	15-Aug-17	14-Sep-18	14-Sep-18	26-Aug-16		24-Aug-21	"Washington University, Saint Louis, Missouri, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02880410
53	NCT02206230	Trial of Hypofractionated Radiation Therapy for Glioblastoma		Unknown status	No Results Available	Glioblastoma	Radiation: Hypofractionated radiation therapy|Radiation: Standard radiation therapy	Overall survival|Progression-free survival (PFS)	AHS Cancer Control Alberta|Cross Cancer Institute	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	132	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BR-02-1401	Aug-14	Aug-19	Aug-20	1-Aug-14		5-Jan-16	"Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT02206230
54	NCT03491683	INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)		"Active, not recruiting"	No Results Available	Glioblastoma	Biological: INO-5401|Biological: INO-9012|Biological: Cemiplimab|Radiation: Radiation Therapy|Drug: Temozolomide	Percentage of Participants with Adverse Events (AEs)|Overall survival at 18 months (OS18)|Change from Baseline in Interferon-gamma Secreting T Lymphocytes in Peripheral Blood Mononuclear Cells (PBMCs)|Change from Baseline in T-Cell Phenotypes in PBMCs|Change from Baseline in T Cell Receptor (TCR) Subtypes in PBMCs|Change from Baseline in Antigen-Specific Humoral Response	Inovio Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	52	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM-001	31-May-18	30-Dec-21	30-Dec-21	9-Apr-18		22-Nov-21	"City of Hope, Duarte, California, United States|Stanford University, School of Medicine, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Rutgers University - Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York University Langone Medical Center; Perlmutter Cancer Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center The Neurological Institute of New York, New York, New York, United States|New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania Health System: Penn Medicine, Philadelphia, Pennsylvania, United States|UPMC Cancer Center Neuro-Oncology; UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Texas Oncology, Austin, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT03491683
55	NCT04856852	Iodine-125 Brachytherapy Together With Chemotherapy in Patients With Newly Diagnosed Glioblastoma	IBCNG	Not yet recruiting	No Results Available	Glioblastoma	Other: Iodine-125+Chemotherapy|Other: Surgical resection+Radiochemotherapy	Progression-free survival (PFS)|Overall Survival (OS)|Survival rates at 6 months and 1 year|EORTC QLQ-C30|ECOG Performance Status|Complications	The Affiliated Hospital of Qingdao University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Not Applicable	84	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IC-SRC-20201119|2019YFE0120100	28-Jun-21	1-Aug-22	31-Aug-23	23-Apr-21		29-Jun-21			https://ClinicalTrials.gov/show/NCT04856852
56	NCT01071837	APG101 in Glioblastoma		Completed	No Results Available	Glioblastoma Multiforme	Drug: APG101|Procedure: Blood drawing	6 months rate of progression free survival (PFS6)|Safety and tolerability of APG101|Progression-free survival|Objective response rates (OR)|Duration of response (DR) in responders|Overall survival|Quality of life|Cognitive function	Apogenix GmbH|Apogenix AG	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	84	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APG101_CD_002	Dec-09	Oct-14	Oct-14	19-Feb-10		16-Jun-15	"Medizinische Universität Graz, Universitätsklinik für Neurologie Landeskrankenhaus Graz, Graz, Austria|Universitätsklinik für Neurologie, Landeskrankenhaus Innsbruck, Innsbruck, Austria|Landesnervenklinik Wagner-Jauregg, Innere Medizin mit Neuroonkologie, Linz, Austria|Allgemeines Krankenhaus der Stadt Wien, Klinische Onkologie, Wien, Austria|Charite Universitätsmedizin Berlin, Klinik für Neurochirugie, Berlin, Germany|Neurologische Universitätsklinik am Knappschaftskrankenhaus, Bochum, Germany|Neurologische Universitätsklinik Bonn, Schwerpunkt klinische Neuroonkologie, Bonn, Germany|Universitätsklinik Dresden, Klinik und Poliklinik für Neurochirurgie, Dresden, Germany|Klinikum Frankfurt/Oder, Klinik für Strahlentherapie/Radioonkologie, Frankfurt/Oder, Germany|Universitätsklinik Hamburg, Klinik für Neurochirugie, Hamburg, Germany|Universitätsklinik Heidelberg, Abteilung Neuroonkologie, Heidelberg, Germany|Universität Leipzig, Klinik für Strahlentherapie, Leipzig, Germany|Universitätsmedizin Mannheim, Klinik für Neurochirurgie, Mannheim, Germany|Philipps-Universität Marburg, Klinik für Neurologie, Marburg, Germany|LMU München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Campus Großhadern & Campus Innenstadt, München, Germany|Klinik und Poliklinik für Strahlentherapie/Radiologische Onkologie, Klinikum rechts der Isar, TU München, München, Germany|Städt. Kliniken München GmbH, Klinikum Bogenhausen, Abt. Neurochirurgie, München, Germany|Klinik und Poliklinik der Universität Regensburg, Im Bezirksklinikum, Regensburg, Germany|Klinikum Stuttgart, Neurozentrum Neurochirurgie, Stuttgart, Germany|Universitätsklinikum Tuebingen, Strahlenonkologie, Tuebingen, Germany|Uniklinik Ulm, Klinik für Strahlentherapie und Radioonkologie, Ulm, Germany"		https://ClinicalTrials.gov/show/NCT01071837
57	NCT02709616	Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)	PERCELLVAC	Unknown status	No Results Available	Glioblastoma	Biological: Personalized cellular vaccine	Incidence of treatment-emergent adverse events and severe adverse events [safety and Tolerability]|Antitumor antigen specific T cell response|Progression-free survival|Overall survival	"Guangdong 999 Brain Hospital|Jinan University Guangzhou|Beijing Tricision Biotherapeutics Inc|Trinomab Biotech Co., Ltd."	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Ag-mRNA-DC-999brain	Mar-16	Mar-20	Jun-20	16-Mar-16		7-Jun-19	"Guangdong 999 Brain Hospital, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT02709616
58	NCT01268566	A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Drug: MEDI-575	Progression-free Survival Rate at 6 Months|Percentage of Participants With Best Overall Response|Percentage of Participants With Objective Response|Time to Response|Duration of Response|Time to Progression|Progression-free Survival Rate at 3 Months and 9 Months|Progression-free Survival|Overall Survival|Percentage of Participants With Expression of PDGFR Alpha in the Tumor Samples|Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events|Number of Participants With Worst ECOG Performance Status On-study and Last Record On-study|Treatment-emergent Adverse Events Related to Laboratory Parameters|Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations|Treatment-emergent Adverse Events Related to Vital Sign Parameters	MedImmune LLC	All	"18 Years to 95 Years   (Adult, Older Adult)"	Phase 2	62	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CD-ON-MEDI-575-1042	Jan-11	Nov-12	Nov-12	31-Dec-10	6-Apr-17	6-Apr-17	"Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Stanford, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, New York, New York, United States|Research Site, Canton, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01268566
59	NCT01865162	Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study	KGDinGBM	Unknown status	No Results Available	Glioblastoma Multiforme	Other: ketogenic diet	To evaluate the safety of ketogenic diet as adjunctive treatment of treatment-refractory glioblastoma multiforme.|To obtain pilot data on efficacy of ketogenic diet as adjunctive treatment of treatment-refractory glioblastoma multiforme|To evaluate tolerability of ketogenic diet as adjunctive treatment of treatment-refractory glioblastoma multiforme.	"Mid-Atlantic Epilepsy and Sleep Center, LLC|University of Pittsburgh Medical Center"	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	maes 002	Jan-13	Jan-21	May-21	30-May-13		22-Aug-19	"MidAtlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01865162
60	NCT03390569	Exercise in Patients With Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Behavioral: Exercise	Progression-Free Survival|Cognitive Decline|Cognitive Complaints|Overall survival|Personality Changes|Quality of Life|Mood|Interference with valued activities and interests|Sleep Quality|Physical Function	"University Health Network, Toronto|Canadian Cancer Society (CCS)|University of Toronto|McMaster University|University of British Columbia"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	54	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	16-5922	29-Aug-17	Aug-21	Dec-21	4-Jan-18		19-Apr-21	"Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT03390569
61	NCT03687099	Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma	GLIOBLASTOMES	Completed	No Results Available	Glioblastoma	Other: no intervention	number of cells which express CD45 in the immunological environment from GBM.	"Centre Hospitalier Universitaire, Amiens"	All	"18 Years and older   (Adult, Older Adult)"		20	Other	Observational	Observational Model: Other|Time Perspective: Retrospective	PI2018_843_0011	30-Apr-18	8-Nov-19	8-Nov-19	27-Sep-18		16-Jul-20	"CHU Amiens-Picardie, Amiens, France"		https://ClinicalTrials.gov/show/NCT03687099
62	NCT02808364	Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)	PerCellVac2	Unknown status	No Results Available	Glioblastoma	Biological: Personalized cellular vaccine	Incidence of treatment-emergent adverse events and severe adverse events (safety and tolerability)|Antitumor antigen specific T cell response|Progression-free survival|Overall survival	"Guangdong 999 Brain Hospital|Beijing Tricision Biotherapeutics Inc|Trinomab Biotech Co., Ltd.|Jinan University Guangzhou"	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Ag-mRNA-Cell-999brain	Jun-16	Jun-20	Sep-20	21-Jun-16		7-Jun-19	"Guangdong 999 Brain Hospital, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT02808364
63	NCT03194971	NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy		Recruiting	No Results Available	Glioblastoma	Other: Tumor samples from patients treated with TTFields at initial diagnosis.|Device: Tumor samples from patients treated with TTFields at tumor recurrence.	Number of mitotically active cells|Number of mitotically inactive cells|Mitotic Ratio	Medical College of Wisconsin	All	"18 Years and older   (Adult, Older Adult)"		20	Other	Observational	Observational Model: Other|Time Perspective: Retrospective	PRO00017446	1-Jun-17	31-May-23	31-May-24	21-Jun-17		21-Sep-21	"Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03194971
64	NCT02997423	Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)		"Active, not recruiting"	No Results Available	Glioblastoma		Overall Survival (OS)	Corinne Griguer|National Institute of Neurological Disorders and Stroke (NINDS)|NeuroNEXT Network|University of Iowa	All	"21 Years and older   (Adult, Older Adult)"		153	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	NN106|U01NS093663	30-Nov-16	30-Nov-22	30-Nov-24	20-Dec-16		8-Apr-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|UC Davis, Sacramento, California, United States|University of Miami, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University Medical School, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Stony Brook, Stony Brook, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT02997423
65	NCT02511405	"A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)"	GLOBE	Completed	No Results Available	Glioblastoma	Drug: VB-111 + bevacizumab|Drug: Bevacizumab	Overall survival|Progression Free Survival|Tumor response as measured by RANO Criteria	Vascular Biogenics Ltd. operating as VBL Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	252	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VB-111-215	Aug-15	3-Nov-17	30-Sep-18	30-Jul-15		23-Oct-18	"University of Alabama, Birmingham, Alabama, United States|Highlands Oncology Group, Rogers, Arizona, United States|University of California Irvine Medical Center, Irvine, California, United States|University of California Los Angeles, Los Angeles, California, United States|The Center for Cancer Prevention and Treatment, Orangevale, California, United States|Kaiser Permanente - Redwood City Medical Center, Redwood City, California, United States|University of California, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Colorado Neurological Institute, Denver, Colorado, United States|The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States|University of Florida Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville, Florida, United States|Orlando Health, Orlando, Florida, United States|Piedmont Physicians Neuro-Oncology, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Louisiana State University Health Science Center, Shreveport, Louisiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Metro-MN Community Oncology Research Consortium, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Dent Neurosciences Research Center, Amherst, New York, United States|North Shore University Hospital, Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|Derald H. Ruttenberg Treatment Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University, Neurology Associates of Stony Brook, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Baylor Health Neuro-Oncology Associates, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|: University of Texas, HSC, Houston, Texas, United States|MD Anderson, Houston, Texas, United States|UTHSCSA, San Antonio, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikvah, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT02511405
66	NCT04224441	Repurposing Chlorpromazine in the Treatment of Glioblastoma	RACTAC	Recruiting	No Results Available	Glioblastoma Multiforme|MGMT-Unmethylated Glioblastoma	Drug: Chlorpromazine Pill	Evaluation of toxicity|Progression-free survival (PFS)|Evaluation of tumor response|Overall survival (OS)	"Marco G Paggi, MD, PhD|Regina Elena Cancer Institute|Carlo Besta Neurological Institute|Istituto Oncologico Veneto IRCCS"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	41	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-001988-75	15-Dec-19	15-Jun-22	15-Dec-22	13-Jan-20		13-Jan-20	"Regina Elena Cancer Institute, Roma, Lazio, Italy|Carlo Besta Neurological Institute, Milano, Lombardia, Italy|Istituto Oncologico Veneto, Padova, Veneto, Italy"		https://ClinicalTrials.gov/show/NCT04224441
67	NCT05109728	A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.		Not yet recruiting	No Results Available	Glioblastoma	Drug: [177Lu]Lu-DOTA-TATE|Drug: [68Ga]Ga-DOTA-TATE|Other: Temozolomide|Other: Radiotherapy	"Group 1: Frequency of dose limiting toxicities (DLTs)|Group 2: Frequency of dose limiting toxicities (DLTs)|Group 3: Frequency of dose limiting toxicities (DLTs)|Incidence and severity of adverse events (AEs), serious AEs (SAEs) of [177Lu]Lu-DOTA-TATE|Incidence and severity of Adverse Events (AEs) and serious Adverse Events (SAEs) within 48 hours after [68Ga]Ga-DOTA-TATE infusion|Overall Objective Status as per modified Response Assessment in Neuro-Oncology (mRANO) criteria|Progression-Free Survival (PFS)|Overall Survival (OS)|Groups 1 and 2: Time activity curves (TACs)|Groups 1 and 2: Absorbed radiation doses of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Concentration of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Observed maximum plasma concentration (Cmax) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Time of maximum observed drug concentration occurrence (Tmax) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Total systemic clearance for intravenous administration (CL) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Volume of distribution during the terminal phase following intravenous elimination (Vz) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Terminal elimination half-life (T^1/2) of [177Lu]Lu-DOTA-TATE|Groups 1 and 2: Terminal-Phase Disposition Rate Constant (λz) of [177Lu]Lu-DOTA-TATE|Group 3: Time activity curves (TACs)|Group 3: Absorbed radiation doses of [177Lu]Lu-DOTA-TATE|Group 3: Concentration of [177Lu]Lu-DOTA-TATE|Group 3: Observed maximum plasma concentration (Cmax) of [177Lu]Lu-DOTA-TATE|Group 3: Time of maximum observed drug concentration occurrence (Tmax) of [177Lu]Lu-DOTA-TATE|Group 3: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of [177Lu]Lu-DOTA-TATE|Group 3: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of [177Lu]Lu-DOTA-TATE|Group 3: Total systemic clearance for intravenous administration (CL) of [177Lu]Lu-DOTA-TATE|Group 3: Volume of distribution during the terminal phase following intravenous elimination (Vz) of [177Lu]Lu-DOTA-TATE|Group 3: Terminal elimination half-life (T^1/2) of [177Lu]Lu-DOTA-TATE|Group 3: Terminal-Phase Disposition Rate Constant (λz) of [177Lu]Lu-DOTA-TATE|Quantification of [177Lu]Lu-DOTA-TATE excreted from the body in urine"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	45	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAAA601A52101|2021-003672-14	14-Feb-22	27-Nov-23	26-Nov-24	5-Nov-21		26-Nov-21			https://ClinicalTrials.gov/show/NCT05109728
68	NCT03739333	Early Diagnosis of Pseudoprogression Using 11C-Methionine PET-MRI After Concomitant Radiochemotherapy Treatment for Glioblastoma.	TIGRE	Recruiting	No Results Available	Glioblastoma	Other: 11C-Methionine PET-MRI	false negatives and false positives description (diagnosis accuracy) of 11C-Methionine PET-MRI|ROC curves for comparison of two diagnostic tests: MRI and PET-MRI|The proportion of pseudoprogression identified by PET-MRI to 11C-MET according to the genetic data|Overall survival analysis	Hospices Civils de Lyon	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	69HCL18_0265|2018-002016-27	26-Feb-19	26-Feb-20	26-Jan-25	13-Nov-18		13-Feb-20	"Hopices Civils de Lyon, Bron, France"		https://ClinicalTrials.gov/show/NCT03739333
69	NCT04243005	Supramarginal Resection in Glioblastoma		Recruiting	No Results Available	Glioblastoma	Procedure: Supramarginal resection|Procedure: Conventional surgery	"Overall survival|Proportion alive|Neurological function|Health-related quality of life assessed by EQ-5D 3L|Health-related quality of life assessed by EORTC QLQ C30|Health-related quality of life assessed by BN20|Neurocognition|Surgical complication|Proportion with contrast remnant|Extent of resection, T2/FLAIR remnant|Margin of resection"	"St. Olavs Hospital|Odense University Hospital|Sahlgrenska University Hospital, Sweden|Turku University Hospital|Karolinska University Hospital|Norwegian University of Science and Technology|University Hospital, Linkoeping|Uppsala University Hospital|University Hospital, Umeå|Skane University Hospital|Haukeland University Hospital|Ullevaal University Hospital|Rikshospitalet University Hospital|University Hospital of North Norway|Tampere University Hospital|Helsinki University Central Hospital|Kuopio University Hospital|Oulu University Hospital|Medical University of Vienna"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	90	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"	2019/1046	1-Jul-20	Mar-24	Mar-27	27-Jan-20		18-Oct-21	"Medical University of Vienna, Vienna, Austria|Odense University Hospital, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Kuopio University Hospital, Kuopio, Finland|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Rikshospitalet, Oslo, Norway|Ullevål University Hospital, Oslo, Norway|University Hospital North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Sahlgrenska University Hospital,, Göteborg, Sweden|Linköping University Hospital, Linköping, Sweden|Skåne University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital of Umeå, Umeå, Sweden|Uppsala University Hospital, Uppsala, Sweden"		https://ClinicalTrials.gov/show/NCT04243005
70	NCT03493932	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Nivolumab|Drug: BMS-986016	Increase of interferon gamma levels|Microdialysis safety|Drug Safety	National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	180077|18-N-0077	24-Sep-18	1-Jan-22	30-Jun-22	11-Apr-18		23-Aug-21	"Emory University, Atlanta, Georgia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03493932
71	NCT04121455	Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients	GLORIA	Recruiting	No Results Available	Glioblastoma	Drug: Olaptesed pegol|Radiation: Radiotherapy|Drug: Bevacizumab	Safety - Number of patients with treatment-related adverse events as assessed by CTCAE|Efficacy - progression free survival at 6 months (PFS-6)|Efficacy - Median progression-free survival (mPFS)|Efficacy - Median overall survival (mOS)|Efficacy - Tumor vascularization as per vascular MRI|Plasma level of olaptesed pegol|Quality of Life (QoL) EORTC QLQ-C30 Module|Quality of Life (QoL) EORTC QLQ BN-20 Module|Neurologic functions as measured by the NANO scale	NOXXON Pharma AG	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	21	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SNOXA12C401|2018-004064-62	12-Sep-19	Dec-24	Dec-24	10-Oct-19		5-Nov-21	"Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie, Bonn, Germany|Klinik für Neurologie, Essen, Germany|Klinik für Strahlentherapie und Radioonkologie, Leipzig, Germany|Klinik für Strahlentherapie und Radioonkologie, Mannheim, Germany|Klinik für Neurologie mit Institut für Translationale Neurologie, Münster, Germany|Abteilung Neurologie mit interdisziplinärem Schwerpunkt Neuroonkologie, Tübingen, Germany"		https://ClinicalTrials.gov/show/NCT04121455
72	NCT04888611	Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma	Biological: Camrelizumab plus GSC-DCV|Biological: Camrelizumab plus Placebo	Overall survival (OS)|Progression-free survival (PFS)|Number of treatment-related adverse events|Treatment Responses Rate	"Huashan Hospital|Jiangsu HengRui Medicine Co., Ltd.|Shanghai Sunstem Biotechnology Co., Ltd."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	40	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	KY2021-547	26-Oct-21	1-May-23	1-May-24	17-May-21		30-Nov-21	"Huashan Hospital, Fudan University, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT04888611
73	NCT02394626	Surgery for Recurrent Glioblastoma	RESURGE	Recruiting	No Results Available	Glioblastoma	Procedure: Surgery followed by adjuvant second-line therapy|Procedure: Second-line therapy alone	Overall survival from the date of inclusion|Recruitment rate for all screened patients|Progression-free survival|Morbidity of surgery|Total number of days spent at home after recurrence|Total number of days spent outside home after recurrence	"University Hospital Inselspital, Berne|European Organisation for Research and Treatment of Cancer - EORTC"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	120	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	368/14	May-15	Oct-23	Oct-23	20-Mar-15		22-Apr-21	"Universitätsklinikum Innsbruck, Innsbruck, Austria|Helios Klinikum Erfurt, Erfurt, Germany|Department of Neurosurgery, Universitätsklinikum Frankfurt, Frankfurt, Germany|Dep. of Neurosurgery, Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Gießen und Marburg, Giessen, Germany|Department of Neurosurgery, Universitätsklinikum Köln, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Münster, Münster, Germany|Department of Neurosurgery, Hospital of Larissa & General Hospital of Larissa, Larissa, Greece|Department of Neurosurgery, AHEPA University Hospital, Thessaloníki, Greece|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy|Department of Neurosurgery, Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria, Lisboa, Portugal|Department of Neurosurgery, Spitalul Clinic De Urgență ""Bagdasar-Arseni"", Bucharest, Romania|Kantonsspital Aarau, Aarau, Switzerland|Universitätsspital Basel, Basel, Switzerland|Dep. of Neurosurgery, Bern University Hospital, Bern, Switzerland|Dep. of Neurosurger, Hôpitaux Universitaires de Genève, Geneva, Switzerland|Dep. of Neurosurgery, Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Ospedale Regionale di Lugano, Lugano, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Department of Neurosurgery, Kantonsspital St. Gallen, Saint Gallen, Switzerland|Dep. of Neurosurgery, University Hospital of Zurich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT02394626
74	NCT03363659	Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Disulfiram|Dietary Supplement: Copper gluconate|Drug: Temozolomide	Progression Free Survival (PFS)|Overall Survival|Quality of life (QOL)	Aurora Health Care	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17.56	28-Mar-18	31-Dec-21	31-Dec-22	6-Dec-17		9-Sep-21	"Aurora Health Care, Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03363659
75	NCT02149225	GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients		Completed	No Results Available	Glioblastoma	Drug: APVAC1 vaccine plus Poly-ICLC and GM-CSF|Drug: APVAC2 vaccine plus Poly-ICLC and GM-CSF	Safety profile of patient-tailored APVAC vaccines when administered with immunomodulators concurrent to maintenance TMZ cycles|Frequency of CD8 T cells specific for vaccinated APVAC peptides as measure of immunological response to and biological activity of the vaccine|Frequency of immune cell populations in the blood and concentrations of a large panel of serum and plasma proteins with immunological relevance as a measure of the immune status of the patient|Overall survival|Progression-free survival	Immatics Biotechnologies GmbH|BioNTech SE|University Hospital Tuebingen|BCN Peptides|EU-funded GAPVAC Consortium	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	16	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GAPVAC-101|2013-002801-71	Oct-14	Jun-18	Jun-18	29-May-14		7-Aug-18	"Rigshospitalet, The Finsen Centre, Department of Oncology, Copenhagen, Denmark|Neurologische Klinik & Nationales Centrum für Tumorerkrankungen Heidelberg, Heidelberg, Germany|Zentrum für Neurologie und Klinik für Neurochirurgie, Tübingen, Germany|Leiden University Medical Center, Department of Medical Oncology, Leiden, Netherlands|Vall d'Hebron University Hospital, Barcelona, Spain|Hôpitaux Universitaires de Genève, Geneva 14, Switzerland"		https://ClinicalTrials.gov/show/NCT02149225
76	NCT04157478	Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma	Drug: Anlotinib Hydrochloride|Radiation: Radiation therapy|Drug: Temozolomide	Progression-free survival|Overall survival|Objective response rate	People's Hospital of Guangxi|First Affiliated Hospital of Guangxi Medical University|Cancer Hospital of Guangxi Medical University|Liuzhou Workers Hospital|Nanxishan Hospital|LiuZhou People's Hospital|Affiliated Hospital of Guilin University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	464	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GXPH-19001	Jan-20	Dec-22	Dec-24	8-Nov-19		12-Nov-19	"Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China|Liuzhou Worker's Hospital, Liuzhou, Guangxi, China|Liuzhou People's Hospital, Liuzhou, Guangxi, China|Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China|People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Yulin First Hospital, Yulin, Guangxi, China"		https://ClinicalTrials.gov/show/NCT04157478
77	NCT02841332	Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma	IMAGLIO	Terminated	No Results Available	Glioblastoma	Drug: F-MISO|Other: Cerebral magnetic resonance imagery|Drug: Bevacizumab|Other: Clinical examination	"Detection capacity of patient clinical status in imagery with F-MISO as assessed by tomography with emission of positron|Detection capacity of patient clinical status in imagery with F-MISO as assessed by Perfusion magnetic resonance imagery|Detection capacity of patient clinical status in imagery with F-MISO as assessed by Diffusion magnetic resonance imagery|Detection capacity of patient clinical status in imagery with F-MISO as assessed by Spectroscopy magnetic resonance imagery|Estimation of predictive parameters of progression free survival with a sensibility of change of at least 75% as assessed with relative cerebral blood volume in Perfusion magnetic resonance imagery|Estimation of predictive parameters of progression free survival with a sensibility of change of at least 75% as assessed with apparent diffusion coefficient on diffusion magnetic resonance imagery|Estimation of predictive parameters of progression free survival with a sensibility of change of at least 75% as assessed with rate of choline on spectroscopy magnetic resonance imagery|Estimation of predictive parameters of progression free survival with a sensibility of change of at least 75% as assessed with rate of N-acetyl aspartate on spectroscopy magnetic resonance imagery|Estimation of predictive parameters of progression free survival with a sensibility of change of at least 75% as assessed with rate of rate of creatinine on spectroscopy magnetic resonance imagery|Estimation of imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% as assessed by relative cerebral blood volume in Perfusion magnetic resonance imagery|Estimation of imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% as assessed by apparent diffusion coefficient on diffusion magnetic resonance imagery,|Estimation of imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% as assessed by rate of choline on spectroscopy magnetic resonance imagery|Estimation of imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% as assessed by N-acetyl aspartate on spectroscopy magnetic resonance imagery|Estimation of imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% as assessed byrate of creatinine on spectroscopy magnetic resonance imagery|Estimation of imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% as assessed by rate of creatinine on spectroscopy magnetic resonance imagery|Variation in imagery predictive parameters for progression free survival with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by relative cerebral blood volume in Perfusion magnetic resonance imagery|Variation in imagery predictive parameters for progression free survival with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by apparent diffusion coefficient on diffusion magnetic resonance imagery|Variation in imagery predictive parameters for progression free survival with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by rate of choline on spectroscopy magnetic resonance imagery|Variation in imagery predictive parameters for progression free survival with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by N-acetyl aspartate on spectroscopy magnetic resonance imagery|Variation in imagery predictive parameters for progression free survival with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by rate of creatinine on spectroscopy magnetic resonance imagery|Variation in imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by relative cerebral blood volume in Perfusion magnetic resonance imagery|Variation in imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by apparent diffusion coefficient on diffusion magnetic resonance imagery|Variation in imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by rate of choline on spectroscopy magnetic resonance imagery|Variation in imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by rate of N-acetyl aspartate on spectroscopy magnetic resonance imagery|Variation in imagery prognostic parameters for global survival at 6 months with a sensibility of change of at least 75% between cycle 1 and cycle 4 of treatment as assessed by rate of creatinine on spectroscopy magnetic resonance imagery"	"University Hospital, Toulouse"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	12 050 03	May-13	Sep-16	Dec-16	22-Jul-16		20-Dec-16	"UHToulouse, Toulouse, France"		https://ClinicalTrials.gov/show/NCT02841332
78	NCT04559230	Sacituzumab Govitecan in Recurrent Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma	Drug: Sacituzumab Govitecan	Progression free survival	The University of Texas Health Science Center at San Antonio	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS# 20-0102|HSC20200576X	Jan-22	Feb-24	Feb-25	22-Sep-20		23-Dec-21	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT04559230
79	NCT00807027	Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea		Completed	No Results Available	Glioblastoma	Drug: Activated T lymphocyte(Immuncell-LC)	"MRI|Overall survival, therapy reaction, EORTC QLQ-C30, and Karnofsky Performance Status (KPS)"	GC Cell Corporation	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IcmLCBT_301	Dec-08	Oct-12	Oct-12	11-Dec-08		25-Oct-12	"Hanyang University Guri Hospital, Guri, Gyeonggi-Do, Korea, Republic of|Gyunghee University Medical Center, Seoul, Korea, Republic of|Konkuk University, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Samsung Seoul Medical Center, Seoul, Korea, Republic of|Seoul Asan Medical Center, Seoul, Korea, Republic of|Yeonsei University Medical Center, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT00807027
80	NCT01280552	A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)		Completed	Has Results	Glioblastoma Multiforme	Biological: ICT-107|Biological: Placebo DC	Overall Survival (OS)|Overall Survival in HLA-A2 Patients|PFS|Progression Free Survival in HLA- A2 Patients	Precision Life Sciences Group	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	124	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	ICT-107-201	Jan-11	Dec-13	Dec-15	20-Jan-11	7-Oct-14	20-Mar-17	"University of Alabama at Birbingham School of Medicine, South Birmingham, Alabama, United States|Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Jewish Hospital Medical Center, Louisville, Kentucky, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetss General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|New Jersey Neuroscience Institute, Edison, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Long Island Brain Tumor Center at Neurological Surgery, PC, Great Neck, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Weil Cornell Medical College, New York, New York, United States|Wake Forest University, Winston Salem, North Carolina, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center, Cleveland, Ohio, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sammons Cancer Center (Baylor), Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT01280552
81	NCT02939378	Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study	KGDinrGBM	Unknown status	No Results Available	Glioblastoma Multiforme	Dietary Supplement: Ketogenic diet|Dietary Supplement: Standard diet	Number of Participants with Treatment-emergent Adverse Effects|The Chemosensitivity of Tumor|Overall Survival|Ketosis|Quality of Life	Song Lin|Beijing Tiantan Hospital	All	18 Years to 60 Years   (Adult)	Phase 1|Phase 2	60	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B0009	Oct-16	Dec-17	Dec-18	20-Oct-16		20-Oct-16	"Beijing Tiantan Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT02939378
82	NCT05074992	A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma	NeAT Glio	Not yet recruiting	No Results Available	Glioblastoma	Drug: Ipilimumab	Survival rate at 24 months|Survival rate at 12 months|Time to treatment failure|Best Overall Objective Response Rate|Treatment emergent adverse events|Treatment Compliance|Changes in Performance Status|Surgical complications|Resection rate	"University College, London|Bristol-Myers Squibb"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	43	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCL/134643	Mar-22	Mar-23	Mar-25	12-Oct-21		12-Oct-21			https://ClinicalTrials.gov/show/NCT05074992
83	NCT01044225	Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma		Terminated	No Results Available	Glioblastoma	Drug: Cetuximab|Drug: Cilengitide EMD 121974	the 1 year overall survival	Bart Neyns|Universitair Ziekenhuis Brussel	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	12	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-012324-83	Sep-09	Sep-11	Sep-11	7-Jan-10		22-Mar-12	"Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|GHdC Charleroi, Charleroi, Belgium|ZOL Campus Sint-Jan, Genk, Belgium|UZ Gent, Gent, Belgium|UCL de Mont-Godinne, Yvoir, Belgium"		https://ClinicalTrials.gov/show/NCT01044225
84	NCT02062372	Spatial Analysis and Validation of Glioblastoma on 7 T MRI		Terminated	No Results Available	Glioblastoma	Device: 7 T MRI|Procedure: Biopsy	The co-localisation of the Gross Tumour Volume (GTV) on 7T MRI and 3T MRI|The correspondence between glioblastoma cells found in the biopsies and region of interest (ROI) on the 7T MRI scan.|The co-localisation of the Clinical Target Volume (CTV) on 7T MRI and 3T MRI|The co-localisation of the organs at risk (OAR) on 7T - and 3T MRI|The correlation between the first tumour recurrence on 3T MRI follow-up images and ROI on the 7T MRI scan|The quantification of tumour heterogeneity on 7T MRI and 3T MRI|The visibility of white matter tracts on 7T MRI and 3T MRI|Tolerability and side effects 3T MRI and 7T MRI scan	Maastricht Radiation Oncology|The Limburg University Fund	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	1335-1812-intern-6485|47894	10-Dec-14	5-Feb-18	5-Feb-18	13-Feb-14		17-Aug-18	"Maastricht Radiation Oncology (MAASTRO clinic), Maastricht, Limburg, Netherlands"		https://ClinicalTrials.gov/show/NCT02062372
85	NCT04599647	EAP for the Treatment of Glioblastoma With PVSRIPO		Available	No Results Available	Glioblastoma	Biological: PVSRIPO		"Istari Oncology, Inc."	All	"18 Years and older   (Adult, Older Adult)"			Industry	Expanded Access:Intermediate-size Population		PVSRIPO GBM EAP				23-Oct-20		21-Apr-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04599647
86	NCT05140902	Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom		Not yet recruiting	No Results Available	Glioblastoma	Device: Point-of-care Portable Perfusion Phantom (P4)	To measure the reproducibility of qDCE-MRI measurement of glioblastoma.|To determine whether the differentiation between the pseudo- and true-progressions of glioblastoma can be improved using qDCE-MRI after P4-based error correction.	University of Alabama at Birmingham	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	300006446	1-Jan-22	Dec-24	Dec-25	2-Dec-21		2-Dec-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT05140902
87	NCT04324840	A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: CC-90010|Drug: Temozolomide	Adverse Events (AEs)|Maximum Tolerated Dose (MTD) of CC-90010|Recommended Phase 2 Dose (RP2D) of CC-90010|Progression-free survival (PFS)|Overall survival (OS)|Time to Progression|Response by Response Assessment in Neuro-Oncology (RANO) criteria|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - VzF	Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	126	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-90010-GBM-002|U1111-1248-0496|2019-004122-25	10-Jul-20	12-Apr-23	20-Nov-24	27-Mar-20		27-Sep-21	"Aalborg Universitets hospital, Aalborg, Denmark|Rigshospitalet University Hospital, Copenhagen, Denmark|Odense University, Region South, Odense, Denmark|Ospedale San Raffaele, Milano, Italy|Istituto Clinico Humanitas, Milan, Italy|Istituto Oncologico Veneto, Padova, Italy|Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy|Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Oslo University Hospital, Rikshospitalet HF, Oslo, Norway|Hospital del Mar, Barcelona, Spain|Hospital Val d´Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Skanes Universitetssjukhus - Lund - Onkologiska Klinik, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Uppsala University, Uppsala, Sweden"		https://ClinicalTrials.gov/show/NCT04324840
88	NCT04583020	Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: Camrelizumab|Radiation: radiation|Drug: Temozolomide	Overall survival (OS)|Progression-free survival (PFS)|Proportion of participants with treatment-related adverse events|Objective response rate (ORR)	"Peking Union Medical College Hospital|Jiangsu HengRui Medicine Co., Ltd."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	42	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HS-2522	12-Nov-20	30-Dec-23	31-Dec-23	12-Oct-20		30-Nov-20	"Peking Union Medical College Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT04583020
89	NCT00397072	Epothilone in Recurrent Glioblastoma Patients		Completed	No Results Available	Glioblastoma	Drug: ZK 219477	Progression Free Survival at six months (PFS-6).|Response rates (CR +PR)|Safety evaluation according to CTC-AE|Median Survival Time (MST)	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	15	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZK219477IV	Jun-06	Mar-08	Dec-08	8-Nov-06		17-Apr-14	"Istituto Nazionale Neurologico, Milan, Italy"		https://ClinicalTrials.gov/show/NCT00397072
90	NCT04730869	Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma Multiforme		Recruiting	No Results Available	Glioblastoma Multiforme	Other: Standard Treatment Plus Metabolic Therapy Program	"Mean daily blood glucose-to-ketone ratio during chemoradiation|Mean daily blood glucose-to-ketone ratio during adjuvant chemotherapy|Mean daily blood glucose-to-ketone ratio during the MTP, calculated separately on fasting and ketogenic diet days|Change in weight|Safety as measured by National Cancer Institute Common Terminology Criteria for Adverse Events (version 4)|Change in performance status as measured by Eastern Cooperative Oncology Group Performance Status scale|Change in leisure/exercise activity as measured by Godin Leisure-Time Exercise questionnaire|Change in quality of life as measured by Functional Assessment of Cancer Therapy - Brain questionnaire|Progression-free survival|Overall survival"	Waikato Hospital	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	22	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RD020132|U1111-1262-0203|Grant #321	26-May-21	1-Nov-22	1-Nov-22	29-Jan-21		2-Jun-21	"Waikato Hospital, Hamilton, Waikato, New Zealand"		https://ClinicalTrials.gov/show/NCT04730869
91	NCT01165671	Carbon Ion Radiotherapy for Primary Glioblastoma	CLEOPATRA	Completed	No Results Available	Primary Glioblastoma	Radiation: Carbon Ion Radiotherapy|Radiation: Proton Radiotherapy	Overall Survival|Progression-free Survival|Toxicity	University Hospital Heidelberg	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLEOPATRA|2009-014668-21|ISRCTN37428883	Jul-10	Jan-15	Jan-15	20-Jul-10		3-Apr-20	"University Hospital of Heidelberg, Department of Radiation Oncology, Heidelberg, Germany"		https://ClinicalTrials.gov/show/NCT01165671
92	NCT01102595	Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma		Completed	No Results Available	Glioblastomas	Drug: Temozolomide|Drug: Bevacizumab|Radiation: Standard radiation therapy	Response Rate|Percentage of patients who finish treatment|Progression-free survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Percentage of patients without neurological deterioration before radiation therapy.|Overall survival	Grupo Español de Investigación en Neurooncología	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	102	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GENOM-009	Dec-09	Oct-13	Dec-14	13-Apr-10		26-Aug-15	"Grupo Español de Investigacion en Neurooncologia, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT01102595
93	NCT04629209	"A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma"		Withdrawn	No Results Available	Glioblastoma	Drug: ONC201	Intra-tumoral ONC201 concentrations|Objective Response Rate	Chimerix	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONC026	15-Feb-21	31-Dec-22	30-Jun-23	16-Nov-20		30-Apr-21	"University of Minnesota, Minneapolis, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT04629209
94	NCT04716699	Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma		Recruiting	No Results Available	Glioblastoma	Procedure: Biospecimen Collection|Drug: Lidocaine|Procedure: Resection	Difference between the concentrations of lidocaine in the tumor tissue and in the blood (baseline level)|Progression free survival (PFS)|Overall survival (OS)|Incidence of adverse events (AEs)	"Kiarash Shahlaie, M.D., Ph.D.|National Cancer Institute (NCI)|University of California, Davis"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	UCDCC#285|NCI-2020-14099|P30CA093373	20-Jan-21	20-Jul-22	20-Jan-23	20-Jan-21		22-Jan-21	"University of California Davis Comprehensive Cancer Center, Sacramento, California, United States"		https://ClinicalTrials.gov/show/NCT04716699
95	NCT04762069	A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme		Recruiting	No Results Available	"Glioblastoma Multiforme, Adult"	Drug: Berubicin|Drug: Lomustine	Overall Survival|Progression Free Survival|Event Free Survival|Overall Response Rate|Safety of the Recommended Phase 2 Dose of Berubicin|Plasma Pharmacokinetics Cmax|Plasma Pharmacokinetics tmax|Plasma Pharmacokinetics AUC0-tau|Plasma Pharmacokinetics AUC0-last|Plasma Pharmacokinetics AUC0-∞|Plasma Pharmacokinetics t1/2|Plasma Pharmacokinetics CL|Plasma Pharmacokinetics Vz|Plasma Pharmacokinetics Css|Plasma Pharmacokinetics Rac	"CNS Pharmaceuticals, Inc.|Worldwide Clinical Trials"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	210	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CNS-201	18-May-21	Oct-24	Feb-25	21-Feb-21		9-Dec-21	"Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|University of California Irvine, Orange, California, United States|University of Califonia San Diego Moores Cancer Center, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States|HCA Healthcare Research Institute, Englewood, Colorado, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Rush University Cancer Center, Chicago, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Tulane Cancer Center Clinic, New Orleans, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Rutgers University, Piscataway, New Jersey, United States|Atlantic Healthcare, Summit, New Jersey, United States|Roswell Park Cancer Center, Buffalo, New York, United States|Weill Cornell, New York, New York, United States|Duke University School of Medicine, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Austin Cancer Center, Austin, Texas, United States|Texas Oncology PA, Austin, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|Huntsman Cancer Center, Salt Lake City, Utah, United States|Swedish Medical Center, Seattle, Washington, United States|University Hospital Zurich, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT04762069
96	NCT02613988	Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas		Recruiting	No Results Available	Adult Glioblastoma	Device: 3 Tesla magnetic resonance imaging|Device: Chemical exchange saturation transfer MRI|Device: Diffusion weighted MRI|Device: Dynamic susceptibility contrast MRI	Diagnostic Performance of Response Rate|Progression Free Survival (PFS)|Quantitative changes to tumor protein content and tumor acidosis|Quantitative changes to tumor cellularity|Quantitative changes to tumor perfusion using dynamic susceptibility contrast MRI|Quantitative changes to tumor perfusion using dynamic contrast enhancement MRI	Asan Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AsanMCHSKim_01	12-Jan-20	Dec-21	Dec-21	25-Nov-15		9-Jul-20	"Asan Medical Center, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT02613988
97	NCT02715297	Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma	GlioCave/NOA17	Recruiting	No Results Available	Glioblastoma	Radiation: SRT to the resection cavity	Progression free survival (PFS) at 12 months|Overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Quality of Life questionnaire|Neurocognitive function	Technische Universität München|Helmholtz Zentrum München	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2	162	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RadOnc MRI TUM - 1	Feb-16	Feb-23	Feb-23	22-Mar-16		10-Mar-20	"Dept. Radiation Oncology, Munich, Bavaria, Germany"		https://ClinicalTrials.gov/show/NCT02715297
98	NCT03743662	Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma		Recruiting	No Results Available	Glioblastoma	Radiation: Re-irradiation (RT)|Drug: Bevacizumab|Drug: Nivolumab|Procedure: Re-resection	Overall survival|6 month progression-free survival|Median progression-free survival|Objective response rate	Memorial Sloan Kettering Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	94	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-400	12-Nov-18	Nov-22	Nov-22	16-Nov-18		17-Dec-21	"Hartford Healthcare (Data Collection), Hartford, Connecticut, United States|Miami Cancer Institute Baptist Health South Florida (Data Collection Only), Miami, Florida, United States|Indiana University (Data Collection Only), Indianapolis, Indiana, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Lehigh Valley Health Network (Data Collection Only), Allentown, Pennsylvania, United States|University of Vermont Medical Center (Data Collection Only), Burlington, Vermont, United States"		https://ClinicalTrials.gov/show/NCT03743662
99	NCT04596930	MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma	EMITT	Recruiting	No Results Available	Glioblastoma	Procedure: Laser ablation thermal therapy	"Inclusion rate of patients meeting the inclusion criteria|Number drop out (informed consent)|Number of patients with completed follow-up at 3 months|30-days mortality|Number of patients with complications|Time from inclusion to procedure|Time from LITT to adjuvant therapy|Ablation of 90 percent of the target lesion in at least 70 percent of patients|Overall survival and progression free survival|Euro quality of life-5D (from 11111, best outcome to 55555 worse outcome)|European Organisation for Research and Treatment of Cancer - BN20 brain module|Tumor volume evolution"	Radboud University	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL73896.091.20	22-Jan-21	15-Sep-21	31-Dec-21	22-Oct-20		14-Sep-21	"Radboud UMC, Nijmegen, Netherlands"		https://ClinicalTrials.gov/show/NCT04596930
100	NCT04863950	Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma	Drug: Lomustine|Drug: Imipramine Hydrochloride	Progression Free Survival	The University of Texas Health Science Center at San Antonio	All	"Child, Adult, Older Adult"	Phase 2	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS# 20-0148	Feb-22	Sep-23	Sep-24	28-Apr-21		27-Dec-21			https://ClinicalTrials.gov/show/NCT04863950
101	NCT04530006	Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma		Recruiting	No Results Available	Glioblastoma Multiforme	Diagnostic Test: Amantadine Hydrochloride	Blood and Urine Acetyl-Amantadine levels in patients with GBM|GBM tumor volume in correlation with serum and urine acetyl-amantadine levels in patients with GBM	CancerCare Manitoba|University of Manitoba|The Metabolomics Innovation Centre|BioMark Diagnostics Inc.|Canadian Institutes of Health Research (CIHR)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	50604	2-Dec-20	Aug-21	Aug-24	28-Aug-20		15-Feb-21	"CancerCare Manitoba, Winnipeg, Manitoba, Canada"		https://ClinicalTrials.gov/show/NCT04530006
102	NCT01873469	Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Radiation: Radiochemotherapy	Time to recurrence as function of [11C]MET uptake before postoperative radiochemotherapy|overall survival	Technische Universität Dresden	All	"18 Years and older   (Adult, Older Adult)"		102	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	STR-PETra-2013	Jul-13	Oct-17	Oct-18	10-Jun-13		18-Feb-19	"Dresden University of Technology, University Hospital Carl Gustav Carus, Department of Radiation Oncology; and DKTK partner site Dresden, Dresden, Saxony, Germany"		https://ClinicalTrials.gov/show/NCT01873469
103	NCT04922723	Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma	PRIDE	Not yet recruiting	No Results Available	Glioblastoma	Drug: Daratumumab	Dose Limiting Toxicity (DLT) rate of Daratumumab|Phase II - Median overall survival of newly diagnosed GBM patients|Phase I - Median overall survival of newly diagnosed GBM patients|Phase I - Evaluate the Progression-Free Survival (PFS)|Phase I - Assess the treatment-emergent adverse events|Phase I - Estimate the tumor response rate|Phase II - Evaluate the Progression-Free Survival (PFS)|Phase II - Assess the treatment-emergent adverse events|Phase II - Estimate the tumor response rate	West Virginia University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WVU010320|IND# Pending	Aug-21	Aug-23	Aug-24	11-Jun-21		30-Jun-21	"West Virginia University Cancer Institute Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States"		https://ClinicalTrials.gov/show/NCT04922723
104	NCT01189513	SCH-900105 in Recurrent Glioblastoma		Withdrawn	No Results Available	Glioblastoma	Drug: SCH 900105	Maximum Tolerated Dose (MTD)	M.D. Anderson Cancer Center|Schering-Plough	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0576	Aug-10	Jan-11	Jan-11	26-Aug-10		20-Feb-12			https://ClinicalTrials.gov/show/NCT01189513
105	NCT04691960	A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging		Recruiting	No Results Available	Glioblastoma	Other: Ketogenic Diet|Drug: Metformin	Ability to achieve and maintain ketosis|Tolerability of metformin	Weill Medical College of Cornell University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1604017166	Aug-16	Dec-24	Dec-24	31-Dec-20		22-Dec-21	"Columbia University, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT04691960
106	NCT04708171	The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections	PROGRAM	Not yet recruiting	No Results Available	Glioblastoma	Procedure: Awake mapping under local anesthesia|Procedure: Asleep mapping under general anesthesia|Procedure: Resection under general anesthesia without mapping	Neurological morbidity|Extent of resection|Progression-free survival|Overall survival|Onco-functional outcome|Frequency and severity of Serious Adverse Events (SAEs)|Residual tumor volume|MRC deterioration (for motor gliomas)	"Erasmus Medical Center|Medical Center Haaglanden|Universitaire Ziekenhuizen Leuven|University of California, San Francisco"	All	"18 Years to 90 Years   (Adult, Older Adult)"		453	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	MEC-2020-081-2	1-Feb-21	1-Oct-25	1-Oct-26	13-Jan-21		13-Jan-21	"University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium|Erasmus MC, Rotterdam, Zuid-Holland, Netherlands|Medical Center Haaglanden, The Hague, Zuid-Holland, Netherlands"		https://ClinicalTrials.gov/show/NCT04708171
107	NCT04516733	Precoce Medical Care by the Mobil Support for Patients With Glioblastoma	GLIOSUPPORT	"Active, not recruiting"	No Results Available	Glioblastoma	Other: supportive care	"Assess the feasibility in terms of compliance with early medical care in glioblastoma patients by palliative care unit.|The recruitment rate (proportion of patients giving consent to participate in the study among eligible patients during screening)|Proportion of patients completing all quality of life assessments (QLQ-C30 (Quality Life Questionnaire) at palliative care unit visits (Ve1, Ve2 and Ve3)|Proportion of patients completing all BN20 assessments (Brain Cancer Module) at palliative care unit visits (Ve1, Ve2 and Ve3)|Proportion of patients completing all anxiety assessments (HADS, Hospital Anxiety and Depression Scale) at palliative care unit visits (Ve1, Ve2 and Ve3)|Changes over time in patients' quality of life|The evolution over time of anxiety and depressive affects in patients|The evolution over time of neurocognitive performance in patients and the delay before neurocognitive degradation (Mattis DRS scale);|Rate of patients who have written advance directives since the diagnostic announcement;|Rate of patients who have designated a support person since the diagnostic announcement|proportion of patients receiving specific medical oncology treatment in their last month of life|Overall survival|The proportion of patients diagnosed with glioblastoma that are available for this medical care"	Institut du Cancer de Montpellier - Val d'Aurelle	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	35	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	PROICM 2018-04 GLI	10-May-19	15-Sep-20	Oct-21	18-Aug-20		1-Mar-21	"ICM Val d'Aurelle, Montpellier, France"		https://ClinicalTrials.gov/show/NCT04516733
108	NCT01310868	Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma		Completed	Has Results	Glioblastoma	Drug: 5-ALA|Drug: Gliadel wafers|Radiation: Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Drug: Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Drug: Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist	"Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide|Time to Clinical Progression|Survival at 24 Months"	"University College, London"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	59	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000696316|CRUK-UCL-09-0398|2010-022496-66|09/0398|10/H0304/100	May-11	Mar-15	Mar-15	9-Mar-11	14-Aug-17	5-Oct-17	"Addenbrooke's Hospital, Cambridge, England, United Kingdom|Royal Preston Hospital, Preston, Lancashire, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Southern General Hospital, Glasgow, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|The Walton Centre, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|University College London Hospital/ National Hospital for Neurology and Neurosurgery, London, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom"		https://ClinicalTrials.gov/show/NCT01310868
109	NCT04881032	AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma	NANO-GBM	Recruiting	No Results Available	Glioblastoma	Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|Radiation: radiotherapy|Drug: Temozolomide	The recommended dose (phase I) of AGuIX in combination with TMZ and and radiotherapy during the radio-chemotherapy period|6-month Progression Free Survival (PFS) rate (phase II)|Pharmacokinetic Cmax of AGuIX|Pharmacokinetic Tmax of AGuIX|Pharmacokinetic AUC of AGuIX|Pharmacokinetic t1/2 of AGuIX|distribution of AGuIX|Overall Survival|Progression Free Survival (PFS)|Toxicity (CTCAE criteria)	"Centre Jean Perrin|Ministry for Health and Solidarity, France"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	66	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-004552-15	Dec-21	May-24	Nov-25	11-May-21		13-Dec-21	"CHU de Brest, Brest, France|Centre Jean Perrin, Clermont-Ferrand, France|CHU de Grenoble, Grenoble, France|Centre Léon Berard, Lyon, France|Institut de Cancérologie de l'Ouest, Saint Herblain, France|Institut de Cancérologie Strasbourg Europe, Strasbourg, France"		https://ClinicalTrials.gov/show/NCT04881032
110	NCT04829097	Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma		Recruiting	No Results Available	Glioblastoma	Combination Product: Temozolomide	Objective response rate	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-307-02	1-Nov-20	1-Nov-23	1-Nov-23	2-Apr-21		2-Apr-21	"The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China"		https://ClinicalTrials.gov/show/NCT04829097
111	NCT04977375	Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: Pembrolizumab|Radiation: Stereotactic Radiation Therapy|Procedure: Surgical Resection	"Safety and tolerability measured by the incidence of adverse events, serious adverse events and grade 3 or above treatment related adverse events.|Overall survival|Progression free survival|Immune action"	Chirag G. Patil|Merck Sharp & Dohme Corp.|Cedars-Sinai Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT2019-13-Patil-NeoPD1SRS	Jul-21	Jul-23	Jul-24	26-Jul-21		26-Jul-21	"Cedars-Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT04977375
112	NCT01737346	Procarbazine and Lomustine in Recurrent Glioblastoma		Unknown status	No Results Available	Recurrent Glioblastoma Multiforme	Drug: lomustine and procarbazine	6-month progression free survival	"Incheon St.Mary's Hospital|National Cancer Center, Korea"	All	"20 Years and older   (Adult, Older Adult)"	Phase 2	52	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KNOG-1201	Oct-12	Sep-13	Apr-14	29-Nov-12		3-Dec-12	"Ajou University Hospital, Wonchon-dong, Suwon, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT01737346
113	NCT01349036	A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma		Terminated	Has Results	Recurrent Glioblastoma	Drug: PLX3397	Summary of Response Rates in Participants on Treatment With PLX3397|Mean Plasma Pharmacokinetic Parameters of PLX3397 After Oral Administration of 1000 mg/Day - Cycle 1 Day 15|Incidence (Number and Percentage of Participants) With Treatment-Emergent Adverse Events Related to Study Drug Occurring in ≥10% Participants During Treatment With PLX3397 (Safety Population)	"Daiichi Sankyo, Inc.|Plexxikon"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	38	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PLX108-04	3-Dec-11	5-Nov-13	5-Nov-13	6-May-11	9-Jan-20	3-Mar-20	"University California, Los Angeles, Los Angeles, California, United States|University California, San Francisco, San Francisco, California, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT01349036
114	NCT02092038	Preoperative Chemoradiation for Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Temozolomide|Radiation: partial brain irradiation|Procedure: stereotactic biopsy of brain tumor|Procedure: craniotomy and tumor resection	toxicity of treatment per Common Toxicity Criteria for Adverse Effects V3.0|Feasibility of measurement of O(6)-Methylguanine-DNA methyltransferase (MGMT) activity on stereotactic samples|progression free survival|overall survival	Tampa General Hospital	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TGH0001	Nov-14	Jul-15	Jul-15	19-Mar-14		10-Nov-15	"Tampa General Hospital, Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT02092038
115	NCT04801147	Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme	DENDR1	Recruiting	No Results Available	Glioblastoma	Biological: Dendritic Cells Vaccine	Percentage of Participants With Progression Free Survival|Incidence of Treatment-related Adverse Events|Evaluation of the treatment effect on the immune response	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	76	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DENDR1	Jun-10	Dec-23	Dec-23	16-Mar-21		16-Mar-21	"UOC Neuro-oncologia Molecolare, Milano, Italy"		https://ClinicalTrials.gov/show/NCT04801147
116	NCT04933422	CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)		Not yet recruiting	No Results Available	Glioblastoma	Drug: CM93	Dose-limiting toxicities|Maximum tolerated dose|Recommended phase 2 dose|Concentration of CM93 in non-enhancing areas of tumor|Half-life of CM93|Maximum plasma concentration (Cmax)|Time to Maximum plasma concentration (Tmax)|Area under the curve (AUC)|EGFR level in tumor specimens	Crimson Biopharm Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	72	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CM93-101	Aug-21	Jul-23	Jul-24	21-Jun-21		21-Jun-21			https://ClinicalTrials.gov/show/NCT04933422
117	NCT01100177	Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients		Completed	No Results Available	Glioblastoma	Drug: Sunitinib|Radiation: Radiation	Objective response rate to Sunitinib therapy|Safety of Sunitinib with Radiation therapy|Assess the number of patients without neurological deterioration before radiation|Evaluation of progression free survival|Overall survival	Grupo Español de Investigación en Neurooncología	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	12	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GENOM-008	Jun-09	Dec-11	Jan-12	8-Apr-10		11-Mar-13	"Grupo Español de Investigacion en Neurooncologia, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT01100177
118	NCT04642937	Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Treatment with hP1A8	Maximum tolerated dose (MTD) of hP1A8 when administered with imiquimod and GBM6-AD|Incidence of serious adverse events (SAEs)|Time to progression (TTP)|Progression free survival (PFS)|Overall survival (OS)	OX2 Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRPC #2017LS096	1-Dec-20	Nov-22	Nov-23	24-Nov-20		1-Oct-21	"University of Minnesota, Minneapolis, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT04642937
119	NCT04280848	Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma	UCPVax-Glio	"Active, not recruiting"	No Results Available	Glioblastoma	Drug: UCPVax	Immunogenicity	Centre Hospitalier Universitaire de Besancon	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	28	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N/2013/67	26-May-20	Dec-21	Jul-23	21-Feb-20		17-Dec-21	"CHU Besançon, Besançon, France|CHU Bordeaux, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Hôpital Saint-Louis, Paris, France"		https://ClinicalTrials.gov/show/NCT04280848
120	NCT03223103	Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Poly-ICLC|Device: Tumor Treating Fields|Biological: Peptides	Dose-limiting toxicities (DLT)|Toxicity grading using CTCAE scale|The percent Progression Free Survival (PFS)|Overall Survival (OS) Rate|Overall Response Rate	Adilia Hormigo|NovoCure Ltd.|Icahn School of Medicine at Mount Sinai	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	13	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 17-0566|16-089	1-Mar-18	31-Jul-20	May-23	19-Jul-17		8-Jul-21	"Icahn School of Medicine at Mount Sinai, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03223103
121	NCT04552886	Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma		Recruiting	No Results Available	Glioblastoma	Biological: TH-1 Dendritic Cell Immunotherapy	Safety and potential toxicity of Th-1 dendritic cell immunotherapy|Overall survival of patients receiving Th-1 dendritic cell immunotherapy|Progression-free survival of patients receiving Th-1 dendritic cell immunotherapy	The Cooper Health System|Baylor College of Medicine|Philadelphia College of Osteopathic Medicine	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8148	11-Oct-21	31-Dec-22	31-Dec-25	17-Sep-20		8-Oct-21	"Cooper University Hospital, Camden, New Jersey, United States"		https://ClinicalTrials.gov/show/NCT04552886
122	NCT03055208	Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma	Gamma-GBM	"Active, not recruiting"	No Results Available	Glioblastoma	Radiation: gamma knife radiosurgery (15 Gy to 50% isodose)	Median Progression-Free Survival Time (PFS)|Median Overall Survival Time (OS)|Radiation-related (acute / early delayed / late) neurotoxicity|Incidence of symptomatic radionecrosis	Universitätsmedizin Mannheim	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Gamma-GBM	8-Feb-17	30-Mar-20	Sep-21	16-Feb-17		28-Apr-21	"Department of Radiotherapy University Hospital Mannheim, Mannheim, Germany"		https://ClinicalTrials.gov/show/NCT03055208
123	NCT04219475	Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients	PROPHETIC	Suspended	No Results Available	Glioblastoma		Response to treatment|Blood levels of proteins|OS|PFS	OncoHost Ltd.	All	"18 Years and older   (Adult, Older Adult)"		1000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	OH-GBMHR	Jan-22	Dec-25	Dec-25	7-Jan-20		16-Sep-21	"Rambam medical center, Haifa, Israel|Rabin medical center, Petah tikva, Israel|Sourasky medical center, Tel Aviv, Israel|Sheba medical center, Tel HaShomer, Israel"		https://ClinicalTrials.gov/show/NCT04219475
124	NCT02157103	A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily	Number of Participants With Change in Peritumoral Enhancement/Edema|Number of Toxicities Reported in Study Participants|Number of Participants With Change in Edema After Conversion From Study Treatment to Intravenous Bevacizumab	Emory University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	3	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00062998|Winship2299-12	Jan-14	Nov-16	Jan-18	5-Jun-14	13-Apr-18	17-May-18	"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Winship Cancer Institutute, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT02157103
125	NCT01622764	89Zr-RO5323441 PET Imaging in Glioblastoma		Withdrawn	No Results Available	Glioblastoma	Radiation: Molecular imaging with 89Zr-RO5323441	Assess the penetration of RO5323441 into recurrent GBM by 89Zr-RO5323441 PET imaging and to quantify its uptake|Visualize and quantify 89Zr-RO5323441 non-tumor organ distribution|Assess the effect of bevacizumab treatment on 89Zr-RO5323441 uptake in recurrent GBM lesions	University Medical Center Groningen	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)	BP28015|2011-004974-27	Sep-14	Sep-15	Sep-16	19-Jun-12		28-Mar-14	"University Medical Center Groningen, Groningen, Netherlands"		https://ClinicalTrials.gov/show/NCT01622764
126	NCT04547855	Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen		Recruiting	No Results Available	Glioblastoma	Drug: anlotinib combined with dose-dense temozolomide	6 months Objective Response Rates|6 months Progression-Free Survival Rates|Progress-free survival (PFS)|overall survival|Toxic side effects	Yonggao Mou|The First Affiliated Hospital of Nanchang University|Sun Yat-sen University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	54	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Qun-Ying YANG	11-Sep-20	11-Sep-22	11-Mar-23	14-Sep-20		14-Sep-20	"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT04547855
127	NCT04225039	"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma"		Recruiting	No Results Available	Glioblastoma	Drug: INCMGA00012|Drug: INCAGN01876|Drug: SRS|Procedure: Brain surgery	Objective radiographic response (ORR)|Incidence of Treatment-Emergent Adverse Events as assessed by NCI CTCAE v 5.0|Overall survival|Progression Free Survival	University of Pennsylvania|Incyte Corporation	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	834197	23-Jun-20	Jun-25	Jun-25	13-Jan-20		5-Feb-21	"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04225039
128	NCT04421378	A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Selinexor|Drug: Temozolomide (TMZ)|Drug: Lomustine (CCNU)|Radiation: Standard Fractionated Radiation therapy (RT)|Drug: Bevacizumab|Device: TTField|Drug: Carmustine	"Phase 1a: Maximum Tolerated Dose Per Arm: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0|Phase 1a: Recommended Phase 2 Dose Per Arm|Phase 1a: Number of Participants with Adverse Events (AEs) with Grade Greater Than or Equal to (>=) 3, Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation|Phase 1b: Progressive Free Survival at 3 Months for All Arms|Phase 1b: Overall Survival (OS) for All Arms|Phase 2: Progression-free Survival (PFS) in Arms A and B|Phase 2: Overall Survival (OS) for Arm C|Phase 1a: Overall Survival (OS) for Each Arm|Phase 1a/1b: Time to Progression (TTP) for Each Arm|Phase 1a/1b: Progressive Free Survival (PFS) for Each Arm|Phase 1a/1b: Overall Response Rate (ORR) Based on Modified Response Assessment in Neuro-Oncology (RANO) Criteria in Arm C, D and E|Phase 1a/1b: Disease Control Rate (DCR) Based on Modified Response Assessment in Neuro-Oncology Criteria in Arm C, D and E|Phase 1a/1b: Duration of Response (DOR) in Arm C, D and E|Phase 1a/1b: Maximum Plasma Concentration (Cmax) of Selinexor|Phase 1a/1b: Area Under the Concentration-time Curve (AUC) of Selinexor|Phase 1a/1b: Apparent Clearance (CL) of Selinexor|Phase 1b: Number of Participants with Adverse Events (AEs) with Grade Greater Than or Equal to (>=) 3, Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation|Phase 1b: Maximum Tolerated Dose|Phase 1b: Recommended Phase 2 Dose|Phase 2: Progression Free Survival Per (PFS) as Assessed by Investigator per Modified Response Assessment in Neuro-Oncology Criteria in Arms A and B|Phase 2: Overall Survival for Participants With Newly Diagnosed Glioblastoma Multiforme in Arms A and B|Phase 2: Progression Free Survival (PFS) as Assessed by Independent Review Committee (IRC) per Modified Response Assessment in Neuro-Oncology Criteria in Arm C|Phase 2: Progression Free Survival (PFS) as Assessed by Investigator per Modified Response Assessment in Neuro-Oncology Criteria in Arm C|Phase 2: Overall Response Rate (ORR) as Assessed by IRC in Arm C|Phase 2: Overall Response Rate (ORR) as Assessed by Investigator in Arm C|Phase 2: Disease Control Rate (DCR) as Assessed by IRC in Arm C(TEAEs) by Severity Grade ≥3, Serious Adverse event (SAEs), and AEs Leading to Treatment Discontinuation|Phase 2: Disease Control Rate (DCR) as Assessed by Investigator in Arm C|Phase 2: Duration of Response (DOR) as Assessed by IRC in Arm C|Phase 2: Duration of Response (DOR) as Assessed by Investigator in Arm C|Phase 2: Progression Free Survival at 6 Months (PFS6) as Assessed by IRC in all Arms|Phase 2: Progression Free Survival at 6 Months (PFS6) as Assessed by Investigator in all Arms|Phase 2: Overall Survival Rate at 12 and 24 Months in all Arms|Phase 2: Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) by Grade >=3, Serious Adverse event (SAEs), and AEs Leading to Treatment Discontinuation"	Karyopharm Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	474	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XPORT-GBM-029|2021-000080-67	8-Jun-20	Jan-23	Jan-23	9-Jun-20		18-Nov-21	"University of Alabama, Birmingham, Alabama, United States|University of Southern California (USC Norris Comprehensive Cancer Center and LAC+USC Medical Center), Los Angeles, California, United States|University of California, San Francisco, California, United States|Baptist Hospital of Miami Cancer Institute, 8900 North Kendall Drive, Miami, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack Meridian Health, 92 Second Street, Hackensack, New Jersey, United States|Atlantic Health Systems Hospital Corp., Morristown, New Jersey, United States|Northwell Health, Lake Success, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Lenox Hill Hospital-Northwell Health, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington - Alvord Brain Tumor Center, Seattle, Washington, United States|Princess Margaret Hospital (PMH), Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT04421378
129	NCT04574856	Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma	Radiation: Dose-Intensified Radiotherapy|Drug: Temozolomide|Drug: Adjuvant temozolomide	12-month overall survival rate|Overall survival|Progression-free survival rate|Proportion of failures classified by relation to the high-dose radiation region|Advanced MRI Gross tumor volume (GTV) and its association with overall survival|Patient-reported quality of life (QOL) using EORTC QLQ-C30 and BN20|Patient-reported symptom burden using MDASI-BT|Patient objective neurocognitive function|Grade 3 or higher treatment-related toxicities	University of Michigan Rogel Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2020.033|HUM00179427	4-Nov-20	Jan-24	Jan-24	5-Oct-20		17-Dec-21	"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States"		https://ClinicalTrials.gov/show/NCT04574856
130	NCT04573192	A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression	GLIOSTAR	Not yet recruiting	No Results Available	Glioblastoma	Drug: L19TNF|Drug: Lomustine	For Phase 1: DLT|For Phase 2: Overall Survival|PFS|PFS-rate at 6 months|OS-rate at 12 months|Adverse Events (AE)|Serious Adverse Events (AE)|Safety (DILI)	Philogen S.p.A.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	142	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PH-L19TNFCCNU-02/20	Nov-20	Nov-23	Dec-25	5-Oct-20		5-Oct-20	"Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT04573192
131	NCT04119674	Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma		Unknown status	No Results Available	Glioblastoma	Biological: Anlotinib|Drug: Temozolomide Capsule	PFS|OS|adverse event|Health-related quality of life|Neurocognitive function	Zhejiang Cancer Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM-AS	15-Jan-19	Jun-20	May-21	8-Oct-19		8-Oct-19	"Zhejiang cancer hospital, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04119674
132	NCT01493219	Biomarkers for Prognosis of Glioblastoma (GBM)		Completed	No Results Available	Glioblastoma		1) To provide preliminary evidence that MMP-2 and MMP-9/NGAL ratio in tissue corresponds with their presence in the urine and blood in patients undergoing surgery for epilepsy (Aim 1a) and in patients with grade IV glioma (Aim 1b)	University of Nebraska	All	"19 Years and older   (Adult, Older Adult)"		19	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	369-11	Sep-11	Sep-17	Sep-17	15-Dec-11		31-Jan-18	"University of Nebraska Medical Center, Omaha, Nebraska, United States"		https://ClinicalTrials.gov/show/NCT01493219
133	NCT04019262	Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma	Radiation: Radiation Therapy|Drug: Temozolomide Oral Product	Overall survival (OS)|Change in Absolute Lymphocyte Count|Progression free survival (PFS)	John Flickinger|University of Pittsburgh	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCC 19-022	May-21	30-Dec-23	30-Dec-28	15-Jul-19		27-Apr-21	"University of Pittsburgh Medical Center, Radiation Oncology, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04019262
134	NCT03374943	A Trial of KB004 in Patients With Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: KB004	Number of Participants With KB004 Treatment-Related Adverse Events as Assessed using CTCAE v4.0. To determine the maximum tolerated dose (MTD).|Biodistribution of 89Zr-KB004|Response rates following KB004 infusion|Plasma concentration versus time (Serum half life) of 89Zr-KB004|Cmax of 89Zr-KB004	"Olivia Newton-John Cancer Research Institute|Humanigen, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONJ2017-002	5-Dec-17	25-Jan-21	22-Sep-21	15-Dec-17		4-Nov-21	"Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Austin Health, Heidelberg, Victoria, Australia"		https://ClinicalTrials.gov/show/NCT03374943
135	NCT04221061	A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: 18F-FluorThanatrace	"Evaluate uptake of [18F]FTT in recurrent glioblastoma after initiation of TTFields therapy.|Correlate [18F]FTT uptake measures with Homologous recombination deficiency (HRD) status or other markers of ""BRCAness""."	University of Pennsylvania	All	"22 Years and older   (Adult, Older Adult)"	Early Phase 1	12	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	833963	20-Feb-20	2-Dec-21	2-Dec-22	9-Jan-20		12-Feb-21	"University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04221061
136	NCT00792012	A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma		Completed	No Results Available	Glioblastoma Multiforme	Radiation: Hypofractionated Intensity-Modulated Radiation Therapy|Drug: Temozolomide	"To identify the maximum dose per fraction of IMRT a patient can tolerate while keeping the total radiation dose at 60 Gy, provided concurrently with daily oral temozolomide chemotherapy|Progression-free survival"	"University of Colorado, Denver"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	37	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-0562.cc	Nov-05	Jul-16	Jul-16	17-Nov-08		27-Mar-17	"University of Colorado Cancer Center, Aurora, Colorado, United States"		https://ClinicalTrials.gov/show/NCT00792012
137	NCT05120284	Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: Dichloroacetate (DCA)|Genetic: Genotype	The efficacy will be measured between the groups by using the Observer Reported Outcome (ObsRO) measure of health.	University of Florida|Food and Drug Administration (FDA)	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	40	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB202101509|FD-R-007271-01|PRO00034631	Mar-22	Jun-25	Jun-25	15-Nov-21		15-Nov-21	"Johns Hopkins Bayview Med Ctr, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT05120284
138	NCT03770468	"Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma"		Recruiting	No Results Available	Glioblastoma	Procedure: Blood drawl	Overall Survival|Molecular profiling on FFPE samples|Molecular profiling on frozen samples|Proteome profiling	European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"		640	Other	Observational	Observational Model: Other|Time Perspective: Cross-Sectional	EORTC-1419-BTG	5-Jul-15	31-Dec-21	31-Dec-22	10-Dec-18		3-Dec-21	"Dana-Farber Cancer Institute & Harvard Medical School, Boston, Massachusetts, United States|Universitaetsklinikum Wien - AKH uniklinieken, Vienna, Austria|Hopitaux Universitaires Bordet-Erasme, Brussel, Belgium|CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron, France|CHRU de Lille, Lille, France|Hopitaux de Marseille - Hôpital de La Timone (APHM), Marseille, France|Institut du Cancer de Montpellier, Montpellier, France|CHU de Nice - Hopital Pasteur, Nice, France|Hopitaux de Paris - Hopital Saint-Louis, Paris, France|Hopitaux de Paris - La Pitie Salpetriere, Paris, France|CHU d'Amiens - CHU Amiens - Hopital Sud, Salouël, France|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum - Essen, Essen, Germany|Ronellenfitsch Michael, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|UniversitaetsKlinikum Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern, Muenchen, Germany|Technische Universitaet Muenchen - Klinikum Rechts Der Isar, Muenchen, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Hygeia Hospital, Athens, Greece|Azienda Ospedaliera Di Padova - Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Giovanni, Torino, Italy|Amsterdam UMC - locatie VUmc, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Centre Hospitalier Universitaire Vaudois - Lausanne, Lausanne, Switzerland|Univ. Spital Zurich, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT03770468
139	NCT00768911	CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: CT-322|Drug: Temozolomide|Procedure: Radiation Therapy	Evaluate the safety and tolerability of CT-322 administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM|Establish the recommended Phase 2 dose for the QW schedule of CT-322 for use in this combination|To describe the PK of TMZ and its active metabolite (MTIC) when TMZ is administered alone and when it is co-administered with CT-322 to a subset of approximately 12 subjects with newly diagnosed GBM|To describe the peak and trough concentrations of CT-322 when administered alone and when co-administered with TMZ|To evaluate the immunogenicity of CT-322 when administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM|To characterize the plasma biomarker response to CT-322 when administered in combination with standard focal brain RT/TMZ to subjects with newly diagnosed GBM	"Adnexus, A Bristol-Myers Squibb R&D Company"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CT-322.003	Oct-08	Oct-10	Jun-11	8-Oct-08		27-Oct-10	"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|Washington University Cancer Center, St. Louis, Missouri, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00768911
140	NCT03663725	Treatment Intensification With Temozolomide in Adults With a Glioblastoma	StrateGlio	Recruiting	No Results Available	Glioblastoma	Drug: Intensified protocol|Drug: Stupp protocol	Overall Survival (OS)|Number of adverse events|Progression-free survival	Centre Oscar Lambret|Association de Neuro-Oncologues d'Expression Francaise|Erasme University Hospital	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	535	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	StrateGlio-1802|2018-000410-38	13-Mar-19	1-May-22	1-May-23	10-Sep-18		19-Apr-21	"Centre Hospitalier d'Amiens, Amiens, France|ICO Centre Paul Papin, Angers, France|Centre François Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|Centre Georges François Leclerc, Dijon, France|CHU Grenoble Alpes, Grenoble, France|CHU de Limoges, Limoges, France|Centre Léon Bérard, Lyon, France|CHU La Timone, Marseille, France|ICM Val d'Aurelle, Montpellier, France|CHRU Nancy, Nancy, France|ICO Centre René Gauducheau, Nantes, France|CHU de Nice - Hôpital de Cimiez, Nice, France|APHP La Pitié Salpêtrière, Paris, France|CH René Dubos, Pontoise, France|Institut Cancérologie Loire, Saint-Priest-en-Jarez, France|Centre Paul Strauss, Strasbourg, France|CHRU Tours, Tours, France"		https://ClinicalTrials.gov/show/NCT03663725
141	NCT01830101	A Phase III Study of Re-Irradiation in Recurrent Glioblastoma		Withdrawn	No Results Available	Recurrent Glioblastoma	Drug: TMZ plus concurrent re-irradiation|Drug: Temozolomide	To determine the overall median survival of the combination of continuous dose-intense temozolomide with or without re-irradiation in patients with recurrent glioblastoma.|To evaluate time to radiographic progression or recurrence of tumour following treatment with continuous dose-intense temozolomide with or without re-irradiation.	AHS Cancer Control Alberta	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCI-Patel-01	Feb-14	May-15	Nov-17	12-Apr-13		16-Mar-16	"Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT01830101
142	NCT03926507	F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery		Unknown status	No Results Available	Glioblastoma	Procedure: Computed Tomography|Other: Fluciclovine F18|Procedure: Positron Emission Tomography	Tumor volume|Changes in F18 fluciclovine defined disease with surgery and radiation|Post-radiation enhancing brain tissue	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	25	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2018-0869|NCI-2019-01532|P30CA016672	30-Apr-19	15-Feb-20	15-Feb-20	24-Apr-19		27-Nov-19	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03926507
143	NCT01006044	Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection		Completed	No Results Available	Glioblastoma Multiforme	Biological: autologous dendritic cells	Evaluation of the treatment impact on progression-free survival|Safety evaluation|Evaluation of impact on other efficiency clinical parameters|Study of specific immune response and correlates with clinical outcome|Cell line characterization and correlate the final product with clinical efficacy	"Clinica Universidad de Navarra, Universidad de Navarra"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	26	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DEND/GM|2009-009879-35	Oct-09	Aug-14	Aug-14	1-Nov-09		3-Sep-14	"Clínica Universidad de Navarra, Pamplona, Spain"		https://ClinicalTrials.gov/show/NCT01006044
144	NCT04015700	"Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma"		Recruiting	No Results Available	Glioblastoma	Biological: Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|Device: CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|Drug: Plasmid encoded IL-12	"Safety and tolerability of a personalized neoantigen DNA vaccine as measured by dose-limiting toxicities (DLTs)|Feasibility of generating a personalized neoantigen DNA vaccine for patients with newly diagnosed, unmethylated GBM as measured by the ability to identify candidate tumor-specific neoantigens|Feasibility of generating a personalized neoantigen DNA vaccine for patients with newly diagnosed, unmethylated GBM as measured by the ability to manufacture a neoantigen-based DNA vaccine|Feasibility of generating a personalized neoantigen DNA vaccine for patients with newly diagnosed, unmethylated GBM as measured by the ability to administer the vaccine to a patient|Immunogenicity of a personalized neoantigen DNA vaccine as measured by the ability to generate a measurable neoantigen-specific CD8 T cell response in vaccinated patients|Immunogenicity of a personalized neoantigen DNA vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable CD8 T cell-specific response is identified|Number of high quality candidates neoantigens present in patients with newly diagnosed GBM|Progression-free survival (PFS) rate|Overall survival rate|Immunogenicity of a personalized neoantigen DNA vaccine as measured by T-cell phenotype, myeloid derived suppressor cell frequency by flow cytometry|Immunogenicity of a personalized neoantigen DNA vaccine as measured by diversity of clonality from T cell receptor sequencing|Immunogenicity of a personalized neoantigen DNA vaccine as measured by putative antigen specificity from T cell receptor sequencing"	Washington University School of Medicine|Geneos Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202003072	14-Jul-20	31-Aug-22	31-Jul-23	11-Jul-19		3-Aug-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT04015700
145	NCT01269424	BG & TMZ Therapy of Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Biological: MGMTP140K-encoding retroviral vector|Drug: O6-benzylguanine|Drug: temozolomide|Other: laboratory biomarker analysis|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: radiation therapy	Feasibility and safety of infusing autologous P140K MGMT-transduced hematopoietic progenitors into patients with GBM|Successful transduction rate|To evaluate the in vivo enrichment of P140K expressing hematopoietic cells by repeated treatments of BG and TMZ|Progression-free|Number of patients with radiological progression|Overall Survival	Stanton Gerson MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	10	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE6307|8274|U01CA062502	22-Nov-11	7-Dec-20	Mar-22	4-Jan-11		22-Dec-21	"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01269424
146	NCT03643549	Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17)	BORTEM-17	Recruiting	No Results Available	Glioblastoma	Drug: Bortezomib and Temozolomide Phase IB|Drug: Bortezomib and Temozolomide Phase II	Bortezomib-Temozolomide Maximum tolerated dose|Overall survival|Progression free survival|Time to progression|Biomarkers of treatment response|Tumour responses|Clinical response|Toxicity assessment	Haukeland University Hospital|Oslo University Hospital|St. Olavs Hospital|University Hospital of North Norway|University of Bergen|University of Bonn|University of Oslo	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	63	Other	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017/2084	30-Aug-18	31-Dec-22	30-Aug-23	22-Aug-18		27-Aug-21	"Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway"		https://ClinicalTrials.gov/show/NCT03643549
147	NCT04006119	Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma		Completed	No Results Available	Glioblastoma	Biological: Ad-RTS-hIL-12|Drug: Veledimex|Drug: Cemiplimab-Rwlc	"Safety of intratumoral Ad-RTS-hIL-12 and oral veledimex in combination with cemiplimab-rwlc in subjects with recurrent or progressive glioblastoma.|Efficacy of intratumoral Ad-RTS-hIL-12 and oral veledimex in combination with cemiplimab-rwlc in subjects with recurrent or progressive glioblastoma.|To determine the survival rates at 6, 12, 18 and 24 months|To determine the progression free survival (PFS)|To determine the rate of pseudoprogression (PSP) at 6, 12, 18 and 24 months|To determine the Investigator's assessment of response, including tumor objective response rate (ORR) at 6, 12, 18 and 24 months|To determine the tumor response rates at 6, 12, 18 and 24 months|Changes from baseline in cellular responses elicited by Ad-RTS-hIL-12 and veledimex in combination with cemiplimab-rwlc|Changes from baseline in humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex in combination with cemiplimab-rwlc"	Ziopharm	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATI001-204	1-Aug-19	5-Aug-21	5-Aug-21	2-Jul-19		11-Nov-21	"Cedars Sinai, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Brigham and Women's, Boston, Massachusetts, United States|JFK Medical Center, Edison, New Jersey, United States|NYU Langone Health, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT04006119
148	NCT02981940	A Study of Abemaciclib in Recurrent Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: Abemaciclib|Procedure: Surgery	Intratumoral abemaciclib concentration|6-Month Progression Free Survival (PFS6)|pRB expression level of tumor tissue|Incidence of Treatment-Emergent Adverse Events|Area under the plasma concentration versus time curve (AUC)|Peak Plasma Concentration (Cmax)|Radiographic Response Rate|Median Progression Free Survival|Overall Survival	Dana-Farber Cancer Institute|Eli Lilly and Company	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	42	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-383	9-Feb-17	Jun-22	Jun-24	5-Dec-16		2-Aug-21	"University of California Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UT, M.D. Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT02981940
149	NCT03149003	A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy		Recruiting	No Results Available	Glioblastoma	Drug: DSP-7888 Dosing Emulsion|Drug: Bevacizumab	Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)|Overall Survival|Twelve-month Survival|Progression Free Survival|Six-month Progression Free Survival|Response Rate|Duration of Response|Number of Patients with Adverse Events	"Sumitomo Dainippon Pharma Oncology, Inc"	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	338	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BBI-DSP7888-201G	8-Dec-17	Sep-22	Nov-23	11-May-17		3-Nov-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Center for Neurosciences, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|UCSD- Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Neuro-Oncology/ US Irvine Medical Center, Orange, California, United States|Sansum Clinic, Santa Barbara, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Piedmont brain tumor center, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky / Department of Internal Medicine / Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tufts Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Dent Neurosciences Research Center, Amherst, New York, United States|Weill Cornell Medicine, New York, New York, United States|Columbia University Medical Center/ Neurological Institute of NY, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University OF Tennessee Academic Medical Center Cancer Institute, Knoxville, Tennessee, United States|Texas Oncology Austin Midtown, Austin, Texas, United States|Baylor Scott and White, Dallas, Texas, United States|Houston Methodist, Houston, Texas, United States|Mischer Neuroscience Associates/Memorial Hermann Hospital, Houston, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital, Madison, Wisconsin, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|University of Sherbrooke, Sherbrooke, Quebec, Canada|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kagoshima University Hospital, Kagoshima-shi, Kagoshima, Japan|Niigata University Medical and Dental Hospital, Chuo Ku, Niigata, Japan|Osaka International Cancer Institute, Otemae Chuo-ku, Osaka, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|National Hospital Organization Kyoto Medical Center, Kyoto, Japan|Tokyo Women's Medical University Hospital, Shinjuku-Ku, Japan|Yamagata University Hospital, Yamagata, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gangnam Severance Hospital, Gangnam-gu, Seoul, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-gu, Seoul, Korea, Republic of|China Medical University Hospital, Yude Road, Taichung, Taiwan|National Taiwan University Hospital, Chung-Shan South Road, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan City, Taiwan"		https://ClinicalTrials.gov/show/NCT03149003
150	NCT01209442	Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Drug: Bevacizumab|Drug: Temozolomide|Radiation: RT (Radiation Therapy)	"6-month Progression-free Survival|Overall Survival, Measured From the Day of Initial Diagnosis (Biopsy or Surgery) to the Time of Death From Any Cause."	"University of Colorado, Denver|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-0274.cc|AVF4733s	16-Sep-10	7-Sep-14	3-Feb-17	27-Sep-10	12-Apr-19	12-Apr-19	"University of Colorado Denver, University of Colorado Cancer Center, Aurora, Colorado, United States"		https://ClinicalTrials.gov/show/NCT01209442
151	NCT02336165	Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Durvalumab|Radiation: Standard radiotherapy|Biological: Bevacizumab	"Overall Survival Rate at 12 Months (OS-12) as Estimated Using the Kaplan-Meier Method (Cohort A)|Progression-free Survival Rate at 6 Months (PFS-6) as Estimated Using the Kaplan-Meier Method (Cohorts B, B2, and B3)|Overall Survival Rate at 6 Months (OS-6) as Estimated Using the Kaplan-Meier Method (Cohort C)|Number of Participants With Treatment-emergent Adverse Events|Median PFS as Estimated Using the Kaplan-Meier Method|Median OS as Estimated Using the Kaplan-Meier Method|Number of Subjects With Best Overall Response|Mean Changes From Baseline in the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30)|Mean Changes From Baseline in the EORTC Brain Cancer Quality of Life Questionnaire (EORTC-QLQ-BN-20)"	"Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City|Cure Brain Cancer Foundation, Australia"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	159	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUD2013-006	26-Feb-15	Nov-18	6-Jul-21	12-Jan-15	28-Oct-19	15-Jul-21	"Research Facility, Los Angeles, California, United States|Research Facility, San Francisco, California, United States|Research Facility, Baltimore, Maryland, United States|Research Facility, Boston, Massachusetts, United States|Research Facility, Boston, Massachusetts, United States|Research Facility, Saint Louis, Missouri, United States|Research Facility, New York, New York, United States|Research Facility, Melbourne, Australia"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/65/NCT02336165/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02336165
152	NCT01604590	Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma	Radiation: Magnetic Resonance Imaging (MRI)	MRI to show differences between bevacizumab responses|Progression Free Survival at 3 months	Medical University of South Carolina	All	"18 Years to 80 Years   (Adult, Older Adult)"		13	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	"101652, MUSC"	Jul-12	Jun-14	Sep-14	23-May-12		13-Apr-15	"Medical University of South Carolina, Charleston, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT01604590
153	NCT03903419	Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients	PAraDiGM	Recruiting	No Results Available	Glioblastomas	Diagnostic Test: Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.	Comparison of Maximum Standardized Uptake Values of 68Ga-PSMA and of 18F-FDOPA PET-CT in glioblastomas recurrences and radiation-related complications after radiotherapy.|Comparison of Target to Background Ratio of 68Ga-PSMA and of 18F-FDOPA PET-CT in glioblastomas recurrences and radiation-related complications after radiotherapy.|Comparison of Target to Background Ratio and Target to Striatum Ratio of 68Ga-PSMA and of 18F-FDOPA PET-CT in glioblastomas recurrences and radiation-related complications after radiotherapy.|Description of the final diagnosis according to clinical and/or MRI follow-up.|Concordance between 68Ga-PSMA and 18F-FDOPA PET-CT from visual interpretation.|PSMA expression on initial glioblastoma sample by immunohistochemistry (IHC).|Association between PSMA expression and 68Ga-PSMA PET-CT imaging data.|Association between PSMA expression (IHC) and 68Ga- PSMA PET-CT imaging data. association between PSMA expression and 68Ga-PSMA PET-CT imaging data.|Assessment of safety will be based mainly on the frequency of adverse events according to the common toxicity criteria (CTCAE v5.0) grade	Centre Leon Berard	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ET18-143	16-Jan-19	16-Aug-21	16-Aug-21	4-Apr-19		14-Oct-20	"Hôpital Pierre WERTHEIMER - HCL, BRON Cedex, France|Centre Léon Berard, Lyon, France"		https://ClinicalTrials.gov/show/NCT03903419
154	NCT03535350	Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: Ibrutinib|Radiation: Radiation|Drug: Temozolomide (TMZ)	Maximum tolerated dose (MTD) of ibrutinib|Number of patients who experience adverse events|Number of patients with Progression Free Survival (PFS)|Length of time of overall survival	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE2317	24-Aug-18	Dec-21	Dec-22	24-May-18		26-Aug-21	"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT03535350
155	NCT04128774	Function and Composition of Regulatory B Cells in Participants With Glioblastoma	GBMdexaB	Recruiting	No Results Available	"Glioblastoma, Adult"	Drug: Dexamethasone	Frequency of regulatory B cells in blood of participant with Glioblastoma|Changes in frequency of regulatory B cells after treatment of participants with Glioblastoma with dexamethasone|Changes in frequency of regulatory B cells in participants with Glioblastoma	VU University Medical Center	All	"18 Years and older   (Adult, Older Adult)"		20	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	2019.554|CCA2018-5-50|NL71359.029.19	1-Jan-21	1-Nov-23	1-Nov-24	16-Oct-19		28-Oct-21	"Amsterdam Medical Universities, Amsterdam, Noord-Holland, Netherlands"		https://ClinicalTrials.gov/show/NCT04128774
156	NCT03231501	HMPL-813 in Treating Patients With Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: epitinib succinate	objective response rate (ORR)	Hutchison Medipharma Limited	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 1	29	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-813-00CH3	26-Jan-18	30-Jun-20	31-Aug-20	27-Jul-17		16-Jun-20	"Huashan Hospital, Shanghai, Shanghai, China|The second hospital affiliated to Zhejiang University Medical School, Hanzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT03231501
157	NCT00575146	Ketogenic Diet for Recurrent Glioblastoma	ERGO	Completed	Has Results	Recurrent Glioblastoma	Dietary Supplement: TAVARLIN	Applicability as Measured by Discontinuation of Study Treatment Due to Intolerability|Progression-free-survival|Overall Survival|Frequency of Seizures|Ketosis|Quality of Life	University Hospital Tuebingen|Evomed MedizinService GmbH	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ERGO	Dec-07	Feb-10	Feb-10	18-Dec-07	13-Dec-13	2-May-14	"Senckenberg Institute of Neurooncology, Frankfurt, Germany|Department of General Neurology and Hertie-Institute of Clinical Brain Research, University of Tuebingen, Tuebingen, Germany"		https://ClinicalTrials.gov/show/NCT00575146
158	NCT01310855	Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma		Terminated	Has Results	Glioblastoma	Drug: cediranib maleate|Drug: gefitinib|Drug: Placebo	Progression-free Survival|Overall Survival|Radiographic Response Rate|Progression-free Survival Rate at 6 Months|Steroid Use|Time to Deterioration of Neurological Status|Safety and Tolerability	"University College, London|AstraZeneca"	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	38	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	CDR0000696313|UCL-10/0035|ZENECA-ISSRECE00002|EUDRACT-2010-021531-13|CRUKE/10/044	May-11	May-13	Jan-14	9-Mar-11	27-Jan-17	31-May-17	"University College Hospital, London, England, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Charing Cross Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT01310855
159	NCT02104882	INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study		Completed	No Results Available	Glioblastoma Multiforme	Radiation: Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)	Maximum Tolerated Dose (MTD)|Progression Free Survival|Overall Survival	Universitätsmedizin Mannheim	All	"50 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INTRAGO-I/II	Mar-14	Sep-16	Sep-16	7-Apr-14		17-Oct-16	"Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany"		https://ClinicalTrials.gov/show/NCT02104882
160	NCT03687034	A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma		Unknown status	No Results Available	Glioblastoma	Drug: Temozolomide|Device: Optune	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Maximum tolerated dose|Levels of metabolites|Progression-free survival	Leaf Vertical Inc.	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 1	21	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Olympian 2	1-Jun-19	30-Sep-19	31-Dec-20	27-Sep-18		26-Feb-19			https://ClinicalTrials.gov/show/NCT03687034
161	NCT02283944	TMS Electrochemotherapy for Glioblastoma Multiforme		Withdrawn	No Results Available	Glioblastoma	Device: TMS	Time to death|Time to progression|Quality of Life	University of Aarhus	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15102014	Jan-15	Jan-18	31-May-19	5-Nov-14		20-Sep-21			https://ClinicalTrials.gov/show/NCT02283944
162	NCT03922984	Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Glioblastoma		Recruiting	No Results Available	Glioblastoma	Procedure: MRI with Arterial Spin Labeling (ASL)	Change in perfusion within enhancing tumor|Progression Free Survival (PFS)|ASL measured perfusion within enhancing tumor|Overall Survival (OS)	University of Texas Southwestern Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	STU 032018-079	16-Apr-19	16-Apr-26	16-Apr-27	22-Apr-19		30-Sep-21	"UT Southwestern Medical Center, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT03922984
163	NCT04566185	Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma	EVA DOPA	Recruiting	No Results Available	Glioblastoma	Other: FDG PET|Other: CT scan|Other: Magnetic resonance imaging (MRI)	Categorization of patients as responders or non-responders to treatment|Metabolic Tumor Volume|Fixation Index|permeability-surface area product|cerebral blood flow|Normalized permeability-surface area product to healthy brain|Normalized cerebral blood flow to healthy brain|Inter-rater reproducibility of FDG PET|Inter-rater reproducibility of CT scan	Centre Hospitalier Universitaire de Nīmes	All	"18 Years and older   (Adult, Older Adult)"		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NIMAO/2018-03/LC-01	16-Dec-20	Sep-22	Sep-22	28-Sep-20		18-Oct-21	"CHU de Nimes, Nîmes, France"		https://ClinicalTrials.gov/show/NCT04566185
164	NCT03481231	In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma	IMMUNOGLIO	Recruiting	No Results Available	Glioblastoma		overall survival	Centre Georges Francois Leclerc	All	"18 Years to 75 Years   (Adult, Older Adult)"		311	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2017-A00531-52	14-Sep-20	14-Sep-22	14-Sep-23	29-Mar-18		24-May-21	"Centre Georges François Leclerc, Dijon, France|CHU de DIJON, Dijon, France|CHU de Nantes, Saint-Herblain, France|Università di Florence, Florence, Italy|Azienda Ospedaliera Università di Padova, Padova, Italy"		https://ClinicalTrials.gov/show/NCT03481231
165	NCT00515086	Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)		Terminated	Has Results	Glioblastoma Multiforme	Drug: Everolimus|Procedure: Surgery	Surgery Group: Percentage Change From the Baseline in S6 Kinase Levels|No Surgery Group: Best Overall Tumor Response|Surgery Group: Blood and Brain Tissue Levels of Everolimus (RAD001)|Surgery Group: Progression-free Survival|Surgery Group: Biomarkers Phosphatase and Tensin Homolog (PTEN) and Epidermal Growth Factor Receptor (EGFR)|No Surgery Group: Progression Free Survival|Surgery Group: Number of Participants With Adverse Events	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	41	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRAD001C2410	Aug-07	Aug-09	Aug-09	13-Aug-07	27-Jul-11	22-Sep-11	"UCLA, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University - Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00515086
166	NCT00821080	Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Sirolimus|Drug: Vandetanib	"To determine the optimal, safe dose of vandetanib in combination with sirolimus. MTD and dose-limiting toxicity (DLT) of this combination therapy will also be established"	Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute|AstraZeneca	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	33	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-396	Oct-08	Feb-15	Feb-15	13-Jan-09		1-May-15	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Instiute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00821080
167	NCT03632135	Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma	CSCRGBM	Recruiting	No Results Available	Recurrent Glioblastoma	Diagnostic Test: ChemoID assay|Drug: Chemotherapy	"Median Overall Survival (OS)|Overall Survival at 6, 9, and 12 months (OS6mo, OS9mo, OS12mo)|Median Progression Free Survival (PFS)|Progression Free Survival at 4, 6, 9, and 12 months (PFS4mo, PFS6mo, PFS9mo, PFS12mo)|Objective Tumor Response|Quality of life questionnaire"	"Cordgenics, LLC"	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	150	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic"	CG01GBM	15-May-18	30-Jun-22	31-Dec-22	15-Aug-18		19-Oct-21	"Kaiser Permanente, Los Angeles, California, United States|Keck School of Medicine of the University of Southern California, Los Angeles, California, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Maine Medical Center Research Institute, Scarborough, Maine, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Toledo University, Toledo, Ohio, United States|Providence Cancer Center Oncology, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|The Penn State Univeristy College of Medicine, Hershey, Pennsylvania, United States|Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Area Medical Center, Charleston, West Virginia, United States"		https://ClinicalTrials.gov/show/NCT03632135
168	NCT03151772	Bioavailability of Disulfiram and Metformin in Glioblastomas	INSIDE	Terminated	No Results Available	Glioblastoma	Drug: Disulfiram|Drug: Metformin	Bioavailabilty disulfiram|Bioavailabilty of metformin	"Sahlgrenska University Hospital, Sweden"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	3	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	1144-16	29-Jan-18	24-Sep-20	24-Sep-20	12-May-17		28-Sep-20	"Sahlgrenska University Hospital, Göteborg, Sweden"		https://ClinicalTrials.gov/show/NCT03151772
169	NCT03293888	Spectral Analysis Probe to Identify Glioblastoma Cells		Terminated	No Results Available	Glioblastoma		Mean ratio of detecting glioblastoma cancer between the Chaos Wand spectral readings and histopathology as ground truth|Number of participants experiencing post-operative intracranial hemorrhage following surgical resection of glioblastoma with use of the Chaos Wand during surgery|Number of participants experiencing post-operative ischemic stroke following surgical resection of glioblastoma with use of the Chaos Wand during surgery|Number of participants experiencing post-operative surgical site infection following surgical resection of glioblastoma with use of the Chaos Wand during surgery	University of Oklahoma	All	"18 Years and older   (Adult, Older Adult)"		12	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	8285	31-Oct-17	30-Sep-18	30-Sep-18	26-Sep-17		25-Jan-19	"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States"		https://ClinicalTrials.gov/show/NCT03293888
170	NCT01939574	A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma		Unknown status	No Results Available	Glioblastoma	Other: Chemoradiation Therapy|Other: Adjuvant Therapy	Correlation between image biomarker change and PFS|To assess overall survival(OS)|To evaluate the overall response rate (ORR)|To evaluate health-related quality of life|To assess the safety profile	Shandong Cancer Hospital and Institute	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML28676	Aug-13	Jun-16	Sep-16	11-Sep-13		21-Jan-16	"Shandong Cancer Hospital and Institute, Jinan, Shandong, China"		https://ClinicalTrials.gov/show/NCT01939574
171	NCT01083719	A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.		Unknown status	No Results Available	Glioblastoma	Procedure: FDG-PET	Tumor infiltration defined on FDG-PET not determined to MRI	Medanta Institute of Clinical Research	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AHD1234	Apr-10	Aug-11	Aug-11	10-Mar-10		10-Mar-10			https://ClinicalTrials.gov/show/NCT01083719
172	NCT03897491	PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: 5-aminolevulinic acid	"To determine the incidence of treatment-emergent Adverse Events (safety and tolerability) of iPDT with PD L 506 in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma.|Progression-free survival rate at 12 months|Overall survival rate at 12 months|Progression-free survival|Overall survival|MGMT promoter methylation status of the patient|Immune status of the patient|Results of investigator's assessment of patient's physical condition using Karnofsky performance status scale|Results of investigator's assessment of patient's mental condition using Mini-mental State Examination|Results of investigator's assessment of patient's mental condition using National Institutes of Health Stroke Scale|Results of investigator's assessment of patient's condition using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life of Cancer Patients Questionnaire (QLQ-C30) together with the Brain module (BM20)|Interstitial light transmittance and fluorescence data recorded|Interstitial fluorescence data recorded|Percentage of cylindrical diffusor laser probes without kinks, cracks etc. before and after iPDT|Percentage of iPDT treatments in which the laser system works properly as planned.|Percentage of fibers/laser ports which show a maximum deviation in the output power of less than +/-10% to the pre-defined output power of 200 mW/cm diffusor length."	photonamic GmbH & Co. KG	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GL 01	3-Sep-21	Mar-23	Mar-27	1-Apr-19		30-Sep-21	"Uniklinik Köln, Köln, Germany|Klinikum der Universität München, München, Germany|Universitätsklinikum Münster, Münster, Germany"		https://ClinicalTrials.gov/show/NCT03897491
173	NCT03567135	Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: Apatinib|Drug: Temozolomide（TMZ）	Progression-Free-Survival(PFS)|Assessment of brain edema|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Fuzhou General Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	20180524	1-Oct-17	1-Apr-19	1-Oct-20	25-Jun-18		3-Mar-20	"Fuzhou General Hospital, Fuzhou, Fujian, China"		https://ClinicalTrials.gov/show/NCT03567135
174	NCT03582514	PreOperative Brain Irradiation in Glioblastoma	POBIG	Not yet recruiting	No Results Available	Glioblastoma Multiforme	Radiation: Preoperative brain irradiation (single fraction)	Maximum tolerated dose (MTD) and maximum tolerated irradiation volume (MTIV) of single-fraction preoperative radiotherapy in patients with a new radiological diagnosis of glioblastoma|Registration of postoperative surgical complications.|Radiotherapy related complications|Progression free survival.|Overall survival.|Steroid dose after preoperative radiotherapy.|The tumor volume differences measured between the post-surgery MRI and pre-radiotherapy MRI|Concordance between MRI based diagnosis of glioblastoma and definitive histological diagnosis.	The Christie NHS Foundation Trust|Liverpool Clinical Trials Centre|The Netherlands Cancer Institute|Salford Royal NHS Foundation Trust|University of Manchester	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CFTSp200|21/NW/0121	30-Nov-21	28-Mar-23	28-Mar-23	11-Jul-18		18-Nov-21	"The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom"		https://ClinicalTrials.gov/show/NCT03582514
175	NCT03587038	OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: OKN 007|Drug: Temozolomide|Radiation: Photon/Proton IMRT	The maximum tolerated dose and the type of dose limiting toxicities|Number of participants who experience progression-free survival|Number of participants who comply with study treatment plan|Number of participants who are able to receive a reduction in steroid dose|Number of participants who experience overall survival	University of Oklahoma	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 1	6	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Oblato-001	3-Sep-18	30-Jun-23	30-Jun-25	16-Jul-18		6-May-21	"Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States"		https://ClinicalTrials.gov/show/NCT03587038
176	NCT03679754	"Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102"		Completed	No Results Available	Glioblastoma	Biological: Ad-RTS-hIL-12|Drug: veledimex	"Safety of intratumoral Ad-RTS-hIL-12 and oral veledimex in subjects with recurrent or progressive glioblastoma based on evaluation of adverse events summarized by incidence, intensity and type of adverse event.|Tolerability of intratumoral Ad-RTS-hIL-12 and oral veledimex in subjects with recurrent or progressive glioblastoma will be assessed based on expected dose compliance|Determine the overall survival (OS) of Ad-RTS-hIL-12 + veledimex|Veledimex pharmacokinetic profile: maximum plasma concentration (Cmax)|Veledimex pharmacokinetic profile: Time to maximum plasma concentration (Tmax)|Veledimex pharmacokinetic profile: Half-life (t1/2)|Veledimex pharmacokinetic profile: Area-under-the-concentration versus time curve (AUC)|Veledimex pharmacokinetic profile: Volume of distribution (Vd)|Veledimex pharmacokinetic profile: Clearance (CL)|Veledimex concentration ratio between the brain tumor and the blood|Tumor objective response rate (ORR)|Progression free survival (PFS)|Rate of pseudo-progression (PSP)|Changes from baseline in cellular responses elicited by Ad-RTS-hIL-12 and veledimex|Changes from baseline in humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex"	Ziopharm	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	36	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATI001-102 EXP Substudy 2.0	5-Sep-18	2-Apr-19	19-Jan-21	20-Sep-18		22-Sep-21	"Cedars-Sinai Medical Center, Los Angeles, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|NYU - Langone Health, New York, New York, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03679754
177	NCT04752813	A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)		Recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: BPM31510|Other: Vitamin K1|Drug: Temozolomide (TMZ)|Radiation: Radiation	Efficacy will be assessed by subject progression free survival|Efficacy will be assessed by subject Overall survival|Safety and tolerability of BPM31510 and Vitamin K1 will be assessed by incidence of dose limiting toxicities (DLTs) and adverse events (AEs).	"Berg, LLC"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BPM31510IV-11	2-Aug-21	Feb-23	Sep-27	12-Feb-21		5-Sep-21	"Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford University Cancer Center, Palo Alto, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Mount Sinai Hospital, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT04752813
178	NCT03388372	Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma		Completed	No Results Available	Glioblastoma	Biological: Nimotuzumab|Drug: Temozolomide|Radiation: Radiotherapy	Progression-free survival (PFS)|Overall survival (OS)|Objective Response Rate (ORR)|Incidence of adverse events	"Biotech Pharmaceutical Co., Ltd.|Sun Yat-sen University"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	39	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NimotuzumabGBM2010	18-Aug-10	23-Mar-17	23-Mar-17	3-Jan-18		3-Jan-18	"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Guangdong Brain Hospital, Guangdong, China|The First Affiliated Hospital/School of Clinical Medicine of Guangdong, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Shenzhen People's Hospital, Shenzhen, China"		https://ClinicalTrials.gov/show/NCT03388372
179	NCT03297125	Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI		Recruiting	No Results Available	Glioblastoma	Device: Standard Magnetic Resonance Imaging (MRI)|Device: Advanced MRI.	Overall survival.	Medical College of Wisconsin	All	"18 Years and older   (Adult, Older Adult)"		60	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	PRO00000087	1-Dec-17	31-Dec-22	31-Dec-23	29-Sep-17		14-Apr-21	"Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03297125
180	NCT01782976	Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)		Withdrawn	No Results Available	Glioblastoma	Drug: Cilengitide|Drug: Bevacizumab|Behavioral: Questionnaire	Progression-Free Survival (PFS)	M.D. Anderson Cancer Center|Brain Tumor Trials Collaborative|EMD Serono	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BTTC11-04	Jun-13	Jun-17		4-Feb-13		19-Jan-18			https://ClinicalTrials.gov/show/NCT01782976
181	NCT04671459	TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine	TaRRGET	Recruiting	No Results Available	Glioblastoma Multiforme|Recurrent Glioblastoma	Combination Product: TTFields and SRS	1-year survival rate|Radiation necrosis range|Progression free survival (PFS)|Steroid needs until treatment failure|Patterns of failure|Objective response rates	Prof. Franciszek Lukaszczyk Memorial Oncology Center|NovoCure GmbH	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KB 2020	26-Dec-20	9-Dec-22	9-Dec-23	17-Dec-20		26-Jan-21	"The Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland"		https://ClinicalTrials.gov/show/NCT04671459
182	NCT02014844	Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: aldoxorubicin	Objective Response Rate (Complete Response and Partial Response)|Safety	CytRx	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	28	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ALDOXORUBICIN-P2-GBM-01	Mar-14	Dec-16	Dec-16	18-Dec-13		6-Jan-17	"City of Hope National Medical Center, Duarte, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|Ochsner Health System, New Orleans, Louisiana, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States"		https://ClinicalTrials.gov/show/NCT02014844
183	NCT04874506	MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)		Not yet recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: MBM-02	Progression Free Survival|Overall Survival|Thrombocytopenia|Neutropenia	"Matrix Biomed, Inc.|MedStar Georgetown"	All	"35 Years to 75 Years   (Adult, Older Adult)"	Phase 2	55	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MBI-10-01	1-Jun-21	Jan-23	Aug-23	5-May-21		5-May-21	"Georgetown, Washington, District of Columbia, United States"		https://ClinicalTrials.gov/show/NCT04874506
184	NCT03347617	Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Ferumoxytol|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Biological: Pembrolizumab	Sensitivity and specificity of ferumoxytol steady state imaging|Progression free survival|Overall survival|Duration of best response|Rate of adverse events	OHSU Knight Cancer Institute|National Cancer Institute (NCI)|Oregon Health and Science University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	54	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00016046|NCI-2017-02008|K08CA237809	20-Dec-17	30-Aug-23	30-May-24	20-Nov-17		10-Nov-21	"OHSU Knight Cancer Institute, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT03347617
185	NCT03636477	A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102		Completed	No Results Available	Glioblastoma	Biological: Ad-RTS-hIL-12|Drug: veledimex|Drug: Nivolumab	Safety of intratumoral Ad-RTS-hIL-12 and oral veledimex doses in combination with nivolumab in subjects with recurrent or progressive glioblastoma.|Tolerability of intratumoral Ad-RTS-hIL-12 and oral veledimex doses in combination with nivolumab in subjects with recurrent or progressive glioblastoma.|Optimal dose of Ad-RTS-hIL-12 and veledimex given in combination with nivolumab|Tumor objective response rate (ORR)|Progression free survival (PFS)|Rate of pseudo-progression (PSP)|Overall survival (OS)|Changes from baseline in cellular responses elicited by Ad-RTS-hIL-12 and veledimex in combination with nivolumab.|Changes from baseline in humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex in combination with nivolumab.|Veledimex pharmacokinetic profile between the brain tumor and the blood.|Veledimex concentration ratio between the brain tumor and the blood.	Ziopharm	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	21	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATI001-102 CPI Substudy 1.0	18-Jun-18	15-Oct-20	30-Jun-21	17-Aug-18		4-Oct-21	"Northwestern Memorial Hospital, Chicago, Illinois, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03636477
186	NCT01301430	Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.	ParvOryx01	Completed	No Results Available	Glioblastoma Multiforme	Drug: H-1PV	Safety and tolerability|Efficacy (treatment response)	Oryx GmbH & Co. KG	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	18	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ParvOryx01	Sep-11	May-15	May-15	23-Feb-11		4-Dec-15	"Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany"		https://ClinicalTrials.gov/show/NCT01301430
187	NCT03548571	Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy	DEN-STEM	Recruiting	No Results Available	Glioblastoma	Biological: Dendritic cell immunization|Drug: Adjuvant temozolomide	"Progression free survival|Overall survival|Patient reported quality of life, overall|Patient reported quality of life, brain specific|Immunological response, skin|Immunological response, cellular|Adverse events"	Oslo University Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2|Phase 3	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DEN-STEM	26-Apr-18	1-May-23	1-May-25	7-Jun-18		14-Apr-21	"Oslo University Hospital, Oslo, Norway"		https://ClinicalTrials.gov/show/NCT03548571
188	NCT02189109	The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma	GBM	Completed	No Results Available	Glioblastoma Multiforme	Drug: NVX-108	Safety and Tolerability of NVX-108 in Combination with Radiation and Temozolomide Defined by no Drug related Adverse Events (AE) in No More than 1 Patient per Treatment Group|Progression Free Survival at 6 months	NuvOx LLC|The Alfred	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	11	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NVX108-GBM1B	May-14	31-Aug-17	Apr-18	14-Jul-14		28-Feb-19	"St. Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Nucleus Network, Melbourne, Victoria, Australia|Epworth Center, Melbourne, Victoria, Australia"		https://ClinicalTrials.gov/show/NCT02189109
189	NCT04019002	Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma		Recruiting	No Results Available	Glioblastoma Multiforme (GBM)	Drug: Hyperpolarized 13C Pyruvate	Number of Treatment Emergent Adverse Events (AEs) Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Number of Dose-Limiting Toxicities (DLTs) Assessed by CTCAE Version 4.0|Describe Changes in 13C pyruvate-to-lactate conversion rate (kPL) in Normal and Diseased Brain Tissues|Describe Changes in 13C Lactate/Pyruvate Ratio in Normal and Diseased Brain Tissues|Compare 13C kPL Between Recurrent Lesions and Regions of Treatment Related Effects|Compare 13C Lactate/Pyruvate Ratio Between Recurrent Lesions and Regions of Treatment Related Effects|Determine the Association Between 13C kPL and Time to Disease Progression|Determine the Association Between 13C Lactate/Pyruvate Ratio and Time to Disease Progression|Determine the Association Between Hydrogen-1 (1H) Choline-to-N-acetylaspartate (NAA) index (CNI) and Time to Disease Progression|Determine the Association Between 13C kPL and Overall Survival|Determine the Association Between 13C Lactate/Pyruvate Ratio and Overall Survival|Determine the Association Between 1H CNI and Overall Survival	"Susan Chang|National Cancer Institute (NCI)|University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	90	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	19105|2P50CA097257|NCI-2019-07406	19-Nov-19	28-Feb-23	28-Feb-23	15-Jul-19		5-Jan-22	"University of California, San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT04019002
190	NCT02904525	Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model	XENOGBM	Recruiting	No Results Available	Glioblastoma	"Device: 7 Tesla MRI, no contrast agent"	GBM metabolites using high resolution spectroscopy|Next generation sequencing of GBM tumor tissue	Andreas Hottinger|Ecole Polytechnique Fédérale de Lausanne|Centre Hospitalier Universitaire Vaudois	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	268/14	Jun-15	27-Jan-21	30-Apr-21	19-Sep-16		27-Jan-21	"CHUV, University Hospital Lausanne, Lausanne, VD, Switzerland"		https://ClinicalTrials.gov/show/NCT02904525
191	NCT03383978	Intracranial Injection of NK-92/5.28.z Cells in Patients With Recurrent HER2-positive Glioblastoma	CAR2BRAIN	Recruiting	No Results Available	Glioblastoma	Biological: NK-92/5.28.z	Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.|Maximum tolerated dose (MTD) or maximum feasible dose (MFD).|Period of detectability of NK-92/5.28.z cells in blood and cerebrospinal fluid (CSF) during the first 24 weeks after NK-92/5.28.z application with qPCR.|Cytokine profile in the blood and the cerebrospinal fluid.|NK-92- and/or CAR 5.28.z-directed immune response.|Objective response rate.|Progression-free survival.|Overall survival.	Johann Wolfgang Goethe University Hospital|DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH|Georg-Speyer-Haus|LOEWE Center Frankfurt Cancer Institute|German Cancer Research Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EudraCT 2016-000225-39	1-Dec-17	Sep-22	Dec-22	27-Dec-17		25-Sep-20	"Johann W. Goethe University Hospital, Department of Neurosurgery, Frankfurt, Germany|Johann W. Goethe University Hospital, Senckenberg Institute of Neurooncology, Frankfurt, Germany"		https://ClinicalTrials.gov/show/NCT03383978
192	NCT03477110	"Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma"		Recruiting	No Results Available	Glioblastoma	Drug: Temozolomide|Radiation: Radiation Therapy|Device: NovoTTF-200A Device|Procedure: Tumor Treating Fields Therapy	NovoTTF-200A device discontinuation rate due to skin toxicity|Progression-free survival|Overall survival|Event-free survival	Sidney Kimmel Cancer Center at Thomas Jefferson University|NovoCure Ltd.|Thomas Jefferson University	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	35	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.346	4-May-18	Jul-21	Sep-21	26-Mar-18		4-Jun-21	"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03477110
193	NCT03246113	Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma		Terminated	No Results Available	Glioblastoma	Drug: Cannabis|Drug: Temozolomide|Radiation: Radiation Therapy	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of Radiation Induced Toxicities|Number of Opioid Medications Administered	New York State Psychiatric Institute	All	"21 Years to 70 Years   (Adult, Older Adult)"	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB#7290	19-Mar-18	9-May-19	9-May-19	11-Aug-17		13-Aug-19	"Columbia University Medical Center- Department of Radiation Oncology, New York, New York, United States|New York State Psychiatric Institute, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03246113
194	NCT02910804	IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma		Unknown status	No Results Available	Glioblastoma	Drug: 68Ga-BBN-IRDye800CW|Device: PET/NIRF|Procedure: PET/NIR fluorescent imaging-guided surgery	Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of GBM|Margin assessment of positive tumors in NIRF fluorescent-guided surgery	Beijing Tiantan Hospital|Peking Union Medical College Hospital|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Chinese Academy of Sciences	All	"18 Years to 70 Years   (Adult, Older Adult)"	Early Phase 1	30	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	BTHospital-N-005|ZIAEB000073	Nov-15	Dec-18	Dec-18	22-Sep-16		18-Jan-18	"Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT02910804
195	NCT02725684	Using Genomic Analysis to Guide Individual Treatment in Glioblastoma		Completed	No Results Available	Glioblastoma	"Other: Observational study, no intervention"	Identification of targetable variants in the tumor	Rockefeller University|Memorial Sloan Kettering Cancer Center|Lenox Hill Hospital|North Shore University Hospital|NYU Langone Health|Weill Medical College of Cornell University|Albert Einstein College of Medicine|New York Genome Center	All	"3 Years to 100 Years   (Child, Adult, Older Adult)"		36	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	RDA-0837	12-Mar-15	7-Jul-17	7-Jul-17	1-Apr-16		25-Oct-17	"New York University Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Rockefeller University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|North Shore University Hospital, New York, New York, United States|Montefiore Medical Center, The Bronx, New York, United States"		https://ClinicalTrials.gov/show/NCT02725684
196	NCT03152708	CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma		Unknown status	No Results Available	Glioblastoma		CD95 Ligand Positive Rate|CpG2 Positive Rate	CANbridge Life Sciences Ltd.	All	"Child, Adult, Older Adult"		62	Industry	Observational	Observational Model: Other|Time Perspective: Retrospective	CAN-B1-008-L-009	1-Nov-17	1-Dec-17	31-Dec-17	15-May-17		21-Sep-17			https://ClinicalTrials.gov/show/NCT03152708
197	NCT04590664	Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma		Recruiting	No Results Available	Glioblastoma|Recurrent Glioblastoma	Drug: Verteporfin	Incidence of adverse events (Phase I)|Progression free survival (PFS) (Phase II)|Response rate (RR) (Phase II)|Overall survival (Phase II)|PFS (Phase I)|RR (Phase I)|Overall survival (Phase I)|Visudyne blood levels (Phase I)|Incidence of adverse events (Phase II)	Emory University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	24	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00000974|NCI-2020-05187|WINSHIP5070-20|P30CA138292	15-Jan-21	15-Aug-23	15-Aug-23	19-Oct-20		17-Feb-21	"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT04590664
198	NCT02364206	Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma	GLYRad	Completed	No Results Available	Adult Glioblastoma	Drug: LY2228820|Drug: Temozolomide|Radiation: radiotherapy	"maximum tolerated dose (MTD) (phase I) of LY2228820 in combination with TMZ and radiotherapy during chemoradiotherapy period|6-month Progression Free Survival (PFS) rate (phase II) defined as the rate of patients who not presented a progression at 6 months from the first dose of LY2228820|Safety profile according to NCI Common Toxicity Criteria for Adverse Effect (CTCAE) criteria version 4.03.|PFS|Overall Survival|12-month PFS rate defined as the rate of patients who not presented a progression at 12 months from the first dose of LY2228820|Objective response rate according to RANO criteria for patients with incomplete resection or only biopsy|The neurologic status evaluated by clinical assessment and Mini-Mental State Examination (MMSE) and evaluation of corticosteroid dosage|Pharmacokinetic of LY2228820 and TMZ (AUC0-12h)|MAPKAPK-2 activation|Validated biomarker of glioblastoma (MGMT, IDH1 (isocitrate dehydrogenase 1), pTEN (phosphatase and tensin homolog), p53)"	"Centre Jean Perrin|National Cancer Institute, France|ARC Foundation for Cancer Research"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2013-005442-11	8-Jun-15	Aug-19	Aug-19	18-Feb-15		14-Aug-19	"CHU Amiens Sud-Salouel, Amiens, France|Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Paul Strauss, Strasbourg, France"		https://ClinicalTrials.gov/show/NCT02364206
199	NCT03233152	Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma	GlitIpNi	Recruiting	No Results Available	Glioblastoma	"Drug: Ipilimumab (YervoyTM, 50 mg/10 mL solution)|Drug: Nivolumab (OpdivoTM, 40 mg/4mL solution)"	Progression-free survival (PFS)|Overall Survival (OS)	Universitair Ziekenhuis Brussel	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-BN-002	17-Nov-16	17-Nov-23	17-Nov-23	28-Jul-17		17-Dec-20	"Universitair Ziekenhuis Brussel, Brussels, Belgium"		https://ClinicalTrials.gov/show/NCT03233152
200	NCT04845919	Sonodynamic Therapy With ExAblate System in Glioblastoma Patients	Sonic ALA	Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: 5-Aminolevulinic Acid	"Presence of hemorrhage, oedema or other damages|Rate of neurological deficits|Radiological response to treatment"	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	Sonic ALA	May-21	May-21	Dec-22	15-Apr-21		15-Apr-21			https://ClinicalTrials.gov/show/NCT04845919
201	NCT04373785	NG101m Adjuvant Therapy in Glioblastoma Patients		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Radiation: Intensity-modulated radiation therapy|Drug: Temozolomide|Drug: NG101m	Number of participants with treatment-emergent adverse events and serious adverse events|Efficacy of NG101m adjuvant chemoradiation therapy assessed by measuring 2-year overall survival rate.|Progression-free survival (PFS)|Response assessment in neuro-oncology (RANO) criteria|Quality of Life (QoL)	NeuGATE Theranostics	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	52	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NG101m	1-Jan-22	30-Jul-25	31-Dec-25	4-May-20		1-Sep-21	"Yvonne Kew MD, PLLC, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04373785
202	NCT04047706	"Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma"		Recruiting	No Results Available	Glioblastoma	Biological: IDO1 Inhibitor BMS-986205|Biological: Nivolumab|Radiation: Radiation Therapy|Drug: Temozolomide	Incidence of adverse events (AEs)|Overall survival|Median survival|Progression free survival at 6 months|Median time to disease progression|Radiographic response rates (RR)|Response rate|Median duration of response	Northwestern University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 18C02|NCI-2019-04922|STU00209583|P30CA060553|P50CA221747	13-Aug-19	9-Jun-22	1-Jun-23	7-Aug-19		2-Jul-20	"Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT04047706
203	NCT00190424	Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: CpG-ODN	Survival|Progression-free survival|Tolerance	Assistance Publique - Hôpitaux de Paris	All	"40 Years and older   (Adult, Older Adult)"	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	P050305|ISOPS 3	Sep-05	Oct-08	Oct-10	19-Sep-05		13-Dec-12	"Hopital Salpetriere, Paris, France|Hopital Lariboisiere, Paris, France"		https://ClinicalTrials.gov/show/NCT00190424
204	NCT01507506	Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma	SPECTRO GLIO	Terminated	No Results Available	Glioblastoma	Radiation: Radiotherapy|Radiation: Experimental arm	"Overall survival defined as the time from randomization to the date of death or date of last follow-up news (censured data)|Progression-free survival, defined as the time from randomization to the date of progression or death|Safety evaluated according to the classification of NCI CTCAE (Common Terminology Criteria for Adverse Events)V3.0"	Institut Claudius Regaud	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	180	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08 TETE 01	15-Mar-11	2-Jan-20	2-Jan-20	11-Jan-12		12-Jan-21	"Clinique Claude Bernard, Albi, France|Centre Jean Perrin, Clermont-ferrand, France|Centre Georges François Leclerc, Dijon, France|Hospices Civils de Lyon (Hôpital Lyon Sud/Hôpital P. Wertheimer), Lyon, France|Centre Leon Berard, Lyon, France|AP HM - Hôpital La Timone, Marseille, France|Centre Val d'Aurelle, Montpellier, France|Institut de Cancerologie Lucien Neuwirth, Saint-Priest-En-Jarez, France|Centre Paul Strauss, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|Institut Claudius REGAUD, Toulouse, France|Centre Marie Curie, Valence, France"		https://ClinicalTrials.gov/show/NCT01507506
205	NCT03631836	"Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma"	MARELLE01	Unknown status	No Results Available	Glioblastoma	Drug: Monoclonal antibody|Drug: Bevacizumab|Biological: Blood sample|Device: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)	Determine the Dose Limiting Toxicity (DLT)	Assistance Publique Hopitaux De Marseille	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	34	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-65	1-Jan-19	1-Jan-22	1-Jan-22	15-Aug-18		17-Aug-18	"Assistance Publique des Hôpitaux de Marseille, Marseille, France"		https://ClinicalTrials.gov/show/NCT03631836
206	NCT01898273	Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma		Terminated	No Results Available	Glioblastoma	Drug: I-124-CLR1404	Optimal Imaging Parameters - Dose|Optimal Imaging Parameters - Imaging Time Point	"Cellectar Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	7	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	DCL-13-002	Feb-14	Sep-15	Dec-15	12-Jul-13		9-Sep-15	"City of Hope, Duarte, California, United States|Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01898273
207	NCT02902757	FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma		Recruiting	No Results Available	Glioblastoma	Procedure: Computed Tomography|Radiation: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography	Changes in glucose uptake|Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria	Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|National Institutes of Health (NIH)	All	"18 Years to 99 Years   (Adult, Older Adult)"	Not Applicable	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	15-000409|NCI-2016-00583	25-Aug-15	25-Aug-22	25-Aug-23	16-Sep-16		26-Nov-21	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT02902757
208	NCT04116658	"First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma"	ROSALIE	Recruiting	No Results Available	"Glioblastoma, Adult"	Biological: Multiple dose of EO2401	"Safety and tolerability of EO2401: National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0|Evaluation of survival|Assessment of the immunogenicity of EO2316, EO2317, EO2318 (Three components of the therapeutic vaccine), and Universal Cancer Peptide that compose EO2401"	Enterome|Covance	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	52	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EOGBM1-18	13-Jul-20	Aug-23	Aug-23	4-Oct-19		8-Dec-21	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Centre Georges François Leclerc, Dijon, France|Hôpital Pitié-Salpétrière, Paris, France|Klinik und Poliklinik für Neurologie Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Frankfurt Goethe-Universität Dr. Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Neurologische Klinik & Nationales Zentrum für Tumorenerkrankungen Heidelberg Universitätsklinikum Heidelberg, Heidelberg, Germany|Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany|Zentrum für Neuroonkologie Universitätsklinikum Tübingen, Tübingen, Germany|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Institit Catala D'Oncologia - Hospital Duran i Reynals, Hospitalet De Llobregat, Spain"		https://ClinicalTrials.gov/show/NCT04116658
209	NCT03776071	"A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1"		Recruiting	No Results Available	Glioblastoma	Drug: Enzastaurin Hydrochloride|Other: Placebo|Drug: Temozolomide|Radiation: Radiotherapy	Overall Survival	Denovo Biopharma LLC	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	300	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	DB102-01	16-Dec-20	Jun-25	Jun-25	14-Dec-18		21-Dec-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, United States|The University of Southern California, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California San Diego Moores Cancer Center, San Diego, California, United States|University of California San Francisco Helen Diller Family Comprehensive CA Ctr, San Francisco, California, United States|University of Colorado Hospital Anschutz Cancer Pavilion, Aurora, Colorado, United States|Blue Sky Neurology, Englewood, Colorado, United States|Smilow Cancer Hospital - New Haven, New Haven, Connecticut, United States|Lynn Cancer Institute, Boca Raton, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute - Multidisciplinary Clinic, Louisville, Kentucky, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|John Nasseff Neuroscience Institute, Minneapolis, Minnesota, United States|Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine Center for Advanced Medicine, Saint Louis, Missouri, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|New York University Medical Oncology Associates, New York, New York, United States|New York - Presbyterian - Weill Cornell Medical Center, New York, New York, United States|Messino Cancer Centers, Asheville, North Carolina, United States|Wake Forest Baptist Health - Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|SCRI - Tennessee Oncology - Nashville - Centennial, Nashville, Tennessee, United States|Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States|Austin Cancer Center - Park St. David's, Austin, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Lynn Cancer Institute, Houston, Texas, United States|University of Texas Health Science Center at Houston (UT Health), Houston, Texas, United States|Mays Cancer Center, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|British Columbia Cancer Agency - Abbotsford, Abbotsford, British Columbia, Canada|British Columbia Cancer Agency - Victoria, Victoria, British Columbia, Canada|First Affiliated Hospital of USTC - Anhui Provincial Hospital, Hefei, Anhui, China|Beijing Tian Tan Hospital, Capital Medical University, Beijing, Beijing, China|Sanbo Brain Hospital, Capital Medical University, Beijing, Beijing, China|Peking Union Medical College Hospital, Beijing, Beijing, China|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdon, China|Tongji Hospital, Wuhan, Hubei, China|Shengjing Hospital - Nanhu Campus, Shenyang, Liaoning, China|Tangdu Hospital, Xian, Shaanxi, China|Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China|Tianjin Huanhu Hospital, Jinnan, Tianjin, China|General Hospital of Tianjin Medical University, Tianjin, Tianjin, China"		https://ClinicalTrials.gov/show/NCT03776071
210	NCT03439332	Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma	ONCOhabitats	Completed	No Results Available	Glioblastoma		Correlation between overall survival (in days) of patients undergoing standard-of-care treatment and the tumor vascular heterogeneity described by the four habitats obtained by the Hemodynamic Multiparametric Tissue Signature (HTS) biomarker|Correlation between progression-free survival (in days) of patients undergoing standard-of-care treatment and the tumor vascular heterogeneity described by the four habitats obtained by the HTS biomarker|Correlation between MTS habitats in longitudinal studies	Juan M Garcia-Gomez|University of Liege|Hospital de Manises|Hospital de la Ribera|Hospital Vall d'Hebron|Hospital Clinic of Barcelona|Azienda Ospedaliero-Universitaria di Parma|Oslo University Hospital|Universitat Politècnica de València	All	"18 Years and older   (Adult, Older Adult)"		305	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	UPV-2018-001	7-Feb-18	1-Jul-18	1-Mar-19	20-Feb-18		22-May-19	"Universitat Politècnica de València, Valencia, Spain"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/32/NCT03439332/Prot_SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT03439332
211	NCT02630030	Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Ixazomib	Concentration of Ixazomib in Tumor Tissue|Number of Patients With Safety and Tolerability of Ixazomib|Number of Participants With Treatment-Emergent Adverse Events	Emory University|Takeda	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	3	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	IRB00083003|NCI-2015-01682|X16071|Winship3017-15	24-Mar-16	1-Jul-18	3-Sep-20	15-Dec-15	26-Mar-21	26-Mar-21	"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/30/NCT02630030/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02630030
212	NCT01778530	TRC105 for Recurrent Glioblastoma		Terminated	Has Results	Glioblastoma Multiforme	Drug: TRC105	Radiographic Response Rate for Patients With Recurrent Glioblastoma Multiforme (GBM) Treated With TRC105.|Number of Participants With Adverse Events	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	2	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	130048|13-C-0048	Dec-12	Feb-14	Feb-14	29-Jan-13	12-May-14	7-Oct-15	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01778530
213	NCT01181193	Vitamin D for Treatment of Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Other: Surgery|Radiation: Radiotherapy to tumour bed and/or residual tumour|Drug: Temozolomide|Drug: Vitamin D3	Progression free survival|Overall survival	Soroka University Medical Center	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SOR504110CTIL	Mar-11	Mar-13	Mar-14	13-Aug-10		29-Mar-11	"Soroka University Medical Center, Beer Sheva, Israel"		https://ClinicalTrials.gov/show/NCT01181193
214	NCT04717999	Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma		Not yet recruiting	No Results Available	Recurrent Glioblastoma	Biological: NKG2D CAR-T	Number of Participants who experience a Dose-Limiting Toxicity (DLT)|Overall Response Rate|Progression-free survival	UWELL Biopharma	All	"20 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UBP-P02-3001-GBM	1-Sep-21	30-Sep-23	31-Dec-23	22-Jan-21		22-Jan-21			https://ClinicalTrials.gov/show/NCT04717999
215	NCT01846871	Tivozanib for Recurrent Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Tivozanib	Number of Patients Alive and Progression Free After 6 Months|Number of Participants With Treatment Related Serious Adverse Events|Median Overall Survival|Median Progression-Free Survival|Best RANO Criteria Response|Steroid Dosage|Change in Tumor Volume|Median Apparent Diffusion Coefficient (ADC)|Median Ktrans|Relative Oxygen Saturation	Massachusetts General Hospital|National Comprehensive Cancer Network	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-069	Jun-13	Sep-14	May-16	3-May-13	8-Jan-19	8-Jan-19	"Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01846871
216	NCT03393000	Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects	INTACT	Terminated	Has Results	Glioblastoma	Drug: Trans Sodium Crocetinate plus SOC|Other: Standard of Care (SOC)	Overall Survival (OS)	Diffusion Pharmaceuticals Inc	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	19	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	100-206	16-Jan-18	6-Nov-20	6-Nov-20	8-Jan-18	22-Jul-21	22-Jul-21	"University of California, Irvine, California, United States|Scott Peak, M.D., Redwood City, California, United States|John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica, California, United States|Piedmont Cancer, Atlanta, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|UNM Comprehensive Cancer Center, Albuquerque, New Mexico, United States|North Shore University Hospital, Manhasset, New York, United States|Mount Sinai Hospital, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Scott Lindhorst, M.D., Charleston, South Carolina, United States|Neuro Oncology Associates, Dallas, Texas, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/00/NCT03393000/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT03393000
217	NCT05043701	Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma	ISM-GBM	Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Personalized drug combination	"Drug screen completion and treatment initiation|Tumor response|Number of grade 3-5 adverse events|Overall survival|Patient reported quality of life, overall (QLQ-C30)|Patient reported quality of life, brain specific(QLQ-BN20)"	Oslo University Hospital|Institute for Molecular Medicine	All	"15 Years to 70 Years   (Child, Adult, Older Adult)"	Early Phase 1	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ISM-GBM	Oct-21	Dec-23	Feb-25	14-Sep-21		14-Sep-21	"Oslo University Hospital, Oslo, Norway"		https://ClinicalTrials.gov/show/NCT05043701
218	NCT01402063	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation		Completed	Has Results	Glioblastoma Multiforme	Drug: PPX (CT2103)|Drug: Temozolomide	Progression Free Survival PPX/RT Versus TMZ/RT for Patients With GBM Without Methylation	"Brown University|Rhode Island Hospital|Milton S. Hershey Medical Center|University of Washington|University of Massachusetts, Worcester|MaineHealth|University of California, San Diego|Thomas Jefferson University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	63	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrUOG 244	Sep-11	Apr-14	Jun-15	26-Jul-11	11-Jun-15	17-Feb-20	"UCSD Cancer Center, La Jolla, California, United States|Maine Medical Center, Scarborough, Maine, United States|UMASS Medical Center Cancer Center, Worcester, Massachusetts, United States|SUNY Medical Center, Syracuse, New York, United States|PSU, Hershey, Pennsylvania, United States|Thomas Jefferson University Cancer Center, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|UT Southwestern Cancer Center, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01402063
219	NCT02876003	Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma		Withdrawn	No Results Available	Glioblastoma	Drug: G-202	"6-month progression-free survival|Safety|Objective tumor response rate, best overall response|Duration of PFS|Overall survival"	"GenSpera, Inc.|John Wayne Cancer Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	G-202-008	Sep-16	Oct-19	Oct-20	23-Aug-16		24-Feb-17	"John Wayne Cancer Institute, Santa Monica, California, United States"		https://ClinicalTrials.gov/show/NCT02876003
220	NCT04963413	RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.		Not yet recruiting	No Results Available	Glioblastoma	Biological: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF	Ability to generate CMV pp65 RNA-pulsed DCs in patients receiving adjuvant temozolomide chemotherapy after radiotherapy.	"University of Florida|Immunomic Therapeutics, Inc."	All	"18 Years to 90 Years   (Adult, Older Adult)"	Phase 1	10	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB202002778|OCR39689	Dec-21	May-23	May-25	15-Jul-21		2-Dec-21			https://ClinicalTrials.gov/show/NCT04963413
221	NCT04900792	A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma	XACT-Fe-GBM-01	Not yet recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Ferumoxytol injection|Drug: Pharmacological ascorbate|Radiation: External beam radiation therapy|Drug: Temozolomide	Determination of recommended phase 2 ferumoxytol dosing regimen|Estimate progression free survival (PFS)|Estimate overall survival (OS)|Estimate Objective Response Rate (ORR)|Tumor size|Clinical response|Number of Treatment-Related Adverse Events	Bryan Allen|Holden Comprehensive Cancer Center|University of Iowa	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202103125	31-Dec-21	30-Jun-23	31-Dec-25	25-May-21		28-Sep-21			https://ClinicalTrials.gov/show/NCT04900792
222	NCT04051606	Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Regorafenib	Median overall survival (OS)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Objective response rate (ORR)|Progression free survival at 6 months (PFS-6).|Median time to progression (TTP)	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	22	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE7318	31-Jul-19	Feb-22	Feb-22	9-Aug-19		26-Jul-21	"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT04051606
223	NCT04674527	Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma		Not yet recruiting	No Results Available	Refractory Glioblastoma	Drug: Elemene|Drug: Temozolomide	overall survival(OS)|progression-free survival(PFS)|objective response rate(ORR)|complete response(CR)|partial response|duration of response	"Second Affiliated Hospital, School of Medicine, Zhejiang University|Hangzhou Normal University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAHZJU-RCT-ELEMENE	1-Jun-21	1-Jun-23	1-Jun-23	19-Dec-20		19-Dec-20	"Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04674527
224	NCT01290263	Amgen 386 for Recurrent Glioblastoma		Completed	Has Results	Glioblastoma Multiforme	Drug: Amgen 386|Drug: Bevacizumab	6-Month Progression-Free Survival (PFS6) [Cohort A and Cohort B]|AMG 386 Maximum Tolerated Dose (MTD) [Cohort B Phase I]|AMG 386 Dose Limiting Toxicity (DLT) [Cohort B Phase I]|Best Radiographic Response [Cohort A and Cohort B]|Overall Survival (OS) [Cohort A and Cohort B]|Progression-Free Survival (PFS) [Cohort A and Cohort B]	Dana-Farber Cancer Institute|Amgen	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	48	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12-185	Dec-10	Jul-15	Jan-17	4-Feb-11	25-May-17	2-Jul-17	"University of California Los Angeles, Los Angeles, California, United States|Massachusetts General Hosptial, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Worcester, Massachusetts, United States|New York - Presbyterian/Columbia University Medical Center, New York, New York, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT01290263
225	NCT03422094	"Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma"		Terminated	No Results Available	Glioblastoma	Biological: NeoVax|Biological: Nivolumab|Biological: Ipilimumab|Procedure: Research blood draw|Procedure: Leukapheresis for research	"Safety and tolerability of regimen as measured by a <= 33% dose-limiting toxicity (DLT) rate for a given cohort|Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to identify candidate tumor-specific neoantigens|Feasibility of generating a personalized neoantigen peptide vaccine as measured by the the ability to manufacture a neoantigen-based synthetic long peptide vaccine|Feasibility of generating a personalized neoantigen peptide vaccine as measured by the ability to administer the vaccine to a patient at 4 weeks post-completion of radiotherapy|Immunogenicity of a personalized neoantigen peptide vaccine as measured by the ability to generate a measurable neoantigen-specific T cell response in vaccinated patients|Immunogenicity of a personalized neoantigen peptide vaccine as measured by the number of individual neoantigens per number of neoantigens vaccinated against, with which a measurable T cell-specific response|Number of high quality candidate neoantigens present in patients with newly diagnosed glioblastoma|Progression-free (PFS) survival rate|Overall survival (OS) rate"	Washington University School of Medicine|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	3	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201804195	31-Oct-18	26-Apr-20	31-Dec-20	5-Feb-18		27-Oct-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/94/NCT03422094/ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT03422094
226	NCT01562197	A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma	AxiGII	Completed	No Results Available	Glioblastoma Multiforme	Drug: axitinib|Drug: Axitinib plus Lomustine	anti-tumor effect of axitinib as a single therapeutic agent and in combination with Lomustine	Bart Neyns|Pfizer|Universitair Ziekenhuis Brussel	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2	56	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AxiGII	Apr-14	Aug-18	Dec-18	23-Mar-12		24-Jan-19	"UZ Brussel, Brussel, Belgium"		https://ClinicalTrials.gov/show/NCT01562197
227	NCT02728349	Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Chlorogenic acid	Number of adverse events|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0，grade ≥3 (DLT)|Maximum Tolerated Dose|Area under the plasma concentration versus time curve (AUC) of chlorogenic acid|Peak Plasma Concentration (Cmax) of chlorogenic acid|Improvement in cancer-related symptoms|disease control rate(DCR)|objective response rate (ORR)|progress free survival(PFS)|overall survival (OS)|Improvement in quality of life	"Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd|Beijing Shijitan Hospital, Capital Medical University"	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1	26	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LYS-I-03	12-Apr-16	23-Aug-17	13-Sep-17	5-Apr-16		1-Nov-18	"Beijing Shijitan Hospital,Capital Medical University, Beijing, China"		https://ClinicalTrials.gov/show/NCT02728349
228	NCT01308632	Metronomic Temozolamide in Patients With Recurrent Glioblastoma		Unknown status	No Results Available	Glioblastoma	"Drug: Temozolamide, irinotecan"	Efficacy of the treatment (Phase I)|Progression-free survival (Phase II)|Assess the toxicity of the treatment|Progression-free survival at 6 months|overall survival	Grupo Español de Investigación en Neurooncología	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	30	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GENOM-007	Nov-07	Jun-12	Jun-12	4-Mar-11		4-Mar-11			https://ClinicalTrials.gov/show/NCT01308632
229	NCT03287063	"Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma"		Suspended	No Results Available	Glioblastoma	Other: Tumor Biopsy	Identify candidate genes with differential expression in therapy-resistant imaging subvolumes	University of Michigan Rogel Cancer Center	All	"18 Years and older   (Adult, Older Adult)"		20	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	UMCC 2017.094|HUM00134165	5-Jul-18	Oct-22	Oct-22	19-Sep-17		16-Sep-21	"University of Michigan, Ann Arbor, Michigan, United States"		https://ClinicalTrials.gov/show/NCT03287063
230	NCT05083754	Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: Retifanlimab|Drug: Temozolomide|Radiation: Radiation Therapy	Safety of combination retifanlimab and radiation with and without temozolomide as assessed by number of participants who experience adverse events|Feasibility of combination retifanlimab and radiation with and without temozolomide as assessed by number of participants who experience adverse events|Maximum Tolerated Dose (MTD) as determined by number of participants with dose limiting toxicities (DLT)|Safety as assessed by number of treatment-emergent adverse events in patients on combination refitanlimab and standard of care (SOC) with newly diagnosed glioblastoma after treatment with carmustine wafers|Progression Free Survival|Overall Response Rate|Overall Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Incyte Corporation	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 1	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J21103	Jan-22	Jan-26	Jan-27	19-Oct-21		8-Nov-21	"Johns Hopkins Medical Institution, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT05083754
231	NCT01317212	Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme		Withdrawn	No Results Available	Glioblastoma Multiforme	Drug: Peritumoural carboplatin administration.	"Maximum tolerated infusion concentration|Complications/side-effects/tolerability/toxicity (As defined by Eastern Cooperative Oncology Group criteria) of treatment.|Serial quality of life measurements at 3-month intervals.|Progression-free survival (PFS) based on serial MRI scans at 3-month intervals.|Overall survival.|Relationship between catheter location and visible carboplatin distribution based on MRI.|Relationship between carboplatin distribution, PFS and overall survival.|Serum carboplatin pharmacokinetics during/after intracranial infusions."	North Bristol NHS Trust	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2467|2010-023454-37	May-15	May-17	May-18	17-Mar-11		17-Apr-15	"Department of Neurosurgery, Bristol, United Kingdom"		https://ClinicalTrials.gov/show/NCT01317212
232	NCT02478164	Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Ponatinib	3-Month Progression-Free Survival (PFS3)|Best Radiographic Response|Overall Survival (OS)|Progression-Free Survival (PFS)	Dana-Farber Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	17	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-163	13-Jul-15	8-Jul-17	9-May-18	23-Jun-15	2-Apr-18	24-Jul-18	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/64/NCT02478164/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02478164
233	NCT00238797	"A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme"		Completed	No Results Available	Glioblastoma	Drug: Gefitinib	"Objective tumour response at 6 months after the end of combination treatment by computerized tomography scan or magnetic resonance imaging of the brain according to Macdonald criteria.|Disease control rate at 6 months after the combination treatment, clinical or radiological progression-free-survival, overall survival and safety of ZD1839 in combination with radiotherapy."	AstraZeneca	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1839IL/0088|D7913L00088	Feb-03		Mar-06	14-Oct-05		21-Jan-11	"Research Site, Linköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden"		https://ClinicalTrials.gov/show/NCT00238797
234	NCT00906893	Evaluation of [18F]-FMISO for Non Operated Glioblastoma	MISOGLIO	Completed	No Results Available	Glioblastoma	Procedure: 18F]-FMISO PET-CT	"determine acquisition protocol and robust quantification parameters representative of tumour hypoxia using [18F]-FMISO PET-CT in glioblastomas|prognostic value of [18F]-FMISO PET-CT in glioblastomas treated by conformational radiotherapy and/or chemotherapy|Evaluate the potential role of a new biological tumour volume (BTV) taking into account hypoxia for the delineation of radiotherapy treatment planning when patients undergone this treatment|Study of pathological processes contributing to [18F]-FMISO uptake such as: microvessel density and endogenous markers (Hypoxia Inducible Factor (HIF1), Carbonic Anhydrase isoenzyme IX (CAIX), Lysyl Oxidase (LOX), p53) determined on biopsy tissues."	"University Hospital, Bordeaux"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	14	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	CHUBX2008/31	Jun-09	Jan-12	Jan-13	21-May-09		28-Feb-13	"CHU de Bordeaux - Hôpital Pellegrin, Bordeaux, France"		https://ClinicalTrials.gov/show/NCT00906893
235	NCT02926222	Regorafenib in Relapsed Glioblastoma	REGOMA	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Drug: Regorafenib|Drug: Lomustine	Overall survival|Progression free survival|Objective response rate|Disease control rate|Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events)	Istituto Oncologico Veneto IRCCS|BAYER S.p.A. - Italia	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	119	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IOV-GB-1-2014 REGOMA|2014-003722-41	Nov-15	Jul-17	Oct-21	6-Oct-16		19-Oct-20	"IRCCS ""Saverio de Bellis, Castellana Grotte, BA, Italy|Ospedale di Bellaria, Bologna, BO, Italy|Azienda Ospedaliera ""G.Rummo"", Benevento, BR, Italy|istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, Cesena, FC, Italy|Istituto Neurologico C. Besta IRCCS, Milano, MI, Italy|Istituto Oncologico Veneto IRCCS, Oncologia Medica 1, Padova, PD, Italy|Ospedale Santa Chiara, Pisa, PI, Italy|Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, UD, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy"		https://ClinicalTrials.gov/show/NCT02926222
236	NCT02343406	Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas	INTELLANCE-2	Completed	Has Results	Glioblastoma	Drug: Depatuxizumab mafodotin|Drug: Temozolomide|Drug: Lomustine	Adult Study: Overall Survival (OS)|Adult Study: Progression-Free Survival (PFS)|Pediatric Study: Percentage of Participants With Adverse Events From the First Visit Until 49 Days After the Last Dose of Study Drug|Pediatric Study: Maximum Observed Serum Concentration (Cmax) of ABT-414|Pediatric Study: Maximum Observed Plasma Concentration (Cmax) of Cys-mcMMAF|Pediatric Study: Half-life (t1/2) Observed for ABT-414|Pediatric Study: Half-life (t1/2) Observed for Cys-mcMMAF|Pediatric Study: Area Under the Concentration-time Curve (AUC) Observed for ABT-414|Pediatric Study: Area Under the Concentration-time-curve (AUC) Observed for Unconjugated Cys-mcMMAF|Adult Study: Objective Response Rate (ORR)|Adult Study: Overall Survival in the Subgroup With Epidermal Growth Factor Receptor (EGFRvIII) Mutation|Pediatric Study: Objective Response Rate (ORR)|Pediatric Study: Best Tumor Response Rate|Pediatric Study: Duration of Response|Pediatric Study: Overall Survival|Pediatric Study: Time to Progression|Pediatric Study: Progression-Free Survival|Pediatric Study: Percentage of Participants With Changes in Neurological Status and Functioning	AbbVie|European Organisation for Research and Treatment of Cancer - EORTC	All	"up to 99 Years   (Child, Adult, Older Adult)"	Phase 2	266	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M14-483|2014-004438-24|EORTC 1410-BTG	17-Feb-15	24-Jun-19	24-Jun-19	22-Jan-15	22-May-20	22-May-20	"Lucile Packard Children's Hosp /ID# 153678, Palo Alto, California, United States|Children's Hospital Colorado /ID# 153677, Aurora, Colorado, United States|Univ of Colorado Cancer Center /ID# 134882, Aurora, Colorado, United States|Sarah Cannon Research Institute at HealthONE - Denver /ID# 141798, Denver, Colorado, United States|Rush University Medical Center /ID# 137542, Chicago, Illinois, United States|Dana-Farber Cancer Institute /ID# 154210, Boston, Massachusetts, United States|Long Island Brain Tumor Center /ID# 134496, Lake Success, New York, United States|Weill Cornell Medicine /ID# 152656, New York, New York, United States|Cleveland Clinic Main Campus /ID# 137540, Cleveland, Ohio, United States|University of Pittsburgh MC /ID# 134491, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC /ID# 134492, Nashville, Tennessee, United States|UT Southwestern Medical Center /ID# 136718, Dallas, Texas, United States|Swedish Medical Center /ID# 136719, Seattle, Washington, United States|Port Macquarie Base Hospital /ID# 134569, Port Macquarie, New South Wales, Australia|Sydney Children's Hospital /ID# 153533, Randwick, New South Wales, Australia|Royal North Shore Hospital /ID# 147092, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 134570, Waratah, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 134495, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 147091, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 135208, Adelaide, South Australia, Australia|Royal Hobart Hospital /ID# 135209, Hobart, Tasmania, Australia|Barwon Health University Hospital Geelong /ID# 134493, Geelong, Victoria, Australia|Royal Children's Hospital /ID# 157624, Melbourne, Victoria, Australia|University Hospital St. Polten /ID# 139070, St. Pölten, Niederoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 139071, Graz, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus /ID# 139068, Linz, Austria|Cliniques Universitaires Saint Luc /ID# 139391, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 139342, Charleroi, Hainaut, Belgium|UZ Gent /ID# 152944, Gent, Oost-Vlaanderen, Belgium|AZ St-Jan Brugge-Oostende AV /ID# 137927, Brugge, West-Vlaanderen, Belgium|ZNA Middelheim /ID# 137926, Antwerp, Belgium|UZ Leuven /ID# 137925, Leuven, Belgium|Montreal Neurological Institut /ID# 136309, Montreal, Quebec, Canada|Fakultni Nemocnice v Motole /ID# 139509, Prague 5, Praha 5, Czechia|Masarykuv onkologikcy ustav /ID# 139508, Brno, Czechia|FN Hradec Kralove /ID# 139510, Hradec Kralove, Czechia|Univ Hosp Ostrava-Poruba /ID# 139507, Ostrava, Czechia|Helsinki Univ Central Hospital /ID# 140078, Helsinki, Finland|Helsinki Univ Central Hospital /ID# 153069, Helsinki, Finland|Turku University Hospital /ID# 140861, Turku, Finland|CHRU Lille - Hôpital Claude Huriez /ID# 137916, Lille CEDEX, Hauts-de-France, France|Centre Oscar Lambret /ID# 169619, Lille, Hauts-de-France, France|CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France|Gustave Roussy /ID# 137912, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 137914, St Herblain CEDEX, Loire-Atlantique, France|Hopital de la Timone /ID# 137911, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU de Nice /ID# 137917, Nice CEDEX 1, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard /ID# 137918, Lyon CEDEX 08, Rhone, France|Institut de Cancer de l'Ouest /ID# 137909, Angers, France|Hospices Civils de Lyon /ID# 137913, Bron, France|Hopital Pitie Salpetriere /ID# 145887, Paris, France|Universitaetsklinik Heidelberg /ID# 137924, Heidelberg, Baden-Wuerttemberg, Germany|Universitatsklinik Regensburg /ID# 137920, Ratisbon, Bayern, Germany|Univ Klinik Eppendorf Hamburg /ID# 137921, Hamburg, Germany|LMU Klinikum der Universität München /ID# 137922, Munich, Germany|Universitatsklinikum Tubingen /ID# 137923, Tuebingen, Germany|Pecsi Tudomanyegyetem /ID# 136111, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 152578, Budapest, Hungary|National Institute of Oncology /ID# 135970, Budapest, Hungary|Orszagos Klinikai Idegtudomany /ID# 135971, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 135969, Debrecen, Hungary|Cork University Hospital /ID# 136828, Cork, Ireland|Beaumont Hospital /ID# 136829, Dublin, Ireland|Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 138335, Bologna, Italy|Ospedale Generale di Bolzano /ID# 138338, Bolzano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy|Istituto Oncologico Veneto /ID# 138336, Padova, Italy|Azienda Ospedaliera Sant' Andrea /ID# 138337, Rome, Italy|Seoul National Univ Bundang ho /ID# 136841, Seongnam, Gyeonggido, Korea, Republic of|Samsung Medical Center /ID# 136842, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 136840, Seoul, Korea, Republic of|Hospital Zambrano Hellion /ID# 138076, San Pedro Garza García, Mexico|Vrije Universiteit Medisch Centrum /ID# 137221, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 138266, Groningen, Netherlands|Erasmus Medisch Centrum /ID# 136981, Rotterdam, Netherlands|Haaglanden Medisch Centrum /ID# 137222, The Hague, Netherlands|Universitair Medisch Centrum Utrecht /ID# 137219, Utrecht, Netherlands|Prinses Maxima Centrum /ID# 204409, Utrecht, Netherlands|Uniwersyteckie Centrum Kliniczne /ID# 137919, Gdansk, Mazowieckie, Poland|Wojewodzkie Wielospecjalistycz /ID# 137654, Lodz, Poland|National University Hospital /ID# 135951, Singapore, Singapore|National Cancer Ctr Singapore /ID# 135952, Singapore, Singapore|KK Women's & Children Hospital /ID# 153676, Singapore, Singapore|Instituto Catalán de Oncología (ICO) Badalona /ID# 140976, Badalona, Barcelona, Spain|Clinica Universitar de Navarra - Pamplona /ID# 140047, Pamplona, Navarra, Comunidad, Spain|Instituto Catalan de Oncologia (ICO) & Hosp. de Bellvitge /ID# 137688, Barcelona, Spain|Hospital Universitario Nino /ID# 153800, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 137908, Madrid, Spain|Centre Hospitalier Univ Vaudoi /ID# 137929, Lausanne, Switzerland|University Hospital Zurich /ID# 137930, Zurich, Switzerland|China Medical University Hosp /ID# 136976, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 136975, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 136977, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 136974, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 136944, Taoyuan City, Taiwan|Guy's and St Thomas' NHS Found /ID# 140312, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 136978, Birmingham, United Kingdom|Gartnavel General Hospital /ID# 136979, Glasgow, United Kingdom|Hull and East Yorkshire NHS /ID# 136917, Hull, United Kingdom|University College Hospitals /ID# 136879, London, United Kingdom|Great Ormond St Hospital NHS /ID# 153421, London, United Kingdom|Christie NHS Foundation Trust /ID# 140313, Manchester, United Kingdom"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/06/NCT02343406/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02343406/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02343406
237	NCT02968940	Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma		Completed	No Results Available	Glioblastoma	Biological: Avelumab|Radiation: Hypofractionated radiation therapy (HFRT)	Safety (adverse events) of the protocol therapy|Progression-free survival (PFS6)|Overall survival (OS)|Median PFS|Response Rate|Median duration of response	NYU Langone Health|EMD Serono	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	6	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-01179	17-Mar-17	29-Aug-19	29-Aug-19	21-Nov-16		18-Jun-21	"University of California, Los Angeles (UCLA), Los Angeles, California, United States|UCSF Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center, New York, New York, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/40/NCT02968940/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02968940
238	NCT03018288	Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Pembrolizumab|Biological: HSPPC-96|Drug: Temozolomide|Other: Placebo	To determine whether the one-year overall survival (OS) is improved in newly diagnosed MGMT unmethylated GBM patients treated with RT + TMZ + Pembrolizumab followed by Pembrolizumab + TMZ +/- HSPPC-96 x 6 cycles (1 cycle is 9 weeks) months.	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	90	NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	170034|17-C-0034	21-Sep-17	9-Jan-23	9-Jan-25	12-Jan-17		12-Nov-21	"Cedars Sinai Medical Center, Los Angeles, California, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northshore University Health System, Evanston, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Henry Ford Health Systems, Detroit, Michigan, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|MUSC Hollings Cancer Center, Charleston, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University Of Texas SW Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Washington Medical Center, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT03018288
239	NCT03345095	A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma	MIRAGE	"Active, not recruiting"	No Results Available	Newly Diagnosed Glioblastoma	Drug: Marizomib|Drug: Temozolomide|Radiation: radiotherapy	Overall Survival (OS)|Progression Free Survival (PFS)|Health-related Quality of life (HRQol)|Mini Mental State Examination (MMSE)	European Organisation for Research and Treatment of Cancer - EORTC|Celgene|Canadian Cancer Trials Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	749	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-BTG-1709	26-Jul-18	Jul-22	Jul-23	17-Nov-17		6-Oct-20	"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|University of California at Irvine, Orange, California, United States|University of California, San Francisco, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Penn State College of Medicine, Hershey Medical Center-Penn State Neuroscience Institute, Hershey, Pennsylvania, United States|Innsbruck Universitaetsklinik, Innsbruck, Austria|Kepler University Hospital, Linz, Austria|Medical University Vienna - General Hospital AKH, Vienna, Austria|Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium|GasthuisZusters Antwerpen - Sint-Augustinus, Antwerpen, Belgium|Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|C.H.U. Sart-Tilman, Liège, Belgium|Saint John Regional Hospital, Saint John, New Brunswick, Canada|London Regional Cancer Center, London, Ontario, Canada|Ottawa Health Research Institute, Ottawa, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada|BCCA - Abbotsford Centre, Abbotsford, Canada|Tom Baker Cancer Centre, Calgary, Canada|QEII Health Sciences Centre-Capital District Health Authority, Halifax, Canada|Hamilton Health Sciences, Juravinski Cancer Centre, Hamilton, Canada|Kingston Health Sciences Centre, Kingston, Canada|Montreal Neurological Institute and Hospital McGill University, Montréal, Canada|CHUM - Centre Hospitalier de l'Université de Montreal - Hopital Notre-Dame, Montréal, Canada|Hopital Du Sacre-Coeur De Montreal, Montréal, Canada|CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec, Canada|Allan Blair Cancer Centre, Regina, Canada|Sault Area Hospital, Sault Ste. Marie, Canada|Regional Cancer Program of Hopital Reg. de Sudbury Reg. Hospital, Sudbury, Canada|Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto, Canada|University Health Network - Oci / Princess Margaret Hospital, Toronto, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivières, Canada|BC Cancer Agency, Vancouver, Canada|Bcca - Vancouver Island Cancer Centre, Victoria, Canada|Cancercare Manitoba, Winnipeg, Canada|Aarhus University Hospitals - Aarhus University Hospital (440), Aarhus, Denmark|University Hospitals Copenhagen - Rigshospitalet, Copenhagen, Denmark|Centre Hospitalier Departemental Vendée, La Roche-sur-Yon, Vendee, France|CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron, France|CHRU de Lille, Lille, France|Institut de Cancerologie de l'Ouest, Nantes, France|Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere, Paris, France|Gustave Roussy, Villejuif, France|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinik Erlangen-Neurologische Klinik (3031), Erlangen, Germany|Klinikum Der J.W. Goethe Universitaet-Klinik und Poliklinik fur Neurochirurgie, Frankfurt, Germany|UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg, Germany|Universitaetsklinikum Leipzig-Klinik für Strahlentherapie und Radioonkologie, Leipzig, Germany|Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center, Mainz, Germany|UniversitaetsMedizin Mannheim, Mannheim, Germany|Technische Universitaet Muenchen - Klinikum Rechts Der Isar, Muenchen, Germany|Universitaetskliniken Regensburg, Regensburg, Germany|Universitaetsklinikum Tuebingen- Crona Kliniken, Tuebingen, Germany|Catharina Ziekenhuis, Eindhoven, North Brabant, Netherlands|Spaarne Gasthuis - Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Radboud University Medical Center Nijmegen, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum - Academisch Ziekenhuis, Utrecht, Netherlands|Oslo University Hospital - Radiumhospitalet, Oslo, Norway|Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Badalona, Spain|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Institut Catala D'Oncologia, L'Hospitalet De Llobregat, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Clinica Universidad de Navarra - Clinica Universitaria De Navarra, Pamplona, Spain|University Hospital of Geneva, Geneva, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital, Saint Gallen, Switzerland|UniversitaetsSpital, Zürich, Switzerland|NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital, Sheffield, United Kingdom"		https://ClinicalTrials.gov/show/NCT03345095
240	NCT02669173	Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Capecitabine|Drug: Bevacizumab	Change of concentration in circulating MDSCs after treatment with low dose capecitabine|Concentration of MDSCs in resected glioblastoma after treatment with low dose capecitabine|Concentration of T-regulatory cells after treatment with low dose capecitabine|Number of participants with adverse events relating to treatment with low-dose capecitabine alone as assessed by CTCAE v4.0|Number of participants with adverse events relating to treatment with low-dose capecitabine combined with bevacizumab as assessed by CTCAE v4.0	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE7315	11-Oct-16	Jan-22	Jan-22	1-Feb-16		5-Sep-21	"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02669173
241	NCT02928575	"Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma"		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: Sunitinib|Drug: Temozolomide|Radiation: Radiation Therapy	Tumor Response Rate|Overall Survival|Progression free survival|Biomarkers (Cytokines) response|Adverse Events|level of functioning|Increase use of corticosteroids	Bassam Abdulkarim|Pfizer|Canadian Cancer Society (CCS)|McGill University Health Centre/Research Institute of the McGill University Health Centre	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	45	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	McG 1132	Aug-12	Dec-16	Jun-17	10-Oct-16		10-Oct-16	"Tom Baker Cancer Center and University of Calgary, Calgary, Alberta, Canada|McGill University Health Centre, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT02928575
242	NCT01043536	Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults	SIB-IMRT	Completed	No Results Available	Glioblastoma	Radiation: radiotherapy|Drug: temozolomide	To determine the OTR (optimal tolerated regimen) of radiotherapy administered in combination with temozolomide as first-line therapy in patients with de novo glioblastoma	"Centre Georges Francois Leclerc|Ligue contre le cancer, France"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0244-1blni08 / 009.020	Sep-09	Jan-12		6-Jan-10		25-Sep-12	"Centre Georges François Leclerc, Dijon, Bourgogne, France"		https://ClinicalTrials.gov/show/NCT01043536
243	NCT02329795	Image-derived Prediction of Response to Chemo-radiation in Glioblastoma	IDEPREG	Terminated	No Results Available	Glioblastoma	Radiation: Radiotherapy|Drug: Temozolomide	Sensitivity and specificity of predicted response|DICE-similarity coefficient and percentage overlap of 64Cu-ATSM and contrast-enhanced T1-weighted MRI|Correlation (volume and maximum values) between lactate and hypoxia	"Rigshospitalet, Denmark"	All	"18 Years and older   (Adult, Older Adult)"		16	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	192/13	Oct-14	Oct-16	Oct-16	1-Jan-15		12-Oct-17	"Department of Oncology, Section for Radiotherapy, Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT02329795
244	NCT02590497	Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery		Withdrawn	No Results Available	Glioblastoma	Procedure: Diffusion Weighted Imaging|Drug: Gadolinium|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Procedure: Perfusion Magnetic Resonance Imaging	Correlation between the genetic and neuroimaging signature of glioblastoma and prognosis|Diffusional kurtosis (DK) values|Genetic tumor profile	Ohio State University Comprehensive Cancer Center	All	"Child, Adult, Older Adult"	Not Applicable	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	OSU-15019|NCI-2015-00873	20-Mar-16	26-Oct-17	26-Oct-17	29-Oct-15		31-Jan-18			https://ClinicalTrials.gov/show/NCT02590497
245	NCT00892931	Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Azixa	To determine the progression-free survival (PFS) rate|Overall survival|Overall response rate	Myrexis Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MPC-6827-019	Apr-09	Jul-11	Sep-11	5-May-09		14-Oct-11	"Barrow Neurological Institute, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Northwestern University, Chicago, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Massachusettes, Worcester, Massachusetts, United States|Darthmouth -Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University, New York, New York, United States|SCCA/University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00892931
246	NCT04573140	A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)		Recruiting	No Results Available	Adult Glioblastoma	"Biological: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)"	Manufacturing feasibility|Safety of RNA-LP vaccine|Determination of Maximum Tolerated Dose	"University of Florida|Pacific Pediatric Neuro-Oncology Consortium|University of California, San Francisco|CureSearch"	All	"21 Years and older   (Adult, Older Adult)"	Phase 1	28	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OCR32702-Adults|IRB202001710	26-Oct-21	Oct-22	Oct-22	5-Oct-20		28-Oct-21	"UF Health, Gainesville, Florida, United States"		https://ClinicalTrials.gov/show/NCT04573140
247	NCT04116411	A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients	VIGAS2	Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Valganciclovir Tablets|Drug: Temozolomide 120 mg|Radiation: Radiotherapy 60 Gy|Drug: Placebo oral tablet	Impact of valganciclovir on median overall survival of glioblastoma patients|Baseline and demographic data|Progression free survival at 12 and 24 months|Incidence of valganciclovir treatment related adverse events|Health related Quality of Life using EORTC QLQ30 module|Cognitive functions|Health related Quality of Life using the EORTC BN20 module	Cecilia Soderberg-Naucler|Karolinska University Hospital|Karolinska Institutet	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	220	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	Eudra CT: 2019-001083-30	4-Sep-19	31-Aug-24	31-Aug-24	4-Oct-19		13-Sep-21	"SE01 Karolinska University Hospital, Solna, Stockholm, Sweden"		https://ClinicalTrials.gov/show/NCT04116411
248	NCT02378532	The Addition of Chloroquine to Chemoradiation for Glioblastoma	CHLOROBRAIN	Completed	No Results Available	Glioblastoma Multiforme	Drug: Chloroquine|Radiation: Radiotherapy|Drug: Temozolomide	"Toxicity (CTC AE 4.0|Pharmacokinetics of chloroquine, desethylchloroquine, bisdesethylchloroquine. Profile parameters will include trough level (Cmin), AUC and elimination half-life.|Presence of autophagic markers (LC3 and autophagic vesicles)|Evaluation of EGFRvIII status in histopathological material"	Maastricht Radiation Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	13	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHLOROBRAIN	Aug-16	17-Jan-19	30-Jul-19	4-Mar-15		23-Jan-20	"Maastricht Radiation Oncology, Maastricht, Netherlands"		https://ClinicalTrials.gov/show/NCT02378532
249	NCT04474353	Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma|Newly Diagnosed Glioblastoma	Device: Optune|Drug: Gadolinium|Drug: Temozolomide|Radiation: Stereotactic radiosurgery (SRS)	Dose-limiting Toxicity (DLTs)|Acute dose limiting toxicity|Progression-free Survival (PFS) at 6 Months|Overall Survival (OS)	Stanford University|NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-53582|BRN0043	21-May-21	Nov-23	May-24	16-Jul-20		1-Nov-21	"Stanford University, Stanford, California, United States"		https://ClinicalTrials.gov/show/NCT04474353
250	NCT03212235	Hypofractionated Radiation Therapy for Glioblastoma		Unknown status	No Results Available	Glioblastoma Multiforme	Radiation: Hypofractionated radiation therapy	Overall survival|Progression-free survival	Instituto do Cancer do Estado de São Paulo	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	58	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Hypofractionated GBM	5-Jun-17	1-Jun-19	1-Jun-20	11-Jul-17		11-Jul-17	"Instituto do Cancer do Estado de São Paulo (ICESP) - FMUSP, São Paulo, Sao Paulo, Brazil"		https://ClinicalTrials.gov/show/NCT03212235
251	NCT02648633	Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma		Terminated	No Results Available	Glioblastoma	Radiation: Stereotactic Radiosurgery|Drug: Nivolumab|Drug: Valproate	Feasibility based on number of subjects who complete 4 doses of nivolumab|Incidence of adverse events|Clinical Response Rate	University of Virginia	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	4	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18574|CA209-378	24-May-16	21-Feb-17	21-Feb-17	7-Jan-16		31-May-17	"University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02648633
252	NCT02049489	A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma Multiforme	Biological: ICT-121 DC vaccine	Safety and tolerability of an autologous ICT-121 DC vaccine|Response rate and immune response to autologous ICT-121 DC vaccine	Precision Life Sciences Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICT-121 DC-01	Dec-13	Mar-17	Mar-17	30-Jan-14		13-Aug-18	"University of Alabama at Birmingham, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|JFK New Jersey Neuroscience Institute, Edison, New Jersey, United States|Penn State Hershey Neuroscience Institute, Hershey, Pennsylvania, United States|Baylor Research Institute - Charles A. Sammons Cancer Center, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT02049489
253	NCT02342379	TH-302 in Combination With Bevacizumab for Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Bevacizumab|Drug: TH-302	Number of Patients With Adverse Events|Progression Free Survival	The University of Texas Health Science Center at San Antonio	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	35	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTRC 12-0105|HSC20130212H	May-15	4-Jan-19	4-Dec-19	19-Jan-15	10-Apr-20	10-Apr-20	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio, Texas, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/79/NCT02342379/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02342379
254	NCT01022918	Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma	TemAvIr	Completed	No Results Available	Naive Unresectable Glioblastoma	Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|Drug: Temodal/radiotherapy	"To determine the rate of non-progressive disease at 6 months after inclusion in each arms|To determine if bevacizumab-based regimen increases the overall survival in comparison of the Stupp regimen|To evaluate if any bevacizumab-based regimen increases the survival without neurologic degradation and the quality of life according to the QLC-C30 and the specific Brain Cancer Module QLQ-BN20 scales.|To evaluate the tolerance of the bevacizumab-based regimens according to the NCI-CTCAE, version 3.0 scale. To record the rate of serious adverse events (mainly the theoretical risk of brain hemorrhage with bevacizumab)"	"Centre Georges Francois Leclerc|National Cancer Institute, France|Association de Neuro-Oncologues d'Expression Francaise|UNICANCER|Hoffmann-La Roche|Pfizer"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	134	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TemAvIr	Jan-09	Jul-10	Jan-11	1-Dec-09		25-Sep-12	"Centre Georges François Leclerc, Dijon, Bourgogne, France"		https://ClinicalTrials.gov/show/NCT01022918
255	NCT01854099	Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens	PERFORMANCE	Withdrawn	No Results Available	Glioblastoma	Biological: PEP-CMV	Safety	University of Florida|American Brain Tumor Association	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PERFORMANCE	Jan-14	Jan-14	Jan-14	15-May-13		14-Jan-14			https://ClinicalTrials.gov/show/NCT01854099
256	NCT00250887	"Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research"		Completed	No Results Available	Recurrent Glioblastoma	Drug: Gefitnib	molecular signature of EGFR responsiveness to ZD1839|PFS	University of Zurich	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	22	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1839IL/0526	Jul-05		May-07	8-Nov-05		23-Oct-07	"University Hospital Zürich, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT00250887
257	NCT01473901	A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: BKM120 + temozolomide|Drug: BKM120 +temozolomide with/without radiotherapy	"Dose Limiting Toxicity (DLT)|No of participants with Adverse events based on abnormal laboratory results, abnormal electrocardiogram (ECG) findings|Objective response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)|Plasma concentration-time profiles and basic pharmacokinetic parameters of BKM120 and temozolomide (Cmax, tmas, AUC, half-life)"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	38	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CBKM120E2101|2011-001157-87	30-Dec-11	17-May-17	17-May-17	17-Nov-11		9-Dec-20	"Highlands Oncology Group Highlands Oncology, Fayetteville, Arkansas, United States|Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States|University of Texas/MD Anderson Cancer Center MD Anderson DeGrout, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT01473901
258	NCT00694837	Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: nelfinavir	Fase I: To determine the MTD of nelfinavir as an adjuvant in the radiochemotherapy treatment in primary glioblastoma patients. Fase 2: Progression free survival at 6 months|Fase 1/2: Incidence of acute toxicity; OS; Metabolic ratios of SUV of serial 18F-FDG: assessed by PET-CT.Fase 1:6-months PFS; Relative blood flow measurement by perfusion MRI. Fase 2: PFS at 12 months; Phosphorylation of AKT in tumour tissue.	Maastricht Radiation Oncology|Maastricht University Medical Center	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-09-04/07|EudraCT number 2008-001078-34	Mar-09	Jan-13	Jan-13	11-Jun-08		10-Apr-15	"Maastricht Radiation Oncology, Maastricht, Netherlands"		https://ClinicalTrials.gov/show/NCT00694837
259	NCT02864368	Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens	PERFORMANCE	Terminated	Has Results	Glioblastoma|Glioblastoma Multiforme	Drug: 5-day TMZ|Drug: 21-day TMZ|Biological: PEP-CMV: Component A|Drug: Tetanus-Diphtheria booster|Drug: Tetanus Pre-Conditioning|Biological: PEP-CMV: Component B	Percentage of Participants With Treatment-related Adverse Events|Immunologic Response as Measured by Peak Number of T Cells That Secrete IFNγ by ELISPOT in Response to Component A of PEP-CMV|Antigen Loss	"Gary Archer Ph.D.|Annias Immunotherapeutics, Inc.|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	27	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00034208_1|2R42CA153845-02	7-Dec-16	15-Jun-20	15-Jun-20	12-Aug-16	9-Nov-21	9-Nov-21	"The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan: Study Protocol Document with SAP, https://ClinicalTrials.gov/ProvidedDocs/68/NCT02864368/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02864368
260	NCT02550249	Neoadjuvant Nivolumab in Glioblastoma	Neo-nivo	Completed	No Results Available	Glioblastoma Multiforme	Drug: Nivolumab	"Changes in percentage and level of expression of Programmed Death-Ligand 1 (PD-L1) by tumor cells and lymphocytes, assessed at baseline and following neoadjuvant nivolumab in Glioblastoma multiforme (GBM).|Efficacy: response rate assessed by Response Assessment in Neuro-Oncology (RANO) criteria|Safety: toxicity assessed by Common Toxicity Criteria (CTC) version 4"	"Clinica Universidad de Navarra, Universidad de Navarra"	All	"1 Year and older   (Child, Adult, Older Adult)"	Phase 2	29	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Neo-nivo	Jun-15	Mar-17	Mar-17	15-Sep-15		11-Apr-17	"Clinica Universidad de Navarra, Pamplona, Navarra, Spain"		https://ClinicalTrials.gov/show/NCT02550249
261	NCT02866747	A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma	STERIMGLI	Recruiting	No Results Available	Glioblastoma	Radiation: Hypofractionated stereotactic radiation therapy|Drug: Durvalumab	Phase I: Dose Limiting Toxicities (DLT) incidence|Phase II: overall survival|Phase I and II: Intracranial progression-free interval|Phase I: Safety and tolerability according to the classification of the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.03|Phase I and II: Quality of life using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ C30).|Phase I and II : Quality of life using the using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Brain Neoplasm (QLQ-BN20).|Phase I and II: Neurologic and neurocognitive functions using Neurologic Assessment in Neuro-Oncology (NANO) scale.|Phase I and II: Neurologic and neurocognitive functions using Neurologic Assessment in Montreal Cognitive Assessment (MoCA) tests.|Phase II: Time to Quality of Life (QoL) deterioration.|Phase II: time to neurocognitive deterioration|Phase II: Immune-related intracranial progression-free interval|Phase II: Acute and late toxicities according to the classification of the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.03	Institut Claudius Regaud|AstraZeneca	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	112	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16TETE04	17-Jan-17	Dec-24	Dec-24	15-Aug-16		28-Jul-21	"Institut de Cancerologie de L'Ouest, Angers, France|Hopital Avicenne, Bobigny, France|Centre Francois Baclesse, Caen, France|Centre Georges Francois Leclerc, Dijon, France|Institut Regional Du Cancer de Montpellier, Montpellier, France|Hopital Pitie Salpetriere, Paris, France|Institut Curie, Saint Cloud, France|Centre Paul Strauss, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France"		https://ClinicalTrials.gov/show/NCT02866747
262	NCT04838782	Role of Repeat Resection in Recurrent Glioblastoma		Not yet recruiting	No Results Available	Recurrent Glioblastoma|Glioblastoma - Category	Procedure: Repeat Surgical Management of Recurrent GBM	"Length of Overall Survival|Total length of hospitalization / palliative care / nursing home|Discharge to a location other than home|Total number of days spent outside a hospital or nursing care facility.|Incidence of peri-operative non-neurological complications (wound infection, CSF leaks)|Incidence of new significant neurological deficits after surgery (defined as new or substantially worsened aphasia, or new weakness (MRC power < 3 in one or more limbs)."	University of Alberta	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	250	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-210049	1-Nov-21	1-Jan-30	1-Jan-31	9-Apr-21		4-Oct-21	"University of Alberta Division of Neurosurgery, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT04838782
263	NCT02359097	Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma		Completed	No Results Available	Glioblastoma	Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Drug: Ferumoxytol|Drug: Gadoteridol|Procedure: Magnetic Resonance Imaging	Assessment of overlay accuracy with 3-dimensional (3D) anatomical T1w post contrast scans (MPRAGE)|Confidence in identifying the lesion corresponding areas on cerebral blood volume (CBV) maps|Assessment of cerebral blood volume (CBV) in small (< 1 cm) enhancing lesions|Delineation of tumor from larger blood vessels|Overall survival|Relative cerebral blood volume (rCBV) values|Ferumoxytol enhancement	OHSU Knight Cancer Institute|Oregon Health and Science University	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	29	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	IRB00009846|NCI-2015-00080|SOL-13090-L|eIRB#9846	6-Jan-15	12-Mar-21	12-Mar-21	9-Feb-15		21-May-21	"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT02359097
264	NCT00385853	PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs		Completed	No Results Available	Glioblastoma	Drug: PTK787/ZK 222584|Drug: Temozolomide|Procedure: Radiation Therapy	"To determine the maximal tolerated dose, safety and feasibility of PTK787/ZK 222584 in combination with temozolomide and radiation in patients with newly diagnosed glioblastoma.|Determine the pharmacologic profile of PTK787/ZK 222584 in this patient population|determine the overall survival of patients with recurrent GM treated with PTK787/ZK 222584, when combined with temozolomide and radiation therapy."	Massachusetts General Hospital|Dana-Farber Cancer Institute|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	06-013	Sep-06	Sep-11	Sep-11	11-Oct-06		21-Oct-13	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00385853
265	NCT02379572	Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas		Completed	No Results Available	Glioblastoma	Device: iMRI-guided surgery|Drug: 5-ALA-guided surgery	Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgery|Patients' clinical condition (KPS)|Patients' clinical condition (NIHSS)|Patients' clinical condition (QoL)|ICU and hospital stay after surgery|Patients' adjuvant treatment|Recurrent tumor growth (RANO criteria)|Follow-up imaging|Histology|MGMT (O6-methylguanine-DNA-methyltransferase) analysis|IDH-1 (isocitrate dehydrogenase) analysis|Progression-free survival (PFS)|Overall survival (OS)	University Hospital Tuebingen	All	"18 Years to 80 Years   (Adult, Older Adult)"	Not Applicable	315	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Nch1	Jun-15	Jun-20	1-Jul-21	5-Mar-15		22-Oct-21	"Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany, Bonn, Germany|Department of Neurosurgery, Universität zu Köln, Köln, Germany, Cologne, Germany|Städtisches Klinikum Dresden Friedrichstadt, Dresden, Germany|Department of Neurosurgery, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Düsseldorf, Germany|Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany|Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main, Frankfurt a.M., Germany|Department of Neurosurgery, Georg-August-Universität Göttingen, Göttingen,, Göttingen, Germany|Department of Neurosurgery, University of Ulm, Hospital Günzburg,, Günzburg, Germany|Asklepios Klinik Hamburg, Klinik für Neurochirurgie, Hamburg, Germany|International Neuroscience Institute Hannover, Hannover, Germany, Hannover, Germany|Department of Neurosurgery, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany|Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany, Kiel, Germany|Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Münster, Germany, Münster, Germany|Department of Neurosurgery, Eberhard Karls University, Tübingen,, Tübingen, Germany|Department of Neurosurgery, Julius-Maximilians-Universität Würzburg, Würzburg, Germany"		https://ClinicalTrials.gov/show/NCT02379572
266	NCT00941460	Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma	DIRECTOR	Completed	No Results Available	Glioblastoma	Drug: Temozolomide in both arms	Median time to treatment failure. Treatment failure is reached (i) upon tumor progression as outlined in protocol (ii) if treatment has to be terminated due to toxicity or (iii) if the patient dies for any reason.|progression free survival	Prof. Dr. Wolfgang Wick|Essex Pharma GmbH|Heidelberg University	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	105	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DIRECTOR|2008-006871-60|ISRCTN68738654	Sep-09	Jun-13	Jun-13	17-Jul-09		15-Aug-14	"Landesnervenklinik Wagner-Jauregg, Linz, Austria|Medical University Vienna, Department of Internal Medicine I, Wien, Austria|Charite, Department of Neurosurgery, Berlin, Germany|Knappschaftskrankenhaus, Department of Neurology, Bochum, Germany|University Hospital Bonn, Department of Neurology, Bonn, Germany|University Hospital Düsseldorf, Düsseldorf, Germany|Klinikum der Johann-Wolfgang von Goethe-Universität, Dr. Senckenbergisches Institut für Neuroonkologie, Zentrum für Neurologie und Neurochirurgie, Frankfurt, Germany|University Hospital Freiburg, Freiburg, Germany|University Hospital Heidelberg, Department of Neurooncology, Heidelberg, Germany|Saarland University, Department of Neurosurgery, Homburg/ Saar, Germany|Klinik für Allgemeine Neurochirurgie, Köln, Germany|Klinik und Poliklinik für Neurochirurgie, Leipzig, Germany|Ludwig Maximilians University of Munich , Grosshadern Hospital, Department of Neurosurgery, Munich, Germany|University of Regensburg, Department of Neurology, Regensburg, Germany|University Hospital Zurich, Department of Neurology, Zurich, CH, Switzerland|Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00941460
267	NCT02410577	89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme		Completed	Has Results	Glioblastoma	Drug: 89Zr-J591|Device: PET/CT Scan|Device: MRI|Other: Blood draw	Binding of 89Zr-J591	Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University	All	"26 Years to 79 Years   (Adult, Older Adult)"	Not Applicable	2	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	15-002	Apr-15	Aug-18	Aug-18	7-Apr-15	19-Mar-19	19-Mar-19	"Memorial Sloan Kettering Cancer Center, New York, New York, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/77/NCT02410577/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02410577
268	NCT03344250	Phase I EGFR BATs in Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: EGFR BATs with TMZ following SOC RT/TMZ|Drug: Weekly EGFR BATs following SOC RT/TMZ	"Maximum tolerated dose|Immune measures in blood- cellular phenotype|Immune measures in blood- interferon-γ|Immune measures in blood- EliSpots|Immune measures in blood- anti-GBM cytotoxicity of peripheral blood mononuclear cells directed at GBM cell lines|Immune measures in blood- serum cytokine patterns|Immune measures in blood- anti-GBM antibodies|Clinical response|Survival|Response Rate|Correlation of imaging to PFS and OS|Correlation of pathology to PFS and OS|Correlation of clinical response to PFS and OS|Correlation of immune response to PFS and OS|Adverse events, including dose limiting toxicities"	University of Virginia	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20105	1-Mar-18	31-Aug-21	31-Aug-22	17-Nov-17		18-Jun-21	"University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT03344250
269	NCT02586857	"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)"		"Active, not recruiting"	Has Results	Glioblastoma Multiforme	Drug: ACP-196	Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.	Acerta Pharma BV	All	"Child, Adult, Older Adult"	Phase 1|Phase 2	24	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACE-ST-209	25-Jan-16	26-Jun-20	31-Dec-25	27-Oct-15	29-Jul-20	29-Oct-21	"Research Site, Los Angeles, California, United States|Research Site, Palo Alto, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Vancouver, Washington, United States"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/57/NCT02586857/Prot_003.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02586857/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02586857
270	NCT03506139	Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma		Withdrawn	No Results Available	Glioblastoma|Glioblastoma Multiforme	Radiation: External beam radiation therapy	Overall survival|Progression free survival (PFS)|Identifying tissue at risk of recurrence|Distinguish progression from pseudoprogression|Adverse events related to treatment	John M. Buatti|Holden Comprehensive Cancer Center|University of Iowa	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201801819	15-May-19	31-Dec-24	31-Dec-26	23-Apr-18		9-Sep-20	"University of Iowa Department of Radiation Oncology, Iowa City, Iowa, United States"		https://ClinicalTrials.gov/show/NCT03506139
271	NCT00817284	Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)		Completed	No Results Available	Glioblastoma Multiforme	Drug: bevacizumab and Irinotecan and radiotherapy|Drug: Bevacizumab and Temozolomide and radiotherapy	Objective response rate according to McDonald criteria|Progression-free survival	"Ulrik Lassen|Rigshospitalet, Denmark"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BIBT-01	Nov-08	Nov-11	Nov-11	6-Jan-09		30-Nov-11	"Rigshospitalet, Copenhagen, Denmark|Odense Hospital, Odense, Denmark|Århus Hospital, Århus, Denmark"		https://ClinicalTrials.gov/show/NCT00817284
272	NCT02029573	Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma	ART	Completed	No Results Available	Glioblastoma Multiforme	Drug: Atorvastatin|Drug: Temozolomide|Radiation: Radiotherapy	Progression free survival at 6 months (PFS-6)|Progression free survival|Overall Survival (OS)|Adverse events	King Fahad Medical City	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	36	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KFMC-CNS-01	1-Jan-14	31-Dec-16	31-Dec-16	8-Jan-14		18-Aug-17	"King Fahad Medical City, Riyadh, Saudi Arabia"		https://ClinicalTrials.gov/show/NCT02029573
273	NCT00753246	Nimotuzumab in Adults With Glioblastoma Multiforma		Completed	No Results Available	Adults With Glioblastoma Multiforma	Drug: nimotuzumab	Progression-free interval determined by MRI|Overall survival Time to reintervention Response rate according to RECIST criteria Toxicity according to CTC criteria Symptom control Quality of life	"Oncoscience AG|Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany|University of Bonn|Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany|Heinrich-Heine University, Duesseldorf|Johann Wolfgang Goethe University Hospital|University of Giessen|Universitätsklinikum Hamburg-Eppendorf|University of Kiel|Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany|Universität Tübingen"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	150	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSAG101-BSA05	Aug-07		Jan-12	16-Sep-08		3-Dec-12	"Dep. Neurosurgery, Univ. Hamburg, Hamburg, Germany"		https://ClinicalTrials.gov/show/NCT00753246
274	NCT01989884	An Efficacy Study Of Ortataxel In Recurrent Glioblastoma	Ortataxel	Completed	No Results Available	Glioblastoma	Drug: Ortataxel	"progression free survival-6|progression free survival|Overall survival-9|Objective response rate|Number of patients with AEs, SAEs, SADRs, SUSARs|treatment compliance"	Mario Negri Institute for Pharmacological Research	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	45	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRFMN-GBM-6272	Nov-13	Dec-15	Dec-16	21-Nov-13		23-Oct-19	"Ospedale di Lecco, Lecco, Italy|A.O. OSpedale Niguarda Ca' Granda, Milano, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Carlo Besta Neurological Foundation, Milan, Italy|Fondazione ""Salvatore Maugeri"", Pavia, Italy|IRCCS Fondazione ""Casimiro Mondino"", Pavia, Italy|Istituti Fisioterapici Ospitalieri, Rome, Italy"		https://ClinicalTrials.gov/show/NCT01989884
275	NCT04485949	A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma - the ImmuneSense Study		Not yet recruiting	No Results Available	Glioblastoma Multiforme|Glioblastoma	Biological: IGV-001 Cell Immunotherapy|Biological: Placebo|Procedure: Standard of Care (SOC): Radiation Therapy|Drug: SOC: Temozolomide	Progression-free Survival (PFS)|Overall Survival (OS)|PFS at 6 Months After Randomization (PFS6)|PFS in Participants With O6-methylguanine-DNA Methyltransferase (MGMT) With Methylation [MGMT+] and MGMT Without Methylation [MGMT-]|OS in Participants With MGMT+ and MGMT-|Time to Definitive Deterioration Karnofsky Performance Status (KPS) Score|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Assessment Abnormalities|Number of Participants With Clinically Significant Vital Signs Measurements|Number of Participants With Clinically Significant Physical Examination Findings	Imvax	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	93	Industry	Interventional	"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	14379-201	Oct-21	Jun-23	Aug-25	24-Jul-20		10-Aug-21	"Investigation Site, Newark, Delaware, United States|Investigation Site, Boston, Massachusetts, United States|Investigation Site, Detroit, Michigan, United States|Investigation Site, Lebanon, New Hampshire, United States|Investigation Site, Hackensack, New Jersey, United States|Investigation Site, New York, New York, United States|Investigation Site, Cleveland, Ohio, United States|Investigation Site, Hershey, Pennsylvania, United States|Investigation Site, Philadelphia, Pennsylvania, United States|Investigation Site, Pittsburgh, Pennsylvania, United States|Investigation Site, Providence, Rhode Island, United States"		https://ClinicalTrials.gov/show/NCT04485949
276	NCT03866109	A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT	TEM-GBM	Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Temferon	Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse events|Long term tolerability and safety of Temferon as determined by the incidence of adverse events|Proportion of patients achieving haematologic recovery by Day +30 (defined as the first of at least 3 consecutive days with a neutrophil count >0.5 x 10^9/L and platelet count >20 x 10^9/L)|Determine the maximum tolerated dose of Temferon|Identify presence of transduced myeloid cells in bone marrow as determined by vector copy number|Incidence of adverse events attributed to the conditioning regimen|Identify presence of transduced myeloid cells in peripheral blood as determined by vector copy number|Determine clinical response in patients as determined by iRANO criteria|Determine progression free survival in patients|Determine overall survival in patients|Changes in functional status (Eastern Cooperative Oncology Group)|Changes in functional status (Karnofsky)|Changes in Quality of Life (European Organisation for Research and Treatment of Cancer EORTC C30)|Changes in Quality of Life (BN20)	Genenta Science	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	21	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TEM-GBM_001|2018-001404-11	5-Mar-19	Dec-22	Dec-22	7-Mar-19		10-Feb-21	"Ospedale San Raffaele, Milan, Italy|Fondazione IRCCS Istituto Neurologico ""Carlo Besta"", Milan, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Rome, Italy"		https://ClinicalTrials.gov/show/NCT03866109
277	NCT02315534	A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma		Completed	Has Results	Glioblastoma	Drug: BBI608|Drug: Temozolomide	Dose-limiting Toxicities (DLTs)|Progression Free Survival (PFS)-6|Progression Free Survival (PFS)-12|Overall Survival (OS)|Disease Control Rate (DCR)|Overall Response Rate (ORR)|Pharmacokinetic Profile of BBI608 and Temozolomide When Administered in Combination With Temozolomide as Assessed by the Area Under the Curve|Pharmacodynamic Activity of BBI608 When Administered in Combination With Temozolomide as Assessed by Tumor Biopsy and Cancer Stem Cell Assays as Well as the Concentration of Study Drug in Tumors	"Sumitomo Dainippon Pharma Oncology, Inc"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	34	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BBI608-251|BBI608-201GBM	Mar-15	9-Oct-18	24-Jun-19	12-Dec-14	24-Sep-21	24-Sep-21	"Laura and Isaac Perlmutter Cancer Center, New York, New York, United States|University of Calgary, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/34/NCT02315534/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02315534/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02315534
278	NCT04810182	Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Regorafenib 40 MG Oral Tablet [STIVARGA]	Overall Survival (OS)|Progression free survival (PFS)|Objective response rate (ORR)|Disease control rate (DCR)|Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events-CTCAE v5.0)	Istituto Oncologico Veneto IRCCS	All	"18 Years to 70 Years   (Adult, Older Adult)"		150	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IOV-GB-1-2020 REGOMA-OSS	10-Sep-20	30-Aug-22	30-Aug-22	22-Mar-21		22-Mar-21	"Ospedale Generale Regionale "" F.Miulli "", Acquaviva Delle Fonti, BA, Italy|Policlinico Universitario di Bari, Bari, BA, Italy|IRCCS ""Saverio de Bellis"", Castellana Grotte, BA, Italy|Ospedlae S. Martino, Belluno, BL, Italy|Ospedale Bellaria, Bologna, BO, Italy|Ospedale Perrino, Brindisi, BR, Italy|Università e ASST Spedali Civili, Brescia, BS, Italy|Irst-Irccs, Meldola, FC, Italy|Ospedale Santa Maria Annunziata, Bagno A Ripoli, FI, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, FI, Italy|Ospedale Civile di Livorno, Livorno, LO, Italy|Ospedale Generale Provinciale, Macerata, MC, Italy|AOU Policlinico ""G.Martino"", Messina, ME, Italy|Istituto Neurologico C. Besta IRCCS, Milano, MI, Italy|Ospedale Humanitas, Rozzano, MI, Italy|Ospedale del Mare, Napoli, NL, Italy|Fondazione Istiuto Giglio Cefalù, Cefalù, PA, Italy|Aulss6 Euganea Padova Sud Ospedali Riuniti, Piove Di Sacco, PD, Italy|Azienda Ospedaliero Universitaria di Pisa, Pisa, PI, Italy|Istituto Nazionale Tumori Regina Elena -IFO, Roma, RM, Italy|Policlinico Universitario Gemelli, Roma, RM, Italy|Ospedale di Rovigo, Rovigo, RO, Italy|Azienda Ospedaliero Universitaria di Siena, Siena, SI, Italy|Azienda Ospedaliero Universitaria della Città della Salute e della Scienza, Torino, TO, Italy|Azienda Ospedaliera Santa Maria, Terni, TR, Italy|Ospedale San Donà di Piave _Azienda ULSS 4 "" Veneto Orientale"", San Dona di Piave, VE, Italy|AULSS 7 Distretto 2 Ospedale Santorso, Santorso, VI, Italy|AULSS 9 Scaligera Ospedale Mater Salutis, Legnago, VR, Italy|Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy"		https://ClinicalTrials.gov/show/NCT04810182
279	NCT01867593	MET-PET for Newly Diagnosed Glioblastoma		Completed	No Results Available	Glioblastoma	Device: C-11 methionine PET	Effect of C-11 methionine PET on progression free survival|Evaluate for discordance in tumor volumes|Compare pre-radiation and follow-up C-11 methionine PET imaging in predicting sites of failure|Compare pre-radiation and follow-up C-11 methionine PET in predicting occurrence of pseudoprogression	Massachusetts General Hospital	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	13-018	Jan-14	Sep-16	Sep-16	4-Jun-13		13-Oct-17	"Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01867593
280	NCT03712293	ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy		Unknown status	No Results Available	Glioblastoma Multiforme	Device: BBB Disruption with Chemotherapy Arm	Adverse Events Safety Profile|Blood Brain Barrier Opening	InSightec	All	"19 Years to 80 Years   (Adult, Older Adult)"	Not Applicable	10	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT008K	28-Aug-18	1-Oct-21	1-Dec-21	19-Oct-18		9-Jan-20	"Severance Hospital, Yonsei University Health System, Seoul, Seodaemun-gu, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT03712293
281	NCT00730262	Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme		Terminated	No Results Available	Glioblastoma Multiforme	Drug: TLN-4601	"To assess the efficacy of TLN-4601 in patients with recurrent glioblastoma multiforme (GBM) as measured by 6-month progression free survival from date of initial infusion of TLN-4601 (Day 1, Cycle 1).|To examine the safety and tolerability of TLN-4601 in patients with recurrent GBM"	Thallion Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TLN-4601-201	Aug-08	Apr-10	Jun-10	8-Aug-08		30-Dec-09	"Sloan-Kettering Institute for Cancer Research, New York, New York, United States|Duke University, Durham, North Carolina, United States|Ottawa Health Research Institute, Ottawa, Ontario, Canada|The Pencer Brain Tumor Center, Princess Margaret Hospital, Toronto, Ontario, Canada|Hôpital Notre-Dame du CHUM, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|L'Hotel-Dieu de Quebec, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00730262
282	NCT01260467	Memantine for Recurrent Glioblastoma		Terminated	Has Results	Glioblastoma	Drug: memantine	Overall Survival|6 Month Progression-free Survival|Number of Participants With Adverse Events	University of Rochester	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	4	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RSRB34285|054835-002	Nov-10	Apr-14	Apr-14	15-Dec-10	10-Dec-15	10-Dec-15	"University of Rochester Medical Center, Rochester, New York, United States"		https://ClinicalTrials.gov/show/NCT01260467
283	NCT02751138	Determination of Immune Phenotype in Glioblastoma Patients		Recruiting	No Results Available	Glioblastoma Multiforme	Procedure: Surgery	Overall survival|Progression free survival|Karnofsky performance score	University of Ulm	All	"18 Years and older   (Adult, Older Adult)"		250	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	University Hospital Ulm	1-Mar-16	1-Mar-23	1-Sep-24	26-Apr-16		6-May-21	"Department of Neurosurgery, Ulm, Germany"		https://ClinicalTrials.gov/show/NCT02751138
284	NCT01872221	Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study	STEMRI	Completed	No Results Available	Glioblastoma	Procedure: Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol	Biologic analysis of the GBM resected samples for the capacity to form neurospheres in vitro|Biologic analysis of the GBM resected samples on the RNA expression of 5 stem cells markers|Biologic analysis of the GBM resected samples for their capacity to form invasive brain tumor after orthotopic implantation of the cells in nude mice|Time to progression|Overall survival	Institut Claudius Regaud	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	21	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	12TETE01	May-13	Apr-18	Apr-18	7-Jun-13		27-Aug-18	"CHU Rangueil, Toulouse, France|Institut Claudius REGAUD, Toulouse, France"		https://ClinicalTrials.gov/show/NCT01872221
285	NCT03722342	TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Recurrent Glioblastoma	Drug: TTAC-0001 and pembrolizumab combination	Dose limiting toxicities|Adverse events|Immunogenicity|Overall response rate|Disease control rate|Progression free survival|Overall survival	PharmAbcine	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	9	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PMC_TTAC-0001_04	16-Jan-19	4-Nov-19	15-Oct-22	26-Oct-18		19-May-21	"Austin Hospital, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"		https://ClinicalTrials.gov/show/NCT03722342
286	NCT03862430	"NVX-108 Combined With Radiation & TMZ, and During Maintenance Phase for Newly-diagnosed Glioblastoma Multiforme"		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: NVX-108|Drug: Placebo Saline Infusion	Progression-Free Survival (PFS)|Overall Survival|Objective Response Rate to study therapy	NuvOx LLC	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	87	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NVX-108-GBM-P2	Aug-21	Dec-24	Feb-25	5-Mar-19		4-May-21			https://ClinicalTrials.gov/show/NCT03862430
287	NCT01285414	"Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Glioblastoma Multiforme	Drug: Verubulin|Drug: Temozolomide & Radiation Therapy	Part A: Safety|Part B: 9 Mo Progression-free survival|Part A: Pharmacokinetic Parameters|Part B: 6 Mo Progression Free Survival|Overall Survival|Part B: 12 Mo Progression Free Survival	Myrexis Inc.	All	"18 Years to 69 Years   (Adult, Older Adult)"	Phase 2	5	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MPC-6827-021	Dec-10	Mar-12	Mar-12	28-Jan-11		11-Apr-12	"Stanford University, Stanford, California, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01285414
288	NCT03750071	VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma	Biological: VXM01|Biological: Avelumab	Treatment-emerging adverse events (safety and tolerability of VXM01 in combination with avelumab)|Clinical response as assessed by time to progression (TTP)|Clinical response as assessed by progression free survival (PFS)|Clinical response as assessed by recurrence-free survival after re-operation (RFS)|Clinical response as assessed by Overall Survival (OS)|Best overall response (OR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)|Duration of Response (DoR) on MRI according to iRANO in subjects with or without surgery prior to trial entry (up to re-operation)	"Vaximm GmbH|Merck KGaA, Darmstadt, Germany|Pfizer"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VXM01-AVE-04-INT	21-Nov-18	31-Dec-21	31-Dec-21	21-Nov-18		24-Jun-21	"Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany|Neurology Clinic, Mannheim, Germany"		https://ClinicalTrials.gov/show/NCT03750071
289	NCT04201873	Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma	Biological: Dendritic Cell Tumor Cell Lysate Vaccine|Biological: Pembrolizumab|Other: Placebo Administration|Drug: Poly ICLC	Cell cycle-related signature|Expansion of T cell receptor (TCR) clones|Incidence of adverse events (AEs)|6 month progression-free survival (PFS6)|Overall survival (OS)	"Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp.|Phase One Foundation|Oncovir, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	40	Other|NIH|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	19-001090|NCI-2019-07994	8-Jan-20	1-Aug-24	1-Aug-25	17-Dec-19		12-Mar-21	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT04201873
290	NCT01225510	A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma		Withdrawn	No Results Available	Glioblastoma	Biological: PF-04856884	"Progression free survival rate at Month 6 (PFS6) defined as the patient progression free status at Month 6.|Corticosteroid doses at baseline and on-study|Overall Response Rate (ORR)|PFS defined as the time from 1st dose of study drug to the 1st documentation of disease progression or death from any cause, whichever comes first.|Time to death is defined as the time from first study drug to death due to any cause.|Overall survival (OS) defined as the time from first dose of study drug to death due to any cause.|OS6 defined as the patient survival status at Month 6. The OS6 rate will be obtained as a Kaplan-Meier estimate of the time to death at Month 6.|Immunogenicity determined by measuring anti-PF-04856884 antibodies following therapy|Dynamic Contrast Enhanced Magnetic Resonance Imaging [DCE-MRI] endpoints to include changes from baseline volume transfer coefficient [Ktrans] and/or the initial area under the contrast agent concentration-time curve [IAUC] or Ki following therapy"	Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B1131003	Jan-11	Jan-13	Jan-13	21-Oct-10		11-Mar-15			https://ClinicalTrials.gov/show/NCT01225510
291	NCT02769806	Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma		Suspended	No Results Available	Glioblastoma|Glioblastoma Multiforme	Procedure: MRI	A novel high resolution DSC-PWI imaging method	"University of Wisconsin, Madison|National Institute for Biomedical Imaging and Bioengineering (NIBIB)"	All	"18 Years to 82 Years   (Adult, Older Adult)"		25	Other|NIH	Observational	Observational Model: Case-Only|Time Perspective: Prospective	UW15098|2016-0007|A539300|SMPH\RADIOLOGY\RADIOLOGY|NCI-2019-06444|R21EB018483-01A1	23-May-16	Apr-22	Apr-22	12-May-16		30-Mar-21	"University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT02769806
292	NCT01907165	Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide		Completed	No Results Available	Glioblastoma	Drug: Temozolomide|Drug: Disulfiram|Dietary Supplement: Copper gluconate	Pharmacological effect of disulfiram in GBM patients|Local tumor control probabilities|Time to tumor progression	Washington University School of Medicine	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	21	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201308038	10-Oct-13	10-Nov-16	9-Feb-18	24-Jul-13		20-Jul-18	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01907165
293	NCT02885272	FDG PET Imaging in Diagnosing Patients With Glioblastoma		Unknown status	No Results Available	Brain Glioblastoma	Procedure: Computed Tomography|Radiation: Fludeoxyglucose F-18|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography	"Differences in length-beam ratio|Quantitative parametric maps based on biophysical principles or pharmacokinetic modeling|Magnetic resonance images of relative blood volume, blood flow, apparent diffusion coefficient and forward volumetric transfer constant|Fluorodeoxyglucose F-18 uptake patterns|Genotypic factors"	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"19 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2016-0261|NCI-2016-01971|P30CA016672	28-Oct-16	31-Oct-21	31-Oct-21	31-Aug-16		30-Dec-19	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02885272
294	NCT04077866	B7-H3 CAR-T for Recurrent or Refractory Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma|Refractory Glioblastoma	Drug: Temozolomide|Biological: B7-H3 CAR-T	"Overall survival (OS)|Incidence and type of adverse events|Maximum tolerated dose (MTD)|Progression-free survival (PFS)|Peak Concentration (Cmax) of B7-H3 CAR-T|Area under the concentration versus time curve (AUC) of B7-H3 CAR-T|Disease response (ORR, CR, PR, DOR)"	"Second Affiliated Hospital, School of Medicine, Zhejiang University|Ningbo Yinzhou People's Hospital|Huizhou Municipal Central Hospital|BoYuan RunSheng Pharma (Hangzhou) Co., Ltd."	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SAHZJU-RCT-BP102	1-May-22	1-Jun-24	1-Jul-24	4-Sep-19		19-May-20	"the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Huzhou Central Hospital, Huzhou, Zhejiang, China|Ningbo Yinzhou People's Hospital, Ningbo, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04077866
295	NCT02209948	Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.		Completed	Has Results	Glioblastoma	Drug: Temozolomide	Progression Free Survival at 6 Month|Number of Participants With Adverse Effects|Progresion Free Survival Median Values|Overall Survival|Median Progression-free Survival (PFS) by Arm and MGMT Methylation Status|Median Overall Survival (OS) by Arm and MGMT Methylation Status|Translational Sub-study - Biomarkers: mutS Homolog 6 (MSH6) Immunoreactivity	Grupo Español de Investigación en Neurooncología	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	166	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEINO 14-01|2014-000838-39	22-Aug-14	Jun-19	14-Jun-19	6-Aug-14	12-Jan-21	12-Jan-21	"Hospital Universitari Germans Trias i Pujol/ICO Badalona, Badalona, Barcelona, Spain|Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Mallorca, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Consorcio Hospitalario Provincial de Castellón, Castelló, Valencia, Spain|Hospital del Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital General de Ciudad Real, Ciudad Real, Spain|Hospital Dr. Josep Trueta de Girona, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain"	"Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/48/NCT02209948/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT02209948/Prot_001.pdf"	https://ClinicalTrials.gov/show/NCT02209948
296	NCT03856099	TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: TTAC-0001	Adverse Events|Progression free survival rate at 4 months|Progression free survival rate at 6 months|Progression free survival|Overall survival|Objective response rate|Disease control rate	PharmAbcine	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PMC_TTAC-0001_03	13-Nov-19	30-Dec-21	30-Jun-22	27-Feb-19		16-Sep-21	"Stanford Avanced Medical Center, Stanford, California, United States|Florida Hospital Cancer Institute & Florida Hospital Orlando, Orlando, Florida, United States|Austin Hospital, Heidelberg, Victoria, Australia"		https://ClinicalTrials.gov/show/NCT03856099
297	NCT02047214	Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy		Terminated	No Results Available	Glioblastoma Multiforme	Drug: TPI 287|Drug: Bevacizumab	"Safety of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|MTD of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab|Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ & prior bevacizumab as measured by median progression free survival (PFS), overall response rate, & PFS rate at 4 & 6 months (PFS4 & PFS6)"	"Cortice Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	17	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TPI-287-18	Jan-14	Dec-15	Dec-15	28-Jan-14		31-Jan-18	"University of Alabama at Birmingham, Birmingham, Alabama, United States|H Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Washington University, School of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|University of Rochester Medical Center, Rochester, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Memorial Hermann Hospital, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT02047214
298	NCT00703859	Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma		Withdrawn	No Results Available	Glioblastoma	Drug: Dichloroacetate (DCA)	"Safety and tolerability of DCA in combination with radiotherapy and temozolomide in an adjuvant setting for the treatment of newly diagnosed GBM patients.|To determine if there is a correlation between MGMT promoter methylation status and progression-free survival for newly diagnosed GBM patients undergoing concurrent TMZ, DCA and RT followed by six monthly cycles of TMZ and DCA"	AHS Cancer Control Alberta	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CNS-24139	Jul-08	Jan-10		24-Jun-08		22-Feb-16			https://ClinicalTrials.gov/show/NCT00703859
299	NCT04250922	2-OHOA With RT and TMZ for Adults With Glioblastoma	CLINGLIO	Recruiting	No Results Available	Primary Glioblastoma|Glioblastoma Multiforme	Drug: 2-OHOA|Drug: TMZ|Radiation: RT	To evaluate the efficacy of 2-OHOA in combination with the standard of care (SoC) treatment of radiotherapy (RT) and TMZ.|To evaluate clinical response|To evaluate additional measures of efficacy|To characterize the pharmacokinetics (PK) parameters|To evaluate Health-related Quality of Life (HRQoL)	"Laminar Pharmaceuticals|Covance|Northern Institute for Cancer Research, Newcastle|Theradis pharma|LIPODOM THERAPEUTICS"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2|Phase 3	180	Industry|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	MIN-003-1806	1-Dec-19	30-Apr-22	30-Oct-23	31-Jan-20		19-Jul-21	"Institut Cancerologie de L'Ouest (ICO), Angers, France|Gustave Roussy University Hospital, Rennes, France|Institut universitaire du cancer, Toulouse, France|Reaserch Fund of the Hadassah Medical Organization, Jerusalem, Israel|Istituto Nazionale Neurologico Carlo Besta, Milan, Italy|Istituto Nazionale Tumori ""Regina Elena"", Roma, Italy|University of Turin, Turin, Italy|Hospital Universitari i Politécnic La Fe., Valencia, Comunidad Valenciana, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 De Octubre, Madrid, Spain|Hospital Parc Tauli, Sabadell, Spain|Freeman Hospital's Northern Centre of Cancer Care, Newcastle, Newcastle Upon Tyne, United Kingdom|Cambridge university hospital, Cambridge, United Kingdom|The Royal Marsden Hospital, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT04250922
300	NCT05163080	SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)	SURVIVE	Recruiting	No Results Available	Newly Diagnosed Glioblastoma	Biological: SurVaxM	Overall Survival|Grade 3 & Grade 4 Toxicities|Progression Free Survival Comparison|Overall Survival at Specified Time Points|Progression-Free Survival at specific time points	"MimiVax, LLC|Translational Drug Development|Imaging Endpoints"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	265	Industry|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	I-813720	18-Nov-21	18-Aug-23	18-Apr-24	20-Dec-21		20-Dec-21	"Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/80/NCT05163080/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT05163080
301	NCT00762255	A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Vorinostat|Drug: Bevacizumab|Drug: Irinotecan	Maximum Tolerated Dose (MTD)|Number of Participants With Progression Free Survival (PFS) at 6 Months|Number of Participants With Adverse Events (AEs)	H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15629|33726	Sep-08	Jul-13	Jul-13	30-Sep-08		25-Jul-13	"H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT00762255
302	NCT03291990	5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Temozolomide	Rate of change of lymphopenia|Percentage change in Cluster of differentiation 4 (CD4) count (antigen found on helper T cells)|Rate of change of lymphocytes|Rate of survival|Rate of change in serious adverse events	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years to 100 Years   (Adult, Older Adult)"	Early Phase 1	3	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	J1745|IRB00129314	18-Oct-17	19-Aug-20	19-Aug-20	25-Sep-17		19-Nov-21	"Sibley Hospital, Washington, District of Columbia, United States|Suburban Hospital, Washington, District of Columbia, United States|SKCCC at Johns Hopkins (East Baltimore), Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03291990
303	NCT01985087	A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70		Recruiting	No Results Available	Glioblastoma	Radiation: Hypofractionated radiotherapy|Drug: Temozolomide	Number of patients who stop treatment due to CTCAE grade 3 or above toxicities|Overall survival|Quality of Life|The number of patients to complete RT+TMZ and a minimum of 3 of the 6 planned cycles of adjuvant chemotherapy	University of Louisville|James Graham Brown Cancer Center	All	70 Years and older   (Older Adult)	Phase 1|Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCC-NEU-13 GB70	Sep-14	May-25	May-25	15-Nov-13		25-Oct-21	"James Graham Brown Cancer Center, Louisville, Kentucky, United States"		https://ClinicalTrials.gov/show/NCT01985087
304	NCT03347097	Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Drug: TIL|Drug: PD1-TIL	Number of Adverse Events related to TIL and PD1-TIL cells infusion|Treatment Responses Rate|Overall Survival Rate|Progression-free Survival Rate	Huashan Hospital|Shanghai Cell Therapy Research Institute	All	"18 Years to 70 Years   (Adult, Older Adult)"	Early Phase 1	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KY2017-241	1-Jan-17	1-Jan-20	1-Dec-21	20-Nov-17		25-Aug-21	"Huashan hospital, Fudan University, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT03347097
305	NCT01582269	A Study in Recurrent Glioblastoma (GB)		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: LY2157299 monohydrate|Drug: Lomustine|Drug: Placebo	Overall survival|Population Pharmacokinetics (PK): median population clearance|Progression free survival (PFS)|Percentage of Participants with Tumor Response|Change from baseline in neurocognitive function|Population Pharmacokinetics (PK): absorption|Population Pharmacokinetics (PK): volume of distribution|Change from baseline in MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) score	Eli Lilly and Company	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	180	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	13849|H9H-MC-JBAL	26-Apr-12	26-Jul-14	31-Dec-22	20-Apr-12		23-Aug-21	"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cleveland, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Leonards, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bobigny, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bonn, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terni, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Udine, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain"		https://ClinicalTrials.gov/show/NCT01582269
306	NCT00715013	Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma		Completed	No Results Available	Recurrent Glioblastoma Planned for Reoperation	Drug: Patupilone	"Progression free survival|PFS, OS translational research"	University of Zurich	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	9	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CEPO906A2401	Jul-08	Dec-10	Dec-10	14-Jul-08		15-Sep-11			https://ClinicalTrials.gov/show/NCT00715013
307	NCT00115453	Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma		Terminated	No Results Available	Glioblastoma	Radiation: irradiation	safety|tumor response|effect on brain tissue	Boneca Corporation	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	50	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BNCT-P01	May-99	Aug-08	Aug-08	23-Jun-05		18-Aug-08	"Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland"		https://ClinicalTrials.gov/show/NCT00115453
308	NCT03310372	Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme	TEMOFRAC	Completed	No Results Available	Glioblastoma Multiforme	Radiation: Ultrafractionated brain irradiation|Drug: Temozolomide	complete response|partial response|stabilization|progression|global survival|treatment tolerance|survival without tumor recurrence|life quality	"Central Hospital, Nancy, France"	All	"18 Years to 74 Years   (Adult, Older Adult)"	Phase 2	46	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2007-004968-41	13-Feb-08	26-Jun-12	26-Jun-12	16-Oct-17		17-Oct-17			https://ClinicalTrials.gov/show/NCT03310372
309	NCT00643825	"Prolonged Adjuvant Temozolomide vs ""Stop & Go"" in Glioblastoma Patients"	PATSGO	Unknown status	No Results Available	Glioblastoma	Drug: Temozolomide	to determine whether prolonged administration of Temozolomide in glioblastoma patients increase their progression-free and overall survival at 6 months|safety and adverse event profile of prolonged adjuvant Temozolomide	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCL-ONCO 06-004	Jan-08	Jan-11	Jan-12	26-Mar-08		23-Jul-10	"Cliniques Universitaires Saint-Luc, Brussels, Europe, Belgium"		https://ClinicalTrials.gov/show/NCT00643825
310	NCT01443676	Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma	ARTE	Completed	No Results Available	Glioblastoma	Drug: Bevacizumab|Radiation: Radiation therapy	median overall survival|progression-free survival	University of Zurich	All	65 Years and older   (Older Adult)	Phase 2	75	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ARTE	Oct-11	Aug-15	Aug-16	30-Sep-11		1-Nov-16	"Department of Neurology, University Hospital Zurich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT01443676
311	NCT01790503	A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma		Completed	Has Results	Patients With Newly Diagnosed Glioblastoma	Drug: PLX3397|Radiation: Radiation Therapy|Drug: Temozolomide	"Summary of the Median Progression-free Survival (mPFS) in the Combined 800 mg, 5 Days/Week Dose Group|Summary of the Median Progression-free Survival (mPFS) in the Study Group Compared With Historical Control From Medical Literature|Summary of the Median Progression-free Survival (mPFS) by Subgroups in the Modified Intent-To-Treat Population on the Recommended Phase 2 Dose|Summary of the Overall Survival in The Study Population|Summary of the Overall Survival in the Study Group Compared With Historical Control From Medical Literature|Summary of the Overall Survival by Subgroups in the Modified Intent-To-Treat Population on the Recommended Phase 2 Dose|Summary of Best Overall Response by Subgroups in the Modified Intent-To-Treat Population on the Recommended Phase 2 Dose|Overview of Most Frequent System Organ Classes Reported in Phase 1b of the Modified Intent-To-Treat Population|Overview of Most Frequent System Organ Classes Reported in Phase 2 of the Modified Intent-To-Treat Population|Number of Patients With Clinically Significant Abnormal Chemistry and Hematology Values Reported as Adverse Events by Preferred Term in Phase 1b of the Modified Intent-To-Treat Population|Number of Patients With Clinically Significant Abnormal Chemistry and Hematology Values Reported as Adverse Events by Preferred Term in Phase 2, the Combined RP2D Groups in Phase 1b, and in the Study Overall Modified Intent-To-Treat Population"	"Daiichi Sankyo, Inc.|Plexxikon"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	65	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PLX108-08	18-Jul-13	3-Nov-17	4-Mar-20	13-Feb-13	9-Oct-19	30-Jun-20	"Northwestern Memorial Hospital, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|James Cancer Hospital/Ohio State University, Columbia, Ohio, United States|Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/03/NCT01790503/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01790503
312	NCT02853565	A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: CAN008	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Recommended Dose for Phase II [RP2D] measured by the Maximum Tolerated Dose [MTD] or the Maximum Administered Dose [MAD]|PK profile measured by CAN008 serum concentrations|PK profile measured by Maximum Plasma Concentration [Cmax]|PK profile measured by Area Under the Curve [AUC]|Preliminary efficacy (Progression Free Survival after 6 months [PFS6])|Preliminary efficacy (Overall Survival [OS])	CANbridge Life Sciences Ltd.	All	"20 Years to 75 Years   (Adult, Older Adult)"	Phase 1	10	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAN-B1-008-L-002	Aug-16	Sep-18	Sep-18	3-Aug-16		8-Nov-18	"Chang Gung Memorial Hospital, Linkou, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan"		https://ClinicalTrials.gov/show/NCT02853565
313	NCT01933815	Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma		Suspended	No Results Available	Glioblastoma Multiforme	Drug: TPI 287|Drug: Bevacizumab	"Phase 1: Safety of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|Phase 1: MTD of TPI 287 + bevacizumab in adults with GBM that progressed following radiation & TMZ|Phase 2: Efficacy of phase 1 MTD of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by median PFS|Phase 1: Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation and TMZ as measured by median progression free survival (PFS), overall response rate, & progression free survival rate at 4 & 6 months (PFS4 & PFS6)|Phase 2: Safety of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation & TMZ as measured by AEs, physical/neurologic exam, KPS, weight, vital signs, hematology, serum chemistry, & urinalysis|Phase 2: Efficacy of phase 1 MTD of TPI 287 + bevacizumab versus bevacizumab alone in adults with GBM that progressed following radiation and TMZ as measured by overall survival and overall response rate"	"Cortice Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	92	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TPI-287-17	Aug-13	Nov-22	May-23	2-Sep-13		13-Nov-20	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|The Long Island Brain Tumor Center at Neurological Surgery, P.C., Commack, New York, United States|The Long Island Brain Tumor Center at Neurological Surgery, P.C., Lake Success, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Memorial Hermann Hospital, Houston, Texas, United States|Swedish Neuroscience Institute, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01933815
314	NCT03216499	HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma	PT2385	Completed	Has Results	Recurrent Glioblastoma	Drug: HIF-2alpha Inhibitor PT2385|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study	Tumor Radiographic Response as Assessed by the RANO Criteria|Progression-free Survival (PFS)|Overall Survival|Incidence of Grade 3 and Grade 4 Adverse Events	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Peloton Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	24	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC 1602|IRB00132128|UM1CA137443	14-Sep-17	31-Aug-19	5-Jun-20	13-Jul-17	21-Sep-20	14-Oct-20	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/99/NCT03216499/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT03216499
315	NCT03899857	Pembrolizumab for Newly Diagnosed Glioblastoma	PERGOLA	Recruiting	No Results Available	Newly Diagnosed Glioblastoma	Drug: Pembrolizumab	Overall survival at 12 months|Response rates using (i)RANO (immunotherapy response assessment in neuro-oncology) criteria|Progression-free survival (PFS) at 6 and 12 months|Time to treatment failure (TTF)|Health-related Quality of life (HRQol)|Correlation of programmed cell death (PD-1) ligand 1 (PD-L1) expression levels with response to treatment and outcome	University of Zurich|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PERGOLA	21-Oct-20	Dec-22	Dec-23	2-Apr-19		16-Dec-20	"University Hospital Bern / Inselspital, Bern, Switzerland|University Hospital Lausanne, CHUV, Lausanne, Switzerland|University Hospital Zurich, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT03899857
316	NCT03232424	NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	"Glioblastoma, Adult"	Device: NovoTTF-200A|Drug: Temozolomide|Radiation: 3D conformal or intensity modulated radiation therapy (IMRT)	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Overall survival time|Progression free survival at 6 months|Quality of life assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ-C30)|Quality of life assessed using a European Organization for Research and Treatment of Cancer (EORTC) Brain Cancer questionnaire (BN20)	Hackensack Meridian Health|NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro2017-0087	26-Jul-17	Jul-27	Jul-27	28-Jul-17		8-Oct-21	"John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States"		https://ClinicalTrials.gov/show/NCT03232424
317	NCT03995706	Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0		Recruiting	No Results Available	Glioblastoma	Drug: Sacituzumab Govitecan	Ratio of SN-38 and its metabolites relative to serum concentration	The University of Texas Health Science Center at San Antonio|Gilead Sciences	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS# 19-0069|HSC20190378H	17-Jul-19	10-Jan-23	10-Jul-23	24-Jun-19		15-Jun-21	"Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT03995706
318	NCT01880008	Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma		Completed	No Results Available	Glioblastoma		"Change in FLT uptake, measured by SUV tumor/SUV normal contralateral white matter|Survival|Ki-67|Radiographic progression defined by MacDonald criteria|O(6)-methylguanine DNA-methyltransferase (MGMT) activity|Time to progression"	Washington University School of Medicine|Barnes-Jewish Hospital	All	"18 Years and older   (Adult, Older Adult)"		5	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	08-0073	Apr-08	Feb-10	Aug-12	18-Jun-13		18-Jun-13	"Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01880008
319	NCT04968366	Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery		Not yet recruiting	No Results Available	Glioblastoma Multiforme of Brain	Biological: Autologous dendritic cells pulsed with multiple neoantigen peptides.|Drug: Temozolomide adjuvant chemotherapy	Incidence of Treatment-Emergent Adverse Events (AEs)|Proportions of patients with positive peripheral tumor specific immune response after the DC vaccinations|Progression-free survival|Overall survival|Rate of the patients who survive for more than one year after surgery in all the included patients who receive the DC vaccine	Beijing Tiantan Hospital|ZhongSheng BioTech Inc.	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KY 2021-021-02	Aug-21	Aug-22	Aug-24	20-Jul-21		20-Jul-21	"Beijing Tiantan Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT04968366
320	NCT04915404	Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)		Not yet recruiting	No Results Available	Recurrent Glioblastoma Multiforme	Drug: Berubicin Hydrochloride	"objective response rate (ORR)|• To confirm the safety profile of Berubicin that was characterized during Phase 1 studies and assess the effect of Berubicin on event-free survival (EFS)|• To confirm the pharmacokinetic (PK) profile of Berubicin and its metabolite, berubicinol, that was characterized during Phase 1 studies|• To assess the effect of Berubicin on disease control rate (DCR) defined as CR or PR or stable disease [SD] per m-RANO criteria in patients with GBM after failure of standard first line therapy"	"WPD Pharmaceuticals Sp. z o.o.|Worldwide Clinical Trials|National Center for Research and Development, Poland"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	50	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WPD-201	15-Jul-21	31-Jan-24	31-Jan-25	7-Jun-21		7-Jun-21			https://ClinicalTrials.gov/show/NCT04915404
321	NCT04846257	Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence		Completed	No Results Available	Glioblastoma	Other: Dynamic contrast-enhanced MRI	Recurrence of tumor	Egyptian Medical Syndicate	All	"Child, Adult, Older Adult"		260	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	DCE_MRI_GBM	1-Jan-18	1-Jan-21	1-Feb-21	15-Apr-21		19-Apr-21	"Department of Neurosurgery, Cairo University Faculty of Medicine, Cairo, Egypt"		https://ClinicalTrials.gov/show/NCT04846257
322	NCT02937844	Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Biological: Anti-PD-L1 CSR T cells|Drug: Cyclophosphamide|Drug: Fludarabine	Number of Adverse Events related to CSR T cell infusion|Treatment Responses Rate|Overall Survival Rate|Progression-free Survival Rate	"Beijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	20	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SBNK-2016-016-01	Jul-16	Jul-18	Jul-19	19-Oct-16		19-Oct-16	"Sanbo Brain Hospital Capital Medical University, Beijing, China"		https://ClinicalTrials.gov/show/NCT02937844
323	NCT00689221	"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status"	CENTRIC	Completed	Has Results	Glioblastoma	Drug: Cilengitide|Drug: Temozolomide|Radiation: Radiotherapy	"Overall Survival (OS) Time|Progression Free Survival (PFS) Time - Investigator and Independent Read|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration Curve From Time 0 to 6 Hours (AUC [0-6]) After Dose|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Sub-scale Scores|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Brain Module (EORTC QLQ-BN20) Sub-scale Scores|EuroQol 5-Dimensions (EQ-5D) Questionnaire Index|Number of Participants With Change From Baseline in Work Status at End of Study|Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment Related AEs of Grade 3 or 4|Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI-CTC Toxicity Grade 3 or 4|Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters"	"EMD Serono|European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA, Darmstadt, Germany"	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	545	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EMD 121974-011|EORTC 26071-22072|2007-004344-78	Sep-08	Nov-12	Aug-13	3-Jun-08	4-Nov-14	4-Nov-14	"Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States|Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany"		https://ClinicalTrials.gov/show/NCT00689221
324	NCT04145115	A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden		Recruiting	No Results Available	Recurrent Glioblastoma|Secondary Glioblastoma	Biological: Ipilimumab|Biological: Nivolumab	Overall response rate|Overall survival (OS)|Progression-free survival (PFS)|Incidence of adverse events (AEs)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	37	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2019-07242|A071702|U10CA180821	30-Oct-20	31-May-23	31-May-23	30-Oct-19		5-Jan-22	"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Cancer Center at Saint Joseph's, Phoenix, Arizona, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California, United States|Mission Hope Medical Oncology - Santa Maria, Santa Maria, California, United States|Torrance Memorial Physician Network - Cancer Care, Torrance, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Low Country Cancer Care, Savannah, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Saint Anthony's Health, Alton, Illinois, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Illinois CancerCare-Dixon, Dixon, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|North Shore Medical Center, Skokie, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Illinois CancerCare - Washington, Washington, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Baptist Health Floyd, New Albany, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Saint Anthony Regional Hospital, Carroll, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|Trinity Regional Medical Center, Fort Dodge, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Ascension Borgess Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Sanford Thief River Falls Medical Center, Thief River Falls, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Sanford Cancer Center Worthington, Worthington, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Saint Louis Cancer and Breast Institute-Ballwin, Ballwin, Missouri, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Parkland Health Center - Farmington, Farmington, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital South, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Mercy Hospital Washington, Washington, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Cancer Partners of Nebraska - Pine Lake, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center - 68th Street Place, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Morristown Medical Center, Morristown, New Jersey, United States|Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Randolph Hospital, Asheboro, North Carolina, United States|Messino Cancer Centers, Asheville, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Cone Heath Cancer Center at Mebane, Mebane, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford South University Medical Center, Fargo, North Dakota, United States|Southpointe-Sanford Medical Center Fargo, Fargo, North Dakota, United States|Sanford Medical Center Fargo, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|WVUH-Berkely Medical Center, Martinsburg, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Pan American Center for Oncology Trials LLC, San Juan, Puerto Rico"		https://ClinicalTrials.gov/show/NCT04145115
325	NCT02844062	Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Biological: anti-EGFRvIII CAR T cells|Drug: cyclophosphamide|Drug: Fludarabine	Safety of infusion of autologous anti-EGFRvIII CAR T cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.|Treatment Responses Rate|Overall Survival Rate|Progression-free Survival Rate|Persistence of CAR T cells in patients	"Beijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	20	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SBNK-2016-015-01	Jul-16	Jul-18	Jul-19	26-Jul-16		26-Jul-16	"Sanbo Brain Hospital Capital Medical University, Beijing, China"		https://ClinicalTrials.gov/show/NCT02844062
326	NCT04725214	Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma		Recruiting	No Results Available	MGMT-Unmethylated Glioblastoma	Drug: Anlotinib	1-year OS|PFS|OS|adverse event|Health-related quality of life|Neurocognitive function	"Second Affiliated Hospital, School of Medicine, Zhejiang University"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	33	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-780	15-Jan-21	Dec-22	Dec-23	26-Jan-21		26-Jan-21	"The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04725214
327	NCT01851733	MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma	Device: MRI-guided Laser Heat Ablation (MLA)|Drug: Doxorubicin|Other: Blood draw - dendritic cells|Device: Dynamic Susceptibility Contrast Magnetic Resonance Imaging	"Ktrans from DSC-MRI|Peritumoral permeability scores, measured by DSC-MRI and serum biomarkers|6-month PFS (rate)|Overall Survival|Quality of Life"	Washington University School of Medicine|The Foundation for Barnes-Jewish Hospital	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	37	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	201305148	13-Aug-13	12-Apr-18	30-May-18	10-May-13		27-Aug-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01851733
328	NCT03250299	Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma|MGMT-Unmethylated Glioblastoma	Drug: Microtubule-Targeted Agent BAL101553|Radiation: Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study	Maximum Tolerated Dose (MTD)|Proportion of subjects with Grade 3 and Grade 4 AEs|Overall Survival|Progression Free Survival|Maximum Plasma Concentration|Time of Maximum Plasma Concentraion|Area Under the Concentration-time Curve (AUC)	Basilea Pharmaceutica|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC 1601|CDI-CS-004|IRB00131687	7-Jun-17	15-Jun-21	15-Jun-22	15-Aug-17		31-Jul-20	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03250299
329	NCT02120287	Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme|Glioblastoma - Category	Drug: Bevacizumab|Procedure: Magnetic Resonance Spectroscopy (MRS)|Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS)	Overall Survival (OS)|6-month Progression-free Survival|6-month Overall Survival|CNS Toxicity|Tumor Response|Potential Value of Magnetic Resonance Spectroscopy (MRS)|Karnofsky Performance Status|Barthel's Index of Activities of Daily Living Assessment|Center for Epidemiological Studies Depression Scale (CES-D)|Functional Assessment of Cancer - General (FACT-G)|Functional Assessment of Cancer Therapy-General - General (FACT-G)|Functional Assessment of Cancer Therapy-Brain Specific Symptom Index (FACT-BrSI)	"Ajay Niranjan|Genentech, Inc.|University of Pittsburgh"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	16	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-063	May-14	31-Mar-18	31-Mar-18	22-Apr-14	25-Apr-19	7-May-19	"University of Pittsburgh, Pittsburgh, Pennsylvania, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/87/NCT02120287/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02120287
330	NCT04840069	Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma		Not yet recruiting	No Results Available	Newly Diagnosed Glioblastoma	Drug: Fluciclovine PET guided Radiotherapy	Patterns of Failure|Defining Tumor Volume|Survival using MRI radiotherapy|Overall survival utilizing MRI+PET radiotherapy|Progression free survival utilizing MRI+PET-based radiotherapy	"St. Joseph's Hospital and Medical Center, Phoenix|Barrow Neurological Foundation|Arizona Biomedical Research Commission (ABRC)|Blue Earth Diagnostics"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	090-20-16	1-Apr-21	30-Mar-24	30-Mar-24	9-Apr-21		9-Apr-21			https://ClinicalTrials.gov/show/NCT04840069
331	NCT02619864	mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: AZD2014	Recommended phase II dose (RP2D) of AZD2014|Number and severity of adverse events|Response rate per RANO criteria|To evaluate the plasma levels of AZD2014 alone at the time of resection	Canadian Cancer Trials Group|AstraZeneca	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I222	13-Jan-16	22-Mar-19	25-Feb-20	2-Dec-15		9-Apr-20	"Tom Baker Cancer Centre, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT02619864
332	NCT01934361	Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Recurrent Glioblastoma Multiforme	Drug: buparlisib|Drug: carboplatin|Drug: lomustine|Drug: placebo	"Number of Total Dose-limiting Toxicity (DLT) during Dose Escalation part to determine Maximum Tolerated Dose (MTD) [Phase Ib]|12 week Progression Free Survival (PFS) rate (Phase II- Carboplatin combination)|Progression Free Survival (PFS) [phase II lomustine combinations]|Frequency and severity of Adverse Events (AEs) [Phase Ib, Phase II, all treatment arms]|Overall Response Rate (ORR) as per Response Assessment in Neuro-Oncology (RANO) [Phase Ib , both combinations]|Progression Free Survival (PFS) [Phase Ib- both combinations]|Overall response rate (ORR) [Phae II, carboplatin combination]|Progression Free Survival (PFS) [Phase II, carboplatin combination]|24 week Progression Free Survival (PFS) rate (Phase II carboplatin combination)|Overall Survival (OS) (Phase II Carboplatin combination)|Overall Response Rate (ORR) (Phase II Lomustine combinations)|12 week Progression Free Survival (PFS) rate (Phase II- lomustine combinations)|24 week Progression Free Survival (PFS) rate (Phase II- lomustine combinations)|Overall survival (OS) [Phase II lomustine combinations]"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	35	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CBKM120E2102|2013-003129-27	28-Feb-14	7-Jul-16	7-Jul-16	4-Sep-13		9-Dec-20	"Barrow Neurological Insitute St. Joseph's Hospital, Phoenix, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Northwestern University, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain"		https://ClinicalTrials.gov/show/NCT01934361
333	NCT01339052	Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma		Completed	Has Results	Glioblastoma	Drug: BKM120|Procedure: Surgery	Change in pAKT (S473) Immunohistochemistry (IHC) Score From Baseline to Surgery [Cohort 1]|6-Month Progression-Free Survival (PFS6) [Cohort 2]|BKM120 Brain-to-Plasma Ratio at Time of Surgery [Cohort 1]|BKM120 Tumor Tissue Concentration at Time of Surgery [Cohort 1]|BKM120 Plasma Concentration at Time of Surgery [Cohort 1]|% Ki-67 Reduction Using Immunohistochemistry (IHC) [Cohort 1]|Radiographic Response [Cohort 2]|Maximum Observed Plasma Concentrations (Cmax) of BKM120 Day 1 and Day 8 [Cohort 1]|Cmax Accumulation Ratio of BKM120 Day 1 and Day 8 Ratio [Cohort 1]|Area Under the Concentration Curve From Time 0 to Last Concentration (AUC0-5h) of BKM120 Day 1 and Day 8 [Cohort 1]|AUC0-5h Accumulation Ratio of BKM120 Day 1 and Day 8 [Cohort 1]|Time to Maximum Observed Plasma Concentration (Tmax) of BKM120 Day 1 and Day 8 [Cohort 1]|Overall Survival (OS) [Cohort 2]|Progression-Free Survival (PFS) [Cohort 2]|Grade 3-5 Treatment-Related Toxicity Rate	"Patrick Y. Wen, MD|Brigham and Women's Hospital|Massachusetts General Hospital|Novartis Pharmaceuticals|M.D. Anderson Cancer Center|Memorial Sloan Kettering Cancer Center|University of California, San Francisco|University of California, Los Angeles|University of Utah|Dana-Farber Cancer Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	65	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-033|CBKM120XUS07T	Sep-11	Oct-16	Feb-19	20-Apr-11	14-Jun-17	19-Mar-19	"University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|UT, MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT01339052
334	NCT03405792	Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)	2-THE-TOP	"Active, not recruiting"	No Results Available	"Glioblastoma|Glioblastoma, WHO Grade IV"	Drug: Temozolomide (TMZ)|Device: Optune System|Drug: Pembrolizumab	Progression-free survival between the groups|Number of adverse events|Overall Survival (OS)|Augmentation of TTFields-initiated glioma-specific immune reaction by pembrolizumab	University of Florida|NovoCure Ltd.	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	31	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB201702270|OCR16397	23-Feb-18	Feb-23	Feb-23	23-Jan-18		16-Nov-21	"University of Florida Health, Gainesville, Florida, United States"		https://ClinicalTrials.gov/show/NCT03405792
335	NCT05033587	Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.		Recruiting	No Results Available	MGMT-Unmethylated Glioblastoma	Drug: Anlotinib|Drug: AK105|Radiation: Radiotherapy	PFSR-6m|Progression-Free Survival（PFS）|Objective Response Rate（ORR）|Overall Survival（OS）|Disease Control Rate（DCR）|Safety	"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Chia Tai Tianqing Pharmaceutical Group Co., Ltd."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	28	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-252-02	Sep-21	1-May-23	1-Nov-23	5-Sep-21		5-Sep-21	"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China"		https://ClinicalTrials.gov/show/NCT05033587
336	NCT03033524	Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma		Completed	No Results Available	Recurrent Glioblastoma	Drug: TTAC-0001	Adverse events|PFS at 6-month time point|Objective response rate (ORR)|Disease control rate(DCR)|Overall survival(OS)	PharmAbcine	All	"19 Years and older   (Adult, Older Adult)"	Phase 2	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PMC_TTAC-0001_02	4-Feb-16	2-Jun-17	2-Jun-17	26-Jan-17		27-Jan-21			https://ClinicalTrials.gov/show/NCT03033524
337	NCT03990285	[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )	Axumin	Completed	No Results Available	Glioma Glioblastoma Multiforme	"Drug: Axumin, Intravenous Solution"	Pseudoprogression or tumor progression by histopathology	Ali Nabavizadeh|Blue Earth Diagnostics|Abramson Cancer Center of the University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	UPCC 08319/ IRB# 832812	12-Jun-19	18-Nov-21	18-Nov-21	18-Jun-19		22-Dec-21	"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03990285
338	NCT01331291	Bosutinib in Adult Patients With Recurrent Glioblastoma		Completed	Has Results	Glioblastoma	Drug: bosutinib	Progression-Free Survival|Intratumoral Concentration|Safety Profile|Anti-tumor Response	Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-190	Apr-11	Dec-14	Dec-14	8-Apr-11	20-Jun-16	25-Jul-16	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana=Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01331291
339	NCT00813943	"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status"	CORE	Completed	Has Results	Glioblastoma	Drug: Cilengitide (2-times weekly)|Drug: cilengitide (5-times weekly)|Drug: Temozolomide|Radiation: Radiotherapy	"Overall Survival (OS) Time|Progression Free Survival (PFS) Time - Investigator and Independent Read|Maximum Observed Plasma Concentration (Cmax)|Time to Maximum Plasma Concentration (Tmax) and Terminal Elimination Half-Life (t1/2)|Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) and Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24])|Plasma Concentration at Pre-dose (Cpre) and Plasma Concentration at End of Infusion (CT)|Apparent Terminal Rate Constant|Mean Residence Time From Time 0 to Infinity (MRT [0-infinity])|Plasma Clearance (CL)|Apparent Volume of Distribution During the Terminal Phase (Vz) and Apparent Volume of Distribution at Steady State (Vss)|Number of Participants With Adverse Events (AEs), Serious AEs, Treatment-Related AEs, Treatment-Related Serious AEs, AEs Leading to Death, Treatment-Related AEs Leading to Death, AEs of Grade 3 or 4 and Treatment-Related AEs of Grade 3 or 4|Number of Participants With AEs Belonging to Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) Thromboembolic Events and Hemorrhage With NCI-CTC Toxicity Grade 3 or 4|Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) and Lab Parameters"	"EMD Serono|Merck KGaA, Darmstadt, Germany"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	265	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EMD121974-012	Mar-09	Feb-13	Aug-13	23-Dec-08	8-Dec-14	30-Jan-17	"Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States|Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany"		https://ClinicalTrials.gov/show/NCT00813943
340	NCT03034135	"Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma"		Completed	Has Results	Recurrent Glioblastoma	Drug: Disulfiram/Copper|Drug: Temozolomide (TMZ)	Objective Response Rate|Progression Free Survival|Overall Survival|Number of Participants With Serious Adverse Events|Median Progression Free Survival|Median Duration of Overall Survival	Cantex Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	23	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAN-201	9-Mar-17	10-Jul-18	10-Jul-18	27-Jan-17	13-Sep-21	13-Sep-21	"Beaumont Hospital, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Lenox Hill Hospital, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/35/NCT03034135/Prot_SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT03034135
341	NCT02344355	A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Drug: Temozolomide|Radiation: radiation therapy|Drug: Ascorbic Acid	Overall Survival (OS)|Progression Free Survival (PFS)|Adverse Event Frequency	Bryan Allen|Holden Comprehensive Cancer Center|National Cancer Institute (NCI)|University of Iowa	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	90	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201504786	13-Mar-17	Apr-22	Dec-24	22-Jan-15		27-Jan-21	"Holden Comprehensive Cancer Center, Iowa City, Iowa, United States"		https://ClinicalTrials.gov/show/NCT02344355
342	NCT02850744	"Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients"		Terminated	No Results Available	Glioblastoma Multiforme	Drug: PQR309	"Progression-free survival rate at 6 months (PFS6) based on RANO criteria [30]glioblastoma, using progression-free survival rate at 6 months (PFS6) based on RANO criteria [30]|Number of Adverse Events and Serious Adverse Events as related to the study medication|Changes in pulse rate|Changes in blood pressure|Changes in body weight|Changes in temperature|Changes in ECG|Physical examination according to Karnofsky Performance Status|Depression Test (PHQ-9)|Depression test PHQ-9|Generalized Anxiety Disorder mood scale score (GAD7)|Generalized Anxiety Disorder mood scale score (GAD)|Changes in routine blood chemistry|Changes in hematology|Changes of urinalysis|Change of Insulin/Glucose/C-Peptide|Change of Haemostasis|Determination of cmax|Determination of AUC0-24|Determination of tmax|Determination of AUClast|Determination of AUC0-∞|Determination of t½|Assessment of tumor concentration,|Assessment of PQR309 concentration in cerebrospinal fluid Day 3,pre-dose,0.5h, 1h, 2h, 4h, 6h, 8h post-dose Day 4 24h after the last dose given|Assessment of PQR309 Skin concentration|Overall Response Rate (ORR) including complete and partial Response based on RANO criteria|Duration of response (DOR) based on RANO criteria|Progression-free survival at 3 months (PFS3) based on RANO criteria"	"PIQUR Therapeutics AG|University Hospital, Basel, Switzerland|University Hospital Inselspital, Berne|University Hospital, Zürich"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	10	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PQR309-004	Jul-15	Nov-17	Nov-17	1-Aug-16		19-Oct-18	"University Hospital Zurich, Neurology, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT02850744
343	NCT00345163	A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)	BRAIN	Completed	No Results Available	Glioblastoma	Drug: bevacizumab|Drug: irinotecan	"Objective response, as determined by the independent review facility (IRF)|Progression-free survival, as determined by the IRF|Incidence of adverse events and serious adverse events|Duration of objective response, as determined by the IRF|Overall survival"	"Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	167	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AVF3708g	Jul-06	Sep-07	Sep-07	27-Jun-06		16-May-17			https://ClinicalTrials.gov/show/NCT00345163
344	NCT04926168	6 Months Adjuvant Temozolomide (TMZ) vs No Adjuvant TMZ in Newly Diagnosed MGMT Methylated Glioblastoma (GBM)		Not yet recruiting	No Results Available	MGMT-Methylated Glioblastoma	Other: Delay of TMZ|Other: Standard of Care (SOC) Adjuvant TMZ (no intervention	Overall Survival|Grade 3 or above adverse events|Change in Lymphocyte count|Change in Quality of life as assessed by MDASI-BT|Change in Quality of life as assessed by NeuroQoL/MID.|Progression-free survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years and older   (Adult, Older Adult)"		120	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	ABTCv2-2101|IRB00285623	1-Mar-22	31-Dec-23	31-Dec-23	15-Jun-21		5-Jan-22	"University of Maryland, Baltimore, Maryland, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04926168
345	NCT00650949	Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma		Terminated	No Results Available	Glioblastoma Multiforme	Drug: CYT997|Drug: Carboplatin	Safety and tolerability of escalating doses of CYT997 when given in combination with standard carboplatin therapy (Phase Ib component)|Progression-free survival at 6 months (PFS-6) utilising the dose of CYT997 identified in the Phase Ib component of this study (Phase II component)|Objective response rate (ORR)|Overall survival|Safety and tolerability|Effects on pharmacodynamic markers of vascular disruption and tumour apoptosis|Pharmacokinetic analysis of carboplatin and CYT997 in combination	Gilead Sciences	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCL08001	Nov-09	Jun-11	Jun-11	2-Apr-08		3-May-13	"Royal North Shore Hospital, St-Leonards, New South Wales, Australia|Gold Coast Hospital, Southport, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Medical Centre, Melbourne, Victoria, Australia"		https://ClinicalTrials.gov/show/NCT00650949
346	NCT01349660	Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Drug: Bevacizumab|Drug: BKM120	Number of Phase I Patients Receiving 60mg or 80mg BKM120 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage|Median Progression-Free Survival (PFS) in Phase II Participants - Prior Bevacizumab and Bevacizumab Naive|Overall Response (CR or PR) of Phase II Participants - Prior Bevacizumab and Bevacizumab Naive|Median Overall Survival (OS) in Phase II Participants - Prior Bevacizumab and Bevacizumab Naive|Number of Participants With Grade 3/4/5 Serious Adverse Events and Adverse Events as a Measure of Safety and Tolerability	"SCRI Development Innovations, LLC|Novartis"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	88	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI CNS 13	Dec-11	Dec-16	29-Dec-18	6-May-11	31-Jan-18	17-Jun-20	"Yale School of Medicine, New Haven, Connecticut, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Grand Rapids Oncology Program, Grand Rapids, Michigan, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Tennessee Oncology, Nashville, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT01349660
347	NCT04002804	Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Recurrence Of Glioblastoma Multiforme	Dendr2	Terminated	No Results Available	Glioblastoma	Biological: Dendritic Cells Vaccine	Percentage of Participants With Progression Free Survival at 6 Months (PFS-6)|Incidence of Treatment-related Adverse Events|Evaluation of the treatment effect on the immune response	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	26	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DENDR2	Apr-10	Oct-11	13-Jun-17	1-Jul-19		1-Jul-19			https://ClinicalTrials.gov/show/NCT04002804
348	NCT02974621	Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Recurrent Glioblastoma	Biological: Bevacizumab|Drug: Cediranib|Drug: Cediranib Maleate|Drug: Olaparib	"Progression-free survival|Overall survival (OS)|Incidence of adverse events (AE)|Levels of circulating cytokines involved with angiogenesis|Levels of serial circulating biomarkers involved with deoxyribonucleic acid (DNA) repair|Tumor genomic alteration|Imaging correlates (vascular permeability, tumor perfusion and oxygenation, brain tumor cellularity)"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	70	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2016-01769|17-735|10067|UM1CA186709	15-Sep-17	31-May-22	31-May-22	28-Nov-16		1-Sep-21	"UC San Diego Moores Cancer Center, La Jolla, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02974621
349	NCT03522298	"Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma"		"Active, not recruiting"	No Results Available	"Glioblastoma, Adult"	Drug: Paxalisib (GDC-0084)	Dose limiting toxicities (DLTs)|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of serious adverse events (SAEs)|Incidence of treatment-emergent Grade 3/4 clinical laboratory abnormalities.|Change in electrocardiogram (ECG) parameter QTc.|Change in left ventricular ejection fraction (LVEF).|Progression-free survival interval using RANO Criteria.|Overall survival using RANO Criteria.	Kazia Therapeutics Limited	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NVGN-0084-201	15-May-18	30-Nov-21	30-Nov-21	11-May-18		1-Sep-21	"University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|University of Oklahoma Health Sciences Center (Stephenson Cancer Center), Oklahoma City, Oklahoma, United States|MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03522298
350	NCT02715609	Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Disulfiram|Drug: Copper Gluconate|Procedure: Surgery|Radiation: Radiation|Drug: Temozolomide	Maximum tolerated dose (MTD) of the regimen (dose-escalation phase only)|Overall survival (dose-expansion phase only)|Toxicity associated with DSF when given concurrently with radiation therapy and temozolomide as measured by the grade and frequency of adverse events (dose- escalation phase only)|Intratumoral drug uptake of DSF and its metabolites in resected GBM tissue (dose-escalation phase only)|Proteasome inhibition of DSF on GBM tissues (dose-escalation phase only)|Effect of DSF on DNA breaks on GBM tissues (dose-escalation phase only)|Time to tumor progression (TTP) (dose-escalation phase only)|Rate of pseudo-progression (PsP) (dose-escalation phase only)|Progression-free survival (PFS)|Overall survival (OS) (dose-escalation phase only)|Active DSF metabolite concentration in plasma and tumor tissues (dose-expansion phase only)|Pharmacodynamic studies on glutamate metabolism as measured by measurement of glutamine levels in plasma and tumor tissues (dose-escalation phase only)|Pharmacodynamic studies on glutamate metabolism as measured by measurement of glutamate levels in plasma and tumor tissues (dose-escalation phase only)|Pharmacodynamic studies on glutamate metabolism as measured by measurement of aspartate levels in plasma and tumor tissues (dose escalation phase only)|Pharmacodynamic studies on glutamate metabolism as measured by measurement of glucose levels in plasma and tumor tissues (dose escalation phase only)|Pharmacodynamic studies on glutamate metabolism as measured by measurement of lactate levels in plasma and tumor tissues (dose escalation phase only)	Washington University School of Medicine	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	36	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201604115	15-Jun-16	15-Dec-23	15-Dec-23	22-Mar-16		26-Oct-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT02715609
351	NCT02286167	Glioma Modified Atkins-based Diet in Patients With Glioblastoma	GLAD	Completed	No Results Available	Glioblastoma Multiforme	Other: Diet modification	"Feasibility of intermittent modified Atkins diet in patients with GBM assessed by percent of patients able to remain on the diet and achieve nutritional goals|Biologic activity measured by pre- and post-study cerebral glutamate and glutamine concentrations assessed by MRS.|Tolerability assessed by percent of patients who have an adverse reaction of any grade attributed to the diet of possible, probable, or definite|Dietary Activity"	Wake Forest University Health Sciences|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	IRB00037347	Nov-14	3-Jan-19	12-Jul-19	7-Nov-14		12-May-20	"The Johns Hopkins Hospital, Baltimore, Maryland, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/67/NCT02286167/ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT02286167
352	NCT01464177	Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme	GBM Hypo RT	"Active, not recruiting"	No Results Available	Recurrent Glioblastoma Multiforme	Radiation: Stereotactic hypofractionated RT 5x5Gy|Radiation: Stereotactic hypofractionated RT 5x7Gy	progression free survival|overall survival|local control|toxicity|quality of life	Andre Tsin Chih Chen|University of Sao Paulo	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment"	RT-01/2011	Oct-11	Jul-21	Dec-22	3-Nov-11		16-Dec-21	"Hospital das Clinicas da Faculdade de Medicina da USP, Sao Paulo, SP, Brazil"		https://ClinicalTrials.gov/show/NCT01464177
353	NCT02546102	"Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma"		Suspended	No Results Available	Glioblastoma Multiforme	Biological: ICT-107|Biological: Placebo	Overall survival|Overall survival in patients with unmethylated MGMT tumors|Overall survival in patients with methylated MGMT (O6-methylguanine-DNA methyltransferase) tumors|Progression-free survival|Type and frequency of treatment emergent adverse events	Precision Life Sciences Group|Novella Clinical	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	414	Industry|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	ICT-107-301	Dec-15	Dec-19	Dec-21	10-Sep-15		13-Aug-18	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|City of Hope Cancer Center, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|University of California Irvine Chao Family Cancer Center, Orange, California, United States|Kaiser Permanente, Redwood City, California, United States|Kaiser Permanente, Sacramento, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|Smilow Cancer Hospital, New Haven, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Delray Medical Center, Boca Raton, Florida, United States|Boca Raton Regional Hospital Lynn Cancer Institute, Boca Raton, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Harvard Medical School Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|John Nasseff Neuroscience Institute, Minneapolis, Minnesota, United States|Metro-Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|JFK New Jersey Neuroscience Institute, Edison, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|North Shore University Hospital, Lake Success, New York, United States|Perlmutter Cancer Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weil Cornell Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Penn State College of Medicine Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, Pennsylvania, United States|University of Tennessee Medical Cancer Institute, Knoxville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Baylor Health Charles Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center Memorial Hermann Hospital, Houston, Texas, United States|CTRC at UTHSCSA, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Ivy Center for Advanced Brain Tumor Treatment Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Medical University Innsbruck, Dept. of Neurology, Innsbruck, Austria|Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria|University Clinic for Neurology, Salzburg, Austria|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Montreal Neurological Institute & Hospital, Montreal, Quebec, Canada|CHUS Service de Neurochirurgie, Sherbrooke, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT02546102
354	NCT04469699	Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma	NOA11	Recruiting	No Results Available	"Glioblastoma Multiforme, Adult"	Drug: Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid|Procedure: Stereotactic biopsy	"Progression free survival (PFS)|6-month PFS rate|Overall survival (OS)|Progression free time|12-month OS rate|Absolute changes from baseline in contrast medium volume uptake from the MRI performed 48 hours after randomization on, and during any MRI performed thereafter to monitor for disease progression|48h response rate on MRI (Complete Remission, Partial Remission, Stable Disease) after treatment with iPDT (interstitial photodynamic therapy)|If a PET (positron emission tomography) was performed less than 2 weeks apart from an MRI: Consistency of both procedures with regard to the region of interest (ROI)|Change in KPS (Karnofsky Performance Score)|Change in NIHSS (National Institutes of Health Stroke Scale)|Change in MMSE (Mini-Mental State Examination)|Brain edema as assessed by MRI within 26 to 48 h after stereotactic surgery|Frequency of Adverse Events|Change in the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire) score during study participation|Change in the EORTC QLQ-BN20 module (European Organisation for Research and Treatment of Cancer Quality of Life Brain Cancer Module) score during study participation"	"University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)|photonamic GmbH & Co. KG|medac GmbH|LifePhotonic GmbH"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	106	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UKM12_0017|2015-002727-25	12-Apr-21	Apr-26	Apr-26	14-Jul-20		15-Apr-21	"Medizinische Fakultät Carl Gustav Carus, Klinik und Poliklinik für Neurochirurgie, Dresden, Germany|Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Abteilung Funktionelle NC & Stereotaxie, Düsseldorf, Germany|Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Germany|LMU München, Campus Großhadern, Neurochirurgische Klinik und Poliklinik, München, Germany|Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie, Münster, Germany"		https://ClinicalTrials.gov/show/NCT04469699
355	NCT04902586	Effect of Radiotherapy Concurrent of TTFields in Patients With Glioblastoma	ECTG001	Not yet recruiting	No Results Available	Glioma|Glioblastoma	Device: TTFields	Disease-free survival|Overall survival	Zhongnan Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	30	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZhongnanH ECTG001	19-Jun-21	19-Dec-21	19-Jul-22	26-May-21		26-May-21	"Zhongnan hospital, Wuhan, Hubei, China"		https://ClinicalTrials.gov/show/NCT04902586
356	NCT02530502	Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma		Terminated	No Results Available	Adult Glioblastoma	Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Radiation: Radiation Therapy|Drug: Temozolomide	The dose-limiting toxicity of Radiation Therapy With Temozolomide and Pembrolizumab will be evaluated|Toxicity of Pembrolizumab	Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	4	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 15C01|NCI-2015-00736|STU00200883|P30CA060553	30-Sep-15	10-May-16	11-Oct-19	21-Aug-15		28-Oct-20	"Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT02530502
357	NCT00171938	Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)		Terminated	No Results Available	Glioblastoma	Drug: imatinib mesylate	"PFS (progression free-survival), defined by the percentage of patients without evidence of progressive disease in 6 months|Objective Tumoral Response defined by RECISt criteria performed by MRI|OS (overall survival)"	Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571BBR03	Apr-04	Jun-06	Jun-06	15-Sep-05		24-Feb-17	"Rio Grande, Brazil"		https://ClinicalTrials.gov/show/NCT00171938
358	NCT04587830	ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme	GBM	Recruiting	No Results Available	Glioblastoma Multiforme (GBM)	Drug: ADI-PEG20|Drug: Temozolomide	Number of Participants with Adverse Events as a Measure of Safety and Tolerability of ADI-PEG 20 in combination with radiotherapy and TMZ|Determine recommended phase 2 dose (RP2D)|Measure progression free survival at the RP2D|Measure overall survival at the RP2D|Minimum blood plasma concentration [Cmin ] of ADI-PEG 20|Blood plasma level of arginine and citrulline|Plasma levels of antibodies against ADI-PEG 20	Polaris Group	All	"20 Years to 75 Years   (Adult, Older Adult)"	Phase 1	32	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	POLARIS2020-001	16-Jun-20	30-Dec-22	30-Dec-23	14-Oct-20		14-Oct-20	"Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan"		https://ClinicalTrials.gov/show/NCT04587830
359	NCT02507102	A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia		Completed	No Results Available	Glioblastoma Multiforme	Device: Voyager	Incidence and evaluation of any serious adverse events associated with the Nativis Voyager System|Tumor Response|Overall survival at six months compared with historical response|Progression free survival	"Nativis, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	11	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NAT-105	Aug-15	Dec-17	26-Mar-18	23-Jul-15		30-Mar-18	"St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia"		https://ClinicalTrials.gov/show/NCT02507102
360	NCT00323115	Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Biological: Autologous Dendritic Cell|Drug: Temozolomide|Procedure: Radiotherapy|Biological: Dendritic Cell Vaccine	Tumor-specific Cytotoxic T-cell Response|Number of Adverse Events: Toxicity Profile of Intra-nodal DC/Tumor Lysate Vaccination|Number of Participants With Evaluable Data: Feasibility of Vaccination|Progression Free Survival (PFS)|Number of Participants With Significant Difference in Tumor Volume Size Pre- and Postvaccination: Neuroimaging and Tumor Assessment|Overall Survival Duration: Efficacy Parameters|Frequency of CD4+ and CD8+ T Cells - the Proportion of Cells in the Parent Population Responding to Glioblastoma Multiforme (GBM) - Median|Percentage of Tumor-specific T-cells - Correlation Between Immunological Parameters and Efficacy- Median|Number of Enzyme-linked Immunosorbent Spots (ELISPOT) - Correlation Between Immunological Parameters and Efficacy - Median|Frequency of CD4+ and CD8+ T Cells - the Proportion of Cells in the Parent Population Responding to Glioblastoma Multiforme (GBM) - Mean|Percentage of Tumor-specific T-cells - Correlation Between Immunological Parameters and Efficacy- Mean|Number of Enzyme-linked Immunosorbent Spots (ELISPOT) - Correlation Between Immunological Parameters and Efficacy - Mean|Evaluation of T Cell Characteristics|Immunohistochemistry	Dartmouth-Hitchcock Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D0536	May-06	Apr-08	Jul-13	9-May-06	26-Sep-12	10-Oct-18	"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States"		https://ClinicalTrials.gov/show/NCT00323115
361	NCT01364064	Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: TMZ	safety and efficacy	King Faisal Specialist Hospital & Research Center|Radiation Therapy Oncology Group	All	"Child, Adult, Older Adult"	Phase 3	1153	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RAC#2081-018	Jan-07	Jun-08	Jun-08	2-Jun-11		25-Feb-16			https://ClinicalTrials.gov/show/NCT01364064
362	NCT03867123	A Study to Evaluate the Safety of 2-OHOA Added to Standard of Care in Newly-diagnosed Glioblastoma Patients		Completed	No Results Available	Glioblastoma (GBM)	Drug: 2-OHOA|Radiation: RT|Drug: TMZ	Safety and Tolerability of 2-OHOA in association with Standard of Care (Stupp Protocol)|Maximum Tolerated dose (MTD)|Plasma concentration of temozolomide (TMZ).	Laminar Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MIN-002-1801|2018-000317-21	4-Dec-18	1-Jul-20	1-Jul-20	7-Mar-19		14-Jul-21	"Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Badalona, Cataluña, Spain|Hospital Universitari de Girona Dr. Josep Trueta, Institut Català d'Oncologia, Girona, Cataluña, Spain|Hospital Duran i Reynals, Institut Català d'Oncologia, L'Hospitalet De Llobregat, Cataluña, Spain"		https://ClinicalTrials.gov/show/NCT03867123
363	NCT00635557	Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: MPC-6827 + Carboplatin	Maximum tolerated dose|Pharmacokinetics|Antitumor activity	Myrexis Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MPC-6827-07-004|MPC-6827 GBM	Mar-08	Oct-10	Aug-11	13-Mar-08		25-Mar-11	"The Angeles Clinic and Research Institute, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Mt. Sinai School of Medicine, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT00635557
364	NCT00003456	Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme of Brain	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066488|BRI-BT-07	14-Mar-95	7-Dec-04	7-Dec-04	27-Jan-03	13-Dec-17	22-Mar-18	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003456
365	NCT01259869	A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression		Completed	Has Results	Glioblastoma	Drug: PX-866	Objective Response Rate	NCIC Clinical Trials Group|Cascadian Therapeutics Inc.|Canadian Cancer Trials Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	34	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I204	9-Dec-10	29-Oct-14	13-Feb-15	14-Dec-10	22-May-20	22-May-20	"Tom Baker Cancer Centre, Calgary, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT01259869
366	NCT02285959	Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Bevacizumab	Number of Participants with Adverse Events as a Measure of Safety|Tumor Response	Global Neurosciences Institute	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GlobalNI	Jun-14	Jun-22	Jun-22	7-Nov-14		5-Mar-21	"Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02285959
367	NCT00209989	Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Zarnestra|Procedure: standard Radiation therapy	"Efficacy will be assessed by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy|Objective response rate (RECIST and volumetric criteria)|Median survival, 6 month and 1 year survival rates|Safety of combination therapy of ZARNESTRA and RT, based on laboratory and clinical parameters"	Institut Claudius Regaud|Janssen-Cilag Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	02 TETE 02	Oct-05	Jun-11	Jun-11	21-Sep-05		24-Nov-11	"Centre Jean Perrin, Clermont Ferrand, France|Institut Claudius Regaud, Toulouse, France"		https://ClinicalTrials.gov/show/NCT00209989
368	NCT03181477	"Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas"	Glio-SIB-Up	Unknown status	No Results Available	"Glioblastoma, Adult"	Device: Radiotherapy	Overall survival	Centre Georges Francois Leclerc	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	67	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Glio-SIB-Up	7-Apr-17	15-Jun-17	15-Sep-20	8-Jun-17		28-Oct-19	"CHU Besançon, Besançon, France|Centre Georges François Leclerc, Dijon, France|Centre d'oncologie et de radiothérapie, Mâcon, France|Institut de cancérologie de Lorraine, Nancy, France|Paul Strauss, Strasbourg, France|Centre de Cancérologie Des Dentellières, Valenciennes, France"		https://ClinicalTrials.gov/show/NCT03181477
369	NCT02177578	Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Temozolomide|Radiation: Subventricular Zone radiation|Radiation: Neural Progenitor Cell Sparing radiation	Change from Baseline to Initial Progression|Progression Free Survival|Rate of Distant Brain Progression|Multifocal Disease Development|Location of Disease Progression|Neurocognitive Function Change from Baseline|Composite Cognitive Function Change from Baseline|Cognitive Function Change from Baseline|Quality of Life Change from Baseline|Acute and Late Toxicity Change from Baseline|Pathologically Confirmed Necrosis Change from Baseline|Pseudo-Progression Change from Baseline|Overall Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1426|IRB00031466	8-Jul-14	Dec-22	Sep-25	27-Jun-14		20-Sep-21	"Sibley Memorial Hospital, Washington, District of Columbia, United States|The SKCCC at Johns Hopkins, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT02177578
370	NCT02296580	A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)		Unknown status	No Results Available	Glioblastoma Multiforme	Device: Nativis Voyager RFE Therapy	Number of any adverse events associated with the investigational therapy.|Clinical Utility: PFS|Clinical Utility: OS	"Nativis, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	32	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NAT-101	Feb-14	31-Jan-20	31-Jan-20	20-Nov-14		15-May-19	"University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States|Center for Neurosciences, Tucson, Arizona, United States|cCARE - California Cancer Associates for Research & Excellence, Encinitas, California, United States|John Wayne Cancer Institute @ Providecne St. Johns Health Center, Santa Monica, California, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States|Providence Brain & Spine Institute, Portland, Oregon, United States|Cancer Care Collaborative, Austin, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Virginia Mason Hospital & Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|St Vincent's Hospital Melbourne, Melbourne, Australia"		https://ClinicalTrials.gov/show/NCT02296580
371	NCT01632228	A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Bevacizumab|Drug: Onartuzumab|Drug: Placebo	"Progression-free survival (PFS) as Assessed by Investigator According to Response Assessment in Neuro-Oncology (RANO) Criteria|Progression-free survival (PFS) as Assessed by Investigator According to RANO Criteria (in Participants With Met-Positive Glioblastoma)|Overall Survival (All Participants)|Percentage of Participants who Survived at Month 9 (All Participants)|Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (All Participants)|Percentage of Participants With Objective Response (OR), as Assessed by RANO Criteria (All Participants)|Duration of Response, as Assessed by RANO Criteria|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Serum Anti-Therapeutic Antibody (ATAs) to Onartuzumab|Overall Survival (in Participants With Met-Positive Glioblastoma)|Percentage of Participants who Survived at Month 9 (in Participants With Met-Positive Glioblastoma)|Percentage of Participants who are Progression Free at Month 6, as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)|Percentage of Participants With Objective Response (OR), as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)|Duration of Response, as Assessed by RANO Criteria (in Participants With Met-Positive Glioblastoma)|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) in Participants With Met-Positive Glioblastoma|Minimum Observed Serum Concentration (Cmin) of Onartuzumab|Maximum Observed Serum Concentration (Cmax) of Onartuzumab|Minimum Observed Serum Concentration (Cmin) of Bevacizumab|Maximum Observed Serum Concentration (Cmax) of Bevacizumab"	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	135	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	GO27819|2011-005912-27	29-Jun-12	21-Jan-16	21-Jan-16	2-Jul-12		5-Feb-18	"University of Alabama At Birmingham; Neuro-Oncology, Birmingham, Alabama, United States|Cedars Sinai Medical Center; Neurosurgery, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|USCF - Neurosurgery, San Francisco, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Florida Cancer Specialists - Englewood, Englewood, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|North Western Univ; Neurology, Chicago, Illinois, United States|Northshore University Health System; Cardiology, Evanston, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Hatton Research Institutes, Cincinnati, Ohio, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States|Baylor Research Inst., Dallas, Texas, United States|University of Virgina, Charlottesville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance; Investigational Drug Service, Seattle, Washington, United States|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727, Toronto, Ontario, Canada|McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada|CHUS Hopital Fleurimont; CRC, Sherbrooke, Quebec, Canada|Hopital Avicenne; Neurologie, Bobigny, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Hopital Roger Salengro, Lille, France|Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille, France|Centre Val Aurelle Paul Lamarque; Medecine B3, Montpellier, France|Hôpital Central; Departement de Neuro-Oncologie, Nancy, France|Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, France|Hopital Purpan, Toulouse Cedex 9, France|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main, Germany|Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie, Hamburg, Germany|Ärztehaus Velen, Ibbenbühren, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie, Mainz, Germany|Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie, München, Germany|Pius-Hospital, Oldenburg, Germany|Ospedale Bellaria; U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Presidio Ospedaliero Marconi Bufalini; U.O. di Oncologia, Cesena, Emilia-Romagna, Italy|A.O. Universitaria Di Parma; Oncologia Medica, Parma, Emilia-Romagna, Italy|Spedali Civili di Brescia, Brescia, Lombardia, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia, Pisa, Toscana, Italy|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Clinic i Provincial; Servicio de Farmacia, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|HUG; Oncologie, Geneve, Switzerland|Universitätsspital Zürich; Klinik für Neurologie, Zürich, Switzerland|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Nottingham City Hospital; David Evans Centre, Nottingham, United Kingdom"		https://ClinicalTrials.gov/show/NCT01632228
372	NCT03170141	Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme		Enrolling by invitation	No Results Available	Glioblastoma Multiforme of Brain|Glioblastoma Multiforme	Biological: Antigen-specific IgT cells	Safety of infusion of autologous IgT cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.|Treatment response rate of recurrent glioblastoma|Overall survival Rate|Progression-free survival rate|Persistence and proliferation of IgT cells in patients|Production of specific immune check point modulatory proteins	Shenzhen Geno-Immune Medical Institute	All	"1 Year to 80 Years   (Child, Adult, Older Adult)"	Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIMI-IRB-17003	31-May-19	1-Aug-19	31-Dec-22	30-May-17		24-Nov-21	"Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China"		https://ClinicalTrials.gov/show/NCT03170141
373	NCT02331498	Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme	PAZOGLIO	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Drug: Pazopanib	"Recommended Phase 2 Dose (RP2D) of pazopanib in oral route in addition to the maintenance phase of the Stupp protocol, according the rate (33 %) of tolerate toxicities|overall tolerance of pazopanib : number of biological toxicities, blood pressure and hemorragic events|antitumor activity of the adjunction of daily dose of pazopanib to the maintenance phase of the Stupp protocol|determine the median Progression-Free-Survival|determine the median Overall Survival (mOS)|pharmacokinetics profile: area under curve regarding plasma concentration /time between 0 and 8 h (AUC0-8 hours) from 0 to 24 h (AUC 0-24 hours), maximum plasma concentration (Cmax), time to the concentration maximum (Tmax) and plasma half-life (t1/2)|determine the pharmacokinetics (PK) profile of TMZ"	Centre Antoine Lacassagne|GlaxoSmithKline	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	51	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2012/49	Jun-15	Aug-22	Aug-23	6-Jan-15		23-Feb-21	"Centre Antoine Lacassagne, Nice, Cedex 2, France"		https://ClinicalTrials.gov/show/NCT02331498
374	NCT04842513	Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma	GLIO-XS15	Recruiting	No Results Available	Glioblastoma Multiforme of Brain	Drug: Multipeptide plus XS15	Adevrse Events|Change of immunogenicity parameter from baselien	University Hospital Tuebingen	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-003357-30	3-May-21	2-May-23	2-May-24	13-Apr-21		18-May-21	"University Hospital Tübingen, Tübingen, BW, Germany"		https://ClinicalTrials.gov/show/NCT04842513
375	NCT01860638	A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Bevacizumab|Drug: Lomustine|Drug: Placebo|Radiation: Radiotherapy|Drug: Temozolomide|Drug: SOC Agent	"Overall Survival (OS)|Percentage of Participants Alive at 6, 12, and 18 Months from Randomization|Progression-Free Survival (PFS) on 2L Treatment According to Modified Response Assessment in Neuro-Oncology (RANO) Criteria|PFS on 3L Treatment According to Modified RANO Criteria|Restricted PFS on 3L Treatment According to Modified RANO Criteria|Percentage of Participants with 2L Objective Response of Complete Response (CR) or Partial Response (PR) According to Modified RANO Criteria|Percentage of Participants with 3L Objective Response of CR or PR According to Modified RANO Criteria|Percentage of Participants with 2L Disease Control as CR, PR, or Stable Disease According to Modified RANO Criteria|Percentage of Participants with 3L Disease Control as CR, PR, or SD According to Modified RANO Criteria|Duration of 2L Objective Response Assessed According to Modified RANO Criteria|Duration of 3L Objective Response According to Modified RANO Criteria|Percentage of Participants with Adverse Events (AEs)|1L Treatment: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30) Global Health Status/Global QoL Scale Score|2L and 3L Treatment: Change From 2L Baseline in EORTC QLQ C30 Global Health Status/Global QoL Scale Score|1L Treatment: Change From Baseline in EORTC QLQ Brain Cancer Module 20 (BN20) Multiple Item Score|2L and 3L Treatment: Change From 2L Baseline in EORTC QLQ BN20 Multiple Item Score|Percentage of Participants with Mini Mental Status Examination (MMSE) Score <27 or >/=27|1L Treatment: Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) z-score|2L and 3L Treatment: Change From 2L Baseline in HVLT-R z-score|1L Treatment: Change From Baseline in Controlled Oral Word Association (COWA) z-score|2L and 3L Treatment: Change From 2L Baseline in COWA z-score|1L Treatment: Change From Baseline in Trail-Making Test (TMT) Part A and B z-score|2L and 3L Treatment: Change From 2L Baseline in TMT Part A and Part B z-score|Number of Participants with Hospitalizations According to Type of Hospitalizations|Duration of Hospitalizations According to Type of Hospitalizations|EuroQol Five-Dimension Questionnaire (EQ-5D) Score"	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	296	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	MO28347|2012-003138-17	19-Aug-13	13-Jan-17	5-May-17	23-May-13		30-Apr-18	"Medizinische Universität Graz; Universitätsklinik für Neurologie, Graz, Austria|Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus; Innere Medizin mit Neuroonkologie, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Kaiser-Franz-Josef-Spital; Neurologische Abteilung, Wien, Austria|MBAL Serdika EOOD, Sofia, Bulgaria|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Hopital Avicenne; Neurologie, Bobigny, France|Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Hopital Cote De Nacre; Unite Neurologie Generale, Caen, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|Hopital Roger Salengro; Service de Neurologie, Lille, France|Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille, France|Hôpital Central; Departement de Neuro-Oncologie, Nancy, France|Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France|Hopital Purpan, Toulouse Cedex 9, France|Agioi Anargyroi Anticancer Hospital; Radiotherapeutic Clinic, Kifisia, Greece|Hygeia Hospital, Marousi, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Ospedale Bellaria; U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Torino, Piemonte, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Riga East Clinical University hospital, Clinic Gailezers, Dept of Neurosurgery, Riga, Latvia|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital de Sao Joao; Servico de Oncologia, Porto, Portugal|Institutul Oncologic Prof. Dr. Al. Trestioreanu Bucuresti, Bucuresti, Romania|Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania|Spital Clinic Judetean Mures; Oncologie, Targu Mures, Romania|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Universitario Infanta Cristina; Servicio de Oncologia, Badajoz, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hosp. Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Universitetssjukhuset; Onkologkliniken, Linkoeping, Sweden|Norrlands Universitetssjukhus; Cancer Centrum, Umea, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Adana City Hospital, Medical Oncology, Adana, Turkey|Baskent Universitesi Tıp Fakultesi; Ic Hastalıkları Anabilim Dalı Tıbbi Onkoloji Bilim Dalı, Ankara, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, Turkey|Kocaeli University Faculty of Medicine; Medical oncology, Izmit, Turkey|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrookes Hospital; Dept of Oncology, Cambridge, United Kingdom|University College Hospital; Department of Oncology, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT01860638
376	NCT00481455	Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)		Completed	No Results Available	Recurrent Glioblastoma Multiforme	Drug: Panzem NCD|Drug: Temozolomide	6-month progression free survival and median overall survival for patients receiving at least one dose	"CASI Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	15	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ME-CLN-007	Apr-07	Sep-07	Oct-08	1-Jun-07		25-Nov-08	"The Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00481455
377	NCT01588769	A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients	ALECSAT-GBM	Completed	No Results Available	Glioblastoma Multiforme	Biological: ALECSAT cell based immunotherapy	"Observation of tolerability and sideeffects of treatment monitored by objective medical examinations, Karnofsky score and QOL interviews.|Potential clinical effect will be monitored by PET-MRI and SPECT scanning of the brain."	CytoVac A/S	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	23	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CV003|2011-002180-22	Aug-11	Nov-12	Apr-13	1-May-12		6-Jun-16	"Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT01588769
378	NCT00029783	Efficacy of Distant Healing in Glioblastoma Treatment		Completed	No Results Available	Glioblastoma	Procedure: Distant Healing		National Center for Complementary and Integrative Health (NCCIH)	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	150	NIH	Interventional	Allocation: Randomized|Primary Purpose: Treatment	R01AT000644-03	Sep-00		Jun-05	24-Jan-02		18-Aug-06	"California Pacific Medical Center Research Institute, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00029783
379	NCT02430363	Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475		Unknown status	No Results Available	Glioblastoma	Drug: MK - 3475|Biological: Suppressor of the PI3K/Akt pathways	Progression Free Survival|Safety and tolerability of Pembrolizumab (Assessed by reported adverse events using CTCAE version 4.0)	Medical Research Council|Aarhus University Hospital|NCRI Clinical Studies Groups|ECCO - the European CanCer Organisation|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	58	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ETIK-W/33-15	Mar-13	Jan-16	Jun-18	30-Apr-15		24-Feb-16	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|M D Anderson Cancer Center, Houston, Texas, United States|UCL- Cliniques Universitaires Saint Luc, Brussels, Belgium|St Johannes Hospital, Duisburg, Germany|Spedali Civili di Brescia, Brescia, Italy|IRCCS San Raffaele, Milan, Italy|Lower-Silesian Oncology Centre, Wroclaw, Lower-Silesian, Poland|Pavlov State Medical University, St. Petersburg, Russian Federation|Hospital Universitario Germans Trias I Pujol, Barcelona,, Spain|Universitätsklinik für Frauenheilkunde, Bern, Switzerland|Regional Cancer Center, Dnepropetrovsk, Ukraine|National Institute of Cancer, Kiev, Ukraine|Royal Victoria Hospital, Belfast, Ulster, United Kingdom"		https://ClinicalTrials.gov/show/NCT02430363
380	NCT01124240	Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene	ExCentric	Unknown status	No Results Available	Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4	Drug: Cilengitide	12 month progression free survival|Objective response|Toxicity|Peripheral WBC MGMT modulation|biomarker correlation with response	"Northern Sydney and Central Coast Area Health Service|Merck KGaA, Darmstadt, Germany"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	48	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0910259M	Nov-09	Nov-12	Jan-14	17-May-10		26-Jul-11	"Royal North Shore Hospital, Sydney, New South Wales, Australia"		https://ClinicalTrials.gov/show/NCT01124240
381	NCT04600817	A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)		Recruiting	No Results Available	Newly Diagnosed Glioblastoma	Drug: TJ107|Drug: TJ107 placebo	The percentage of patients with average of ALC at 3w after first TJ107 dose and at pre-dose 3rd TMZ ≥1.5X109/L	I-Mab Biopharma Co. Ltd.	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	160	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	TJ107001GBM201	31-Dec-20	30-Nov-23	28-Feb-24	23-Oct-20		7-Jul-21	"Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Second Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Tangdu Hospital of The Fourth Military Medical University of Chinese PLA, Xi'an, Shaanxi, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Chongqiong Cancer Hospital, Chongqing, China|Huashan Hospital Affiliated to Fudan University, Shanghai, China|Tianjin Huanhu Hospital, Tianjin, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|Prince of Wales Hospital, Hong Kong, Hong Kong"		https://ClinicalTrials.gov/show/NCT04600817
382	NCT00944801	Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Pegylated Liposomal Doxorubicine	"progression free survival probability at 12 months to detect an improvement of the PFS-12 of 15.6% as compared to EORTC26981/NCIC-CE.3 combination arm (PFS-12: 26.9%)|PFS-24, mOS, OS-12, OS-24, mTTP, response rate, rate of stabilizations , and toxicity profile"	University of Regensburg|Essex Pharma Germany	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	63	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RNOP-09	Jul-02	May-09	May-09	23-Jul-09		23-Jul-09	"University of Regensburg, Department of Neurology, Regensburg, Germany"		https://ClinicalTrials.gov/show/NCT00944801
383	NCT02340156	Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma		Terminated	Has Results	RECURRENT GLIOBLASTOMA	Genetic: SGT-53|Drug: Temozolomide	Tumor Response|Incidence of Treatment-Emergent Adverse Events|Progression-free Survival (PFS)|Overall Survival (OS)|Anti-tumor Activity|Induction of Apoptosis|Nanoparticle Tumor Delivery	"SynerGene Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	1	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SGT53-02-2	Dec-14	Nov-18	Nov-18	16-Jan-15	3-Mar-21	3-Mar-21	"MD Anderson Cancer Center, Houston, Texas, United States|China Medical University Hospital, Taichung, Taiwan"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/56/NCT02340156/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02340156
384	NCT02302235	Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study	GBMXRT	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme of Brain	Other: Ketogenic Diet|Other: Standardized Diet	"survival time|time to radiological (MRI) tumor progression|The incidence of treatment-emergent adverse events during treatment|Tolerability of ketogenic diet: Rate of early discontinuation of subjects from the diet because of intolerability, defined as unwillingness by the subject to continue with the diet because of possible diet related side effects"	"Mid-Atlantic Epilepsy and Sleep Center, LLC|Neuroscience Research Foundation, Sewickley,PA"	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 2	42	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	maesc 006	Feb-14	Dec-21	May-22	26-Nov-14		22-Aug-19	"MidAtlantic Epilepsy and Sleep Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT02302235
385	NCT00895180	Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	Has Results	Adult Glioblastoma Multiforme	Biological: olaratumab|Biological: ramucirumab	"Percentage of Participants Who Achieved Progression-Free Survival Rate at 6 Months (PFS-6)|Number of Participants With Treatment Emergent Adverse Events as Assessed by NCI CTCAE v4.0 (National Cancer Institute-Common Terminology Criteria for Adverse Events)|Percentage of Participants (Pts) With Complete Response (CR), Partial Response (PR) and Minor Response (MR) (Objective Response Rate [ORR])|Median Overall Survival (OS)|Pharmacokinetics (PK): Concentration Maximum (Cmax) and Concentration Minimum (Cmin) of Ramucirumab|PK: Cmax and Cmin of Olaratumab|Pharmacodynamics (PD) Profiles|Percentage of Participants With Anti-Olaratumab Antibodies (ADA)|Percentage of Participants With Anti-Ramucirumab Antibodies (ADA)"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Eli Lilly and Company	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	80	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC-0901 CDR0000641230|U01CA137443|ABTC-0901|IMCL-CP-19-0801	Jul-10	22-Jun-12	4-Mar-14	8-May-09	29-Mar-17	27-Dec-17	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00895180
386	NCT00948389	Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)		Terminated	Has Results	Glioblastoma	Drug: Dasatinib|Drug: Lomustine	"Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs|Number of Participants With Dose-limiting Toxicities (DLTs)|Deaths Within 30 Days of Protocol Treatment Discontinuation|Number of Participants With Worst Grade of Hematological Toxicity Per NCI CTCAE Version 3.0 Criteria|Number of Participants With Worst Grade of Biochemistry Abnormality Per NCI CTCAE Version 3.0 Criteria"	Bristol-Myers Squibb|European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	28	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA180-274|Protocol 26083|2009-010576-21	Oct-09	May-11	May-11	29-Jul-09	28-Aug-12	31-Aug-12	"Local Institution, Paris Cedex, France|Local Institution, Bologna, Italy|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00948389
387	NCT02296476	A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)		Terminated	Has Results	Glioblastoma Multiforme	Drug: Birabresib	Progression-free Survival (PFS) at 6 Months|Objective Response Rate (ORR)|Duration of Response (DOR)|Overall Survival (OS)|Progression-free Survival|Number of Participants Who Experienced at Least One Adverse Event (AE)|Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE|Number of Participants Who Discontinued Study Treatment Due to an AE|Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1|Observed Maximum Concentration (Cmax) of MK-8628|Time to Maximum Concentration (Tmax) of MK-8628|Apparent Terminal Half-Life (t1/2) of MK-8628|Apparent Total Body Clearance (Cl/F) of MK-8628|Apparent Volume of Distribution During the Terminal Phase (Vz/F) of MK-8628|Observed Minimum Concentration (Cmin) of MK-8628|Area Under the Concentration-time Curve of MK-8628 From Time 0 to Infinity (AUC 0-∞)	Oncoethix GmbH	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8628-002|OTX015_107|MK-8628-002|2014-001469-28	29-Oct-14	20-Oct-15	20-Oct-15	20-Nov-14	17-May-18	26-Jan-21			https://ClinicalTrials.gov/show/NCT02296476
388	NCT00535379	"SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme"	SURGE01-07	Unknown status	No Results Available	Glioblastoma Multiforme	Drug: Sunitinib	Progression-free survival rate at 6 months|Median time to tumor progression|Overall survival|Overall survival rate at 12 months	Medical University Innsbruck|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	70	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EUDRACT-Nr. 2007-002142-37	Oct-07	Dec-10	Jan-11	26-Sep-07		30-Aug-10	"LKH Feldkirch, Feldkirch, Austria|Medical University Innsbruck, Innsbruck, Austria|LNK Wagner-Jauregg, Linz, Austria|Paracelsus Medical University, Salzburg, Austria|Medical University Vienna, Vienna, Austria|Kaiser-Franz-Josef Spital Wien, Wien, Austria|University Hospital of Heidelberg, Heidelberg, Baden-Württemberg, Germany|University Hospital of Mannheim, Mannheim, Baden-Württemberg, Germany|University Hospital of Bonn, Bonn, Nordrhein-Westfalen, Germany|University Hospital of Berlin, Berlin, Germany"		https://ClinicalTrials.gov/show/NCT00535379
389	NCT03047473	Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme	SEJ	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme of Brain	Biological: avelumab	Safety and tolerability according to emergent adverse event leading to avelumab interruption or termination|iRANO criteria	Clinique Neuro-Outaouais	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CNO-006	10-Mar-17	9-Aug-21	9-Aug-21	9-Feb-17		28-Jul-21	"Clinique Neuro-Outaouais, Gatineau, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT03047473
390	NCT04065087	Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Newly Diagnosed Glioblastoma	Biological: GX-I7|Other: Placebo	lymphocyte count|Overall survival|Progression free survival	"Genexine, Inc."	All	"19 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	54	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	GX-I7-CA-007	22-Aug-19	27-May-22	27-Aug-22	22-Aug-19		22-Aug-19	"St. Vincent Hospital, Suwon-si, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT04065087
391	NCT01149109	Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients	CeTeG	Completed	No Results Available	Glioblastoma	Drug: Temozolomide and lomustine|Drug: Temozolomide	overall survival|progression free survival|best response rate determined by MRI|frequency of delay of the next Lomustine/Temozolomide or Temozolomide course|acute toxicity during radiotherapy and chemotherapy according to CTC AE V3.0|quality of life|Evaluation of late neurotoxicity	"University Hospital, Bonn"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	141	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CeTeG|2009-011252-22	Oct-10	6-Apr-17	6-Apr-17	23-Jun-10		14-Jun-17	"Depatment of Neurosurgery, Charité, University Hospital Berlin, Berlin, Germany|Department of Neurology, University Hospital Bochum, Bochum, Germany|Department of Neurology, University Hospital Bonn, Bonn, Germany|Department of Neurosurgery, University Hospital Cologne, Cologne, Germany|Department of Neurosurgery, University Hospital Dresden, Dresden, Germany|Department of Neurosurgery, University Hospital Duesseldorf, Duesseldorf, Germany|Department of Neurosurgery, University Hospital Frankfurt, Frankfurt, Germany|Department of Radiooncology, University Hospital Leipzig, Leipzig, Germany|Department of Neurosurgery, University of Heidelberg, Medical Faculty of Mannheim, Mannheim, Germany|Department of Neurosurgery, University Hospital Muenster, Muenster, Germany|Department of Neurosurgery, University Hospital Munich (LMU), Munich, Germany|Department of Neurology, University Hospital Regensburg, Regensburg, Germany"		https://ClinicalTrials.gov/show/NCT01149109
392	NCT02772094	Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)		Unknown status	No Results Available	Glioblastoma Multiforme|Glioblastoma	"Biological: Single arm, open-label"	"Overall survival with measures of medium survival period (in days) and annual survival rates (in %)|Adverse effects, acute and chronic, assessed according to NCI CTCAE Version 3|Disease progression-free period"	"China Medical University Hospital|Den-Mei Brain Tumor Education Foundation, Taichung, Taiwan|Ministry of Health and Welfare, Taiwan"	All	"13 Years to 70 Years   (Child, Adult, Older Adult)"	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DMR94-IRB-043-1	May-05	Dec-14	Dec-16	13-May-16		13-May-16	"China Medical University Hospital, Taichung, Taiwan"		https://ClinicalTrials.gov/show/NCT02772094
393	NCT02017249	Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme	ArginineGBM	Completed	No Results Available	Glioblastoma Multiforme	Drug: arginine in powder form|Drug: Silica and cellulose placebo powder	Change in GBM patients immune function through arginine supplementation|Change in control group immune function through arginine supplementation	Inova Health Care Services	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	1	Other	Interventional	"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	13-1364	Mar-14	Sep-15	6-Oct-15	20-Dec-13		16-Sep-19	"Inova Outpatient Surgery Clinic and Inova Fairfax Hospital, Fairfax, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02017249
394	NCT00990496	A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)		Terminated	No Results Available	Glioblastoma Multiforme	Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CMV Specific Cytotoxic T Lymphocytes (CTL)	"To determine the incidence of tumor responses, as defined as stable disease, partial, or complete responses after the infusion of CMV CTL.|To determine the duration and magnitude of donor chimerism post infusion by micro chimerism assays.|To determine the incidence of increases in CMV pp65 or IE-1 T cells post infusion of allogeneic CMV CTL of GBM patients.|To determine safety of allogeneic CTL infusions in this patient population."	Milton S. Hershey Medical Center	All	"5 Years to 65 Years   (Child, Adult, Older Adult)"	Phase 1	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	31717|PSHCI #09-045	Sep-09	28-Oct-10	28-Oct-10	6-Oct-09		2-May-18			https://ClinicalTrials.gov/show/NCT00990496
395	NCT03619239	Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma	GBM	Completed	No Results Available	Newly Diagnosed Glioblastoma	Drug: GX-I7	"DLT(Dose-Limiting Toxicity) Assessment|Incidence, nature and severity of Adverse events|PD(pharmacodynamic) profile [ALC result]|Anti-tumor Activity [OS]|Anti-tumor Activity [PFS]|Immunogenicity[ ADA and neutralizing antibody]|Exploratory Biomarker [serum Interleukin-7]"	"Genexine, Inc."	All	"19 Years and older   (Adult, Older Adult)"	Phase 1	15	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GX-I7-CA-004	20-Jun-18	25-Sep-20	25-Sep-20	7-Aug-18		10-Nov-20	"The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT03619239
396	NCT01800695	Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: ABT-414|Drug: Temozolomide|Radiation: Whole Brain Radiation	Number and percentage of participants with adverse events|Maximum concentration of ABT-414|Number of Dose Limiting Toxicities|Minimum Concentration of ABT-414|Half-life of ABT-414|Biomarker EGFR expression|Progression Free Survival|Overall Survival	AbbVie	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 1	202	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M12-356|2012-003884-23	2-Apr-13	19-Jun-17	19-Jun-17	28-Feb-13		21-Nov-17			https://ClinicalTrials.gov/show/NCT01800695
397	NCT00615186	Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy	Glass-Art	Terminated	No Results Available	Glioblastoma Multiforme	Drug: Neuradiab + Radiotherapy + Temozolomide|Drug: Radiation Therapy + Temozolomide	The primary measure of efficacy is overall survival (OS).|Progression-free survival (PFS) is the sole secondary measure of efficacy.	Bradmer Pharmaceuticals Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	9	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BRAD-301	Jun-08	Aug-13	Dec-13	14-Feb-08		10-Feb-11			https://ClinicalTrials.gov/show/NCT00615186
398	NCT00797940	Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)	CLARITY-1	Withdrawn	No Results Available	Glioblastoma Multiforme	Drug: IL-4PE	"To evaluate the efficacy (expressed as overall survival at 6 months [OS-6]) of intratumoral infusion of PRX321 in subjects with first recurrence or progression of glioblastoma multiforme (GBM)|To evaluate objective response rate (ORR), duration of response (DR), overall survival (OS), and progression-free survival (PFS). To assess the safety of intratumoral infusion with PRX321 in subjects with recurrent or progressive GBM."	Sophiris Bio Corp|Protox Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRX321-1-05	Jan-09	Dec-10		25-Nov-08		3-Dec-12			https://ClinicalTrials.gov/show/NCT00797940
399	NCT00003474	Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme of the Brain	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066511|BRI-BT-20	14-Mar-96	21-Jun-03	21-Jun-03	27-Jan-03	13-Dec-17	22-Mar-18	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003474
400	NCT02820584	A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma	DENDR-STEM	Completed	No Results Available	de Novo Glioblastoma	Biological: GSC-loaded autologous dendritic cells	"Safety: - incidence, nature, severity and seriousness of AEs, according to NCI-CTCAE version 4.0; - maximum toxicity grade and percentage of patients experiencing grade 3-4 by each patient for each specific toxicity; - patients with at least a SAE.|Incidence, severity and type of AEs throughout the study, and toxicities will be graded according to the National Cancer Institute Common Toxicity Criteria for AE (CTCAE), version 4.0|Probability to obtain the full vaccine dosage, i.e. the percentage of patients who will be treated with at least 2 vaccine injections.|Immunologic activity|Progression free survival (PFS)|Quality of life|Overall survival (OS)"	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DENDR-STEM	Sep-16	Jun-17	Jun-17	1-Jul-16		12-Sep-19			https://ClinicalTrials.gov/show/NCT02820584
401	NCT00892177	Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Biological: bevacizumab|Drug: dasatinib|Other: placebo	"Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I)|Progression-free Survival at 6 Months (PFS6) (Phase II)|Number of Participants With Adverse Events According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 (Phase II)|Overall Survival (Phase II)|Time-to-disease Progression (Phase II)|Patient-reported QOL, as Measure by the Functional Assessment of Cancer Therapy-Brain (FACT-Br) (Phase II)|Objective Response (Phase II)"	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	144	Other|NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCCTG-N0872|NCI-2011-01921|CDR0000641746	Oct-09	Nov-14	1-Jul-19	4-May-09	27-Jun-17	21-Oct-19	"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Palchak David MD, Pismo Beach, California, United States|Aurora Presbyterian Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Ella Milbank Foshay Cancer Center at Jupiter Medical Center, Jupiter, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Kapiolani Medical Center at Pali Momi, 'Aiea, Hawaii, United States|Oncare Hawaii, Incorporated - Pali Momi, 'Aiea, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Lusitana, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Incorporated, Honolulu, Hawaii, United States|University of Hawaii, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Kuakini, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Kauai Medical Clinic, Lihue, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital Cancer Care Services, Indianapolis, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Mercy Cancer Center - West Lakes, Clive, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Women's Health - Wichita, Wichita, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Main Office, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Toledo Clinic Cancer Centers - Adrian, Adrian, Michigan, United States|Toledo Clinic Cancer Centers-Adrian, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Sanford Clinic North-Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Duluth Clinic, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Frontier Cancer Center and Blood Institutes-Billings, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Billings Clinic, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Benefis Healthcare - Sletten Cancer Institute, Great Falls, Montana, United States|Benefis Sletten Cancer Institute, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center, Grand Island, Nebraska, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Callahan Cancer Center at Great Plains Regional Medical Center, North Platte, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States|New Hampshire Oncology-Hematology PA, Concord, New Hampshire, United States|New Hampshire Oncology - Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Lakes Region General Hospital, Laconia, New Hampshire, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Valley Hospital - Ridgewood, Ridgewood, New Jersey, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|Mount Kisco Medical Group at Northern Westchester Hospital, Mount Kisco, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Dakota Cancer Institute at Dakota Clinic - South University, Fargo, North Dakota, United States|Essentia Health Cancer Center-South University Clinic, Fargo, North Dakota, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Precision Radiotherapy at University Pointe, West Chester, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Cancer Care Associates - Norman, Norman, Oklahoma, United States|Cancer Care Associates - Mercy Campus, Oklahoma City, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazelton, Hazleton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westfields Hospital/Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Oconomowoc Memorial Hospital-ProHealth Care Inc, Oconomowoc, Wisconsin, United States|Regional Cancer Center at Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00892177
402	NCT05053880	A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme		Recruiting	No Results Available	Recurrent Glioblastoma Multiforme(GBM)	Drug: ACT001|Drug: ACT001 + Pembrolizumab	"1b-Incidence, type and severity of treatment-emergent AEs (TEAEs)|1b-Dose limiting toxicities (DLTs)|1b-Mean changes in vital sign measurements-Heart Rate|1b-Mean changes in vital sign measurements- supine blood pressure|1b-Mean changes in vital sign measurements- body temperature|1b-Mean changes in vital sign measurements- respiratory rate|1b-Mean changes in electrocardiogram (ECG) parameters|1b-Mean changes in Karnofsky Performance Scale score|2a-Progression free survival (PFS) at 6 months|1b-Incidence of DLTs according to the MTD/RP2D evaluation process.|1b- Pharmacokinetics (PK) of ACT001 in Plasma concentrations in tumor.|2a-Overall survival|2a-Incidence, type and severity of TEAEs|2a-Concentration of ACT001 in resected tumor biopsy tissue."	Accendatech USA Inc.|C3 Research Associates|Avance Clinical Pty Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	48	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACT001-US-001	22-Sep-21	Nov-22	Nov-23	23-Sep-21		19-Nov-21	"UT MD Anderson Cancer Center, Dept of Neuro-Oncology, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT05053880
403	NCT01849146	"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma"		"Active, not recruiting"	No Results Available	Glioblastoma|Recurrent Glioblastoma	Drug: Adavosertib|Radiation: Radiation Therapy|Drug: Temozolomide	Maximum tolerated dose of adavosertib with 6 weeks of radiotherapy and temozolomide (Arm I)|Maximum tolerated dose of adavosertib with adjuvant temozolomide (Arm II)|Incidence of toxicities|Overall survival|Progression-free survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	74	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2013-00858|ABTC 1202|ABTC-1202|UM1CA137443	19-Aug-13	29-Jul-21		8-May-13		13-Aug-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT01849146
404	NCT02718443	VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: VXM01	"Safety and tolerability taking into account treatment-limiting toxicities (TLTs)|Immune Response by Enzyme Linked Immuno Spot (ELISpot)|Serum biomarker Response by Enzyme Linked Immuno Sorbent Assay (ELISA)|Vascular normalization index (VNI) including tumor perfusion acc. to Sorensen 2009|Tumor immune cell infiltration by tumor tissue immunohistochemistry|Tumor response or progression on MRI acc. to Response Assessment in Neuro-Oncology (RANO) criteria|Clinical Response including time to progression, progression free survival, overall survival|Biodistribution and shedding of VXM01 bacteria"	Vaximm GmbH	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	14	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VXM01-02-DE	May-16	Aug-17	Jul-18	24-Mar-16		19-Oct-18	"Neurology Clinic and National Center for Tumor Diseases, Heidelberg, Germany"		https://ClinicalTrials.gov/show/NCT02718443
405	NCT00394628	AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: AQ4N|Drug: Temozolomide|Procedure: Radiotherapy	Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODAR®)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.|Phase 2a: Rate of progression-free survival at 6 months.|Phase 2a: Rate of progression-free survival at 12 months|Percent of subjects alive at 12 months|Duration of progression-free survival|Time to progression|Duration of overall survival	Novacea	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	021-003	Oct-06			1-Nov-06		30-May-07	"University of California, Los Angeles, Los Angeles, California, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Baylor Research Institute, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT00394628
406	NCT01805453	"Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma"	ASTER	Completed	No Results Available	Newly-diagnosed Glioblastoma	Drug: Losartan|Drug: Placebo	"Steroid dosage required to control brain edema on the last day of radiotherapy in each arm|Steroids dosage 1 month after the end of RT|Assessment of cerebral edema on MRI|Tolerance (NCI-CTCAE v3.0)|Blood pressure|HbA1C|glycemia|body weight|side-effects of steroids|Executive functions ( "" Moca test "")|Quality of life (EORTC)|Progression free survival|Overall survival|Survival|Performance status (KPS) at the end, 1 month , and 2 months after the end of RT"	Assistance Publique - Hôpitaux de Paris|ANOCEF (french association of neuro-oncologists)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	80	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	P120105|2012-004536-34	29-Mar-13	15-Jan-15	15-May-17	6-Mar-13		8-May-20	"Neurology Department - Avicenne Hospital, Bobigny, France"		https://ClinicalTrials.gov/show/NCT01805453
407	NCT01777919	Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform	GLIODIS	Unknown status	No Results Available	Glioblastoma Multiforme	Drug: Temozolomide|Drug: Disulfiram|Drug: Copper	Progression-free survival|Overall survival	Olympion Medical Center|University of Ioannina|University of Eastern Finland|University of Ulm	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PK-18081973	Jan-17	Jan-19	Jan-20	29-Jan-13		17-Oct-16	"Olympion Medical Center, Patras, Greece"		https://ClinicalTrials.gov/show/NCT01777919
408	NCT01564914	A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma	105GM201	Completed	Has Results	Glioblastoma|Glioblastoma Multiforme	Drug: TRC105|Drug: Bevacizumab	Median Overall Survival (OS)|Median Duration That Patients Remained Progression Free on Study|Number of Participants With Adverse Events|Number of Patients Who Respond to Study Treatment According to Modified RANO Criteria (Objective Response Rate (ORR)).	Tracon Pharmaceuticals Inc.|The Cleveland Clinic|Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	22	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	105GM201/Case 1312	May-12	Jun-15	Jun-15	28-Mar-12	12-Jun-19	12-Jun-19	"University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01564914
409	NCT01251484	BIBF 1120 in Recurrent Glioblastoma Multiforme		Completed	No Results Available	Recurrent Glioblastoma	Drug: BIBF1120	Response rate|Adverse events	"Ulrik Lassen|Boehringer Ingelheim|University of Copenhagen|Rigshospitalet, Denmark"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	25	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BIBF1120 GBM	Jan-11	Aug-12	Aug-12	2-Dec-10		4-Oct-12	"Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT01251484
410	NCT00295815	Enzastaurin Versus Lomustine in Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: enzastaurin|Drug: lomustine	The primary objective is to compare Enzastaurin versus Lomustine in patients who for the second time have brain cancer (specifically intracranial glioblastoma) to see what effect the drugs have on keeping the disease from progressing (worsening).|To measure survival to see how the tumor responded to the therapy and how long the response lasted using MRI (a scanning technique).|To measure changes in patient's ability to care for themselves (this will be determined through a standard survey).|To measure changes from baseline and a neurologic exam.|To review all bad reactions reported by the patient and detected in blood tests.|To review the effect of the cancer on the patient's ability to care for themselves and on their general health status.|To determine through blood tests how long the medication is in the patient's body.|To review through testing of tumor and blood samples to see if there are reasons why some patients responded to the drugs better than other patients.	Eli Lilly and Company	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	397	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9817|H6Q-MC-JCBF	Jan-06	Aug-07	May-14	24-Feb-06		12-Sep-19	"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berkeley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peoria, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lebanon, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buffalo, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlottesville, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Leonards, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auchenflower, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bonn, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vellore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Obregon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tijuana, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalpan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hospitalet Llobregat, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cambridge, Cambridgeshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edinburgh, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom"		https://ClinicalTrials.gov/show/NCT00295815
411	NCT00684567	Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)		Completed	Has Results	Glioblastoma	Radiation: Radiotherapy|Drug: Temozolomide	Adverse Events With an Incidence of Greater Than or Equal to 20%|Adverse Drug Reactions With an Incidence of Greater Than or Equal to 20%|Abnormal Changes in Laboratory Test Values With an Incidence of Greater Than or Equal to 20%|Number of Participants With Progression Free Survival (PFS) for 1 Year|Number of Participants With a Response (Complete Response [CR] + Partial Response [PR]) in Terms of Overall Tumor Response	Merck Sharp & Dohme Corp.	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P04661|JPC-05-351-22	27-Sep-05	31-Oct-07	31-Oct-07	26-May-08	12-Mar-09	7-Jun-17			https://ClinicalTrials.gov/show/NCT00684567
412	NCT00777153	Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma	REGAL	Completed	Has Results	Recurrent Glioblastoma	Drug: Cediranib|Drug: Lomustine Chemotherapy|Drug: Placebo Cediranib	Progression Free Survival (PFS)|Overall Survival (OS)|Response Rate|Alive and Progression Free Rate at 6 Months (APF6)|Daily Steroid Dose|Steroid Free Days	AstraZeneca	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 3	423	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	D8480C00055	Oct-08	Apr-10	Sep-16	22-Oct-08	21-Dec-12	28-Dec-16	"Research Site, Birmingham, Alabama, United States|Research Site, Pheonix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Gainesville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Kansas City, Kansas, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Amherst, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Nedlands, Australia|Research Site, Parkville, Australia|Research Site, St Leonards, Australia|Research Site, Woodville, Australia|Research Site, Graz, Austria|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Liberec, Czech Republic|Research Site, Bobigny, France|Research Site, Marseille, France|Research Site, Paris cedex 13, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Villejuif, France|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Nordhausen, Germany|Research Site, Regensburg, Germany|Research Site, Amsterdam, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT00777153
413	NCT01618747	An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse		Completed	No Results Available	Glioblastoma Multiforme		Progression-free survival at 6 months|Progression-free survival|Time to disease progression|Duration of objective response|Overall survival|Safety: Incidence of adverse events	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"		20	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	ML25550	15-Mar-13	24-Dec-15	24-Dec-15	13-Jun-12		28-Feb-18	"Kaohisung, Taiwan|Taipei, Taiwan|Taipei, Taiwan"		https://ClinicalTrials.gov/show/NCT01618747
414	NCT01508117	Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients		Terminated	Has Results	Glioblastoma Multiforme	Drug: Axitinib|Radiation: Radiation Therapy	Overall Survival	University of Cincinnati|Pfizer	All	70 Years and older   (Older Adult)	Phase 2	1	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCCR-2	Aug-11	Oct-12	Oct-12	11-Jan-12	19-Sep-17	19-Sep-17	"University of Cincinnati, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01508117
415	NCT04013672	Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence		"Active, not recruiting"	No Results Available	Recurrent Glioblastoma	Drug: Pembrolizumab|Drug: SurVaxM|Drug: Sargramostim|Drug: Montanide ISA 51	Progression free survival (PFS)|Safety and tolerability of Pembrolizumab and SurVaxM as measure by CTCAE v 5 grading as per NCI	"David Peereboom, MD|Case Comprehensive Cancer Center"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE6318	19-Mar-20	May-24	May-24	10-Jul-19		24-Aug-21	"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT04013672
416	NCT03400917	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Newly Diagnosed Glioblastoma	Biological: AV-GBM-1	Primary Efficacy Endpoint: Overall Survival	"Aivita Biomedical, Inc."	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	55	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CL-GBM-P01	20-Jun-18	1-Dec-21	Feb-23	17-Jan-18		16-Dec-21	"Scripps Health, La Jolla, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|UC Irvine Medical Center, Orange, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, United States"		https://ClinicalTrials.gov/show/NCT03400917
417	NCT00337883	A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)		Completed	No Results Available	Glioblastoma	Drug: Erlotinib HCl (OSI-774)		"Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	110	Industry	Interventional	Primary Purpose: Treatment	OSI2691g	Jul-03		Oct-05	20-Jun-06		4-Mar-14			https://ClinicalTrials.gov/show/NCT00337883
418	NCT01474239	A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma		Completed	Has Results	Glioblastoma Multiforme	Drug: bevacizumab [Avastin]|Drug: fotemustine	"Percentage of Participants Alive 6 Months After Start of Treatment|Overall Survival (OS)|Percentage of Participants Who Were Alive and Progression Free 6 Months After Start of Treatment|Progression-Free Survival (PFS)|Percentage of Participants Alive 9 Months After Start of Treatment|Percentage of Participants Alive 12 Months After Start of Treatment|Percentage of Participants Alive 30 Days After Last Dose of Study Drug|Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR)|Change From Screening in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scores at Weeks 8, 16, 24, 32, 40, 48, 56, 64, and 72|Percentage of Participants With Corticosteroid Initiation During the Study Period|Time to Corticosteroid Initiation|Percentage of Participants in Each Class of Corticosteroid Use|Percentage of Participants With Karnofsky Performance Status (KPS) Deterioration|Time to Karnofsky Performance Status (KPS) Deterioration|Percentage of Participants With World Health Organization (WHO) Performance Status (PS) Deterioration|Time to WHO PS Deterioration"	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	91	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML25739	Nov-11	Dec-13	Dec-13	18-Nov-11	7-Aug-15	15-Mar-16	"Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|San Giovanni Rotondo, Puglia, Italy|Terni, Umbria, Italy|Padova, Veneto, Italy|Treviso, Veneto, Italy"		https://ClinicalTrials.gov/show/NCT01474239
419	NCT01435395	"Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme"		Completed	No Results Available	Glioblastoma Multiforme	"Drug: Temozolomide, bevacizumab and bortezomib"	"Determination of progressive disease, complete or partial responses|Assess the time to progression"	"Emory University|Schering-Plough|Genentech, Inc.|Millennium Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00014595|WCI1837-10	Dec-11	Apr-16	Apr-16	16-Sep-11		27-Apr-16	"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT01435395
420	NCT02395692	Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma		Terminated	Has Results	Adult Brain Glioblastoma	Other: Treatment|Drug: Methoxyamine|Drug: Temozolomide	Objective Response as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria (Arm 1 and Arm 2)|Toxicity as Assessed by Number of Participants Who Experienced Adverse Events|Progression-free Survival|Progression-free Survival at 6 Months|Overall Survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2015-00356|1402|ABTC-1402|ABTC 1402|UM1CA137443	18-Dec-15	16-Feb-17	16-Feb-17	24-Mar-15	4-Apr-19	4-Apr-19	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Adult Brain Tumor Consortium, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Henry Ford Cancer Institute¿Downriver, Brownstown, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/92/NCT02395692/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02395692
421	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients	CheckMate 143	"Active, not recruiting"	No Results Available	Recurrent Glioblastoma	Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab	"Percentage of Participants with Drug-Related Adverse Events Leading to Discontinuation by Worst CTC Grade for All Treated Participants in Cohorts 1, 1b, 1c and 1d Who Permanently Discontinued Study Medication Prior to Completing Four Doses|Percentage of Participants with Adverse Events (Worst Grade) in Cohorts 1, 1b, 1c and 1d|Percentage of Participants with Serious Adverse Events (Worst Grade) in Cohorts 1, 1b, 1c and 1d|Percentage of Participants with Specific Laboratory Abnormalities in Liver Tests (Worst Grade) in Cohorts 1, 1b, 1c and 1d|Percentage of Participants with Specific Laboratory Abnormalities in Thyroid Tests (Worst Grade) in Cohorts 1, 1b, 1c and 1d|Cohort 2: Overall Survival (OS)|Cohort 2: Overall Survival rate (OS) at 12 months|Cohort 2: Progression Free Survival (PFS)|Cohort 2: Objective Response Rate (ORR)|Cohort 1c and 1d: Overall Survival rate (OS)"	Bristol-Myers Squibb	All	"Child, Adult, Older Adult"	Phase 3	530	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-143|2013-003738-34	7-Feb-14	17-Jun-19	3-Jan-23	23-Dec-13		19-Nov-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington - Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Aarhus University Hospital, Aarhus C, Denmark|Odense University Hospital, Odense C, Denmark|Local Institution, Bron cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Liverpool, United Kingdom"		https://ClinicalTrials.gov/show/NCT02017717
422	NCT00943826	A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma		Completed	Has Results	Glioblastoma	Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation therapy|Drug: Placebo	"Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator|Co-Primary: Overall Survival (OS)|PFS as Assessed by an Independent Review Facility|Kaplan-Meier (KM) Estimate of One Year Overall Survival|Kaplan-Meier (KM) Estimate of Two Year Overall Survival|PFS in Participants With Stable/Improved Health Related Quality of Life (HRQoL) Based on European Organization for Research & Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (C30)(EORTC QLQ-C30) & EORTC QLQ Brain Neoplasm 20 (BN20)|Number of Participants With Non-Serious Adverse Events, Serious Adverse Events and Death"	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	921	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	BO21990|2008-006146-26	29-Jun-09	28-Feb-13	9-Sep-15	22-Jul-09	20-May-13	25-Sep-17	"University of Alabama At Birmingham; Neuro-Oncology, Birmingham, Alabama, United States|UCLA, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr, Evanston, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Hatton Research Institutes, Cincinnati, Ohio, United States|Sarah Cannon Cancer Center and Research Institute, Nashville, Tennessee, United States|University of Virgina, Charlottesville, Virginia, United States|Prince of Wales Hospital; Department of Medical Oncology, Randwick, New South Wales, Australia|North Shore Private Hospital; Northern Specialist Centre, St Leonards, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Princess AleXandra Hospital; Department of Medical Oncology, Woolloongabba, Queensland, Australia|Calvary North Adelaide; North Adeliade Oncology Centre, North Adelaide, South Australia, Australia|Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Antwerpen, Edegem, Belgium|AZ Sint Lucas (Sint Lucas), Gent, Belgium|CHU Sart-Tilman, Liège, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|BC Cancer Agency, Vancouver Clinic; Dept. of Medical Oncology, Vancouver, British Columbia, Canada|CancerCare Manitoba; Neuro-Oncology, Winnipeg, Manitoba, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario; Kingston General Hospital, Kingston, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital Regional Cancer Centre; Neuro-Oncology, Ottawa, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727, Toronto, Ontario, Canada|Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada|Chuq - Hopital Hotel Dieu de Quebec, Quebec City, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd., Aalborg, Denmark|Righospitalet, Hæmatologisk Klinik, København Ø, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, Denmark|Hopital Avicenne; Rhumatologie, Bobigny, France|Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France|Institut Bergonie; Gastro Enterologie Oncologie, Bordeaux, France|Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron, France|Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, France|Hopital Beaujon; Oncologie, Clichy, France|Centre Georges François Leclerc, Dijon, France|Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille, France|Centre Val Aurelle Paul Lamarque; Medecine B3, Montpellier, France|Hôpital Central; Departement de Neuro-Oncologie, Nancy, France|Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris, France|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Neurochirurgie, Dresden, Germany|Justus-Liebig-Universität Giessen; Neurochirurgische Klinik, Gießen, Germany|Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie, Hamburg, Germany|Universitatsklinikum Heidelberg; Abteilung Neuroonkologie, Heidelberg, Germany|Ärztehaus Velen, Ibbenbühren, Germany|Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie, Mainz, Germany|Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie, München, Germany|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|University Hospital of Larissa; Oncology, Larissa, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Dr Stephen Yau; Clinical oncology, Hong Kong, Hong Kong|Hong Kong Sanatorium & Hospital; Comprehensive Oncology Centre, Hong Kong, Hong Kong|Queen Mary Hospital; Microbiology Dept., Hong Kong, Hong Kong|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház; Neurosurgery, Miskolc, Hungary|Pécsi Tudományegyetem Áok; Onkoterapias Intezet, Pecs, Hungary|Rambam Medical Center; Oncology, Haifa, Israel|Hadassah Hebrew University Hospital; Leslie and Michael Gaffin Center for Neuro-Oncology, Jerusalem, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba MC; Pediatric Hematology Oncology, Tel Hashomer, Israel|Ausl Di Bologna-Ospedale Bellaria;U.O. Oncologia Medica, Bologna, Emilia-Romagna, Italy|Ospedale Bufalini, Forli, Emilia-Romagna, Italy|Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milano, Lombardia, Italy|Azienda Ospedaliera Le Molintte di Torino; Dipartimento Di Neurologia - Oncologia, Torino, Piemonte, Italy|Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy|Ospedale di Treviso, Universita di Padova; Neurosurgery Dept, Treviso, Veneto, Italy|Hiroshima University Hospital; Neurosurgery, Hiroshima, Japan|Tsukuba University Hospital; Neurology, Ibaraki, Japan|Kumamoto University Hospital; Neurosurgery, Kumamoto, Japan|Kitano Hospital; Neurosurgery, Osaka, Japan|Saitama Medical University International Medical Center; Clinical and Medical Oncology, Saitama, Japan|National Cancer Center Hospital; Neurosurgery, Tokyo, Japan|Komagome Hospital; Neurosurgery, Tokyo, Japan|Kyorin University Hospital; Neurosurgery, Tokyo, Japan|Pusan National University Hospital; Neuro Sugery, Busan, Korea, Republic of|Kyungpook National University Hosital; Neuro Sugery, Daegu, Korea, Republic of|National Cancer Centre; Neurosurgery Dept, Goyang-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology, Seoul, Korea, Republic of|Asan Medical Center; Medical Oncology, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Samsung Medical Center; Neurosurgery Department, Seoul, Korea, Republic of|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands|Catharina Ziekenhuis; Dept of Internal Medicin, Eindhoven, Netherlands|Utrecht University Medical Centre; Dept of Medical Oncology and UPC, Utrecht, Netherlands|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Christchurch Hospital; Dept of Oncology, Christchurch, New Zealand|Waikato Hospital; Regional Cancer Center, Hamilton, New Zealand|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland|Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii, Bydgoszcz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie; Klinika Neurochirurgii i Neurochirurgii Dzi, Lublin, Poland|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|IPO de Lisboa; Servico de Neurologia, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital de Sao Joao; Servico de Oncologia, Porto, Portugal|Institut Oncologic Prof. Dr. Alexandru Trestioreanu; Departament Radioterapie, Bucharest, Romania|Institut Oncologic Ion Chiricuta; Departament Radioterapie, Cluj-napoca, Romania|Spital Clinic Judetean Mures; Oncologie, Targu Mures, Romania|N.N.Burdenko Main Military Clinical Hospital; Oncology Dept, Moscow, Russian Federation|Russian Research Oncology Center n.a. N.N. Blokhin of the RAMS; Department of Neurosurgery, Moscow, Russian Federation|Scientific Research Neurosurgery Institute; Dept. of Neurooncology, Moscow, Russian Federation|Institution of Higher Professional Learning Military; Neurooncology, St. Petersburg, Russian Federation|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Sahlgrenska Universitetssjukhuset; Jubileumskliniken, Göteborg, Sweden|Skånes University Hospital, Skånes Department of Onclology, Lund, Sweden|Norrlands Universitetssjukhus; Cancer Centrum, Umea, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|HUG; Oncologie, Geneve, Switzerland|Queen Elizabeth Medical Centre; Neurosurgery, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|The Royal Marsden NHS Foundation Trust; Oncology, London, United Kingdom|Northern Centre for Cancer Care;Oncology, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom|Queen's Hospital; Oncology, Romford, United Kingdom|Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom|The Clatterbridge Cancer Ctr For Oncolgy, Wirral, United Kingdom"		https://ClinicalTrials.gov/show/NCT00943826
423	NCT03296696	Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma		Completed	No Results Available	Glioblastoma or Malignant Glioma	Drug: AMG 596|Drug: AMG 404	Subject grade of dose limiting toxicities (DTLs)|Number of subject with treatment-emergent adverse events|Number of subjects with treatment-related adverse events|Number of subjects with clinically significant changes in vital signs|Number of subjects with clinically significant changes in physical examinations|Number of subjects with clinically significant changes in clinical laboratory tests|Average steady-state concentration (Css) for serum AMG 596|Area under the concentration-time curve (AUC) for serum AMG 596|Clearance for serum AMG 596|Volume of distribution for serum AMG 596|Half-life (t1/2) for serum AMG 596|Maximum abserved serum concentration (Cmax) for AMG 404|Time to achieve Cmax (tmax) for AMG 404|Area under the concentration-time curve (AUC) for AMG 404|Average steady-state concentration (Css) for serum AMG 596 in combination with AMG 404|Area under the concentration-time curve (AUC) for serum AMG 596 in combination with AMG 404|Clearance for serum AMG 596 in combination with AMG 404|Half-life (t1/2) for serum AMG 596 in combination with AMG 404|Objective response (OR) as per modified RANO for AMG 596|Time to response for serum AMG 596 in combination with AMG 404|Response duration for serum AMG 596 in combination with AMG 404|Time to progression (TTP) for serum AMG 596 in combination with AMG 404|Progression free survival (PFS) at 6 and 12 months after treatment initiation with AMG 596 monotherapy|Progression free survival (PFS) at 6 and 12 months after treatment initiation with AMG 596 in combination with AMG 404|Objective response (OR) as per modified RANO with AMG 596 monotherapy|Time to response with AMG 596 monotherapy|Response duration with AMG 596 monotherapy|Time to progression (TTP) with AMG 596 monotherapy	Amgen	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 1	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20160132|2017-001658-32	18-Apr-18	1-Jul-21	28-Aug-21	28-Sep-17		23-Dec-21	"University of California Los Angeles, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Royal North SHore Hospital, St Leonards, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Gustave Roussy, Villejuif, France|UniversitÃ¤tsklinikum Carl Gustav Carus der Technischen UniversitÃ¤t Dresden, Dresden, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Wuerzburg, WÃ¼rzburg, Germany|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Hospital Universitari Germans Trias i Pujol, Badalona, CataluÃ±a, Spain"		https://ClinicalTrials.gov/show/NCT03296696
424	NCT01754350	"Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma"	ERGO2	Completed	Has Results	Recurrent Glioblastoma	Dietary Supplement: calorie-restricted ketogenic diet and transient fasting|Dietary Supplement: standard nutrition	Progression-free-survival|Feasibility Measured as Median Number of Days on Diet Per Patient and Average Calorie and Carbohydrate Intake Per Day During Day 1-9|Safety and Tolerability as Defined as Number of Patients With Adverse Events|Overall Survival|Frequency of Seizures|Ketosis|Quality of Life as Measured by the EORTC Quality of Life Questionnaire|Depression|Attention|Response	"Johann Wolfgang Goethe University Hospital|TAVARLIN (Darmstadt, Germany)"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	50	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ERGO2	May-13	Dec-17	Mar-19	21-Dec-12	2-Jun-21	2-Jun-21	"Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany|University of Tuebingen, Tuebingen, Germany"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/50/NCT01754350/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01754350
425	NCT03980249	Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells		Withdrawn	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Carvedilol	Survival curve of overall survival|Survival curve of progression free survival|Quantify Circulating Tumor Cells (CTCs)	West Virginia University|NovoCure Ltd.|West Virginia Clinical and Translational Science Institute	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WVU020318	Sep-20	Dec-21	Jun-22	10-Jun-19		12-Apr-21	"WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/49/NCT03980249/ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT03980249
426	NCT02649582	Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients	ADDIT-GLIO	Recruiting	No Results Available	Glioblastoma Multiforme of Brain	Biological: Dendritic cell vaccine plus temozolomide chemotherapy	Overall survival|Number of glioblastoma patients post surgical resection with feasible and safe DC vaccine production|Feasibility of DC vaccine administration to glioblastoma patients combined with chemotherapy|Number of participants with adverse events as a measure of safety and tolerability|Immunological responses to the DC vaccine|Objective clinical responses by tumor evaluation (clinical efficacy)	"University Hospital, Antwerp"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCRG14-001	Dec-15	Dec-23	Dec-24	7-Jan-16		19-Jan-21	"Antwerp University Hospital, Edegem, Antwerp, Belgium"		https://ClinicalTrials.gov/show/NCT02649582
427	NCT00521482	Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma		Unknown status	No Results Available	Glioblastoma	Drug: Temozolomide|Drug: Temozolomide plus Thalidomide	Proportion of patients with progression free survival|Proportion of patients with a clinical response. Time to disease progression. Progression free survival.	University of Zurich	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TMZ/05|P04932	Sep-07		Jan-09	28-Aug-07		28-Aug-07	"University Zurich, Departement of Neurosurgery, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT00521482
428	NCT00704808	Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)		Completed	Has Results	Glioblastoma	Procedure: Primary surgical treatment|Radiation: Radiotherapy|Drug: Temozolomide	"Median Progression Free Survival After Primary Surgical Treatment, Concomitant and Adjuvant Chemotherapy With Temozolomide, for Patients With Newly Diagnosed Glioblastoma Multiforme"	Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"		180	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	P04739	May-06	Dec-08	Dec-08	25-Jun-08	2-Apr-10	9-Sep-15			https://ClinicalTrials.gov/show/NCT00704808
429	NCT03861598	Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells		Terminated	No Results Available	Glioblastoma Multiforme|Glioblastoma	Drug: Carvedilol	Identify the correlation between our new RT-qPCR assay for circulating tumor cells and the change in responses in patients on treatment to MRI results.|Evaluate response with the addition of carvedilol to standard chemotherapy in the second line treatment in glioblastoma multiforme|Evaluate incidents of adverse events during the time subjects are taking carvedilol with chemotherapy	West Virginia University|West Virginia Clinical and Translational Science Institute	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	4	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WVU010318	19-Jul-19	21-Aug-20	17-Jun-21	4-Mar-19		24-Sep-21	"WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States"		https://ClinicalTrials.gov/show/NCT03861598
430	NCT01666600	NOA-12: BIBF1120 and R-RT in Glioblastoma		Terminated	No Results Available	Glioblastoma Multiforme	Drug: BIBF 1120|Radiation: radiotherapy	Maximal tolerated dose of BIBF 1120 in combination with reirradiation (Phase I)|Number of participants with adverse events as a measure of safety and tolerability of BIBF1120|Progression-free survival|Objective response rates (OR)|Overall survival|Quality of life as determined by EORTC QLQ-C15 PAL and the EORTC brain module QLQ-BN 20|Cognitive function determined by MMSE	Prof. Dr. Wolfgang Wick|University Hospital Heidelberg	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	63	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NONK-3/NOA-12	Aug-12	Mar-17	Sep-17	16-Aug-12		1-Nov-17	"University Hospital Heidelberg, Department of Neurooncology, Heidelberg, Baden-Württemberg, Germany|University Hospital Heidelberg, Department of Pharmacology, Heidelberg, Baden-Württemberg, Germany"		https://ClinicalTrials.gov/show/NCT01666600
431	NCT00686725	Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)		Completed	Has Results	Glioblastoma	Drug: Temozolomide|Radiation: Radiotherapy	Overall Survival (OS)|Progression-Free Survival (PFS)|Objective Tumor Assessment After Surgery: Overall Response|Relationship Between O6-methylguanine-DNA Methyltransferase (MGMT) Status and Therapy Response: Overall Survival for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: Overall Survival for the MGMT Negative Group|Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: Overall Survival Rate for the MGMT Negative Group|Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Positive Group|Relationship Between MGMT Status and Therapy Response: PFS for the MGMT Negative Group	Merck Sharp & Dohme Corp.	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 4	99	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P05572	24-Jun-08	28-Sep-11	28-Sep-11	30-May-08	4-Apr-13	14-Jun-17			https://ClinicalTrials.gov/show/NCT00686725
432	NCT03707457	Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma		Terminated	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Nivolumab|Drug: Anti-GITR Monoclonal Antibody MK-4166|Drug: IDO1 inhibitor INCB024360|Drug: Ipilimumab	Proportion of subjects with dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	3	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17154|IRB00129944	22-Mar-19	30-Nov-19	18-Jun-20	16-Oct-18		2-Jul-20	"Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03707457
433	NCT01450449	Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Radiation: Radiotherapy	Overall Survival|Progression-free survival|Quality of Life	International Atomic Energy Agency|Fundación Escuela de Medicina Nuclear|N.N. Alexandrov National Cancer Centre of Belarus|Hospital A.C. Camargo|Irmandade Santa Casa de Misericórdia de Porto Alegre|Instituto de Radiomedicina (IRAM)|Postgraduate Institute of Medical Education and Research|Dr Cipto Mangunkusumo General Hospital|Maria Sklodowska-Curie National Research Institute of Oncology|Chiang Mai University|Salah Azaïz Cancer Institute|Wilson Roa Professional Corporation|Cancer Trials Ireland|Ege University|High Technology Medical Center	All	"50 Years and older   (Adult, Older Adult)"	Phase 3	115	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E33033	Feb-09	Dec-13	Nov-14	12-Oct-11		24-Mar-15	"Fundacion Escuela de Medicina Nuclear, Mendoza, Argentina|N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus|Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital ""A.C. Camargo"", Fundacao ""Antonio Prudente"", Sao Paulo, Brazil|Wilson Roa Professional Corporation, Edmonton, Canada|Instituto de Radiomedicina (IRAM), Santiago, Chile|Regionaalhailga, Tallinn, Estonia|High Technology Medical Center, University Clinic, Tbilisi, Georgia|Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Cipto Magunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia|ICORG The All Ireland Cooperative Oncology, Dublin, Ireland|Marie Curie- Sklodowska Institute of Oncology, Warsaw, Poland|Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand|Institut National de Cancer Salah Aziz, Ministere de la Sante Publique, Tunis, Tunisia|Ege University Hospital, Izmir, Turkey"		https://ClinicalTrials.gov/show/NCT01450449
434	NCT00376103	Radiation Boost for Newly Diagnosed Glioblastoma Multiforme		Terminated	No Results Available	Glioblastoma Multiforme	Drug: temozolomide|Procedure: Brachytherapy|Procedure: External Beam Radiation Therapy	"Treatment-related toxicity.|6 month, 1 year and overall survival.|Tumor progression.|Progression-free survival.|Quality of life."	Methodist Healthcare	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	3	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MHIRB 2006-032	Aug-06	Mar-08		14-Sep-06		18-Sep-09	"Methodist University Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00376103
435	NCT01587144	Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)		Terminated	No Results Available	Glioblastoma Multiforme	Drug: Lucanthone|Drug: Temozolomide (TMZ)|Radiation: Radiation|Drug: Placebo	Progression Free Survival|Objective response rate (ORR)|Overall Survival|Safety Profile of Lucanthone	"Spectrum Pharmaceuticals, Inc"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	18	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	SPI-LUC-11-01	19-Jun-12	15-Apr-13	15-Apr-13	30-Apr-12		19-Oct-21	"UCSD Moores Cancer Center, La Jolla, California, United States|UCI Medical Center, Orange, California, United States|Dent Neurologic Institute, Amherst, New York, United States|Fairview Hospital Moll Cancer Center/Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Hillcrest Hospital Hirsh Cancer Center/Cleveland Clinic, Mayfield, Ohio, United States|Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India|Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India|Bhagwan Mahaveer Cancer Hospital & Reseach Centre, Jaipur, Rajasthan, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India"		https://ClinicalTrials.gov/show/NCT01587144
436	NCT00544817	Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Sorafenib	Progression-free Survival|Overall Survival|Objective Response	"SCRI Development Innovations, LLC|Bayer"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	47	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI CNS 09	Apr-07	Jun-08	Aug-10	16-Oct-07	13-Dec-12	1-Sep-16	"Florida Cancer Specialists, Fort Myers, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Tennessee Oncology, Nashville, Tennessee, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00544817
437	NCT01972750	Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma	TKI258	Unknown status	No Results Available	First or Second Recurrence of Glioblastoma	Drug: Dovitinib	"safety and tolerance|Tumor response (CR, PR)|Overall safety|Disease Control Rate (CR + PR + SD)|Progression free survival rate|Quality of life"	"PD Dr. Martin Glas|University Hospital, Bonn"	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTKI258ADE02T	Oct-13	Nov-16	Nov-16	30-Oct-13		19-Apr-16	"Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany"		https://ClinicalTrials.gov/show/NCT01972750
438	NCT02474966	Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study		Completed	No Results Available	Glioblastoma Multiforme of Brain	Device: Deep Transcranial Magnetic Stimulation (dTMS)	Change in blood-brain barrier permeability|Number of patients with adverse events as a measure of safety and tolerability	University of Roma La Sapienza	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 2	15	Other	Interventional	"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science"	3403/23.10.14	Nov-14	Apr-15	May-15	18-Jun-15		18-Jun-15			https://ClinicalTrials.gov/show/NCT02474966
439	NCT01308684	A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma Multiforme	Drug: RO5323441 + bevacizumab [Avastin]|Drug: bevacizumab [Avastin]	Dose-Finding Part: Dose limiting toxicity|Efficacy-Finding part: Progression-free survival|Dose-Finding part: Pharmacokinetics of RO5323441 and Avastin when combined|Dose-Finding part: Safety (incidence of adverse events)|Dose-Finding part: Efficacy (tumor response according to Response Assessment in Neurooncology (RANO) criteria|Dose-Finding part: Glioblastoma biomarker|Efficacy-Finding part: Overall Response Rate|Efficacy-Finding part: Disease Control Rate|Efficacy-Finding part: Duration of Response|Efficacy-Finding part: Overall Survival|Efficacy-Finding part: Safety (incidence of adverse events)|Efficacy-Finding part: Glioblastoma biomarker|Efficacy-Finding part: Pharmacokinetics (serum levels) of RO5323441 and Avastin when combined	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	22	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BP25389|2010-021795-29	May-11	Feb-13	Feb-13	4-Mar-11		2-Nov-16	"København Ø, Denmark|Marseille, France|Zürich, Switzerland|Manchester, United Kingdom"		https://ClinicalTrials.gov/show/NCT01308684
440	NCT01115491	A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Drug: bevacizumab [Avastin]|Drug: temozolomide	Progression-Free Survival (PFS) - Percentage of Participants With an Event|PFS - Time to Event|PFS: Probability of Remaining Progression Free at 24 Weeks After Beginning the Study|Overall Survival - Percentage of Participants With an Event|Overall Survival - Time to Event|Percentage of Participants Achieving an Overall Response of Complete Response (CR) or Partial Response (PR)	Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML25152|2010-019051-21	Jun-10	Jul-12	Jul-12	4-May-10	8-Dec-14	8-Dec-14	"Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Valencia, Spain"		https://ClinicalTrials.gov/show/NCT01115491
441	NCT00800917	A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Temsirolimus|Drug: Bevacizumab	Progression-free survival in months|Adverse events|Objective tumor response rate|Pre- vs post-treatment measurements of biomarkers and vascular system/immune system parameters|Correlation with biomarkers	"Rigshospitalet, Denmark|University of Copenhagen|Wyeth is now a wholly owned subsidiary of Pfizer|Roche, Copenhagen"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	12	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BEV-CCI-779-GBM-02|Eudract no.: 2008-003679-40	Nov-08	Feb-10	Feb-10	2-Dec-08		2-Jun-10	"Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT00800917
442	NCT01091792	Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)		Completed	No Results Available	Glioblastoma Multiforme	Drug: Bevacizumab	"Changes in the peripheral blood T-reg profile between pretreatment and 4 weeks after completion of treatment with the addition of bevacizumab to RT and TMZ in patients with glioblastoma|Immunologic shift in the phenotypic T cell, B cell, NK cell and DC repertoire induced by RT-TMZ-BEV comparing pretreatment and 4 weeks after completion of treatment"	"Dartmouth-Hitchcock Medical Center|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	13	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	D0947	Mar-10	2-Apr-15	2-Apr-15	24-Mar-10		25-May-18	"Dartmouth Hithcock Medcial Center, Lebanon, New Hampshire, United States"		https://ClinicalTrials.gov/show/NCT01091792
443	NCT00704288	Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: XL184	"To evaluate the objective response rate for subjects with recurrent or progressive glioblastoma multiforme following treatment with XL184|Evaluate safety and tolerability of XL184|Assess duration of response, 6-month progression-free survival rate,and overall survival|Further characterize pharmacokinetics and pharmacodynamic effects of XL184|Correlate pathway dysfunction of glioblastoma multiforme-relevant genes such as MET and relevant downstream signaling molecules with clinical outcome|Correlate changes in serial vascular MRI with clinical outcome and analyze tumor volumetrics based on MRI|Evaluate the glucocorticoid-sparing effect of XL184"	Exelixis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	222	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XL184-201	May-08	Jun-12	Dec-12	24-Jun-08		16-Jul-14	"University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Duke University, The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00704288
444	NCT02626364	Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification		Completed	No Results Available	Recurrent/Refractory Glioblastoma	Drug: crenolanib	Progression-free survival at 6 months|Overall response rate by RANO criteria|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Change in symptom burden using The MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)|Overall survival	"Arog Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	11	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ARO-015	Apr-16	Jul-20	Jul-20	10-Dec-15		20-Jul-20	"MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02626364
445	NCT00984438	Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme		Withdrawn	No Results Available	Glioblastoma Multiforme	Drug: BCNU Wafer|Drug: Irinotecan|Drug: Bevacizumab	To assess disease free survival	University of Cincinnati|Eisai Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8081101	Jun-09	Jun-10	Jun-10	25-Sep-09		25-Nov-19	"University of Cincinnati, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00984438
446	NCT00589095	Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities		Terminated	No Results Available	Glioblastoma Multiforme	Other: dynamic contrast enhanced magnetic resonance imaging	"To detect the early ""local"" treatment responses from the physician recognized GBM ""gross tumor volume"" (GTV)"	Yale University	All	"18 Years to 80 Years   (Adult, Older Adult)"		5	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	606001531	Nov-06	Aug-11	Aug-11	9-Jan-08		2-Jul-14	"Yale University School of Medicine, New Haven, Connecticut, United States"		https://ClinicalTrials.gov/show/NCT00589095
447	NCT00083447	Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme		Withdrawn	No Results Available	Glioblastoma Multiforme	Drug: TransMID™	Overall survival time i.e. to to death|12 month survival rate|Tumor Response|Duration of Response|Time to Progression|6 and 12 month progression rates|Progression Free Survival|6 and 12 progression free survival rate|Quality of Life	Xenova Biomedix	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	323	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KSB311R/CIII/001	May-04	Mar-06	Jun-07	26-May-04		7-Jan-09	"University of California-San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals in Clinics, Cedar Rapids, Iowa, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|NINDS National Institutes of Health, Bethesda, Maryland, United States|Fairview University Medical Center, Minneapolis, Minnesota, United States|Saint Louis University Hospital, St. Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center, New York,, New York, United States|SUNY Upstate Medical University at Syracuse, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Legacy Emanuel Hospital and Technology Center, Portland, Oregon, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Semmes-Murphey Neurologic Institute, Memphis, Tennessee, United States|University of Utah, Salt Lake City, Utah, United States|Medical College of Virginia, Richmond, Virginia, United States|Neville Knuckey, MD, Nedlands, Western Australia, Australia"		https://ClinicalTrials.gov/show/NCT00083447
448	NCT03480867	Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)	PARADIGMA	Withdrawn	No Results Available	"Glioblastoma Multiforme, Adult"	Drug: Temozolomide|Radiation: Pre-Operative Radiation	To assess toxicity of the regimen|Number of patients completing the study treatment	McGill University Health Centre/Research Institute of the McGill University Health Centre	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MUHC-2016-1524	Mar-17	Jun-21	Nov-23	29-Mar-18		14-Aug-19	"McGill University Health Centre-Cedars Cancer Centre, Montréal, Québec, Canada, Canada"		https://ClinicalTrials.gov/show/NCT03480867
449	NCT03294486	"Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients"	ONCOVIRAC	Unknown status	No Results Available	Glioblastoma|Brain Cancer	"Drug: Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)"	"Number of Participant with Dose Limiting Toxicities defined as Any of the following treatment-related adverse events (AEs) is evaluated and reported from Day 1 through Day 26; as assessed by NCI-CTCAE, version 4.03|Number of patients without documented tumor progression at 6 months from date of first TG6002 infusion according to Response Assessment Neuro-Oncology Criteria (Wen et al., 2010, JCO, PMID:20231676)|TG6002 recommended dose prior to the Phase 2a part of the study (RP2D) in combination with 5-FC (Maximum Plasma Concentration [Cmax])|Overall Survival (OS)|Relative quantification of circulating viral DNA|Blood pharmacokinetics of 5-FC|Blood pharmacokinetics of 5-Fluorouraril (5-FU)|Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)|Viral shedding in saliva, urine and feces|Humoral response|Isolation of peripheral blood mononuclear cells (PBMC);|Metabolic Response|Safety and tolerability : Incidence of Treatment; evaluation of treatement-releated adverse events"	Assistance Publique - Hôpitaux de Paris|Transgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	78	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P150936|2015-004452-21	12-Oct-17	May-19	Sep-21	27-Sep-17		6-Nov-17	"Groupe Hospitalier Pitié-Salpêtrière, Paris, France"		https://ClinicalTrials.gov/show/NCT03294486
450	NCT03573986	Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment		Terminated	No Results Available	Recurrent Glioblastoma	Biological: [18F]fluoromisonidazole|Drug: Bevacizumab|Radiation: positron emission tomography (PET/CT).	Number of Adverse Events	Abramson Cancer Center of the University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	2	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	UPCC 02318	18-Apr-18	14-Jan-20	14-Jan-20	29-Jun-18		17-Feb-20	"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03573986
451	NCT04523688	Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma	Combi G-Vax	Not yet recruiting	No Results Available	Glioblastoma|Vaccination	Biological: Autologous Dendritic Cells (DC) vaccine|Drug: Temozolomide	clinical activity|Incidence of Treatment-Emergent Adverse Events|Immune response in vivo|Clinical Outcome (Overall Survival (OS))|Immunological efficacy|Human leukocyte antigen (HLA) class I and II characterization characterization of patients	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	28	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRST191.05	Mar-21	Jul-25	Dec-25	24-Aug-20		1-Mar-21	"Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, FC, Italy"		https://ClinicalTrials.gov/show/NCT04523688
452	NCT03291314	Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma	GliAvAx	Completed	No Results Available	Recurrent Glioblastoma (WHO-Grade IV Glioma)	Drug: Axitinib|Drug: Avelumab	6-month PFS%|Median OS (Overall survival)|Objective Tumor Response (OR)|Overall Safety profile|Evolution of neuro-cognitive function|Continuous activity	Universitair Ziekenhuis Brussel	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	52	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-BN-001	3-May-17	1-Jan-19	1-Jan-19	25-Sep-17		23-Jan-19	"UZ Brussel, Brussel, Belgium"		https://ClinicalTrials.gov/show/NCT03291314
453	NCT03631823	Gut Microbiota and Glioblastoma Multiforme Prognosis		Unknown status	No Results Available	"Gut Microbiota, Glioblastoma Multiforme, Microglia, Tumor Related Macrophagocyte, Prognosis"	Other: Chemotherapy with temozolomide or no chemotherapy	Pre-operative gut microbiota in molecular subtype glioblastoma mutiforme multiform|The perturbation of gut microbiota by temozolomide chemotherapy|Link the gut microbiota and prognosis of GBM	Huashan Hospital|Shandong Provincial Hospital	All	"18 Years to 75 Years   (Adult, Older Adult)"		200	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	GBM2018-2020	10-Aug-18	10-Aug-19	1-May-20	15-Aug-18		15-Aug-18			https://ClinicalTrials.gov/show/NCT03631823
454	NCT00590681	Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Drug: Bevacizumab and Temozolomide	Objective Response|Progression-free Survival (PFS)|Safety of Avastin in Combination With Temozolomide in This Study Population|Duration of Response|Overall Survival|Changes in Relative Cerebral Blood Volume (rCBV) of Tumors After (2 Infusions) of Avastin	"University of Chicago|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	62	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15149A	Feb-07	Sep-14	Sep-14	11-Jan-08	1-Mar-21	30-Mar-21	"The University of Chicago, Chicago, Illinois, United States|NorthShore University health system, Evanston, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Medical college of Wisconsin, Milwaukee, Wisconsin, United States|Waukesha health care, Waukesha, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00590681
455	NCT02078648	"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme"		Completed	No Results Available	Adult Brain Glioblastoma|Glioblastoma Multiforme	Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Drug: Bevacizumab	Characterize the safety and tolerability of SL-701|Estimate the percent of patients alive 12 months after the initiation of SL-701 (OS-12)|Estimate the objective response rate (ORR)|Estimate duration of response|Estimate the percent of patients alive and progression-free survival at 6 months (PFS-6) after the initiation of SL-701.|Estimate the distributions of progression-free survival (PFS) and overall survival (OS).	"Stemline Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	74	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STML-701-0114	May-14	1-Sep-17	22-Jan-18	5-Mar-14		26-Jan-18	"University of Alabama, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|Center for Neurosciences, Tucson, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|George Washington University, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Piedmont Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Columbia University Medical Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02078648
456	NCT04209790	Neoadjuvant Chemoradiation for Resectable Glioblastoma	NeoGlio	Recruiting	No Results Available	Glioblastoma|Surgery|High Grade Glioma	Radiation: Neoadjuvant chemoradiation|Drug: Drug Therapy with Temozolomide (benzolamide) (Standard of Care)|Procedure: Surgery post Radiation and Temozolomide (benzolamide)	No study related undue toxicity or progression in >6 of 11 patients.|Progression Free Survival	Geisinger Clinic	All	"18 Years to 89 Years   (Adult, Older Adult)"	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-0623	1-Apr-20	31-Dec-21	31-Dec-23	24-Dec-19		19-Dec-20	"Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04209790
457	NCT02227576	Prevention of Thrombocytopenia in Glioblastoma Patients	PLATUM	Terminated	No Results Available	Thrombocytopenia|Glioblastoma	Drug: Romiplostim	Proportion of patients receiving 100% of the planned TMZ dosage in the whole Stupp protocol. The primary endpoint will consider dose reduction and dose delay.|Incidence of serious adverse events according to CTCAE 4.0 criteria.|Incidence of delayed chemotherapy cycles and the incidence of chemotherapy cycles with dose reduction due to severe TP|Number and percentage of patients with TP of grade 3 or grade 4 after receiving Romiplostim.|Number and percentage of patients receiving platelets transfusion for TP|Incidence and type of adverse events linked to TP episodes during Romiplostim and Temozolomide combined treatment.|6 months Progression Free Survival:	"University Hospital, Lille"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011_29|2012-001751-38	10-Jul-14	14-Dec-17	14-Dec-17	28-Aug-14		25-Apr-18	"CHRU de Lille, Hôpital Roger Salengro,Clinique de Neurochirurgie, Lille, France|Hôpital Neurologique Pierre Wertheimer, Lyon,, Lyon, France|AP-HM,Hôpital La Timone, AP-HM, Marseille, Marseille, France|AH-HP, Hôpital Pitié-Salpêtrière, Service de Neurologie 2, Paris, France"		https://ClinicalTrials.gov/show/NCT02227576
458	NCT00224978	Chloroquine for Treatment of Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Chloroquine	"Survival after surgery|End-point evaluation, survival at two years"	"National Institute of Neurology and Neurosurgery, Mexico"	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 3		Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment	14/99	Jan-05		Aug-05	23-Sep-05		18-Nov-09	"National Institute of Neurology and Neurosurgery, Mexico City, Mexico"		https://ClinicalTrials.gov/show/NCT00224978
459	NCT00904852	Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme		Withdrawn	No Results Available	Glioblastoma Multiforme	"Drug: Tandutinib, bevacizumab, and temozolomide"	"Maximum tolerated dose of tandutinib, adverse events, serious adverse events and dose limiting toxicities, clinical laboratory values and vital sign measurements"	"Millennium Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C03003	Jun-09	May-10	Jun-10	20-May-09		20-May-09			https://ClinicalTrials.gov/show/NCT00904852
460	NCT00083512	Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme		Recruiting	No Results Available	Glioblastoma Multiforme		"To determine if an increase in urinary VEGF and MMP level, from the end of treatment to a patient's one-month follow-up examination following radiotherapy is predictive of one-year recurrence in patients with Glioblastoma multiforme"	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"		200	NIH	Observational	Observational Model: Case-Only|Time Perspective: Prospective	040200|04-C-0200	22-Jun-04			25-May-04		28-Dec-21	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00083512
461	NCT01788280	Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab		Withdrawn	No Results Available	Glioblastoma Multiforme (GBM)	"Drug: Fluciclitite , PET imaging, and Bevacizumab"	Time to progression|Change in standardized uptake value (SUV)	University of Utah	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI60947	Jan-18	Jan-22	Jan-22	11-Feb-13		7-Feb-18	"Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT01788280
462	NCT02197169	DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors	TARGET-I	Completed	No Results Available	Glioblastoma or Gliosarcoma	Drug: Single intratumoral injection of DNX-2401|Drug: Interferon-gamma	"Objective response rate (ORR) determined by MRI scan review|Incidence and severity of adverse events, including changes in laboratory test results and neurological examination findings|Number of subjects with immunological and biological effects after DNX-2401 with Interferon gamma|Changes in steroid use (dose and frequency) and clinical and KPS status overall and per study arm assignment|Overall survival (OS), progression-free survival (PFS), and clinical benefit rate (CBR).|Changes in responses to quality of life questionnaires"	"DNAtrix, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	37	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2401BT-IFN-001	11-Sep-14	15-Mar-18	15-Mar-18	22-Jul-14		16-Jul-18	"Moffitt Cancer Center, Tampa, Florida, United States|The Ohio State University, Columbus, Ohio, United States|Baylor University: Charles A. Sammons Cancer Center, Dallas, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02197169
463	NCT00311857	"Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)"		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: Cetuximab|Drug: Temozolomide|Procedure: Radiation therapy	Toxicity|Overall survival	"Heidelberg University|Merck KGaA, Darmstadt, Germany"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	46	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Eudract-2005-003911-63|PEI 119/01	Feb-06			6-Apr-06		8-Sep-06	"University of Heidelberg, Heidelberg, Baden-Württemberg, Germany"		https://ClinicalTrials.gov/show/NCT00311857
464	NCT01759810	Proteome-based Personalized Immunotherapy of Glioblastoma		Unknown status	No Results Available	Glioblastoma	"Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes"	All cause mortality|Complete disappearance of all tumor foci	NeuroVita Clinic|Blokhin's Russian Cancer Research Center|Russian Foundation of Technological Development|The Serbsky State Scientific Center for Social and Forensic Psychiatry|National Institute of Regenerative Medicine|SRC Bioclinicum	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2|Phase 3	60	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM/2012	Dec-12	Dec-18	Dec-20	3-Jan-13		12-Oct-17	"ZAO ""NeuroVita Clinic of Interventional and Restorative Neurology and Therapy"", Moscow, Russian Federation"		https://ClinicalTrials.gov/show/NCT01759810
465	NCT00068952	Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma	Drug: Edotecarin|Drug: Temozolomide|Drug: Carmustine (BCNU)|Drug: Lomustine (CCNU)	To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy|To assess measures of tumor control To evaluate measures of clinical benefit To assess the safety profile of edotecarin To assess the PK profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin	Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EDOAGL-8725-001|A5921009	Aug-03		Mar-06	16-Sep-03		1-Apr-08	"Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Evanston, Illinois, United States|Pfizer Investigational Site, Edgewood, Kentucky, United States|Pfizer Investigational Site, Edgweood, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Edison, New Jersey, United States|Pfizer Investigational Site, Summit, New Jersey, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, St. Leonards, New South Wales, Australia|Pfizer Investigational Site, East Bentleigh, Victoria, Australia|Pfizer Investigational Site, Clayton, Australia|Pfizer Investigational Site, Graz, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Moncton, New Brunswick, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Split, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Nantes St. Herblain, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Regensburg, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Bangalore, India|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Badalona, Spain|Pfizer Investigational Site, Hospitalet de Llobregat, Spain|Pfizer Investigational Site, Oviedo, Spain|Pfizer Investigational Site"		https://ClinicalTrials.gov/show/NCT00068952
466	NCT00509821	"Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma"		Completed	Has Results	Glioblastoma Multiforme	Drug: Enzastaurin 500 milligram (mg) Once Daily (QD)|Drug: Enzastaurin 250 mg Twice Daily (BID)	"Percentage of Participants With Progression Free Survival at 6 Months (PFS-6)|Percentage of Participants With Overall Survival at 1 and 2 Years After Surgery|Response Rate|Change in Neurologic Status as Measured by Mini Mental Status Questionnaire, Total Score"	Eli Lilly and Company	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11491|H6Q-MC-S039	Oct-07	Feb-10	Mar-16	1-Aug-07	5-Apr-19	5-Apr-19	"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany"		https://ClinicalTrials.gov/show/NCT00509821
467	NCT00267592	Safety and Efficacy of Talampanel in Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Talampanel|Radiation: Radiation Therapy (RT) 5 days a week +|Drug: temozolomide(TMZ) 75mg|Drug: adjuvant TMZ 200mg	Overall Survival|Talampanel-related toxicity	"Teva Branded Pharmaceutical Products R&D, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	72	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IXR-207-21-189 / NABTT 0304	Dec-05	Sep-08	Feb-11	21-Dec-05		19-May-16			https://ClinicalTrials.gov/show/NCT00267592
468	NCT00076986	The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: IL13-PE38QQR|Procedure: surgery and catheter placement (2 procedures)|Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer)|Procedure: surgery and wafer placement (1 procedure)		INSYS Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IL13PEI-301-R03|PRECISE Trial	Feb-04	Mar-07	Mar-07	10-Feb-04		6-Jun-11	"University of Alabama at Birmingham - Division of Neurosurgery, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|Los Angeles County/USC, Los Angeles, California, United States|Cedars-Sinai Medical Center - Neurological Institute, Los Angeles, California, United States|University of California - Los Angeles Neuro-Oncology Program, Los Angeles, California, United States|University of California San Francisco - Dept. of Neurological Surgery, San Francisco, California, United States|University of Colorado Hospital - Anschutz Cancer Pavillion, Aurora, Colorado, United States|Yale University School of Medicine - Department of Neurosurgery, New Haven, Connecticut, United States|Florida Hospital Neuroscience Institute, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern Medical Faculty Foundation, Inc. - Dept of Neurological Surgery, Chicago, Illinois, United States|CINN at Rush Unversity Medical School, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|St. Louis University, St. Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center Department of Neurology, New York, New York, United States|Weill Cornell Medical College - Department of Neurological Surgery, New York, New York, United States|Columbia University Medical Center - Neurological Institute, New York, New York, United States|Carolina Neurosurgery & Spine Assoc., Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences - Department of Neurosurgery, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation Department of Neurological Surgery, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Insitute, Salt Lake City, Utah, United States|University of Virginia Health Systems - Department of Neurological Surgery, Charlottesville, Virginia, United States|Benaroya Research Institute at Virginia Mason Medical Center, Seattle, Washington, United States|West Virginia University Department of Neurosurgery, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinic, Madison, Wisconsin, United States|Calgary Health Region, Calgary, Alberta, Canada|Walter MacKenzie Health Sciences Center, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnepeg, Manitoba, Canada|London Regional Cancer Center, London, Ontario, Canada|Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Toronto Western Hospital Division of Neurosurgery, Toronto, Canada|Techniche Universität Dresden Klinik und Poliklinik für Neurochirurgie, Dresden, Germany|Universitätsklinikum Hamburg-Eppendorf - Klinik für Neurochirurgie, Hamburg, Germany|Klinikum der Universität Heidelberg, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein - Klinik für Neurochirurgie, Kiel, Germany|Ludwig-Maximilians-Universität München - Klinikum Großhadern - Neurochirurgische Klinik und Poliklinik, München, Germany|Rabin Medical Center - Department of Neurosurgery, Petach Tikva, Israel|Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel|Sheba Medical Center - Department of Neurosurgery, Tel Hashomer, Israel|Academisch Ziekenhuis Groningen Afd. Neurochirurgie, Groningen, Netherlands|Erasmus University MC, Rotterdam, Rotterdam, Netherlands|Institute of Neurological Sciences, Glasgow, United Kingdom|The Walton Centre for Neurology & Neurosurgery, Liverpool, United Kingdom"		https://ClinicalTrials.gov/show/NCT00076986
469	NCT03451799	Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma		"Active, not recruiting"	No Results Available	GBM|Glioblastoma	Other: Ketogenic Diet|Radiation: Standard-of-care radiation|Drug: Standard-of-care Temozolomide	Safety of the intervention|Feasibility of the intervention|Overall Survival|Time-to-progression|Quality of Life (two months)|Quality of Life (four months)|Cognitive function (Hopkins Verbal Learning Test-Revised)|Cognitive function (Trail Making Test)|Cognitive function (Controlled Word Association Test)|Cognitive function (Montreal Cognitive Assessment)	Jethro Hu|Cedars-Sinai Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	21	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT2016-17-HU-KETORADTMZ	13-Apr-18	3-Sep-21	Oct-23	2-Mar-18		8-Dec-21	"Cedars Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT03451799
470	NCT03460782	An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas		No longer available	No Results Available	Glioblastoma|Glioma of Brain	Biological: Ipilimumab		Center Trials & Treatment|BioGene Pharmaceutical Inc.	All	"18 Years to 80 Years   (Adult, Older Adult)"			Other	Expanded Access:Individual Patients		PST-9-IP				9-Mar-18		8-Nov-19	"University ""Mother Theresa"" Hospital Center; Oncology Department, Tirana, Albania|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Complex Oncology Center, Plovdiv, Bulgaria|Clinical Hospital Osijek; Dept For Oncology & Radiotherapy, Osijek, Croatia|Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucharest,, Romania|Regional Oncology Hospital, Irkutsk, Russian Federation|Rostov Cancer Research Institute, Rostov-on-Don, Russian Federation|Primorsky Regional Oncology Center, Vladivostok, Russian Federation|Clinical Hospital Center Bezanijska kosa; Clinic for Oncology, Belgrade, Serbia|Inselspital Bern; Medizinische Onkologie, Bern, Switzerland|Stadtspital Triemli; Frauenklinik, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT03460782
471	NCT00050986	Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme	Drug: Temozolomide|Drug: R115777	Maximal Tolerating Dose (MTD for Phase I)|Progression-free Survival (Phase II)	M.D. Anderson Cancer Center|Johnson & Johnson	All	"Child, Adult, Older Adult"	Phase 1|Phase 2	55	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ID02-126	Dec-02	Oct-08	Oct-08	3-Jan-03	16-Sep-10	22-Sep-20	"MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00050986
472	NCT00677716	Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse		Completed	No Results Available	Glioblastoma Multiforme	Drug: 131I-chTNT-1/B MAb (Cotara)	"To confirm the safety and tolerability of the maximum tolerated dose|To estimate overall survival, progression free survival and proportion of patients alive at six months after treatment."	Peregrine Pharmaceuticals	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	41	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PPHM 0503	Jul-07	Sep-11	Nov-11	14-May-08		24-Apr-14	"Barrow Neurological Institute, Phoenix, Arizona, United States|University of Pennsylvania, Department of Neurosurgery, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston,, South Carolina, United States|Amrita Institute of Medical Sciences and Research Center,, Cochin, Kerala, India|Manipal Institute for Neurological Disorders,, Bangalore, India|Department of Neurosurgery Jaslok Hospital and Research Centre, Mumbai, India|All India Instutite of Medical Sciences, New Delhi, India"		https://ClinicalTrials.gov/show/NCT00677716
473	NCT00116376	Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)		Completed	No Results Available	Glioblastoma Multiforme	Drug: AEE788	"Maximum tolerated dose|Dose limiting toxicity|Safety, tolerability, pharmacokinetic profiles, change in plasma markers of angiogenesis, tumor PK levels"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	64	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAEE788A2103	Jan-04	Nov-05	Nov-05	29-Jun-05		10-Nov-15	"University of California at Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624 DUMC, Trent Drive, Durham, North Carolina, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00116376
474	NCT01866449	Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme (GBM) WHO Grade IV	Drug: Cabazitaxel	"Response including SD, PR or CR determined by MRI (modified RANO criteria)|Overall and progression-free survival|Safety and tolerability|Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction)|Quality of life and neurocognitive functioning"	University of Ulm	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	24	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C-GBM (XRP6258)	Oct-13	Dec-16	25-Aug-17	31-May-13		26-Oct-17	"Hämatologisch onkologische Praxis, Augsburg, Germany|Stiftungsklinikum Mittelrhein GmbH, Koblenz, Germany|Lars Bullinger, MD, Ulm, Germany"		https://ClinicalTrials.gov/show/NCT01866449
475	NCT02270034	Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme (Grade IV) of Cerebellum	Drug: Crizotinib	Treatment safety|Recommended dose in phase II|Anti-tumor activity|Overall Survival	Grupo Español de Investigación en Neurooncología|Pfizer	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	24	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEINO 1402	13-Aug-14	26-Oct-20	Aug-21	21-Oct-14		8-Jan-21	"Institut Català D'Oncologia L'Hospitalet (Ico), L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT02270034
476	NCT04910022	Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma|Diffuse Glioma	Drug: NMS-03305293 + TMZ|Drug: Lomustine	Phase 1: Number of Participants with first-cycle dose limiting toxicity|Phase 2: Progression Free Survival rate at 6 months (PFS6)|Number of participants with Adverse Events (AEs)|Maximum concentration (Cmax) of NMS-03305293 after single and multiple doses of drug|Time to observed Cmax (Tmax) of NMS-03305293 after single and multiple doses of drug|Area under the concentration-time curve up to the last detectable plasma concentration (AUClast) of NMS-03305293 after single and repeated dose of drug.|Terminal elimination half-life (t1/2) of NMS-03305293 after single and multiple doses of drug|Area under the plasma concentration vs. time curve to infinity (AUCinf) of NMS-03305293 after multiple doses of drug.|Accumulation ratio (Rac) of NMS-03305293 after multiple doses of drug.|Oral plasma clearance (CL/F) of NMS-03305293 after multiple doses of drug|Apparent volume of distribution (Vd/F) of NMS-03305293 after multiple doses of drug|Phase 1: Renal clearance of NMS-03305293 after multiple doses of drug|Phase 1: Cumulative amount recovered unchanged in the urine (Ae) of NMS-03305293 after multiple doses of drug|Phase 1: Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03305293 after multiple doses of drug|Phase 1: Objective Tumor Response|Phase 2: Objective Tumor Response Rate|Duration of Response|Progression Free Survival|Overall Survival|Phase 2: 9 and 12-Months Overall Survival Rates	Nerviano Medical Sciences	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	125	Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PARPA-293-002|2020-003417-35	30-Sep-21	31-Dec-24	30-May-25	2-Jun-21		12-Aug-21	"Mayo Clinic Cancer Center, Rochester, Minnesota, United States|IRCCS Istituto Neurologico Carlo Besta, Milan, Italy|Erasmus Medical Center, Rotterdam, Netherlands|University Hospital Zurich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT04910022
477	NCT01712542	Curcumin Bioavailability in Glioblastoma Patients		Completed	No Results Available	Patient Harboring Glioblastoma That Will Undergo Surgery		Concentration of Curcumin in Glioblastoma	Johann Wolfgang Goethe University Hospital	All	"18 Years and older   (Adult, Older Adult)"		15	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	JohannWGUH_Curcumin-01	Oct-12	May-13	May-13	23-Oct-12		4-Jun-13	"Department of Neurosurgery, Johann Wolfgang Goethe-University, Frankfurt, Hessen, Germany"		https://ClinicalTrials.gov/show/NCT01712542
478	NCT04406272	VB-111 in Surgically Accessible Recurrent/Progressive GBM		Recruiting	No Results Available	Glioblastoma|Recurrent Glioblastoma	Drug: VB11|Procedure: Surgery|Other: Placebo|Drug: Bevacizumab	Tumor infiltrating T cell (TIL) density|Rate of Dose Limiting Toxicity|6-month progression-free survival|Overall Survival	Dana-Farber Cancer Institute|Vascular Biogenics Ltd. operating as VBL Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	45	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	19-792	1-Aug-20	1-Feb-23	1-Feb-24	28-May-20		5-Oct-21	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|UT Health San Antonio MD Anderson Cancer Center (Mays Cancer Center), San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT04406272
479	NCT01591577	Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Newly Diagnosed Glioblastoma Multiforme	Other: Lapatinib/Temozolomide/radiation	Overall survival	Jonsson Comprehensive Cancer Center|GlaxoSmithKline|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12-000493	7-Dec-12	7-Dec-22	7-Dec-23	4-May-12		6-Jan-22	"UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT01591577
480	NCT00093964	Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)		Completed	Has Results	Glioblastoma Multiforme	Drug: Cilengitide 500 mg|Drug: Cilengitide 2000 mg	Percentage of Subjects With Progression-free Survival|Percentage of Subjects With Overall Response Rate|Time to Disease Progression|Overall Survival Time|Percentage of Subjects With 1-year of Survival Rate|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration-time Curve From Time Zero to Infinity After Administration (AUC 0-infinity)|Apparent Terminal Rate Constant (Lambda z)|Terminal Half-life (t1/2)|Mean Residence Time of Drug in the Body (MRT)|Total Body Clearance (CL) of Drug From Plasma/Cerebro Spinal Fluid (CSF)|Apparent Volume of Distribution During the Terminal Phase (Vz)|Apparent Volume of Distribution at Steady State (Vss)|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	EMD Serono	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	81	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EMD 121974-009	13-Oct-04	28-Oct-05	21-Oct-10	11-Oct-04	16-Apr-19	16-Apr-19	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurological Institute, Phoenix, Arizona, United States|UCLA Medical Center, Los Angeles, California, United States|Denise Damek, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Good Samaritan Hospital/Tri Health Hatton Center, Cincinnati, Ohio, United States|Baylor University Medical Center at Dallas, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Vermont/Fletcher Allen Healthcare, Burlington, Vermont, United States|University of Virginia Health System, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00093964
481	NCT00574964	Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme	Temodar	Terminated	No Results Available	Primary Glioblastoma Multiforme	"Other: Gliadel Wafer, Temodar and Radiotherapy"	"Determine the safety and feasibility of Gliadel 3.85% wafers plus surgery and limited field radiation therapy with concomitant temozolomide, followed by adjuvant temozolomide, in subjects undergoing initial surgery for newly-diagnosed malignant gliomas.|Determine the progression free survival at 6 months, medial survival, and one year survival rate of this subject population. Determine objective response rate."	University of Iowa|Eisai Inc.	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 2	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200408035	Oct-05	Nov-07	Jun-08	17-Dec-07		27-Oct-16	"Holden Comprehensive Cancer Clinic, Iowa City, Iowa, United States"		https://ClinicalTrials.gov/show/NCT00574964
482	NCT01526837	Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence		Terminated	No Results Available	Glioblastoma Multiforme	Drug: Avastin	Maximum Tolerated Dose of bevacizumab (Avastin) following local administration.|Number of Adverse Events|Progression Free Survival	Brain & Spine Surgeons of New York	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BSSNY-B-001	Oct-11	Jan-12	Jan-12	6-Feb-12		12-Jul-17	"Brain & Spine Surgeons of New York, White Plains, New York, United States"		https://ClinicalTrials.gov/show/NCT01526837
483	NCT03665545	Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	IMA950-106	Recruiting	No Results Available	"Glioblastoma Multiforme|Glioblastoma, Adult|Glioma of Brain|Glioblastoma Multiforme of Brain"	Drug: IMA950/Poly-ICLC|Drug: IMA950/Poly-ICLC and pembrolizumab	"Incidence of Treatment-Emergent Adverse Events|Progression-free survival at 6, 9, 12 months|Overall Survival|Patient-reported Quality of life"	"University Hospital, Geneva"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IMA950-106/CER 2018-00718|MK3475-480	25-Oct-18	30-Oct-21	10-Nov-23	11-Sep-18		11-Dec-20	"University Hospitals of Geneva, Geneva, Switzerland"		https://ClinicalTrials.gov/show/NCT03665545
484	NCT04200066	A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma|Brain Tumor	"Drug: Temozolomide, Tamoxifen, Maprotiline"	Maximum Tolerated Dosing Regimen (MTDR) of maprotiline in combination with temozolomide (TMZ) and tamoxifen (TMX)|Mean Maprotiline drug level|Median Maprotiline drug level|6 mo Progression Free Survival|Overall Survival	University of Rochester	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UBRT19062	1-Dec-21	1-Oct-23	1-Feb-24	16-Dec-19		17-Nov-21			https://ClinicalTrials.gov/show/NCT04200066
485	NCT00660543	MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy		Completed	Has Results	Adult Brain Glioblastoma	Drug: Gadolinium|Drug: Ferumoxytol Non-Stoichiometric Magnetite|Other: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Other: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Other: Diffusion Weighted Imaging|Other: MRI-Based Angiogram	Mean Cerebral Blood Volume (CBV)|Tumor Progression on Conventional MR	OHSU Knight Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	14	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IRB00002753|NCI-2015-00224|SOL-06062-LX|813|NCI-2015-00204|8097|2753|P30CA069533	Dec-06	Jun-14	Jun-14	17-Apr-08	16-May-16	16-May-17	"OHSU Knight Cancer Institute, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT00660543
486	NCT00509301	Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Recurrent Glioblastoma Multiforme	Drug: 131-I-chTNT-1/B MAB	To confirm dose limit and maximum tolerated dose and to characterize radiation distribution	Peregrine Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PPHM 0602	Nov-06	Mar-10	Mar-10	31-Jul-07		5-Aug-11	"Barrow Neurological Institute, Phoenix, Arizona, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT00509301
487	NCT00790452	Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma		Terminated	Has Results	Glioblastoma	Drug: Aspirin|Drug: Placebo	Frequency of VTE Events	M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	1	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	2007-0266	Nov-08	Oct-09	Oct-09	13-Nov-08	8-Dec-11	8-Dec-11	"The University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00790452
488	NCT00038493	Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: Temozolomide and SCH66336		M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	23	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DM01-258	21-Sep-01	1-Aug-05	1-Aug-05	3-Jun-02		29-Oct-18	"UTMD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00038493
489	NCT04822688	"Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues"		Recruiting	No Results Available	Glioblastoma|Malignant Solid Neoplasm	Procedure: Biospecimen Collection	Cell yield|Percentage cell viability	Thomas Jefferson University	All	"18 Years and older   (Adult, Older Adult)"		60	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	21C.030	3-Feb-21	31-Jan-23	31-Jan-23	30-Mar-21		30-Mar-21	"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04822688
490	NCT04469075	Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields		Recruiting	No Results Available	Glioblastoma|Skin Toxicity	Drug: Clindamycin Phosphate|Drug: Triamcinolone Acetonide	Number of patients without grade 2 or higher skin toxicity|skin-related quality of life	Memorial Sloan Kettering Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	58	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-342	9-Jul-20	Jul-23	Jul-23	13-Jul-20		2-Dec-21	"Northwestern University, Evanston, Illinois, United States|Tufts Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT04469075
491	NCT03075514	Ketogenic Diets as an Adjuvant Therapy in Glioblastoma	KEATING	Completed	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioblastoma, Adult"	Other: MKD|Other: MCT	To assess retention and drop out rates|Estimation of recruitment rates|Enrollment of patients|Long term retention|Dietary adjustments required to achieve ketosis|Self reported dietary compliance|Calculated dietary compliance|MCT compliance|Ketosis levels|Dietetic time required for interventions|Protocol refinements required|Sample size estimates for future trials|Quality of life|Food acceptability|Gastrointestinal side effects|Changes to biochemical markers|Anthropometric changes|Completeness of data	"University of Liverpool|Walton Centre NHS Foundation Trust|Vitaflo International, Ltd"	All	"16 Years and older   (Child, Adult, Older Adult)"	Not Applicable	12	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UoL001277	1-Apr-17	5-Mar-19	5-Mar-19	9-Mar-17		4-Apr-19	"Univeristy of Liverpool/ The Walton Centre NHS Foundation Trust, Liverpool, Merseyside, United Kingdom"		https://ClinicalTrials.gov/show/NCT03075514
492	NCT00306618	Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma		Completed	No Results Available	Recurrent Glioblastoma Multiforme	Drug: Panzem Nanocrystal Colloidal Dispersion	6 month progression free survival and median overall survival	"CASI Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	27	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ME-CLN-005	Jan-06	Nov-07	Dec-08	24-Mar-06		10-Dec-08	"The Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00306618
493	NCT02129335	"Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner"	TOGETHER	Terminated	No Results Available	Neoplasms|Glioblastoma	Other: stress	Progression free survival|Overall survival	"University Hospital, Basel, Switzerland|University Hospital, Zürich|Luzerner Kantonsspital|University Hospital Inselspital, Berne"	All	"18 Years and older   (Adult, Older Adult)"		12	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	TOGETHER	Apr-14	Oct-16	May-17	2-May-14		17-May-17	"University Hospital Basel, Basel, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|University Hospital Neurology, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT02129335
494	NCT02678975	Disulfiram in Recurrent Glioblastoma		Completed	No Results Available	Glioma|Glioblastoma	Drug: Disulfiram|Dietary Supplement: Copper|Drug: Alkylating Agents	Survival 6 mo|Progression free survival|Survival 12 and 24 mo|Median overall survival|Health related quality of life|Volumetric tumor assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	"Sahlgrenska University Hospital, Sweden|St. Olavs Hospital|Lund University Hospital|Karolinska University Hospital|University Hospital, Linkoeping|Region Örebro County|Ryhov County Hospital|Uppsala University Hospital"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	88	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	no ID yet	Jan-17	15-Jan-21	15-Jan-21	10-Feb-16		18-Mar-21	"Cancer Clinic, St.Olavs University Hospital, Trondheim, Norway|Dept. of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden|Ryhov County Hospital, Jönköping, Sweden|Linköping University Hospital, Linkoping, Sweden|Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden|Örebro University Hospital, Örebro, Sweden"		https://ClinicalTrials.gov/show/NCT02678975
495	NCT03341806	Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|GBM	Drug: Avelumab|Combination Product: MRI-guided LITT therapy	Dose Limiting Toxicity level|Objective response rate (ORR)|Progression-free survival|Overall response rate	Icahn School of Medicine at Mount Sinai	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	13	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 17-1866	13-Jun-18	13-Oct-21	13-Oct-21	14-Nov-17		4-Jan-22	"Icahn School of Medicine at Mount Sinai, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03341806
496	NCT02919332	Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma		Withdrawn	No Results Available	Glioblastoma|Glioma	Procedure: Computed Tomography|Radiation: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography	Tumor-to-background ratio on delayed scans (240 min after injection)|Tumor-to-background ratio on standard scans (60 min after injection)|Standard uptake value comparison	Jonsson Comprehensive Cancer Center	All	"18 Years to 99 Years   (Adult, Older Adult)"		0	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	16-000600|NCI-2016-01214|JCCCID655	8-Jun-16	12-Dec-18	12-Dec-18	29-Sep-16		24-Jul-20	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT02919332
497	NCT00290771	Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)		Terminated	Has Results	Recurrent Glioblastoma Multiforme (GBM)	Drug: Imatinib tablets|Drug: Hydroxyurea capsules	"Percentage of Patients With an Objective Overall Response (OOR)|Duration of Objective Overall Response (OOR)|Percentage of Patients Who Had Clinical Benefit|Percentage of Patients With Progression-free Survival at Months 6 and 12|Percentage of Patients Surviving at Months 6, 12, and 24|Number of Patients With at Least 1 Adverse Event"	Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	231	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571H2201|CSTI571H2202	Feb-06	Aug-08	Aug-08	13-Feb-06	16-May-11	16-May-11	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00290771
498	NCT03115138	Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.	Bi-GLAM	Terminated	No Results Available	Glioblastoma|Molecular Disease	Other: Correlation between molecular anomalies of the primary tumor and circulating tumor DNA	Presence of a correlation between the molecular abnormalities of the primary tumor and the circulating tumor DNA	"Centre Hospitalier Universitaire, Amiens"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	19	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	PI2015_843_0029	9-Mar-16	6-Nov-17	6-Nov-17	14-Apr-17		15-Jul-20	"CHU Amiens Picardie, Amiens, Picardie, France"		https://ClinicalTrials.gov/show/NCT03115138
499	NCT01266031	Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma		Completed	Has Results	Malignant Glioma|Recurrent Glioblastoma	Drug: vorinostat|Drug: bevacizumab	"Progression Free Survival (PFS) at 6 Months|Maximum Tolerated Dose (MTD) of Oral Vorinostat Used With Bevacizumab|Time to Progression (TTP)|Overall Survival (OS)|Effects of Bevacizumab With and Without Vorinostat Upon Biomarkers of Angiogenesis Vascular Endothelial Growth Factor (VEGF), Placental Growth Factor (PIGF), and Basic Fibroblast Growth Factor (bFGF)|Effects of Bevacizumab With and Without Vorinostat Upon Biomarkers of Angiogenesis Stromal Cell-derived Factor α (SDF1α), and Angiopoietin 1 (Ang 1) and 2 (Ang 2) by Enzyme-linked Immunosorbent Assay (ELISA)|Percentage of Patients Rating Their Symptoms to be 7 or Greater on a 0-10 Scale Using the Mean Severity of the MD Anderson Symptom Inventory-Brain Tumor Module (MDSAI-BT) Self Reporting Tool|Mean Symptom Severity Using the MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) Self Reporting Tool|Mean Symptom Interference at the Time of Clinical Evaluation|Radiological Response|Number of Participants With Serious and Non-Serious Adverse Events"	"National Cancer Institute (NCI)|M.D. Anderson Cancer Center|Genentech, Inc.|Merck Sharp & Dohme Corp.|Brain Tumor Trials Collaborative|Ohio State University Wexner Medical Center|Northwestern University Feinberg School of Medicine|UF Health Cancer Center at Orlando Health|Baylor Health Care System|MUSC Hollings Cancer Center|University of Utah Health System|University of Washington|Henry Ford Health System|Columbia University|Rush University Medical Center|NorthShore University HealthSystem|The Cleveland Clinic|University of North Carolina, Chapel Hill|Washington University School of Medicine|Texas Oncology-Austin|National Institutes of Health Clinical Center (CC)"	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 1|Phase 2	96	NIH|Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	999916116|16-C-N116	12-Jul-11	30-Jun-15	31-Jan-17	24-Dec-10	23-Sep-16	31-Jul-18	"Baylor University Medical Center, Dallas, Texas, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/31/NCT01266031/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01266031
500	NCT00841555	Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma		Completed	Has Results	Glioblastoma Multiforme/Anaplastic Astrocytoma	Drug: temozolomide|Radiation: Hypofractionated radiation therapy|Radiation: Intensity-modulated radiation therapy	Maximum Tolerated Dose(MTD)of Temozolomide(TMZ)|Time to Neuroradiological Evidence of Tumor Recurrence or Progression|Survival Time|Time Spent in a Karnofsky Performance Status of 60-100%	Ohio State University Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	9	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-08119|NCI-2011-03149	13-Feb-09	13-Feb-13	25-Nov-14	11-Feb-09	27-Apr-16	18-Apr-18	"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00841555
501	NCT04143425	Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma		Recruiting	No Results Available	Adult Glioblastoma|Magnetic Resonance Imaging|Bevacizimab	Diagnostic Test: 3-Tesla conventional magnetic resonance imaging|Diagnostic Test: Advanced imaging without contrast use|Diagnostic Test: Dynamic susceptibility contrast-weighted imaging	Progression free survival|6-month progression|Overall survival	Ho Sung Kim|Asan Medical Center	All	"18 Years to 80 Years   (Adult, Older Adult)"		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	AsanMCHSKim_05	6-Feb-20	Jun-22	Dec-22	29-Oct-19		7-Feb-20	"Asan Medical Center, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT04143425
502	NCT02768389	Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|Brain Tumor	Drug: Bevacizumab|Behavioral: Modified Atkins Diet	Number of subjects following Modified Atkins Diet|Number of subjects with ketosis|Correlation of blood sugar levels by compliance level|Correlation of ketosis values by compliance level|Correlation of ketosis values by tumor response|Correlation of blood sugar levels by tumor response	Case Comprehensive Cancer Center|University of Cincinnati|OhioHealth Research Institute	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE10314	6-Sep-16	Nov-18	Nov-18	11-May-16		15-Mar-19	"University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive cancer Center, Cleveland, Ohio, United States|OhioHealth Research and Innovation Institute, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02768389
503	NCT03916757	V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer	GBM	Unknown status	No Results Available	Glioblastoma Multiforme|Glioma of Brain	Biological: V-Boost	Effect on tumor size|Effect on progression-free survival	Immunitor LLC	All	"5 Years to 99 Years   (Child, Adult, Older Adult)"	Phase 2	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Imm008	16-Apr-19	15-Apr-20	15-Jun-20	16-Apr-19		17-Apr-19	"Immunitor LLC, Ulaanbaatar, Mongolia"		https://ClinicalTrials.gov/show/NCT03916757
504	NCT01925573	Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)		Terminated	No Results Available	RECURRENT GLIOBLASTOMA|Brain Tumor	Device: Optune(NOVOTTF-100A)	Number of Adverse Events with a grade 3 or high toxicity (Primary Measure)	"University of Maryland, Baltimore|NovoCure Ltd."	All	"22 Years and older   (Adult, Older Adult)"	Not Applicable	7	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00056719	May-14	Aug-19	Aug-19	19-Aug-13		4-Nov-20	"Ummc Msgcc, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01925573
505	NCT05118776	Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM		Not yet recruiting	No Results Available	Recurrent Glioblastoma	Drug: ASC40 tablets|Drug: Placebo tablets|Drug: Bevacizumab	Progression-free survival|Total survival|Objective remission rate	"Ascletis Pharmaceuticals Co., Ltd."	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	180	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	ASC40-301	16-Jan-22	16-Jul-23	16-Sep-23	12-Nov-21		4-Jan-22			https://ClinicalTrials.gov/show/NCT05118776
506	NCT05063682	The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients	CARTREMENDOUS	"Active, not recruiting"	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioma, Malignant"	Biological: EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes	"Incidence of adverse events|Overall survival|CAR (chimeric antigen receptor) T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Endogenous T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Cell phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Cytokine levels (Procartaplex panel) in PB, TCF and CSF|Disease response|Time to progression|CAR T and endogenous cells detected in tumor tissue|EGFRvII (epidermal growth factor receptor) antigen expression levels in tumor tissue."	"Chembrain LTD|University of Oulu|Jyväskylä Central Hospital|Apollo Hospital, New Delhi, India"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6678EGFRvIII	15-May-20	Oct-23	Oct-23	1-Oct-21		1-Oct-21	"Jyväskylä Central Hospital, Jyväskylä, Finland|University Of Oulu, Oulu, Finland|Apollo Hospital, New Delhi, India"		https://ClinicalTrials.gov/show/NCT05063682
507	NCT02898012	Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status	ATAG	Completed	No Results Available	Glioblastoma Multiforme|Primary Brain Tumor	Drug: Temozolomide|Drug: Bevacizumab	"Median Overall Survival (OS)|Progression-free survival (PFS)|Toxicity grade according to the National Cancer Institute Common Toxicity Criteria (NCI CTCAE, version 3.0)|Health-related quality of life using QLQ-C30 questionnaire|Health-related quality of life using QLQ-BN20|Cognitive assessment MMSEs|Radiological responses"	Assistance Publique - Hôpitaux de Paris|Roche Pharma AG	All	70 Years and older   (Older Adult)	Phase 2	70	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P081213	Oct-10	May-13	Jun-13	13-Sep-16		13-Sep-16	"Groupe Hospitalier Pitié-Salpêtrière, Paris, France"		https://ClinicalTrials.gov/show/NCT02898012
508	NCT01702792	Derivation of Tumor Specific Hybridomas		Terminated	No Results Available	Glioblastoma	Biological: Tumor Vaccine	number of hybridoma clones that produce anti-glioma antibodies|Production of Antibodies|Toxicity of Vaccine|Clone Production Rate|Lymph Node Biopsy	Dartmouth-Hitchcock Medical Center|University of Vermont	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	W12209	Jan-14	6-May-15	6-May-15	8-Oct-12		4-Apr-18			https://ClinicalTrials.gov/show/NCT01702792
509	NCT00777686	Measuring Non-Enhancing Glioblastoma Progression		Completed	No Results Available	Brain Tumor|Glioblastoma	Procedure: MRI/MRS Scan	Functional MR Measurements	M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"		7	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	2007-0492	Aug-08	Mar-11	Mar-11	22-Oct-08		30-Mar-12	"UT MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00777686
510	NCT02330991	A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Temozolomide	Progress-Free Survival at 6 months (PFS6)|Overall Survival(OS)|Progression free survival|Objective Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability	Beijing Sanbo Brain Hospital	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	204	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014062501	Jan-15	Apr-20	Oct-20	5-Jan-15		12-Feb-20			https://ClinicalTrials.gov/show/NCT02330991
511	NCT01260506	Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Multiforme	Drug: VB-111|Drug: Bevacizumab	Overall Survival|Progression Free Survival	Vascular Biogenics Ltd. operating as VBL Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	75	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VB-111-122	Dec-10	23-Jul-15	20-Dec-18	15-Dec-10		24-Apr-20	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Uthsc- Ctrc, San Antonio, Texas, United States|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT01260506
512	NCT01956734	Virus DNX2401 and Temozolomide in Recurrent Glioblastoma	D24GBM	Completed	No Results Available	Glioblastoma Multiforme|Recurrent Tumor	Procedure: DNX2401 and Temozolomide	Number of participans with adverse events|Efficacy of the combination: PFS6 and OS12|Tumor response|Quality of life|Biological response	"Clinica Universidad de Navarra, Universidad de Navarra|DNAtrix, Inc."	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	31	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D24GBM EudraCT: 2011-005935-21	Sep-13	Dec-15	Mar-17	8-Oct-13		24-Oct-17	"Clinica Universidad de Navarra, Pamplona, Navarra, Spain"		https://ClinicalTrials.gov/show/NCT01956734
513	NCT03618667	GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification		Recruiting	No Results Available	"Glioblastoma, Adult|EGFR Amplification"	Drug: GC1118	Progression-free survival|overall survival|overall response rate|Exploration of predictive/prognostic biomarkers	Samsung Medical Center	All	"19 Years and older   (Adult, Older Adult)"	Phase 2	23	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SMC2017-06-111	30-Apr-18	31-Dec-20	31-Jul-21	7-Aug-18		15-Jul-20	"Samsung Medical Center, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT03618667
514	NCT02754362	A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma		Withdrawn	No Results Available	Glioblastoma|Glioma	Drug: Bevacizumab|Biological: Peptide Vaccine|Drug: Poly-ICLC as immune adjuvant|Drug: Keyhole limpet hemocyanin (KLH)	Assays to determine immunity to the vaccine's antigen|Measure of Humoral Immune Responses measured by ELISA|Antigen specific CD4+ and CD8+ T-cell reactivity to the peptide antigens measured by intracellular cytokine staining|CD4+ and CD8+ T cell reactivity to KLH measured by T cell proliferation quantified by tritiated thymidine incorporation|Measure of Tumor Responses measured by the Response Evaluation Criteria in Solid Tumors (RECIST).	NYU Langone Health|MOUNT SINAI HOSPITAL	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-00044	Nov-16	Jun-19	Jun-19	28-Apr-16		13-Jan-20	"NYU Perlmutter Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02754362
515	NCT04205357	Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma	SAS-GKRS	Recruiting	No Results Available	Glioma|Glioblastoma|Recurrent Glioblastoma	Drug: Sulfasalazine	Toxicity (Common Terminology Criteria for Adverse Event v 4.0)|Intratumoral Glutathione production|Presence of radiation necrosis|Progression free survival|Overall survival|Quality of life (Functional Assessment of Cancer Therapy-Brain)|Karnofsky performance score (KPS)|Steroid use in mg over time	Haukeland University Hospital|Norwegian Cancer Society|Northwell Health|Weill Medical College of Cornell University|University of Bergen|Helse Stavanger HF	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019/6834	1-Mar-20	31-Dec-22	31-Dec-22	19-Dec-19		25-Aug-21	"Haukeland University Hospital, Bergen, Norway"		https://ClinicalTrials.gov/show/NCT04205357
516	NCT03463733	Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)	HUTMZ	Recruiting	No Results Available	Glioma|Glioblastoma	Drug: Hydroxyurea|Drug: Temozolomide	Maximal tolerated dose (MTD) hydroxyurea in combination with dose intense temozolomide	M.E. van Linde|Massachusetts General Hospital|VU University Medical Center	All	"Child, Adult, Older Adult"	Phase 1	54	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro-16/11	2-Mar-18	1-Jun-21	1-Jun-22	13-Mar-18		8-Oct-20	"VU University Medical Center, Amsterdam, Noord-Holland, Netherlands"		https://ClinicalTrials.gov/show/NCT03463733
517	NCT01987830	Bevacizumab w / Temozolomide PET & Vascular MRI For GBM		Completed	Has Results	Recurrent Glioblastoma	Device: MRI-PET|Device: TMZ-PET	Number of Patients With a Decrease in Median Tumor SUV	Massachusetts General Hospital|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	13	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	13-322	Nov-13	Apr-19	Apr-19	19-Nov-13	4-Sep-20	4-Sep-20	"Massachuesett General Hospital, Boston, Massachusetts, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/30/NCT01987830/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01987830
518	NCT00657267	Dose-Intense Temozolomide in Recurrent Glioblastoma		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Temozolomide	6 Month Progression Free Survival|Overall Survival|Radiographic Response|Time to Progression.	"Patrick Y. Wen, MD|Brigham and Women's Hospital|Massachusetts General Hospital|University of Pennsylvania|Wake Forest University Health Sciences|Tufts Medical Center|Dartmouth-Hitchcock Medical Center|Schering-Plough|Dana-Farber Cancer Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	58	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-013|P05516	May-08	Nov-11	Oct-13	14-Apr-08	14-Mar-14	14-Mar-14	"Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Wake Forest Univsersity, Winston-Salem, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00657267
519	NCT03970447	A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma	GBM AGILE	Recruiting	No Results Available	Glioblastoma	Drug: Temozolomide|Drug: Lomustine|Drug: Regorafenib|Radiation: Radiation|Drug: Paxalisib|Drug: VAL-083	Overall Survival (OS)|Progression-free survival (PFS)|Tumor Response|Duration of Response (CR + PR)	"Global Coalition for Adaptive Research|Bayer|Kazia Therapeutics Limited|Kintara Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	1030	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCAR-7213	30-Jul-19	Dec-23	Jun-24	31-May-19		21-Dec-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|St. Joseph Hospital, Orange, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale Cancer Center / Smilow Cancer Hospital, New Haven, Connecticut, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|LSU Health Sciences Center - New Orleans, New Orleans, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center - Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Comprehensive Cancer Center of Wake Forest, Winston-Salem, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Cancer Center, Columbus, Ohio, United States|University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States|Texas Oncology - Austin, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, McGill University, Montréal, Quebec, Canada|Université de Sherbrooke, Sherbrooke, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT03970447
520	NCT03463265	ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma	Drug: ABI-009|Drug: Bevacizumab|Drug: Temozolomide|Drug: Lomustine|Radiation: Radiation|Drug: Marizomib	objective overall response rate according to RANO 2010 criteria|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|progression free survival|overall survival	"Aadi, LLC"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM007	1-Aug-18	Dec-22	Dec-22	13-Mar-18		4-Jun-21	"St. Joseph Heritage Healthcare, Fullerton, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States"		https://ClinicalTrials.gov/show/NCT03463265
521	NCT04933942	Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma	RIGOLETTO	Not yet recruiting	No Results Available	First Progression of MGMT Promoter-methylated Glioblastoma	Drug: Lomustine|Drug: Romiplostim	Progression Free Survival (PFS)|Overall Survival (OS)|the Health-related Quality of Life (HRQoL)|Frequency of worst Adverse Events (AEs)	European Organisation for Research and Treatment of Cancer - EORTC|Amgen	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-1926-BTG	Dec-21	May-24	Dec-24	22-Jun-21		25-Jun-21			https://ClinicalTrials.gov/show/NCT04933942
522	NCT02844439	Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma		Completed	Has Results	Glioblastoma|Recurrent Glioblastoma|Brain Tumor	Drug: Tesevatinib	Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6)|Efficacy: Median PFS|Efficacy: Median Overall Survival Rate at 9 Months (OS-9)|Efficacy: Median OS|Efficacy: Best Overall Response|Efficacy: Objective Response Rate (ORR)|Exposure to Tesevatinib: Overall Mean|Exposure to Tesevatinib: Overall Median|Exposure to Tesevatinib: Mean Number of Cycles|Exposure to Tesevatinib: Median Number of Cycles	"Kadmon Corporation, LLC"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KD019-208	Jun-16	30-Apr-20	30-Apr-20	26-Jul-16	22-Sep-21	22-Sep-21	"Center for Neurosciences, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|University of California, San Francisco (UCSF), San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/39/NCT02844439/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02844439/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02844439
523	NCT01811121	MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS	RESECT	Unknown status	No Results Available	Glioblastoma	Drug: 5-aminolévulinique acid (5-ALA)|Drug: Placebo	Comparison of complete tumor resection between the 2 arms	Hospices Civils de Lyon	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	170	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2011-697	Feb-13	Mar-13	Aug-19	14-Mar-13		5-Oct-16	"Guyotat, Lyon, France"		https://ClinicalTrials.gov/show/NCT01811121
524	NCT04717739	"TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study"		Not yet recruiting	No Results Available	Glioblastoma	Device: TTFields	"Time of usage of TTFields treatment in follow-up derived from monitoring data of the devices, standardised to usage days, as measure of compliance with TTFields treatment.|Number of TTFields treatment-related SAEs as assessed by the CEC standardized to one year of FU time|Changes in daily physical activity as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy|Changes in sleep quality as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy|Changes in neurocognitive functioning as a potential quality of life parameter in TTFields treatment compared to baseline for up to four months after start of TTFields therapy."	NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"		500	Industry	Observational	Observational Model: Other|Time Perspective: Prospective	13.01.2021	Mar-21	1-Jun-23	1-Jul-23	22-Jan-21		22-Jan-21	"University Hospital Essen, Essen, Germany"		https://ClinicalTrials.gov/show/NCT04717739
525	NCT04047303	"CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma"		"Active, not recruiting"	No Results Available	Astrocytoma|Glioblastoma	Drug: CC-90010	Intratumoral concentration of CC-90010 in tumor tissue collected intraoperatively|Pharmacokinetics - AUC24|Pharmacokinetics - AUClast|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL/F|Pharmacokinetics - V2/F|Adverse Events (AEs)	Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-90010-GBM-001|U1111-1235-8082|2019-000241-12	2-Jan-20	17-Mar-22	17-Mar-22	6-Aug-19		4-Jan-22	"Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Moffit Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT04047303
526	NCT02345824	Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma		Unknown status	No Results Available	Glioblastoma|Glioma	Drug: Ribociclib	Inhibition of CDK4/CDK6 Signaling Pathway in Cell Proliferation|Ribociclib Concentration in Tissues|Ribociclib Concentration in Plasma|Tumor Progression|Survival Outcomes|Ribociclib Safety Profile	University of Virginia|Novartis Pharmaceuticals	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 1	3	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D13223|18729	Mar-16	Sep-19	Jan-20	26-Jan-15		7-Jun-18	"University of Virginia Health System, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02345824
527	NCT03235934	Glycemic Impact on Glioblastoma Outcomes		Withdrawn	No Results Available	Glioblastoma Multiforme|Hyperglycemia		Total time spent in target glucose level|Area under the curve for glycemic exposure and variability|Neurocognitive Function|prevalence of sensor site problems	"University Health Network, Toronto|Sinai Health System"	All	"18 Years and older   (Adult, Older Adult)"		0	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	15-9329	1-Dec-18	1-Oct-19	24-Jan-20	1-Aug-17		25-Oct-21	"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT03235934
528	NCT02599090	Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma		Withdrawn	No Results Available	Glioblastoma|Gliosarcoma	Drug: Temozolomide|Radiation: Radiation|Drug: Sorafenib	Time to Progression	M.D. Anderson Cancer Center|Bayer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008-0059 Phase II|NCI-2012-01617	Dec-08	Dec-12	Dec-12	6-Nov-15		6-Nov-15			https://ClinicalTrials.gov/show/NCT02599090
529	NCT02432417	"The Addition of Chloroquine to Chemoradiation for Glioblastoma,"		Not yet recruiting	No Results Available	"Glioblastoma|Astrocytoma, Grade IV"	Drug: Chloroquine	"Six-month progression-free survival|Overall survival|Adverse Events (AE) and serious AEs|Gene mutation, deletion or amplification|Tumor hypoxia"	Maastricht Radiation Oncology	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	156	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHLOROBRAINII	Jan-22	Jan-24	Jan-24	4-May-15		27-Sep-21			https://ClinicalTrials.gov/show/NCT02432417
530	NCT01149850	Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma		"Active, not recruiting"	No Results Available	Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma	Biological: bevacizumab|Drug: temozolomide|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: DNA methylation analysis	Overall survival|Time to progression|progression free survival	"Jonsson Comprehensive Cancer Center|Genentech, Inc."	All	70 Years and older   (Older Adult)	Phase 2	50	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AVF4535s|10-000760|09-06-032	28-Apr-10	1-Jan-22	1-Jan-23	24-Jun-10		12-Feb-21	"Kaiser Foundation Hospital, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Kaiser Permanente at San Diego, San Diego, California, United States"		https://ClinicalTrials.gov/show/NCT01149850
531	NCT05095376	Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma|Gliosarcoma	Drug: Lomustine|Radiation: Photon Beam Radiation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Temozolomide	Overall Survival|Progression Free Survival (PFS)|Incidence of Adverse Events|Patient reported outcomes for Brain Tumors	NRG Oncology|National Cancer Institute (NCI)	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	306	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NRG-BN011|NCI-2021-10331|U10CA180868	6-May-22	8-Aug-26	8-Aug-31	27-Oct-21		27-Oct-21			https://ClinicalTrials.gov/show/NCT05095376
532	NCT03426891	Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma|Brain Tumor|GBM	Drug: Pembrolizumab|Drug: Vorinostat|Drug: Temozolomide|Radiation: Radiotherapy	Maximum Tolerated Dose (MTD)|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	21	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19342	16-Mar-18	18-Oct-21	Dec-22	8-Feb-18		19-Oct-21	"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT03426891
533	NCT02137759	MRSI to Predict Response to RT/TMZ ± Belinostat in GBM		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme of Brain	Radiation: Standard Radiation Therapy|Drug: Standard Temozolomide|Drug: Belinostat	Progression Free Survival (PFS) (Cohort 1)|Maximum Tolerated Dose of Belinostat (Cohort 2a)|Progression Free Survival (PFS) (Cohort 2b)|Overall Survival|Progression Free Survival|IDS-SR score change	"Emory University|Johns Hopkins University|Spectrum Pharmaceuticals, Inc|National Cancer Institute (NCI)|National Institute of Neurological Disorders and Stroke (NINDS)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	29	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00065425|Winship2434-13|U01CA172027|F30CA206291|R21NS100244	7-May-14	30-Aug-22	30-Aug-22	14-May-14		5-Sep-21	"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/59/NCT02137759/ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT02137759
534	NCT04555577	"Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma"		Recruiting	No Results Available	Glioblastoma|Gliosarcoma	Drug: Nedisertib|Radiation: Radiation Therapy|Procedure: Resection|Drug: Temozolomide	Maximum tolerated dose (MTD) (Stage I)|Ability of nedisertib (M3814) to cross the blood brain barrier (Stage II)|Dose-limiting toxicities (DLT) (Stage I)|Overall response rate (Stage I)|Median progression-free survival (Stage I)|Median overall survival (Stage I)|Overall response rate (Stage II)|Median progression-free survival (Stage II)|Median overall survival (Stage II)	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	29	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-1035|NCI-2020-04491	20-Sep-20	30-Oct-23	30-Oct-23	18-Sep-20		19-Nov-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04555577
535	NCT04397679	"Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma"		Not yet recruiting	No Results Available	Glioblastoma|Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy (IMRT)|Drug: Temozolomide|Drug: Chloroquine|Procedure: Tumor Treating Fields Therapy (TTF)	Proportion of patients who develop a specific acute toxicity (dermatitis)|Incidence of adverse events	Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-148|P30CA022453	30-Jul-21	11-Mar-22	11-Sep-22	21-May-20		28-Jun-21	"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States"		https://ClinicalTrials.gov/show/NCT04397679
536	NCT04007185	Surgically Induced Neurological Deficits in Glioblastomas (SIND Study)	SIND	Recruiting	No Results Available	Glioblastoma	"Procedure: Maximal, safe resection of brain tumour"	Impact of new deficit on quality of life|Anatomical disruption|Recovery of visual deficits|Recovery of cognitive deficits using OCS-Bridge tool|Quantifying white matter tract disruption|Impact of deficits on overall survival	Cambridge University Hospitals NHS Foundation Trust	All	"16 Years and older   (Child, Adult, Older Adult)"		150	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	SIND-2018|CDF-2018-11-ST2-003	15-May-21	Jul-24	Dec-24	5-Jul-19		19-Jul-21	"Stephen Price, Cambridge, United Kingdom"		https://ClinicalTrials.gov/show/NCT04007185
537	NCT02766699	"A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)"	CerebralEDV	Unknown status	No Results Available	"Glioblastoma|Astrocytoma, Grade IV"	Drug: EGFR(V)-EDV-Dox	Safety outcome measures|Efficacy outcome measure|Identification of a recommended Phase 2 dose (RP2D) of EGFR(V)-EDV-Dox in subjects with recurrent GBM|Overall survival outcome measure.	Engeneic Pty Limited|Johns Hopkins University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ENG7	25-Oct-16	Dec-19	Jun-20	10-May-16		29-Aug-19	"John Hopkins Hospital, Baltimore, Maryland, United States|Lenox Hill Hospital, Northwell Health, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02766699
538	NCT01752491	A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma|GBM|Glioblastoma Multiforme	Drug: Ascorbate|Drug: Temozolomide|Radiation: Radiation therapy	"Number of grade 3, 4, & 5 adverse events|Time to progression|Overall survival"	"Joseph J. Cullen, MD, FACS|National Institutes of Health (NIH)|National Cancer Institute (NCI)|University of Iowa"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	13	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201211713|P30CA086862|U01CA140206	1-Apr-13	30-Nov-15	31-Dec-21	19-Dec-12		6-Oct-20	"Holden Comprehensive Cancer Center at the University of Iowa, Iowa City, Iowa, United States"		https://ClinicalTrials.gov/show/NCT01752491
539	NCT03137888	Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma	Radiation: Dose-Escalated Radiation Therapy|Procedure: Spectroscopic Magnetic Resonance Imaging|Drug: Temozolomide	Feasibility as assessed by successful co-registration of sMRI-based treatment volumes with clinical images into the radiation treatment execution platform|Incidence of adverse event assessed by Common Terminology Criteria for Adverse Events version 4.0|Progression free survival (PFS)	Emory University|Johns Hopkins University|University of Miami|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	34	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00094188|NCI-2017-00424|RAD3383-17|R01CA214557	20-Sep-17	Jan-22	Jan-22	3-May-17		1-Mar-21	"University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/88/NCT03137888/ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT03137888
540	NCT01252459	Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme	GLIAA	Unknown status	No Results Available	Recurrent Glioma (Glioblastoma Multiforme)	Radiation: Radiation Therapy	Progression Free Survival (PFS)|Overall survival|Volumetrical assessment of GTV and PTV|Topography of recurrence|Localisation of necrosis after re-irradiation|Rate of long-term survivors|Quality of Life (QoL)|Rate of side effects	University Hospital Freiburg|Clinical Trials Center Freiburg|University of Freiburg|AG-NUK-RT	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	200	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AG NUK/RT 2010-1	Jul-11	Jul-13	Jul-14	3-Dec-10		16-Dec-10	"Department of Radiotherapy, University Hospital Freiburg, Freiburg i. Br., Baden-Wuerttemberg, Germany"		https://ClinicalTrials.gov/show/NCT01252459
541	NCT03119064	BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma	329	Completed	No Results Available	Glioblastoma Multiforme|Glioblastoma|GBM	Drug: Nanoliposomal Irinotecan|Drug: Temozolomide	MTD|Response|PFS|Toxicities	"Heinrich Elinzano, MD|Merrimack Pharmaceuticals|Rhode Island Hospital|Brown University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	12	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrUOG 329	30-Nov-17	10-Apr-20	10-Apr-20	18-Apr-17		26-Aug-20	"Rhode Island Hospital, Providence, Rhode Island, United States"		https://ClinicalTrials.gov/show/NCT03119064
542	NCT01413438	Bevacizumab With or Without Surgery for Adult Glioblastomas		Withdrawn	No Results Available	Glioblastoma|Brain Neoplasm	Procedure: Craniotomy	"Median Overall Survival|Progression-free survival (PFS) at 6 months &amp; median PFS in each arm, objective response rate by the RANO criteria (OR), and overall survival rate at 6 and 12 months in each arm, compare rate of change in health-related quality of life."	National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	110204|11-N-0204	15-Jul-11	26-Sep-13	26-Sep-13	10-Aug-11		2-Jul-17			https://ClinicalTrials.gov/show/NCT01413438
543	NCT00846456	Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma		Completed	No Results Available	Glioblastoma|Brain Tumor	Biological: Dendritic cell vaccine with mRNA from tumor stem cells	"Adverse events|Evaluation of immunological response, time to disease progression and survival time"	Oslo University Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DC-CAST-GBM	Jan-09	Feb-13	Feb-13	18-Feb-09		20-Oct-15			https://ClinicalTrials.gov/show/NCT00846456
544	NCT02573324	A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification	Intellance1	"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma	Drug: Temozolomide|Drug: ABT-414|Radiation: Radiation|Drug: Placebo for ABT-414	Overall Survival (OS)|Progression-Free Survival (PFS)|OS for the O6-methylguaninemethlytransferese (MGMT) Unmethylated Group|OS for the MGMT Methylated Group|Time to Deterioration in Symptom Severity Score M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)|Time to Deterioration in Symptom Interference Score MDASI-BT|Time to Deterioration in Neurocognitive Functioning on the Hopkins Verbal Learning Test Revised (HVLT-R)|OS for the Epidermal Growth Factor Receptor (EGFR)vIII-Mutated Tumor Subgroup|PFS for EGFRvIII-Mutated Tumor Subgroup|Number of Adverse Events (AE)	AbbVie|Radiation Therapy Oncology Group	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2|Phase 3	640	Industry|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	M13-813|2015-001166-26	7-Dec-15	31-Dec-21	31-Dec-21	9-Oct-15		24-May-21	"St. Josephs Hosp and Med Ctr /ID# 144149, Phoenix, Arizona, United States|Highlands Oncology Group /ID# 142050, Springdale, Arkansas, United States|Universtiy of Southern California /ID# 147543, Los Angeles, California, United States|University of California, Los Angeles /ID# 149239, Los Angeles, California, United States|Sharp Memorial Hospital /ID# 148193, San Diego, California, United States|Univ California, San Francisco /ID# 145889, San Francisco, California, United States|St. John's Health Center /ID# 148192, Santa Monica, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 148472, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 148194, Aurora, Colorado, United States|Associated Neurologists of Sou /ID# 147701, Fairfield, Connecticut, United States|Yale University /ID# 144170, New Haven, Connecticut, United States|Christiana Care Health Service /ID# 144127, Newark, Delaware, United States|Boca Raton Regional Hospital /ID# 163659, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 156764, Fort Lauderdale, Florida, United States|Baptist Hospital Miami /ID# 152451, Miami, Florida, United States|Advent Health /ID# 144128, Orlando, Florida, United States|Moffitt Cancer Center /ID# 144130, Tampa, Florida, United States|Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University /ID# 144015, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 147895, Chicago, Illinois, United States|The University of Chicago Medical Center /ID# 144158, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston Hospital /ID# 144017, Evanston, Illinois, United States|Northwestern Medicine Cancer Center - Warrenville /ID# 148476, Warrenville, Illinois, United States|Parkview Research Ctr, Hosp /ID# 144150, Fort Wayne, Indiana, United States|Univ Kansas Cancer Ctr - Overl /ID# 145895, Westwood, Kansas, United States|Maine Medical Partners Neurolo /ID# 160864, Scarborough, Maine, United States|Tufts Medical Center /ID# 145897, Boston, Massachusetts, United States|Massachusetts General Hospital /ID# 144145, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 148475, Boston, Massachusetts, United States|Wayne State University /ID# 145890, Detroit, Michigan, United States|Henry Ford Health System /ID# 145896, Detroit, Michigan, United States|St. Joseph Mercy Hospital /ID# 144143, Ypsilanti, Michigan, United States|Mmcorc /Id# 144146, Saint Louis Park, Minnesota, United States|Washington University-School of Medicine /ID# 144174, Saint Louis, Missouri, United States|Nebraska Methodist Hospital /ID# 144140, Omaha, Nebraska, United States|Univ Nebraska Med Ctr /ID# 145899, Omaha, Nebraska, United States|MD Anderson Cancer Center at Cooper - Camden /ID# 145891, Camden, New Jersey, United States|Rutgers Cancer Institute of NJ /ID# 148190, New Brunswick, New Jersey, United States|Columbia University Medical Center /ID# 144020, New York, New York, United States|Univ Rochester Med Ctr /ID# 144166, Rochester, New York, United States|Levine Cancer Ins, Carolina Me /ID# 144124, Charlotte, North Carolina, United States|University of Cincinnati /ID# 144164, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 144153, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 144023, Cleveland, Ohio, United States|The Ohio State University /ID# 144016, Columbus, Ohio, United States|University of Toledo /ID# 156763, Toledo, Ohio, United States|Univ Oklahoma HSC /ID# 144161, Oklahoma City, Oklahoma, United States|St. Luke's Hospital /ID# 148191, Bethlehem, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 147525, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 157623, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 144191, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center /ID# 145893, Philadelphia, Pennsylvania, United States|Allegheny General Hospital /ID# 144126, Pittsburgh, Pennsylvania, United States|University of Pennsylvania Medical Center - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina /ID# 144141, Charleston, South Carolina, United States|Austin Cancer Centers /ID# 151061, Austin, Texas, United States|Baylor Sammons Cancer Center /ID# 155542, Dallas, Texas, United States|The University of Texas Health Science Center at Houston /ID# 144013, Houston, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 144018, Houston, Texas, United States|Scott and White Medical Center /ID# 160743, Temple, Texas, United States|Intermountain Medical Center /ID# 144142, Murray, Utah, United States|University of Utah /ID# 144160, Salt Lake City, Utah, United States|Inova Health System /ID# 152956, Falls Church, Virginia, United States|Virginia Commonwealth University Medical Center Main Hospital /ID# 149014, Richmond, Virginia, United States|Virginia Mason - Seattle Orthapedics /ID# 144022, Seattle, Washington, United States|University of Washington /ID# 144162, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 144167, Madison, Wisconsin, United States|Froedtert Memorial Lutheran Hospital /ID# 144139, Milwaukee, Wisconsin, United States|Sanatorio Parque S.A. - Grupo /ID# 142825, Rosario, Santa Fe, Argentina|Instituto Med Alex Flem /ID# 142884, Buenos Aires, Argentina|Liverpool Hospital /ID# 144392, Liverpool, New South Wales, Australia|The Prince of Wales Hospital /ID# 144882, Randwick, New South Wales, Australia|Royal North Shore Hospital /ID# 143870, St Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 143860, Waratah, New South Wales, Australia|Southern Medical Day Care Centre /ID# 143868, Wollongong, New South Wales, Australia|Princess Alexandra Hospital /ID# 143857, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital /ID# 143867, Adelaide, South Australia, Australia|Calvary North Adelaide Hospita /ID# 143866, Adelaide, South Australia, Australia|St Vincent's Hospital Melbourne /ID# 143858, Fitzroy, Victoria, Australia|Austin Hospital /ID# 143859, Heidelberg, Victoria, Australia|St John Of God Subiaco Hospital /ID# 143869, Subiaco, Western Australia, Australia|Medizinische Universität Graz /ID# 141982, Graz, Steiermark, Austria|Medizinische Universitat Wien /ID# 141981, Vienna, Wien, Austria|Medizinische Universitat Innsbruck,Universitatsklinik fur Innere Medizin 1 /ID# 141984, Innsbruck, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus /ID# 141983, Linz, Austria|UCL Saint-Luc /ID# 141648, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 141645, Charleroi, Hainaut, Belgium|UZ Gent /ID# 141647, Gent, Oost-Vlaanderen, Belgium|Universitair Ziekenhuis Leuven /ID# 143872, Leuven, Vlaams-Brabant, Belgium|Centre Hospitalier Jolimont /ID# 143873, La Louvière, Belgium|CHU de Liege /ID# 162860, Liege, Belgium|UCL Mont Godinne /ID# 141644, Yvoir, Belgium|Liga Norte Rigrandese Contra o /ID# 143878, Natal, Rio Grande Do Norte, Brazil|Hospital Sao Lucas da PUCRS /ID# 143879, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 143876, Barretos, Sao Paulo, Brazil|Icesp /Id# 144031, São Paulo, Sao Paulo, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 143877, Rio de Janeiro, Brazil|Cancer Care Manitoba /ID# 149253, Winnipeg, Manitoba, Canada|Qe Ii Hsc /Id# 151600, Halifax, Nova Scotia, Canada|Juravinski Cancer Clinic /ID# 152117, Hamilton, Ontario, Canada|Victoria Hospital /ID# 144184, London, Ontario, Canada|The Ottawa Hospital /ID# 150120, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre /ID# 166277, Toronto, Ontario, Canada|Hospital Maisonneuve-Rosemont /ID# 149315, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Center /ID# 144187, Montreal, Quebec, Canada|Jewish General Hospital /ID# 144029, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 144027, Montréal, Quebec, Canada|CHU de Quebec-Universite Laval /ID# 144189, Quebec City, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 149771, Sherbrooke, Quebec, Canada|Anhui Provincial Hospital /ID# 166320, Hefei, Anhui, China|Sun Yat-Sen Uni Cancer Center /ID# 143919, Guangzhou, Guangdong, China|Xiangya Hospital Central South University /ID# 166791, Changsha, Hunan, China|The First Affiliated Hospital of Soochow University /ID# 165596, Suzhou, Jiangsu, China|Huashan Hospital of Fudan University /ID# 159999, Shanghai, Shanghai, China|'The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 165593, Hangzhou, Zhejiang, China|Sanbo Brain Hospital Capital M /ID# 166422, Beijing, China|Beijing Tian Tan Hospital /ID# 167160, Beijing, China|Peking Union Medical College H /ID# 157430, Beijing, China|1st Affiliated Hosp Fujian Med /ID# 159166, Fuzhou, China|Shengjing Hospital of China Medical University /ID# 167016, Shenyang, China|Tianjin Med Univ General Hosp /ID# 143923, Tianjin, China|Tongji Hosp Tongji Med College /ID# 163820, Wuhan, China|Fourth Military Medical University Tangdu Hospital, PLA /ID# 143920, Xi'an, China|Administradora del Country_S.A-Clinica Del Country /ID# 143881, Bogota, Cundinamarca, Colombia|Centro Medico Imbanaco de Cali /ID# 143882, Cali, Colombia|Hospital Pablo Tobon Uribe /ID# 143780, Medellín, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 147223, Montería, Colombia|Oncologos de Occidente SA /ID# 147713, Pereira, Colombia|Masarykuv onkologicky ustav /ID# 143884, Brno, Czechia|FN Hradec Kralove /ID# 143885, Hradec Kralove, Czechia|Krajska nemocnice Liberec, a.s. /ID# 142024, Liberec, Czechia|Univ Hosp Ostrava-Poruba /ID# 143883, Ostrava, Czechia|Fakultni Nemocnice v Motole /ID# 142023, Praha, Czechia|CHRU Lille - Hopital Claude Huriez /ID# 143915, Lille CEDEX, Hauts-de-France, France|CHU-Hopital Avicenne /ID# 143910, Bobigny, Ile-de-France, France|Gustave Roussy /ID# 143912, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 143914, St Herblain CEDEX, Loire-Atlantique, France|Hopital de la Timone /ID# 143911, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU de Nice /ID# 143916, Nice CEDEX 1, Provence-Alpes-Cote-d Azur, France|Insititut de Cancerologie /ID# 143908, Angers, France|Hopital Pitie Salpetriere /ID# 143917, Paris, France|Universitaetsklinik Heidelberg /ID# 143927, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Leipzig /ID# 143962, Leipzig, Sachsen, Germany|Universitaetsklinikum Knappschaftskrankenhaus Bochum GmbH /ID# 143961, Bochum, Germany|Universitaetsklinikum Tuebingen /ID# 143926, Tuebingen, Germany|Prince of Wales Hospital /ID# 143952, Hong Kong, Hong Kong|Beaumont Hospital /ID# 142969, Dublin, Ireland|Tel Aviv Sourasky Medical Center /ID# 143956, Tel Aviv-Yafo, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 143959, Haifa, Israel|Gastroenterology Institute, Division of Medicine /ID# 143958, Jerusalem, Israel|Rabin Medical Center /ID# 143957, Petakh Tikva, Israel|Sheba Medical Center /ID# 143960, Ramat Gan, Israel|AOU Citta della Salute Scienza /ID# 141801, Turin, Piemonte, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 141800, Milan, Italy|Istituto Oncologico Veneto /ID# 143821, Padova, Italy|Regina Elena National Cancer I /ID# 141795, Rome, Italy|National Cancer Center /ID# 141845, Goyang, Gyeonggido, Korea, Republic of|Severance Hospital /ID# 141846, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 143886, Seoul, Korea, Republic of|Samsung Medical Center /ID# 143887, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 141844, Seoul, Korea, Republic of|Hospital Zambrano Hellion /ID# 143845, San Pedro Garza Garcia, Nuevo Leon, Mexico|Vrije Universiteit Medisch Centrum /ID# 143889, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 141408, Groningen, Netherlands|Maastricht Universitair Medisch Centrum /ID# 143585, Maastricht, Netherlands|Haaglanden Medisch Centrum /ID# 141405, The Hague, Netherlands|Universitair Medisch Centrum Utrecht /ID# 141406, Utrecht, Netherlands|Canterbury District Health Boa /ID# 143861, Christchurch, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 143890, Wellington, New Zealand|CCA Braga - Hospital de Braga /ID# 141940, Braga, Portugal|Centro Hospitalar Universitário do Algarve, EPE - Hospital Faro /ID# 141939, Faro, Portugal|IPO Lisboa FG, EPE /ID# 141938, Lisboa, Portugal|Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 141941, Lisboa, Portugal|Centro Hospitalar Universitário de São João, EPE /ID# 142830, Porto, Portugal|Interregional clin.diagnostic cntr /ID# 141702, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|State budgetary healthcare institution Republican Clinical Oncology Dispensary /ID# 141706, UFA, Republic Of Bashkortosta, Kirovskaya Oblast, Russian Federation|GEMC - European Medical Center /ID# 141703, Moscow, Moskovskaya Oblast, Russian Federation|Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Resea /ID# 141707, Moscow, Moskva, Russian Federation|Scientific and Research Inst. /ID# 141701, Moscow, Moskva, Russian Federation|Federal State Treatment and rehabilitation center /ID# 141704, Moscow, Moskva, Russian Federation|Sverdlovsk Regional Oncology Center Dispensary /ID# 141700, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|National University Hospital /ID# 143933, Singapore, Singapore|National Cancer Ctr Singapore /ID# 143932, Singapore, Singapore|University of Free State, Universitas Annex (National Hospital Grounds) /ID# 144064, Bloemfontein, Free State, South Africa|Unitas Hospital /ID# 152936, Centurion, Gauteng, South Africa|The Oncology Centre /ID# 143950, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 143951, Cape Town, Western Cape, South Africa|Cape Town Oncology Trials /ID# 143948, Cape Town, Western Cape, South Africa|GVI Rondebosch Oncology Centre /ID# 143949, Cape Town, Western Cape, South Africa|Hospital Regional de Malaga /ID# 143902, Málaga, Malaga, Spain|Hospital Clinic de Barcelona /ID# 143906, Barcelona, Spain|Hospital Santa Creu i Sant Pau /ID# 143900, Barcelona, Spain|Hospital Clinico Universitario San Carlos /ID# 143901, Madrid, Spain|Hospital Universitario 12 de Octubre /ID# 143930, Madrid, Spain|Hospital Universitario HM Sanchinarro /ID# 143496, Madrid, Spain|Hospital General Universitario de Valencia /ID# 143903, Valencia, Spain|Universitaetsspital Zuerich /ID# 141887, Zurich, Zuerich, Switzerland|Kantonsspital Aarau /ID# 141885, Aarau, Switzerland|Ente Ospedaliero Cantonale /ID# 143936, Bellinzona, Switzerland|Inselspital, Universitaetsklinik /ID# 141886, Bern, Switzerland|National Taiwan Univ Hosp /ID# 143940, Taipei City, Taipei, Taiwan|Taipei Veterans General Hosp /ID# 143955, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 143941, Taoyuan City, Taiwan|Guy's and St Thomas' NHS Found /ID# 142652, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 154592, Birmingham, United Kingdom|Velindre Cancer Centre /ID# 141996, Cardiff, United Kingdom|Ninewells Hospital /ID# 141651, Dundee, United Kingdom|Western General Hospital /ID# 141802, Edinburgh, United Kingdom|St. James University Hospital /ID# 141653, Leeds, United Kingdom|University College Hospitals /ID# 142658, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust Freeman Hospital /ID# 141999, Newcastle Upon Tyne, United Kingdom|Royal Marsden Hospital /ID# 142827, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT02573324
545	NCT00960492	Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma		Completed	No Results Available	Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma	Drug: XL184|Drug: temozolomide|Radiation: Radiation Therapy	"Evaluate the safety and tolerability of oral administration of XL184 added to first-line treatment for subjects with newly diagnosed GB|Determine the maximum tolerated dose (MTD) of oral XL184 when added to the concurrent phase of treatment with TMZ and RT and when added to the maintenance phase of treatment with TMZ for subjects with newly diagnosed GB|Determine the safety and tolerability of XL184 when administered in combination with first-line treatment throughout the concurrent, rest and maintenance phases in an expanded MTD cohort|Evaluate the plasma pharmacokinetics of XL184 and TMZ when XL184 is administered in combination with TMZ, and of XL184 when it is administered alone, in subjects with newly diagnosed GB|Evaluate the pharmacodynamic effects of XL184 (with or without TMZ) and RT in the first line treatment of subjects with GB.|Evaluate the preliminary efficacy of XL184 (with or without TMZ) and RT in the MTD expansion cohort in the first line treatment of subjects with GB"	Exelixis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	26	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XL184-002	Sep-09	Nov-12	Oct-13	17-Aug-09		22-Sep-14	"UCLA, Los Angeles, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Beth Israel Medical Center, New York, New York, United States|Duke University Medical Center; The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Virginia Health System/Division of Neuro-Oncology, Charlottesville, Virginia, United States|University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00960492
546	NCT03849105	131I-IPA and Concurrent XRT in Recurrent GBM	IPAX-1	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Radiation: 4-L-[131I]iodo-phenylalanine (131I-IPA)	Safety and tolerability parameter Adverse Events|Safety parameter heart rate|Safety parameter blood pressure|Safety parameter Liver function test|Safety parameter Renal function test|Safety parameter Full Blood Count|To evaluate the maximum tolerated dose (MTD) of 131I -IPA administered concomitantly to 2nd line XRT in recurrent GBM 2|To evaluate the efficacy of a fractionated administration of 131I-IPA|Dosimetry|To explore the antineoplastic effect of 131I-IPA + XRT combination therapy|To explore the occurrence and frequency of pseudo-progression (PP) in response to 131I-IPA + XRT combination therapy|To explore the cognitive function of participants	Telix International Pty Ltd	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	44	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	131I-IPA-TLX-101-001	9-Apr-19	31-Jul-22	31-Oct-22	21-Feb-19		29-Nov-21	"Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia|Kepler University Clinic, Linz, Austria|Medical University of Vienna, Vienna, Austria|The Netherlands Cancer Institute, Amsterdam, Netherlands|UMC Utrecht Cancer Center, Utrecht, Netherlands"		https://ClinicalTrials.gov/show/NCT03849105
547	NCT01135875	Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients		Completed	No Results Available	Glioblastoma Multiforme|Healthy Volunteers	Other: GBM Patients|Other: Normal Controls	Identification of Human GBM CD Antigen Signature.|Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood.|Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.|Prospective Evaluation of the Routine Medical History of GBM Patients.	University of Florida	All	"18 Years to 89 Years   (Adult, Older Adult)"		130	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	CTC-01	Oct-09	Apr-13	Apr-13	3-Jun-10		17-Oct-13	"University of Florida, Gainesville, Florida, United States"		https://ClinicalTrials.gov/show/NCT01135875
548	NCT00864864	Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|Brain Tumor	Drug: Sunitinib	"To assess the ability of sunitinib to achieve a target tumor: plasma ration greater than or equal to 0.2 in patients with recurrent GM.|To determine if there is an association between growth factor receptor inhibition and tumor phenotype, tumor: plasma ratio of sunitinib and overall survival."	Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	8	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	06-307	May-07	May-11	May-13	19-Mar-09		7-Jul-16	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00864864
549	NCT03514069	Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma		Recruiting	No Results Available	Glioma|Glioblastoma	Drug: ruxolitinib|Radiation: radiation|Drug: temozolomide	Maximum tolerated dose (MTD) of ruxolitinib with radiation in study patients|Maximum tolerated dose (MTD) of ruxolitinib with radiation and daily Temozolomide in study patients|Number of patient study specific adverse events as a measure of safety|Number of patients who have experienced progression free survival as defined by the response assessment in neuro-oncology (RANO) criteria|Average time patients stayed alive on study	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3317	5-Jun-18	Dec-21	Dec-21	2-May-18		4-Jun-21	"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT03514069
550	NCT03778294	18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy		"Active, not recruiting"	No Results Available	Glioblastoma|Malignant Glioma	Procedure: Computed Tomography|Other: Fluorodopa F 18|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Radiation: Proton Beam Radiation Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Temozolomide	Overall survival (OS)|Progression free survival|Progression Free Survival|Incidence of adverse events (AEs)	Mayo Clinic|National Cancer Institute (NCI)	All	65 Years and older   (Older Adult)	Phase 2	43	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1774|NCI-2018-02800|P30CA015083	28-Mar-19	3-Jun-21	26-Nov-22	19-Dec-18		9-Dec-21	"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT03778294
551	NCT05039281	Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma		Not yet recruiting	No Results Available	Recurrent Glioblastoma|Recurrent Gliosarcoma	Biological: Atezolizumab|Drug: Cabozantinib	Progression-free survival (PFS)|Objective response rate|Incidence of adverse events	M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-0041|NCI-2021-09119	30-Dec-21	15-Feb-24	15-Feb-24	9-Sep-21		24-Nov-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT05039281
552	NCT05017610	Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma		Not yet recruiting	No Results Available	Recurrent Glioblastoma|Recurrent Gliosarcoma	Drug: Liothyronine|Drug: Lomustine|Drug: Methimazole	Incidence of adverse events|Overall response rate|Progression free survival|Overall survival	Emory University	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00002497|NCI-2021-02249|WINSHIP5264-21|P30CA138292	31-Dec-21	1-Feb-25	1-Feb-27	24-Aug-21		24-Aug-21	"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT05017610
553	NCT02575027	Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma|Recurrent Brain Neoplasm	Radiation: Palliative Radiation Therapy|Other: Questionnaire Administration|Radiation: Radiation Therapy Treatment Planning and Simulation	"Accuracy of dose delivery|Normal tissue dose volume|Patient comfort with treatment time, determined by a patient-completed questionnaire completed at the end of each fraction"	Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	10	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-001086|NCI-2015-01449|P30CA016042	12-Nov-14	20-Jun-18	20-Jun-18	14-Oct-15		28-Feb-19	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT02575027
554	NCT02466828	qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.		Completed	No Results Available	Glioblastoma|Hypoxia	Drug: Feraheme®	Oxygen saturation in GBM with qBOLD MRI and its correlation with histological markers of tissue hypoxia and angiogenesis|Oxygen saturation in GBM with qBOLD MRI and its correlation with targeted intraoperative oxygen measurement	Sunnybrook Health Sciences Centre|Unity Health Toronto	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	127-2014	Mar-15	Apr-18	Apr-18	9-Jun-15		18-Apr-18	"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT02466828
555	NCT01520870	"Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT."		Completed	Has Results	"Glioblastoma|Brain Tumor, Recurrent"	Drug: PF-299804 (Dacomitinib)	Progression-free Survival (PFS) at Six Months (PFS6m)|Safety and Tolerability of Oral Administration of PF-00299804.|Anti-tumor Response|Overall Survival (OS)|Response Duration|Changes in the Use of Glucocorticoids|Changes in Neurological Status.	Grupo Español de Investigación en Neurooncología|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	49	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEINO 11	Feb-12	Apr-15	9-Mar-17	30-Jan-12	6-Jul-21	6-Jul-21	"Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Institut Català D'Oncologia L'Hospitalet (Ico), L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario A Coruña, A Coruna, Coruña (A), Spain|Hospital Del Mar, Barcelona, Spain|Hospital de La Santa Creu I Sant Pau, Barcelona, Spain|Complejo Hospitalario Regional Virgen de Las Nieves, Granada, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil, Palmas de Gran Canaria, Spain|Hospital Universitario Y Politécnico La Fe, Valencia, Spain"		https://ClinicalTrials.gov/show/NCT01520870
556	NCT04477200	Mycophenolate Mofetil Combined With Radiation Therapy in Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma|Recurrent Gliosarcoma	Drug: Mycophenolate Mofetil|Radiation: Radiation Therapy|Procedure: Re-resection (as part of standard of care)	Phase 0: Concentration of mycophenolic acid (MPA) in tumor tissue|Phase 1: Number of participants who experience dose-limiting toxicities (DLTs) at each dose level|Phase 0: Concentrations of guanosine triphosphate (GTP) in tumor tissue|Phase 0: Concentrations of guanosine triphosphate (GTP) in plasma|Phase 1: Adverse events associated with MMF + re-irradiation|Phase 1: Overall Response Rate|Phase 1: Median Progression Free Survival (PFS)|Phase 1: Median Freedom from Local Progression (FFLP)|Phase 1: Median Overall Survival (OS)	University of Michigan Rogel Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	38	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2019.192|HUM00175785	5-Aug-20	Oct-24	Oct-27	20-Jul-20		19-Nov-20	"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States"		https://ClinicalTrials.gov/show/NCT04477200
557	NCT02375841	"Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers"		"Active, not recruiting"	No Results Available	Brain Cancer|Glioblastoma	"Behavioral: psychometric tests, questionnaires and neurocognitive assessments"	"number of responses from patients, to 3 yes/no questions|number of responses from caregivers to 3 yes/no questions|number of responses from physicians to 3 yes/no questions"	Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University	All	"18 Years and older   (Adult, Older Adult)"		309	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	15-034	Feb-15	Feb-23	Feb-23	3-Mar-15		17-Dec-21	"Henry Ford Hospital, Detroit, Michigan, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memoral Sloan Kettering Cancer Center, New York, New York, United States|University of Vermont Medical Center, Burlington, Vermont, United States"		https://ClinicalTrials.gov/show/NCT02375841
558	NCT03174197	Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma	Drug: Atezolizumab|Radiation: Radiation Therapy|Drug: Temozolomide	Dose-limiting toxicities (DLTs) (Phase I)|Overall survival (OS) (Phase II)|Incidence of adverse events|Overall response rate|Duration of response (DoR)|Progression-free survival (PFS)	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	80	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0867|NCI-2018-02629|P30CA016672	30-Jun-17	30-Jun-21	30-Jun-21	2-Jun-17		15-Jan-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03174197
559	NCT03224104	Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma	STEAM	"Active, not recruiting"	No Results Available	"Astrocytoma, Grade III|Glioblastoma"	Drug: TG02|Radiation: Radiation Therapy|Drug: Temozolomide	Maximum Tolerated Dose (MTD)|Progression-free survival at 6 months (PFS-6)|Progression-free survival|Overall survival (OS)|Response to treatment|Neurological progression-free survival|Toxicity according CTCAE version 4.0|Molecular markers	"European Organisation for Research and Treatment of Cancer - EORTC|Tragara Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	71	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-1608-BTG|2017-001029-42|TG02-402	12-Jun-18	Jan-22	Jan-22	21-Jul-17		21-Sep-21	"Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH uniklinieken, Vienna, Austria|CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron, France|CHRU de Lille, Lille, France|Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone, Marseille, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der J.W. Goethe Universitaet-Klinik und Poliklinik fur Neurochirurgie, Frankfurt, Germany|Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg, Germany|Universitaetskliniken Regensburg - Universitaetsklinikum Regensburg, Regensburg, Germany|Erasmus MC Cancer Institute - location Daniel den Hoed, Rotterdam, Netherlands|UniversitaetsSpital Zurich, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT03224104
560	NCT03681028	Feasibility of Individualized Therapy for Recurrent GBM		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Individualized therapy	Percentage of patients who have successfully initiated therapy|Overall survival at 9 months (OS)|Incidence of treatment-related Adverse Events (AEs)|Progression-Free Survival (PFS) at 6 months|Progression-Free Survival (PFS)|Time to Treatment Failure (TTF)|Overall survival (OS)	"Jennifer Clarke|University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18108|NCI-2018-02194	19-Dec-18	31-Dec-22	31-Jan-27	21-Sep-18		10-Nov-21	"University of California San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT03681028
561	NCT00936052	Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma	HBO	Unknown status	No Results Available	Glioblastomas|Gliosarcoma	Other: Hyperbaric Oxygen Therapy	"to generate preliminary data of the anti-tumor efficacy of hyperbaric oxygenation in conjunction with radiotherapy and chemotherapy,to determine median progression-free survival, to determine median survival and to determine median 2 year survival.|to determine the health related quality of life of this treatment regimen and its influence upon subjects'' perceived level of traumatic stress throughout the course of treatment."	"Neurological Surgery, P.C."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LIBTC-2008-2	Dec-08	Dec-10	Dec-10	9-Jul-09		16-Jul-10	"Long Island Brain Tumor Center at Neurological surgery P.C., Commack, New York, United States|Long Island Brain Tumor Center at Neurological Surgery P.C., Great Neck, New York, United States"		https://ClinicalTrials.gov/show/NCT00936052
562	NCT01822275	Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme	GCC 1224	Terminated	No Results Available	Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)	Drug: Chemotherapy with Temodar.|Radiation: Radiation therapy	Efficacy of low-dose whole brain RT (WBRT)in patients with GBM|Radiographic (CT-MRI) response assesment and treatment failure patterns of patients with GBM	"University of Maryland, Baltimore"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	23	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00053043	May-13	Sep-19	Sep-19	2-Apr-13		4-Nov-20	"Ummc Msgcc, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01822275
563	NCT04790097	FET-PET Directed Simultaneous In-field Boost for Primary GBM	dualFETboost	Completed	No Results Available	Glioblastoma Multiforme	Radiation: Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost	Overall survival|Progression Free Survival|Objective response|Location of treatment failure|Radiation necrosis|Side effects	Prof. Franciszek Lukaszczyk Memorial Oncology Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	17	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FET-PET SIB Boost	21-Feb-17	30-Dec-19	30-Dec-20	10-Mar-21		6-May-21	"The Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland"		https://ClinicalTrials.gov/show/NCT04790097
564	NCT02455557	SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma		"Active, not recruiting"	Has Results	Glioblastoma|Gliosarcoma	Other: Laboratory Biomarker Analysis|Drug: Montanide ISA 51 VG|Biological: Sargramostim|Biological: SVN53-67/M57-KLH Peptide Vaccine|Drug: Temozolomide	"Progression-free Survival (PFS)|Immune Responses to SurVaxM and Predictors of Response|Incidence of Grade 3 or 4 Toxicities, According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4|Overall Survival"	Roswell Park Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	66	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 259614|NCI-2015-00694|P30CA016056	4-May-15	23-Oct-19	30-Dec-21	28-May-15	1-Feb-21	22-Jun-21	"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/57/NCT02455557/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02455557
565	NCT03367715	"Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma"		"Active, not recruiting"	No Results Available	MGMT-unmethylated Glioblastoma (GBM)|GBM	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy (RT)	1-yr OS|2-year Overall Survival (OS)|Median Overall Survival (OS)|Median Progression Free Survival (PFS)	NYU Langone Health	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-00218	7-Feb-18	20-May-21	May-22	11-Dec-17		15-Nov-21	"New York University School of Medicine, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03367715
566	NCT02133183	Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib|Procedure: Therapeutic Conventional Surgery	"Proportion of patients who achieve a drug concentration >= 70 nM in contrast enhancing tumor tissue|Difference in ratio of the S6 phosphorylation over the total between the two groups|Difference of the pS6 concentration between the two groups|Sapanisertib concentration in non-enhancing tumor|Sapanisertib concentration in blood|Inhibition TORC1/2 in the non-enhancing components of the tumor as determined by modulation of RPS6 pS235 in reverse phase protein array (RPPA) assays|Pharmacodynamic marker such as pS6 (by immunohistochemistry), p4EBP, pmTOR, and AKTpSer473 compared to the control|Incidence of toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0|Tumor response|Progression-free survival (PFS)|Overall survival (death)"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	40	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-00907|ABTC-1301|1301|U01CA137443|UM1CA137443	12-May-14	31-Jan-20		7-May-14		26-Jul-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02133183
567	NCT05116137	The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors	RESIST	Not yet recruiting	No Results Available	Glioblastoma Multiforme of Brain|Brain Cancer	Behavioral: Circuit-based resistance exercise (CRT)	"Functional Performance|Grip strength|Body Mass Index (BMI)|Body composition and Muscle Mass|Muscle Mass|Aerobic fitness|Physical activity|Physical, functional, emotional, and social/family quality of Life|Fatigue|Cognitive functioning 1|Cognitive functioning 2|General Health (EuroQol) 5 Dimension - 5 Level|General Health (EuroQol) Visual Analog Scale"	Nova Scotia Health Authority|Canadian Cancer Society (CCS)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	24	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	NSH RESIST Trial	15-Jan-22	31-Dec-24	31-Dec-24	10-Nov-21		10-Nov-21			https://ClinicalTrials.gov/show/NCT05116137
568	NCT01112527	PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|GBM|Glioblastoma Multiforme	Drug: PF-00299804	Progression-Free Survival|Ability of PF-00299804 to cross the blood-brain barrier|Safety and tolerability|Anti-tumor response	Massachusetts General Hospital|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Henry Ford Hospital|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	58	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	09-468|WS573383	Apr-10	Sep-15	Sep-15	28-Apr-10		16-Aug-18	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cleveland Clinic, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01112527
569	NCT05168423	CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM		Not yet recruiting	No Results Available	Glioblastoma	Drug: 5x10(7) CART-EGFR-IL13Ra2|Drug: 1x107 CART-EGFR-IL13Ra2|Drug: 1x10(8) CART-EGFR-IL13Ra2|Drug: 5x108 CART-EGFR-IL13Ra2|Drug: Cyclophosphamide|Drug: Fludarabine	Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V5.0|Number of subjects with dose-limiting toxicities|Determination of maximum tolerated dose assessed by collection of adverse events as graded by CTCAE.|Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Proportion of subjects who enroll on the study who receive study treatment|Frequency of manufacturing failures as determined by production of study treatment that meets protocol defined targeted dose	University of Pennsylvania|Tmunity Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16321	19-Dec-21	19-Dec-24	19-Dec-39	23-Dec-21		23-Dec-21			https://ClinicalTrials.gov/show/NCT05168423
570	NCT04388475	Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Malignant Glioma|Brain Glioblastoma	Drug: OKN-007|Drug: Temozolomide (TMZ)	Incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide|Number of subjects with decreased neurological function|Number of subjects with decreased performance|Overall Survival (OS) rate|Radiographic response rate|Progression Free Survival (PFS) rate|Cmax of OKN-007 in blood plasma|AUC of OKN-007 in blood plasma|Tmax of OKN-007 in blood plasma|Cmax of Temozolomide in blood plasma|AUC of Temozolomide in blood plasma|Tmax of Temozolomide in blood plasma	"Oblato, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OKN-007-IV-RMG-201	12-Jun-20	25-May-22	25-Oct-22	14-May-20		15-Nov-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Providence Saint John's Health Center - John Wayne Cancer Institute, Santa Monica, California, United States|Swedish Medical Center, Englewood, Colorado, United States|AdventHealth Orlando, Orlando, Florida, United States|Henry Ford Health System, Detroit, Michigan, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|The University of Toledo, Toledo, Ohio, United States|The University of Oklahoma, Oklahoma City, Oklahoma, United States"		https://ClinicalTrials.gov/show/NCT04388475
571	NCT04868396	Patient-derived Glioma Stem Cell Organoids		"Active, not recruiting"	No Results Available	Glioblastoma	Procedure: Tumor biopsy	Organoid cultures|Long term culturing and biobanking conditions for GM organoids|Intra-organoid heterogeneity reflects intra-tumoral genetic and epigenetic heterogeneity|GM organoid model|Define oncogenic drivers|Organoid platform|ctDNA	Maastricht Radiation Oncology	All	"18 Years and older   (Adult, Older Adult)"		60	Other	Observational	Observational Model: Other|Time Perspective: Prospective	Glioma stem cell organoids	10-Apr-21	1-Sep-21	1-Jan-22	30-Apr-21		30-Apr-21	"Maastricht UMC+, Maastricht, Limburg, Netherlands|Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands"		https://ClinicalTrials.gov/show/NCT04868396
572	NCT02815410	Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: levetiracetam	6 months Progression free survival|Overall survival	Seoul National University Hospital	All	"20 Years to 76 Years   (Adult, Older Adult)"	Phase 2	73	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	cykim	Jul-16	Jun-19	Jun-22	28-Jun-16		28-Jun-16			https://ClinicalTrials.gov/show/NCT02815410
573	NCT01954576	NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme		Terminated	No Results Available	Glioblastoma|Brain Neoplasms	Device: NovoTTF-100A|Procedure: Quality-of-life assessment|Genetic: Laboratory biomarker analysis	ORR (CR + PR + SD) (bevacizumab-naive)|ORR (CR + PR + SD) (bevacizumab-refractory)|Genetic signature of response (CR + PR + SD)|Genetic signature of response (CR + PR) and SD|Progression-free survival in bevacizumab-naïve and bevacizumab-refractory glioblastoma patients|Quality of Life	University of Florida|Washington University School of Medicine|NovoCure Ltd.	All	"22 Years and older   (Adult, Older Adult)"	Not Applicable	21	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB201500287|09-27-2013|201306042|OCR14655	10-Oct-13	14-May-21	14-May-21	7-Oct-13		2-Dec-21	"University of Florida, Gainesville, Florida, United States|Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01954576
574	NCT02152982	Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma	Other: Laboratory Biomarker Analysis|Other: Placebo Administration|Other: Quality-of-Life Assessment|Drug: Temozolomide|Drug: Veliparib	Overall survival (OS)|Interaction with Optune device|Progression-free survival (PFS)|Objective tumor response|Overall adverse event rates for grade 3 or higher adverse events|Change in quality of life (QOL)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	447	NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCI-2014-00616|A071102|CALGB-A071102|P50CA108961|U10CA180821|U10CA031946	15-Dec-14	1-Dec-21	15-Dec-22	2-Jun-14		17-Dec-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente-Fresno, Fresno, California, United States|Saint Jude Medical Center, Fullerton, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Northbay Cancer Center, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Kaiser Permanente-Franklin, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Kaiser Permanente-Rock Creek, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Kaiser Permanente-Lone Tree, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Midstate Medical Center, Meriden, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Lakeland Regional Health Hollis Cancer Center, Lakeland, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Orlando Health Cancer Institute, Orlando, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Edward Hospital/Cancer Center, Naperville, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Edward Hospital/Cancer Center?Plainfield, Plainfield, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Baptist Health Louisville, Louisville, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|The NeuroMedical Center-Clinic, Baton Rouge, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine, United States|Maine Center for Cancer Medicine-Topsham, Topsham, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|TidalHealth Peninsula Regional, Salisbury, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Simonds-Sinon Regional Cancer Center, Fitchburg, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Ascension Providence Hospitals - Novi, Novi, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Ascension Providence Hospitals - Southfield, Southfield, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Saint Luke's Hospital, Chesterfield, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Faith Regional Health Services Carson Cancer Center, Norfolk, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Nebraska Cancer Specialists - Omaha, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Renown Regional Medical Center, Reno, Nevada, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Solinsky Center for Cancer Care, Manchester, New Hampshire, United States|Portsmouth Regional Hospital, Portsmouth, New Hampshire, United States|John F Kennedy Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Valley Health System-Hematology/Oncology, Westwood, New Jersey, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mary Imogene Bassett Hospital, Cooperstown, New York, United States|Mount Sinai Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Vidant Oncology-Kinston, Kinston, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Cleveland Clinic Mercy Hospital, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio, United States|Miami Valley Hospital North, Dayton, Ohio, United States|Armes Family Cancer Center, Findlay, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Orion Cancer Care, Findlay, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|Mercy Health - Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Jefferson Abington Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|UPMC Susquehanna, Williamsport, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Roper Hospital, Charleston, South Carolina, United States|Charleston Oncology - Roper, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-North Charleston, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Charleston, South Carolina, United States|Charleston Oncology - Saint Francis, Charleston, South Carolina, United States|Lowcountry Hematology Oncology PA-West Ashley, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Lowcountry Hematology Oncology PA-Mount Pleasant, Mount Pleasant, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Avera Cancer Institute-Aberdeen, Aberdeen, South Dakota, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|University of Tennessee - Knoxville, Knoxville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Danville Regional Medical Center, Danville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Jefferson Healthcare, Port Townsend, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Aurora Cancer Care-Southern Lakes VLCC, Burlington, Wisconsin, United States|HSHS Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Aurora Health Center-Fond du Lac, Fond Du Lac, Wisconsin, United States|Aurora Health Care Germantown Health Center, Germantown, Wisconsin, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Mercyhealth Hospital and Cancer Center - Janesville, Janesville, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Bay Area Medical Group-Marinette, Marinette, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Medical Center, Marshfield, Wisconsin, United States|Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Lakeview Medical Center-Marshfield Clinic, Rice Lake, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Vince Lombardi Cancer Clinic-Sheboygan, Sheboygan, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Vince Lombardi Cancer Clinic-Two Rivers, Two Rivers, Wisconsin, United States|Aurora Cancer Care-Waukesha, Waukesha, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Marshfield Medical Center - Weston, Weston, Wisconsin, United States|Fundacion De Investigacion de Diego, San Juan, Puerto Rico"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/82/NCT02152982/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02152982
575	NCT03939858	Bioenergetic Profiling and Cognition in GBM Patients		Recruiting	No Results Available	Glioblastoma	Procedure: Cognitive Assessment|Diagnostic Test: Blood Collection|Diagnostic Test: Bioenergetic Profiling	Number of Patients Completing Bioenergetics Profiling|Proportion of Participants with Decline in Cognitive Function|Bioenergetics Profiling Testing - Seahorse XFe24 Analyzer|Bioenergetics Profile Testing - Oroboros O2K	Wake Forest University Health Sciences	All	"18 Years and older   (Adult, Older Adult)"		10	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRB00058347|NCI-2019-02984|WFBCCC 01219	24-Oct-19	Apr-22	Jul-22	7-May-19		27-Dec-21	"Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03939858
576	NCT04729959	"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma"		Recruiting	No Results Available	"Diffuse Astrocytoma, IDH-Wildtype|Recurrent Glioblastoma"	Biological: Atezolizumab|Procedure: Conventional Surgery|Radiation: Fractionated Stereotactic Radiation Therapy|Biological: Tocilizumab	"Dose-limiting toxicities (Safety Run-In)|Maximum-tolerated dose (Safety Run-In)|Objective radiographic response rate (Phase II, Non-Surgical Cohort)|Progression-free survival (PFS) (Phase II, Non-Surgical Cohort)|Overall survival (Phase II, Non-Surgical Cohort)|Progression-free survival (Phase II, Non-Surgical Cohort)|Overall survival (Phase II, Surgical Cohort)|Incidence of adverse events (Surgical Cohort and Non-Surgical Cohort)"	National Cancer Institute (NCI)|NRG Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	12	NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2021-00410|NRG-BN010|U10CA180868	6-Jul-21	1-Jun-25	1-Jun-25	29-Jan-21		3-Dec-21	"Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Illinois CancerCare - Washington, Washington, Illinois, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT04729959
577	NCT00250211	Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide		Completed	No Results Available	Glioblastoma|Glioma	Procedure: Functional MRI imaging and tomotherapy	determine tumor response and pattern of failure using functional MRI imaging|time to disease progression|distinguish residual tumor from treatment-related necrosis|survival|acute late toxicity of tomotherapy and hypofractionation	AHS Cancer Control Alberta|Cross Cancer Institute	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1|Phase 2	26	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CNS-09-0027 / ethics 21780	Mar-05	Mar-11	Apr-11	8-Nov-05		24-Feb-16	"Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT00250211
578	NCT03782415	Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma		Recruiting	No Results Available	Glioblastoma|Recurrent Glioblastoma|GBM|Newly Diagnosed Glioblastoma	Drug: MN-166|Drug: Temozolomide	"Evaluate safety and tolerability of ibudilast and temozolomide combination treatment|Evaluate efficacy of ibudilast and TMZ combination treatment|Evaluate Tmax|Cmax|AUC|Terminal rate constant|Terminal half-life|Maximum tolerated dose determination|Evaluate the safety of fixed-dose ibudilast in combination with TMZ|Evaluate overall survival, response rate, and median 6-month progression-free survival (PFS6)"	MediciNova	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	50	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MN-166-GBM-1201	29-Dec-18	Dec-21	Dec-22	20-Dec-18		5-Aug-21	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT03782415
579	NCT04802447	SurVaxM Expanded Access Protocol	EAP	No longer available	No Results Available	Glioblastoma	Drug: SurVaxM		Roswell Park Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"			Other	Expanded Access:Treatment IND/Protocol		I 546319				17-Mar-21		16-Nov-21			https://ClinicalTrials.gov/show/NCT04802447
580	NCT04313842	A Explorative Study to Evaluate the Clinical Feasibility of AVATAMED		Recruiting	No Results Available	Glioblastoma	Device: AVATAMED	6 month PFS rate	Doo-Sik Kong|Samsung Medical Center	All	"19 Years to 90 Years   (Adult, Older Adult)"		40	Other	Observational	Observational Model: Other|Time Perspective: Prospective	2018-12-071	1-Jul-19	1-Jun-21	1-Jan-22	18-Mar-20		18-Mar-20	"Samsung Medical Center, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT04313842
581	NCT00734526	Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma		Terminated	No Results Available	Glioblastoma|Gliosarcoma	Drug: Temozolomide|Radiation: Radiation|Drug: Sorafenib	Phase I: Sorafenib Maximum Tolerated Dose (MTD)|Second MTD|Phase II: Time to Progression	M.D. Anderson Cancer Center|Bayer	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008-0059|NCI-2012-01617	18-Dec-08	Dec-12	Dec-12	14-Aug-08		9-Nov-18	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00734526
582	NCT03454295	Easing Psychosocial Burden for Informal Caregivers		"Active, not recruiting"	No Results Available	Glioblastoma	Behavioral: Focus Group|Behavioral: Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|Behavioral: Enhanced Usual Care / EUC	Feasibility of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) delivered to caregivers of participants with GBM|Acceptability of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) delivered to caregivers of participants with GBM	Memorial Sloan Kettering Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	64	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	18-075	12-Feb-18	Aug-22	Aug-22	5-Mar-18		16-Dec-21	"Memorial Sloan Kettering Commack (Consent only), Commack, New York, United States|Memoral Sloan Kettering Westchester (Consent only), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03454295
583	NCT01813877	Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma		Completed	No Results Available	Glioma|Glioblastoma	Radiation: FDOPA PET/CT	Diagnostic accuracy compared to standard diagnostics without PET|Impact of FDOPA PET on patient management	Jonsson Comprehensive Cancer Center|Kaiser Permanente|The Methodist Hospital Research Institute	All	"18 Years to 99 Years   (Adult, Older Adult)"	Not Applicable	37	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	12-000939|NCI-2013-01421|FDOPA12-000939	22-Aug-12	14-Jan-20	14-Jan-20	19-Mar-13		27-Jul-20	"UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT01813877
584	NCT02337686	Pembrolizumab in Treating Patients With Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Recurrent Glioblastoma|Recurrent Gliosarcoma	Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Other: Pharmacological Study|Procedure: Therapeutic Conventional Surgery	Progression free survival at 6 months|Time to progression|Overall survival|Response rate|Rate of toxicities|Changes in peripheral blood mononuclear cells immune response kinetics|Changes in circulating cytokines to pembrolizumab	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0820|NCI-2015-00174|P30CA016672	28-Apr-15	31-Dec-22	31-Dec-22	14-Jan-15		8-Dec-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02337686
585	NCT01903330	ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma	Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Oral Control (Sucrose pill)|Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Drug: Bevacizumab/Bevacizumab Biosimilar	"Overall Survival at 12 months of patients with recurrent, bevacizumab naïve glioblastoma treated with ERC1671 in combination with GM-CSF and cyclophosphamide plus bevacizumab as compared with patients receiving bevacizumab plus placebo controls.|Rate of Progression-Free Survival|Immune Response|Percentage of Grade 3-5 Adverse Events|Rate of Radiographic Response as assessed using MacDonald Criteria or IRANO"	"University of California, Irvine|Epitopoietic Research Corporation"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	84	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	UCI13-14 ERC1671-H02 2013-9863|UCI 13-14|2013-9863	Mar-14	Mar-23	Mar-23	19-Jul-13		21-Jul-21	"University of California, Irvine, Orange, California, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01903330
586	NCT03419403	UNITE Study: Understanding New Interventions With GBM ThErapy		Terminated	Has Results	Glioblastoma Multiforme	Drug: Steroid eye drops|Drug: Vasoconstrictor eye drops|Other: Cold compress|Drug: Ophthalmic steroid ointment|Drug: Depatuxizumab mafodotin|Drug: Temozolomide|Radiation: Radiation	Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management|Maximum Change From Baseline on the Logarithm of the Minimum Angle of Resolution (LogMAR) Scale|Time to Bandage Contact Lens (BCL) Intervention|Number of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE)|Cumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment|Treatment-Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit|Change From Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale After Bandage Contact Lens (BCL) Intervention|Percentage of Participants That Recovered to <3-line Decline From Baseline (≤ +0.3 LogMAR) in Visual Acuity After Bandage Contact Lens (BCL) Intervention|Number of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention|Time to Restart Depatuxizumab Mafodotin if Interrupted Due to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention|Treatment Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit After Bandage Contact Lens (BCL) Intervention|Time to Ocular Side Effect (OSE) Symptom Resolution After Drug Discontinuation (Reversibility)|Time to Re-initiation of Depatuxizumab Mafodotin After Dose Interruption	AbbVie	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16-534|2017-003171-64	30-Jul-18	5-Sep-19	3-Mar-20	5-Feb-18	14-Apr-21	14-Apr-21	"Usc /Id# 164235, Los Angeles, California, United States|Moffitt Cancer Center /ID# 164234, Tampa, Florida, United States|Rush University Medical Center /ID# 171003, Chicago, Illinois, United States|Northshore University Health System-Evanston /ID# 164221, Evanston, Illinois, United States|CDH-Delnor Health System /ID# 169909, Warrenville, Illinois, United States|Columbia University Medical Center /ID# 164220, New York, New York, United States|Levine Cancer Ins, Carolina Me /ID# 171271, Charlotte, North Carolina, United States|UT Health Science Ctr-Houston /ID# 164223, Houston, Texas, United States|Baylor Scott & White Medical Center- Temple /ID# 170792, Temple, Texas, United States|Royal North Shore Hospital /ID# 169673, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 169672, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 169674, Herston, Queensland, Australia|Austin Hospital /ID# 169671, Heidelberg, Victoria, Australia|Universitaetsklinik Heidelberg /ID# 169970, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Leipzig /ID# 169969, Leipzig, Sachsen, Germany|Klinikum Univ. Regensburg /ID# 169963, Regensburg, Germany|Universitatsklinikum Tubingen /ID# 169965, Tuebingen, Germany|Vrije Universiteit Medisch Centrum /ID# 170152, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 170149, Utrecht, Netherlands|Guy's and St Thomas' NHS Found /ID# 207752, London, London, City Of, United Kingdom|Queen Elizabeth Hospital - BIRMINGHAM /ID# 200657, Birmingham, United Kingdom|Castle Hill Hospital /ID# 200662, Cottingham, United Kingdom"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/03/NCT03419403/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03419403/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT03419403
587	NCT04223999	Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)	OptimalTTF-2	Recruiting	No Results Available	Recurrent Glioblastoma	Procedure: Skullremodeling surgery|Other: Control	OS12|Median OS|Median PFS|OS24|OS36|PFS6|ORR|Standardised and verified quality of life assessment questionnaires (QLQ-C30 and QLQ-BN20) for cancer and brain tumor patients.|Steroid dose|KPS|AE	"Anders Rosendal Korshøj|NovoCure GmbH|Odense University Hospital|Aalborg University Hospital|Rigshospitalet, Denmark|University of Aarhus"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	150919V1|68928/1-10-72-214-19|658876/1-16-02-277-19|2019081231	1-Oct-20	1-Mar-23	1-Mar-24	13-Jan-20		20-Sep-21	"Nikola Mikic, Aarhus, Denmark"		https://ClinicalTrials.gov/show/NCT04223999
588	NCT01107522	Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas		Unknown status	No Results Available	"Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas"	"Drug: CTO|Drug: CTO and Temodar®|Drug: CTO, Temodar®, Radiation therapy"	"To determine the MTD/RD of single agent CTO in patients with advanced or metastatic solid tumors; or CTO in combination with Temodar® in patients with glioblastoma or other recurrent malignant gliomas|Preliminary tumor response|Pharmacokinetics (maximum concentration, Tmax, AUC, T1/2, clearance, volume of distribution)|Voluntary Exploratory objective|Exploratory Objective"	"Tactical Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	100	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T09-10644	May-10	Jun-18		21-Apr-10		24-Apr-18	"New York University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Providence Cancer Center, Portland, Oregon, United States|Oregon Health and Sciences University, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT01107522
589	NCT04974983	Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|Angiogenesis	Other: Observation of neurological deficits	Functional outcome	University Hospital Regensburg		"18 Years and older   (Adult, Older Adult)"		203	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	Z-2017-0901-5	1-Sep-17	30-Jun-20	30-Aug-20	23-Jul-21		23-Jul-21	"University Hospital Regensburg, Regensburg, Germany"		https://ClinicalTrials.gov/show/NCT04974983
590	NCT00365222	Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma		Terminated	No Results Available	Glioblastoma|Gliosarcoma	Drug: Temozolomide	Evaluate overall survival|Progression-free survival at six and nine months|Response rate measured by a reduction in tumor size|Frequency and severity of adverse events|Quality of life measured at each cycle utilizing the QOL FACT-BR	H. Lee Moffitt Cancer Center and Research Institute|Schering-Plough	All	70 Years and older   (Older Adult)	Phase 2	1	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-14714	Jul-06	Jun-07	Jun-07	17-Aug-06		22-Jan-09	"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT00365222
591	NCT01067469	Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)		Completed	Has Results	Brain Cancer|Glioblastoma	Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab|Drug: Lomustine	Progression Free Survival (PFS)|Radiographic Response (RR)|6-month Progression-free Survival (PFS-6)|Overall Survival (OS)|Time to Progression (TTP)|Summary of Treatment Related Toxicities	M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	83	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0597|NCI-2011-00559	Jan-10	Oct-16	Oct-16	11-Feb-10	17-Mar-20	17-Mar-20	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01067469
592	NCT00301418	Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma		Completed	Has Results	Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: Erlotinib	Safety of Twice a Day Oral 150 mg Erlotinib Dosing|6-month Progression Free Survival (PFS)|Overall Survival (OS)	"Northwell Health|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	11	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	501007705	Mar-06	May-14	May-14	10-Mar-06	10-Feb-16	10-Feb-16	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00301418
593	NCT03197506	Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma		Recruiting	No Results Available	Glioblastoma|Gliosarcoma|Supratentorial Glioblastoma	Radiation: External Beam Radiation Therapy|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Radiation: Radiation Therapy|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery	Incidence of dose limiting toxicities (DLT) (Group 1)|Overall survival (OS) (Group 2)|Incidence of adverse events|Time until any treatment related adverse event|Time until treatment related grade 3+ adverse event|Time until hematologic nadirs|Time to progression (Group 2)|Progression-free survival (Group 2)|Time to treatment failure (Group 2)	Mayo Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1572|NCI-2017-01106|P30CA015083	15-Sep-17	31-Jul-22	31-Jul-22	23-Jun-17		25-Aug-21	"Mayo Clinic in Rochester, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT03197506
594	NCT03726515	CART-EGFRvIII + Pembrolizumab in GBM		Completed	No Results Available	Glioblastoma	Biological: CART-EGFRvIII T cells|Biological: Pembrolizumab	"Number of subjects with treatment-related adverse events, using NCI CTCAE v5.0.|Overall survival Rate|Progression-free survival (PFS)|Objective response rate (ORR)"	University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	7	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	"831706, UPCC 13318"	11-Mar-19	27-Feb-21	27-Feb-21	31-Oct-18		3-Mar-21	"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03726515
595	NCT03115333	DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma		Recruiting	No Results Available	Gliosarcoma|Recurrent Glioblastoma	Diagnostic Test: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging	Change in rCBV within enhancing tumor|OS|CBF|Change in CBF|PFS|rCBV	ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	146	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	EAF151|NCI-2016-01357|U10CA180820	14-Apr-17	7-May-22	7-May-27	14-Apr-17		20-Dec-21	"Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|VA Palo Alto Health Care System, Palo Alto, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Moffitt Cancer Center-International Plaza, Tampa, Florida, United States|Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Maryland Proton Treatment Center, Baltimore, Maryland, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Froedtert West Bend Hospital/Kraemer Cancer Center, West Bend, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03115333
596	NCT01115036	A Panobinostat Presurgery	CLBH589C	Withdrawn	No Results Available	Recurrent Glioblastoma	Drug: panobinostat	Anti-tumor Activity as Measured by Percentage of Patients Who Remain Progression-free after Six Months|Safety Evaluation of Panobinostat|Evaluation of Intratumoral Pharmacokinetics and Pharmacodynamics of Panobinostat|Evaluation of Systemic Pharmacokinetics	Duke University|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00020612	Apr-10	Apr-11	Apr-12	3-May-10		19-Jun-13	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01115036
597	NCT02510950	Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma		Terminated	No Results Available	"Glioblastoma Multiforme|Astrocytoma, Grade IV"	Biological: Personalized peptide vaccine|Drug: Poly-ICLC|Drug: Temozolomide	Safety and tolerability of adjuvant personalized neoantigen peptide vaccine with poly-ICLC as measured by grade 3 and 4 adverse events as defined by CTCAE v. 4.03|Feasibility of the peptide vaccine with poly-ICLC as measured by the ability to identify patient tumor-derived candidate neoantigens and generate a tumor-specific vaccine from time of initial diagnosis to time of proposed administration of the vaccine|Progression-free survival (PFS) rate|Overall survival (OS) rate|Number of neoantigens present in patients with newly diagnosed GBM	Washington University School of Medicine	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201510022	3-Dec-15	14-Feb-17	14-Feb-17	29-Jul-15		17-Nov-17	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT02510950
598	NCT00525525	Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma	AVF4120s	Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Bevacizumab|Drug: Tarceva|Drug: Temozolomide	Overall Survival (OS)|Unexpected Toxicities During First 2 Cycles of Study Drug|Progression-free Survival	"University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	74	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7105	Sep-07	May-13	May-13	5-Sep-07	14-Nov-14	14-Nov-14	"University of California San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00525525
599	NCT03477513	Personalized Radiation Therapy for GBM		Recruiting	No Results Available	Glioblastoma	Radiation: Radation Therapy	Adverse Events	Abramson Cancer Center of the University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 24317	1-Mar-18	31-Dec-21	1-Jun-22	26-Mar-18		26-Apr-21	"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03477513
600	NCT04266977	Restrictive Use of Dexamethasone in Glioblastoma	RESDEX	Recruiting	No Results Available	Glioblastoma|Dexamethasone|Steroids	Drug: Dexamethasone	Failure rate of the restrictive DEX regimen|Secondary neurological or systemic complication|Cumulative dexamethasone dosage|National Institutes of Health Stroke Scale (NIHSS) over time of the study period|Glasgow Coma Scale (GCS) over time of the study period and correlation with steroid medication|Volume of contrast enhancing tumor on preoperative MRI|Volume of contrast enhancing tumor on postoperative MRI|Volume of edema on preoperative MRI and correlation with steroid medication|Volume of edema on postoperative MRI|Time to start of adjuvant treatment|Rate of reoperations|Cause of reoperations	"University Hospital Inselspital, Berne"	All	"18 Years to 90 Years   (Adult, Older Adult)"	Not Applicable	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RESDEX	8-May-20	Apr-22	Apr-23	12-Feb-20		9-Jul-21	"Department of Neurosurgery, Bern, Switzerland"		https://ClinicalTrials.gov/show/NCT04266977
601	NCT04492163	Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM		Recruiting	No Results Available	Glioblastoma Multiforme	Device: TTFields	Progression free survival (PFS)|Overall Survival (OS)|Progression Free Survival at 6 months (PFS6)|1-year and 2-year survival rates|Overall radiological response|Severity and frequency of adverse events|Pathological changes in resected GBM tumors following study treatment|Dependence of Progression Free Survival on TTFields dose delivered to the tumor bed|Dependence of Overall Survival on TTFields dose delivered to the tumor bed	NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	25	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EF-33	14-Jul-20	Jan-22	Jan-22	30-Jul-20		31-Aug-21	"Nemocnice Na Homolce, Prague, Czechia"		https://ClinicalTrials.gov/show/NCT04492163
602	NCT01110876	"Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)"		Terminated	Has Results	Brain Cancer|Glioblastoma Multiforme	Drug: Vorinostat|Drug: Erlotinib|Drug: Temozolomide	Maximum Tolerated Dose (MTD) of Vorinostat in Combination With Escalating Doses of Erlotinib and Temozolomide|Progression Free Survival (PFS)	M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	21	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0651|NCI-2011-00469	Jun-11	Jul-14	Jul-14	27-Apr-10	25-Aug-21	25-Aug-21	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01110876
603	NCT03020017	NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery		Completed	No Results Available	Gliosarcoma|Recurrent Glioblastoma	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Targeted Molecular Therapy	Incidence of Adverse Events|Drug concentration in blood after drug administration|Biodistribution of NU-0129 in tumor tissue|Feasibility of giving NU-0129 as a standard treatment	Northwestern University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	8	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16C01|STU00203790|P30CA060553|NCI-2016-02007	25-May-17	6-Sep-18	19-Aug-20	13-Jan-17		27-Oct-20	"Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT03020017
604	NCT03452579	Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: Nivolumab|Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab	Overall Survival at 12 Months (OS-12)|Progression-Free Survival at Six Months|Overall Survival (OS)|Overall Response Rate (ORR)|Progression-Free Survival|Duration of Response	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE1317	21-May-18	30-Dec-20	30-Dec-22	2-Mar-18		25-May-21	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/79/NCT03452579/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03452579/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT03452579
605	NCT00979017	Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme		Completed	Has Results	Glioblastoma Multiforme|Gliosarcoma	Drug: Avastin|Drug: Temozolomide|Drug: Irinotecan	Response Rate|Incidence and Severity of Central Nervous System (CNS) Hemorrhage and Systemic Hemorrhage|Incidence of Grade ≥ 4 Hematologic and ≥ Grade 3 Non-hematologic Toxicities|Median Progression-free Survival (PFS)|Median Overall Survival (OS)	"Katy Peters|Genentech, Inc.|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	41	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00019065	Nov-09	Feb-11	Jan-13	17-Sep-09	12-Aug-13	19-Mar-14	"The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00979017
606	NCT02893137	Enhancing Optune Therapy With Targeted Craniectomy		Completed	No Results Available	Glioblastoma	Device: Optune|Procedure: Craniectomy	Frequency of serious adverse events|Overall survival|Progression free survival|Progression free survival at six months|% 1-year survival|Objective response rate|Quality of life|Cumulative corticosteroid dosage|Karnofsky performance score	Aarhus University Hospital|NovoCure Ltd.|University of Aarhus	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	54762	1-Oct-16	31-May-19	31-May-19	8-Sep-16		27-Nov-19	"Aarhus University Hospital, Aarhus C, Aarhus, Denmark"		https://ClinicalTrials.gov/show/NCT02893137
607	NCT00262730	Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM		Completed	Has Results	Glioblastoma Multiforme	Drug: poly ICLC|Drug: temozolomide|Radiation: radiation therapy	Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	97	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTT-0501|U01CA062475|NABTT-0501 CDR0000454915|NA_00001963	Jan-06	Aug-09	Apr-10	7-Dec-05	16-Jul-14	12-Jun-19	"Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00262730
608	NCT00761280	Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma	SAPPHIRE	Terminated	Has Results	Anaplastic Astrocytoma|Glioblastoma	Drug: trabedersen|Drug: temozolomide|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System|Drug: carmustine|Drug: lomustine	"Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Survival at 24 Months in the Intent-to-treat Population - Number of Participants|Survival Rate at 12, 18, and 21 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Survival at 12, 18, and 21 Months in the Intent-to-treat Population - Number of Participants|Median Overall Survival (Days) From Randomization in the Intent-to-treat Population (Descriptive Analysis, Only)|Response Category by Independent Review in the Intent-to-treat Population - Number of Participants|Overall Response Rate (CR+PR) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Tumor Control Rate (CR+PR+SD) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Median Duration of Response (Days) by Independent Review (Descriptive Analysis, Only)|Disease Progression at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Number of Participants|Disease Progression Rate at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Median Time to Progression (Days) by Independent Review for the Intent-to-treat Population (Descriptive Analysis, Only)"	Isarna Therapeutics GmbH	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	27	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AP 12009-G005	Dec-08	Feb-12	Jun-12	29-Sep-08	22-Aug-14	14-Nov-14	"NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Hospital Británico, Ciudad Autónoma de Buenos Aires, Argentina|FLENI, Ciudad Autónoma de Buenos Aires, Argentina|Sanatorio Allende, Córdoba, Argentina|Universitätsklinik Innsbruck, Abteilung für Neurologie, Innsbruck, Austria|AKH Wien, Klinik für Neurochirurgie, Wien, Austria|Hospital de Câncer de Barretos, Barretos / SP, Brazil|Centro Goiano de Oncologia (CGO), Goiania, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil|Hospital do Servidor Público Estadual, Sao Paulo, Brazil|ECOGENE-21 Centre d'études cliniques, Chicoutimi, Quebec, Canada|Foothills Medical Centre, Calgary, Canada|Montreal Neurological Institute and Hospital, Montreal, Canada|La Timone University Hospital, Marseille, France|Klinik und Poliklinik für Neurochirurgie, Frankfurt/M., Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Neurochirurgische Klinik an der Universität Ulm am Bezirkskrankenhaus Günzburg, Günzburg, Germany|Universitätklinikum Hamburg-Eppendorf, Klinik für Neurochirurgie, Hamburg, Germany|Medizinische Hochschule Hannover Neurochirurgische Klinik, Hannover, Germany|Universitätsklinik Heidelberg Neurologische Klinik, Heidelberg, Germany|Universitätsklinikum Leipzig, Neurochirurgische Klinik, Leipzig, Germany|Otto-von-Guericke-Universität, Klinik für Neurochirurgie, Magdeburg, Germany|Klinik und Poliklinik für Neurochirurgie, Münster, Germany|Klinik und Poliklinik für Neurologie, Regensburg, Germany|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged, Hungary|Manipal Hospital & Manipal Institute for Neurological Disorders, Bangalore, India|NIMHANS, Bangalore, India|BGS Global Hospital, Bangalore, India|Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Apollo Speciality Hospitals, Chennai, India|Amrita Institute of Medical Sciences Research Center, Cochin, India|Care Hospitals, Hyderabaad, India|AMRI Hospitals, Kolkata, India|SGPGI of Medical Sciences, Lucknow, India|Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Mumbai, India|All India Institute of Medical Sciences (AIIMS), New Delhi, India|SCTIMST, Dept. of Neurosurgery, Thiruvananthapuram, India|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Kangnam St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital San Javier, Guadalajara, Mexico|Hospital General de Mexico, Mexico City, Mexico|Medica Sur, Mexico City, Mexico|Wojskowy Szpital Kliniczny, Klinika Neurochirurgii, Bydgoszcz, Poland|Akademickie Centrum Kliniczne, Gdańsk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Neurochirurgii i Neurochirurgii Dziecięcej, Lublin, Poland|Kliniczny Oddzial Neurochirurgii SUM w Sosnowcu Wojewódzki Szpital Specjalistyczny nr 5, Sosnowiec, Poland|Centrum Onkologii - Instytut Im. Marii Sklodowskiej-Curie, Warszawa, Poland|SP ZOZ Uniwersytecki Szpital Kliniczny nr 1, Klinika Neurochirurgii, Łódź, Poland|Chelyabinsk City Hospital #3; Department of Neurosurgery, Chelyabinsk, Russian Federation|State Institution Russian Oncology Research Center N.N. Blokhin, Moscow, Russian Federation|Samara Region Clinical Hospital M.I. Kalinin, Samara, Russian Federation|Russian Scientific Research Neurosurgical Institute A.L. Polenov, St. Petersburg, Russian Federation|Military Medical Academy, Neurosurgery Dept, St. Petersburg, Russian Federation|Hospital de Cruces, Baracaldo, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan|Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, United Kingdom|The National Hospital for Neurology and Neurosurgery, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT00761280
609	NCT01186406	"Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)"		Terminated	Has Results	Glioblastoma Multiforme|Gliosarcoma	Drug: Gliadel|Radiation: Radiation Therapy|Drug: Avastin|Drug: Temodar	21-month Overall Survival|Median Overall Survival|Median Progression-free Survival|Unacceptable Toxicity Related to the Treatment Regimen	"Duke University|Genentech, Inc.|Eisai Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	41	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00025180	Apr-11	16-Jun-14	16-Jun-14	23-Aug-10	22-Oct-14	15-Feb-19	"The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01186406
610	NCT02905643	Discerning Pseudoprogression vs True Tumor Growth in GBMs		Completed	No Results Available	Glioblastoma	Other: Study subjects	Imaging parameter utility for pseudoprogression vs. true tumor growth	Ascension St. Vincent	All	"18 Years to 99 Years   (Adult, Older Adult)"		1	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	R20150109	Sep-16	13-Feb-18	13-Feb-18	19-Sep-16		9-Oct-18			https://ClinicalTrials.gov/show/NCT02905643
611	NCT03008148	Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM		Recruiting	No Results Available	Glioblastoma	Radiation: CCRT|Drug: Temozolomide|Drug: Siroquine	Overall survival time.|Progression-free survival time|OS rate at 1 year.|PFS rate at 1 year.|The time and rate of OS in different RPA class.|The time and rate of PFS in different RPA class.|Objective response rate.|Changes in score of EORTC QLQ-C30|Changes in score of EORTC QLQ-BN20.|Changes in grade of ECOG performance status.	"Johnpro Biotech, Inc."	All	"20 Years to 80 Years   (Adult, Older Adult)"	Phase 2|Phase 3	288	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JP001-GM-001	11-Oct-18	Apr-25	Apr-25	2-Jan-17		11-May-21	"Taipei Veterans General Hospital, Taipei City, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan"		https://ClinicalTrials.gov/show/NCT03008148
612	NCT03452930	Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma		Recruiting	No Results Available	Glioblastoma|Gliosarcoma|MGMT-Unmethylated Glioblastoma	Radiation: Radiation Therapy|Drug: Tinostamustine	Maximum tolerate dose (MTD) (Stages 1 & 2)|Incidence of adverse events (Stage 1)|Objective response rate (ORR) (Stage 2)|Overall survival (OS) (Stage 2)|Progression-free survival (PFS) (Stage 2)	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	128	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0555|NCI-2018-00872|P30CA016672	13-Aug-18	31-Oct-21	31-Oct-21	2-Mar-18		15-Jan-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03452930
613	NCT01240460	Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection		Completed	No Results Available	"Glioblastoma|Astrocytoma, Grade IV"	Drug: XL765 (SAR245409)|Drug: XL147 (SAR245408)	"To explore the biological effect of XL765 and XL147 measured by modulation of PI3K/ mTOR pathway readouts in GB tumor tissue|To examine the safety profile of daily oral administration of XL765 and XL147 in subjects with recurrent GB|To determine the levels of XL765 and XL147 in plasma and GB tumor tissue|To assess the anti-proliferative and pro-apoptotic effects of XL765 and XL147 on tumor cells|To measure changes in tumor after surgery in subjects receiving XL765 and XL147|To conduct genetic analyses of GB tumor tissue comparing, where feasible, tumor tissue removed during the on-study resection with tissue removed during the initial surgical resection|To evaluate the pharmacodynamic effects of XL765 and XL147 in blood and/or blood cells for identification and characterization of surrogate biomarkers associated with the biological effects of XL765 and XL147|To explore the relationship between clinical response and genomic and proteomic biomarkers in the PI3K and EGFR pathways"	Sanofi	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TED11605|XL765-202	Jan-11	Jun-12	Jun-12	15-Nov-10		27-Jul-12	"Investigational Site Number 840001, Los Angeles, California, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840002, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01240460
614	NCT02026271	A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Oligoastrocytoma	Biological: Ad-RTS-hIL-12|Drug: veledimex	Safety and tolerability of varying doses of intratumoral Ad-RTS-hIL-12 and oral veledimex doses in subjects with recurrent or progressive glioblastoma or Grade III malignant glioma|Veledimex maximum tolerated dose (MTD) when given with varying doses of intratumoral Ad-RTS-hIL-12|Veledimex pharmacokinetic profile and veledimex concentration ratio between the brain tumor and the blood|Cellular and humoral immune responses elicited by Ad-RTS-hIL-12 and veledimex|Tumor Objective Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)	Ziopharm	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	40	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATI001-102	Jun-15	Aug-19	Aug-19	1-Jan-14		22-Sep-21	"Cedars-Sinai, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Northwestern, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Brigham & Women's, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02026271
615	NCT03744026	Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9	SC9-GBM-01	"Active, not recruiting"	No Results Available	"Glioblastoma, Adult"	Device: SonoCloud-9|Drug: Carboplatin	Dose limiting toxicity (DLT) of number of activated ultrasound beams|Blood-Brain Barrier (BBB) opening	CarThera	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	33	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SC9-GBM-01	18-Feb-19	23-Jun-21	Dec-21	16-Nov-18		15-Nov-21	"Northwestern University, Chicago, Illinois, United States|MD Anderson Cancer Center, Houston, Texas, United States|CHU, Angers, France|Hôpital Neurologique Pierre Wertheimer, Bron, France|Hôpital de La Timone, Marseille, France|Hôpital de la Pitié-Salpêtrière, Paris, France"		https://ClinicalTrials.gov/show/NCT03744026
616	NCT02869243	A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients		"Active, not recruiting"	No Results Available	Glioblastoma	Drug: hrBMP4	DLTs|Tumor response|EORTC QLQ-C30 Summary Score|Maximum observed plasma concentration of BMP4 (Cmax)|Lowest concentration of BMP4 in the blood (Ctrough)|Area under the curve (AUC∞)|Central and peripheral volumes of distribution (Vd)|Clearance|Half-life (t1/2)	Stemgen|ORION Clinical Services	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	15	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	hrBMP4-001	18-Jul-17	16-Oct-20	31-Mar-21	16-Aug-16		19-Nov-20	"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Istituto Neurologico Carlo Besta, Milano, Italy|VU University Medical Center, Amsterdam, Netherlands|Erasmus University Medical Center, Department of Neurosurgery, Rotterdam, Netherlands"		https://ClinicalTrials.gov/show/NCT02869243
617	NCT02337491	Pembrolizumab +/- Bevacizumab for Recurrent GBM		Completed	Has Results	Glioblastoma	Drug: Pembrolizumab|Drug: Bevacizumab	Pembrolizumab Maximum Tolerated Dose (MTD) [Cohort A Safety Lead-In]|Pembrolizumab Dose Limiting Toxicity (DLT) [Cohort A Safety Lead-In]|6-Month Progression-Free Survival (PFS6)|Progression-Free Survival (PFS)|Overall Survival (OS)|Overall Radiographic Response (ORR)	Dana-Farber Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-477	9-Feb-15	28-Aug-16	14-Sep-20	13-Jan-15	9-Apr-18	22-Dec-20	"University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|UT, MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT02337491
618	NCT03360708	Vaccine Therapy in Treating Patients With Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Giant Cell Glioblastoma|Recurrent Glioblastoma|Recurrent Gliosarcoma	Other: Laboratory Biomarker Analysis|Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine	"Incidence of significant toxicity, defined as a dose limiting toxicity (DLT) that is possibly, probably, or definitely related to treatment as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Clinical benefit rate|Duration of response|Feasibility|Overall response rate|Overall survival|Progression-free survival|Time to response"	Mayo Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1772|NCI-2017-02159|P30CA015083	3-Jun-19	2-Jul-21	1-Dec-22	4-Dec-17		12-Jul-21	"Mayo Clinic, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT03360708
619	NCT01208909	Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI)		Unknown status	No Results Available	Glioblastoma	Procedure: diagnostic 5-ALA and MRI for tumor resection		University of Zurich	All	"20 Years to 70 Years   (Adult, Older Adult)"		40	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	ZU-XYZ-002	Aug-09	Dec-11	Dec-11	24-Sep-10		22-Oct-10	"UniversitätsSpital Zürich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT01208909
620	NCT00916409	Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)		Completed	No Results Available	Glioblastoma Multiforme	Device: NovoTTF-100A device|Drug: Temozolomide	Progression Free Survival (PFS) time|Overall survival (OS)	NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	700	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EF-14	Jun-09	Dec-16	Mar-17	9-Jun-09		10-Apr-17	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|University of California San Diego Moores Cancer Center (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|University of Illinois at Chicago (UIC), Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|New Jersey Neuroscience Center - JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, Department of Neurosurgery, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|The Ohio State University Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Geisinger Health System, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Baylor, Dallas, Texas, United States|Methodist Hospital, Houston, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|The University of Texas Health Science Center at Houston (UTHSC), Houston, Texas, United States|Scott and White Healthcare, Temple, Texas, United States|Memorial Hermann The Woodlands, The Woodlands, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|University Hospital Graz, Graz, Austria|Medical University of Vienna, Vienna, Austria|SMZ-Süd/Kaiser-Franz-Josef-Spital, Vienna, Austria|Tom Baker Cancer Center, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Juravinski Cancer Centre, Hamilton,, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Notre-Dame Hospital (CHUM), Montreal, Quebec, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|McGill - Gerald Bronfman Centre for Clinical Research in Oncology -, Montreal, Quebec, Canada|(CHUS) Centre Hospitalier Universitaire de Sherbrooke, Service de Neurochirurgie, Sherbrooke, Quebec, Canada|Na Homolce Hospital, Prague, Czech Republic|CHU Amiens Sud-Salouel, Amiens, France|CHU Angers, Angers, France|Hôpital Saint André Centre Hospitalier Universitaire (CHU) des Hôpitaux de Bordeaux, Bordeaux, France|Hospital of Neurology Pierre Wertheimer, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|Centre Hospitalo-Universitaire de Toulouse Purpan, Toulouse, France|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|Medical University Heidelberg, Heidelberg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Az. Ospedaliero-Universitaria - Ospedali Riuniti, Ancona, Italy|Ospedale Lecco, Lecco, Italy|C. Besta Neurological Institute, Milan, Italy|Foundation Hospital Greater Policlinico, Milan, Italy|Istituti Fisioterapici Ospitalieri - Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Asan Medical Center, Asan, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital (CNUH), Daejeon, Korea, Republic of|Samsung Medical Center (SMC), Seoul, Korea, Republic of|Seoul National University Bundang Hospital (SNUBH), Seoul, Korea, Republic of|Seoul National University Hospital (SNUH), Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital (CMC Seoul), Seoul, Korea, Republic of|Yonsei University Severance Hospital (YUHS), Seoul, Korea, Republic of|Ajou University Hospital (AUH), Suwon, Korea, Republic of|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari de Bellvitge-ICO Duran i Reynals, Barcelona, Spain|Fundacion Jimenes Diaz, Madrid, Spain|Hospital 12 de Octubre, Servicio de Oncología Médica, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Karolinska Institute, Stockholm, Sweden|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitätsSpital Zürich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT00916409
621	NCT02311920	Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma		"Active, not recruiting"	No Results Available	Gliosarcoma|Supratentorial Glioblastoma	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Drug: Temozolomide	"Immune-related dose-limiting toxicities for the single-agent treatment with ipilimumab|Immune-related dose-limiting toxicities for the single-agent treatment with nivolumab|Immune-related dose-limiting toxicities for the combination of ipilimumab and nivolumab when given with temozolomide|Incidence of adverse events, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Biomarker analysis of immune cells within tumor samples using standard immunohistochemistry|Number of patients who are alive"	National Cancer Institute (NCI)|NRG Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	32	NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-02404|NRG-BN002|PNRG-BN002_R05PAPP02|U10CA180868	16-Apr-15	31-Dec-17		9-Dec-14		6-Jul-21	"UCSF Medical Center-Parnassus, San Francisco, California, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02311920
622	NCT00555399	"Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)"		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme|Anaplastic Glioma	Drug: Vorinostat|Drug: Isotretinoin|Procedure: Surgical Resection|Drug: Temozolomide	Maximum Tolerated Dose (MTD)	M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	135	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2006-0709|NCI-2010-00782|4808704|BTTC09-02	28-Nov-07	20-Apr-24	20-Nov-24	8-Nov-07		30-Oct-20	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00555399
623	NCT01331616	Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab		Withdrawn	No Results Available	Glioblastoma|Optic Neuropathy	Drug: Bevacizumab (Avastin)	Measurement of Visual Evoked Potentials (optic nerve function and visual processing) and optic nerve function in 10 patients.|Number of patients diagnosed with optic neuropathy following treatment with chemo and radiation in combination with avastin treatment	West Penn Allegheny Health System	All	"Child, Adult, Older Adult"	Early Phase 1	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RC-5148	Mar-11	Jul-12	Jul-12	8-Apr-11		9-Dec-21			https://ClinicalTrials.gov/show/NCT01331616
624	NCT04396860	Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma		Recruiting	No Results Available	Gliosarcoma|MGMT-Unmethylated Glioblastoma	Biological: Ipilimumab|Biological: Nivolumab|Device: NovoTTF-100A Device|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy|Drug: Temozolomide	Progression-free survival (PFS) (Phase II)|Overall survival (OS) (Phase III)|PFS for the entire cohort (Phase II/III)|OS proportion|Comparative frequency of specific adverse events of interest|Frequency summaries for all adverse event types|Patient reported symptom burden|Neurocognitive function (NCF)|Patient-reported toxicity outcomes	National Cancer Institute (NCI)|NRG Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	485	NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2020-03404|NRG-BN007|U10CA180868	6-Aug-20	23-Aug-24	23-Aug-24	21-May-20		6-Jan-22	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Kaiser Permanente-Ontario, Ontario, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Torrance Memorial Physician Network - Cancer Care, Torrance, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Beebe Medical Center, Lewes, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Augusta University Medical Center, Augusta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Island Urology, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Edward Hospital/Cancer Center, Naperville, Illinois, United States|Cancer Care Center of O'Fallon, O'Fallon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Illinois CancerCare - Washington, Washington, Illinois, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Jennie Edmundson Memorial Hospital, Council Bluffs, Iowa, United States|Heartland Oncology and Hematology LLP, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Broadlawns Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|MaineHealth Coastal Cancer Treatment Center, Bath, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|Penobscot Bay Medical Center, Rockport, Maine, United States|MaineHealth Cancer Care Center of York County, Sanford, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Maine Medical Partners Neurology, Scarborough, Maine, United States|Maine Medical Partners - South Portland, South Portland, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Central Maryland Radiation Oncology in Howard County, Columbia, Maryland, United States|UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie, Maryland, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Minnesota Oncology - Burnsville, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, United States|Cancer Partners of Nebraska - Pine Lake, Lincoln, Nebraska, United States|Southeast Nebraska Cancer Center - 68th Street Place, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Good Samaritan Hospital Medical Center, West Islip, New York, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Atrium Health Pineville/LCI-Pineville, Charlotte, North Carolina, United States|Atrium Health Cabarrus/LCI-Concord, Concord, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Crozer-Keystone Regional Cancer Center at Broomall, Broomall, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Lancaster General Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Forbes Hospital, Monroeville, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Wexford, Pennsylvania, United States|Rock Hill Radiation Therapy Center, Rock Hill, South Carolina, United States|Avera Cancer Institute at Pierre, Pierre, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|VCU Community Memorial Health Center, South Hill, Virginia, United States|Legacy Cancer Institute Medical Oncology and Day Treatment, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT04396860
625	NCT02520635	Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients		Unknown status	No Results Available	Glioblastoma	Drug: supra-early TEMODAL® chemotherapy|Drug: standard TEMODAL® chemotherapy|Radiation: Radiotherapy 60Gy	progression free survival|Overall Survival (OS)|Objective Response Rate|Treatment-related adverse event	Beijing Tiantan Hospital	All	"18 Years to 75 Years   (Adult, Older Adult)"		180	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	B0008	Jan-15	Dec-20	Dec-20	13-Aug-15		11-Jul-19	"Beijing Tiantan Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT02520635
626	NCT05095441	A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma		Not yet recruiting	No Results Available	Solid Tumor|Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain	Biological: C5252	Evaluate the safety and tolerability of C5252|Characterize Dose Limiting Toxicities|Identify the maximum tolerated dose (MTD) and/or the RD of C5252|Evaluate the PK of C5252|Evaluate the viral shedding of C5252|Overall response rate (ORR)|Progression-free survival (PFS)|Overall Survival (OS)	ImmVira Pharma Co. Ltd	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	51	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MVR-C5252-001	31-Dec-21	30-Apr-23	30-Apr-26	27-Oct-21		27-Oct-21			https://ClinicalTrials.gov/show/NCT05095441
627	NCT04765514	Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Other: Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)|Combination Product: Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.	Overall survival|Progression-free survival|Frequency of Adverse Events related to the treatment administered|Health Related Quality of Life (EORTC QLQ-C30)|Health Related Quality of Life (EORTC QLQ-BN20)|Cost effectiveness|Cognitive and mental function	AHS Cancer Control Alberta	Male	65 Years and older   (Older Adult)	Phase 2	121	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-0012	Dec-21	Jan-31	Jan-31	21-Feb-21		20-Aug-21	"Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT04765514
628	NCT02046187	Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma		Terminated	No Results Available	Glioblastoma (GBM)	Dietary Supplement: Ketogenic Diet|Radiation: Radiation therapy|Drug: Temozolomide	Number of participants with adverse events|overall survival|time to progression|quality of life	"St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	14	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KD-13BN069	Oct-13	Feb-17	Feb-17	27-Jan-14		16-Jun-21	"Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT02046187
629	NCT02287428	Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM		Recruiting	No Results Available	Glioblastoma	Radiation: Radiation Therapy|Biological: Personalized NeoAntigen Vaccine|Drug: Pembrolizumab|Drug: Temozolomide	"Cohorts 1, 1a, 1b, & 1c: Number of participants with Adverse Events as a measure of safety and tolerability|Cohorts 1d: Number of participants with Adverse Events as a measure of safety and tolerability|Cohort 1: Number of participants with at least 10 actionable peptides as a measure of study feasibility|Cohort 1: Number of participants who are clinically able to initiate post-RT vaccine therapy within 12 weeks or less from date of surgery|All Cohorts: Number of participants who achieve IFN-γ T-cell response at week 16 via ELISPOT assessments|Cohorts 1, 1a, 1b, & 1c: Number of participants who are alive without progression at eight months after surgery resection|Cohort 1d: Number of participants who are alive without progression at 11 months after surgery resection"	Dana-Farber Cancer Institute|The Ben & Catherine Ivy Foundation|Accelerate Brain Cancer Cure|Merck Sharp & Dohme Corp.|National Institutes of Health (NIH)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	56	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-362|51986	Nov-14	Jan-25	Jan-26	10-Nov-14		21-May-21	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT02287428
630	NCT04284306	Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM		Not yet recruiting	No Results Available	Glioblastoma Multiforme		This research will provide valuable insights into the pathogenesis of glioblastoma and the expression of PD-L1 &LC3B in this tumor especially in our locality. It will add to the literature a very important data regarding this field.	Assiut University	All	"18 Years to 70 Years   (Adult, Older Adult)"		61	Other	Observational	Observational Model: Other|Time Perspective: Other	PDL-1 and LC3B in GBM	1-Mar-20	Jul-20	Sep-22	25-Feb-20		25-Feb-20			https://ClinicalTrials.gov/show/NCT04284306
631	NCT02458508	Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	GLIOMELA	Completed	No Results Available	Glioblastoma		progression-free survival|overall survival	"University of Pisa|Azienda Ospedaliero, Universitaria Pisana"	All	"18 Years and older   (Adult, Older Adult)"		65	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	University of Pisa	Mar-15	Dec-16	Mar-17	1-Jun-15		25-Oct-17	"Division of Radiotherapy, Department Of Oncology, University Hospital of Pisa, Pisa, Italy"		https://ClinicalTrials.gov/show/NCT02458508
632	NCT05100641	AV-GBM-1 vs Control as Adjunctive Therapy After RT/TMZ for Newly Diagnosed GBM		Not yet recruiting	No Results Available	Primary Glioblastoma	Biological: AV-GBM-1|Biological: Autologous monocytes	Overall survival from date of first AV-GBM-1 injection|PFS from date of first AV-GBM-1 injection|PFS from date of randomization|OS from date of randomization|Determine and compare TEAE for both study arms	"Aivita Biomedical, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	726	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	CL-GBM-P02-US	Mar-22	Mar-26	Mar-27	29-Oct-21		4-Jan-22			https://ClinicalTrials.gov/show/NCT05100641
633	NCT02663440	Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme		Unknown status	No Results Available	Glioblastoma Multiforme	Radiation: Hypofractionated IMRT|Biological: Granulocyte-macrophage Colony-stimulating Factor|Drug: Temozolomide	PFS	Zhejiang Cancer Hospital	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	41	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZJZLYY-HN-2016-01	Jan-16	Dec-17		26-Jan-16		26-Jan-16	"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT02663440
634	NCT04715620	Niraparib Combined With Radiotherapy in rGBM		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Niraparib	PFS-6	Tianjin Huanhu Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TJHH-2306	Jan-21	Jan-22	Jan-23	20-Jan-21		20-Jan-21	"Tianjin Huanhu Hosptal, Tianjin, Tianjin, China"		https://ClinicalTrials.gov/show/NCT04715620
635	NCT00576641	Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma		Completed	No Results Available	Brain Stem Glioma|Glioblastoma	Biological: autologous dendritic cells	"Evaluate safety/toxicity of Dendritic cell vaccine, Monitor survival and time to progression and monitor the cellular immune responses."	Cedars-Sinai Medical Center	All	"Child, Adult, Older Adult"	Phase 1	22	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6657	May-07	Jan-10	Apr-12	19-Dec-07		30-Oct-14	"Cedars Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00576641
636	NCT04391595	LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients		Recruiting	No Results Available	Glioblastoma|GBM|Glioma	Drug: Abemaciclib|Drug: LY3214996	Phase 0: Pharmacokinetic analysis of tumor tissue|Phase 0: Pharmacokinetic analysis of cerebrospinal fluid (CSF)|Pharmacokinetic analysis of plasma|Phase 2: Progression-free survival|Phase 0: PD Analysis|Number of Adverse Events|Incidence of drug-related toxicity|Incidence of treatment-emergent adverse events|Deaths|Incidence of clinical laboratory abnormalities per CTCAE	"Nader Sanai|Barrow Neurological Institute|Ivy Brain Tumor Center|Eli Lilly and Company|St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	50	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-07	8-Jul-20	Dec-21	Feb-22	18-May-20		31-Dec-20	"Chandler Regional Medical Center, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States"		https://ClinicalTrials.gov/show/NCT04391595
637	NCT00977431	Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform		Completed	Has Results	Glioblastoma	Drug: Temozolomide|Procedure: Radiotherapy|Drug: BIBW2992	"Number of Patients With Investigator Defined Dose Limiting Toxicities (DLT) During the RT Phase|Maximum Tolerated Dose (MTD) of Afatinib|Incidence and Intensity of Adverse Events (AE) According to Common Terminology Criteria of Adverse Events (CTCAE v.3.0)|The Objective Tumour Response According to the Macdonald Criteria|Concentration of Afatinib in Plasma at Steady State Pre-dose on Days 8, 15 and 29"	Boehringer Ingelheim	All	"18 Years to 69 Years   (Adult, Older Adult)"	Phase 1	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1200.38|2008-007284-17	17-Sep-09	12-Sep-17	12-Sep-17	15-Sep-09	18-Feb-19	18-Feb-19	"Addenbrooke's Hospital, Cambridge, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|The Christie Hospital, Manchester, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/31/NCT00977431/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT00977431/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT00977431
638	NCT04195139	Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM	NUTMEG	"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Drug: Nivolumab|Drug: Temozolomide	Overall survival outcomes|Progression Free Survival|Number and severity of adverse events|Health related quality of life of participants|Neurologic function of participants|Correlating modified RANO and immune related RANO in the experimental arm	"University of Sydney|Cooperative Trials Group for Neuro-Oncology|National Health and Medical Research Council, Australia"	All	65 Years and older   (Older Adult)	Phase 2	103	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	"COGNO 16/01, CTC 0156|ACTRN12617000267358"	22-Feb-18	31-Dec-21	31-Dec-22	11-Dec-19		29-Jun-21	"Duke University Medical Center, Durham, North Carolina, United States|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Newcastle Private Hospital, New Lambton Heights, New South Wales, Australia|Port Macquarie Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, Saint Leonards, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Icon Cancer Centre, South Brisbane, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"		https://ClinicalTrials.gov/show/NCT04195139
639	NCT00606008	A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma		Completed	Has Results	Anaplastic Astrocytoma|Glioblastoma	Drug: Sunitinib Malate	"Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse|Best Overall Response|Number of Participants With Related Grade 3 and Greater Adverse Events"	H. Lee Moffitt Cancer Center and Research Institute|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-14916	Mar-07	Aug-12	Aug-12	1-Feb-08	31-Oct-12	19-Nov-12	"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT00606008
640	NCT01957956	Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma		"Active, not recruiting"	No Results Available	Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma	Other: Laboratory Biomarker Analysis|Biological: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Drug: Temozolomide	"Incidence of significant toxicity, defined as grade 3 or higher adverse event that is possibly, probably, or definitely related to treatment measured using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Change in immunologic correlates|Clinical benefit rate|Duration of response|Overall response rate|Time to response"	Mayo Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	21	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1272|NCI-2013-01743|P30CA015083	11-Nov-13	16-Nov-16	15-Nov-22	8-Oct-13		4-Nov-21	"Mayo Clinic, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT01957956
641	NCT01089868	Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients		Completed	No Results Available	Glioblastoma Multiforme		Overall Survival|Progression Free Survival	"Ludwig-Maximilians - University of Munich|Deutsche Krebshilfe e.V., Bonn (Germany)"	All	"18 Years and older   (Adult, Older Adult)"		79	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	GGN-ZP9	Jan-07	Jun-11	Jul-12	19-Mar-10		7-Aug-12	"Department of Stereotactic Neurosurgery, Freiburg, Baden Wuertemberg, Germany|University Hospital Munich, Department of Neurosurgery, Munich, Bavaria, Germany|University Hospital Bonn, Department of Neurosurgery, Bonn, North Rhine-Westphalia, Germany"		https://ClinicalTrials.gov/show/NCT01089868
642	NCT01582516	Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma		Completed	No Results Available	Brain Tumor|Recurring Glioblastoma	Biological: delta-24-RGD adenovirus	treatment related serious adverse events|The number of participants alive after 6 months and after 1 year : Progression free survival after 6 months and overall survival after 6 months and one year.	Erasmus Medical Center|VU University Medical Center	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL24958.000.08	Jun-10	Dec-14	Dec-14	20-Apr-12		9-Mar-15	"ERasmus Medical Center, Rotterdam, Netherlands"		https://ClinicalTrials.gov/show/NCT01582516
643	NCT00883298	Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Recurrent Glioblastoma Multiforme|Recurrent Gliosarcoma	Drug: temozolomide and bevacizumab	6-month progression-free survival.|Radiographic response (Gd-MRI) including specialized MRI sequences (T2/FLAIR).|Incidence and severity of toxicity.|Tumor DNA (MGMT) analysis as it relates to survival.	"Center for Neurosciences, Tucson|Genentech, Inc."	All	"18 Years to 83 Years   (Adult, Older Adult)"	Phase 2	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AVF4514s	Apr-09	Dec-14	1-Dec-14	17-Apr-09		30-Mar-17	"Center for Neurosciences, Tucson, Arizona, United States"		https://ClinicalTrials.gov/show/NCT00883298
644	NCT04988750	Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients		Recruiting	No Results Available	Recurrent Glioblastoma	Device: NaviFUS System	Adverse events|Objective response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Corticosteroid consumption|Quality of life (QoL)	NaviFUS Corporation	All	"20 Years and older   (Adult, Older Adult)"	Not Applicable	8	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NF-2020-01	23-Sep-21	7-Oct-22	6-Jan-23	3-Aug-21		29-Sep-21	"Chang Gung Medical Foundation, Taoyuan, Taiwan"		https://ClinicalTrials.gov/show/NCT04988750
645	NCT00112502	Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme		Completed	Has Results	Brain and Central Nervous System Tumors|Glioblastoma Multiforme	Drug: Celecoxib|Drug: Isotretinoin|Drug: Temozolomide|Drug: Thalidomide	Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms|Median Progression-Free Survival (PFS) Comparison of Celecoxib Arms Versus no Celecoxib Arms|Median Progression-Free Survival (PFS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms|Median Progression-Free Survival (PFS) Comparison of Doublet Versus Triplet Therapy|Median Progression-Free Survival (PFS) of Individual Arms|Median Overall Survival (OS) Comparison of Thalidomide Arms Versus no Thalidomide Arms|Median Overall Survival (OS) Comparison of Celecoxib Arms Versus no Celecoxib Arms|Median Overall Survival (OS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms|Median Overall Survival (OS) Comparison of Doublet Versus Triplet Therapy|Overall Survival of Individual Arms	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	178	Other|NIH	Interventional	"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	2004-0662|MDA-ID-02586|NCI-6636|MDA-2004-0662|CDR0000432954|NCI-2009-00076	Sep-05	Sep-14	Sep-14	3-Jun-05	18-Oct-21	18-Oct-21	"Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas, United States|University of Texas MD Anderson Cancer Center at Orlando, Orlando, Florida, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00112502
646	NCT02605746	Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis		Completed	No Results Available	Glioblastoma|Brain Metastases	Drug: ceritinib 750mg	Plasma Concentration|Cerebrospinal Concentration|Intratumoral Concentration|Tumor Tissue|Tumor Cells in M-Phase|Double Strand DNA|Tissue Concentration	"St. Joseph's Hospital and Medical Center, Phoenix|Novartis|Wayne State University|Translational Genomics Research Institute"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	10	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	PHX15BN068	17-Feb-16	29-Nov-18	12-Jul-19	16-Nov-15		11-Dec-20	"Barrow Brain and Spine, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT02605746
647	NCT04440358	Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM		Recruiting	No Results Available	Recurrent Glioblastoma	Device: Exablate BBBD|Drug: Carboplatin	Occurrence of Adverse Events|Contrast intensity on MR imaging	InSightec	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	50	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT009 [OUS]	13-Oct-20	Oct-22	Apr-23	19-Jun-20		7-Dec-21	"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Sheba Medical Center, Tel Hashomer, Israel|Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy|Yonsei University Medical Center, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT04440358
648	NCT03276286	Nativis Voyager for Newly Diagnosed GBM	NAT109	Unknown status	No Results Available	Glioblastoma Multiforme	Device: Nativis Voyager	Treatment-related Adverse Events (Safety)|Clinical Utility PFS|Clinical Utility OS	"Nativis, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	37	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	NAT109	10-Nov-17	31-Jan-20	31-Jan-20	8-Sep-17		20-Aug-19	"Center for Neurosciences, Tucson, Arizona, United States|California Cancer Care Associates, Encinitas, California, United States|John Wayne Cancer Institute @ Providence St Johns Health Center, Santa Monica, California, United States|Associated Neurologists of Southern CT, PC, Fairfield, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Cancer Care Collaborative, Austin, Texas, United States|Baylor Scott and White Health, Temple, Texas, United States"		https://ClinicalTrials.gov/show/NCT03276286
649	NCT00392548	URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol		Unknown status	No Results Available	Glioblastoma			Tel-Aviv Sourasky Medical Center|Radiation Therapy Oncology Group	All	"18 Years and older   (Adult, Older Adult)"		130	Other	Observational	Observational Model: Defined Population|Time Perspective: Prospective	RTOG0611	Oct-06		Oct-06	26-Oct-06		26-Oct-06	"tel Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT00392548
650	NCT04417088	Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Carboplatin|Device: Exablate BBBD	Adverse events|Contrast intensity on MR imaging	InSightec	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT009	6-Nov-20	Apr-23	Nov-23	4-Jun-20		1-Dec-21	"Stanford University, Palo Alto, California, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT04417088
651	NCT02176720	Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma		Terminated	No Results Available	Glioma|Glioblastoma|Glioblastoma Multiforme	Drug: FDOPA PET	Diagnostic accuracy compared to standard diagnostics without PET|Impact of FDOPA PET on patient management	"The Methodist Hospital Research Institute|University of California, Los Angeles"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	31	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Pro00009857|121638|1013-0158	May-14	Mar-16	Mar-16	27-Jun-14		17-Aug-18	"Houston Methodist Research Institute PET Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02176720
652	NCT00104091	Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors		Completed	No Results Available	Glioblastoma Multiforme	Drug: TP-38	"Evaluate TP-38 at a 100 nanograms/mL concentration for sufficient activity|Efficacy parameters including time to progression, safety, and survival"	"Teva Branded Pharmaceutical Products R&D, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IXR-202-22-188	Dec-04	Apr-07	Jun-07	23-Feb-05		23-May-11			https://ClinicalTrials.gov/show/NCT00104091
653	NCT00335075	Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)		Completed	No Results Available	Glioblastoma|Astrocytoma	Drug: Temozolomide|Drug: Semustine	Progression-free survival|Overall survival|Objective response|Scoring of health-related quality of life	Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	151	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P03644	2-Mar-05	23-Feb-06	23-Feb-06	8-Jun-06		15-May-17			https://ClinicalTrials.gov/show/NCT00335075
654	NCT00456612	Radiosurgery for Glioblastoma Multiforme		Terminated	Has Results	Glioblastoma Multiforme	Procedure: CyberKnife	"The Percent Progression -Free Survival at 6 Months Will be Tabulated|Progression Free Survival|Response, Median Time to Tumor Progression,Overall Survival, Percent Overall Survival at 1 Year Will be Tabulated."	Beth Israel Deaconess Medical Center	All	66 Years and older   (Older Adult)	Phase 1|Phase 2	4	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2006P-000464	Feb-07	Dec-10	Dec-10	5-Apr-07	5-Oct-15	6-Mar-17	"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00456612
655	NCT00200161	Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma		Completed	Has Results	Glioblastoma|Gliomas	Drug: Temozolomide	12 Month Overall Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concurrent Temozolomide and Radiotherapy Followed by Dose Dense or Metronomic Dosing of Temozolomide and Maintenance Cis-retinoic Acid.|Progression Free Survival at 6 Months|Prognostic Impact of Methylated MGMT Status.|To Collect Preliminary Data on the Efficacy of This Regimen and Impact of MGMT Status in Other Malignant Glioma Subtypes.	Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	127	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-079	9-Aug-05	4-May-17	4-May-17	20-Sep-05	7-Mar-18	7-Mar-18	"Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/61/NCT00200161/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT00200161
656	NCT00154375	Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma		Completed	Has Results	Glioblastoma Multiforme|Astrocytoma	Drug: Imatinib mesylate|Drug: Hydroxyurea	"Percentage of Participants With Progression Free Survival (PFS) During the Study Duration|Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations"	Novartis Pharmaceuticals|Novartis	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	240	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSTI571BDE40	Oct-04	Aug-08		12-Sep-05	2-Feb-11	26-Apr-11	"Novartis Investigative Site, Duelmen, Germany"		https://ClinicalTrials.gov/show/NCT00154375
657	NCT01062425	Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma		"Active, not recruiting"	Has Results	Adult Glioblastoma|Adult Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Cediranib Maleate|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Placebo Administration|Drug: Temozolomide	6-month Progression-free Survival Rate|Overall Survival (OS)|Progression-free Survival (PFS)|Incidence of Grade 3+ Toxicities	National Cancer Institute (NCI)|NRG Oncology|Radiation Therapy Oncology Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	261	NIH|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCI-2011-02012|CDR0000665163|RTOG-0837|RTOG 0837|U10CA180868|U10CA021661	26-Feb-10	6-Dec-15		4-Feb-10	19-Sep-16	15-Dec-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|AdventHealth Orlando, Orlando, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Queen's Medical Center, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Sparta Cancer Treatment Center, Sparta, New Jersey, United States|University of Rochester, Rochester, New York, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Summa Health System - Barberton Campus, Barberton, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, United States|UH Seidman Cancer Center at Salem Regional Medical Center, Salem, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|Cancer Treatment Center, Wooster, Ohio, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Jefferson Abington Hospital, Abington, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|University of Washington Medical Center - Montlake, Seattle, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01062425
658	NCT02227901	"Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: Tipifarnib|Radiation: External Beam Radiation Therapy|Drug: Temozolomide|Other: Laboratory Biomarker Analysis	"Dose limiting toxicity (DLT) of tipifarnib, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0|MTD of tipifarnib, defined as the dose level at which 0 or 1/6 patients experience DLT with the next higher dose having at least 2/3 or 2/6 patients encountering DLT, graded according to the NCI CTCAE v4.0|Incidence of adverse events of tipifarnib in combination with EBRT and temozolomide, graded according to the NCI CTCAE v4.0|Anti-tumor activity of tipifarnib"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-01809|NCI-03-C-0189|NABTC-0202|NABTC02-02|NABTC-02-02|U01CA062399	Sep-02	Jun-07	Apr-14	28-Aug-14		23-Dec-14	"Ronald Reagan UCLA Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT02227901
659	NCT04471844	"Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM"	EF-32	Recruiting	No Results Available	Glioblastoma Multiforme	Device: Optune®	Overall Survival (OS)|Progression Free Survival (PFS)|1- and 2-year survival rates|Overall Radiological response (ORR)|Next progression-free survival (PFS2)|Progression-free survival at 6 (PFS6) and 12 months (PFS12)|Severity and frequency of adverse events|Pathological changes in resected GBM tumors following study treatments|Quality of Life EORTC Questionnaire|Dependence of overall survival on TTFields dose at the tumor|The NANO scale	NovoCure GmbH|NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	950	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TRIDENT EF-32	8-Dec-20	Aug-24	Aug-26	15-Jul-20		15-Dec-21	"Grandview Cancer Center, Birmingham, Alabama, United States|St. Joseph's Hospital and Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States|Mayo Clinic- Arizona, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center, Fullerton, California, United States|University of California at San Diego - Moores Cancer Center, La Jolla, California, United States|Norris Comprehensive Cancer Center at USC, Los Angeles, California, United States|Cedars - Sinai Medical Center, Los Angeles, California, United States|Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center, Los Angeles, California, United States|Hoag Memorial Hospital - Hoag Cancer Center, Newport Beach, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|St. Joseph's Hospital, Orange, California, United States|University of California - Irvine/UCI Medical Center, Orange, California, United States|Stanford University Cancer Institute, Palo Alto, California, United States|Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|John Wayne Cancer Institute at St. John's Health Center, Santa Monica, California, United States|Stanford Cancer Institute, Stanford, California, United States|University of Colorado Cancer Center Anschutz, Aurora, Colorado, United States|HCA Research Institute - Blue Sky Neurology - Denver, Englewood, Colorado, United States|Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center, New London, Connecticut, United States|Lynn Cancer Institute, Marcus Neuroscience Institute, Boca Raton, Florida, United States|Baptist Health - Jacksonville, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth, Orlando, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States|Piedmont Healthcare Brain Tumor Center, Atlanta, Georgia, United States|The Emory Clinic - Emory Healthcare - Winship Cancer Institute, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates, Fort Wayne, Indiana, United States|The University of Kansas Cancer Center, Overland Park, Kansas, United States|St. Elizabeth, Edgewood, Kentucky, United States|University of Louisville - James Graham Brown Cancer Center, Louisville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|NeuroMedical Center - Mary Bird Cancer Center, Baton Rouge, Louisiana, United States|LSU Health Sciences Center, New Orleans, New Orleans, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|Maine Medical Partners Neurology - Neurosurgery & Spine Associates, South Portland, Maine, United States|John Hopkins School of Medicine, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Abbott Northwestern Hospital - Givens Brain Tumor Center, Minneapolis, Minnesota, United States|University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States|University of Missouri - Ellis Fischel Cancer Center, Columbia, Missouri, United States|Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|JFK Neuroscience Institute, HMH JFK University Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States|Northwell Health System Brain Tumor Center, Lake Success, New York, United States|NYU Langone - Laura & Issac Perimutter Cancer Center, New York, New York, United States|Mount Sinai - Icahn School of Medicine, New York, New York, United States|New York Presbyterian - Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Novant Health Medical Center Huntersville, Charlotte, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Forsyth Medical Center-Novant Health, Winston-Salem, North Carolina, United States|Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Case Western - University Hospitals Case Medical Center, Cleveland, Ohio, United States|The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Geisinger Health System, Danville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|MUSC Radiation Oncology Brain & Spine Tumor Program, Charleston, South Carolina, United States|SCRI - Tennessee Oncology, Chattanooga, Tennessee, United States|West Cancer Center - Germantown, Germantown, Tennessee, United States|SCRI - Tennessee Oncology, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology Midtown - Austin Brain Tumor Center, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center, Dallas, Texas, United States|John Peter Smith Health Network - JPS Cancer Center, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences, Houston, Texas, United States|San Antonio Cancer Institute, San Antonio, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|The University of Vermont Medical Center - University of Vermont Cancer Center, Burlington, Vermont, United States|Massey Cancer Center - VCU Medical Center, Richmond, Virginia, United States|Swedish Health Services, Seattle, Washington, United States|UW Medical Center - Alvord Brain Tumor Center, Seattle, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|GenesisCare St Vincent's Hospital, Darlinghurst, New South Wales, Australia|GenesisCare Newcastle, Gateshead, New South Wales, Australia|GenesisCare Hurstville - Centre for radiation oncology Waratah Private Hospital, Hurstville, New South Wales, Australia|GenesisCare Wesley - Wesley Medical Centre, Brisbane, Queensland, Australia|GenesisCare Kurralta Park, Kurralta Park, South Australia, Australia|Innsbruck University Hospital, Innsbruck, Austria|Kepler University Hospital, Linz, Austria|University Hospital Salzburg, Salzburg, Austria|Hospital Erasme, Brussels, Belgium|University Hospital Liege - Sart Tilman, Liège, Belgium|BC Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM Centre de Recherche, Montréal, Quebec, Canada|Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita, Sherbrooke, Quebec, Canada|Masaryk Memorial Cancer Institute, Brno, Czechia|University Hospital Plzeň, Pilsen, Czechia|Na Homolce Hospital, Prague, Czechia|Institut de cancérologie de l'Ouest, Angers, France|Pierre Wertheimer Hospital, Bron, France|Marseille University Hospital Timone, Marseille, France|University Hospital Nice, Nice, France|Pitié-Salpêtrière University Hospital, Paris, France|Institute Cancer Westerly Nantes, Saint Herblain, France|University Institute Cancer Toulouse Oncopole, Toulouse, France|Gustave Roussy Institute, Villejuif, France|University Hospital Berlin, Berlin, Germany|University Hospital Essen, Essen, Germany|University Medical Center Freiburg, Freiburg, Germany|University Hospital Leipzig, Leipzig, Germany|Rechts der Isar Hospital, Munich, Germany|University Hospital Tübingen, Tübingen, Germany|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center - Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Lausanne University Hospital, Lausanne, Switzerland|University Hospital Zurich, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT04471844
660	NCT01120639	Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform	Tx-Treatment	Completed	Has Results	Glioblastoma|Cancer of Brain and Nervous System|Glioblastoma Multiforme	Drug: Temozolomide|Procedure: Stereotactic Radiosurgery (SRS)	Number of Dose-limiting Toxicities (DLTs)|Number of Acute Toxicity Within 30 Days|Long-term Toxicity After More Than 30 Days|Percent of Participants With Radiographic Response|Progression-free Survival|Overall Survival (OS)|Quality of Life by European Organisation for Research and Treatment of Cancer (EORTC-QLQ C30) Survey|Quality of Life by Brain-20 Survey|Quality of Life by MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) Survey|Treatment Failure Analysis	Stanford University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-17774|SU-04202010-5726|BRN0012	Apr-10	Nov-16	15-Nov-20	11-May-10	31-Jul-19	6-Aug-21	"Stanford University School of Medicine, Stanford, California, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/39/NCT01120639/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01120639
661	NCT04479241	LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|Brain Tumor	Biological: lerapolturev|Biological: pembrolizumab	"Objective Response Rate (ORR), Duration of response (DOR) and Durable Radiographic Response (DRR)|Frequency and severity of treatment-emergent adverse events|Disease control rate (DCR)|Duration of disease control (DDC)|Progression free survival time|Survival assessed by Kaplan-Meier methods"	"Istari Oncology, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUMINOS-101	21-Oct-20	Mar-23	Mar-23	21-Jul-20		14-Dec-21	"University of California San Francisco, San Francisco, California, United States|UConn Health, Farmington, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT04479241
662	NCT01468324	AZD7451 for Recurrent Gliomas		Completed	No Results Available	Glioblastoma Multiforme	Drug: AZD7451	To establish the maximum tolerated dose of AZD7451 on a continuous once daily schedule in patients with recurrent gliomas not on enzyme-inducing anti-epileptic drugs (EIAED).|To obain exploratory information about the anti-tumor activity of AZD7451.	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 1	14	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	120005|12-C-0005	5-Oct-11	23-Apr-14	23-Apr-14	9-Nov-11		17-Dec-19	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01468324
663	NCT01430351	"Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy"		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma|Supratentorial Glioblastoma	Drug: Mefloquine|Drug: Memantine Hydrochloride|Drug: Metformin Hydrochloride|Drug: Temozolomide	Incidence of toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Median progression free survival (PFS)|PFS|Median overall survival (OS)	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	144	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0374|NCI-2011-03038|P30CA016672	14-Sep-11	30-Sep-22	30-Sep-22	8-Sep-11		18-Jun-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01430351
664	NCT01702610	Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma Mutliforme	Radiation: IMRT Technique|Radiation: IMRT and accelerated hypofractionation technique|Radiation: neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Drug: Temozolomide and Accelerated Hypofractionation RT	Percent of patients completing the study treatment|To assess toxicity of the regimen	McGill University Health Centre/Research Institute of the McGill University Health Centre	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEN-08-013|MGRT01:TMZ/GBM	Dec-08	Dec-14	Dec-14	8-Oct-12		28-Sep-16	"McGill University Health Center, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT01702610
665	NCT00805961	"RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM"		Completed	Has Results	Glioblastoma Multiforme	Radiation: Radiation therapy|Drug: Temozolomide|Drug: Bevacizumab|Drug: Everolimus	Progression-free Survival (PFS)|Number of Participants Experiencing Toxicity After This Novel Multimodality Regimen|Overall Survival of Patients With Glioblastoma Multiforme Following Treatment With This Novel Multimodality Regimen|Objective Response Rate of Patients With Glioblastoma Multiforme Following Treatment With This Novel Multimodality Regimen	"SCRI Development Innovations, LLC|Genentech, Inc.|Novartis"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	68	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI CNS 10	Jan-09	Oct-09	May-13	10-Dec-08	21-Sep-12	8-Dec-21	"Clearview Cancer Institute, Huntsville, Alabama, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|St. Louis Cancer Care, Chesterfield, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Methodist Cancer Center, Omaha, Nebraska, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00805961
666	NCT02654964	Cancer Stem Cell High-Throughput Drug Screening Study		Unknown status	No Results Available	Glioblastoma Multiforme	Drug: Combination Drug Therapy	Tumor size|Progression free survival|Overall response rate|Overall survival	Swedish Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HTS Drug Screening Study	Nov-15	Dec-17	Dec-18	13-Jan-16		5-Dec-16	"Swedish Medical Center, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT02654964
667	NCT02441322	Evaluating Therapeutic Response to Novo-TTF		Recruiting	No Results Available	Glioblastoma Multiforme	Device: Novo-TTF	Radiological response using standard of care bi monthly MRI scans|Overall survival (OS)|Progression free survival time|Treatment Response using modified RANO criterion	Abramson Cancer Center of the University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	12314|820817	Dec-14	Dec-22	Dec-22	12-May-15		4-Oct-21	"University Of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02441322
668	NCT02761070	"Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III"	RE-GEND	Recruiting	No Results Available	Glioblastoma|Recurrence|Progression	Drug: Temozolomide|Drug: Bevacizumab	Overall survival|Progression-free survival (PFS)|6-month progression-free survival (6m-PFS)|Complete response rate|Response rate|Adverse events|Serious adverse events|Progression-free survival (PFS) from bevacizumab (BEV) initiation|6-month progression-free survival (6m-PFS) after initiation of bevacizumab (BEV) (Experimental Arm Only)|Overall survival after initiation of bevacizumab (BEV)|MMSE non-deterioration rate|KPS non-deterioration rate	Kyorin University|Japan Clinical Oncology Group	All	"20 Years to 75 Years   (Adult, Older Adult)"	Phase 3	146	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JCOG1308C	11-Jul-16	10-Nov-25	10-Nov-25	4-May-16		2-Sep-21	"Nagoya University Hospital, Nagoya, Aichi, Japan|Fujita Health University Hospital, Toyoake, Aichi, Japan|Hirosaki University School of Medicine, Hirosaki, Aomori, Japan|Ehime University Graduate School of Medicine, Shizukawa, Ehime, Japan|Kurume University Hospital, Kurume-shi, Fukuoka, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe University Hospital, Kobe, Hyougo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University, Morioka, Iwate, Japan|Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan|Nagasaki University Hospital, Nagasaki-shi, Nagasaki, Japan|Kansai Medical University, Hirakata, Osaka, Japan|Osaka University Graduate School of Medicine, Suita, Osaka, Japan|Saga University Hospital, Saga-shi, Saga, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Dokkyo Medical University, Shimotsuge, Tochigi, Japan|Tokyo Medical And Dental University, Medical Hospital, Bunkyō-Ku, Tokyo, Japan|University of Yamanashi, Chuo-shi, Yamanashi, Japan|Chiba University Hospital, Chiba, Japan|Kusyu University Graduate School of Medical Sciences, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan|Kitasato University School of Medicine, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kyoto University Graduate School of Medicine, Kyoto, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Nakamura Memorial Hospital, Sapporo, Japan|Hokkaido University Graduate School of Medicine, Sapporo, Japan|Shizuoka Canser Center Hospital, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|The University of Tokyo Hospital, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|Nihon University School of Medicine Itabashi Hospital, Tokyo, Japan|Kyorin University Faculty of Medicine, Department of Neurosurgery, Tokyo, Japan|Yamagata University Hospital, Yamagata, Japan"		https://ClinicalTrials.gov/show/NCT02761070
669	NCT02780024	"Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM"		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Drug: Metformin	Number of patients completing the study treatment|To assess toxicity of the regimen	McGill University Health Centre/Research Institute of the McGill University Health Centre	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MUHC ID: 4315	Mar-15	Dec-21	Dec-23	23-May-16		5-Sep-21	"Montreal Neurological Institute - McGill University Health Centre, Montréal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT02780024
670	NCT02337426	"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Adult Brain Glioblastoma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma	Drug: Dimethyl Fumarate|Drug: Temozolomide|Radiation: Radiation Therapy	RP2D for DMF when combined with concurrent temozolomide and radiotherapy determined by the incidence of dose limiting toxicities (DLTs) graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Incidence of adverse events graded according to NCI CTCAE version 4.0|Progression free survival (PFS)|Overall survival (OS)|Response rate assessed as per the Response Assessment in Neuro-oncology for magnetic resonance imaging scans or Macdonald criteria for computed tomography scans	Virginia Commonwealth University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-13-09950|NCI-2014-02619|HM20003022|P30CA016059	13-Feb-15	8-Nov-16	9-Nov-17	13-Jan-15		28-Jun-19	"Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02337426
671	NCT03144167	Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy	SPECTROBEVA	Unknown status	No Results Available	Glioblastoma|Radiotherapy|Chemotherapy	Other: Analysis of spectroscopic biomarkers of proliferation for six-month survival	Analyze 6-month survival defined as the time between inclusion in the protocol and death	"Centre Hospitalier Universitaire, Amiens"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	170	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	PI2016_843_0027	20-Aug-17	20-Jan-21	20-Jan-21	8-May-17		21-Jul-17	"CHU Amiens Picardie, Amiens, Picardie, France"		https://ClinicalTrials.gov/show/NCT03144167
672	NCT00967330	A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma		Completed	Has Results	Glioblastoma Multiforme	Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: temozolomide	"Percentage of Participants Achieving Progression-Free Survival (PFS) Without Disease Progression or Death at 6 Months|Progression-Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants Who Discontinued|Number of Participants With A Best Overall Response (BOR) of Complete Response (CR) and With A BOR of CR or Partial Response (PR)|Percentage of Participants With Response on FLAIR Imaging|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ - C30) at Baseline, Post-Baseline (up to Month 30)|Change From Baseline for EORTC QLQ Brain Neoplasm 20 (BN20) at Baseline, Post-Baseline (up to Month 30)|Change From Baseline for Mini-Mental Status Examination (MMSE) at Baseline, Post-Baseline (up to Month 30)|Change From Baseline for Karnofsky Performance Status (KPS) Score at Baseline, Post-Baseline (up to Month 30)|Percentage of Participants Who Received Corticosteroid for Glioblastoma|Time to Treatment Failure"	Hoffmann-La Roche	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	182	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ML21965|2009-010390-21	Jun-10	Sep-14	Sep-14	27-Aug-09	20-Nov-15	20-Nov-15	"Aachen, Germany|Berlin, Germany|Bochum, Germany|Bonn, Germany|Chemnitz, Germany|Dresden, Germany|Düsseldorf, Germany|Erfurt, Germany|Erlangen, Germany|Frankfurt am Main, Germany|Freiburg, Germany|Göttingen, Germany|Idar-Oberstein, Germany|Kiel, Germany|Köln, Germany|Leipzig, Germany|Mannheim, Germany|Marburg, Germany|Muenchen, Germany|München, Germany|Münster, Germany|Regensburg, Germany|Tübingen, Germany|Ulm, Germany"		https://ClinicalTrials.gov/show/NCT00967330
673	NCT04003649	IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM		Recruiting	No Results Available	Recurrent Glioblastoma|Refractory Glioblastoma	Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Biological: Ipilimumab|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	"Incidence of adverse events|Dose-limiting toxicity (DLT)|Feasibility (neoadjuvant therapy)|Feasibility (adjuvant therapy)|Overall Survival|T cell levels|Cytokine levels in TCF, PB, and CSF|Disease response|Time to progression|Overall survival (OS)|Quality of life (QOL)|Area under the curve (AUC) for CD3, IFNgamma, and IP-10 levels over time for the DLT evaluation period|CAR T and endogenous cells detected in tumor tissue|IL13Ralpha2 antigen expression levels in tumor tissue|PD-L1 levels on tumor cells|Biomathematical modeling of tumor growth|Progression free survival (PFS)"	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	60	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18251|NCI-2018-02764|R01CA236500	26-Sep-19	1-Dec-22	1-Dec-22	1-Jul-19		5-Nov-21	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT04003649
674	NCT02179086	Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Radiation: photon beam radiation therapy|Radiation: proton beam radiation therapy|Drug: temozolomide|Other: laboratory biomarker analysis	"Overall survival (OS) compared between dose-escalated and -intensified photon IMRT or proton beam therapy with concomitant and adjuvant temozolomide and the standard-dose photon irradiation with concomitant and adjuvant temozolomide|OS when compared between dose-escalated and -intensified photon IMRT to dose-escalated and -intensified proton beam therapy|Progression-free survival (PFS)|Incidence of treatment-related toxicity, as measured by the Common Terminology Criteria for Adverse Events version 4|Change in perceived cognitive function, as measured by M.D. Anderson Symptom Inventory Brain Tumor|Change in neurocognitive function, as measured by Hopkins' Verbal Learning Test-Revised, Trail Making Test Parts A and B, and Controlled Oral Word Association Test|Change in CD4 lymphopenia count|Use of magnetic resonance diffusion and perfusion imaging to differentiate between tumor progression and pseudo-progression"	NRG Oncology|National Cancer Institute (NCI)|Radiation Therapy Oncology Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	606	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NRG-BN001|NCI-2014-01072|U10CA180868	27-Oct-14	May-24	May-26	1-Jul-14		5-Nov-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Arizona Oncology Associates-West Orange Grove, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Fresno Cancer Center, Fresno, California, United States|Marin General Hospital, Greenbrae, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Pomona Valley Hospital Medical Center, Pomona, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory Proton Therapy Center, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Community Cancer Center East, Indianapolis, Indiana, United States|Community Cancer Center South, Indianapolis, Indiana, United States|Community Cancer Center North, Indianapolis, Indiana, United States|IU Health Ball Memorial Hospital, Muncie, Indiana, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Willis-Knighton Medical and Cancer Center, Shreveport, Louisiana, United States|Maryland Proton Treatment Center, Baltimore, Maryland, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|UM Upper Chesapeake Medical Center, Bel Air, Maryland, United States|Central Maryland Radiation Oncology in Howard County, Columbia, Maryland, United States|UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|McLaren Cancer Institute-Lapeer Region, Lapeer, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Central Michigan, Mount Pleasant, Michigan, United States|McLaren Cancer Institute-Owosso, Owosso, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|North Kansas City Hospital, Kansas City, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Saint Mary's Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States|ProCure Proton Therapy Center-Somerset, Somerset, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio, United States|University Hospitals Parma Medical Center, Parma, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio, United States|Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio, United States|University of Toledo, Toledo, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Ephrata Cancer Center, Ephrata, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|UPMC Pinnacle Cancer Center/Community Osteopathic Campus, Harrisburg, Pennsylvania, United States|Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Jefferson Torresdale Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Tennessee Cancer Specialists-Dowell Springs, Knoxville, Tennessee, United States|Dell Seton Medical Center at The University of Texas, Austin, Texas, United States|Austin Cancer Centers-Central Austin, Austin, Texas, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, United States|Austin Cancer Centers-North, Austin, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Texas Oncology - Denison Cancer Center, Denison, Texas, United States|Texas Oncology-Flower Mound, Flower Mound, Texas, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Memorial Hermann Memorial City Medical Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|UTMB Cancer Center at Victory Lakes, League City, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|Texas Oncology-Seton Williamson, Round Rock, Texas, United States|Texas Oncology - Round Rock Cancer Center, Round Rock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Logan Regional Hospital, Logan, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|SCCA Proton Therapy Center, Seattle, Washington, United States|Seattle Cancer Care Alliance at Northwest Hospital, Seattle, Washington, United States|University of Washington Medical Center - Montlake, Seattle, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|BCCA-Vancouver Island Cancer Centre, Victoria, British Columbia, Canada|Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada|CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT02179086
675	NCT00725010	Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)		Completed	Has Results	Glioblastoma	Drug: Temozolomide|Radiation: Radiotherapy	Safety: Number of Adverse Events in the Indicated Categories|Number of Participants Who Discontinued Due to Toxicity	Merck Sharp & Dohme Corp.	All	"Child, Adult, Older Adult"		64	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	P04816	Apr-07	Apr-09	Apr-09	30-Jul-08	18-Nov-10	9-Sep-15			https://ClinicalTrials.gov/show/NCT00725010
676	NCT03158389	NCT Neuro Master Match - N²M² (NOA-20)	N²M²	Recruiting	No Results Available	"Glioblastoma, Adult"	Drug: APG101|Drug: Alectinib|Drug: Idasanutlin|Drug: Atezolizumab|Drug: Vismodegib|Drug: Temsirolimus|Drug: Palbociclib	PFS-6 rate|Incidence of Treatment-Emergent Adverse Events (AE)|Overall survival (OS)	"University Hospital Heidelberg|German Cancer Aid|German Cancer Research Center|National Center for Tumor Diseases, Heidelberg"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	350	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCT-2014-0235/N2M2|2015-002752-27	7-May-18	30-Sep-23	30-Sep-24	18-May-17		27-Feb-20	"Charité Berlin, Neurosurgery, Berlin, Germany|Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic, Bochum, Germany|University Hospital Bonn, Neurology Clinic, Bonn, Germany|University Hospital Cologne, Neurosurgery, Cologne, Germany|University Hospital Dresden, Neurosurgery, Dresden, Germany|University Hospital Essen, Neurology Clinic, Essen, Germany|University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany|University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany|University Hospital Saarland, Neurosurgery, Homburg, Germany|University Hospital Mainz, Neurosurgery, Mainz, Germany|University Hospital Mannheim, Neurology Clinic, Mannheim, Germany|University Hospital Regensburg, Neurology Clinic, Regensburg, Germany|University Hospital Tuebingen, Neurooncology, Tübingen, Germany"		https://ClinicalTrials.gov/show/NCT03158389
677	NCT00088400	Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors		Completed	No Results Available	Glioblastoma	Drug: TransMID		National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	"Child, Adult, Older Adult"	Phase 3	30	NIH	Interventional	Primary Purpose: Treatment	040244|04-N-0244	Jul-04		Nov-05	26-Jul-04		22-Sep-16	"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00088400
678	NCT00884741	Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma		Completed	Has Results	Glioblastoma|Gliosarcoma|Supratentorial Glioblastoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Biological: Bevacizumab|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Drug: Temozolomide	Overall Survival (OS)|Progression-free Survival (PFS)|Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0	National Cancer Institute (NCI)|Radiation Therapy Oncology Group|NRG Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	637	NIH|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCI-2009-01670|RTOG-0825|RTOG 0825|CDR0000640428|U10CA180868|U10CA021661	15-Apr-09	17-Mar-13	17-Mar-13	21-Apr-09	12-Oct-16	24-Jul-19	"Providence Hospital, Mobile, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Arizona Oncology Associates-West Orange Grove, Tucson, Arizona, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|California Cancer Center - North Fresno, Fresno, California, United States|Cancer Care Associates of Fresno Medical Group Inc, Fresno, California, United States|Saint Jude Medical Center, Fullerton, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Pomona Valley Hospital Medical Center, Pomona, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Mercy General Hospital Radiation Oncology Center, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Vincent's Medical Center, Bridgeport, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Yale University, New Haven, Connecticut, United States|William Backus Hospital, Norwich, Connecticut, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Integrated Community Oncology Network-Florida Cancer Center Beaches, Jacksonville Beach, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Integrated Community Oncology Network-Southside Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|21st Century Oncology-Orange Park, Orange Park, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|21st Century Oncology-Palatka, Palatka, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Integrated Community Oncology Network-Flager Cancer Center, Saint Augustine, Florida, United States|Robert and Carol Weissman Cancer Center at Martin Health, Stuart, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Memorial University Medical Center, Savannah, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|Edward Hospital/Cancer Center, Naperville, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|IU Health Bloomington, Bloomington, Indiana, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Community Cancer Center East, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers-East, Indianapolis, Indiana, United States|Community Cancer Center North, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|IU Health Ball Memorial Hospital, Muncie, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Physicians' Clinic of Iowa PC, Cedar Rapids, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Saint Anne's Hospital, Fall River, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|D'Amour Center for Cancer Care, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Cape Radiation Oncology, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center-South, Kansas City, Missouri, United States|The University of Kansas Cancer Center-North, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Concord Hospital, Concord, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Elliot Hospital, Manchester, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Sparta Cancer Treatment Center, Sparta, New Jersey, United States|Lovelace Medical Center-Downtown, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|New York Oncology Hematology PC - Albany, Albany, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Sands Cancer Center, Canandaigua, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|South Nassau Communities, Oceanside, New York, United States|Hudson Valley Oncology Associates, Poughkeepsie, New York, United States|Highland Hospital, Rochester, New York, United States|University Radiation Oncology, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|FirstHealth of the Carolinas-Moore Regional Hosiptal, Pinehurst, North Carolina, United States|Duke Women's Cancer Care Raleigh, Raleigh, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Akron General Medical Center, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Mercy Medical Center, Canton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|Southwest General Health Center Ireland Cancer Center, Middleburg Heights, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Cancer Care Center, Incorporated, Salem, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Trinity's Tony Teramana Cancer Center, Steubenville, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|University Pointe, West Chester, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Salem Hospital, Salem, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|The Regional Cancer Center, Erie, Pennsylvania, United States|Fox Chase Cancer Center Buckingham, Furlong, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|Armstrong Center for Medicine and Health, Kittanning, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|Intercommunity Cancer Center, Monroeville, Pennsylvania, United States|Allegheny Valley Hospital, Natrona Heights, Pennsylvania, United States|UPMC Jameson, New Castle, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Aria Health-Torresdale Campus, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC Jefferson Regional Radiation Oncology, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States|Erlanger Medical Center, Chattanooga, Tennessee, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology Bedford, Bedford, Texas, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Texas Oncology Methodist Charlton Cancer Center, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|The Klabzuba Cancer Center, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|West Texas Cancer Center, Odessa, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Texas Cancer Center-Sherman, Sherman, Texas, United States|Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Inova Alexandria Hospital, Alexandria, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Radiology Associates of Appleton/ThedaCare Regional Medical Center, Appleton, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|UW Cancer Center Johnson Creek, Johnson Creek, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Dean Hematology and Oncology Clinic, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Medical Center, Marshfield, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Saint Michael's Hospital, Stevens Point, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Aspirus UW Cancer Center, Wisconsin Rapids, Wisconsin, United States|Doctor H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|Health Sciences North, Sudbury, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT00884741
679	NCT00402116	Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients		Completed	Has Results	Glioblastoma|Glioblastoma Multiforme|Gliosarcoma	Drug: enzastaurin|Drug: temozolomide|Radiation: radiation therapy	"Phase 1- Determination of the Maximum Tolerated Dose (MTD) of Enzastaurin|Phase 1 and Phase 2 - Overall Survival (OS)|Phase 1 - Number of Participants With Adverse Events (AEs)|Phase 1 and 2: Association Between Biomarkers and Clinical Outcome|Phase 1 - Response Rate With Macdonald Criteria|Phase 2 - Number of Participants With Adverse Events (AEs)|Number of Participants Undergoing Magnetic Resonance Imaging/Magnetic Resonance Spectroscopy (MRI/MRS) for Clinical Evaluation at Baseline|Phase 1 and 2 - Progression-Free Survival (PFS)|Functional Assessment of Cancer Therapy - Brain (FACT-Br)|M.D. Anderson Symptom Inventory - Brain Tumor (MDASI-BT)|Phase 1- Pharmacokinetics (PK): Maximum Observed Drug Concentration During 1 Dosing Interval at Steady State (Cmax,ss) for Enzastaurin, LY326020, and Total Analyte (Enzastaurin + LY326020) When Enzastaurin Administered With or Without Temozolomide|Phase 1 and 2- Pharmacokinetics: Area Under the Concentration-Time Curve During 1 Dosing Interval at Steady State (AUCτ,ss) for Enzastaurin, LY326020 and Total Analyte (Enzastaurin + LY326020) When Enzastaurin Administered With or Without Temozolomide"	"Eli Lilly and Company|University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	72	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9815|H6Q-MC-S008	Sep-06	Dec-09	Dec-09	22-Nov-06	6-Aug-20	6-Aug-20	"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00402116
680	NCT00508456	Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM		Terminated	No Results Available	Glioblastoma Multiforme	Drug: Temodar (Temozolomide)|Dietary Supplement: Hominex-2	Time to Disease Progression	M.D. Anderson Cancer Center	All	"Child, Adult, Older Adult"	Phase 1	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ID03-0066	Aug-04	Nov-08	Nov-08	30-Jul-07		16-Jan-12	"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00508456
681	NCT00379470	Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)		Completed	No Results Available	Recurrent Glioblastoma Multiforme	Device: NovoTTF-100A	Overall Survival|Progression free survival at 6 months (PFS6)|Median Time to Disease Progression (TTP)|% 1-year survival|Radiological response (Macdonald criteria)|Quality of life assessment (EORTC QLQ-C30)|Adverse events severity and frequency	NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	236	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EF-11	Sep-06	Nov-09	Jan-11	21-Sep-06		1-May-12	"Northwestern University, Chicago, Illinois, United States|University of Illinois in Chicago, Chicago, Illinois, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|NJ Neuroscience Institute - JFK Medical Center, Edison, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Graz, Graz, Austria|FN Brno - Masaryk University, Brno, Czech Republic|Na Homolce Hospital, Prague, Czech Republic|Hospital of Neurology Lyon - University Claude Bernard Lyon 1, Lyon, France|Group Hospitals Pitie-Salpetriere, Paris, France|University Hospital Augsburg, Augsburg, Germany|University Medical Center Hamburg-Eppendorf, Hamburg, Germany|University Hospital of Schleswig-Holstein, Kiel, Germany|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00379470
682	NCT01478854	Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide		Completed	Has Results	Glioblastoma Multiforme	Radiation: Radiation|Drug: Chemotherapy	"Number of Participants With Local Recurrence in the Spared NPC Niches|Extent of NPC Sparing|Distance of Tumor to Spared NPC Niches|Change in Neurocognitive Function as Measured by Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Subtest|Change in Neurocognitive Function as Measured by Trail Making Test|Change in Neurocognitive Function (Verbal Fluency) as Measured by Controlled Oral Word Association Test (COWAT)|Change in Neurocognitive Function (Total Recall, Delayed Recall, Recognition Discrimination) as Measured by Hopkins Verbal Learning Test-Revised (HVLT-R)|Radiation Dose to Spared NPC Region|Volume (cc) of ""NPC for Sparing"" Region"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	33	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J10100|NA_00042009	27-Dec-11	25-Apr-18	25-Apr-18	23-Nov-11	12-Jun-19	13-Jun-19	"The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/54/NCT01478854/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01478854
683	NCT01975701	A Phase 2 Study of BGJ398 in Patients With Recurrent GBM		Completed	Has Results	Recurrent Glioblastoma or Other Glioma Subtypes	Drug: BGJ398	Progression Free Survival|Overall Response Rate|Overall Survival|Safety and Tolerability	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	26	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CBGJ398X2201	9-Dec-13	3-Oct-18	3-Oct-18	5-Nov-13	4-Dec-19	4-Dec-19	"Novartis Investigative Site, Los Angeles, California, United States|University of California San Francisco Dept of Onc., San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|University Medical Center Utrecht, Utrecht, The Netherlands, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zürich, Switzerland"	"Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/01/NCT01975701/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT01975701/Prot_001.pdf"	https://ClinicalTrials.gov/show/NCT01975701
684	NCT04614493	Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.	SonoFIRST	Recruiting	No Results Available	Initial Radiological Diagnosis Eligible for Tumor Resection|Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)|Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide	Device: SonoCloud-9 (SC9) device|Drug: Temozolomide according Stupp protocol	"Progression Free Survival (PFS), PFS is defined as the time between randomization and disease progression which is the first documented tumor progression (per local Investigator assessment according to the RANO criteria) or death due to any cause.|Overall Survival improvement (OS)|central review Progression Free Survival (crPFS)|immune Progression Free Survival (iPFS)|Mean score of Patient quality of life preservation - EORTC Quality of Life Questionnaire C30|Mean score Patient quality of life preservation - BN20 Quality of Life Questionnaire|Karnofsky Performance Status (KPS)|Mean score of Patient cognitive preservation|Visual analogic scale (VAS) Pain score from surgical area|Esthetical|Safety : Type, frequency and severity of adverse events and serious adverse events"	Assistance Publique - Hôpitaux de Paris	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	66	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APHP200080|2020-001488-10	11-Sep-21	Mar-24	Mar-24	4-Nov-20		23-Sep-21	"Katholieke Universiteit Leuven, Leuven, Belgium|Centre hospitalier Universitaire d'Angers, Angers, France|Groupe Hospitalier Saint-André, Bordeaux, France|Hospices Civils de Lyon, Hôpital Pierre Wertheimer, Bron, France|AP-HM, La Timone, Hôpital Universitaire, Marseille, France|APHP-Sorbonne, Pitié Salpêtrière Hospital, Paris, France|Centre hospitalier universitaire vaudois CHUV, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT04614493
685	NCT01169415	Effects of Steroid Tapering on Functional Capacity and Neurocognition		Withdrawn	No Results Available	Glioblastoma Multiforme	Drug: Dexamethasone acetate|Drug: Dexamethasone	Functional Capacity (6-minute walk test)|Neurocognitive Function|Skeletal Muscle Strength|Patient-Reported Outcomes (PROs)|Body composition|Biochemical metabolic measurements	Duke University	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00024406	Jun-10	May-14	May-14	26-Jul-10		19-May-14			https://ClinicalTrials.gov/show/NCT01169415
686	NCT01213407	Dendritic Cell Cancer Vaccine for High-grade Glioma	GBM-Vax	Completed	No Results Available	Glioblastoma Multiforme	"Drug: Trivax, Temozolomide, Surgery, Radiotherapy|Drug: Temozolomide, Surgery, Radiotherapy"	Progression free survival|Quality of Life|Progression free survival at 18 and 24 months|Overall survival	Activartis Biotech	All	"3 Years to 70 Years   (Child, Adult, Older Adult)"	Phase 2	87	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBM-Vax-TRX2	Apr-10	Jun-15	Nov-15	4-Oct-10		19-May-16	"Landesnervenklinik Wagner-Jauregg, Linz, Oberösterreich, Austria|Landeskrankenhaus Feldkirch, Feldkirch, Austria|Department of Neurosurgery, Medical University Graz, Graz, Austria|Clinical Department of Neurology, Medical University Innsbruck, Innsbruck, Austria|Department of Neurosurgery, Christian Doppler Klinik, Paracelsus Medizinische Privatuniversität, Salzburg, Austria|Neuroonkologisches Tumorboard KFJ-KA; Rudolfsstiftung, Vienna, Austria|Department of Paediatrics, Medical University Vienna, Vienna, Austria|Medical Department of Oncology, Donauspital, SMZ-Ost, Vienna, Austria"		https://ClinicalTrials.gov/show/NCT01213407
687	NCT00731731	"Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		"Active, not recruiting"	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Procedure: Cognitive Assessment|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Drug: Vorinostat	"Maximum Tolerated Dose of Vorinostat, Defined as the Dose at Which Fewer Than One-third of Patients Experience DLTs, Graded According to NCI CTCAE (Common Toxicity Criteria for Adverse Effects) Version 3.0 (Phase I)|Overall Survival at 15 Months (Phase II)|Incidence of Adverse Events, Based on CTC (Common Toxicity Criteria) Severity Grade|Time to Tumor Progression (Phase II)|Incidence of Adverse Events, as Per NCI CTCAE Version 3.0 (Phase II)"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	125	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00672|N0874|ABTC 0902|CDR0000609743|U10CA180821|U10CA025224	10-Jul-09	2-Feb-14		11-Aug-08	13-May-15	1-Dec-21	"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|Presence Resurrection Medical Center, Chicago, Illinois, United States|Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States|Porubcin, Michael MD (UIA Investigator), Moline, Illinois, United States|Sharis, Christine M MD (UIA Investigator), Moline, Illinois, United States|Spector, David MD (UIA Investigator), Moline, Illinois, United States|Stoffel, Thomas J MD (UIA Investigator), Moline, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|McFarland Clinic PC - Ames, Ames, Iowa, United States|Constantinou, Costas L MD (UIA Investigator), Bettendorf, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Cancer Trials Support Unit, Rockville, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00731731
688	NCT04116138	Antisecretory Factor in Primary Glioblastoma 1	AFGBM1	Completed	No Results Available	Glioblastoma|Cerebral Edema|Chemotherapy Effect	Dietary Supplement: Salovum	Number of participants with treatment-related adverse|Number of participants with completion of prescribed Salovum treatment|Number of participants with altered blood levels of triglycerides and cholesterol|Number of participants with reduced or no steroid intake|Number of participants with detetable blood levels antisecretory factor|Number of participants with altered blood levels of inflammatory cytokines	Peter Siesjö|Region Skane|Lund University|Skane University Hospital|Lantmannen Medical AB	All	"18 Years to 69 Years   (Adult, Older Adult)"	Phase 1|Phase 2	8	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AFGBM1	1-Sep-19	31-Mar-21	31-Mar-21	4-Oct-19		28-Apr-21	"Department of Neurosurgery, Lund, Sweden"		https://ClinicalTrials.gov/show/NCT04116138
689	NCT00662506	"Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma"		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: Cediranib Maleate|Procedure: Diffusion Tensor Imaging|Procedure: Diffusion Weighted Imaging|Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Radiation: Fludeoxyglucose F-18|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Procedure: Perfusion Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Drug: Temozolomide	Progression-free survival (Phase II)|Safety profile and optimal dose of cediranib during chemoradiotherapy (Phase I)|Blood biomarkers (Phase II)|MRI parameters (Phase II)|Tumor biomarkers (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	46	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00267|MGH-07-344|R01CA129371|PHS 398/2590|CDR0000593717|8030|P30CA006516	Apr-08	Apr-14	Apr-14	21-Apr-08		21-Sep-17	"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00662506
690	NCT04765098	Tamoxifen Versus Etoposide After First Recurrence in GBM Patients		Not yet recruiting	No Results Available	Glioblastoma Multiforme	Drug: Tamoxifen|Drug: Etoposide	3 month progression-free survival|One-year progression-free survival|Overall survival|Health-related quality-of-life status|Adverse events	AHS Cancer Control Alberta	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT-0014	Aug-21	Aug-26	Dec-26	21-Feb-21		28-Jul-21	"Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT04765098
691	NCT00943007	Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors	RACING	Completed	No Results Available	Glioblastoma Multiforme	Device: Stealth Station|Device: PoleStar N20	"Difference in Residual tumor volume|Complications, Clinical Performance, and Quality of Life|Survival"	Maastricht University Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	14	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	MEC 08-2-055	Feb-10	Jun-13	Dec-13	21-Jul-09		10-Apr-15	"Centre Hospitalier Universitaire de Liege, Liege, Belgium|Maastricht University Medical Center, Maastricht, Netherlands"		https://ClinicalTrials.gov/show/NCT00943007
692	NCT00597493	Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM		Completed	Has Results	Recurrent Glioblastoma Multiforme	Drug: Sorafenib and Temozolomide	6 Month Progression Free Survival (PFS)|Safety and Toxicity of Combination|Pharmacokinetics: C-max|Pharmacokinetics: T-max|Pharmacokinetics: AUC-24	Duke University|Bayer|Schering-Plough	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000464	Sep-07	Feb-09	Dec-10	18-Jan-08	24-Jun-13	24-Jun-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00597493
693	NCT00316849	"Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Other: pharmacological study|Procedure: adjuvant therapy|Radiation: 3-dimensional conformal radiation therapy|Radiation: intensity-modulated radiation therapy|Drug: temsirolimus|Drug: temozolomide	"Maximally tolerated dose (MTD), determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0)|Time to treatment related toxicity as assessed by hematologic measures and CTCAE v3.0|Time to treatment related toxicity greater than grade 3, assessed by CTCAE v3.0|Time to progression|Time to treatment failure|Response to therapy associated with patient outcome, as assessed by automated morphological MRI change detector and physiological MRI techniques, including diffusion-weighted imaging, perfusion-weighted imaging, and chemical shift imaging"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	56	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00642|N027D|CDR0000467232|NCCTG-N027D|U10CA025224	May-06	Nov-10		21-Apr-06		10-Apr-13	"Mayo Clinic in Florida, Jacksonville, Florida, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mayo Clinic, Rochester, Minnesota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States"		https://ClinicalTrials.gov/show/NCT00316849
694	NCT04967690	"A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM"	TARGLIO	Not yet recruiting	No Results Available	Newly Diagnosed Glioblastoma Multiforme	Drug: SI-053	Incidence rate and the grade (severity) of dose-limiting toxicities (DLTs) of a single i.c dose of SI-053|SI-053 related adverse events (AEs) and toxicity|Determination of plasma concentration of TMZ and its metabolite 5-amino-1H-imidazole-4-carboxamide (AIC) and PK parameters	Double Bond Pharmaceutical AB	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	27	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DBP-053-01	Sep-21	Mar-23	May-23	19-Jul-21		19-Jul-21			https://ClinicalTrials.gov/show/NCT04967690
695	NCT01205334	Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme	COGLI	Terminated	No Results Available	Glioblastoma Multiforme|GBM|Brain Cancer	Biological: Autologous CMV-specific CTL	Number of subjects with dose limiting toxicity|Patients with a decrease in disease after the CTL infusion|Area under the growth curves (AUC) over time for T cell frequencies	"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute"	All	"Child, Adult, Older Adult"	Phase 1|Phase 2	2	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	26901-COGLI	Nov-10	Jan-12	Mar-12	20-Sep-10		26-Aug-13	"Texas Children's Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01205334
696	NCT01856933	BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)		Completed	Has Results	GBM|Glioblastoma Multiforme|Gliosarcoma	Drug: PSMA ADC	"Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab.|Number of Patients Who Experienced Toxicities (Adverse Events) Who Received PSMA ADC for Recurrent Glioblastoma."	"Heinrich Elinzano, MD|Progenics Pharmaceuticals, Inc.|Rhode Island Hospital|University of Texas|Brown University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	6	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	263	May-13	Nov-14	Feb-15	20-May-13	17-Jun-15	23-Nov-21	"Rhode Island Hospital, Providence, Rhode Island, United States|UT Southwestern, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT01856933
697	NCT01342757	Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma		Completed	Has Results	Adult Glioblastoma|Depression|Recurrent Adult Brain Tumor	Drug: vorinostat|Drug: temozolomide|Procedure: magnetic resonance spectroscopic imaging|Other: survey administration	Proportion of Patients With Magnetic Resonance Spectroscopy (MRS) Response to Initial Vorinostat by MRI and MRS Scans as Determined by Spectroscopic Index|Proportion of Patients Who Experience Metabolic Restoration Between the Responders and Non-responder Groups by MRS Scans|Measurable Change on Magnetic Resonance Spectroscopy Imaging After Vorinostat Administration|Mean Change in Metabolite Levels	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	12	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NCI-2011-02569|EMORY IRB #00044064|WCI-44064|R21CA141836	Dec-10	May-12	May-12	27-Apr-11	11-Jun-14	29-Jan-18	"Emory University, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT01342757
698	NCT00305864	"Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma"		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Motexafin Gadolinium|Drug: Temozolomide	Maximum Tolerated Dose of MGd (Phase I)|Median Overall Survival (Phase II)|Progression-free Survival (Phase II)	National Cancer Institute (NCI)|Radiation Therapy Oncology Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	118	NIH|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-01092|CDR0000467802|RTOG 0513|RTOG-0513|U10CA021661	9-Feb-06	16-Feb-11	15-Mar-11	22-Mar-06	17-May-13	5-Mar-18	"Mobile Infirmary Medical Center, Mobile, Alabama, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|East Bay Radiation Oncology Center, Castro Valley, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Valley Medical Oncology Consultants-Fremont, Fremont, California, United States|Saint Rose Hospital, Hayward, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|El Camino Hospital, Mountain View, California, United States|Highland General Hospital, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Hematology and Oncology Associates-Oakland, Oakland, California, United States|Tom K Lee Inc, Oakland, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Valley Care Health System - Pleasanton, Pleasanton, California, United States|Valley Medical Oncology Consultants, Pleasanton, California, United States|Doctors Medical Center- JC Robinson Regional Cancer Center, San Pablo, California, United States|Denver Veterans Administration Medical Center, Denver, Colorado, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Heartland Cancer Research NCORP, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Kewanee Hospital, Kewanee, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Franciscan Saint Margaret Health-Hammond Campus, Hammond, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Mercy Hospital-Joplin, Joplin, Missouri, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|John F Kennedy Medical Center, Edison, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Duke Women's Cancer Care Raleigh, Raleigh, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Main Line Health NCORP, Wynnewood, Pennsylvania, United States|Audie L Murphy Veterans Affairs Hospital, San Antonio, Texas, United States|Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States|University Hospital, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Cottonwood Hospital Medical Center, Murray, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Intermountain Health Care, Salt Lake City, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|University of Washington Medical Center, Seattle, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00305864
699	NCT01109095	CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM	HERT-GBM	Completed	No Results Available	Glioblastoma Multiforme (GBM)	Biological: HER.CAR CMV-specific CTLs	Number of subjects with dose limiting toxicity after CTL infusion|Decrease in tumor after the CTL infusion|Area under the growth curves (AUC) over time for T cell frequencies.|Impact of gene modified CTL on CMV-specific T lymphocyte immune response	"Baylor College of Medicine|The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine"	All	"Child, Adult, Older Adult"	Phase 1	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-24487 - HERT GBM	Oct-10	Jun-14	7-Mar-18	22-Apr-10		25-Apr-19	"Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01109095
700	NCT01465347	Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma		Completed	Has Results	Glioblastoma|GBM|Glioma	Drug: Trans Sodium Crocetinate (TSC)	"Dose Limiting Toxicities (DLTs)|Overall Survival|Progression-Free Survival (PFS)|Number of Participants With Reduction in Tumor Size, According to Percentage of Tumor Reduction"	Diffusion Pharmaceuticals Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	59	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DP100-202	Feb-12	Nov-15	Feb-16	4-Nov-11	14-Jul-17	14-Jul-17	"St. Joseph's Medical Center Barrow Neurology Clinics, Phoenix, Arizona, United States|University of Arkansas Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|The George Washington University Medical Center, Washington, D.C., District of Columbia, United States|University of Florida McKnight Brain Institute, Gainesville, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|North Shore University Hospital, Manhasset, New York, United States|Forsyth Regional Cancer Center, Winston-Salem, North Carolina, United States|Penn State University Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Health Science Center Memorial Hermann Medical Center, Houston, Texas, United States|UVA Health Sciences Center Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01465347
701	NCT00014170	Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: gefitinib|Other: pharmacological study|Other: laboratory biomarker analysis|Other: questionnaire administration|Procedure: quality-of-life assessment	Survival|Post-RT progression-time|Toxicity patterns assessed using NCI CTC version 2.0	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	92	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01855|N0074|CDR0000068511|NCCTG-N0074|U10CA025224	Mar-01	Jul-03		10-Jun-03		16-Jul-13	"North Central Cancer Treatment Group, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT00014170
702	NCT01086345	Radiosurgery Plus Bevacizumab in Glioblastoma		Terminated	No Results Available	Glioblastoma|Gliosarcoma|Brain Tumor	Radiation: radiosurgery|Biological: bevacizumab|Drug: irinotecan hydrochloride	"Overall survival of patients with recurrent GBM treated with bevacizumab, irinotecan and radiosurgery|Treatment-related toxicity|Progression-free survival, defined as the interval from randomization to progression or death, whichever occurs first"	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	9	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE4309|NCI-2010-00309	Feb-10	Dec-14	Dec-14	15-Mar-10		3-Jul-18	"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01086345
703	NCT00400322	Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection		Completed	No Results Available	Glioblastoma Multiforme|Cytomegalovirus Infection	Drug: Valganciclovir (Valcyte)|Other: Placebo	Tumor size|Disease status|Patient survival	Karolinska Institutet|Karolinska University Hospital	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	42	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment	MV20145|2006-002022-29	Aug-06	Jun-08	Jun-08	16-Nov-06		1-Mar-21	"Department of neurosurgery, Karolinska University Hospital, Solna, Stockholm, Sweden|Department of Oncology, Norrland University Hospital, Umea, Sweden|Department of Oncology, Akademiska Hospital, Uppsala, Sweden"		https://ClinicalTrials.gov/show/NCT00400322
704	NCT00005856	Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Terminated	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: oxaliplatin|Other: pharmacological study	Maximum-tolerated dose (MTD) defined as the dose level at which 2 out of 6 or the dose level below that at which >= 2 of 3 or > 2 of 6 patients experience dose-limiting toxicity (DLT) assessed by Common Toxicity Criteria (CTC) version 2.0 (Phase I)|DLT is defined as grade 3 or 4 nonhematological toxicities or hematological toxicities as assessed by CTC version 2.0 (Phase I)|Pharmacokinetics of oxaliplatin (Phase I)|Response rate (Phase II)|Duration of survival (Phase II)|Frequency of toxicity as assessed by CTC version 2.0 (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	59	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02336|9902|U01CA062475|CDR0000067883	Dec-00	Jan-07		27-Jan-03		24-Jan-13	"New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00005856
705	NCT02207010	A Phase 0 Study of AZD1775 in Recurrent GBM Patients		Completed	No Results Available	Glioblastoma|GBM	Biological: AZD1775	Plasma concentration of AZD1775 following single dose of AZD1775|Intratumoral concentration of AZD1775|Degree of CDC2 (Tyr15) phosphorylation in tissue|Number of GBM cells in M-phase of cell cycle (PH3)|Presence of double-strand DNA damage (γH2AX).	"St. Joseph's Hospital and Medical Center, Phoenix|The Ben & Catherine Ivy Foundation|American Society of Clinical Oncology|Barbara Ann Karmanos Cancer Institute|Translational Genomics Research Institute"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	BBTRC 001	Jul-14	31-Dec-15	25-Mar-19	1-Aug-14		10-Dec-20	"Barrow Neurological Institute at St. Joseph's Hospital Medical Center, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT02207010
706	NCT00058097	Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: tipifarnib|Radiation: radiation therapy	"Overall survival|Response rate|Progression free survival|Toxicities, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v4.0"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	54	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03013|NABTT 2200|CDR285732|U01CA062475	Aug-03	Jan-07		9-Apr-03		9-Apr-13	"New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00058097
707	NCT03603405	HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM		Recruiting	No Results Available	Glioblastoma|Anaplastic Astrocytoma	Drug: ADV/HSV-tk (gene therapy)	Overall Survival in months up to 5 years from Study drug administration (Day 0)|Progression free survival assessments will be done every 6-8 weeks for 1st year thereafter every 12-14 weeks until disease progression or death	The Methodist Hospital Research Institute	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	62	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00018178	28-Feb-18	31-Dec-23	31-Dec-25	27-Jul-18		7-Sep-20	"Houston Methodist Neurological Institute, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03603405
708	NCT00085254	"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: cilengitide|Drug: temozolomide|Radiation: radiation therapy|Other: laboratory biomarker analysis|Other: pharmacological study	Dose Limiting Toxicities of EMD + RT and TMZ|Maximum Tolerated or Tolerable Dose (MTD) - 3 Pre-defined Doses|Overall Survival (Phase II)|Overall Survival Based on Dose Level - Phase 2|Frequency of Hematologic and Nonhematologic Adverse Events	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	112	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02932|NABTT 0306|CDR0000368451|U01CA062475	Apr-05	Nov-12	Nov-12	11-Jun-04	25-Feb-16	25-Feb-16	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00085254
709	NCT04216329	Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma		Recruiting	No Results Available	Gliosarcoma|Newly Diagnosed|Glioblastoma	Drug: Selinexor|Drug: Temozolomide|Radiation: Generic Radiation therapy (RT)	MTD|Dose-limiting toxicities	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	NIH	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200027|20-C-0027	7-Jul-20	30-Aug-24	30-Jul-26	2-Jan-20		14-Dec-21	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT04216329
710	NCT01567202	Study of DC Vaccination Against Glioblastoma		Recruiting	No Results Available	Glioma|Glioblastoma Multiforme|Neoplasms	Procedure: Surgery|Drug: Chemotherapy|Radiation: Radiotherapy|Biological: DC vaccination|Drug: blank placebo	Objective response rate (ORR) of the treatment using DC Vaccination for Glioblastoma with molecular markers for immunotherapy.|Progression free survival|Overall survival	Huashan Hospital|Fudan University	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	100	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	DC81001115	Mar-12	1-Nov-20	1-Feb-21	30-Mar-12		9-Sep-20	"Huashan hospital, Fudan university, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT01567202
711	NCT00052208	Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: gefitinib|Radiation: radiation therapy|Other: laboratory biomarker analysis	"Maximum tolerated dose of gefitinib defined as the dose at which no patients develop acute grade 5 toxicity and less than 30% of patients developed acute dose limiting toxicity graded by the National Cancer Institute Common Toxicity Criteria v2.0|Rate of late toxicities associated with gefitinib and standard cranial radiation, graded according to the NCI CTC v2.0|Overall survival, by EGFR status|Progression-free survival"	National Cancer Institute (NCI)|NRG Oncology	All	"Child, Adult, Older Adult"	Phase 1|Phase 2	158	NIH|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2013-00849|RTOG-0211|CDR0000069330|RTOG-BR-0211|U10CA021661	Mar-02	Jun-05		27-Jan-03		30-Oct-20	"Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00052208
712	NCT00039494	Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: erlotinib hydrochloride|Radiation: 3-dimensional conformal radiation therapy|Drug: temozolomide	"Survival|Overall survival distribution|Time-to-disease progression|Maximum toxicity grade, assessed by Common Terminology Criteria for Adverse Events (CTCAE)"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	171	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00640|N0177|CDR0000069388|NCCTG-N0177|U10CA025224	Dec-02	Jul-07		27-Jan-03		2-Aug-13	"Mobile Infirmary Medical Center, Mobile, Alabama, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Northeast Georgia Cancer Care LLC, Athens, Georgia, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Saint Anthony Memorial Hospital, Effingham, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Kewanee Hospital, Kewanee, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States|Porubcin, Michael MD (UIA Investigator), Moline, Illinois, United States|Sharis, Christine M MD (UIA Investigator), Moline, Illinois, United States|Stoffel, Thomas J MD (UIA Investigator), Moline, Illinois, United States|Vigliotti, Antonio, P.G. M.D. (UIA Investigator), Moline, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Valley Cancer Center, Spring Valley, Illinois, United States|Carle Clinic-Urbana Main, Urbana, Illinois, United States|Saint Anthony Memorial Health Center, Michigan City, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|Constantinou, Costas L MD (UIA Investigator), Bettendorf, Iowa, United States|Saint Anthony Regional Hospital, Carroll, Iowa, United States|Saint Luke's Hospital, Cedar Rapids, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Community Memorial Hospital, Missouri Valley, Iowa, United States|Burgess Memorial Hospital, Onawa, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Main Office, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Wichita CCOP, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium Community Clinical Oncology Program, Ann Arbor, Michigan, United States|Oakwood Hospital, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Harris, John Gilbert MD (UIA Investigator), Alexandria, Minnesota, United States|Medini, Eitan MD (UIA Investigator), Alexandria, Minnesota, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Brainerd Medical Center Inc, Brainerd, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Essentia Health Duluth Clinic CCOP, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Etzell, Paul S MD (UIA Investigator), Fergus Falls, Minnesota, United States|Swenson, Wade II, MD (UIA Investigator), Fergus Falls, Minnesota, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Chippewa County - Montevideo Hospital, Montevideo, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|CentraCare Clinic, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Joseph's Hospital - Healtheast, Saint Paul, Minnesota, United States|Adult and Pediatric Urology PLLP, Sartell, Minnesota, United States|Woodwinds Health Campus, Woodbury, Minnesota, United States|Montana Cancer Consortium CCOP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies PC, Billings, Montana, United States|Billings Clinic, Billings, Montana, United States|Deaconess Medical Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Internal Medicine of Bozeman, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Fremont Area Medical Center, Fremont, Nebraska, United States|Bryan LGH Medical Center West, Lincoln, Nebraska, United States|Bryan LGH Medical Center East, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|University of Virginia, Charlottesville, Virginia, United States|Welch Cancer Center, Sheridan, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT00039494
713	NCT00004262	Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Procedure: conventional surgery|Radiation: 3-dimensional conformal radiation therapy|Radiation: stereotactic radiosurgery|Drug: motexafin gadolinium|Procedure: magnetic resonance imaging|Procedure: spectroscopy	"Maximum-tolerated dose (MTD) based on the incidence of dose-limiting toxicity (DLT), as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 2.0|Concentration of gadolinium in tumor, normal brain, and plasma by plasma-atomic emission spectroscopy and liquid chromatography with mass spectrometry"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01400|99H0239|CDR0000067517|NCI-T99-0041|OSU-9976|OSU-99H0239|U01CA076576	Nov-99	May-05		27-Jan-03		4-Jun-13	"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00004262
714	NCT00049387	"Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma"		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: tipifarnib|Drug: temozolomide|Radiation: radiation therapy	MTD of tipifarnib|Incidence of adverse events|Antitumor activity	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03106|NCI-03-C-0189|NABTC-0202|NABTC-02-02|U01CA062399	Sep-02	Jun-07	Jun-07	27-Jan-03		15-Apr-15	"Adult Brain Tumor Consortium, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00049387
715	NCT02887417	Glioblastoma Platelet Activation Study	GPAS	Completed	No Results Available	Glioblastoma|Circulating Platelet-monocyte Conjugates		Mean P-selectine expression in all platelets|Mean CD63 expression in all platelets|Mean CD40 Expression in all platelets|Mean platelet-monocyte-conjugate formation in the monocyte population	University Medicine Greifswald	All	"18 Years to 100 Years   (Adult, Older Adult)"		21	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Glioma-HGW	Jan-16	Oct-16	Dec-16	2-Sep-16		1-Aug-17	"Department of Neurosurgery, Greifswald, Germany"		https://ClinicalTrials.gov/show/NCT02887417
716	NCT03275558	Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma		Withdrawn	No Results Available	Recurrent Glioblastoma|Gliosarcoma|Anaplastic Gliomas	Drug: Axitinib 1 MG|Drug: Sunitinib 5 MG|Drug: Pazopanib 5 MG	The definition of survival without progression of disease|The definition of overall survival|The definition late toxicity to maximum tolerated dose (MTD)	Center Trials & Treatment	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NST-4-G	17-Jul-18	17-Jul-18	17-Jul-18	7-Sep-17		19-Jul-18	"The Hong Kong Cancer Institute, Hong Kong, Hong Kong|National University Cancer Institute,, Singapore, Singapore"		https://ClinicalTrials.gov/show/NCT03275558
717	NCT04218019	Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation	GERAS	Suspended	No Results Available	Newly Diagnosed Glioblastoma in Patients ≥70 Years	Device: TTFields	Safely conducted therapy rate (SCTR)|Number of participants with treatment related adverse events as assessed by CTCAE V 5.0.|Progression-free survival|The correlation between the Optune device usage and the health-related quality of life of elderly patients and families undergoing this therapy in combination with radiotherapy/chemo-radiotherapy.	Juergen Debus|University Hospital Heidelberg	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	68	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GERAS	1-Aug-22	1-Feb-23	1-Feb-24	6-Jan-20		6-Oct-21	"University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany"		https://ClinicalTrials.gov/show/NCT04218019
718	NCT02743078	Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma		Terminated	Has Results	Glioblastoma|Glioma|Gliosarcoma	Drug: Bevacizumab|Device: TTFields Therapy	Overall Survival at 6 Months|Overall Survival (OS)|Progression-Free Survival|Number of Participants With Partial or Complete Response|Number of Participants With Grade 3+ Treatment-related Adverse Events	"RTOG Foundation, Inc.|NovoCure Ltd."	All	"22 Years and older   (Adult, Older Adult)"	Phase 2	3	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG 3503|RF 3503	9-May-17	15-Oct-19	15-Oct-19	19-Apr-16	17-Nov-20	2-Jun-21	"University of California, San Diego, La Jolla, California, United States|University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/78/NCT02743078/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02743078/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT02743078
719	NCT01111097	Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors		Completed	No Results Available	Brain Tumor|Glioblastoma	Drug: Dichloroacetate	Determine the safety and tolerability of DCA in RMBTs.|Conduct an exploratory investigation of the metabolites of patients with RMBTs and the effects of DCA thereon.	University of Florida|National Institutes of Health (NIH)	All	"21 Years to 90 Years   (Adult, Older Adult)"	Phase 1	15	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	99-2010|CTSI|UL1TR000064	Apr-10	Mar-14	Mar-14	27-Apr-10		22-Sep-15	"University of Florida, Gainesville, Florida, United States"		https://ClinicalTrials.gov/show/NCT01111097
720	NCT04854044	ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma		Withdrawn	No Results Available	Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Supratentorial Glioblastoma|Supratentorial Gliosarcoma	Drug: Akt/ERK Inhibitor ONC201|Radiation: Radiation Therapy|Procedure: Resection	Incidence of adverse events|Percentage of neurosphere formation|Expression of glioma stem cells using ribonucleic acid-sequencing (RNA-Seq)|Pharmacodynamic (PD) markers	"Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)|Oncoceutics, Inc.|University of California, Los Angeles"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21-000054|NCI-2021-02121|P50CA211015	1-May-21	1-Jul-25	1-Jul-26	22-Apr-21		12-May-21	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT04854044
721	NCT02202993	TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM		Completed	No Results Available	Glioblastoma Multiforme (GBM)	Drug: Mibefradil with Radiation	Dose limiting toxicities|Maximum tolerated dose|Adverse events|Mibefradil dihydrochloride steady state plasma concentrations|Progression-free survival of treated patients|Overall survival of treated patients	Jazz Pharmaceuticals|Yale University	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	18	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1406014067	Aug-14	29-Sep-17	29-Sep-17	29-Jul-14		24-Jul-19	"Yale University, New Haven, Connecticut, United States"		https://ClinicalTrials.gov/show/NCT02202993
722	NCT01700569	Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma	FOLAGLI	Terminated	No Results Available	Grade IV Astrocytoma|Glioblastoma	Drug: Temozolomide|Drug: folinic acid at pharmacological dose is the escalated drug|Radiation: High voltage radiation therapy (linear accelerator)	Maximal Tolerated Dose|MGMT gene re-methylation	Institut Cancerologie de l'Ouest|Centre Antoine Lacassagne|Hospices Civils de Lyon	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	24	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICO 2012-02|2012-000774-31	Jan-13	12-Dec-19	Dec-20	4-Oct-12		24-May-21	"Institut de Cacerologie de l'ouest - site Paul Papin, Angers, France|CHU de Lyon, Bron, France|ICO site Gauducheau, Nantes, France|CLCC Antoine Lacassagne, Nice, France"		https://ClinicalTrials.gov/show/NCT01700569
723	NCT00902577	MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: FMISO|Other: MRI|Other: PET|Other: MRS	"Association of Baseline FMISO PET and MRI Features With OS as Assessed Using Cox-regression Model|Association of Baseline FMISO PET and MRI Features With Time-to-Progression (TTP)|Reproducibility of the Baseline FMISO PET Uptake Parameters as Assessed by Baseline ""Test"" and ""Retest"" PET Scans|Correlation Between T/Cmax and T/Bmax|Correlation Between MRS Markers and MR Imaging Markers of Vascularity as Well as Between MRS Markers and PET Markers of Tumor Hypoxia"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NCI-2011-01912|CDR0000640413|ACRIN 6684|ACRIN-6684|U01CA080098	24-Aug-09	31-Jan-18	31-Jan-18	15-May-09	8-Apr-19	8-Apr-19	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mount Sinai Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|American College of Radiology Imaging Network, Philadelphia, Pennsylvania, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Washington Medical Center, Seattle, Washington, United States"	"Study Protocol, Statistical Analysis Plan, and Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/77/NCT00902577/Prot_SAP_ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT00902577
724	NCT04991870	Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma		Not yet recruiting	No Results Available	Recurrent Gliosarcoma|Recurrent Supratentorial Glioblastoma|Supratentorial Gliosarcoma	Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Procedure: Resection	Incidence of dose-limiting toxicities (DLTs) (Group 1)|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Time to progression (TTP)|Progression-free survival (PFS)	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	25	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-0960|NCI-2021-00598	31-Jan-22	31-Jan-24	31-Jan-24	5-Aug-21		5-Aug-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04991870
725	NCT02858895	Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma		Completed	No Results Available	Glioblastoma|Grade IV Astrocytoma|Glioblastoma Multiforme|Grade IV Glioma	Drug: MDNA55	Overall Survival (OS)|Objective Response Rate (ORR)|Progression Free Survival (PFS)	"Medicenna Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	46	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDNA55-05	11-Apr-17	12-Sep-19	31-Oct-19	8-Aug-16		15-Jan-21	"University of California San Francisco, San Francisco, California, United States|John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Duke University Medical Center, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT02858895
726	NCT02871843	RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas	G-FORCE-1	"Active, not recruiting"	No Results Available	Glioblastoma|Oligodendroglioma|Anaplastic Oligodendroglioma	Drug: RRx-001 dose escalation with TMZ + RT|Radiation: Radiation|Drug: Fixed dose Temozolomide (75 mg/m2)|Drug: TMZ Maintenance	"Number, frequency and type of adverse events|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Intracranial Progression Free Survival|Overall Survival"	"EpicentRx, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	39	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RRx001-17-02	14-Feb-17	11-Oct-19	Dec-20	18-Aug-16		23-Jul-20	"University of California San Francisco (UCSF), San Francisco, California, United States|The Cancer Institute of New Jersey (Rutgers University), New Brunswick, New Jersey, United States|Weill Cornell Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02871843
727	NCT00562419	CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan		Unknown status	No Results Available	Brain and Central Nervous System Tumors|Recurrent Glioblastoma Multiforme	Drug: CT-322|Drug: irinotecan hydrochloride	"Safety and tolerability of CT-322 when administered alone or in combination with irinotecan hydrochloride (Part 1)|Progression-free survival at 6 months (Part 2)|To assess the plasma pharmacokinetics of CT-322 (Cmax, Tmax, AUC, T-HALF) derived from plasma concentration vs time for CT-322 given alone and in combination with irinotecan|To assess the presence of anti CT-322 antibodies|To assess the biological activity of CT-322 as measured by plasma biological markers and neuroimaging"	"Adnexus, A Bristol-Myers Squibb R&D Company"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	72	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CT-322.002	Oct-07	Jun-11	Dec-11	22-Nov-07		27-Oct-10	"University of California, San Diego, La Jolla, California, United States|University of Kentucky, Lexington, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Rhode Island Hospital, Providence, Rhode Island, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Virgina, Charlottesville, Virginia, United States|University of Wisconsin Hospital, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00562419
728	NCT03022578	Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma		Completed	No Results Available	IDH Family Wildtype|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma	Procedure: Laser Interstitial Thermal Therapy|Drug: Lomustine	Disease control rate|Clinical characteristics|Length of hospital stay|Biomarkers in peripheral blood and tumor tissue|Inflammatory/immunologic profile|Overall survival (OS)|Time to progression (TTP)|Incidence of toxicity|Long-term steroid requirements|MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT) data	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	7	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0443|NCI-2018-01286|P30CA016672	7-Nov-17	16-Feb-21	16-Feb-21	16-Jan-17		21-Feb-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03022578
729	NCT02663271	TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma		Terminated	No Results Available	Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|GBM	Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires	Progression-free survival between the groups|Number of adverse events|Karnofsky Performance Scale|Mini-Mental Status Exam|Response Assessment in Neuro-Oncology (RANO) Measurement Form	University of Florida|NovoCure Ltd.	All	"22 Years and older   (Adult, Older Adult)"	Phase 2	9	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB201600074|OCR14874	Aug-16	11-Jun-21	11-Jun-21	26-Jan-16		11-Aug-21	"University of Florida, Gainesville, Florida, United States|Washington University, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT02663271
730	NCT01227434	A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma	PD0332991	Terminated	Has Results	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma	Drug: PD 0332991 (pre-surgery)|Drug: PD 0332991|Procedure: Resection as clinical care	Progression Free Survival|Number of Participants With Adverse Events as a Measure of Safety and Tolerability	"University of California, San Francisco|Pfizer"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	23	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10105	Sep-10	Dec-13	Dec-13	25-Oct-10	12-Jun-15	17-Jul-15	"University of California, San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT01227434
731	NCT00576537	Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors		Completed	No Results Available	Glioblastoma	Biological: Dendritic Cell Immunotherapy	Evaluate the safety/toxicity of subcutaneous injections of autologous dendritic cells	Cedars-Sinai Medical Center	All	"Child, Adult, Older Adult"	Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3368	Mar-01	Oct-11	Oct-11	19-Dec-07		3-May-19	"Cedars Sinai Medical center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00576537
732	NCT03291977	Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)	FLEGME	Recruiting	No Results Available	"Glioblastoma, Adult"	Drug: Fluorescéine Sodique Faure|Procedure: White-light surgery	Gross total removal rates|Absolute volumes of tumor remnants|Relative volumes of tumor remnants|Occurrence of new neurological deficits|Occurrence of anaphylactic events related to the administration of fluorescein	Rennes University Hospital	All	"18 Years to 79 Years   (Adult, Older Adult)"	Phase 3	62	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	35RC16_9758_FLEGME	5-Oct-17	Apr-22	Apr-23	25-Sep-17		6-Jan-21	"CHU Rennes, Rennes, France"		https://ClinicalTrials.gov/show/NCT03291977
733	NCT04614909	Study of Pamiparib in Newly Diagnosed and rGBM		Recruiting	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme, Adult"	Drug: Pamiparib|Drug: Olaparib|Radiation: Radiation therapy|Drug: Temozolomide	Systemic plasma PK profile parameters|Progression-free survival in participants with demonstrated PK effects|Overall survival|Drug-related toxicity|Adverse events|Treatment-emergent adverse events|Deaths|Pharmacodynamics (PD) of pamiparib	"Nader Sanai|Barrow Neurological Institute|Ivy Brain Tumor Center|BeiGene|St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-12	11-Jan-21	Mar-22	Dec-23	4-Nov-20		9-Dec-21	"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT04614909
734	NCT01124539	Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma		Unknown status	No Results Available	Glioblastoma Multiforme|GBM|Gliosarcoma	Drug: AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)	Determine the 6-month Progression free survival (PFS) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (> 90 days) recurred after treatment bevacizumab.|The primary objective in the rapid bevacizumab failure group (< 90 days) is to determine the 2-month PFS.|the effect of AR-67 on overall survival (OS)|the effect of AR-67 on overall PFS|the effect of AR-67 on event-free survival (EFS)|the impact of AR-67 on tumor response in patients with measurable disease|the safety and tolerability of AR-67	Arno Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	58	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ARN-AR67-IIS202	Dec-09	Sep-14	Feb-15	17-May-10		9-Dec-14	"Northwestern University - Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|University of Kentucky - Markey Cancer Center, Lexington, Kentucky, United States|North Shore - Long Island Jewish Hospital/Monter Cancer Center, Lake Success, New York, United States|Duke University Medical Center - The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States|Derrick L Davis Forsyth Regional Cancer Center, Winston-Salem, North Carolina, United States|The Ohio State University - James Comprehensive Cancer Center, Columbus, Ohio, United States|University of Utah - Huntsman Cancer Center, Salt Lake City, Utah, United States|University of Calgary - Tom Baker Cancer Center, Calgary, Alberta, Canada|University of Alberta - Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT01124539
735	NCT01814813	Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery		"Active, not recruiting"	Has Results	Recurrent Glioblastoma|Recurrent Adult Brain Tumor|Gliosarcoma	Biological: HSPPC-96|Drug: bevacizumab	"Overall Survival (OS)|Progression Free Survival (PFS)|Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (v5)"	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Agenus Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	90	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A071101|U10CA031946|NCI-2013-00444	May-13	3-Apr-17		20-Mar-13	12-Jun-19	18-Aug-21	"Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Mercy Cancer Center-Hot Springs, Hot Springs, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Sutter Auburn Faith Hospital, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Mills - Peninsula Hospitals, Burlingame, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Eden Hospital Medical Center, Castro Valley, California, United States|Sutter Davis Hospital, Davis, California, United States|Epic Care-Dublin, Dublin, California, United States|Bay Area Breast Surgeons Inc, Emeryville, California, United States|Epic Care Partners in Cancer Care, Emeryville, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fresno Cancer Center, Fresno, California, United States|Kaiser Permanente, Fresno, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente-Modesto, Modesto, California, United States|Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States|Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Bay Area Tumor Institute, Oakland, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Palo Alto Medical Foundation Health Care, Palo Alto, California, United States|Stanford Cancer Institute, Palo Alto, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Roseville Medical Center, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter General Hospital, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Sutter Pacific Medical Foundation, Santa Rosa, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program NCORP, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Centers-Greenwood Village, Greenwood Village, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Vincent's Medical Center, Bridgeport, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Norton Hospital Pavilion and Medical Campus, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Northwest Hospital Center, Randallstown, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Marquette General Hematology Oncology, Marquette, Michigan, United States|Marquette General Hospital, Marquette, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hemotology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Neurosurgeons of New Jersey-Ridgewood, Ridgewood, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Valley Health System-Hematology/Oncology, Westwood, New Jersey, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|University Pointe, West Chester, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|Cancer Care Center at Island Hospital, Anacortes, Washington, United States|Swedish Cancer Institute-Eastside Oncology Hematology, Bellevue, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Medical Center-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Minor and James Medical PLLC, Seattle, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Group Health Cooperative-Seattle, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Rockwood Clinic Cancer Treatment Center-Valley, Spokane Valley, Washington, United States|Rockwood Cancer Treatment Center-DHEC-Downtown, Spokane, Washington, United States|Evergreen Hematology and Oncology PS, Spokane, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Aurora Cancer Care-Racine, Racine, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/13/NCT01814813/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01814813
736	NCT02146066	Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221	DCVax-L EAP	Available	No Results Available	GBM|Glioblastoma Multiforme	Biological: DCVax-L		Northwest Biotherapeutics	All	"18 Years to 70 Years   (Adult, Older Adult)"			Industry	Expanded Access		0202EA				23-May-14		26-Feb-16	"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|University of California, Irvine Medical Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|University of Florida, Gainesville, Florida, United States|Memorial Healthcare System Memorial Cancer Institute, Hollywood, Florida, United States|Cadence Cancer Center at Warrenville, Warrenville, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Spectrum Health, Grand Rapids, Michigan, United States|John Nasseff Neuroscience Institute - Abott Northwestern Hospital, Minneapolis, Minnesota, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|North Shore University Hospital, Manhasset, New York, United States|Columbia University Medical Center Neurological Institute of New York, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Saint Thomas Research Institute, Nashville, Tennessee, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT02146066
737	NCT04817254	Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma		Recruiting	No Results Available	Glioblastoma|Gliosarcoma|Malignant Glioma	Drug: TMZ|Drug: ipilimumab 3mg/kg|Drug: Nivolumab|Drug: ipilimumab 1mg/kg	"Determine if the outcomes, as measured by overall survival, is improved in patients with newly diagnosed glioblastoma when treatment with immune checkpoint inhibitors result in an immune response in peripheral blood T lymphocytes.|Determine if the T cell response measured by the ex vivo tosylactivated bead assay correlates with subsequent systemic response to treatment with immune checkpoint inhibitors.|Determine if T cell response to immune checkpoint inhibitors measuring the change in the pre-treatment and post-treatment blood correlates with progression-free survival|Determine if in vitro peripheral blood T cell response to a stimulation paradigm including nivolumab and ipilimumab correlates with progression-free survival, evaluating 2 different dosing regimens of the ICIs.|Determine if in vitro peripheral blood T cell response to a stimulation paradigm including nivolumab and ipilimumab correlates with overall survival, evaluating 2 different dosing regimens of the ICIs.|Evaluate changes in patient reported outcome measures using self-reported symptom severity and interference with daily activities using the MDASI-BT with treatment response and progression-free and overall survival."	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	48	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	210015|21-C-0015	8-Dec-21	31-Dec-23	31-Dec-24	26-Mar-21		4-Jan-22	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT04817254
738	NCT01810744	Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma	BEVACAPI	Completed	No Results Available	Metastatic Colorectal Cancer|Glioblastoma|Bevacizumab|Capillaroscopy	Other: capillaroscopy|Other: blood pressure measurement	change in the density of capillaries	Centre Georges Francois Leclerc	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	47	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	001-FANI-2012	May-13	May-15	May-15	13-Mar-13		15-Mar-19	"Centre Georges François Leclerc, Dijon, France"		https://ClinicalTrials.gov/show/NCT01810744
739	NCT01753713	Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: dovitinib|Other: laboratory biomarker analysis	Arm 1: Progression Free Survival (PFS)|Arm 2: Determine Median Time to Progression|Toxicity Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Objective Response Rate Using Modified Revised Assessment in Neuro-Oncology (RANO) Criteria|Median Progression Free Survival|Overall Survival	"Manmeet Ahluwalia, MD|National Cancer Institute (NCI)|Novartis|Case Comprehensive Cancer Center"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	33	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE4312|NCI-2012-02284	20-Dec-12	28-Jan-15	20-Sep-17	20-Dec-12	8-Aug-17	12-Dec-17	"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01753713
740	NCT01730950	Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma		"Active, not recruiting"	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Biological: bevacizumab|Radiation: radiation therapy	Overall Survival|Percentage of Participants With Complete or Partial Best Response|Percentage of Participants Progression-free at 6 Months|Progression-free Survival|Percentage of Participants With Grade 3+ Central Nervous System (CNS) Toxicity Within 90 Days of Start of Radiation Therapy Reported as Possibly/Probably/Definitely Related to Protocol Treatment|Number of Participants With Grade 3+ CNS Toxicity More Than 90 Days of Start of Radiation Therapy Reported as Possibly/Probably/Definitely Related to Protocol Treatment	Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	182	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-1205|NCI-2012-01732|U10CA021661	20-Dec-12	3-Sep-18		21-Nov-12	17-Mar-20	23-Oct-20	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Services Foundation, Phoenix, Arizona, United States|Arizona Oncology-Deer Valley Center, Phoenix, Arizona, United States|John Muir Medical Center, Walnut Creek, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Radiation Oncology Associates PC, Fort Wayne, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Norton Health Care Pavilion - Downtown, Louisville, Kentucky, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Lowell General Hospital, Lowell, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|University of Rochester, Rochester, New York, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Summa Akron City Hospital, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Texas Medical Branch, Galveston, Texas, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Mary's Hospital, Green Bay, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Door County Cancer Center, Sturgeon Bay, Wisconsin, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/50/NCT01730950/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT01730950/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT01730950
741	NCT03596086	HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM		Recruiting	No Results Available	"Glioblastoma Multiforme|Astrocytoma, Grade III"	Drug: ADV/HSV-tk (gene therapy)	Survival in months from Study drug administration (Day 0)|Progression Free Survival assessments will be done every 6-8 weeks for 1st year thereafter every 12-14 weeks until disease progression or death	"David Baskin MD|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	62	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00016414	11-Dec-17	30-Dec-23	30-Dec-25	23-Jul-18		7-Sep-20	"Houston Methodist Neurological Institute, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03596086
742	NCT01575275	Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme		Terminated	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: aminolevulinic acid|Procedure: therapeutic conventional surgery	"Change in Volume of Residual Enhancing Tumor, as Determined by Intraoperative Volume MRI at a Single Time Point Without and With Gadolinium, Following Maximal Resection With Use of Aminolevulinic Acid|Comparison Between the Volume of Resected Tissue (Defined as the Volume of the Resection Cavity) and the Pre-operative Enhancing Tumor Volume|Time to Disease Progression (TTP), Determined by Review of MRIs Performed Post Operatively as Clinically Indicated, Evaluated With Use of the New International Criteria Proposed by the Response in NeuroOncology (RANO) Committee|Overall Survival, by Periodic Follow up Review of the Patient Charts and by Correlation With the Social Security Death Index"	"Michael Vogelbaum, MD, PhD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	8	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CASE1311|NCI-2012-00452	May-12	May-14	Aug-14	11-Apr-12	31-Jul-18	31-Jul-18	"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01575275
743	NCT02704858	Safety and Efficacy Study in Recurrent Grade IV Glioma		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: Perillyl alcohol	Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment|Phase 2 Primary Outcome: Number of Participants Who Are Alive Each Month For 6 Months|Phase 2 Primary Outcome: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related To Treatment	"Neonc Technologies, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	49	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NEO100-01	8-Apr-16	Jun-22	Dec-22	10-Mar-16		26-Oct-21	"University of Southern California, Los Angeles, California, United States|Cleveland Clinic, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02704858
744	NCT01894061	NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment	Progression Free Survival (PFS)|Objective response rate based on RANO Criteria|Number of patients that experience toxicities with this combination of therapies|Median overall survival|To assess time-to-progression|Neurocognitive function (NCF)|Quality of Life (QOL)	Case Comprehensive Cancer Center|NovoCure Ltd.|National Cancer Institute (NCI)	All	"22 Years and older   (Adult, Older Adult)"	Phase 2	25	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3313	12-Jun-13	28-Jul-19	28-Jul-19	9-Jul-13		24-Jul-20	"University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01894061
745	NCT00895960	Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma		Terminated	No Results Available	Glioblastoma|CNS Disease|Brain Diseases	Drug: Dasatinib|Radiation: RT (Radiotherapy)|Drug: TMZ (Temozolomide)	Maximum tolerated dose (MTD)|Overall survival (OS)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	16	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008-0318	7-May-09	Aug-13	Aug-13	11-May-09		8-Nov-18	"UT MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00895960
746	NCT02367482	Tryptophan Metabolism in Human Brain Tumors		Recruiting	No Results Available	Glioblastoma		Interval Changes of Tumoral Metabolism|Interval changes of tumoral tryptophan metabolism	Wayne State University|NovoCure Ltd.	All	"22 Years and older   (Adult, Older Adult)"		10	Other|Industry	Observational	Observational Model: Case-Control|Time Perspective: Prospective	Novocure rGBM AMT-PET	Jul-14	31-Dec-21	31-Dec-21	20-Feb-15		6-Apr-21	"Wayne State University, Detroit, Michigan, United States"		https://ClinicalTrials.gov/show/NCT02367482
747	NCT03869242	NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM	NovoTTF-200A	Unknown status	No Results Available	Glioblastoma	Device: NovoTTF-200A	PFS12|PFS6|One and two year survival rate|Radiological response|adverse events	Tel-Aviv Sourasky Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TLV-0492-18	1-Oct-18	1-Mar-21	1-Dec-21	11-Mar-19		11-Mar-19	"Tel Aviv saurasky medical center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT03869242
748	NCT03277638	Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)		Recruiting	No Results Available	"Glioblastoma, Adult"	Drug: Pembrolizumab at 7 days prior|Drug: Pembrolizumab at 14 days post|Drug: Pembrolizumab at 35 days post|Procedure: Laser Interstitial Thermotherapy	Phase I endpoint: Optimal timing of LITT with pembrolizumab|Phase II endpoint: Tumor Response|Progression free survival (PFS)|Overall survival (OS)|The proportion of patients who achieve progression free survival at 6 months (PFS6)|The proportion of patients who achieve progression free survival at 12 months (PFS12)|The proportion of patients who achieve progression free survival at 24 months (PFS24)	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	34	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3316|NCI-2017-02417	29-Nov-17	Dec-21	Dec-21	11-Sep-17		11-May-21	"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT03277638
749	NCT01004874	Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma		"Active, not recruiting"	Has Results	Malignant Glioma|Glioblastoma|Gliosarcoma	Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Topotecan	6-month Progression-free Survival|One and Two Year Overall Survival|Median Overall Survival|Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage|Number of Patients Experiencing a Greater Than or Equal to Grade 4 Hematologic or a Greater Than or Equal to Grade 3 Non-hematologic Toxicity|Median Progression-free Survival	"Duke University|Genentech, Inc.|GlaxoSmithKline"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	80	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00019960	30-Dec-09	Jul-12	Dec-21	30-Oct-09	18-Jan-13	23-Feb-21	"The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01004874
750	NCT00980343	GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: vismodegib|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis|Other: pharmacological study	6 Months Progression-free Survival (PFS)|Overall Survival Time|Best Tumor Response Assessed by the Modified Macdonald Radiographic Response Criteria|Toxicity Incidence Grade 3 or 4 According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|Incidence of CD133+ Neurospheres by Arm|Changes in Sonic Hedgehog Pathway Activation|Determine Drug Effect (Pharmacokinetics) in Plasma for Arm 1	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	44	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02922|CDR0000654829|ABTC-0904|U01CA137443	Feb-10	May-12	Jun-12	21-Sep-09	16-Aug-17	16-Aug-17	"University of California at Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00980343
751	NCT01122901	Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma		Terminated	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Procedure: therapeutic conventional surgery|Other: pharmacological study|Other: laboratory biomarker analysis	Overall Median Progression-free Survival (6-month PFS)|Efficiency of Neurosphere Generation After Pretreatment With RO4929097 (Group B)|Radiographic Response Rate According to the Radiographic Assessment in Neuro-Oncology Criteria (Group A) and Group (B)|Number of Participants With Toxicities Associated With Study Drug (Group A and Group B)|Overall Survival|Expression Levels of Notch Pathway Components and Downstream (Group B)|Tumor Propagation (Group B)|Progression Free Survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	47	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02931|CDR0000672628|ABTC-0906|U01CA137443	Dec-10	Aug-15	Aug-15	13-May-10	3-May-17	3-May-17	"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Henry Ford Hospital, Detroit, Michigan, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01122901
752	NCT03258021	TTFields In GErmany in Routine Clinical Care	TIGER	"Active, not recruiting"	No Results Available	Glioblastoma	Device: TTFields	"Time to death of any cause (overall survival (OS)) from diagnosis|Number of TTFields treatment-related serious adverse events (SAEs) standardized to one year of FU time|Number of SAEs after start of TTFields treatment|Time of usage (compliance) of TTFields treatment over time|Time to first progression of GBM (progression-free survival (PFS)), defined within radiological and/or clinical/neurological assessment during routine clinical care in patients who started TTFields treatment at baseline|Changes in quality of life at month 2 and month 4 after start of TTFields treatment compared to baseline in patients who started TTFields treatment at baseline|Patients' reason(s) for refusing TTFields at baseline"	NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"		710	Industry	Observational	Observational Model: Other|Time Perspective: Prospective	05.07.2017	31-Aug-17	Jun-21	Jul-21	22-Aug-17		28-Jan-21	"Clinical center Aschaffenburg-Alzenau, Aschaffenburg, Bavaria, Germany"		https://ClinicalTrials.gov/show/NCT03258021
753	NCT00459381	Pazopanib in Treating Patients With Recurrent Glioblastoma		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: pazopanib hydrochloride|Other: laboratory biomarker analysis	6 Months Progression-free Survival|Number of Participants Discontinuing Treatment Due to Toxicity|Most Common Toxicities Experienced After at Least One Dose of Pazopanib|Overall Radiographic Response (ORR) Rate|Best Radiographic Response|Overall Survival|Time to Progression or Progression Free Survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	35	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02710|NABTC-0602|U01CA062399|CDR0000538083	May-07	Dec-08	Dec-08	11-Apr-07	15-Mar-17	15-Mar-17	"University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00459381
754	NCT00165477	Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Glioblastoma|Gliosarcoma|Malignant Gliomas	Drug: lenalidomide|Radiation: Radiation	To determine the efficacy of lenalidomide with conventional radiation therapy in the treatment of patients with newly-diagnosed supratentorial glioblastoma or gliosarcoma.|To assess the proportion of patients treated with lenalidomide and radiation therapy surviving at 12 months|to evaluate the time to tumor progression|the radiologic response|to determine the safety and toxicity of the combination of lenalidomide and radiation therapy.	Dana-Farber Cancer Institute|Celgene Corporation|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Massachusetts General Hospital|University of Virginia	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	23	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-222	Sep-05	Nov-07	Jul-09	14-Sep-05		10-Mar-10	"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00165477
755	NCT00305656	AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: cediranib maleate	Proportion of patients alive and progression-free at 6 months|Radiographic response proportion|Overall survival|Toxicity proportion	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	31	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00127|05-254|N02CO12400|CDR0000460079	Jan-06	Apr-12		22-Mar-06		22-Aug-13	"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00305656
756	NCT00540722	Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: R-(-)-gossypol acetic acid|Other: laboratory biomarker analysis	"Overall Survival|Percent of Patients With Grade 3 and 4 Adverse Events Related to Treatment|Tumor Response Rate|Progression-free Survival Rate, Defined as Patient Who is Alive and Disease Progression Free at the Time of 26-week (6 Months) From First Day of the Treatment"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2013-00018|0702|CDR0000569405|ABTC-0702|NABTT 0702|U01CA062475	Jan-08	Jun-12	Jun-12	8-Oct-07	12-Jul-17	11-Aug-17	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Moffitt Cancer Center, Tampa, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00540722
757	NCT00921167	A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas		Completed	No Results Available	Glioblastoma|Astrocytoma	Drug: Bevacizumab/Irinotecan	Progression-free survival|Objective response rate|Overall survival|Disease-control rate|Adverse event	"Clinical Research Center for Solid Tumor, Korea|Seoul National University Hospital"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRCST-L-0006	Jun-09	Jun-12	Dec-13	16-Jun-09		4-Dec-13	"Seoul National University Hospital, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT00921167
758	NCT00641706	"Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme"		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: vorinostat|Procedure: therapeutic conventional surgery|Drug: bortezomib	"Progression-free Survival at 6 Months|Overall Survival|Time to Progression|Proportion of Confirmed Tumor Response Defined as an Objective Status of Confirmed Response (CR), Partial Response (PR), or Regression (REGR) on Two Consecutive Evaluations"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	44	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00668|CDR0000590113|NCCTG-N0779|N0779|U10CA025224	Jul-08	Jul-10	Nov-10	24-Mar-08	10-Jul-13	14-May-14	"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Cottage, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States|Porubcin, Michael MD (UIA Investigator), Moline, Illinois, United States|Sharis, Christine M MD (UIA Investigator), Moline, Illinois, United States|Stoffel, Thomas J MD (UIA Investigator), Moline, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Carle Clinic-Urbana Main, Urbana, Illinois, United States|Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Constantinou, Costas L MD (UIA Investigator), Bettendorf, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Mercy Health Partners-Hackley Campus, Muskegon, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital, St. Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Duluth Clinic CCOP, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro-Minnesota CCOP, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States|Montana Cancer Consortium CCOP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies PC, Billings, Montana, United States|Billings Clinic, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|North Coast Cancer Care-Clyde, Clyde, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Saint Luke's Hospital, Maumee, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Genesis HealthCare System, Zanesville, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Upstate Carolina CCOP, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Midelfort Clinic-Clairemont Campus, Eau Claire, Wisconsin, United States|Mayo Clinic Health System Eau Claire Hospital - Luther Campus, Eau Claire, Wisconsin, United States|Agnesian Cancer Center, Fond Du Lac, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT00641706
759	NCT00597402	"Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas"		Completed	Has Results	Glioblastoma|Gliosarcoma|Brain Tumor	Drug: Avastin|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Irinotecan	16-month Overall Survival (OS)|12-month Progression-free Survival (PFS)|Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage|Number of Patients Experiencing a Grade ≥ 4 Hematologic or Grade ≥ 3 Non-hematologic Toxicity	"Duke University|Genentech, Inc.|Schering-Plough"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	125	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000458	Jul-07	Aug-11	May-13	18-Jan-08	18-Jan-13	7-May-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00597402
760	NCT01480479	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma	ACT IV	Completed	No Results Available	Glioblastoma|Small Cell Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma|Glioblastoma With Oligodendroglial Component	Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: Temozolomide|Drug: KLH	Overall Survival|Progression-free survival|Safety and Tolerability	Celldex Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	745	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	CDX110-04	Nov-11	Nov-16	Nov-16	29-Nov-11		16-Jan-18	"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona Health Network, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente, Redwood City Medical Center, Redwood City, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford Cancer Institute, Stanford University, Stanford, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale University Medical Center, New Haven, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Medical Center, Comprehensive Cancer Center, Miami Beach, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Atlanta Cancer Care, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Covenant Clinic / Iowa Spine and Brain Institute, Waterloo, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Dana-Farber Cancer Institute and Mass General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Edward W. Sparrow Hospital Association - Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary's of Michigan Medical Center/Field Neurosciences Institute, Saginaw, Michigan, United States|Allina Health, Abbott Northwestern Hospital, John Nasseff Neuroscience Institute, Minneapolis, Minnesota, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|New Jersey Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Dent Neurosciences Research Institute, Amherst, New York, United States|Montefiore Medical Center, Bronx, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|The Long Island Brain Tumor Center at Neurology Surgery, P.C., Great Neck, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Columbia University Medical Center - The Neurologic Institute of New York, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Brain and Spine Surgeons of New York, White Plains, New York, United States|The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|University Hospitals, Case Medical Center (Cleveland), Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Oncology & Hematology Care, Portland, Oregon, United States|Pacific Neurosurgical, Portland, Oregon, United States|Lehigh Valley Physician Group-Hematology-Oncology Associates, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|West Penn. Allegheny Health System, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina - Department of Neuroscience, Charleston, South Carolina, United States|University of Tennessee Medical Center - Knoxville, Knoxville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology Midtwon, Austin, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|The Methodist Neurological Institute, Houston, Texas, United States|University of Utah Department of Neurosurgery, Salt Lake City, Utah, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia Healthcare System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, Mater Misericordiae Health Services Brisbane Limited, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Calvary North Adelaide Hospital, North Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Liverpool Hospital, Liverpool, Australia|Medical University Innsbruck, Dept of Neurology, Anichstrabe 35, Innsbruck, Austria|Medizinische Universität Wien, Innere Medizin I, Onkologie, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Edegem, Antwerp, Belgium|ZNA Middelheim, Antwerpen, Belgium|Ghent University Hospital, Ghent, Belgium|Hospital Mae de Deus-Centro de Pesquisa em Oncologia Clinica, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisas Clinicas da Fundação Dr Amaral Carvalho, Jaú, São Paulo, Brazil|Fundação Faculdade Regional de Medicina de de São José do Rio Preto - Hospital de Base, São José do Rio Preto, São Paulo, Brazil|Instituto Nacional do Cancer (INCA), Rio de Janeiro, Brazil|Hospital Albert Einstein, Sao Paulo, Brazil|Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiência/ Hospital São José, São Paulo, Brazil|Hospital A C Camargo, São Paulo, Brazil|Foothills Hospital Medical Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver Clinic, Vancouver, British Columbia, Canada|BC Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada|University of Manitoba-Cancer Care Manitoba, Winnipeg, Manitoba, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital, Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|CHUS Hôpital Fleurimont, Shenbrooke, Quebec, Canada|CHUQ L'Hotel Dieu de Qujebec, Quebec, Canada|Fundacion Santa Fe, Bogota, Bogota D.C, Colombia|Hospital Ceske Budejovice, Ceske Budejovice, Czechia|Umiversity Hospital (Fakultni Nemocnice), Prague, Czechia|Hospital Na Homolce, Prague, Czechia|Multiscan s.r.o., Praha 5, Czechia|Masaryk´s Hospital Usti nad Labem, Usti nad Labem, Czechia|Institut de Cancerologie de I'Quest-Paul Papin, Angers, France|Institute Bergonie, Bordeaux, France|Centre Leon Berard de Lyon, Lyon, France|ICM Val d'Aurel Montpellier, Montpellier, France|Institut de Cancerologie de L'Quest-Center Rane Gauducheau, Nantes, France|Service de Neurologie-GH, Paris, France|Centre Eugene Marquis, Rennes, France|Institut de Cancerologie de l'ouest-Center Rene Gauducheau, St Herblain, France|Institut Gustave Roussy, Villejuif, France|Klinik und Poliklinik fur Neurologie der Universitat Regensburg, Regensburg, Bavaria, Germany|Strahlenklinik Universitatsklinikum Erlangen, Erlangen, Germany|Dr. Senchkenbergisches Institut fur Neuroonkologie, Frankfurt, Germany|University Hospital Hamburg Kopf und Neurozentrum, Hamburg, Germany|Universitaetsklinikum Heidelberg, Neurologische Klinik, IM Neuenheimer Feld 672, Heidelberg, Germany|University Medical Centre, Kiel, Germany|Universitaetsklinikum Muenster, Muenster, Germany|LMU Munich, Munich, Germany|NNA, Athens, Attiki, Greece|""HYGEIA"" Hospital, Marousi, District Of Attica, Greece|Országos Onkológiai Intézet Sugárterápiás Osztály, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Intézet, Debrecen, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Sugárterápiás Osztály, Miskolc, Hungary|Pécsi Tudományegyetem Általános Orvostudományi Kar, Pécs, Hungary|Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged, Hungary|Vas Megyei Markusovszky Lajos Általános Rehabilitációs és Gyógyfürdő Kórház, Egyetemi Oktatókórház Nonprofit Zrt, Szombathely, Hungary|City Cancer Centre, Vijayawada, Vijayawada, Andhra Pradesh, India|HCG - Bangalore Institute of Oncology, Bangalore, Bengaluru, Karnataka, India|Amrita Institute of Medical Sciences and Research Centre, Kochi, Kochi, Kerala, India|Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, Thiruvananthapuram, Kerala, India|Marathwada Regional Cancer Centre and Research Institute - Government, Aurangabad, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Andheri-West, Mumbai, India|Tata Memorial Hospital , Mumbai, Parel, Mumbai, India|Indraprastha Apollo Hospital, New Delhi, Jasola Viha, New Delhi, India|Sahyadri Hospitals Limited, Erandauame, Pune, India|Dr. Rai Memorial Medical Centre, Chennai, Chennai, Tamil Nadu, India|HCG Shanti Mukand Hospital - Curie Cancer Centre, Delhi, Delhi, India|Soroka University M.C., Beer-Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|SHEBA Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|UO Oncologie Medica Dipartimento Oncologico, Bologna, Italy|Fondazione IRCCS Instituto Neurologico Carlo Besta, Milano, Italy|Sacred Heart Catholic University, Rome, Italy|Universita e AO Citta delia Scienza, Universita Di Torino, Torino, Italy|Grupo Médico Camino S.C., Mexico, D.F, Mexico|Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, Jalisco, Mexico|Ensayos Clínicos y Medicina de Alta Especialidad, S.C., Culiacán, Sinaloa, Mexico|Servicios Medicos de Investigacion Clinica Sc, Durango, Mexico|Hospital Central ""Ignacio Morones Prieto"", San Luis Potosí, Mexico|Medisch Centrum Haaglanden, The Hague, Zuid Holland, Netherlands|VUMC, Amsterdam, Netherlands|Radboud University Nijmegen Medical Center, Nijmegen, Netherlands|Christchurch Hospital, Christchurch Central, Christchurch, New Zealand|Palmerston North Hospital, Roslyn, Palmerston North, New Zealand|Waikato Hospital, Regional Cancer Centre, Hamilton, Waikato District, New Zealand|Waikato Hospital, Regional Cancer Center, Hamilton, Waikato Distric, New Zealand|Hospital Almanzor Aguinaga Asenjo, Chiclayo, Peru|Instituto Oncologico Miraflores, Lima, Peru|Clinica Anglo Americana, Lima, Peru|Clinica Ricardo Palma, Lima, Peru|Oncosalud, Lima, Peru|Institut Catala d Oncologia, LaHospitalet De Lubregat, Catalonia, Spain|Dra. Sonia Del Barco Berron, ICO Girona Avda,, Franca, Girona, Spain|Hospital Clinic, Barcelona, Spain|ICO Badalona-Hospital Germans Trias i Pujol, Barcelonia, Spain|Hospital 12 de Octubre, Madrid, Spain|Kantonsspital Aarau Medizinische Onkologie Tellstrasse, Aarau, AG, Switzerland|CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, VD, Switzerland|Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland|Inselspital, Universitatsspital Bern, Universitatsklinik fur Medizinische Onkologie, Freiburgstrasse, Bern, Switzerland|Hopitaux Universitaires de Geneve-HUG-Centre d'Oncologie, Geneva, Switzerland|Brain Tumor Center, University Hospital Zurich, Zurich, Switzerland|National Cheng Kung University Hospital, Tainan City, Bei District, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan City - Yongkang District, Taiwan|Tri-Service General Hospital, Taipei city - Neihu District, Taiwan|Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Patumwan, Bankok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Amphoe Muang, Chiang Mai, Thailand|Songkhlanagarind Hospital, Hat Yai, Songkla, Thailand|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centrel, Glasgow, United Kingdom|Guy's and St Thomas' NHS, Westminister Bridge Road, London, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom"		https://ClinicalTrials.gov/show/NCT01480479
761	NCT04741984	Monocyte Antigen Carrier Cells for Newly Diagnosed GBM	DEMAND	Not yet recruiting	No Results Available	"Glioblastoma|Glioma, Malignant"	Biological: MT-201-GBM monocyte vaccine	Maximum Tolerated Dose (MTD) of MT-201-GBM|pp65 T-cell Immune Response After 2 Weeks Post Infusion Three Compared to Baseline|Percentage of patients with a dose-limiting toxicity (DLT) during DLT observation period within each dose level|Median Overall Survival (OS)|Median Progression Free Survival (PFS)|pp65 T-cell Immune Response After Each Infusion Compared to Baseline	Michael Gunn|National Cancer Institute (NCI)|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	27	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00105363|5P01CA225622	Mar-22	Dec-22	Mar-24	5-Feb-21		21-Dec-21	"The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04741984
762	NCT03672721	IA Carboplatin + Radiotherapy in Relapsing GBM		Unknown status	No Results Available	Glioblastoma Multiforme|Relapse	Drug: IA Carbo+ Radiation	Response on MRI using the RANO Criteria|Incidence of treatment related Neurocognitive decline|Quality of life (QOL) using SNAS questionnaire (Sherbrooke neuro assessment scale for quality of life). Scale range from 30 to 120; the lower scores indicate better quality of life.|In vitro intracellular carboplatin accumulation	Université de Sherbrooke	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	35	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-2452	10-Jul-18	10-Jul-20	10-Jul-21	14-Sep-18		14-Sep-18	"CHUS, Sherbrooke, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT03672721
763	NCT03732352	18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma		"Active, not recruiting"	No Results Available	EGFR Gene Amplification|EGFR Gene Mutation|Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|TP53 wt Allele	Other: Fludeoxyglucose F-18|Drug: Osimertinib|Procedure: Positron Emission Tomography	Intrapatient variance of tumor fludeoxyglucose F-18 (FDG) uptake as determined by a double baseline FDG positron emission tomography (PET) prior to osimertinib exposure|Change in FDG uptake in tumor after short course exposure to osimertinib|Incidence and severity of adverse events (AEs) assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Percentage of participants surviving 6 months from the start of study treatment without progression of disease determined by progression free survival (PFS) according to Response Assessment in Neuro-oncology criteria|Correlation between the reduction in glucose uptake and 6 months PFS|Concentrations of osimertinib and metabolites AZ5104 and AZ7550 in post-dosing plasma samples.	Jonsson Comprehensive Cancer Center|AstraZeneca	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-001000|NCI-2018-02010	28-Nov-18	1-Nov-22	1-Nov-23	6-Nov-18		6-Jan-22	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT03732352
764	NCT00735436	A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)		Terminated	Has Results	Malignant Glioma|Glioblastoma Multiforme|Gliosarcoma	Drug: Gliadel/Avastin/CPT-11	24-week Overall Survival|24-week Progression-free Survival (PFS)|Median Progression-free Survival (PFS)|Median Overall Survival (OS)|Incidence and Severity of Central Nervous System (CNS) Hemorrhage|Incidence of Grade ≥ 4 Hematologic and ≥ Grade 3 Non-hematologic Toxicities	"Duke University|Eisai Inc.|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	18	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00006308	Dec-08	Jul-11	Oct-12	15-Aug-08	4-Feb-13	11-Feb-13	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00735436
765	NCT00445588	Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: erlotinib hydrochloride|Drug: sorafenib tosylate|Other: pharmacological study	Overall Survival|6months -Progression-free Survival Rate	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03018|CDR531731|NABTT 0502|NABTT-0502|U01CA062475	Jan-07	Aug-09	Aug-09	9-Mar-07	27-Apr-16	27-Apr-16	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00445588
766	NCT02521090	EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma		Withdrawn	No Results Available	Adult Brain Glioblastoma|Adult Gliosarcoma|Recurrent Brain Neoplasm	Biological: EGFRBi-Armed Autologous T Cells|Other: Laboratory Biomarker Analysis	Incidence of toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|Overall survival (OS) (Phase II)|Change in cytokines profiles|Changes in activated T cells|Changes in cytotoxic T-lymphocyte as measured by IFN-gamma EliSpots directed at autologous tumor or GBM cell lines|Changes induced by IMT|Human anti-mouse antibody responses|Peripheral blood measures	Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-112|NCI-2015-00232|P30CA022453	Aug-15	Mar-16		13-Aug-15		15-Feb-16			https://ClinicalTrials.gov/show/NCT02521090
767	NCT00238303	Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: vorinostat|Procedure: conventional surgery	Proportion of Successes (Patients Alive and Progression-free)|Survival|Confirmed Tumor Response|Time to Progression	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	103	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00646|CDR0000445405|NCCTG-N047B|N047B|U10CA025224	Sep-05	Jul-08	Mar-10	13-Oct-05	10-Jul-13	23-May-14	"North Central Cancer Treatment Group, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT00238303
768	NCT01044966	A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma		Terminated	Has Results	Glioblastoma Multiforme|Glioma|Astrocytoma|Brain Tumor	Drug: ITV DepoCyt + Temozolomide	Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0|Proportion of Patients With Recurrent GBM Treated With ITV DepoCyt in Combination With Oral Temozolomide Who Are Progression-free at 16 Weeks.|Progression Free Survival|Response Rate of Drug Treatment|Quality of Life Outcomes Measurement	Medical University of South Carolina	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 1|Phase 2	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3542|R01FD003542-01	Sep-09	Aug-13	Sep-14	8-Jan-10	12-Feb-19	12-Feb-19	"Medical University of South Carolina, Charleston, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT01044966
769	NCT03475186	Testing Ramipril to Prevent Memory Loss in People With Glioblastoma		Recruiting	No Results Available	Glioblastoma|Radiotherapy; Complications|Cognitive Decline|Chemoradiation	Drug: Ramipril	Change from Baseline Neurocognitive Function at 10 weeks - Hopkins Verbal Learning Test-Revised (HVLT-R)|Change from Baseline Neurocognitive Function at 10 weeks - Trail Making Test Part A and B (TMT A & B)|Change from Baseline Neurocognitive Function at 10 weeks - Controlled Oral Word Association Test (COWA)|Efficacy of Ramipril of Neurocognitive Function at Baseline - Shipley Institute of Living Scale-Version 2 Vocabulary|Retention Rate at 10 weeks|Efficacy of Ramipril on Non-Memory Cognitive Functions-EORTC Quality of Life Questionnaire-Core 30/Brain Cancer Module-20 (EORTCQLQ30/BN20)|Estimate Time of Neurocognitive Decline- HVLT-R|Estimate Time of Neurocognitive Decline- TMT A & B|Estimate Time of Neurocognitive Decline- COWA|Determine Presence of Apolipoprotein Epsilon (ApoE)|Efficacy of neurocognitive function in surviving patients- HVLT-R|Efficacy of neurocognitive function in surviving patients- TMT A & B|Efficacy of neurocognitive function in surviving patients- COWA|Efficacy of neurocognitive function in surviving patients- EORTCQLQ30/BN20	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	75	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB00053531|3UG1CA189824-04S1|NCI-2018-01807|WF-1801	25-Mar-19	30-Sep-22	30-Sep-22	23-Mar-18		24-Sep-21	"Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Porter Adventist Hospital, Denver, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Regional Cancer Center-Lee Memorial Health System, Fort Myers, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital - Duluth, Duluth, Georgia, United States|Northside Hospital - Gwinnett, Lawrenceville, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Suburban Hematology Oncology Associates - Snellville, Snellville, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States|The Cancer Center of Hawaii-Pali Momi, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii, United States|Queen's Cancer Cenrer - POB I, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Queen's Cancer Center - Kuakini, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Saint Luke's Hospital, Cedar Rapids, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Culicchia Neurological Clinic LLC, Marrero, Louisiana, United States|West Jefferson Medical Center, Marrero, Louisiana, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|AtlantiCare Health Park-Cape May Court House, Cape May Court House, New Jersey, United States|AtlantiCare Surgery Center, Egg Harbor Township, New Jersey, United States|Lovelace Medical Center-Saint Joseph Square, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, United States|Northwell Health Imbert Cancer Center, Bay Shore, New York, United States|Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Mission Hospital, Asheville, North Carolina, United States|Cone Health Cancer Center at Alamance Regional, Burlington, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Novant Health Cancer Institute - Kernersville, Kernersville, North Carolina, United States|Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Saint Joseph's/Candler - Bluffton Campus, Bluffton, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Duluth Clinic Ashland, Ashland, Wisconsin, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic - Ladysmith Center, Ladysmith, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Marshfield Medical Center - Weston, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03475186
770	NCT04045847	CD147-CART Cells in Patients With Recurrent Malignant Glioma.		Recruiting	No Results Available	Recurrent Glioblastoma|CD147 Positive	Biological: CD147-CART	Incidence and type of adverse events induced by CD147-CART|DLT and MTD of CD147-CART cell|Clinical Activity of CD147-CART cell|CD147-CART detection in Peripheral Blood	Xijing Hospital	All	"18 Years to 65 Years   (Adult, Older Adult)"	Early Phase 1	31	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Chen Zhinan-2	30-May-19	30-Oct-20	30-May-22	6-Aug-19		7-May-20	"National Translational Science Center for Molecular Medicine & Department of Cell Biology, Xi'an, Shaanxi, China"		https://ClinicalTrials.gov/show/NCT04045847
771	NCT04105374	"Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma"		Withdrawn	No Results Available	Anaplastic Astrocytoma|Glioblastoma|Oligodendroglioma|Supratentorial Glioblastoma	Drug: Extended Release Flucytosine|Device: NovoTTF-100A Device|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery|Biological: Vocimagene Amiretrorepvec	Progression free survival (PFS) (Phase II)|Overall survival (OS) (Phase III)|Incidence of grade 3 or higher adverse events|Overall survival (OS) (Phase II)|Progression free survival (PFS) (Phase III)|Objective response rate (ORR)	NRG Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	0	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NRG-BN006|NCI-2019-04562|U10CA180868	31-Jan-20	30-Nov-25	30-Nov-30	26-Sep-19		24-Mar-20			https://ClinicalTrials.gov/show/NCT04105374
772	NCT03025893	"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme"	STELLAR	Recruiting	No Results Available	"Glioblastoma Multiforme|Glioblastoma, Adult|Glioblastoma|Recurrent Brain Tumor|GBM"	Drug: Sunitinib|Drug: Lomustine	"Six-month progression-free survival (PFS-6)|Overall survival (OS)|Objective radiological response rate|Adverse events (AEs)|Health-related quality of life (HRQoL)|Blood markers (TEP: tumor educated platelets, and miRNA)|MGMT promoter methylation status"	VU University Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2|Phase 3	100	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016.221	31-Aug-18	1-Jan-22	1-Jan-22	20-Jan-17		19-Apr-21	"VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Radboud UMC, Nijmegen, Netherlands"		https://ClinicalTrials.gov/show/NCT03025893
773	NCT00112866	Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme		Terminated	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: cilengitide|Procedure: therapeutic conventional surgery|Other: pharmacological study|Other: laboratory biomarker analysis	6m-Progression-free Survival|Changes in avb3 Integrin Expression on Tumor Cells and Endothelial Cells|Changes in Vitronectin Expression|Changes in Tumor Cell Apoptosis|Changes in Tumor Cell Proliferation|Changes in Endothelial Cell Apoptosis|Plasma Concentration of EMD 121974|Tumor Tissue Concentrations	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02653|CDR0000428409|NABTC-03-02|U01CA062399	Jan-05	Dec-08	Mar-09	3-Jun-05	14-Jun-17	14-Jun-17	"North American Brain Tumor Consortium, Watertown, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00112866
774	NCT04315584	FDG and FDOPA PET Demonstration of Functional Brain Abnormalities		Recruiting	No Results Available	Glioblastoma	Procedure: Positron Emission Tomography|Procedure: Computed Tomography|Procedure: Multiparametric Magnetic Resonance Imaging Scan|Radiation: Fludeoxyglucose F-18|Radiation: fluorine F 18 fluorodopa	"Quantitative parametric maps indicating differences in rates of glucose and amino acid uptake (Ki) obtained from dynamic FDG and FDOPA scans respectively.|Quantitative parametric maps indicating differences in details (d) components of the wavelet transform analysis, d6 and d8, based on established tumor feature criterions.|Semi-quantitative standardize uptake value (SUV) parametric maps based on static PET scans (last 20 minutes of the dynamic PET scans).|MRI brain metrics|Surgical pathology or 3-6 month interval multidisciplinary clinical evaluation."	University of Virginia	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	HSR190096	15-Mar-20	20-Dec-23	20-Jun-24	19-Mar-20		24-Mar-20	"University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT04315584
775	NCT00016328	CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: temsirolimus|Other: laboratory biomarker analysis|Other: pharmacological study	"Percentage of patients being progression free|Percentage of patients that have not progressed|Confirmed tumor response defined as an objective status of complete response (CR), partial response (PR), or regression (REGR) on two consecutive evaluations|Time to progression and death"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	33	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01858|N997B|CDR0000068623|NCCTG-N997B|U10CA025224	May-01	Aug-05		27-Jan-03		18-Jul-13	"North Central Cancer Treatment Group, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT00016328
776	NCT04074785	Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6		Recruiting	No Results Available	"GBM|Glioblastoma|Brain Tumor|Brain Tumor, Recurrent"	Drug: Abemaciclib|Drug: Bevacizumab	Number of participants with adverse event|Median Overall Survival|Median Progression Free Survival	Edward Pan|University of Texas Southwestern Medical Center	All	"18 Years to 99 Years   (Adult, Older Adult)"	Early Phase 1	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCCC-06319; STU-2019-1214	13-Dec-19	24-Oct-21	24-Oct-22	30-Aug-19		16-Dec-20	"UT Southwestern Medical Center, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT04074785
777	NCT04221503	Niraparib/TTFields in GBM		Recruiting	No Results Available	Glioblastoma|Recurrent Glioblastoma|GBM	Drug: Niraparib|Device: Optune|Procedure: Planned surgical resection	"Disease control, defined as achievement of either CR, PR, or SD, as defined by modified Response Assessment in Neuro-Oncology (mRANO) criteria.|Number of AEs (Adverse Events)|Duration of disease control.|Objective radiographic response (ORR)|Progression-free survival (PFS)|Overall survival (OS)"	"University of Pennsylvania|Tesaro, Inc.|NovoCure Ltd."	All	"22 Years and older   (Adult, Older Adult)"	Phase 2	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3319	30-Dec-19	Dec-25	Dec-25	9-Jan-20		19-Jul-21	"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04221503
778	NCT02709226	Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma		Recruiting	No Results Available	"Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme|Gliosarcoma"	Radiation: Radiation	To determine maximum tolerated re-irradiation dose (MTD).|To determine QOL and impact on neurocognition in the setting of re-irradiation of recurrent glioblastoma|To determine progression free survival and overall survival.|To determine late toxicity secondary to re-irradiation	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	NIH	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	160081|16-C-0081	15-Jun-16	30-Oct-24	30-Oct-26	16-Mar-16		30-Dec-21	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT02709226
779	NCT01174537	"New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma"		Withdrawn	No Results Available	Glioblastoma|Sarcoma|Neuroblastoma	Biological: New Castle Disease Virus	Progression-free survival	Hadassah Medical Organization	All	"3 Years to 75 Years   (Child, Adult, Older Adult)"	Phase 1|Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NDV-HUJ-HMO-CTIL	Jul-11	Jul-11	Jul-11	3-Aug-10		11-Jun-15	"Hadassah Medical Organization, Jerusalem, Israel"		https://ClinicalTrials.gov/show/NCT01174537
780	NCT00335764	"Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma"		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: sorafenib tosylate|Drug: erlotinib hydrochloride|Drug: tipifarnib|Drug: temsirolimus	Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I)|Pharmacokinetic Max Concentration (Cmax) of Group 2 Sorafenib and Temsirolimus (Phase I)|Pharmacokinetic cMax Group 1 Sorafenib and Erlotinib (Phase I)|Pharmacokinetic AUC 0-12 Group 1 Sorafenib and Erlotinib (Phase I)|Trough Concentration Group 2 Sorafenib and Temsirolimus (Phase I)|Plasma Time Curve (AUC) of Group 2 Sorafenib and Temsirolimus (Phase I)|Pharmacokinetic Cpmax Group 3 Sorafenib and Tipifarnib (Phase I) 100 mg QD (Level -1)|Pharmacokinetic CpMax Concentration of Group 3 Sorafenib and Tipifarnib (Phase I) 100mg BID|Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg QD (Level -1)|Plasma Time Curve (AUC) of Group 3 Phase I Sorafenib and Tipifarnib 100mg BID (Level 1)|12 Month Survival Rate (Phase II)|Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase I)|Number of High Grade (3 and 4) Related Adverse Events of Each Combination Agent Combined With BAY 43-9006 (Phase 2)|Progression-free Survival at 6 Months (Phase II)|Objective Response Rate in Patients With Measurable Disease (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	92	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00676|CDR0000476286|NABTC-05-02|U01CA137443	Apr-06	Feb-10	Sep-12	12-Jun-06	2-Jul-18	2-Jul-18	"University of California at Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00335764
781	NCT04937413	The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation		Recruiting	No Results Available	Malignant Glioma|Glioblastoma	Drug: Evolocumab	Presence of evolocumab in surgical tumor tissue and tissue from a matched control group|Level of lipid metabolism within the surgical tumor tissue and tissue from a matched control group|Major histocompatibility complex-1 (MHC-I) expression within the surgical tumor tissue and tissue from a matched control group|Correlation between serum and surgical tumor tissue levels of evolocumab	Duke University	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Pro00108375	8-Oct-21	Mar-22	Mar-22	24-Jun-21		9-Nov-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04937413
782	NCT03688178	DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab	DERIVe	Recruiting	No Results Available	Glioblastoma	Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Drug: Temozolomide|Biological: Varlilumab|Biological: Td|Biological: Unpulsed DCs	"Median Overall Survival (OS) of Subjects Receiving Td pre-conditioning|Safety of administering Varlilumab to GBM patients receiving temozolomide and dendritic cell vaccines ± Td pre-conditioning as measured by the percentage of patients with unacceptable toxicity regardless of attribution|Median percent change between baseline, assessed on day 14, and nadir levels of Treg before the time that the second cycle of adjuvant TMZ would be administered. Treg determined by flow cytometry (CD3+ CD4+ CD25+ Foxp3+).|Median Overall Survival (OS) of Subjects Receiving DC vaccines, varlilumab, and Td pre-conditioning|Median Progression-free Survival (PFS)|Median Chemokine (C-C motif) ligand 3 (CCL3) Levels in Serum at 24, 48, and 72 hours after Pre-conditioning"	Gary Archer Ph.D.|Celldex Therapeutics|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	112	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	Pro00082570	26-Aug-20	Mar-25	Mar-25	28-Sep-18		28-Jul-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03688178
783	NCT01242566	Temozolomide in Elderly Patients With KPS < 70	TAG	Completed	No Results Available	Primary Brain Tumor|Glioblastoma	Drug: Temozolomide	Overall survival|Progression-free survival|adverse events|Health-related quality of life|Cognitive functioning|Efficacy according to MGMT Promoter methylation status	Assistance Publique - Hôpitaux de Paris|Association de Neuro-Oncologues d'Expression Francaise	All	70 Years and older   (Older Adult)	Phase 2	70	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P060102	Jul-07	May-10	Sep-10	17-Nov-10		17-Nov-10	"Pitie salpetriere hospital, Paris, France"		https://ClinicalTrials.gov/show/NCT01242566
784	NCT03927222	Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma	I-ATTAC	Suspended	No Results Available	Glioblastoma	Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|Drug: Temozolomide|Biological: Tetanus-Diphtheria Toxoid (Td)|Biological: GM-CSF|Biological: 111-Indium-labeling of Cells for in vivo Trafficking Studies	Median overall survival of subjects receiving Td pre-conditioning with GM-CSF|Migration and Survival from vaccine 4|Chemokine (C-C motif) ligand 3 (CCL3) and Survival from vaccine 4|Polyfunctionality and Survival from vaccine 4|Maximum peak increase from vaccine 1 in percent Regulatory T cells (TReg) of CD4+ T cells|Proportion of patients with unacceptable toxicity	Gary Archer Ph.D.|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	48	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00090683	30-Sep-19	Dec-23	Dec-23	25-Apr-19		27-Sep-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03927222
785	NCT01923922	CT Perfusion in the Prognostication of Cerebral High Grade Glioma		Unknown status	No Results Available	Glioblastoma Multiforme	Radiation: CT Perfusion	Survival of patients with high grade cerebral glioma based on the CT perfusion parameters irrespective of the pathological grade and irrespective of the treatment given.|Number of Adverse Events as a Measure of Safety and Tolerability	Jai Shankar|Nova Scotia Health Authority	All	"15 Years and older   (Child, Adult, Older Adult)"	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CTP GBM	Sep-13	Dec-16	Dec-17	16-Aug-13		27-Jan-16	"QE II Health Sciences Centre, Halifax, Nova Scotia, Canada"		https://ClinicalTrials.gov/show/NCT01923922
786	NCT04826393	ASP8374 + Cemiplimab in Recurrent Glioma		Not yet recruiting	No Results Available	Glioblastoma|Recurrent Glioblastoma	Drug: ASP8374|Drug: cemiplimab|Drug: 89Zr-Df-IAB22M2C	Maxium Tolerated Dose-MTD/ Phase 2 Recommend Dose-RP2D - Cohort 1|CD8+ TIL Tumor Density-Cohort 2|Rate of Adverse Events|progression-free survival (PFS)|overall survival (OS).	"Dana-Farber Cancer Institute|Regeneron Pharmaceuticals|Astellas Pharma Inc|ImaginAb, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	65	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21-054	Dec-21	1-Jun-22	30-Dec-22	1-Apr-21		16-Nov-21	"Brigham and Women's Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT04826393
787	NCT04214392	Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma	Biological: Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes	"Dose limiting toxicity (DLT)|Chimeric antigen receptor (CAR) T cell|Endogenous T cell|Cytokine levels in TCF, PB and CSF|Progression free survival time|Disease response|Overall survival (OS)|CAR T cells detected in tumor tissue|Chlorotoxin-targeted antigen expression levels in tumor tissue|Biomathematical modeling of tumor growth"	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19309|NCI-2019-08393	26-Feb-20	6-Feb-23	6-Feb-23	2-Jan-20		15-Jun-21	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT04214392
788	NCT00687765	Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma		Completed	No Results Available	Glioblastoma	Drug: bsi-201 plus temozolomide	"To determine the Maximum Tolerated Dose (MTD) of BSI-201, administered as an IV infusion in patients with newly diagnosed malignant glioma when given with temozolomide (TMZ) after the completion of standard radiation therapy and concomitant TMZ"	Sanofi	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	126	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TCD11616|20070104	Jul-08	Jun-15	Jun-15	2-Jun-08		13-Jul-15	"Research Site, Birmingham, Alabama, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00687765
789	NCT04180046	Utility of Primary Glioblastoma Cell Lines		Recruiting	No Results Available	Tumor|Brain Tumor		Establishment of primary glioblastoma cell lines	Neuromed IRCCS	All	"Child, Adult, Older Adult"		10	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NeuroPath_01	26-Jun-19	26-Jun-19	30-Dec-21	27-Nov-19		12-Apr-21	"Neuromed IRCCS, Pozzilli, IS, Italy"		https://ClinicalTrials.gov/show/NCT04180046
790	NCT03780569	TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM		Unknown status	No Results Available	Glioblastoma Multiforme	Device: NovoTTF-200A|Radiation: Radiotherapy|Drug: Temozolomide	"Safety of concomitant Radiotherapy/Temozolomide with NovoTTF-200A: The incidence of Radiotherapy treatment delays during concomitant Radiotherapy/Temozolomide/NovoTTF-200A will be documented including severity and relationship to NovoTTF-200A.|Progression free survival|Overall survival|Adverse events, severity and frequency"	NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	10	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICH-1	27-Apr-17	Jan-19	Jan-19	19-Dec-18		20-Dec-18	"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT03780569
791	NCT00075491	Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme		Terminated	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: fenretinide|Procedure: therapeutic conventional surgery|Other: pharmacological study|Other: laboratory biomarker analysis	"Progression-free survival (PFS)|Plasma and tissue concentrations of fenretinide and its metabolite, 4-MPR using high-performance liquid chromatography (HPLC) assay|Tumor apoptotic index after fenretinide treatment by immunohistochemistry|Correlation between tumor apoptotic index with serum and tissue fenretinide levels|Correlation of time to progression with drug levels and apoptotic index|Fenretinide effects on retinol, RBP, retinoid receptor levels and IGF-1|Fenretinide activity using magnetic resonance spectroscopy (MRS)|Radiological response|Overall survival|Unexpected toxicity associated with fenretinide as assessed by CTC version 3.0"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	42	NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCI-2012-02566|ID02-701|R21CA097767|CDR0000346722	Dec-03	Mar-05		12-Jan-04		24-Jan-13	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00075491
792	NCT05091866	Natural Progesterone for the Treatment of Recurrent Glioblastoma		Recruiting	No Results Available	Gliosarcoma|Recurrent Glioblastoma	Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Biological: Therapeutic Progesterone	Natural progesterone blood levels|Incidence of adverse events|Overall response rate|Progression free survival (PFS)|Overall survival (OS)	Emory University	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	32	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00002155|NCI-2021-01498|WINSHIP5184-20|P30CA138292	25-Aug-21	25-Aug-24	25-Aug-25	25-Oct-21		25-Oct-21	"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT05091866
793	NCT01811498	Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme|Brain Tumor	Drug: Bevacizumab	Composite overall response rate (CORR)|Progression-free survival (PFS) and Overall survival (OS)|Toxicities	Northwell Health|Feinstein Institute for Medical Research	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-352	Feb-13	Dec-21	Feb-22	14-Mar-13		3-Mar-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01811498
794	NCT01756352	FET-PET for Evaluation of Response of Recurrent GBM to Avastin		Completed	Has Results	Glioblastoma Multiforme|GBM	Drug: 18F-FET	Progression-free Survival|Overall Survival	"Marcelo F. Di Carli, MD, FACC|Brigham and Women's Hospital"	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 2	13	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2012P002678	Feb-13	13-Sep-15	13-Sep-15	25-Dec-12	30-Oct-19	30-Oct-19	"Brigham and Women's Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01756352
795	NCT00329719	Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma		Completed	Has Results	Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm	Procedure: Conventional Surgery|Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate|Drug: Temsirolimus	"Progression-free Survival|Overall Survival|Objective Response, as Determined by a Neurological Exam, MRI, and/or CT Measurement"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	115	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00652|CDR0000472240|NCCTG-N0572|N0572|U10CA180821|U10CA025224	24-Mar-06	1-Feb-13	2-Feb-13	25-May-06	2-Jun-15	16-Oct-18	"Providence Alaska Medical Center, Anchorage, Alaska, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Heartland Cancer Research NCORP, Decatur, Illinois, United States|Saint Anthony Memorial Hospital, Effingham, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Kewanee Hospital, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Medini, Eitan MD (UIA Investigator), Alexandria, Minnesota, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Etzell, Paul S MD (UIA Investigator), Fergus Falls, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Swenson, Wade II, MD (UIA Investigator), Fergus Falls, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Minnesota Cooperative Group Outreach Program, Minneapolis, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Saint Joseph's Hospital - Healtheast, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Woodwinds Health Campus, Woodbury, Minnesota, United States|Nebraska Cancer Research Center, Lincoln, Nebraska, United States|Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Southeast Clinical Oncology Research (SCOR) Consortium NCORP, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Sanford Cancer Center Oncology Clinic, Sioux Falls, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|Medical X-Ray Center, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|HSHS Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00329719
796	NCT00433381	Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma		Completed	Has Results	Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm	Biological: Bevacizumab|Drug: Irinotecan Hydrochloride|Drug: Temozolomide	"Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm|Count/Percentage of Patients Discontinuing Treatment Due to Treatment-related Medical Complications(Bevacizumab and Temozolomide Arm)|Number of Participants With Predicted Progression-free Survival at 6 Months (PFS-6)|Number of Participants With Predicted Overall Survival (OS) at 12 Months|Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Temozolomide Arm|Patients' Best Objective Response (Complete Response, Partial Response, Stable Disease, Progression)|Agreement Between Local Interpretation and Central Interpretation of Standard MRI|Accuracy of Local PFS 6-mo Interpretation Using Central Review PFS-6 as the Reference Standard|Correlation of Degree of Cerebral Blood Volume (CBV) and Lactate (Lac) to N-acetylaspartate (NAA) (Lac/NAA) Ratio|Correlation of Degree of Cerebral Blood Volume (CBV) and Lactate (Lac) to Patient Response|Predictive Value of CBV and Lac/NAA in Assessing 6-month Progression-free Survival|Change in Perfusion MRI Markers at Week 2 as Predictors of 12mo Overall Survival (OS)|Change in Perfusion MRI Markers at Week 8 as Predictors of 12mo Overall Survival (OS)|Change in Perfusion MRI Markers at Week 16 as Predictors of 12mo Overall Survival (OS)"	National Cancer Institute (NCI)|American College of Radiology Imaging Network|Radiation Therapy Oncology Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	123	NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00743|RTOG-0625|ACRIN-6677|CDR0000528259|RTOG 0625|U10CA021661	1-Mar-07	21-Jan-10	16-Feb-11	12-Feb-07	1-May-13	17-Sep-18	"Mobile Infirmary Medical Center, Mobile, Alabama, United States|Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|John Muir Medical Center-Concord Campus, Concord, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Marin General Hospital, Greenbrae, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|John Muir Medical Center-Walnut Creek, Walnut Creek, California, United States|Yale University, New Haven, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Vincent Anderson Regional Hospital/Cancer Center, Anderson, Indiana, United States|Franciscan Saint Francis Health-Beech Grove, Beech Grove, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Cheshire Medical Center-Dartmouth-Hitchcock Keene, Keene, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|John F Kennedy Medical Center, Edison, New Jersey, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States|Veteran Affairs Medical Center, Dayton, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Adventist Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|M D Anderson Cancer Center, Houston, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Cottonwood Hospital Medical Center, Murray, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Intermountain Health Care, Salt Lake City, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Saint Francis Hospital, Federal Way, Washington, United States|EvergreenHealth Medical Center, Kirkland, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00433381
797	NCT02085304	"Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM"		Unknown status	No Results Available	Glioblastoma	Procedure: Gross total resection and Gliadel(R) wafers implanted|Radiation: GammaKnife(R) stereotactic Radiosurgery|Radiation: Standard fractionated radiation therapy|Drug: Temozolomide	Change in health related quality of life|time without Cognitive impairment|incidence of symptomatic radiation necrosis|Disease-free survival|Overall survival	"St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	80	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12BN101	Oct-12	Jun-17	Dec-17	12-Mar-14		13-Dec-16	"Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT02085304
798	NCT00979862	Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm	Drug: Cediranib Maleate|Drug: Cilengitide|Other: Laboratory Biomarker Analysis	Safety profile of cediranib maleate based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Change in markers|Overall survival (OS)|Progression-free survival|Radiographic responses using MRI scan	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	47	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02919|CDR0000654715|0903|ABTC-0903|U01CA137443	Mar-10	May-12	Feb-14	18-Sep-09		15-Apr-15	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Adult Brain Tumor Consortium, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00979862
799	NCT04545177	Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue		Recruiting	No Results Available	Glioblastoma	Device: NICO Myriad and Tissue Preservation System (TPS)	"Feasibility, as measured by percentage of the sample deemed viable by flow cytometry"	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	CASE8319	17-Sep-20	Feb-22	Feb-22	10-Sep-20		29-Jun-21	"Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT04545177
800	NCT05076513	Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma		Recruiting	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioma|GBM|Glioma, Malignant|Glioblastoma Multiforme of Brain"	Drug: Niraparib|Radiation: Radiation therapy	Phase 0 Arm A: Total and unbound niraparib concentration in enhancing and nonenhancing tissue|Phase 0 Arm B: Presence of Chromosomal fusion|Phase 0 Expansion Arm A: Progression-free survival in participants with demonstrated PK effects|Phase 0 Expansion Arm B: Progression-free survival in participants with demonstrated PD effects|Drug-related toxicity|Adverse events|Deaths|Incidence of clinical laboratory abnormalities per CTCAE|Overall survival|Phase 0 Arm A: Pharmacodynamics (PD) of niraparib|Phase 0 Arm B: Pharmacokinetics (PK) of niraparib	"Nader Sanai|Barrow Neurological Institute|Ivy Brain Tumor Center|University of California, San Francisco|GlaxoSmithKline|St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	42	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2021-13	29-Oct-21	Oct-22	Oct-24	13-Oct-21		9-Dec-21	"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of California San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT05076513
801	NCT02717962	"Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting"		"Active, not recruiting"	No Results Available	Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer	"Drug: VAL-083, Dianhydrogalactitol"	Overall Survival|Estimate Progression-free Survival|Estimate Median Progression-Free Survival|Estimate Median Overall Survival|Estimate Overall Response Rate|Estimate Duration of Response|Safety evaluation of VAL-083 in patients|Quality of Life|Plasma Pharmacokinetics	"Kintara Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	119	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DLM-16-001	20-Jan-17	Sep-21	Dec-21	24-Mar-16		8-Jun-21	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02717962
802	NCT00423735	Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm	Drug: Dasatinib|Other: Pharmacological Study	"Number of Patients Achieving 6-month Progression-free Survival (6mPFS)|Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS)|Overall Survival|Treatment Response Rates at Six Months|Progression-free Survival|Rate of Adverse Events|Correlation of Molecular Markers and Tumor Response|Correlation of Pharmacokinetic Data With Dosing, Toxicity, and Efficacy"	National Cancer Institute (NCI)|Radiation Therapy Oncology Group|NRG Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	64	NIH|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00744|CDR0000526070|RTOG 0627|RTOG-0627|U10CA180868|U10CA021661	24-Jan-07	9-Mar-11	4-Sep-18	18-Jan-07	6-Jan-15	24-Jul-19	"Mobile Infirmary Medical Center, Mobile, Alabama, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Mercy General Hospital Radiation Oncology Center, Sacramento, California, United States|Sutter Cancer Centers Radiation Oncology Services-Vacaville, Vacaville, California, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Integrated Community Oncology Network-Florida Cancer Center Beaches, Jacksonville Beach, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Integrated Community Oncology Network-Southside Cancer Center, Jacksonville, Florida, United States|University of Florida Health Science Center - Jacksonville, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Jupiter Medical Center, Jupiter, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|21st Century Oncology-Orange Park, Orange Park, Florida, United States|21st Century Oncology-Palatka, Palatka, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Integrated Community Oncology Network-Flager Cancer Center, Saint Augustine, Florida, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Saint John's Hospital, Springfield, Illinois, United States|Saint Vincent Anderson Regional Hospital/Cancer Center, Anderson, Indiana, United States|Franciscan Saint Francis Health-Beech Grove, Beech Grove, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Reid Health, Richmond, Indiana, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|Shawnee Mission Medical Center-KCCC, Shawnee Mission, Kansas, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Cape Radiation Oncology, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Renown Regional Medical Center, Reno, Nevada, United States|Cheshire Medical Center-Dartmouth-Hitchcock Keene, Keene, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Virtua Memorial, Mount Holly, New Jersey, United States|Sparta Cancer Treatment Center, Sparta, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Veteran Affairs Medical Center, Dayton, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|UH Seidman Cancer Center at Salem Regional Medical Center, Salem, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|University Pointe, West Chester, Ohio, United States|Cancer Treatment Center, Wooster, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Salem Hospital, Salem, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Upper Delaware Valley Cancer Center, Milford, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Wellmont Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center - West, Knoxville, Tennessee, United States|Thompson Cancer Survival Center at Methodist, Oak Ridge, Tennessee, United States|University of Texas Medical Branch, Galveston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Medical Center-Lakeside, Lubbock, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Cottonwood Hospital Medical Center, Murray, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Intermountain Health Care, Salt Lake City, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Southwest VA Regional Cancer Center, Norton, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Wheeling Hospital/Schiffler Cancer Center, Wheeling, West Virginia, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Green Bay Oncology - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|London Regional Cancer Program, London, Ontario, Canada|CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia"		https://ClinicalTrials.gov/show/NCT00423735
803	NCT04528680	Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma	SC9/ABX	Recruiting	No Results Available	"Glioblastoma|Gliosarcoma|GBM|Glioblastoma Multiforme|Glioblastoma, IDH-wildtype|Recurrent Glioblastoma"	"Device: Sonication for opening of blood-brain barrier|Drug: Chemotherapy, albumin-bound paclitaxel"	Dose limiting toxicity|1-year survival rate|Incidence of side effects/toxicity associated with Sonication/ABX treatment	Northwestern University|CarThera|Bristol-Myers Squibb|Lantheus Medical Imaging	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	39	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 20C03	Oct-20	Aug-24	Sep-25	27-Aug-20		12-Oct-20	"Northwestern Memorial Hospital, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT04528680
804	NCT03616860	Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma		Recruiting	No Results Available	Glioblastoma	Device: Focused Ultrasound (FUS) BBB Disruption	Device and procedure related adverse events|Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging|Effectiveness of BBB disruption in the treated tumor region	InSightec	All	"18 Years to 80 Years   (Adult, Older Adult)"	Not Applicable	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT008C|277981	16-Oct-18	Mar-22	Dec-24	6-Aug-18		22-Jan-21	"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT03616860
805	NCT03603379	Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas	GBM-LIPO	Completed	No Results Available	Glioblastoma	Drug: C225-ILs-dox	Ratio of C225-ILs-dox concentration|Tumour response according to RANO criteria on the final MRI scan|Best achieved tumour response (1st or second MRI scan) during treatment phase according to RANO criteria (|Event free survival|Progression free survival|Overall survival|Toxicity as graded by the CTCAE Version 4.0	"University Hospital, Basel, Switzerland"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	9	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	2018-01160; me17Kasenda2	16-Nov-18	1-Nov-20	1-Nov-20	27-Jul-18		8-Dec-20	"Kantonsspital Aarau (KSA), Oncology, Aarau, Switzerland|Department of Oncology University Hospital Basel, Basel, Switzerland"		https://ClinicalTrials.gov/show/NCT03603379
806	NCT00102648	Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide		"Active, not recruiting"	No Results Available	Malignant Supratentorial Neoplasm|Recurrent Glioblastoma|Recurrent Gliosarcoma	Drug: Lonafarnib|Drug: Temozolomide	"Maximum tolerated dose (MTD) of lonafarnib when given with temozolomide, defined as the dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT)|Tolerability of regimen in patients with disease progression or recurrence during or after recent completion of treatment with temozolomide|Progression free survival (PFS)|Objective response|Overall survival|Treatment-related toxicities"	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	35	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2004-0424|NCI-2012-01311|NCI-2010-00417	21-Dec-04	1-Dec-22	1-Dec-22	1-Feb-05		3-Jan-22	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00102648
807	NCT00115440	BNCT to Treat Glioma That Has Progressed Following Radiotherapy		Completed	No Results Available	Glioblastoma|Anaplastic Astrocytoma	Radiation: Bononophenylalanine (BPA)-based BNCT	safety|survival|adverse effects of BNCT|quality-of-life	Boneca Corporation	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	22	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FIN-BNCT-03/2000|BNCT P-03	Mar-01	Dec-08	Jan-09	23-Jun-05		28-Jan-09	"Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland"		https://ClinicalTrials.gov/show/NCT00115440
808	NCT01870726	Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma		Terminated	Has Results	"c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM"	Drug: INC280|Drug: Buparlisib	Number of Patients Reporting Dose Limiting Toxicities (DLTs) in Cycle 1|Phase II: Progression Free Survival Rate (PFSR)|Phase II Surgical Arm: Concentrations of INC280 and Buparlisib in Tumor.|Number of Participants With Adverse Events|Pharmacokinetic Profile of INC280 - AUCtau|Pharmacokinetic Profile of INC280 - Cmax|Pharmacokinetic Profile of INC280 - Tmax|Pharmacokinetic Profile of INC280 - T1/2|Pharmacokinetic Profile of Buparlisib - AUCtau|Pharmacokinetic Profile of Buparlisib - Cmax|Pharmacokinetic Profile of Buparlisib - Tmax|Pharmacokinetic Profile of Buparlisib - T1/2|Best Overall Response (BOR)|Overall Survival (OS)	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	43	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CINC280X2204|2013-000699-14	9-Jan-14	23-Dec-16	23-Dec-16	6-Jun-13	24-May-18	30-May-18	"Dana Farber Cancer Institute SC, Boston, Massachusetts, United States|Columbia University Medical Center- New York Presbyterian Dept of Oncology, New York, New York, United States|Memorial Sloan Kettering Cancer Center Neurology, New York, New York, United States|Duke University Medical Center Duke - Baker, Durham, North Carolina, United States|University of Texas MD Anderson Cancer Center SC-3, Houston, Texas, United States|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Tübingen, Germany|ErasmusMC Cancer Institute - Neurooncology, RM G3-55, Rotterdam, Netherlands|University Medical Center Utrecht, Rm Q05.4.300, P.O. Box 85500, Utrecht, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, St. Gallen, Switzerland"		https://ClinicalTrials.gov/show/NCT01870726
809	NCT03914768	Immune Modulatory DC Vaccine Against Brain Tumor		Enrolling by invitation	No Results Available	Diffuse Intrinsic Pontine Glioma or Glioblastoma	Biological: Immunomodulatory DC vaccine to target DIPG and GBM	Safety of infusion of autologous immunomodulatory DC Vaccine is assessed by the NCI CTCAE V4.0 criteria.|Overall survival (OS) at 12 months (OS12).|Treatment response rate of DIPG or GBM|Overall survival Rate|Progression-free survival rate|ELISPOT or antigen specific functional assays for evaluation of antigen specific immune response in patients|Magnetic resonance imaging for evaluation of disease progression and prognosis	Shenzhen Geno-Immune Medical Institute|Shenzhen Hospital of Southern Medical University|Shenzhen Children's Hospital	All	"1 Year to 75 Years   (Child, Adult, Older Adult)"	Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GIMI-IRB-19001	31-Mar-19	31-Jan-21	31-Dec-22	16-Apr-19		12-Jun-20	"Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Children's Hospital, Shenzhen, Guangdong, China|Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China"		https://ClinicalTrials.gov/show/NCT03914768
810	NCT00612339	Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Avastin and Temozolomide	Response Rate	"Duke University|Genentech, Inc.|Schering-Plough"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	41	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00001022	Aug-07	May-12	May-12	11-Feb-08	10-Sep-12	27-May-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00612339
811	NCT02899663	MRI Detection of Microbleeds in Glioma Patients	SWIGLI	Completed	No Results Available	Glioblastoma		Number of microbleeds diagnosed with MRI (susceptibility weighted imaging sequence)	Fondation Ophtalmologique Adolphe de Rothschild	All	"18 Years and older   (Adult, Older Adult)"		58	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	NI_ALR_2016_1	Jan-15	Aug-15		14-Sep-16		14-Sep-16			https://ClinicalTrials.gov/show/NCT02899663
812	NCT02060955	Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan		Terminated	No Results Available	Glioblastoma Multiforme	Biological: ALECSAT|Drug: Bevacizumab/Irinotecan	Progression-free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Quality of Life by European Organization for Research and Treatment of Cancer (EORTC) questionnaire|Overall Response Rate (ORR)	CytoVac A/S	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	25	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CV-005	Feb-14	Jun-15	Jul-15	12-Feb-14		6-Jun-16	"Aalborg Universityhospital, Department of Oncology, Aalborg, Hobrovej 18-22, Denmark|Aarhus University Hospital, Department of Oncology, Aarhus, Nørrebrogade 44, Denmark|Odense University Hospital, Department of Oncology, Odense, Sdr. Boulevard 29, Denmark|Department of Oncology, Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT02060955
813	NCT00612989	Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM		Completed	No Results Available	Glioblastoma|Gliosarcoma	Drug: Temodar and O6-Benzylguanine	Dose limiting toxicity|Progression-free survival	"Duke University|Schering-Plough|Keryx / AOI Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	42	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00004058|6788	Feb-05	Aug-07	Jul-08	12-Feb-08		16-Jul-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00612989
814	NCT03382977	"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects"		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme	Biological: VBI-1901	Dose limiting toxicity (DLT) occurring during Part A of the study and the occurrence of AEs during each treatment cycle in both Part A and Part B of the study|Immunogenicity and optimal vaccine-induced immunity-serum IgG anti-gB antibodies (Part A and B)|Cellular immunity against HCMV gB and pp65 antigens (Part A and B)|Changes in frequencies of myeloid suppressor cells and regulatory T cells (Part A and B)|Progression free survival (PFS) (Part A and B)|Overall survival (OS) (Part A and B)|Median overall survival (Part A and B)|Reduction in steroid use compared to baseline (Part A and B)|Change in quality of life (QOL questionnaire) compared to baseline (Part A and B)|Immunogenicity of the optimal dose of VBI-1901 formulated with either GM-CSF or AS01B adjuvants (Part B).	VBI Vaccines Inc.	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	38	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VBI-1901-01	6-Dec-17	Mar-22	Mar-22	26-Dec-17		12-Oct-21	"University of California, Los Angeles Neuro-Oncology Program, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|The Neurological Institute of New York Columbia University Medical Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03382977
815	NCT02698280	Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma		Completed	No Results Available	Glioblastoma	Drug: Bevacizumab|Drug: Nimustine	All cause response to treatment|All cause mortality|All cause disease progression|All cause severe toxicities	Huashan Hospital	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	23	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KY-2015-289; 02	Jul-15	Jan-18	May-18	3-Mar-16		31-Jul-18	"Huashan hospital, Fudan University, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT02698280
816	NCT02631655	POSitron Emission Imaging Using 18F-FDOPA in Neurooncology	POSEIDON	Completed	No Results Available	Glioblastoma	Other: impact of device 18F-FDOPA PET on treatment decisions	"percentage of modified therapeutic decisions connected to the data supplied by 18F-FDOPA PET|Percentage of variation in the confidence level of diagnosis incorporating 18F-FDOPA PET findings (reduced, unchanged, increased)."	Centre Antoine Lacassagne	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	110	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2014/60	Dec-15	Jun-20	Jun-20	16-Dec-15		16-Feb-21	"Centre Antoine Lacassagne, Nice, France"		https://ClinicalTrials.gov/show/NCT02631655
817	NCT02047058	Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics		Unknown status	No Results Available	Glioblastoma|Malignant Glioma		The effect of each single molecular marker of Q cell on progression-free survival|The effect of each single molecular marker of Q cell on overall survival|We will correlate molecular markers of Q cell with other genetic alterations	"Nanfang Hospital of Southern Medical University|Guangzhou General Hospital of Guangzhou Military Command|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|First Affiliated Hospital of Fujian Medical University|The First Affiliated Hospital of Nanchang University|Capital Medical University|Tianjin Medical University General Hospital|Shenzhen Second People's Hospital|Huashan Hospital|West China Hospital|Xiangya Hospital of Central South University|The First Hospital of Jilin University|First Hospital of China Medical University|Qilu Hospital of Shandong University|Second Affiliated Hospital of Soochow University|Sun Yat-sen University|Guangzhou First People's Hospital|Health Science Center of Xi'an Jiaotong University|Southern Medical University, China|Second Affiliated Hospital of Guangzhou Medical University"	All	"18 Years to 70 Years   (Adult, Older Adult)"		240	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NFGC-001-MCP	Mar-14	Dec-16	Mar-17	28-Jan-14		28-Jan-14	"Nanfang Glioma Centre, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT02047058
818	NCT02585219	Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas		Unknown status	No Results Available	Glioblastoma		Visual comparison of pre- and post-surgery 11C-MET-PET	University Medical Center Groningen	All	"18 Years and older   (Adult, Older Adult)"		10	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NL50485.042.14	Jan-16	Jan-17	Jul-17	23-Oct-15		23-Oct-15			https://ClinicalTrials.gov/show/NCT02585219
819	NCT02010606	Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|Glioblastoma Multiforme|Glioma|Astrocytoma|Brain Tumor	"Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab"	"Assess safety and tolerability according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEs) Version 4.03|Assess the number of serious adverse events|Assess treatment-related toxicities|Evaluate Overall Survival (OS) and Progression-Free Survival (PFS)|Evaluate health-related quality of life parameters|Assess the overall response rate, defined as the percentage of patients showing either partial response or complete response, in patients with subtotal resection|Evaluate immune response by assessing cytotoxic T cell activity in vitro pre- vs post-vaccination|Assess tumor stem cell antigen expression"	Cedars-Sinai Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	39	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	33203	8-Jan-14	23-Jan-19	10-Jul-21	13-Dec-13		22-Nov-21	"Cedars-Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT02010606
820	NCT00611728	Ph I SU011248 + Irinotecan in Treatment of Pts w MG		Completed	No Results Available	Glioblastoma	Drug: SU011248 & Irinotecan	Determine MTD & DLT of SU011248 + Irinotecan in pts w RMG not on EIAEDs|Demographic & baseline characteristics|Efficacy observations & measurements|Safety observations & measurements|PK measurements	Duke University|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	25	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000931	Mar-08	Jun-10	Sep-10	11-Feb-08		21-Jul-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00611728
821	NCT02022384	Immunophenotyping From Blood of Patients With Malignant Gliomas		"Active, not recruiting"	No Results Available	Anaplastic Astrocytoma|Glioblastoma Multiforme	Other: Blood sample and life quality questionnaires	"immunological state of patients comprising number, type and activation state of immune cells, cytokines and danger signals from peripheral blood|Acquisition of toxicities according to Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|documentation of medication|Acquisition of changes in imaging|Acquisition of life quality according to quality of life questionnaire (QLQ) (EORTC QLQ -BN20)|correlation of immunological parameters with clinical data|overall survival|progression free survival"	University of Erlangen-Nürnberg Medical School	All	"18 Years and older   (Adult, Older Adult)"		50	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	IMMO-GLIO 01	Dec-13	31-Dec-21	31-Dec-22	27-Dec-13		27-Apr-21	"Departement of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität erlangen-Nürnberg, Erlangen, BAY, Germany"		https://ClinicalTrials.gov/show/NCT02022384
822	NCT01836536	Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients	AVA-CELL	Completed	No Results Available	Glioblastoma|Glioma	Drug: Bevacizumab standard of care	blood cells populations|Cells variation and RMI response|Survival	Center Eugene Marquis	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	AVA-CELL	Sep-12	Mar-15	Aug-15	22-Apr-13		1-Mar-17	"Hôpital Avicenne, Bobigny, France|Center Eugene Marquis, Rennes, France"		https://ClinicalTrials.gov/show/NCT01836536
823	NCT04763031	Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT		Recruiting	No Results Available	Glioblastoma|GBM|Recurrent GBM	Radiation: Intra-operative Radiation Therapy - IORT	"The primary endpoint is Overall Survival (OS)|Patients treated with Xoft IORT device median overall survival (OS)|Local Progression-free Survival (PFS)|Quality of Life Assessment (Fact-Br)|Karnofsky Performance Status (KPS)|Radiation-related Neurotoxicity|The rate and severity of Adverse Events (AEs), Adverse Device Effects (ADEs), and Unanticipated Adverse Device Effects (UADEs)"	Parkridge Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PMC-3422401	5-Mar-21	22-Feb-24	31-Dec-24	21-Feb-21		9-Mar-21	"Southeastern Spine Neurosurgery, Chattanooga, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT04763031
824	NCT01386710	Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma		Suspended	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: Bevacizumab and Carboplatin	"Composite overall response rate|Six-month progression-free survival (PFS) and overall survival (OS)|The safety of repeated SIACI of Mannitol, Bevacizumab plus Carboplatin at 15mg/kg and 150mg/m2 respectively."	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	54	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1012011410	Sep-11	May-23	May-23	1-Jul-11		28-Oct-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01386710
825	NCT02348255	NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse		Withdrawn	No Results Available	Adult Brain Glioblastoma|Recurrent Adult Brain Neoplasm	Procedure: Electric Field Therapy|Biological: Bevacizumab|Drug: Carmustine|Other: Quality-of-Life Assessment	"Incidence of adverse events, assessed by National Cancer Institute-Common Terminology Criteria 4.0 toxicity criteria|Progression Free Survival|Overall Survival|Quality of life as measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and BN-20 brain cancer module|Change in tumor volume using magnetic resonance imaging (MRI)|Change in linear dimension using MRI"	"University of California, Davis|National Cancer Institute (NCI)|NovoCure Ltd."	All	"22 Years and older   (Adult, Older Adult)"	Phase 2	0	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCDCC#249|663113|P30CA093373|NCI-2014-02628	Jan-16	Jan-17	Jan-17	28-Jan-15		9-Jan-18	"University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Piedmont Hospital, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT02348255
826	NCT01269853	Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA		Recruiting	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: Bevacizumab	Composite overall response rate (CORR)|Progression-free survival (PFS) and overall survival (OS)|The safety of repeated SIACI of mannitol and Bevacizumab at 15mg/kg.	Northwell Health|Feinstein Institute for Medical Research	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	54	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-353	Oct-10	Oct-22	Oct-23	4-Jan-11		28-Oct-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01269853
827	NCT01180816	Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: Super-Selective Intraarterial Intracranial Infusion of Temozolomide	Determine the safety of superselective intra-arterial cerebral infusion of Temozolomide up to a dose of 250 mg/m2 IA.|Composite overall response rate.|Six-month progression-free survival (PFS) and overall survival (OS)	Northwell Health|Feinstein Institute for Medical Research|Hofstra North Shore	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	21	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-292A	Aug-10	Dec-17	11-Aug-20	12-Aug-10		4-Mar-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01180816
828	NCT00693095	Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer	ERaDICATe	Completed	No Results Available	Glioblastoma	Biological: CMV-ALT + CMV-DCs|Biological: CMV-ALT + Saline	To evaluate if vaccinating adult patients with newly-diagnosed GBMs using CMV-DCs during recovery from therapeutic TMZ-induced lymphopenia with ALT in patients that are seropositive for CMV enhances the T-cell response.|To evaluate the safety of ALT with CMV pp65-activated T-cells in adult patients with newly-diagnosed GBMs during recovery from therapeutic TMZ-induced lymphopenia.	John Sampson|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	23	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	Pro00000580|SPORE Project 3	Sep-08	Dec-13	Apr-15	6-Jun-08		30-Jan-18	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00693095
829	NCT01498328	A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma	ReACT	Completed	No Results Available	Glioblastoma|Small Cell Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma|Glioblastoma With Oligodendroglial Component|Recurrent Glioblastoma|Relapsed Glioblastoma	Drug: Bevacizumab|Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: KLH	Groups 1 and 2: Progression-free survival rate|Group 2C: Objective Response Rate|Safety and Tolerability|Anti-tumor activity|EGFRvIII-specific immune response	Celldex Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	127	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	CDX110-06	Dec-11	Apr-15	17-May-16	23-Dec-11		17-Feb-20	"University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph's Hospital and Medical Center / Barrow Neurological Institute, Phoenix, Arizona, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, California, United States|UC Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford Cancer Institute, Stanford University, Stanford, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Atlanta Cancer Care, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana-Farber Cancer Institute and Mass General Hospital, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Sparrow Cancer Center, Lansing, Michigan, United States|John Nasseff Neuroscience Institute, Abbott Northwestern Hospital, 800 e. 28th Str. MR, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New Jersey Neuroscience Institute JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Dent Neurologic Institute, 3980 Sheridan Dr, 3rd Flr Clinical Rsch, Amherst, New York, United States|The Long Island Brain Tumor Center at Neurology Surgery, P.C., Commack, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Legacy Research Institute, Portland, Oregon, United States|Lehigh Valley Hospital-John and Dorothy Morgan Cancer Center, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology Midtown, Austin, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|UT Health Science Center, Houston Memorial Hermann Hospital, 6400 Fannin Street, #2800, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Swedish Neuroscience Research, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01498328
830	NCT01653834	Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas		Completed	No Results Available	Glioblastoma	Procedure: Lymphocyte harvesting & reinfusion	the feasibility of lymphocyte harvesting and reinfusion|the number of lymphocytes that can be harvested in this pt population|duration of lymphocyte rise following lymphocyte reinfusion|changes in lymphocyte subtypes following collection and reinfusion	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J11162|NA_00068991	Jul-12	Jan-14	Mar-14	31-Jul-12		7-Nov-18	"Johns Hopkins University, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01653834
831	NCT01602588	A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)	HCQ	Completed	No Results Available	Glioblastoma	Drug: Hydroxychloroquine|Radiation: Radiotherapy	1 year Survival|Toxicity	"University College, London|Cancer Research UK"	All	70 Years to 100 Years   (Older Adult)	Phase 2	54	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCL11/0404	May-13	Oct-16	Nov-17	21-May-12		3-May-18	"St James's University Hospital, Leeds, West Yorkshire, United Kingdom|Glan Clwyd Hospital, Bodelwyddan, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|University College Hospital, London, United Kingdom|Guy's and St Thomas's Hospitals, London, United Kingdom|Charing Cross Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Norfolk & Norwich University Hospitals, Norwich, United Kingdom|The Royal Preston Hospital, Preston, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom"		https://ClinicalTrials.gov/show/NCT01602588
832	NCT00968240	Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB	"To determine the safety of superselective intracranial intraarterial infusion of Avastin up to a dose of 10mg/kg IA.|Composite overall response rate: The composite overall response rate (CORR) will be examined. The overall response proportion along with a 95% confidence interval will be estimated via binomial proportions.|Six-month progression-free survival (PFS) and overall survival (OS) will be assessed by Kaplan-Meier survival analysis, assuming adequate follow-up time."	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	901010185	Jul-09	Jan-14	Jan-14	28-Aug-09		22-Apr-15	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00968240
833	NCT04726397	UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: A Phase 2 Trial	UNITED	Recruiting	No Results Available	Glioblastoma Multiforme	Radiation: Reduced margin adaptive radiotherapy	"Imaging-detected tumor recurrence at the edge of the radiation volume (""marginal"" failure)|Tumor volume changes during RT|Acute radiation toxicity based on RTOG/EORTC Common Toxicity Criteria|Quality of life changes based on EORTC QLQ-C30|Dexamethasone usage|Quality of life based on EORTC QLQ-BN20"	Sunnybrook Health Sciences Centre	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3412	29-Mar-21	Sep-22	Mar-24	27-Jan-21		21-Sep-21	"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT04726397
834	NCT04321694	Expanded Access for KHK2455		No longer available	No Results Available	Glioblastoma Multiforme	Drug: KHK2455		"Kyowa Kirin, Inc.|University of New Mexico Cancer Center"		"Child, Adult, Older Adult"			Industry|Other	Expanded Access:Individual Patients		Expanded Access for KHK2455				25-Mar-20		10-Aug-21			https://ClinicalTrials.gov/show/NCT04321694
835	NCT03027388	"Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma"		Enrolling by invitation	No Results Available	"Astrocytoma, Grades II, III and IV|Glioblastoma Multiforme|Giant Cell Glioblastoma|Glioma|Oligodendrogliomas"	Drug: LB-100	Drug Level in tumor tissue|Relationship between drug concentration at the site of action and the resulting effect and the presence of correlation to identify predictive markers.|Plasma concentration and calculated LB100|Concentration of LG100 and its major metabolite LB100 in glioblastoma tumor tissue|Changes in phospho-protein expression in circulating PBMC	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	25	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	170037|17-C-0037	9-Jan-19	31-Aug-23	31-Aug-23	23-Jan-17		3-Jan-22	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03027388
836	NCT01105988	Evaluating Tumor Pseudoprogression With FLT-PET and MRI		Terminated	No Results Available	Glioblastoma	Other: Radiologic exams	Primary Outcome Measure|Secondary Outcome Measure	Massachusetts General Hospital|Dana-Farber Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	2	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	10-008	May-11	Oct-11	Oct-11	19-Apr-10		6-Jan-12	"Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01105988
837	NCT03961971	Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM		Recruiting	No Results Available	Glioblastoma Multiforme	Drug: MBG453	"Number of participants with serious adverse events (SAE) graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 5.0|Proportion of participants who experience grade 3 or higher toxicity, graded according to the NCI CTC v5.0|Progression-free survival|Overall survival|Objective Response"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Novartis Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J18150|IRB00104226	18-Feb-20	Sep-22	Sep-24	23-May-19		2-Nov-21	"Stanford University, Stanford, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03961971
838	NCT02386826	INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme		"Active, not recruiting"	No Results Available	Glioblastoma Multiforme|Gliosarcoma|Colorectal Cancer|Renal Cell Carcinoma	Drug: INC280|Biological: bevacizumab	Maximum Tolerated Dose (MTD) of INC280|Progression-free Survival|Overall Response Rate	"SCRI Development Innovations, LLC|Novartis"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	65	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI REFMAL 365	22-Sep-15	31-Jul-21	Mar-22	12-Mar-15		23-Aug-21	"Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Yale School of Medicine, New Haven, Connecticut, United States|HCA Midwest - Kansas City, Kansas City, Missouri, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT02386826
839	NCT04674579	Automatic Segmentation MRI Cerebral Glioma		Not yet recruiting	No Results Available	Cerebral Glioblastoma	Device: MRI	evaluate the role of automatic segmentation of cerebral gliomas in multi-sequence MR images in correlation with operative findings.	Assiut University	All	"Child, Adult, Older Adult"		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	MRI cerebral glioma	1-Jan-21	Feb-23	Apr-23	19-Dec-20		19-Dec-20			https://ClinicalTrials.gov/show/NCT04674579
840	NCT00412542	Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas		Completed	Has Results	Glioblastoma Multiforme|Glioma	Drug: Thalidomide|Drug: CPT-11|Procedure: MRI Scan|Procedure: Quantitative Sensory Tests (QST)	Number of Participants Progression Free at 6 Months With Malignant Gliomas	M.D. Anderson Cancer Center|Celgene Corporation	All	"Child, Adult, Older Adult"	Phase 2	78	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DM02-595	Oct-03	Oct-09	Oct-09	18-Dec-06	28-Feb-12	28-Feb-12	"U.T.M.D. Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00412542
841	NCT02414165	The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma	Toca5	Terminated	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma	Biological: Toca 511|Drug: Toca FC|Drug: Lomustine|Drug: Temozolomide|Biological: Bevacizumab	To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma|Durable Response Rate (CR or PR ≥ 24 weeks)|Durable Clinical Benefit Rate (CR or PR ≥ 24 weeks or SD ≥ 18 months)|Duration of Durable Response|Overall Survival at 12 months	Tocagen Inc.	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2|Phase 3	403	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Tg 511-15-01|FD-R-5732	30-Nov-15	31-May-19	20-Dec-19	10-Apr-15		7-Feb-20	"Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California San Diego, La Jolla, California, United States|University of California, Los Angeles, Los Angeles, California, United States|St. Joseph Hospital, Orange, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Associated Neurologists of Southern Connecticut, Fairfield, Connecticut, United States|Yale University/Yale Cancer Center, New Haven, Connecticut, United States|University of Florida McKnight Brain Institute, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|NorthShore University Health System, Evanston, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Abbott Northwestern Hospital / Allina Health, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|HCA Midwest / Sarah Cannon, Kansas City, Missouri, United States|Washington University St. Louis, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|JFK Medical Center Neuroscience Institute, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|North Shore University Hospital, Lake Success, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Cincinnati's Children's Hospital Medical Center, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Sanford Research, Sioux Falls, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Houston Methodist Hospital Outpatient Center, Houston, Texas, United States|University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Dwight and Martha Schar Cancer Institute, Fairfax, Virginia, United States|Sentara Neurosurgery Specialists, Norfolk, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia / Vancouver General Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|London Regional Cancer Centre, London, Ontario, Canada|Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Hospital / Sunnybrook Research Institute, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Sherbrooke Hospital University Centre (CHUS), Sherbrooke, Quebec, Canada|Rambam Health Care, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT02414165
842	NCT00961090	Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery		Completed	No Results Available	Glioblastoma	Drug: Aminolevulinic Acid	More complete resection of malignant brain tumors|Safety of drug	"Matthew R Quigley|DUSA Pharmaceuticals, Inc.|Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	72	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	104974	Sep-09	22-Apr-15	23-Apr-15	18-Aug-09		12-Apr-19	"Allegheny General Hospital, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00961090
843	NCT03642080	MRI Predictors of Response to Tumor Treating Fields		Recruiting	No Results Available	Glioblastoma Multiforme		Progression of disease	New York Presbyterian Brooklyn Methodist Hospital	All	"18 Years and older   (Adult, Older Adult)"		48	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	1137708	1-Dec-18	30-Sep-21	31-Dec-23	22-Aug-18		19-Dec-18	"New York Presbyterian - Brooklyn Methodist Hospital, Brooklyn, New York, United States"		https://ClinicalTrials.gov/show/NCT03642080
844	NCT03014804	Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma		Withdrawn	No Results Available	Giant Cell Glioblastoma|Gliosarcoma|Oligodendroglioma|Recurrent Glioblastoma|Small Cell Glioblastoma	Biological: autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	Incidence of adverse events assessed by National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03|Overall Survival (OS)|Overall Survival rate|Progression Free Survival (PFS)|Quality of Life (QoL)|Number of participants with complete response (CR)|Number of participants with partial response (PR)|Number of participants with stable disease (SD)|Number of participants with progressive disease (PD)|Objective response rate (ORR) defined as the percentage of participants with CR + PR|Response/Stable Disease Rate (RSDR) defined as the percentage of participants demonstrating CR+PR+SD	Jonsson Comprehensive Cancer Center|Northwest Biotherapeutics|Bristol-Myers Squibb|Brain Tumor Funders Collaborative	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	0	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-001706|NCI-2016-01587	1-Dec-19	1-Dec-20	1-Dec-22	9-Jan-17		24-Jul-20	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT03014804
845	NCT03746080	Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma		Recruiting	No Results Available	Glioblastoma|Glioblastoma With Primitive Neuronal Component|Gliosarcoma|Malignant Glioma|Oligodendroglial Component Present	Drug: Plerixafor|Drug: Temozolomide|Radiation: Whole-Brain Radiotherapy (WBRT)|Radiation: Radiation Therapy	Progression-free survival (PFS) at six months|Median Survival|Toxicity associated with Plerixafor/WBRT|Patterns of treatment failure	Lawrence D Recht|Sanofi|Stanford University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	20	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-46410|NCI-2018-02159|BRN0037	4-Dec-18	11-Jul-22	11-Jan-27	19-Nov-18		5-May-21	"Stanford Cancer Institute Palo Alto, Palo Alto, California, United States"		https://ClinicalTrials.gov/show/NCT03746080
846	NCT00187486	"Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors"		Completed	Has Results	Glioblastoma Multiforme|Gliosarcoma	Drug: Tarceva|Drug: Temodar|Procedure: Radiation Therapy	Overall Survival|Progression Free Survival	"University of California, San Francisco|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	66	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC 04101|OSI 2725s	Aug-04	Mar-11	Mar-11	16-Sep-05	27-Sep-12	5-Sep-17	"UCSF Department of Neurological Surgery, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00187486
847	NCT01808820	Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma		"Active, not recruiting"	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|High Grade Glioma	Biological: Dendritic Cell Vaccine|Biological: Tumor Lysate|Drug: Imiquimod|Procedure: Leukapheresis	Number of Participants with Treatment-Related Adverse Events|Rate of Overall Survival (OS) in Study Participants|Rate of Progression-Free Survival (PFS) in Study Participants|Change in MDSC Levels|Change in blood counts|Comparison of clinical parameters associated with outcomes in study participants to patients on other DC/Imiquimod studies.|Proportion of participants completing intervention.	"Macarena De La Fuente, MD|University of Miami"	All	"13 Years to 99 Years   (Child, Adult, Older Adult)"	Phase 1	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20120750	21-Aug-13	7-Nov-18	Nov-23	11-Mar-13		28-Dec-21	"University of Miami, Miami, Florida, United States"		https://ClinicalTrials.gov/show/NCT01808820
848	NCT01920191	Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma		Completed	No Results Available	"CNS Tumor, Adult"	Biological: IMA 950|Biological: Poly ICLC|Other: Immunomonitoring	"Tolerability and safety of IMA950 adjuvanted with Poly-ICLC when given together with temozolomide, using CTCAE V 4.0|6, 9 month progression free survival (PFS) using gadolinium enhanced MRI and clinical assessment according to revised RANO criteria|Overall survival (OS)|Immunologic endpoints"	"University Hospital, Geneva|Immatics Biotechnologies GmbH|Oncovir, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	19	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IMA950 Poly ICLC	Aug-13	Mar-16	Mar-16	9-Aug-13		20-Apr-16	"Geneva University Hospitals, Centre of Oncology, Geneva, Switzerland"		https://ClinicalTrials.gov/show/NCT01920191
849	NCT02465268	Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme	ATTAC-II	Recruiting	No Results Available	"Glioblastoma Multiforme|Glioblastoma|Malignant Glioma|Astrocytoma, Grade IV|GBM"	Biological: pp65-shLAMP DC with GM-CSF|Biological: unpulsed PBMC and saline|Drug: Td|Drug: Saline|Biological: pp65-flLAMP DC with GM-CSF	Change in median overall survival|Changes in immune response|Change in progression-free survival	"Immunomic Therapeutics, Inc.|University of Florida|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	120	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	IRB201400697-N|R01CA175517|OCR14127	Aug-16	Jun-23	Jun-24	8-Jun-15		23-Nov-20	"University of Florida, Gainesville, Florida, United States|Orlando Health, Orlando, Florida, United States|Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT02465268
850	NCT03879512	"Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG"		Recruiting	No Results Available	Childhood Glioblastoma	Drug: depletion of regulatory T cells|Procedure: reoperation|Biological: cancer vaccine|Biological: checkpoint blockade	6 month overall survival|overall survival|progression-free survival|toxicity metronomic cyclophosphamide|toxicitiy vaccine|toxicity checkpoint blockade|Treg frequency|Treg numbers|T-cell response|serum cytokine levels|correlation with histopathological tumor characteristics	Wuerzburg University Hospital	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1|Phase 2	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIT-HGG Rez Immunovac	7-Feb-18	30-Apr-24	30-Apr-24	18-Mar-19		17-Sep-20	"University Children's Hospital, Würzburg, Bavaria, Germany"		https://ClinicalTrials.gov/show/NCT03879512
851	NCT04606316	Surgical Nivolumab And Ipilimumab For Recurrent GBM		Recruiting	No Results Available	Glioblastoma|GBM|Glioblastoma Multiforme|Grade IV Astrocytoma	Drug: Nivolumab-Placebo|Drug: Nivolumab|Drug: Ipilimumab-Placebo|Drug: Ipilimumab|Procedure: Surgery	Tumor Infiltrating T Lymphocyte (TIL) Density|Safety of Study Drug Therapy|Cell Cycle-Related Genetic Signature within the Tumor Microenvironment|Percentage of Progression Free Survival (PFS-6)	"Patrick Y. Wen, MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	60	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	20-494	1-Feb-21	31-Dec-22	31-Dec-23	28-Oct-20		13-Dec-21	"Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT04606316
852	NCT03997136	Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas.		Unknown status	No Results Available	Supratentorial Glioblastoma	Procedure: Supratentorial high grade gliomas resection.	Clinical picture using Modified Rankin's Scale (mRS).|Recurrence or increased residual	Assiut University	All	"Child, Adult, Older Adult"		28	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	Brain Gliomas Surgery	1-Sep-19	1-Apr-21	1-Jul-21	25-Jun-19		7-Aug-19			https://ClinicalTrials.gov/show/NCT03997136
853	NCT04681677	Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab	IORT	Recruiting	No Results Available	Glioblastoma|Recurrent Glioblastoma|GBM|Recurrent GBM	Radiation: Radiation: Intra-operative Radiation Therapy - IORT|Drug: Bevacizumab|Drug: Avastin	median overall survival (mOS)|6 Month rate progression-free survival (PFS)|tumor progression at four weeks|Local and distant progression-free survival|Quality of Life and radiation-related neurotoxicity|Rate of adverse events/safety	"Xoft, Inc.|Icad, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	100	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTPR-0017	2-Nov-21	Nov-26	Feb-27	23-Dec-20		4-Nov-21	"Providence Saint John's Health Center, Santa Monica, California, United States"		https://ClinicalTrials.gov/show/NCT04681677
854	NCT01011231	Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma	GKS	Terminated	No Results Available	Glioblastoma	Procedure: Gamma Knife Radiosurgery	"To assess the efficacy, as measured by progression-free survival at six months (PFS-6), of treating patients with recurrent glioblastoma using GKS to target a tumor volume defined by a combination of gadolinium enhancement and MRS.|To describe PFS and OS in pts with recurrent GBM following GKS targeting a tumor volume defined by a combination of gad enhancement and MRS|To further assess the safety of GKS in patients with recurrent glioblastoma|To gather initial data regarding the safety and efficacy of treatment of patients with recurrent low-grade or anaplastic glioma with GKS targeting a tumor volume as defined by a combination of gadolinium enhancement and MRS."	"University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	1	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9103	Dec-09	Apr-11	Apr-11	11-Nov-09		6-May-13	"UCSF Department of Neurosurgery, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT01011231
855	NCT04657315	"Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients"	MSC11FCD-GBM	Enrolling by invitation	No Results Available	"Glioblastoma|Adult Gliosarcoma|Neoplasms, Brain|Neoplasms, Germ Cell and Embryonal|Recurrent Glioblastoma"	Drug: MSC11FCD	Maximum tolerated dose (MTD)|Number Of Adverse Events related to the treatment|Overall Survival improvement (OS)|Progression Free Survival (PFS)|Tumor assessment in regard to the investigational drug based on the RANO criteria|Clinical efficacy assessment	CHA University|Ajou University School of Medicine	All	"19 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHAMC 2019-08-022	24-Jun-20	31-Dec-21	31-Dec-22	8-Dec-20		29-Mar-21	"Bundang CHA Medical Center, Seongnam, Kyunggido, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT04657315
856	NCT00441142	Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors	Zactima	Completed	Has Results	Glioblastoma Multiforme|Gliosarcoma	Drug: ZD6474|Drug: temozolomide|Radiation: Radiation Therapy	"Number of Participants That Experienced a Dose-limiting Toxicity (DLT)|Median Overall Survival (OS) of Phase II Patients|Median Progression-free Survival (PFS), as Calculated by the # of Months Patients Remain Progression-free|PHASE II: Percentage of Grade 3-5 Treatment-Related Adverse Events|PHASE I: Percentage of Grade 3-5 Treatment-Related Adverse Events"	"Patrick Y. Wen, MD|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|University of Virginia|Memorial Sloan Kettering Cancer Center|Henry Ford Hospital"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	119	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	06-377|IRUSZACT0018	25-May-07	31-Aug-13	10-Oct-17	28-Feb-07	2-Mar-15	5-Mar-19	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber / Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00441142
857	NCT00616005	Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide		Completed	No Results Available	Glioblastoma	Drug: Temodar and Irinotecan	Progression-free survival|Toxicity assessment	Duke University|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	41	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00012939|8044	Nov-05	Jul-07	Jun-09	14-Feb-08		18-Aug-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00616005
858	NCT04689087	"A Prospective, Open-label, Single-arm Clinical Study"		Recruiting	No Results Available	Recurrent Glioblastoma Multiforme	Combination Product: TTFields	OS6|Overall survival at 12 months (OS12)|overall survival OS(refers to the time from enrollment to tumor disease death from various causes)|Progression-free survival PFS|security	Sun Yat-sen University	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	M-TTFields	1-Apr-20	1-Jul-21	1-Jul-22	30-Dec-20		30-Dec-20	"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT04689087
859	NCT01756729	Post-approval Study of NovoTTF-100A in Recurrent GBM Patients		Terminated	No Results Available	Recurrent Glioblastoma Multiforme	Device: NovoTTF-100A	Overall Survival|Change in neuro-cognitive function from baseline based on MMSE|Genetic profiling of tumors and correlation with response to NovoTTF-100A treatment|Adverse events severity and frequency	NovoCure Ltd.	All	"22 Years and older   (Adult, Older Adult)"	Phase 4	13	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EF-19	Dec-12	Jan-18	Jan-18	27-Dec-12		2-Mar-16	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Barrow Neurology Clinics, Phoenix, Arizona, United States|University of California San Diego Moores Cancer Center, La Jolla, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Washington University School of Medicine, Division of Oncology, St. Louis, Missouri, United States|The Long Island Brain Tumor Center, Lake Success, New York, United States|Geisinger Health System, Danville, Pennsylvania, United States|Baylor Research Institute, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT01756729
860	NCT02443194	"The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients"		Terminated	No Results Available	Depression	Drug: duloxetine|Drug: PLACEBO	changes in patients mood and cognitive function according to the neuropsychological assessment	michal roll|Tel-Aviv Sourasky Medical Center	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 3	50	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention"	0124-15 TLV	May-15	Nov-15	Nov-15	13-May-15		3-Dec-15			https://ClinicalTrials.gov/show/NCT02443194
861	NCT02253212	Safety of BBB Opening With the SonoCloud	SONOCLOUD	Completed	No Results Available	Glioblastoma|Glioma|Brain Tumor	Device: SonoCloud|Drug: Carboplatin	Safety of transient disruption of the blood-brain barrier using the SonoCloud system in patients with recurrent glioblastoma.|Maximum tolerated dose of ultrasound with the SonoCloud system for transient disruption of the BBB.|Quantification of the disruption of the BBB by the SonoCloud system using dynamic T1 contrast-enhanced MRI.|Progression-free survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.|Overall survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.	Assistance Publique - Hôpitaux de Paris	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	27	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P120905|2014-000393-19	Jul-14	Jul-18	Jul-18	1-Oct-14		12-Oct-18	"Groupe Hospitalier Pitié Salpetriere - Neurosurgery Department, Paris, France"		https://ClinicalTrials.gov/show/NCT02253212
862	NCT03278249	Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma		"Active, not recruiting"	No Results Available	Glioblastoma	Other: Modified Atkins Ketogenic Diet	Assessment of inducing ketosis|Assessment of progression free survival|Assessment of survival	University of Cincinnati	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCCI-BRAIN-16-01	12-Oct-17	1-Dec-21	1-Jan-22	11-Sep-17		24-Nov-21	"UC Health, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT03278249
863	NCT04488783	Potentiation of Chemotherapy in Brain Tumors by Zinc		Recruiting	No Results Available	Newly Diagnosed Glioblastoma Who Underwent at Least Partial Resection of the Tumor Surgically	Dietary Supplement: zinc and ascorbate	progression free survival (PFS)|overall survival (OS)|Tcell count|Level of Interleukin 6|Tumor Necrosis Factor quantification	Sheba Medical Center	All	"18 Years to 90 Years   (Adult, Older Adult)"	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4266-17-SMC	30-Jul-20	30-Jul-22	30-Dec-22	28-Jul-20		28-Jul-20	"Sheba Medical Center, Ramat Gan, Israel"		https://ClinicalTrials.gov/show/NCT04488783
864	NCT02843230	Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI		Recruiting	No Results Available	Glioblastoma	Radiation: Avastin|Radiation: Lomustine|Radiation: Temozolomide|Device: MRI|Device: MRS|Device: DSC	Progression Free Survival For Patients Receiving Advanced MRI and MRS|Overall Survival For Patients Receiving Advanced MRI and MRS|Progression Free Survival For Patient Receiving Dynamic Susceptibility Contrast|Overall Survival Rate For Patient Receiving Dynamic Susceptibility Contrast	Massachusetts General Hospital	All	"18 Years and older   (Adult, Older Adult)"		85	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	16-147	1-Aug-16	31-Aug-21	31-Aug-22	25-Jul-16		9-Sep-20	"Massachusetts general Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT02843230
865	NCT00179907	A Phase I/II Study of the Photon Radiosurgery System		Completed	No Results Available	"Brain Tumor, Recurrent|Glioblastoma Multiforme"	Procedure: Photon Radiosurgery System (Intrabeam)	To determine the maximum tolerated dose of radiation that can be delivered using the Photon Radiosurgery System (PRS) in children with radiation recurrent brain tumors.|To determine the maximum tolerated dose of radiation that can be delivered with a combination of external irradiation and radiosurgery using PRS in children with glioblastoma multiforme and children with recurrent ependymoma|To determine the tumor response following reirradiation with PRS.|To determine the quality of life of children following irradiation with PRS.|To study gene expression in tumors before and after irradiation with PRS	Ann & Robert H Lurie Children's Hospital of Chicago|Photoelectron Corporation	All	"2 Years to 32 Years   (Child, Adult)"	Phase 1|Phase 2	35	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CNS 0201	May-01	Dec-13	Dec-13	16-Sep-05		2-Mar-15	"Children's Memorial Hospital, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00179907
866	NCT03965494	AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery		Recruiting	No Results Available	Brain and Central Nervous System Tumors	Drug: BGB 324 (before surgery)|Drug: BGB 324 (after surgery)	Proportion of patients who achieve a drug concentration at >= 1.0 uM level in contrast enhancing tumor tissue|Change in AXL expression level|Pharmacokinetics as measured by plasma maximum concentration (Cmax) (ug/mL)|Pharmacokinetics as measured by plasma minimum concentration (Cmin) (ug/mL)|Pharmacokinetics as measured by area under the curve (AUC) (ug/mL*hr)|Toxicity as assessed by number of participants experiencing of adverse events|Overall survival|Progression-free survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|BerGenBio ASA	All	"18 Years to 120 Years   (Adult, Older Adult)"	Early Phase 1	20	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC-1701|IRB00184546|UM1CA137443	2-Jan-20	1-Dec-22	1-Dec-23	29-May-19		7-Oct-21	"Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03965494
867	NCT03225963	Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.		Unknown status	No Results Available	Glioblastoma Multiforme|Angiogenesis	Radiation: Chemoradiation with temozolomide	Response of bevacizumab therapy.	Taichung Veterans General Hospital	All	"20 Years to 85 Years   (Adult, Older Adult)"		60	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CE15180B	1-Aug-15	31-Jul-18	31-Jul-18	21-Jul-17		24-Jul-17	"Taichung Veterans General Hospital, Taichung, Taiwan"		https://ClinicalTrials.gov/show/NCT03225963
868	NCT02473484	Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas	GLIOMIC	Completed	No Results Available	Glioblastoma		"To evaluate the correlation between the WHO classification 2007 only established standard diagnostic and classification by mass spectrometry gliomas (lipids, peptides, proteins)"	"University Hospital, Lille"	All	"18 Years and older   (Adult, Older Adult)"		78	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	2013_27|2014-A00185-42	24-Jun-14	Oct-17	Oct-17	16-Jun-15		22-Dec-17	"Le Rhun, Lille, France"		https://ClinicalTrials.gov/show/NCT02473484
869	NCT04945148	Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide	OPTIMUM	Not yet recruiting	No Results Available	"Glioblastoma, IDH-wildtype"	Drug: Metformin|Radiation: Radiation IMRT|Drug: Temozolomide	Assessement of Progression Free Survival (PFS) of patients with newly-diagnosed IDH wild-type OXPHOS + GBM (either with or without FGFR3-TACC3 gene fusion) treated with RT plus TMZ combined with metformin|Assessement of the Overall survival (OS) of treated patients|Assessement of the Overall Response rate (ORR)|Assessement of the the safety of metformin in association with concomitant RT-TMZ|Assessement of the the tolerability of metformin in association with concomitant RT-TMZ	"Hopital Foch|National Cancer Institute, France"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	640	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019_0007	Dec-21	Dec-25	Dec-25	30-Jun-21		22-Nov-21	"Foch Hospital, Suresnes, Hauts De Seine, France|Hôpital Neurologique Pierre Wertheimer, Bron, Lyon, France|Timone Hospital, Marseille, France|Saint Louis Hospital, Paris, France|Pitié Salpêtrière Hospital, Paris, France|Istituto Nazionale Carlo Besta, Milano, Italy"		https://ClinicalTrials.gov/show/NCT04945148
870	NCT00379080	Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma		Completed	Has Results	Adult Brain Tumor|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Procedure: conventional surgery|Drug: tandutinib|Other: pharmacological study|Other: Tissue samples	Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1)|To Determine the Tumor/Plasma Ratio of in Subjects With Recurrent GBM Undergoing Resections (Phase 0)|Number of Dose Limiting Toxicities Per Dose Level|Tumor Response (Complete Response and Partial Response) Rate (Phase II)|Pharmacokinetics (Max Concentration of Plasma) for Tandutinib in Phase 1 and Phase 2|Pharmacokinetics (Apparent Terminal Phase Half-life) for Tandutinib in Phase 1 and Phase 2|Pharmacokinetics (Area Under the Plasma Concentration Time Profile From Zero to Infinity (AUC)) for Tandutinib in Phase 1 and Phase 2|Pharmacokinetics; Apparent Oral Clearance for Tandutinib in Phase 1 and Phase 2|Pharmacokinetics; Apparent Oral Total Body Volume of Distribution for Tandutinib in Phase 1 and Phase 2|Pharmacokinetics; Steady-state Trough Concentration for Tandutinib in Phase 1 and Phase 2|Overall Survival (Phase II)|Six-month Progression-free Survival Rate (Phase II)|Overall Failure Rate (Phase II)|Proportion of Patients With Serious or Life Threatening Toxicities|Protein Expression Patterns Post Treatment - Loss or Gain	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	60	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00681|CDR0000495253|NABTT 0504|NABTT-0504|U01CA137443	Jan-07	Sep-12	Jun-13	21-Sep-06	7-Apr-17	7-Apr-17	"University of Alabama at Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00379080
871	NCT00463073	"Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas"		Completed	No Results Available	Malignant Gliomas	Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan		"Rigshospitalet, Denmark|Aalborg University Hospital|Odense University Hospital"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	CBI-GBM-01	Aug-06	Dec-08	Dec-08	20-Apr-07		11-Dec-08	"Aalborg University Hospital, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark"		https://ClinicalTrials.gov/show/NCT00463073
872	NCT03861299	The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.	SAFE	Recruiting	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain|Astrocytoma, Grade IV|Brain Tumor|Brain Cancer|Brain Neoplasms"	Procedure: Awake craniotomy|Procedure: Craniotomy under general anesthesia	Postoperative neurological morbidity|Proportion of gross-total resections|Health-related quality of life assessed by EQ-5D questionnaire|Health-related quality of life assessed by EORTC-QLQ-BN20 questionnaire|Health-related quality of life assessed by EORTC-QLQ-C30 questionnaire|Progression-free survival|Overall survival|Postoperative (serious) adverse events	"Jasper Gerritsen|Elisabeth-TweeSteden Ziekenhuis|University Medical Center Groningen|Medical Center Haaglanden|University Hospital, Ghent|Universitair Ziekenhuis Brussel|Erasmus Medical Center"	All	"18 Years to 90 Years   (Adult, Older Adult)"	Not Applicable	246	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL66673.078.18|MEC-2018-1564	1-Apr-19	1-Apr-23	1-Apr-24	4-Mar-19		27-Oct-20	"University Hospital Brussels, Brussels, Belgium|University Hospital Ghent, Ghent, Belgium|Elisabeth-Tweesteden Ziekenhuis, Tilburg, Noord-Brabant, Netherlands|Erasmus MC, Rotterdam, Zuid-Holland, Netherlands|Medical Center Haaglanden, The Hague, Zuid-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands"		https://ClinicalTrials.gov/show/NCT03861299
873	NCT01535911	Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors	Ketones	"Active, not recruiting"	No Results Available	Glioblastoma	Other: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)	MRI imaging will be used to measure changes in brain tumor size.	Michigan State University|Sparrow Health System	All	"18 Years to 90 Years   (Adult, Older Adult)"	Not Applicable	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-452FS	1-Apr-12	1-Jun-24	1-Jun-24	20-Feb-12		5-Nov-20	"Michigan State University/Sparrow Hospital, East Lansing, Michigan, United States"		https://ClinicalTrials.gov/show/NCT01535911
874	NCT03626896	Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients		Completed	No Results Available	"Glioblastoma Multiforme|Brain Tumor|Glioblastoma|Glioma|Neoplasms|Neoplasms, Nerve Tissue"	Device: NaviFUS System	Number and severity of AE|Tolerated dose of FUS with the NaviFUS System for transient disruption of the BBB|Quantify the BBB disruption following BBB disruption by the NaviFUS System	NaviFUS Corporation|Chang Gung Memorial Hospital	All	"20 Years and older   (Adult, Older Adult)"	Not Applicable	6	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	NF-2017-01	17-Aug-18	20-May-19	19-Jun-19	13-Aug-18		21-Jun-19	"Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan"		https://ClinicalTrials.gov/show/NCT03626896
875	NCT01466686	Low Dose Radiation Therapy for Glioblastoma Multiforme		Recruiting	No Results Available	High Grade Glioma	Radiation: Low Dose Fractionated Radiation Therapy (LDFRT)|Drug: Temozolomide	Response Rate|Time to Progression|Overall Survival Rate|Hematologic Toxicity|Radiation-Associated Long-Term Toxicity	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 2	49	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J11120|NA_00065863	Sep-12	Mar-22	Mar-23	8-Nov-11		11-Oct-21	"Sibley Memorial Hospital, Washington, District of Columbia, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01466686
876	NCT02654041	Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients		Terminated	No Results Available	Glioblastoma Multiforme (GBM)	Drug: Combined T3 and Methimazole treatment	Response rate at 6 months (6 months PFS)|Response rate at 2 months (2 months PFS)|Response rate at 4 months (4 months PFS)|Time to disease progression or cancer-related death|Safety endpoint evaluation	Musli Thyropeutics Ltd.|Tel-Aviv Sourasky Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	3	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	MusliGBM002	Mar-16	Jun-17	Jun-17	13-Jan-16		22-Mar-18	"Tel-Aviv Medical Center, Israel, Tel-Aviv, Israel"		https://ClinicalTrials.gov/show/NCT02654041
877	NCT00943462	Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM		Withdrawn	No Results Available	"Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme"	Radiation: External-beam radiation therapy|Drug: Temozolomide		Centre hospitalier de l'Université de Montréal (CHUM)|Schering-Plough	All	"18 Years to 70 Years   (Adult, Older Adult)"		0	Other|Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CE-08-234|Schering-P06046	Jun-09	Jun-11	Jun-11	22-Jul-09		23-Jul-20			https://ClinicalTrials.gov/show/NCT00943462
878	NCT03005132	Integrative Analysis of Human Glioblastoma Multiforme		Recruiting	No Results Available	GBM	Other: Normal brain tissue	5 years overall survival|5 years disease-free survival|10 years overall survival|10 years disease-free survival	Shanghai 10th People's Hospital|Jilin University|Ganzhou City People's Hospital	All	"18 Years to 75 Years   (Adult, Older Adult)"		1000	Other	Observational	Observational Model: Case-Control|Time Perspective: Retrospective	2016-521-Rainy	Jan-16	Dec-26	Dec-26	29-Dec-16		29-Dec-16	"Shanghai Tenth People's Hospital, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT03005132
879	NCT02765165	Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)		Terminated	Has Results	Solid Tumors (Phase 1)|Relapsed/Recurrent GBM (Phase 2)	Drug: USL311|Drug: Lomustine	Phase 1: Maximum Tolerated Dose (MTD)|Percentage Progression Free Survival (PFS) at 6 Months (PFS-6m)|Overall Survival (OS)|Median Progression Free Survival (PFS)|Objective Response Rate (ORR%)|Peak Concentration (Cmax)|Time to Peak Concentration (Tmax)|Area Under the Concentration Versus Time Curve (AUC)	"Proximagen, LLC"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	26	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P311-201	Apr-16	1-Jul-20	1-Jul-20	6-May-16	23-Jul-21	23-Jul-21	"Washington University, Saint Louis, Missouri, United States|University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States|UT Health San Antonio Cancer Center, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics (START) - FJD, Madrid, Spain"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/65/NCT02765165/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02765165/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02765165
880	NCT00501891	Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma		Completed	Has Results	Glioblastoma Multiforme	Drug: Bevacizumab|Drug: Metronomic Temozolomide	6-Month Progression-free Survival|Response Rate|Incidence and Severity of CNS Hemorrhage and Systemic Hemorrhage|Incidence of Grade ≥ 4 Hematologic or Grade ≥ 3 Non-hematologic Toxicity	"Duke University|Genentech, Inc.|Schering-Plough"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000404|AVF3821s|P04860	Jul-07	Dec-07	Nov-09	16-Jul-07	22-Apr-13	27-May-13	"Duke University Medical Center (Brain Tumor Center), Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00501891
881	NCT01558687	Cilengitide Imaging Trial in Glioblastoma		Terminated	No Results Available	Supratentorial Newly Diagnosed Inoperable Gliobastoma	Drug: Drug (including placebo)|Other: Standard therapy	Rate constant for passive contrast agent plasma/interstitium transfer (ktrans)|Fractional blood plasma volume (vp)|Maximum tumor to brain ratio (TBRmax)|Total tumor volume and enhancing tumor volume|Interstitial space volume fraction (putative contrast agent distribution volume) (=ve)|Apparent Diffusion coefficient (ADC)|Fractional anisotropy (FA)|Kinetic behavior of [18F]FET uptake|Mean spin-lattice relaxation time of unbound protons in water	"Merck KGaA, Darmstadt, Germany"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	1	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	EMR062041-017|2011-003794-29	Aug-12	Feb-13	Feb-13	20-Mar-12		4-Feb-14	"Merck KGaA Communication Center located in, Darmstadt, Germany"		https://ClinicalTrials.gov/show/NCT01558687
882	NCT04222309	Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)		Recruiting	No Results Available	"Glioma|Glioma, Malignant|Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain|GBM|Brain Cancer"	Procedure: Laparoscopically harvested omental free flap	"Safety parameter: proportion of patients experiencing rapidly progressive disease as indicated by MRI using RANO Criteria|Safety parameter: proportion of patients experiencing increase in seizures, stroke, and infection|Progression Free Survival (PFS)|Overall Survival (OS)|Percent of screen fails"	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19-0801	6-Jan-20	31-Jan-22	31-Jan-22	9-Jan-20		3-Mar-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT04222309
883	NCT00004146	Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM		Completed	Has Results	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Radiation: radiation therapy|Drug: carboxyamidotriazole|Other: pharmacological study	Overall Survival Rate|Toxicity of CAI When Combined With RT|Correlation Between PK CAI and Toxicity in This pt Population	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	55	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03011|CDR67378|NABTT-9904|U01CA062475	Mar-00	Jan-10	Jan-10	4-Jun-04	8-May-15	8-May-15	"University of Alabama Birmingham, Birmingham, Alabama, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University, Winston-Salem, North Carolina, United States|University of Pennsylavania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004146
884	NCT01290939	Bevacizumab and Lomustine for Recurrent GBM		Completed	No Results Available	Glioblastoma Multiforme|Cognition Disorders|Disability Evaluation	Biological: bevacizumab|Drug: lomustine|Genetic: DNA methylation analysis|Other: laboratory biomarker analysis|Procedure: cognitive assessment|Procedure: quality-of-life assessment	"Overall Survival|PFS (RANO criteria), median , PFS 6 mo and PFS 12 mo, Overall survival: OS 9,12,24 mo|Response rate, duration of response and progression pattern|CTCAE version 4.0. NYHA criteria will be used for assessing heart failure|Patient-oriented criteria: clinical/neurological deterioration free survival, steroid use, quality of life (reported by patients and caregivers/relatives) and development of cognitive deterioration.|Molecular basis of gliomas and the identification of biomarkers to translate into advances in screening, diagnosis, treatment, and monitoring with improved clinical outcomes"	European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	592	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26101|EU-21103|2010-023218-30|MO22968	Oct-11	Oct-15	Apr-20	7-Feb-11		15-Feb-21	"Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands"		https://ClinicalTrials.gov/show/NCT01290939
885	NCT02942264	Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma		Completed	Has Results	Brain Tumor|Astrocytoma|Astroglioma|Glioblastoma|Gliosarcoma	Drug: Zotiraciclib (TG02)|Drug: Temozolomide (TMZ)	Phase I: Maximum Tolerated Dose (MTD) of Zotiraciclib in Combination With Dose Dense (dd) Temozolomide (TMZ) in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma|Phase I: Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) in Combination of Metronomic (mn) Temozolomide (TMZ) in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma|% of Participants Free of Disease Progression at 4mos Treated w/Zotiraciclib at the Maximum Tolerated Dose in Combination Temozolomide w/Dose Dense Temozolomide Schedules in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma|% of Participants Free of Disease Progression at 4mos Treated w/Zotiraciclib at the Maximum Tolerated Dose (MTD) in Combination With the Metronomic (mn) Temozolomide (TMZ) in Adult Patients With Recurrent Anaplastic Astrocytoma or Glioblastoma/Gliosarcoma|Phase II: Progression Free Survival in Subjects Taking Zotiraciclib (TG02) Plus Temozolomide (TMZ) Versus TMZ Alone in Patients With Recurrent World Health Organization (WHO) Grade III or IV Astrocytoma.	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	53	NIH	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	170009|17-C-0009	14-Dec-16	26-Aug-20	26-Aug-20	24-Oct-16	28-Sep-21	28-Sep-21	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/64/NCT02942264/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT02942264/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT02942264
886	NCT03890952	Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Adult Brain Tumor	Drug: Nivolumab|Drug: Bevacizumab	Number of indels as determined using mRNA sequencing|Progression-Free Survival (PFS)	"Ulrik Lassen|Herlev Hospital|University of Copenhagen|Rigshospitalet, Denmark"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CA209-9UP|2017-003925-13	1-Oct-18	1-Feb-22	1-Aug-22	26-Mar-19		6-Oct-20	"Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT03890952
887	NCT03294434	Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)	PRaM-GBM	Recruiting	No Results Available	High Grade Glioma	Other: Diffusion tensor Imaging (DTI)	Site of glioblastoma true progression correctly predicted by DTI scan|Accuracy of DTI as a biomarker|Perfusion imaging|Time to progression|Extent of resection and volume of tumour that remains post-surgery by standard imaging and DTI|Radiotherapy dose according to DTI-defined invasive region	CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust|Cancer Research UK|Experimental Cancer Medicine Centre	All	"16 Years and older   (Child, Adult, Older Adult)"		120	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	PRaM-GBM	2-Mar-17	30-Jun-21	30-Sep-21	27-Sep-17		22-Oct-20	"Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom"		https://ClinicalTrials.gov/show/NCT03294434
888	NCT00390299	Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	Has Results	Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma|Recurrent Glioblastoma	Biological: Carcinoembryonic Antigen-Expressing Measles Virus|Other: Laboratory Biomarker Analysis|Procedure: Therapeutic Conventional Surgery	"Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose Limiting Toxicities|Number of Patients Experiencing Grade 3+ Adverse Events, Per NCI CTCAE Version 3.0|Best Response, Defined as the Best Objective Status Recorded From the Start of the Treatment Until Disease Progression/Recurrence|Progression-free Survival (PFS)|Survival"	Mayo Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	23	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC0671|NCI-2009-01198|P30CA015083|P50CA108961	23-Oct-06	29-Nov-18	30-Nov-19	19-Oct-06	2-Jan-20	2-Jan-20	"Mayo Clinic, Rochester, Minnesota, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/99/NCT00390299/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT00390299
889	NCT00274833	"Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	"CNS Tumor, Adult"	Drug: erlotinib hydrochloride|Drug: temozolomide|Radiation: radiation therapy	Progression-free survival|Progression Free Survival|Number of patients that experience toxicity (CTCAE V2)|Overall Survival	David Peereboom|National Cancer Institute (NCI)|Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	27	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3304|P30CA043703|CCF-6320	Oct-05	Oct-07	Sep-12	11-Jan-06		6-Dec-12	"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00274833
890	NCT03539731	[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers		Recruiting	No Results Available	Healthy Subject|Intracranial Neoplasm|Glioblastoma	Drug: Fluorine F 18 DASA-23|Procedure: Positron Emission Tomography	Change in [18F]DASA-23 PET scan signal in patients with suspected recurrent glioblastoma|Sensitivity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Specificity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Accuracy of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Progression-free survival in patients with suspected recurrent glioblastoma|Overall survival in patients with suspected recurrent glioblastoma	"Guido A. Davidzon, MD, SM|Stanford University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	25	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	BRN0038|NCI-2018-00826|44597	23-Apr-18	30-Jul-22	30-Dec-22	29-May-18		10-Sep-21	"Stanford University, School of Medicine, Palo Alto, California, United States"		https://ClinicalTrials.gov/show/NCT03539731
891	NCT04115761	Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients		Recruiting	No Results Available	GBM	Biological: autologous dendritic cells	One-year progression-free survival (PFS) rate	"Ever Supreme Bio Technology Co., Ltd."	All	"20 Years to 75 Years   (Adult, Older Adult)"	Phase 2	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ES-CDCV01-A2201	6-Jun-19	31-Dec-21	30-Jun-22	4-Oct-19		5-Oct-20	"Taichung Veterans General Hospital, Taichung, Non-US, Taiwan|Chang-Gung Memorial Hospital at Lin-Ko, Taoyuan, Non-US, Taiwan|China Medical University Hospital, Taichung, Taiwan"		https://ClinicalTrials.gov/show/NCT04115761
892	NCT02152748	Disease Progression and Treatment-induced Alterations in Glioblastoma		Unknown status	No Results Available	Brain Tumor	Genetic: analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance	Morphology- based analysis|Molecular analysis	Medical University of Vienna	All	"Child, Adult, Older Adult"		60	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	KLI 394	Apr-14	Dec-17	Dec-17	2-Jun-14		22-Mar-17	"Medical University of Vienna, Institute of Neurology, Vienna, Austria"		https://ClinicalTrials.gov/show/NCT02152748
893	NCT02623231	"The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients"	Cipralex&GBM	Unknown status	No Results Available	GBM|Depression	Drug: Escitalopram|Drug: placebo	changes in patients mood and cognitive function according to the neuropsychological assessment that includes patient health questionnaire (PHQ9)	Tel-Aviv Sourasky Medical Center	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2|Phase 3	100	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care"	0600-15	Dec-15	Dec-17	Dec-17	7-Dec-15		7-Dec-15	"The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT02623231
894	NCT00071539	Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors		Completed	No Results Available	Recurrent Glioblastoma Multiforme	Drug: TP-38|Drug: TP38	Survival|Time to progression (TTP)	"Teva Branded Pharmaceutical Products R&D, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IXR-102-22-188	Oct-03	Jan-06	Jul-06	29-Oct-03		20-Jan-12			https://ClinicalTrials.gov/show/NCT00071539
895	NCT03705351	Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM		"Active, not recruiting"	No Results Available	Glioblastoma|Cancer of Brain|Glioblastoma Multiforme|Brain Tumor	Device: Tumor Treating Fields|Drug: Temozolomide|Radiation: Radiation Therapy	Rate of treatment-related adverse events associated with trimodal therapy|Severity of treatment-related adverse events associated with trimodal therapy|Progression-free survival at 6 months and 24 months|Overall Survival Rate	"Providence Health & Services|University of California, San Francisco|NovoCure Ltd."	All	"22 Years and older   (Adult, Older Adult)"	Phase 1	7	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UNITYGBM01	2-Dec-19	1-Nov-23	1-Nov-25	15-Oct-18		13-Apr-21	"University of California San Francisco, San Francisco, California, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT03705351
896	NCT01019434	Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Drug: temsirolimus	"Overall survival at 1 year|Percentages of worst Adverse Events or Laboratory Event grades as measured by CTCAEs Version 4.0 criteria|Progression-free survival (PFS) probability at 6 months and at 12 months, and overall survival (OS) probability at 2 years|Correlation between biomarkers relevant to temsirolimus and PFS and OS"	European Organisation for Research and Treatment of Cancer - EORTC|Pfizer	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	111	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26082-22081|EORTC-26082|EORTC-22081|EU-20987|2008-003003-31	Oct-09	Dec-13	Mar-14	25-Nov-09		9-Jul-18	"UZ Leuven, Leuven, Belgium|Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau, Nantes-Saint Herblain, France|CHU Pitie-Salpetriere AP-HP, Paris, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Ospedale Bellaria, Bologna, Italy|Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands|ICO Badalona - Hospital Germans Trias i Pujol, Badalona, Spain|Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland|Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|Western General Hospital, Edinburgh, United Kingdom"		https://ClinicalTrials.gov/show/NCT01019434
897	NCT03526822	Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.	MM-Predict	Recruiting	No Results Available	Brain Tumor	Biological: Blood sample|Biological: Tumor sample	correlate the plasma levels of MMP2 and MMP9 to their RNA and protein tissue expression by ELISA	Assistance Publique Hopitaux De Marseille	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2017-56|2018-A00740-55	2-Jul-18	1-Jan-22	1-May-22	16-May-18		24-Jul-18	"Assistance Publique Hôpitaux de Marseille, Marseille, France"		https://ClinicalTrials.gov/show/NCT03526822
898	NCT03746288	To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)		Unknown status	No Results Available	GBM	Drug: CAN008	Overall survival|Progression free survival (PFS)|6-month progression free survival rate (PFS6)|Objective response rate (ORR)|Duration of response (DOR)	CANbridge Life Sciences Ltd.	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAN-B1-008-L-005	20-Nov-18	1-Jul-21	31-Dec-21	19-Nov-18		19-Nov-18			https://ClinicalTrials.gov/show/NCT03746288
899	NCT03123952	Expanded Access to ABT-414		No longer available	No Results Available	"Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis"	Drug: ABT-414		AbbVie	All	"18 Years and older   (Adult, Older Adult)"			Industry	Expanded Access:Individual Patients|Intermediate-size Population		C16-478|C19-919				21-Apr-17		15-Jul-19			https://ClinicalTrials.gov/show/NCT03123952
900	NCT02895360	Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma		Completed	Has Results	Neoplasms	Drug: BAL101553|Drug: BAL101553 at MTD	Maximum Tolerated Dose (MTD) of BAL101553|Safety and Tolerability of BAL101553 Treatment Based on Number of Patients With Related Treatment-emergent Adverse Events (TEAEs) in the Phase 1 and Phase 2a Safety Population at Various Dose Levels and Indication|AUC of BAL101553 and BAL27862|Cmax of BAL101553 and BAL27862|Tmax of BAL101553 and BAL27862|Bioavailability of Daily Oral BAL101553 Measured by BAL27862 in Phase 1|Anti-tumor Activity of BAL101553 by Best Response Rate Per RECIST / RANO Criteria	Basilea Pharmaceutica	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	43	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDI-CS-003	24-Aug-16	7-Aug-20	7-Aug-20	9-Sep-16	11-Oct-21	11-Oct-21	"Oncology Institute of Southern Switzerland; Ospedale Regionale San Giovanni Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Cantonal Hospital of Grisons, Department of Oncology/ Haematology, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Cantonal Hospital of St. Gallen, Dep. Medical Oncology & Hematology, St. Gallen, Switzerland|UniversitaetsSpital Zürich, Zürich, Switzerland"	"Study Protocol and Statistical Analysis Plan: Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/60/NCT02895360/Prot_SAP_000.pdf|""Statistical Analysis Plan: Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02895360/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02895360
901	NCT02805179	A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma		Completed	Has Results	Glioma	Radiation: High Dose Radiation|Drug: Temozolomide	Overall Survival at 12 Months|Median Overall Survival|Median Progression-free Survival|Median Change in Tumor Volume From Baseline to Mid-radiation Treatment (Week 4)|Percentage of Patients That Experienced Deterioration in Quality of Life (QOL)|Percentage of Patients With Failure; Central or In-field vs. Marginal or Distant	University of Michigan Rogel Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	26	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2012.006|HUM00113549	22-Sep-16	6-Feb-20	18-Nov-20	17-Jun-16	15-Apr-21	15-Apr-21	"University of Michigan Hospital, Ann Arbor, Michigan, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/79/NCT02805179/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02805179
902	NCT00540176	The Safety and Efficacy of DCA for the Treatment of Brain Cancer		Completed	No Results Available	"Malignant Gliomas, Glioblastoma Multiforme"	Drug: Dichloroacetate (DCA)	"To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas."	"University of Alberta|Capital Health, Canada"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DCA 10002	Oct-07	Aug-09	Aug-09	5-Oct-07		13-Oct-14	"University of Alberta Hospital, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT00540176
903	NCT00362921	Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Recurrent Adult Brain Tumor	Drug: Gliadel wafers in combination with O6-benzylguanine	6-month overall survival|One year overall survival|2 year overall survival|Median overall survival|Toxicity prevalence	Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	52	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00004127|DUMC-5515-06-1R2|DUMC-5515-04-1R0|GP-DUMC-5515-06-1R2|CDR0000483768	Apr-04	Aug-07	Jul-08	15-Aug-06		10-Jul-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00362921
904	NCT02209376	Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma		Terminated	No Results Available	Patients With Residual or Reccurent EGFRvIII+ Glioma	Biological: CART-EGFRvIII T cells	Number of adverse events	"University of Pennsylvania|University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	"UPCC 35313, 820381"	18-Nov-14	4-Apr-18	4-Apr-18	5-Aug-14		5-Mar-19	"UCSF, San Francisco, California, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02209376
905	NCT02490800	Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma		Recruiting	No Results Available	Neoplasms	Drug: Oral daily administration of BAL101553	Phase 1: Maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of daily oral BAL101553 based on the number of participants with adverse effects as measure of tolerability at various dose levels|Phase 2a: Best objective response according to RANO criteria|Safety and tolerability of daily oral BAL101553 based on the number of participants with adverse events at various dose levels|Safety and tolerability of daily oral BAL101553 based on the number of participants with safety laboratory changes versus baseline|Safety and tolerability of daily oral BAL101553 based on the number of participants with ECG changes versus baseline|Cmax of BAL101553 and BAL27862|Tmax of BAL101553 and BAL27862|AUC of BAL101553 and BAL27862|Half-life of BAL101553 and BAL27862|Anti-tumor activity of daily oral BAL101553 in cancer patients based on RECIST 1.1 -criteria (measurable disease of advanced or recurrent solid tumors).|Anti-tumor activity of daily oral BAL101553 in cancer patients by contrast-enhanced MRI based on RANO criteria (recurrent or progressive GBM or high-grade glioma).	Basilea Pharmaceutica	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	104	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDI-CS-002	Jun-15	Jun-22	Jun-22	7-Jul-15		21-Dec-21	"UZ Leuven, Leuven, Belgium|Klinikum der Goethe-Universität Frankfurt, Frankfurt, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsspital Basel, Basel, Switzerland|Inselspital Universitätsspital Bern, Bern, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|University College London NHS Foundation Trust, London, United Kingdom|Sir Bobby Robson Cancer Trials Research Centre; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT02490800
906	NCT05024175	Long-term Follow-up of Subjects Treated With CARv3-TEAM-E T Cells		Not yet recruiting	No Results Available	"Glioblastoma Recurrent, EGFR vIII Mutant|Newly Diagnosed Glioblastoma, EGFRvIII Mutant|Recurrent Glioblastoma, EGFR vIII Negative"	Diagnostic Test: Disease assessments|Procedure: Tumor Biopsy|Diagnostic Test: Blood test	Overall Survival|Progresison Free Survival|New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder|New incidence of a hematologic disorder|Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v 5.0|Vector-derived RCL|Assessment of CAR T cells persistence by VCN in peripheral blood|Disease specific response	Massachusetts General Hospital	All	"18 Years and older   (Adult, Older Adult)"		18	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20-721	Dec-21	1-Aug-38	1-Aug-39	27-Aug-21		27-Aug-21	"Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT05024175
907	NCT01547546	A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma		Completed	No Results Available	"Glioblastoma, Glioma"	Drug: GDC-0084	"Safety: Incidence of adverse events|Maximum tolerated dose (MTD)|Pharmacokinetics: Area under the concentration-time curve|Best overall response rate, tumor assessments according to Response Assessment in Neuro-Oncology (RANO)|Duration of response|Progression-free survival"	"Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	29	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GO28070|2011-004479-35	Apr-12	Jan-15	Jan-15	8-Mar-12		2-Nov-16	"Los Angeles, California, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Houston, Texas, United States|Barcelona, Spain"		https://ClinicalTrials.gov/show/NCT01547546
908	NCT02433392	"Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme."		Terminated	No Results Available	Glioma	Procedure: CM-BC2	"Safety measured by incidence of adverse events as assessed by CTCAE v4.0|Progression-free survival|Systemic serum levels of irinotecan|Systemic serum levels of SN-38, irinotecan metabolite"	Boston Scientific Corporation|University of Birmingham	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	9	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA1021	Dec-11	Jul-15	Jul-15	5-May-15		21-Apr-21	"Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom"		https://ClinicalTrials.gov/show/NCT02433392
909	NCT05052957	hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)	hSTAR GBM	Not yet recruiting	No Results Available	"Glioblastoma Multiforme|Glioblastoma Multiforme, Adult|Supratentorial Glioblastoma|Supratentorial Gliosarcoma"	Biological: P140K-MGMT|Drug: O6-benzylguanine|Radiation: Photon Based Radiotherapy|Drug: temozolomide|Drug: Filgrastim|Drug: carmustine	Percent of participants able to complete treatment|Incidence of adverse events|Overall Survival|Myelosuppression|Detection of P140K transduced BG and TMZ resistant cells|Enrichment of P140K-MGMT|Tumor Response using imaging|PFS using imaging	"Andrew Sloan, MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	16	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE5320|1U01CA236215-01	15-Oct-21	1-Jun-23	1-Dec-23	22-Sep-21		7-Oct-21	"NIH-Clinical Center, Bethesda, Maryland, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT05052957
910	NCT01812603	A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma		Completed	No Results Available	Cancer	Drug: Sativex	The incidence of adverse events in patients receiving Sativex in combination with dose-intense Temozolomide in the open-label phase of the study|The number of patients with Progression Free Survival at six months (PFS6)|Overall Survival	GW Research Ltd	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	6	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GWCA1208 Part A	Sep-13	Jan-15	Jun-16	18-Mar-13		11-Aug-16	"The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|St James's Institute of Oncology, St James's University Hospital, Leeds, Yorkshire, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Guy's and St Thomas NHS Foundation Trust, of St Thomas' Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom"		https://ClinicalTrials.gov/show/NCT01812603
911	NCT01812616	A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients		Completed	No Results Available	Cancer	Drug: Sativex|Drug: Placebo	Incidence of Adverse Events as a Measure of Patient Safety.|The number of patients with Progression Free Survival at six months (PFS6)|Overall Survival	GW Research Ltd	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	21	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	GWCA1208 Part B	Sep-14	Jun-16	Jun-16	18-Mar-13		11-Aug-16	"Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen RWTH, Aachen, Germany|Neurologie des Klinikums Altenburger Land, Altenburg, Germany|Zentrum für Neuroonkologie der Universität Duesseldorf, Duesseldorf, Germany|Strahlenklinik der Universität Erlangen, Erlangen, Germany|The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom|St James's Institute of Oncology, St James's University Hospital, Leeds, Yorkshire, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Queen's Centre for Haematology & Oncology, Castle Hill Hospital, Cottingham, United Kingdom|West of Scotland Beatson Cancer Centre, Glasgow, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, of St Thomas' Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom"		https://ClinicalTrials.gov/show/NCT01812616
912	NCT04610229	Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.	GLIORAD	Completed	No Results Available	"Glioblastoma Multiforme|Glioblastoma|Glioblastoma, Adult"	Radiation: Hypofractionation guioded by dose painting	Number of adverse events occuring after treatment|Local control according to the RANO criteria|Incidence of radionecrosis|Proportion of patients alive 3 months after treatment|Change in health related global quality of life (QOL)|Change in health related quality of life (QOL) for brain cancer disease|Proportion of patients with disease progression 3 months after treatment	Arcispedale Santa Maria Nuova-IRCCS	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GLIORAD_15-18	1-Feb-16	12-Aug-19	26-Aug-19	30-Oct-20		30-Oct-20	"Radiotherapy Unit Ausl Irccs Reggio Emilia, Reggio Emilia, Italy"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/29/NCT04610229/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT04610229
913	NCT00586508	Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas		Completed	Has Results	Recurrent Glioblastoma	Drug: enzastaurin|Drug: bevacizumab|Drug: Enzyme-inducing antiepileptic drugs (EIAED)|Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)	Progression-Free Survival at 6 Months (PFS-6)|Time to Progressive Disease (PD)|Number of Participants With Adverse Events (AEs) or Deaths (Safety)|Overall Response Rate (ORR)|To Evaluate Tumor Markers and Genes|Change From Baseline in Health-Related Quality of Life (HRQoL) Subscales	"Eli Lilly and Company|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	81	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11394|H6Q-MC-S033	Nov-07	Oct-13	Oct-13	4-Jan-08	24-Sep-20	24-Sep-20	"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00586508
914	NCT02540161	Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma		Completed	Has Results	Malignant Glioma	Drug: Sym004 - 18 mg/kg|Drug: Sym004 - 24 mg/kg	"Six-month Progression-free Survival (PFS6)|Percentage of Participants Who Experience Grade 3, 4 or 5 Adverse Events|Radiographic Response|Median Progression-free Survival (PFS)|Median Overall Survival (OS)"	Annick Desjardins|Symphogen A/S|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	43	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00063483	1-Feb-16	10-Jul-19	27-Apr-20	3-Sep-15	24-Jul-20	5-Aug-20	"The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/61/NCT02540161/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02540161
915	NCT02062827	Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma	M032-HSV-1	Recruiting	No Results Available	Recurrent Glioblastoma Multiforme|Progressive Glioblastoma Multiforme|Anaplastic Astrocytoma or Gliosarcoma	Biological: M032 (NSC 733972)	Highest safe dose/MTD (maximum tolerated dose) or maximally planned dose if no dose-limiting toxicity observed|Time to progression assessment|The time of survival assessment|The time of biologic assessment	University of Alabama at Birmingham	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UAB-1317	25-Nov-13	Sep-22	Sep-23	14-Feb-14		13-Oct-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT02062827
916	NCT03107780	Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer		Recruiting	No Results Available	Glioblastoma|Gliosarcoma|MGMT-Unmethylated Glioblastoma|Recurrent Glioblastoma	Other: Laboratory Biomarker Analysis|Drug: Navtemadlin|Other: Pharmacological Study|Radiation: Radiation Therapy	Pharmacokinetics (PK) parameters with target inter-tumor drug concentration at >= 25 nm (Part 1)|Maximum tolerated dose (MTD) of MDM2 inhibitor AMG 232 (KRT-232) when combined with concomitant radiation therapy (Part 2)|Incidence of adverse events (Part 1)|Variability of MDM2 inhibitor AMG 232 (KRT-232) concentration in tumor enhancing versus (vs.) infiltrative tissue (Part 1)|p21 elevation in tissue (Part 1)|Incidence of adverse events (Part 2)|MIC-1 elevation in serum (Part 2)|MDM2 inhibitor AMG 232 (KRT-232) exposure (Part 2)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	NIH	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2017-00568|ABTC-1604|UM1CA137443	26-Feb-18	31-Dec-21	31-Dec-21	11-Apr-17		22-Dec-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03107780
917	NCT01854554	Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)		Completed	No Results Available	Brain Cancer	Radiation: IMPT|Radiation: IMRT|Behavioral: Cognitive Tests|Behavioral: Questionnaires	Time to Cognitive Failure|Local Control in the Brain Post Radiation Treatment	M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	90	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2013-0097|NCI-2013-01089	17-May-13	13-Oct-21	13-Oct-21	15-May-13		18-Oct-21	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01854554
918	NCT02366728	DC Migration Study for Newly-Diagnosed GBM	ELEVATE	Unknown status	No Results Available	"Glioblastoma|Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme"	Biological: Unpulsed DCs|Biological: Td|Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs|Biological: 111In-labeled DCs|Drug: Temozolomide|Drug: Saline|Drug: Basiliximab	Median overall survival|Percentage of 111In-labeled dendritic cells migrating to the inguinal lymph nodes|Median overall survival in CMV positive participants|Median overall survival in CMV negative participants|Median progression-free survival|Median progression-free survival in CMV positive participants|Median progression-free survival in CMV negative participants	Gary Archer Ph.D.|Duke University	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	100	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	Pro00054740	12-Oct-15	Aug-20	Aug-20	19-Feb-15		7-Nov-19	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT02366728
919	NCT04661384	"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma"		Recruiting	No Results Available	Leptomeningeal Metastases	Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes	"Incidence of adverse events|Overall survival|CAR T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Endogenous T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Cell phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Cytokine levels in PB, TCF and CSF|Disease response|Time to progression|CAR T and endogenous cells detected in tumor tissue|IL13Raphs2 antigen expression levels in tumor tissue.|Biomathematical Modeling of tumor growth|Biomathematical Modeling of perfusion/diffusion"	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19497|NCI-2020-06010|P30CA033572	5-Mar-21	15-Dec-23	15-Dec-23	10-Dec-20		12-Aug-21	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT04661384
920	NCT01931098	Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab		Completed	Has Results	Glioblastoma|Glioblastoma Multiforme|Gliosarcoma|Brain Neoplasms|Central Nervous System Neoplasms	Drug: topotecan|Drug: pazopanib	Proportion of Patients That Have Progressive Survival (PFS) at Six Months From Patient Registration for Bevacizumab Naive Patients and PFS at 3 Months for Patients With Prior Bevacizumab Treatment|Overall Survival|Mean Symptom Severity Score Between Responders and Non-responders at Baseline and by Cycle|Mean Symptom Interference Score Between Responders and Non-responders at Baseline and by Cycle|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	35	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	160034|16-C-0034	10-Dec-15	12-Sep-19	12-Sep-19	29-Aug-13	18-Sep-20	24-Nov-20	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/98/NCT01931098/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01931098
921	NCT03630289	Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM		Recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer	Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)	"Safety parameter: proportion of patients experiencing rapidly progressive disease as indicated by MRI using RANO Criteria|Safety parameter: proportion of patients experiencing increase in seizures, stroke, and infection|Progression Free Survival (PFS)|Overall Survival (OS)"	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-0498	27-Jul-18	27-Jul-22	27-Jul-22	14-Aug-18		28-Oct-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03630289
922	NCT02861898	Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma		Recruiting	No Results Available	"Glioblastoma|Brain Cancer|Brain Neoplasm|Brain Tumor|Brain Neoplasm, Malignant|EGFR Gene Overexpression|GBM"	Drug: Intra-arterial Cetuximab|Drug: Intra-arterial Mannitol	Progression Free Survival (PFS)|Overall Survival (OS)|Composite overall response rate (CORR) through the Response Assessment in Neuro-Oncology (RANO)|Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	33	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HS16-0257	Jun-16	Jun-23	Jun-23	10-Aug-16		28-Oct-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02861898
923	NCT03423628	A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer		Recruiting	No Results Available	"Recurrent Glioblastoma Multiforme|Primary Glioblastoma Multiforme|Brain Neoplasms, Malignant|Leptomeningeal Disease (LMD)"	Radiation: Radiation Therapy|Drug: AZD1390	Incidence of dose-limiting toxicities (DLTs)|Incidence of adverse events (AEs) and serious adverse events (SAEs)|Event free survival (EFS) for Arms A and C only|Objective response rate defined by RANO criteria for Arms A and C only|Objective response rate defined by RANO-BM criteria for Arm B only. **Arm B has now closed to recruitment**|Objective response rate defined by RECIST 1.1 criteria for Arm B only. **Arm B has now closed to recruitment**|Maximum Observed Plasma Concentration (Cmax) of AZD1390|Time to observed Cmax (Tmax) for AZD1390|Area under the plasma concentration-time curve (AUC) for AZD1390|Renal clearance (CLR) for AZD1390|Overall survival for Arms A and C only|Assessment of the food effect of AZD1390 at the MTD for Arm A (if conducted)	AstraZeneca	All	"18 Years to 130 Years   (Adult, Older Adult)"	Phase 1	120	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D6940C00002|2017-002451-28|135803	2-Apr-18	26-Mar-24	26-Mar-24	6-Feb-18		20-Dec-21	"Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Richmond, Virginia, United States|Research Site, Cambridge, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom"		https://ClinicalTrials.gov/show/NCT03423628
924	NCT00645385	Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.	Gliadel-MRS	Withdrawn	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma	Other: MRS Spectroscopy	"Stabilization or reduction of tumor on gadolinium enhanced MRI and changes in choline/creatine ratio and NAA on MR Spectroscopy|Median survival, 6-month survival, and progression free survival."	Weill Medical College of Cornell University|Eisai Inc.	All	"18 Years to 85 Years   (Adult, Older Adult)"		0	Other|Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	7090991	Jun-07	1-Jun-11	1-Jun-11	27-Mar-08		4-Jun-19	"Weill Cornell Medical College Department of Neurosurgery, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00645385
925	NCT01222221	"Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: glioblastoma multiforme multipeptide vaccine IMA950|Biological: sargramostim|Drug: temozolomide|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: radiation therapy	"Causality of each adverse event (AE) to glioblastoma multiform multi-antigen vaccine IMA950 and GM-CSF and AE severity according to NCI CTCAE Version 4.0|Total number of patients showing patient-individual T-cell responses against a single or multiple tumor-associated peptides (TUMAP) contained in the study vaccine IMA950 at one or more post-vaccination time points by HLA multimer analysis|Progression-free survival (PSF) at 6 and 9 months post-surgery as assessed by the Macdonald criteria from conventional gadolinium-enhanced MRI and clinical assessment|Correlation between steroid levels and observed T-cell responses|Correlation between O6-methyl-DNA-methyltransferase (MGMT) promoter methylation status in tumor tissue using methylation-specific polymerase chain reaction and clinical benefit (PFS at 6 months and 9 months)|Kinetics of vaccine-induced TUMAP responses including summary descriptions of the time of onset, sustainability, and magnitude of the observed response"	Cancer Research UK|Immatics Biotechnologies GmbH	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	45	Other|Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000686559|CRUK-CR0902-11|EUDRACT-2009-015971-28	Jul-10	Feb-15	Feb-15	18-Oct-10		14-Oct-15	"Addenbrooke's Hospital, Cambridge, England, United Kingdom|UCL Cancer Institute, London, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|St James' University Hospital, Leeds, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom"		https://ClinicalTrials.gov/show/NCT01222221
926	NCT00770471	"ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Drug: veliparib|Genetic: DNA methylation analysis|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: proteomic profiling|Other: high performance liquid chromatography|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: radiation therapy	Maximum tolerated dose of ABT-888 (Phase I)|Overall survival (Phase II)|Toxicity (Phase I)|Pharmacokinetics of ABT-888 (Phase I)|Frequency of toxicity (Phase II)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	24	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTT-0801 CDR0000616542|U01CA062475|ABTC-0801|NABTT-0801|ABBOTT-M10-190	13-Jul-09	1-Mar-12	1-Mar-12	10-Oct-08		27-Jun-18	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00770471
927	NCT01062399	"Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"	RTOG 0913	Unknown status	Has Results	Brain and Central Nervous System Tumors	Drug: concurrent RAD001 10 mg/day|Drug: concurrent temozolomide|Radiation: Radiation therapy|Drug: concurrent RAD001 2.5 mg/day|Drug: concurrent RAD001 5 mg/day|Drug: post-radiation RAD001 10 mg/day|Drug: post-radiation temozolomide	Phase I: Number of Patients With Dose-limiting Toxicity (DLT)|Phase II: Progression-free Survival (PFS)|Phase II: Overall Survival (OS)|Phase I: Distribution of Worst Adverse Event Grade|Phase II: Distribution of Worst Adverse Event Grade	Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	279	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG 0913|RTOG-0913|CDR0000664302|NCI-2011-00885	Dec-10	Jun-16		4-Feb-10	23-Jan-18	7-May-19	"CCOP - Christiana Care Health Services, Newark, Delaware, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Integrated Community Oncology Network, Jacksonville Beach, Florida, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Integrated Community Oncology Network at Southside Cancer Center, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Integrated Community Oncology Network - Orange Park, Orange Park, Florida, United States|Florida Cancer Center - Palatka, Palatka, Florida, United States|Flagler Cancer Center, Saint Augustine, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|St. Vincent Oncology Center, Indianapolis, Indiana, United States|St. Agnes Hospital Cancer Center, Baltimore, Maryland, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|St. Barnabas Medical Center Cancer Center, Livingston, New Jersey, United States|New York Oncology Hematology, PC at Albany Regional Cancer Care, Albany, New York, United States|University Radiation Oncology at Parkridge Hospital, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, United States|Barberton Citizens Hospital, Barberton, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Willamette Valley Cancer Center - Eugene, Eugene, Oregon, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|York Cancer Center at Apple Hill Medical Center, York, Pennsylvania, United States|Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States|Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel"		https://ClinicalTrials.gov/show/NCT01062399
928	NCT05086497	WBSI Guided Personalized Delivery of TTFields		Not yet recruiting	No Results Available	"GBM|Glioma Glioblastoma Multiforme|Tumor, Brain"	Diagnostic Test: Whole Brain Spectroscopy Imaging Array Mapping Layout	Time to Progression|Overall Survival	Abramson Cancer Center of the University of Pennsylvania|NovoCure Ltd.|National Institutes of Health (NIH)|National Cancer Institute (NCI)	All	"22 Years and older   (Adult, Older Adult)"	Not Applicable	155	Other|Industry|NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic"	09321|848715|1R01CA262584-01	Jan-22	30-Jun-26	30-Jun-26	21-Oct-21		21-Oct-21			https://ClinicalTrials.gov/show/NCT05086497
929	NCT01433991	A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)		Terminated	Has Results	Advanced Solid Tumors	Drug: Golvatinib|Drug: Lenvatinib	Phase 1b: Number of Participants Who Experienced Any Dose Limiting Toxicity (DLT)- Combination Treatment|Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Golvatinib in Combination With Lenvatinib|Phase 1b: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Golvatinib|Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Laboratory Values- Combination Treatment|Phase 1b: Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values- Combination Treatment|Phase 1b: Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Values- Combination Treatment|Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)- Combination Treatment|Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib When Administered as a Single Agent at Day -7|Phase 1b: Cmax; Maximum Observed Plasma Concentration for Lenvatinib When Administered as a Single Agent at Day -8|Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib When Administered as a Single Agent at Day -7|Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Lenvatinib When Administered as a Single Agent at Day -8|Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib When Administered as Single Agent at Day -7|Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Lenvatinib When Administered as Single Agent at Day -8|Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib When Administered as Single Agent at Day -7|Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Lenvatinib When Administered as Single Agent at Day -8|Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7|Phase 1b: AUC∞; Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Calculated Using the Observed Value for the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8|Phase 1b: t1/2; Terminal Elimination Half-life for Golvatinib When Administered as Single Agent at Day -7|Phase 1b: t1/2; Terminal Elimination Half-life for Lenvatinib When Administered as Single Agent at Day -8|Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib When Administered as Single Agent at Day -7|Phase 1b: CL/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Lenvatinib When Administered as Single Agent at Day -8|Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Golvatinib When Administered as Single Agent at Day -7|Phase 1b: Vz/F; Apparent Volume of Distribution at Terminal Phase for Lenvatinib When Administered as Single Agent at Day -8|Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1|Phase 1b: Cmax; Maximum Observed Plasma Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1|Phase 1b: Tmax; Time to Reach the Maximum Plasma Concentration (Cmax) for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1|Phase 1b: AUC24; Area Under the Plasma Concentration-time Curve From Time 0 to Time 24 Hours for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Single Dose on Day 1 Cycle 1|Phase 1b: AUCt; Area Under the Plasma Concentration-time Curve From Time 0 to Time t Over the Dosing Interval for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: CLss/F; Apparent Clearance After Extravascular Administration Calculated Using the Observed Value of the Last Quantifiable Concentration for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: Rac(AUC); Accumulation Ratio Based on AUC Calculated as AUC24 at Steady State/AUC24 for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: Rac(Cmax); Accumulation Ratio Based on Cmax Calculated as Cmax at Steady State/Cmax for Golvatinib and Lenvatinib When Administered in Combination Treatment as Multiple Dose on Day 1 Cycle 2|Phase 1b: Objective Response Rate (ORR); Combination Treatment	Eisai Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7050-G000-901	13-Oct-11	18-Mar-15	1-Mar-17	14-Sep-11	8-Jun-21	8-Jun-21	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01433991
930	NCT00974987	"Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Radiation: BNCT(boron neutron capture therapy)|Radiation: XRT(X-ray radiation treatment)|Drug: TMZ(temozolomide)	Overall survival (OS)|Tumor response（RECIST）|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Adverse event	"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Department of Nuerosurgery, Osaka Medical College"	All	"15 Years to 75 Years   (Child, Adult, Older Adult)"	Phase 2	32	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSAKA-TRIBRAIN0902|CDR0000650829|UMIN000002385	1-Sep-09	29-Feb-16	29-Feb-16	11-Sep-09		25-Apr-18	"Osaka Medical College, Takatsuki, Osaka, Japan"		https://ClinicalTrials.gov/show/NCT00974987
931	NCT00639639	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	ATTAC	"Active, not recruiting"	No Results Available	Malignant Neoplasms of Brain	Biological: tetanus toxoid|Biological: therapeutic autologous dendritic cells|Biological: therapeutic autologous lymphocytes	Feasibility and safety of vaccination with cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells (DCs) with or without autologous lymphocyte transfer|Humoral and cellular immune responses|Time to progression|Differential ability of indium In-111-labeled DCs to track to the inguinal lymph nodes under different skin preparative conditions|Differential ability of indium In-111-labeled DCs to track to lymph nodes on the tumor bearing and non-tumor bearing side of the cervical lymph nodes|Immunologic cell infiltrate in recurrent tumors|Evidence of antigen-escape outgrowth in recurrent or progressive tumors	Gary Archer Ph.D.|National Cancer Institute (NCI)|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	42	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00003877|CDR0000589624|DUMC-8108-07-1R1|Discretionary Funds	Jan-06	15-Apr-17	Jan-22	20-Mar-08		26-Jan-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00639639
932	NCT00331526	Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Procedure: adjuvant therapy|Procedure: conventional surgery	Side effects and toxicity|Progression-free survival and overall survival	Hoag Memorial Hospital Presbyterian	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 2	83	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000471241|HOAG-CBRG-98-09	Feb-99	Dec-08	Apr-12	31-May-06		25-Mar-13	"Hoag Cancer Center at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"		https://ClinicalTrials.gov/show/NCT00331526
933	NCT00869401	"Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: dasatinib|Drug: temozolomide|Other: placebo|Radiation: radiation therapy	Overall Survival|The Number of Dose Limiting Toxicities(DLT) in Order to Determine Maximum Tolerable Dose(MTD) of Dasatinib Combined With Radiation and Temozolomide in This Patient Population.|Progression-free Survival|Objective Response	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	217	Other|NIH|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCCTG-N0877|NCI-2009-01179|CDR0000637854|U10CA025224	Jun-09	Oct-14	15-Nov-19	26-Mar-09	8-May-17	13-Feb-20	"Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Resurrection Medical Center, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|Valley Cancer Center, Spring Valley, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|St. Francis Hospital Cancer Care Services, Indianapolis, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Mercy Cancer Center - West Lakes, Clive, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Methodist West Hospital, West Des Moines, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health - Duluth Clinic, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Benefis Sletten Cancer Institute, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care, Concord, New Hampshire, United States|New Hampshire Oncology - Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Lakes Region General Hospital, Laconia, New Hampshire, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|CCOP - Hematology-Oncology Associates of Central New York, East Syracuse, New York, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center Cancer Center, Portsmouth, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Precision Radiotherapy at University Pointe, West Chester, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Eastside, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Greer Radiation Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Center for Cancer Treatment & Prevention at Sacred Heart Hospital, Eau Claire, Wisconsin, United States|Marshfield Clinic Cancer Care at Regional Cancer Center, Eau Claire, Wisconsin, United States|Central Wisconsin Cancer Program at Agnesian HealthCare, Fond Du Lac, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Saint Joseph's Hospital, Marshfield, Wisconsin, United States|Marshfield Clinic - Lakeland Center, Minocqua, Wisconsin, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Clinic - Indianhead Center, Rice Lake, Wisconsin, United States|Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Saint Michael's Hospital Cancer Center, Stevens Point, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00869401
934	NCT05171127	Differentiation Between Healthy Cerebral Tissue and Tumor Tissue Using a Tissue Sensing Instrument		"Active, not recruiting"	No Results Available	Glioblastoma|Surgical Margin	Procedure: Diffuse Reflectance Spectroscopy	DRS pattern	Karolinska University Hospital|Philips Healthcare	All	"Child, Adult, Older Adult"		50	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	2019-00100	30-Apr-19	31-Dec-22	31-Dec-22	28-Dec-21		28-Dec-21	"Karolinska University Hospital, Stockholm, Sweden"		https://ClinicalTrials.gov/show/NCT05171127
935	NCT00019058	Radiation Therapy in Treating Patients With Glioblastoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: chemotherapy|Drug: hydroxyurea|Drug: pentoxifylline|Radiation: radiation therapy		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	34	NIH	Interventional	Primary Purpose: Treatment	CDR0000064077|NCI-95-C-0069|NCI-95-C-0069A|NCI-95-C-0069D	Apr-95			5-Apr-04		29-Apr-15	"Radiation Oncology Branch, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00019058
936	NCT00052715	Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	Poly-ICLC	Terminated	Has Results	Brain and Central Nervous System Tumors	Drug: poly ICLC	Overall Survival in Pts With Newly Diagnosed GBM|To Determine 6 Months Progression Free Survival|Determine the 12-month Survival Rate|to Determine Grade 3 and 4 Toxicities Associated With Poly-ICLC in Newly Diagnosed Patients|To Determine the Change in Neurological Status in Patients With Glioblastoma Treated With External Beam Radiotherapy and Poly-ICLC|To Determine Tumor Response	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	31	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTC-0105|CDR0000258685|NCI-2012-02506	23-Oct-02	25-Feb-06	1-Jan-09	27-Jan-03	16-Mar-17	18-Jul-18	"UCSF Comprehensive Cancer Center, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00052715
937	NCT00005826	Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: rubitecan		European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	17	Other	Interventional	Primary Purpose: Treatment	EORTC-16996G	Mar-00	Sep-00		18-Jun-04		24-Sep-12	"Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France|Centre Eugene Marquis, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Azienda Ospedaliera di Padova, Padua, Italy|Academisch Ziekenhuis der Vrije Universiteit, Amsterdam, Netherlands|Hospital Universitario 12 de Octubre, Madrid, Spain|Ospedale San Giovanni, Bellinzona, Switzerland|Clinique De Genolier, Genolier, Switzerland"		https://ClinicalTrials.gov/show/NCT00005826
938	NCT00486603	"Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: hydroxychloroquine|Drug: temozolomide|Other: pharmacological study|Radiation: Radiation	(Phase I) Maximum Tolerated Dose (MTD) of Hydroxychloroquine (HCQ)|(Phase I) Number of Participants Who Experienced Dose Limiting Toxicity (DLT)|(Phase II) Overall Survival|(Phase II) Number of Participants With Grade 3 and 4 Toxicity|Pharmocodynamics as Determined by Number of Participants With Autophagy Inhibition|Pharmocodynamics as Determined by Number of Participants With Autophagy Inhibition in Relation to Maximal Concentration (Cmax) of HCQ|Pharmacokinetics (PK) of Hydroxychloroquine as Measured by Lag Time (Tlag)|PK of Hydroxychloroquine as Measured by Oral Clearance (Liters/Hour) From Central Compartment (CL/F)|PK of Hydroxychloroquine as Measured by Volume of Distribution of Central Compartment (V/F)|PK of Hydroxychloroquine as Measured by Distribution Volume of Peripheral Compartment (V2/F)|PK of Hydroxychloroquine as Measured by First-order Absorption Rate Constant (Ka)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	92	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTT-0603|U01CA062475|ABTC-0603|CDR0000549734|NA_00012420	29-Oct-07	Jun-13	Jan-14	14-Jun-07	10-Jul-19	10-Jul-19	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00486603
939	NCT00004073	Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: suramin|Radiation: radiation therapy		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	54	Other|NIH	Interventional	Primary Purpose: Treatment	NABTT-9808 CDR0000067281|U01CA062475|P30CA006973|NABTT-9808|JHOC-NABTT-9808	Dec-99	May-03	Jun-04	20-May-04		3-May-12	"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004073
940	NCT03409549	Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma		Unknown status	No Results Available	"Tumor, Brain"	Radiation: Fluciclovine PET/CT	Measurment od tumour volumes following scans	The Leeds Teaching Hospitals NHS Trust	All	"18 Years to 100 Years   (Adult, Older Adult)"		12	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	RD17/101925	1-Jun-19	31-Oct-20	31-Oct-20	24-Jan-18		6-Aug-19	"Department of Nuclear Medicine, St James's University Hospitals, Leeds, United Kingdom"		https://ClinicalTrials.gov/show/NCT03409549
941	NCT00482677	Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: temozolomide|Genetic: DNA methylation analysis|Procedure: quality-of-life assessment|Radiation: Radiation	Overall Survival|Progression-free Survival|Adverse Events|Methylation Status of the O6-methylguanine-DNA Methyltransferase Promoter	Canadian Cancer Trials Group|European Organisation for Research and Treatment of Cancer - EORTC|Trans Tasman Radiation Oncology Group	All	65 Years to 120 Years   (Older Adult)	Phase 3	562	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CE6|CAN-NCIC-CE6|EORTC-26062-22061|TROG 08.02|SPRI-CAN-NCIC-CE.6|CDR0000547163	1-May-07	1-Mar-16	10-Aug-16	5-Jun-07	23-Jan-18	9-Apr-20	"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|BCCA - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Odette Cancer Centre, Toronto, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University - Dept. Oncology, Montreal, Quebec, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, Canada|Klinikum Der J.W. Goethe Universitaet, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Hiroshima University Hospital, Hiroshima, Japan|Maastro - Maastricht Radiation Oncology, Maastricht, Netherlands"		https://ClinicalTrials.gov/show/NCT00482677
942	NCT00010036	Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carboplatin|Drug: irinotecan hydrochloride|Radiation: radiation therapy		NYU Langone Health|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068435|P30CA016087|NYU-9902|P-UPJOHN-986475197|NCI-G00-1909	May-99	Oct-01		4-Sep-03		28-Mar-11	"NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00010036
943	NCT00004015	Boron Neutron Capture Therapy Following Surgery in Treating Patients With Glioblastoma Multiforme Removed During Surgery		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: sodium borocaptate|Procedure: adjuvant therapy	Acute toxicity as measured by NCIC-Common Toxicity Criteria up to 30 days after the first BSH administration|Late toxicity as measured by RTOC and EORTC late radiation morbidity scale from 90 days after completion of irradiation treatment until death|Overall survival as measured by Logrank until death	European Organisation for Research and Treatment of Cancer - EORTC	All	"50 Years and older   (Adult, Older Adult)"	Phase 1	36	Other	Interventional	Primary Purpose: Treatment	EORTC-11961	Jun-02	Jul-03		27-Jan-03		18-Jul-12	"Karl-Franzens-University Graz, Graz, Austria|Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hopital Pasteur, Nice, France|Universitaetsklinikum Essen, Essen, Germany|Klinikum der Universitaet Muenchen - Grosshadern Campus, Munich, Germany|Ospedale Santa Chiara Pisa, Pisa, Italy|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|EC Joint Research Centre - Institute for Energy, Petten, Netherlands"		https://ClinicalTrials.gov/show/NCT00004015
944	NCT00003751	"Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: penicillamine|Radiation: radiation therapy		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other|NIH	Interventional	Primary Purpose: Treatment	NABTT-9704 CDR0000066872|U01CA062475|NABTT-9704|JHOC-NABTT-9704	Mar-99	Jun-04	Jul-05	18-Aug-04		3-May-12	"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003751
945	NCT03501134	Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields	ACTION	Completed	No Results Available	Malignant Glioma	Device: NovoTTF	"Change in physical activity between baseline and week 24|Change in quality of life between baseline and week 24|Change in sleep quality between baseline and week 24|Change in patient's mood state between baseline and week 24|Change in functional capacity between baseline and week 24|Change from baseline in average daily number of steps taken at 8, 16, and 24 (±3) weeks"	Duke University|NovoCure Ltd.	All	"18 Years and older   (Adult, Older Adult)"		20	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00088890	8-Aug-18	3-Jun-21	3-Jun-21	18-Apr-18		9-Jun-21	"The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03501134
946	NCT00253448	Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme		Completed	Has Results	Brain and Central Nervous System Tumors	Radiation: radiation therapy|Radiation: stereotactic radiosurgery	Overall Survival After Treatment	Case Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	35	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CWRU1302|P30CA043703|CASE-CWRU-1302	Dec-02	Dec-09	Jul-11	15-Nov-05	26-Jul-11	29-Aug-11	"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Southwest General Health Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00253448
947	NCT00003464	Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Radiation: radiation therapy		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Other|NIH	Interventional	Primary Purpose: Treatment	1171|DUMC-1171-01-6R4|DUMC-1016-97-7|DUMC-1056-98-7R1|DUMC-1058-98-7R1|DUMC-1171-00-6R3|DUMC-1231-99-7R2|DUMC-97081|NCI-G98-1465|CDR0000066498	Sep-97		Aug-03	20-Aug-03		20-Jun-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00003464
948	NCT00814593	Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Biological: lymphokine-activated killer cells|Drug: polifeprosan 20 with carmustine implant	Overall survival|Rate of significant surgical wound infection (grade 3 or 4)|Rate of grade 3 or 4 non-infectious wound complications|Toxicity as assessed by NCI CTCAE version 3.0	"Caladrius Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000630437|HOAG-HCC-08-01	Nov-08	Apr-11	Sep-11	25-Dec-08		10-May-19	"Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"		https://ClinicalTrials.gov/show/NCT00814593
949	NCT03225300	Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation		Unknown status	No Results Available	Glioblastoma Multiforme|Chemoradiation	Radiation: Simultaneous integrated boost	Progression Free survival rate|Surgical extent	Taichung Veterans General Hospital	All	"18 Years to 85 Years   (Adult, Older Adult)"	Not Applicable	120	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CE17194B	1-Jan-05	31-Dec-17	31-Dec-17	21-Jul-17		21-Jul-17	"Taichung Veterans General Hospital, Taichung, Taiwan"		https://ClinicalTrials.gov/show/NCT03225300
950	NCT00390403	Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: R-(-)-gossypol acetic acid|Drug: temozolomide|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: protein expression analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: adjuvant therapy|Radiation: radiation therapy	"Maximum tolerated dose|Toxicity|Pharmacokinetic profile of gossypol|Therapeutic activity|Cellular and molecular outcomes (intratumoral expression levels of biomarkers, including Bcl-2 family protein expression [e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, BH3 domain], MGMT gene methylation status, and gene expression array)"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	50	Other|NIH	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	NABTT-0602 CDR0000507451|U01CA062475|NABTT-0602	Feb-07	Jun-09		19-Oct-06		3-May-12	"Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00390403
951	NCT00006460	Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: hyperbaric oxygen|Radiation: radiation therapy		Barrett Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other	Interventional	Primary Purpose: Treatment	CDR0000068256|UCMC-00021401|NCI-V00-1626	Aug-00			3-Feb-04		4-Dec-13	"Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00006460
952	NCT00626483	Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia	REGULATe	Completed	No Results Available	Malignant Neoplasms Brain	Biological: RNA-loaded dendritic cell vaccine|Drug: basiliximab	"Functional capacity of CD4+,CD25+, CD127- T-regulatory cells|Safety of CMV pulsed pp65 DC vaccines|Effect of basilixiumab on pp65 vaccine|Effect of basilixiumab on immune profiles|Progression-free survival (PFS)|Characterize immune cells in recurrent tumors"	Gary Archer Ph.D.|National Cancer Institute (NCI)|Duke University	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	34	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000581|P50CA108786|P30CA014236|SPORE Project 3|CDR0000579683	24-Apr-07	6-Jul-16	6-Jul-16	29-Feb-08		9-Mar-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00626483
953	NCT00006388	Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: tamoxifen citrate|Radiation: radiation therapy	Overall Survival	Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	77	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-BR-0021|CDR0000068266	Dec-00	Oct-03		12-Feb-04		22-Oct-20	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Huntsville Hospital System, Huntsville, Alabama, United States|Comprehensive Cancer Institute of Huntsville, Huntsville, Alabama, United States|MBCCOP - Gulf Coast, Mobile, Alabama, United States|Alabama Oncology, LLC, Montgomery, Alabama, United States|Radiation Oncology Associates of West Alabama, Tuscaloosa, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Mount Diablo Medical Center, Concord, California, United States|Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States|California Cancer Center, Fresno, California, United States|Saint Agnes Cancer Center, Fresno, California, United States|Glendale Memorial Hospital and Health Center, Glendale, California, United States|Sutter Health West Cancer Research Group, Greenbrae, California, United States|University of California San Diego Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Huntington Cancer Center, Pasadena, California, United States|Cancer Care Center, Pomona, California, United States|Radiation Oncology Center - Sacramento, Sacramento, California, United States|Radiation Medical Group, Inc., San Diego, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|O'Connor Hospital, San Jose, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|Memorial Hospital Cancer Center, Colorado Springs, Colorado, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Saint Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Lykes Center for Radiation Therapy, Clearwater, Florida, United States|Halifax Medical Center, Daytona Beach, Florida, United States|Radiation Therapy Associates - Fort Myers, Fort Myers, Florida, United States|University of Florida Health Science Center, Gainesville, Florida, United States|Health First Holmes Regional Medical Center, Melbourne, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Veterans Affairs Medical Center - Miami, Miami, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Radiation Oncology Group, Orange Park, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Gulf Coast Cancer Treatment Center, Panama City, Florida, United States|Sarasota Radiation and Medical Oncology Center, Sarasota, Florida, United States|Tallahassee Memorial Healthcare, Tallahassee, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Medical Center/John B. Amos Community Cancer Center, Columbus, Georgia, United States|InterCommunity Cancer Center at Rome, Rome, Georgia, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Provena St. Joseph Hospital- Regional Cancer Care Center, Elgin, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|St. John's Medical Center, Anderson, Indiana, United States|Bloomington Hospital, Bloomington, Indiana, United States|Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis, Indiana, United States|Clarion Health Partners Inc., Indianapolis, Indiana, United States|Community Hospitals of Indianapolis - Regional Cancer Center, Indianapolis, Indiana, United States|Ball Memorial Hospital, Muncie, Indiana, United States|Wendt Regional Cancer Center of Finley Hospital, Dubuque, Iowa, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Louisville Radiation Oncology, Louisville, Kentucky, United States|Merle M. Mahr Cancer Center, Madisonville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Romagosa Radiation Oncology Center, Lafayette, Louisiana, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Anne Arundel Oncology Center, Annapolis, Maryland, United States|Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States|Harbor Hospital Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Radiation Oncology Affiliates of Maryland, P.A., Baltimore, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Regional Cancer Center, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Marquette General Hospital, Marquette, Michigan, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|St. Mary's Medical Center, Saginaw, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|North Mississippi Medical Center/Cancer Center, Tupelo, Mississippi, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Mallinckrodt Institute of Radiology, Saint Louis, Missouri, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Nebraska Health System, Omaha, Nebraska, United States|Methodist Cancer Center - Omaha, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Elliot Regional Cancer Center, Manchester, New Hampshire, United States|Veterans Affairs Medical Center - East Orange, East Orange, New Jersey, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Trinitas Hospital - Jersey Street Campus, Elizabeth, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|South Jersey Regional Cancer Center, Millville, New Jersey, United States|Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Atlantic City Medical Center, Pomona, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|St. Francis Medical Center, Trenton, New Jersey, United States|Associated Radiologists, P.A., Warren, New Jersey, United States|Saint Joseph Medical Center, Albuquerque, New Mexico, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Finger Lakes Radiation Oncology, P.C., Clifton Springs, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Beth Israel Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Champlain Valley Physicians Hospital Medical Center, Plattsburgh, New York, United States|Vassar Brothers Hospital, Poughkeepsie, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Riverhill Radiation Oncology, Yonkers, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Northeast Medical Center, Concord, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|Catawba Memorial Hospital, Hickory, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Meritcare Roger Maris Cancer Center, Fargo, North Dakota, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Akron City Hospital, Akron, Ohio, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|CCOP - Dayton, Kettering, Ohio, United States|CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States|St. Anthony Hospital, Oklahoma City, Oklahoma, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|St. John Health System, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Hospital Regional Cancer Center, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Fitzgerald Mercy Hospital, Darby, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Pocono Cancer Center, East Stroudsburg, Pennsylvania, United States|Penn State Geisinger Cancer Center, Hershey, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Mercy Hospital Cancer Center - Scranton, Scranton, Pennsylvania, United States|Grand View Hospital, Sellersville, Pennsylvania, United States|Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|York Hospital, York, Pennsylvania, United States|Roger Williams Medical Center/BUSM, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|Julie and Ben Rogers Cancer Institute, Beaumont, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Wilford Hall - 59th Medical Wing, Lackland Air Force Base, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Bayshore Medical Center, Pasadena, Texas, United States|East Texas Medical Center - Cancer Institute, Tyler, Texas, United States|Dixie Regional Medical Center, Saint George, Utah, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|CCOP - Southwestern Vermont Regional Cancer Center, Bennington, Vermont, United States|Vermont Cancer Center, Burlington, Vermont, United States|Martha Jefferson Hospital, Charlottesville, Virginia, United States|Cancer Center at the University of Virginia, Charlottesville, Virginia, United States|RMH Regional Canter Center, Harrisonburg, Virginia, United States|Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States|Bon-Secours - St. Mary's Hospital, Richmond, Virginia, United States|Massey Cancer Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Schiffler Cancer Center, Wheeling, West Virginia, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Foundation, La Crosse, Wisconsin, United States|Southern Wisconsin Radiotherapy Center, Madison, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|St. Joseph's Hospital, Milwaukee, Wisconsin, United States|Columbia Hospital, Milwaukee, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Veterans Affairs Medical Center - Milwaukee (Zablocki), Milwaukee, Wisconsin, United States|Southeastern Wisconsin Regional Cancer Center, Racine, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada|Northeastern Ontario Regional Cancer Centre, Sudbury, Sudbury, Ontario, Canada|Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00006388
954	NCT00099125	"Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irinotecan hydrochloride|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy	Overall survival|Progression-free survival	Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	170	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-0420|CDR0000389229	Nov-04	Oct-06	Nov-13	9-Dec-04		24-Jan-14	"Foundation for Cancer Research and Education, Phoenix, Arizona, United States|Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|Saint Agnes Medical Center, Fresno, California, United States|Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States|Providence Holy Cross Cancer Center, Mission Hills, California, United States|Pomona Valley Hospital Medical Center, Pomona, California, United States|Radiological Associates of Sacramento Medical Group, Inc., Sacramento, California, United States|Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven, Connecticut, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|John B. Amos Community Cancer Center, Columbus, Georgia, United States|Regional Radiation Oncology Center at Rome, Rome, Georgia, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|St. Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Tulane Cancer Center, New Orleans, Louisiana, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Cancer Institute of Cape Girardeau, Cape Girardeau, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, St Louis, Missouri, United States|Methodist Cancer Center at Methodist Hospital - Omaha, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Dartmouth - Hitchcock Concord, Concord, New Hampshire, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, United States|Cooper Cancer Institute, Camden, New Jersey, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Lipson Cancer and Blood Center at Rochester General Hospital, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|John Smith, Jr./Dalton McMichael Cancer Center at Morehead Memorial Hospital, Eden, North Carolina, United States|Wayne Radiation Oncology, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Annie Penn Cancer Center, Reidsville, North Carolina, United States|Akron City Hospital, Akron, Ohio, United States|McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States|Radiation Oncology Center, Alliance, Ohio, United States|Aultman Hospital Cancer Center at Aultman Health Foundation, Canton, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Middletown Regional Hospital, Middletown, Ohio, United States|Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford, Salem, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Cancer Treatment Center, Wooster, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Legacy Mount Hood Medical Center, Glesham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Institute of Oncology at Vilnius University, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Hospital Cancer Center, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|UPMC Cancer Center - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|UPMC McKeesport, McKeesport, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center at Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center at UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|UPMC St. Margaret, Pittsburgh, Pennsylvania, United States|Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|UPMC - Shadyside, Pittsburgh, Pennsylvania, United States|UPMC - Passavant Hospital, Pittsburgh, Pennsylvania, United States|Cancer Center at St. Clair Memorial Hospital, Pittsburgh, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburg, Pennsylvania, United States|Reading Hospital and Medical Center, West Reading, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|Lankenau Cancer Center at Lankenau Hospital, Wynnewood, Pennsylvania, United States|York Cancer Center at Wellspan Health, York, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Cottonwood Hospital Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center - Provo, Provo, Utah, United States|Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Dixie Regional Medical Center, St. George, Utah, United States|Green Mountain Oncology Group, Bennington, Vermont, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|Community Cancer Center at Rutland Regional Medical Center, Rutland, Vermont, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|North Star Lodge Cancer Center, Yakima, Washington, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00099125
955	NCT00082797	High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: leucovorin calcium|Drug: methotrexate	Response rate (complete and partial)|Frequency of toxicity	Eastern Cooperative Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000360834|E1F02	Feb-05	May-07		19-May-04		29-Jan-10	"Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago Westside Hospital, Chicago, Illinois, United States|Mercy Hospital and Medical Center, Chicago, Illinois, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Galesburg Clinic, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Midwest Center for Hematology/Oncology, Joliet, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|Kewanee Hospital, Kewanee, Illinois, United States|North Shore Oncology and Hematology Associates, Limited - Libertyville, Libertyville, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Northwest Medical Specialist, PC, Niles, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Swedish-American Regional Cancer Center, Rockford, Illinois, United States|Hematology Oncology Associates - Skokie, Skokie, Illinois, United States|Hematology/Oncology of the North Shore at Gross Point Medical Center, Skokie, Illinois, United States|Midwest Cancer Research Group, Incorporated, Skokie, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Borgess Medical Center, Kalamazooaa, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Minnesota Oncology Hematology, PA at Maplewood Cancer Center, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Health Services, St. Louis Park, Minnesota, United States|United Hospital, St. Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division, Charleston, West Virginia, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00082797
956	NCT03954691	Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies		Unknown status	No Results Available	Cancer of Head and Neck	Other: brain tumor-immune cells communication	glioblastoma cells	Neuromed IRCCS	All	"Child, Adult, Older Adult"		50	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	RF-2018-12366215	1-Oct-19	1-Apr-20	1-Oct-21	17-May-19		21-May-19	"Cristina Limatola, Pozzilli, Is, Italy|Cristina Limatola, Pozzilli, Italy"		https://ClinicalTrials.gov/show/NCT03954691
957	NCT00006353	Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Radiation: radiation therapy		European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	575	Other	Interventional	Primary Purpose: Treatment	EORTC-26981-22981|EORTC-26981|CAN-NCIC-CE3|EORTC-22981	Jul-00	Mar-02		24-Dec-03		24-Sep-12	"Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Doctor Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Cancer Care Ontario - Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00006353
958	NCT01113463	TPI 287 in Patients With Recurrent Glioblastoma Multiforme		Terminated	Has Results	Brain Cancer	Drug: TPI 287	Progression-Free Survival (PFS) at 6 Months|Number of Participants by Response Criteria	"M.D. Anderson Cancer Center|Cortice Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	17	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0759|NCI-2011-01303	Apr-10	Jun-11	Dec-12	30-Apr-10	31-Oct-16	31-Oct-16	"UT MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01113463
959	NCT00006452	Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: motexafin gadolinium|Radiation: radiation therapy		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	6	Other|NIH	Interventional	Primary Purpose: Treatment	NABTT-9712 CDR0000066986|P30CA006973|NABTT-9712|JHOC-NABTT-9712	10-Apr-02	9-May-03	16-Mar-04	8-Mar-04		27-Jun-18			https://ClinicalTrials.gov/show/NCT00006452
960	NCT00027612	Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: irinotecan hydrochloride|Radiation: radiation therapy	Survival at 52 weeks	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	58	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N997D|NCCTG-N997D|CDR0000069048|NCI-2012-02428|U10CA025224	Jul-02	Oct-06	Jul-09	17-Jun-03		7-Dec-16			https://ClinicalTrials.gov/show/NCT00027612
961	NCT00002545	Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Radiation: low-LET photon therapy		Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	200	Other|NIH	Interventional	Allocation: Randomized|Primary Purpose: Treatment	RTOG-9305|CDR0000063286	Feb-94	Dec-04		19-Jul-04		13-Aug-13	"Veterans Affairs Medical Center - Birmingham, Birmingham, Alabama, United States|University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|Huntsville Hospital System, Huntsville, Alabama, United States|Urology Associates - Mobile AL, Mobile, Alabama, United States|MBCCOP - University of South Alabama, Mobile, Alabama, United States|Alabama Oncology, LLC, Montgomery, Alabama, United States|Radiation Oncology Associates of West Alabama, Tuscallosa, Alabama, United States|Providence Cancer Therapy Center, Anchorage, Alaska, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|Mount Diablo Medical Center, Concord, California, United States|California Cancer Center, Fresno, California, United States|Saint Agnes Cancer Center, Fresno, California, United States|Glendale Memorial Hospital and Health Center, Glendale, California, United States|Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States|Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Beckman Research Institute, City of Hope, Los Angeles, California, United States|Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Cancer Care Center, Pomona, California, United States|Mercy Medical Center - Redding, Redding, California, United States|Radiation Oncology Center - Sacramento, Sacramento, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|O'Connor Hospital, San Jose, California, United States|Santa Cruz Radiation Oncology Medical Group, Inc., Santa Cruz, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Stanford University, Stanford, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|Radiation Oncology Center - Walnut Creek, Walnut Creek, California, United States|Memorial Hospital Cancer Center, Colorado Springs, Colorado, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Whittingham Cancer Center, Norwalk, Connecticut, United States|CCOP - Christiana Care Health Services, Wilmington, Delaware, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Lykes Center for Radiation Therapy, Clearwater, Florida, United States|Halifax Medical Center, Daytona Beach, Florida, United States|Radiation Therapy Associates - Fort Myers, Fort Myers, Florida, United States|University of Florida Health Science Center, Gainesville, Florida, United States|Health First Holmes Regional Medical Center, Melbourne, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Radiation Oncology Group, Orange Park, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Gulf Coast Cancer Treatment Center, Panama City, Florida, United States|West Florida Cancer Institute - Pensacola, Pensacola, Florida, United States|Bayfront Medical Center, Saint Petersburg, Florida, United States|Sarasota Radiation and Medical Oncology Center, Sarasota, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Medical Center/John B. Amos Community Cancer Center, Columbus, Georgia, United States|InterCommunity Cancer Center at Rome, Rome, Georgia, United States|South Georgia Medical Center, Valdosta, Georgia, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|CCOP - Central Illinois, Springfield, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. John's Medical Center, Anderson, Indiana, United States|Clarion Health Partners Inc., Indianapolis, Indiana, United States|Community Hospitals of Indianapolis - Regional Cancer Center, Indianapolis, Indiana, United States|Ball Memorial Hospital, Muncie, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|St. Joseph's Radiation Oncology Center, South Bend, Indiana, United States|Wendt Regional Cancer Center of Finley Hospital, Dubuque, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Medical Center at Bowling Green, Bowling Green, Kentucky, United States|Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Louisville Radiation Oncology, Louisville, Kentucky, United States|Merle M. Mahr Cancer Center, Madisonville, Kentucky, United States|Western Baptist Hospital, Paducah, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Romagosa Radiation Oncology Center, Lafayette, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Anne Arundel Oncology Center, Annapolis, Maryland, United States|Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States|Harbor Hospital Center, Baltimore, Maryland, United States|Radiation Oncology Affiliates of Maryland, P.A., Baltimore, Maryland, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Joint Center for Radiation Therapy, Boston, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Regional Cancer Center, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Marquette General Hospital, Marquette, Michigan, United States|MidMichigan Regional Medical Center, Midland, Michigan, United States|St. Mary's Medical Center, Saginaw, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Veterans Affairs Medical Center - Saint Louis, Saint Louis, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Mallinckrodt Institute of Radiology, Saint Louis, Missouri, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Methodist Cancer Center - Omaha, Omaha, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Elliot Regional Cancer Center, Manchester, New Hampshire, United States|Veterans Affairs Medical Center - East Orange, East Orange, New Jersey, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Trinitas Hosptial - Jersey Street Campus, Elizabeth, New Jersey, United States|South Jersey Hospital - Millville, Millville, New Jersey, United States|Fox Chase Cancer Center at Virtua-Memorial Hospital Burlington County, Mount Holly, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|St. Francis Medical Center, Trenton, New Jersey, United States|Saint Joseph Medical Center, Albuquerque, New Mexico, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|Veterans Affairs Medical Center - Albany, Albany, New York, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Finger Lakes Radiation Oncology, P.C., Clifton Springs, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Beth Israel Medical Center, New York, New York, United States|Kaplan Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Champlain Valley Physicians Hospital Medical Center, Plattsburgh, New York, United States|Vassar Brothers Hospital, Poughkeepsie, New York, United States|Genesee Hospital - Rochester, Rochester, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Northeast Medical Center, Concord, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|Catawba Memorial Hospital, Hickory, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Meritcare Roger Maris Cancer Center, Fargo, North Dakota, United States|UNI-MED Medical Center, Minot, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Akron City Hospital, Akron, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Kettering, Ohio, United States|CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States|St. John Medical Center, Tulsa, Oklahoma, United States|Samaritan Regional Cancer Center, Corvallis, Oregon, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Hospital Regional Cancer Center, Bethlehem, Pennsylvania, United States|Penn State Geisinger Medical Center, Danville, Pennsylvania, United States|Mercy Catholic Medical Center, Mercy Fitzgerald Divison, Darby, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Penn State Geisinger Cancer Center, Hershey, Pennsylvania, United States|Allegheny University Hospitals- Hahnemann, Philadelphia, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Mercy Hospital Cancer Center - Scranton, Scranton, Pennsylvania, United States|Grand View Hospital, Sellersville, Pennsylvania, United States|Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|York Hospital, York, Pennsylvania, United States|Roger Williams Medical Center/BUSM, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Baptist Regional Cancer Center - Knoxville, Knoxville, Tennessee, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|Julie and Ben Rogers Cancer Institute, Beaumont, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Wilford Hall - 59th Medical Wing, Lackland Air Force Base, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Bayshore Medical Center, Pasadena, Texas, United States|East Texas Medical Center - Cancer Institute, Tyler, Texas, United States|Dixie Regional Medical Center, Saint George, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|CCOP - Southwestern Vermont Regional Cancer Center, Bennington, Vermont, United States|Vermont Cancer Center, Burlington, Vermont, United States|Green Mountain Oncology Group, Rutland, Vermont, United States|Veterans Affairs Medical Center - White River Junction, White River Junction, Vermont, United States|Martha Jefferson Hospital, Charlottesville, Virginia, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|Virginia Baptist Hospital, Lynchburg, Virginia, United States|Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States|Massey Cancer Center, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Schiffler Oncology Center, Wheeling, West Virginia, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Foundation, La Crosse, Wisconsin, United States|Veterans Affairs Medical Center - Madison, Madison, Wisconsin, United States|Southern Wisconsin Radiotherapy Center, Madison, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|St. Joseph's Hospital, Milwaukee, Wisconsin, United States|Columbia Hospital, Milwaukee, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Veterans Affairs Medical Center - Milwaukee (Zablocki), Milwaukee, Wisconsin, United States|Southeastern Wisconsin Regional Cancer Center, Racine, Wisconsin, United States|Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada|Doctor Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Centre - Civic Campus, Ottawa, Ontario, Canada|Northeastern Ontario Regional Cancer Centre, Sudbury, Sudbury, Ontario, Canada|Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|McGill University Department of Oncology, Montreal, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00002545
962	NCT00003417	Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Radiation: radiation therapy		Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	40	Other|NIH	Interventional	Primary Purpose: Treatment	RTOG-9803|CDR0000066432	Sep-98	May-04		27-Jan-03		17-Nov-15	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Comprehensive Cancer Institute of Huntsville, Huntsville, Alabama, United States|Huntsville Hospital System, Huntsville, Alabama, United States|MBCCOP - Gulf Coast, Mobile, Alabama, United States|Alabama Oncology, LLC, Montgomery, Alabama, United States|DCH Cancer Treatment Center, Tuscaloosa, Alabama, United States|Foundation for Cancer Research and Education, Phoenix, Arizona, United States|Mount Diablo Medical Center, Concord, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Saint Agnes Cancer Center, Fresno, California, United States|California Cancer Center, Fresno, California, United States|Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Huntington Cancer Center, Pasadena, California, United States|Robert and Beverly Lewis Family Cancer Care Center, Pomona, California, United States|Radiation Oncology Center - Sacramento, Sacramento, California, United States|Radiation Medical Group, Incorporated, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|O'Connor Hospital, San Jose, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|Memorial Hospital Cancer Center, Colorado Springs, Colorado, United States|University of Colorado Cancer Center, Denver, Colorado, United States|CCOP - Colorado Cancer Research Program, Incorporated, Denver, Colorado, United States|Saint Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|University of Florida Health Science Center, Gainesville, Florida, United States|Florida Radiation Oncology Group, Jacksonville, Florida, United States|Holmes Regional Medical Center, Melbourne, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Veterans Affairs Medical Center - Miami, Miami, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Gulf Coast Cancer Treatment Center, Panama City, Florida, United States|Sarasota Radiation and Medical Oncology Center, Sarasota, Florida, United States|Tallahassee Memorial Healthcare, Tallahassee, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Medical Center/John B. Amos Community Cancer Center, Columbus, Georgia, United States|Regional Radiation Oncology Center at Rome, Rome, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|St. John's Medical Center, Anderson, Indiana, United States|Bloomington Hospital, Bloomington, Indiana, United States|Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis, Indiana, United States|Clarian Health Partners Inc., Indianapolis, Indiana, United States|Community Regional Cancer Care, Indianapolis, Indiana, United States|Ball Memorial Hospital, Muncie, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Wendt Regional Cancer Center of Finley Hospital, Dubuque, Iowa, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Cancer Center at Lexington Clinic, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Louisville Radiation Oncology, Louisville, Kentucky, United States|Merle M. Mahr Cancer Center, Madisonville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Anne Arundel Oncology Center, Annapolis, Maryland, United States|Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States|Harbor Hospital Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Regional Cancer Center, Flint, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Marquette General Hospital, Marquette, Michigan, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Mallinckrodt Institute of Radiology, Saint Louis, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Methodist Hospital Cancer Center - Omaha, Omaha, Nebraska, United States|Nebraska Health System, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Elliot Regional Cancer Center, Manchester, New Hampshire, United States|Veterans Affairs Medical Center - East Orange, East Orange, New Jersey, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Trinitas Hospital - Jersey Street Campus, Elizabeth, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|South Jersey Regional Cancer Center, Millville, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital, Mount Holly, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Atlantic City Medical Center, Pomona, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|St. Francis Medical Center, Trenton, New Jersey, United States|Associated Radiologists, P.A., Warren, New Jersey, United States|Radiation Oncology Associates of Albuquerque, Albuquerque, New Mexico, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Finger Lakes Radiation Oncology Center, Clifton Springs, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Champlain Valley Physicians Hospital Medical Center, Plattsburgh, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|Riverhill Radiation Oncology, Yonkers, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Northeast Medical Center, Concord, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Akron City Hospital, Akron, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anthony Hospital, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|St. John Health System, Tulsa, Oklahoma, United States|CCOP - Oklahoma, Tulsa, Oklahoma, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Hospital Cancer Center, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Mercy Fitzgerald Hospital, Darby, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Pocono Cancer Center, East Stroudsburg, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Mercy Hospital Cancer Center - Scranton, Scranton, Pennsylvania, United States|Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States|York Cancer Center, York, Pennsylvania, United States|Roger Williams Medical Center/BUSM, Providence, Rhode Island, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Wilford Hall Medical Center, Lackland Air Force Base, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Bayshore Medical Center, Pasadena, Texas, United States|Dixie Regional Medical Center, Saint George, Utah, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Latter Day Saints Hospital, Salt Lake City, Utah, United States|Green Mountain Oncology Group, Burlington, Vermont, United States|Vermont Cancer Center, Burlington, Vermont, United States|Cancer Center at the University of Virginia, Charlottesville, Virginia, United States|RMH Regional Cancer Center, Harrisonburg, Virginia, United States|Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States|Bon Secours - St. Mary's Hospital, Richmond, Virginia, United States|Massey Cancer Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Schiffler Cancer Center, Wheeling, West Virginia, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Foundation, La Crosse, Wisconsin, United States|Southern Wisconsin Radiotherapy Center, Madison, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|Columbia Hospital, Milwaukee, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Veterans Affairs Medical Center - Milwaukee (Zablocki), Milwaukee, Wisconsin, United States|All Saints Cancer Center, Racine, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|Northeastern Ontario Regional Cancer Centre, Sudbury, Sudbury, Ontario, Canada|Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00003417
963	NCT00006355	Pyrazoloacridine Followed by Radiation Therapy in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: pyrazoloacridine|Procedure: adjuvant therapy|Radiation: radiation therapy		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	NABTT-9804 CDR0000068223|U01CA062475|P30CA006973|NABTT-9804|JHOC-NABTT-9804	May-00	Oct-04	Oct-06	27-Jan-03		3-May-12	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00006355
964	NCT00046878	Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: carmustine		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	3318|DUMC-3318-01-12|NCI-5632|CDR0000256332			Aug-02	11-Aug-03		28-Mar-13			https://ClinicalTrials.gov/show/NCT00046878
965	NCT03650257	A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96		Recruiting	No Results Available	Glioma of Brain	Biological: gp96|Drug: Temozolomide|Radiation: radiotherapy	1-year survival rate|Progression-free survival rate|Progression-free survival|Overall survival|changes in antigen specific T cells|Number of participants with adverse events related to gp96 immunotherapy	"Cure&Sure Biotech Co., LTD|Beijing Tiantan Hospital|Shenzhen Second People's Hospital"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	150	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CS-TT-G-02	21-Aug-19	20-Aug-21	20-Aug-24	28-Aug-18		12-Mar-20	"Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT03650257
966	NCT00003996	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: chemotherapy|Drug: cisplatin|Drug: etoposide|Radiation: radiation therapy	overall survival|quality of life	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	93	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCCTG-987252|NCI-2012-02308|CDR0000067206	May-99	Aug-01	May-08	17-Jun-04		7-Dec-16	"CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States|Altru Health Systems, Grand Forks, North Dakota, United States|CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States|CCOP - Geisinger Clinical and Medical Center, Danville, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States"		https://ClinicalTrials.gov/show/NCT00003996
967	NCT00003409	Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: motexafin gadolinium|Radiation: radiation therapy		Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000066421|UCLA-HSPC-970904203|COOPER-RP-97-126|LAC-USC-6G971|UCD-RW-98-01|UCLA-HSPC-970904201|UCLA-HSPC-970904202|NCI-T97-0108	Jul-98			2-Dec-03		9-Feb-09	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|University of California Davis Cancer Center, Sacramento, California, United States"		https://ClinicalTrials.gov/show/NCT00003409
968	NCT00006386	Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Radiation: radiation therapy|Radiation: stereotactic radiosurgery	Overall Survival|Progression-free Survival	Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"Child, Adult, Older Adult"	Phase 2	80	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-BR-0023|CDR0000068264	Mar-01	Nov-04	Feb-09	27-Jan-03		22-Oct-20	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Comprehensive Cancer Institute of Huntsville, Huntsville, Alabama, United States|Huntsville Hospital System, Huntsville, Alabama, United States|MBCCOP - Gulf Coast, Mobile, Alabama, United States|Alabama Oncology, LLC, Montgomery, Alabama, United States|DCH Cancer Treatment Center, Tuscaloosa, Alabama, United States|Foundation for Cancer Research and Education, Phoenix, Arizona, United States|Mount Diablo Medical Center, Concord, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Saint Agnes Cancer Center, Fresno, California, United States|California Cancer Center, Fresno, California, United States|Sutter Health West Cancer Research Group, Greenbrae, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Veterans Affairs Medical Center - Long Beach, Long Beach, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Huntington Cancer Center, Pasadena, California, United States|Robert and Beverly Lewis Family Cancer Care Center, Pomona, California, United States|Radiation Oncology Center - Sacramento, Sacramento, California, United States|Radiation Medical Group, Incorporated, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|O'Connor Hospital, San Jose, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|Memorial Hospital Cancer Center, Colorado Springs, Colorado, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Saint Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|Hospital of St. Raphael, New Haven, Connecticut, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|University of Florida Health Science Center, Gainesville, Florida, United States|Florida Radiation Oncology Group, Jacksonville, Florida, United States|Health First Holmes Regional Medical Center, Melbourne, Florida, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States|Veterans Affairs Medical Center - Miami, Miami, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Bay Medical Center, Panama City, Florida, United States|Gulf Coast Cancer Treatment Center, Panama City, Florida, United States|Sarasota Radiation and Medical Oncology Center, Sarasota, Florida, United States|Tallahassee Memorial Healthcare, Tallahassee, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Medical Center/John B. Amos Community Cancer Center, Columbus, Georgia, United States|Regional Radiation Oncology Center at Rome, Rome, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|St. John's Medical Center, Anderson, Indiana, United States|Bloomington Hospital, Bloomington, Indiana, United States|Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis, Indiana, United States|Clarian Health Partners Inc., Indianapolis, Indiana, United States|Regional Cancer Center, Indianapolis, Indiana, United States|Ball Memorial Hospital, Muncie, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Wendt Regional Cancer Center of Finley Hospital, Dubuque, Iowa, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Cancer Center at Lexington Clinic, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Louisville Radiation Oncology, Louisville, Kentucky, United States|Merle M. Mahr Cancer Center, Madisonville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Anne Arundel Oncology Center, Annapolis, Maryland, United States|Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States|Harbor Hospital Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Peninsula Regional Medical Center, Salisbury, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|McLaren Regional Cancer Center, Flint, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Marquette General Hospital, Marquette, Michigan, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Mallinckrodt Institute of Radiology, Saint Louis, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Methodist Hospital Cancer Center - Omaha, Omaha, Nebraska, United States|Nebraska Health System, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Elliot Regional Cancer Center, Manchester, New Hampshire, United States|Veterans Affairs Medical Center - East Orange, East Orange, New Jersey, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Trinitas Hospital - Jersey Street Campus, Elizabeth, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|South Jersey Regional Cancer Center, Millville, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital, Mount Holly, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Atlantic City Medical Center, Pomona, New Jersey, United States|Valley Hospital, Ridgewood, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|St. Francis Medical Center, Trenton, New Jersey, United States|Associated Radiologists, P.A., Warren, New Jersey, United States|Radiation Oncology Associates of Albuquerque, Albuquerque, New Mexico, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Finger Lakes Radiation Oncology Center, Clifton Springs, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Champlain Valley Physicians Hospital Medical Center, Plattsburgh, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States|Riverhill Radiation Oncology, Yonkers, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Northeast Medical Center, Concord, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|Akron City Hospital, Akron, Ohio, United States|Christ Hospital, Cincinnati, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anthony Hospital, Oklahoma City, Oklahoma, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|St. John Health System, Tulsa, Oklahoma, United States|CCOP - Oklahoma, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Hospital Cancer Center, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Mercy Fitzgerald Hospital, Darby, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Pocono Cancer Center, East Stroudsburg, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Mercy Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Mercy Hospital Cancer Center - Scranton, Scranton, Pennsylvania, United States|Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States|York Cancer Center, York, Pennsylvania, United States|Roger Williams Medical Center/BUSM, Providence, Rhode Island, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Wilford Hall Medical Center, Lackland Air Force Base, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Bayshore Medical Center, Pasadena, Texas, United States|Dixie Regional Medical Center, Saint George, Utah, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Latter Day Saints Hospital, Salt Lake City, Utah, United States|Vermont Cancer Center, Burlington, Vermont, United States|Cancer Center at the University of Virginia, Charlottesville, Virginia, United States|RMH Regional Cancer Center, Harrisonburg, Virginia, United States|Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States|Bon Secours - St. Mary's Hospital, Richmond, Virginia, United States|Massey Cancer Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Schiffler Cancer Center, Wheeling, West Virginia, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Foundation, La Crosse, Wisconsin, United States|Southern Wisconsin Radiotherapy Center, Madison, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|Columbia Hospital, Milwaukee, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Veterans Affairs Medical Center - Milwaukee (Zablocki), Milwaukee, Wisconsin, United States|All Saints Cancer Center, Racine, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Newfoundland Cancer Treatment and Research Foundation, St. Johns, Newfoundland and Labrador, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Cancer Care Ontario-Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|Northeastern Ontario Regional Cancer Centre, Sudbury, Sudbury, Ontario, Canada|Northwestern Ontario Regional Cancer Centre, Thunder Bay, Thunder Bay, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00006386
969	NCT01390571	Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: olaparib|Drug: temozolomide|Genetic: gene expression analysis|Genetic: protein expression analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: diffusion-weighted magnetic resonance imaging|Procedure: dynamic contrast-enhanced magnetic resonance imaging|Procedure: therapeutic conventional surgery	Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study|Maximum-tolerated dose of olaparib in combination with temozolomide (stage 2)|Toxicity profile and dose-limiting toxicity as assessed by NCI CTCAE Version 4.02 (stage 2)|Measurement of blood-brain barrier (BBB) disruption and permeability biomarkers by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) (stage 1 and stage 2 MTD expansion cohort)|Progression-free survival at 6 months post-surgery as assessed by the Response Assessment in Neuro-Oncology Working Group (RANO) criteria from conventional MRI and clinical assessment (stage 2)	Cancer Research UK	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	34	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000702605|CRUK-CR0901-11|EUDRACT-2010-018615-15	Jul-11	20-Jun-17	20-Jun-17	11-Jul-11		5-Feb-18	"Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Royal Marsden Hospital, Sutton, England, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Western General Hospital, Edinburgh, United Kingdom"		https://ClinicalTrials.gov/show/NCT01390571
970	NCT00005813	Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: bispecific antibody MDX447|Biological: lymphokine-activated killer cells|Procedure: conventional surgery		Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	D9705|P30CA023108|NCI-G00-1783	Mar-97	Jan-03	Jan-03	20-May-03		27-Oct-11	"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States"		https://ClinicalTrials.gov/show/NCT00005813
971	NCT00053183	Surgery Followed by Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Procedure: conventional surgery|Radiation: brachytherapy|Radiation: radiation therapy		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000269300|NABTT-2105|JHOC-NABTT-2105	Oct-03			28-Jan-03		9-Feb-09	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00053183
972	NCT00906516	Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme		Unknown status	No Results Available	Brain Tumors	Drug: Neuradiab in combination with Bevacizumab (Avastin)	"The safety of Neuradiab® when followed by Avastin therapy will be assessed based on Investigator reported symptomatic toxicity findings on physical exam, and Adverse Events.|Overall survival (OS). Data will be reported based on a dataset of 60 patients.|Time to progression (TTP). Data will be reported based on a dataset of 60 patients."	Bradmer Pharmaceuticals Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BRAD-302	May-09	Sep-10	Dec-10	21-May-09		21-May-09	"The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00906516
973	NCT00022256	Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: motexafin gadolinium|Radiation: radiation therapy		Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	MSKCC-01051|CDR0000068799|PCI-PCYC-0206|NCI-G01-1999	Apr-01	Apr-03	Apr-03	5-Apr-04		18-Jun-13	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00022256
974	NCT00424060	Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: sagopilone|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study	Treatment success (complete or partial response or a progression-free survival at 6 months)|Objective response|Duration of response|Toxicity|Progression-free survival at 6 months|Overall survival at 6 and 12 months	European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	38	Other	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26061|EUDRACT-2006-001659-37|SPRI-EORTC-26061	Dec-06	Aug-07		18-Jan-07		24-Sep-12	"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00424060
975	NCT00032097	Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: motexafin gadolinium|Radiation: radiation therapy		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000069257|NABTT-2116|JHOC-NABTT-2116	Apr-02			27-Jan-03		9-Feb-09	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00032097
976	NCT00671801	Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I		Terminated	No Results Available	Malignant Gliomas	Drug: Irinotecan|Drug: Lenalidomide	Maximum Tolerated Dose (MTD) of Lenalidomide and Irinotecan	M.D. Anderson Cancer Center|Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2006-0472|NCI-2012-01684	29-Apr-08	Feb-14	Feb-14	5-May-08		13-Nov-18	"UT MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00671801
977	NCT02122822	Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96		Completed	No Results Available	Glioma	Biological: gp96	blood count|blood chemistries|electrocardiogram|progression-free survival rate of six month|tumor control rate|progress free survive|overall survive|quality of life|changes in antigen specific T cells	"Cure&Sure Biotech Co., LTD|Beijing Tiantan Hospital"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	20	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CS-TT-G-01	Jul-13	Jul-15	May-17	25-Apr-14		17-Nov-17	"Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China"		https://ClinicalTrials.gov/show/NCT02122822
978	NCT00004200	Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: prinomastat|Drug: temozolomide		Pfizer	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 2		Industry	Interventional	Allocation: Randomized|Primary Purpose: Treatment	AG-3340-019|CDR0000067443|MCC-12151|MDA-DM-99254|MSKCC-99116	Oct-99	Jan-02		25-May-04		8-Aug-12	"Agouron Pharmaceuticals, Inc., La Jolla, California, United States"		https://ClinicalTrials.gov/show/NCT00004200
979	NCT04165941	Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma	DRI	Recruiting	No Results Available	Brain Tumor Adult	Biological: DRI cell therapy	"Primary: Highest safe dose frequency or maximally planned dose, if no dose-limiting toxicity observed.|Time to progression|Overall survival|Assessment of biological activity"	University of Alabama at Birmingham|In8bio Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UAB 1773	11-Feb-20	Jan-22	Jan-23	18-Nov-19		19-Apr-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT04165941
980	NCT00028678	Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: dalteparin|Radiation: radiation therapy		Eastern Cooperative Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000069119|E1F01	May-02	Jul-06		6-Feb-03		28-Jan-10	"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|CCOP - Oklahoma, Tulsa, Oklahoma, United States|Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00028678
981	NCT00621686	Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	Has Results	Brain and Central Nervous System Tumors	Biological: bevacizumab|Drug: sorafenib tosylate	6-month Progression-free Survival|Time to Progression|Overall Survival	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	54	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCCTG-N0776|NCI-2009-00832|CDR0000587614	Sep-08	Oct-10	19-Feb-14	22-Feb-08	4-Jan-17	8-May-18	"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Cancer Care Associates, Fresno, California, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|McCreery Cancer Center at Ottumwa Regional, Ottumwa, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Drs. Carrol, Sheth, Raghavan, Louisville, Kentucky, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Haematology-Oncology Associates of Ohio and Michigan, PC, Lambertville, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Alexandria, Minnesota, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls Medical Group, PA, Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|North Coast Cancer Care - Clyde, Clyde, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Luke's Hospital, Maumee, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Fisher-Titus Medical Center, Norwalk, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Precision Radiotherapy at University Pointe, West Chester, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Legacy Good Samaritan Hospital & Comprehensive Cancer Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|Adventist Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Northwest Cancer Specialists at Rose Quarter Cancer Center, Portland, Oregon, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Luther Midlelfort Hospital, Eau Claire, Wisconsin, United States|Midelfort Clinic - Luther, Eau Claire, Wisconsin, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT00621686
982	NCT00006916	Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme		Terminated	Has Results	Brain and Central Nervous System Tumors	Biological: bleomycin|Device: Ommaya reservoir|Radiation: radiation therapy	Overall Survival	Radiation Therapy Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	19	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-BR-0013|CDR0000068343	Jun-01	Dec-05	Dec-05	27-Jan-03	3-Feb-14	26-Oct-20	"Foundation for Cancer Research and Education, Phoenix, Arizona, United States|Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha, Omaha, Nebraska, United States|South Jersey Regional Cancer Center, Millville, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital, Mount Holly, New Jersey, United States|Cancer Treatment Center, Wooster, Ohio, United States|St. John Health System, Tulsa, Oklahoma, United States|Cottonwood Hospital Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center - Provo, Provo, Utah, United States|Dixie Regional Medical Center, Saint George, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States|Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00006916
983	NCT03997617	Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.		Recruiting	No Results Available	Oncology	Diagnostic Test: Personalized Functional Profiling	"Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP|Quantity of cells needed for the PFP analysis|Duration of the PFP process for one specific patient|Number of drugs recommended by using the PFP approach|Number of patients for which the treatment recommendation issued by PFP were followed by the investigator"	Luxembourg Institute of Health|Integrated Biobank of Luxembourg|Laboratoire National de Santé (Luxembourg)|Centre Hospitalier du Luxembourg|Hopitaux Robert Schuman (Luxembourg)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PFP-001	11-Mar-19	1-Dec-21	30-Mar-22	25-Jun-19		15-Jan-21	"Centre hospitalier de Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schmuan, Luxembourg, Luxembourg"		https://ClinicalTrials.gov/show/NCT03997617
984	NCT01833273	Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA	DESSTINI_A	Completed	No Results Available	Glioblastoma Multiform (Grade IV Astrocytoma)	Drug: PolyMVA	The Number and Severity of Adverse events as a Measure of Safety and Tolerability	Stony Brook University|Garnett McKeen Laboratory Inc.	All	"18 Years to 79 Years   (Adult, Older Adult)"	Phase 1	13	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DESSTINI_A	Jul-10	Oct-13	Jun-15	16-Apr-13		3-Jun-16	"Stony Brook University Medical Center, Stony Brook, New York, United States"		https://ClinicalTrials.gov/show/NCT01833273
985	NCT02590263	Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma		Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme	Radiation: Whole Brain Radiation|Drug: Temozolomide|Drug: ABT-414	Percentage of participants with adverse events|Number of Dose Limiting Toxicities|Progression-free survival|Area under the plasma concentration-time curve (AUC) of ABT-414|Maximum plasma concentration (Cmax) of ABT-414|Objective Response Rate|Overall Survival|Duration of Overall Response	AbbVie	All	"20 Years to 99 Years   (Adult, Older Adult)"	Phase 1|Phase 2	53	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M13-714	24-Aug-15	27-Aug-20	27-Aug-20	29-Oct-15		3-Sep-20	"Nagoya University Hospital /ID# 138559, Nagoya-shi, Aichi, Japan|Hiroshima University Hospital /ID# 139399, Hiroshima-shi, Hiroshima, Japan|Hokkaido University Hospital /ID# 150589, Sapporo-shi, Hokkaido, Japan|University of Tsukuba Hospital /ID# 140433, Tsukuba-shi, Ibaraki, Japan|Iwate Medical University Hospital /ID# 149145, Shiwa-gun, Iwate, Japan|Kitasato University Hospital /ID# 148493, Sagamihara-shi, Kanagawa, Japan|Kumamoto University Hospital /ID# 138558, Kumamoto-shi, Kumamoto, Japan|Kyoto Prefect Univ Med /ID# 149093, Kyoto-shi, Kyoto, Japan|Kyoto University Hospital /ID# 163206, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 138464, Sendai-shi, Miyagi, Japan|Okayama University Hospital /ID# 148674, Okayama-shi, Okayama, Japan|Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan|Saitama Medical University International Medical Center /ID# 140361, Hidaka-shi, Saitama, Japan|Shizuoka Cancer Center /ID# 148673, Sunto-gun, Shizuoka, Japan|Dokkyo Medical University Hospital /ID# 150990, Shimotsuga-gun, Tochigi, Japan|National Cancer Center Hospital /ID# 140435, Chuo-ku, Tokyo, Japan|Nihon University Itabashi Hospital /ID# 149385, Itabashi-ku, Tokyo, Japan|Kyorin University Hospital /ID# 140360, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 140436, Shinjuku-ku, Tokyo, Japan|Chiba Cancer Center /ID# 164375, Chiba, Japan|NHO Kyoto Medical Center /ID# 140437, Kyoto, Japan|Osaka International Cancer Institute /ID# 148494, Osaka, Japan"		https://ClinicalTrials.gov/show/NCT02590263
986	NCT00387894	Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma		Terminated	Has Results	Adult Brain Tumors	Drug: erlotinib hydrochloride	Disease Response Measured Objectively by MRI of Brain|Duration of Progress-free Survival (PFS)	"Michael Prados|National Cancer Institute (NCI)|Genentech, Inc.|University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	6	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000492762|UCSF-06102|UCSF-H5941-28905-01|GENENTECH-OSI3765s	Jan-07	Mar-09	Mar-09	13-Oct-06	17-May-13	4-Jun-13	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00387894
987	NCT01549392	Imaging Study of Glioblastomas Treated With Avastin		Terminated	Has Results	Malignant Gliomas	Device: DECT|Device: MR spectroscopy	3 Month Response	"London Health Sciences Centre|University of Western Ontario, Canada|London Regional Cancer Program, Canada"	All	"18 Years to 90 Years   (Adult, Older Adult)"	Not Applicable	3	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LRCP02	Feb-12	Mar-14	Mar-14	9-Mar-12	15-Sep-14	15-Sep-14	"London Regional Cancer Centre, London, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT01549392
988	NCT00003185	Biological Therapy in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: autologous tumor cell vaccine|Biological: sargramostim|Biological: tumor-draining lymph node lymphocyte therapy|Drug: cyclophosphamide|Procedure: conventional surgery		The Cleveland Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000066013|CCF-BB-IND-6154|NCI-H98-0008	Aug-97		Jul-98	9-Feb-04		4-Dec-13	"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00003185
989	NCT00387400	"Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: everolimus|Drug: temozolomide|Genetic: microarray analysis|Other: immunohistochemistry staining method	Safety and tolerability of everolimus as measured by NCI CTCAE v3.0|Response as measured by CT scan and/or brain MRI at baseline and after every other course and clinical neurologic assessment at baseline and after every course|Correlation of clinical outcome with pretreatment tumor tissue molecular markers as measured by molecular studies of paraffin-embedded tumor samples|Pharmacokinetics of everolimus during course 1	NCIC Clinical Trials Group|Canadian Cancer Trials Group	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	32	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I162|CAN-NCIC-IND162|CDR0000507616	25-Jul-06	24-Sep-10	6-Jan-12	13-Oct-06		8-Apr-20	"Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Center, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada|McGill University - Dept. Oncology, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00387400
990	NCT00047073	Sirolimus in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: Rapamycin|Procedure: Surgery|Procedure: Supportive Care	Maximum tolerated dose (for phase 1)|Efficacy in terms of progression-free survival at 6 months and objective response (phase II)|Safety Profile (phase I)|Further evaluate safety profile	Jonsson Comprehensive Cancer Center	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	13	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000257255|UCLA-0203078|NCI-G02-2114	Jul-02	Jun-05	Oct-07	27-Jan-03		3-Aug-20	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00047073
991	NCT00227032	Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme		Terminated	No Results Available	Brain and Central Nervous System Tumors	Drug: erlotinib hydrochloride	Progression-free survival|Correlation between presence of the EGFRvIII mutation with treatment outcomes	UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCCC 0424|CDR0000550155	Sep-05	Feb-08	Mar-08	27-Sep-05		6-Mar-12	"Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00227032
992	NCT04623931	Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas		Recruiting	No Results Available	"Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Diffuse Astrocytoma, IDH-Wildtype|Glioblastoma|Oligoastrocytoma|Oligodendroglioma|WHO Grade II Glioma|WHO Grade III Glioma"	Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy|Drug: Temozolomide	Progression free survival (PFS)|Overall survival (OS) rate	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-0715|NCI-2019-08264	30-Jan-20	6-Sep-22	6-Sep-22	10-Nov-20		19-Nov-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04623931
993	NCT00014105	Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: carboplatin|Drug: temozolomide		Atlantic Health System|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other	Interventional	Primary Purpose: Treatment	CDR0000068432|NYU-9948|SPRI-NYU-9948|NCI-G00-1907|NCI-V01-1650	Dec-00			4-Feb-04		4-Dec-13	"Overlook Hospital, Summit, New Jersey, United States"		https://ClinicalTrials.gov/show/NCT00014105
994	NCT00004937	Acridine Carboxamide in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: acridine carboxamide		European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other	Interventional	Primary Purpose: Treatment	EORTC-16991G|XENOVA-XR5000/014/98	Oct-99	May-00		9-Aug-04		11-Jul-12	"Beatson Oncology Centre, Glasgow, Scotland, United Kingdom"		https://ClinicalTrials.gov/show/NCT00004937
995	NCT00021307	Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Drug: carboplatin|Drug: temozolomide		Fox Chase Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Other|NIH	Interventional	Primary Purpose: Treatment	FCCC-01004|CDR0000068768|NCI-G01-1981		Apr-02	Apr-02	14-Jan-04		11-Jul-13			https://ClinicalTrials.gov/show/NCT00021307
996	NCT00003293	SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: leflunomide|Drug: procarbazine hydrochloride		Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 3		Industry	Interventional	Allocation: Randomized|Primary Purpose: Treatment	SUGEN-SU101.015|CDR0000066226|MSKCC-98020|UCLA-HSPC-980105201	Feb-98	May-01	May-01	3-Jun-04		11-Sep-12	"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Beckman Research Institute, City of Hope, Los Angeles, California, United States|St. Francis Hospital, San Francisco, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Medical College of Georgia Hospital and Clinics, Augusta, Georgia, United States|Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|Western Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Washington Medical Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT00003293
997	NCT00014300	Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: glufosfamide		European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other	Interventional	Primary Purpose: Treatment	EORTC-16994G-26002	Jan-01	Sep-01		17-Mar-04		24-Sep-12	"Kaiser Franz Josef Hospital, Vienna (Wien), Austria|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France|Centre Antoine Lacassagne, Nice, France|CHU Pitie-Salpetriere, Paris, France|Centre Eugene Marquis, Rennes, France|Institut Gustave Roussy, Villejuif, France|University of Ioannina, Ioannina, Greece|Schneider Children's Medical Center of Israel, Petah-Tikva, Israel|Azienda Ospedaliera di Padova, Padova (Padua), Italy|Istituti Fisioterapici Ospitalieri - Roma, Rome, Italy|Rotterdam Cancer Institute, Rotterdam, Netherlands|Academisch Ziekenhuis Utrecht, Utrecht, Netherlands|Instituto Portugues de Oncologia de Francisco Gentil, Lisbon, Portugal|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland"		https://ClinicalTrials.gov/show/NCT00014300
998	NCT00016991	ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: gefitinib		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	2421|DUMC-2421-03-2R2|DUMC-2421-01-2|NCI-1253|CDR0000068639	Jun-01		Apr-05	27-Jan-03		20-Jun-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00016991
999	NCT00054496	Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: erlotinib hydrochloride	Response rate|Progression-free survival|Overall survival|Efficacy of erlotinib in inhibiting epidermal growth factor receptor (EGFR) signaling|Efficacy of tumor EGFR amplification in predicting response to treatment	The Cleveland Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	73	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000270723|CCF-IRB-5478	Aug-02			6-Feb-03		10-Jan-14	"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00054496
1000	NCT02544178	Study of Neurological Complication After Radiotherapy for High Grade Glioblastoma	EPIBRAINRAD	Unknown status	No Results Available	Leukoencephalopathy	Radiation: brain radiotherapy	decrease of 1.5 SD of Compurerized Speed Cognitive test|sensitivity and specificity of the Compurerized Speed Cognitive test|dosimetric prognostic factors of neurocognitive defects|levels of biomarkers before and after radiotherapy|radiological prognostic factors of neurocognitive defects	"Sophie JACOB|Centre National de la Recherche Scientifique, France|Institut de Radioprotection et de Surete Nucleaire"	All	"18 Years and older   (Adult, Older Adult)"		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IRSN_02	Apr-15	Apr-18	Apr-20	9-Sep-15		22-Sep-16	"Hopital Pitié Salpétriere, Paris, France|Centre paul Strauss, Strasbourg, France"		https://ClinicalTrials.gov/show/NCT02544178
1001	NCT00086879	Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: erlotinib hydrochloride|Drug: temozolomide	Progression-free survival at 6 months|Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment|Severe toxic events assessed by CTCAE v3.0 at the end of each course|Progression-free survival at 1 year|Overall survival at 6 months and 1 year	European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	110	Other	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26034-16031	May-04	Mar-06	Mar-11	12-Jul-04		27-Jul-17	"U.Z. Gasthuisberg, Leuven, Belgium|Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France|Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France|Centre Antoine Lacassagne, Nice, France|CHU Pitie-Salpetriere, Paris, France|Institut Gustave Roussy, Villejuif, France|Azienda Ospedaliera di Padova, Padova, Italy|Medisch Centrum Haaglanden, 's-Gravenhage, Netherlands|University Medical Center Rotterdam at Erasmus Medical Center, Rotterdam, Netherlands|Western Infirmary, Glasgow, Scotland, United Kingdom"		https://ClinicalTrials.gov/show/NCT00086879
1002	NCT00006656	Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine in ethanol|Procedure: conventional surgery		Direct Therapeutics|National Cancer Institute (NCI)	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2		Industry	Interventional	Primary Purpose: Treatment	CDR0000068207|DTI-9901|UCMC-00042402|NCI-V00-1623	Jun-00			27-Jan-03		6-Nov-13	"USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Evanston Northwestern Health Care, Evanston, Illinois, United States|John F. Kennedy Medical Center, Edison, New Jersey, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00006656
1003	NCT02343549	A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)		Terminated	Has Results	Cancer of Brain and Nervous System	Device: NovoTTF100A|Drug: Bevacizumab|Drug: Temozolomide	Number of Participants With 12-Month Survival|Overall Survival (OS)|Progression Free Survival (PFS)|Number of Participants With Objective Response|Number of Participants With Disease Control|Duration of Response|Duration of Disease Control	Ashley Love Sumrall|NovoCure Ltd.|Atrium Health	All	"22 Years and older   (Adult, Older Adult)"	Phase 2	13	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCI-NEU-NOV-001|00010270	Jan-15	11-Jul-20	11-Jul-20	22-Jan-15	10-Aug-21	19-Oct-21	"Levine Cancer Institute, Charlotte, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/49/NCT02343549/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02343549
1004	NCT00128635	Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Radiation: iodine I 131 monoclonal antibody TNT-1/B	"Maximum tolerated dose based on CTCAE v3.0 weekly for 8 weeks then every 8 weeks|Biodistribution and radiation dosimetry by blood, urine, and whole body scans daily for 10 days|Toxicity by CTCAE v3.0 weekly for 12 weeks then every 8 weeks|Overall survival, median time of survival, and percent alive at 6 months"	Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	22	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000438768|NABTT-0404	Oct-05		Oct-07	10-Aug-05		19-Feb-16	"Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00128635
1005	NCT00720356	Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: bevacizumab|Drug: erlotinib hydrochloride	Overall Survival|Progression-free Survival at 12 Months|Response Rate (RR)|Safety of the Combination of Erlotinib and Bevacizumab in This Patient Population|Progression Free Survival at 18 Months	Northwestern University|M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	115	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 07C3|BTTC08-01|STU00002792	7-Jul-09	24-Jun-14	5-Jul-18	22-Jul-08	26-Oct-18	26-Oct-18	"Cedars-Sinai Medical Center, Los Angeles, California, United States|M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States|Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Evanston Hospital, Evanston, Illinois, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Neuro-Oncology Associates at Baylor University Medical Center, Dallas, Dallas, Texas, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|The Methodist Hospital Neurological Institute, Houston, Texas, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00720356
1006	NCT01770626	A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients	BEAM	Completed	No Results Available	Brain Cancer	Other: Nutrition	To evaluate the use of Bioelectrical Impedance Analysis as a clinical assessment tool in Glioblastoma Multiforme patients|To compare estimated caloric needs determined by BIA and Harris Benedict Equation to Resting Energy Expenditure from Indirect Calorimetry	University of Alabama at Birmingham	All	"19 Years and older   (Adult, Older Adult)"	Early Phase 1	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	UAB 1106	Apr-11	Jul-13	Jun-14	18-Jan-13		28-Oct-14	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT01770626
1007	NCT00039468	Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irinotecan hydrochloride|Drug: thalidomide	Response|Toxicity / QOL / Survival	Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	26	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D0134|DMS-15615|NCI-G02-2078	Mar-02	Sep-07	Feb-08	27-Jan-03		27-Oct-11	"Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00039468
1008	NCT02852655	"A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma"		Completed	No Results Available	Brain Cancer	Drug: MK-3475	Tumor Infiltrating T Lymphocyte (TIL) Density|Incidence of Treatment-Emergent Adverse Events|Progression Free Survival	Dana-Farber Cancer Institute|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	25	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-225	21-Sep-16	1-Oct-21	1-Oct-21	2-Aug-16		12-Oct-21	"University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer, New York, New York, United States|UT, MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT02852655
1009	NCT00107237	AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: AEE788|Drug: everolimus	"Maximum tolerated dose and dose-limiting toxicity of AEE788|Safety|Tolerability|Single-dose and repeated-dose pharmacokinetic profile|Efficacy (response rate, progression-free survival, and overall survival)|Antiangiogenic effects"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	16	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CAEE788A2106|UCLA-0409004-01|CDR0000422335	Oct-03	Jun-06	Jun-06	6-Apr-05		12-Jun-13	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Duke Univaersity Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00107237
1010	NCT02667587	"An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)"	CheckMate548	"Active, not recruiting"	No Results Available	Brain Neoplasms	Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy|Other: Nivolumab Placebo	"Progression-free survival (PFS), Blinded Independent Central Review (BICR) assessed|Overall survival (OS) defined as time from the date of randomization to the date of death.|Overall Survival (OS)|Progression free survival (PFS), investigator assessed"	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	716	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	CA209-548|2015-004722-34	9-May-16	22-Dec-20	1-Aug-23	29-Jan-16		25-Oct-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Local Institution, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School OF Medicine-Siteman Cancer Center, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Local Institution, Lille Cedex, France|Hopital Neurologique Pierre Wertheimer, Lyon Cedex 03, France|Local Institution, Marseille, France|Local Institution, Nancy, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, France|Hopital Saint Louis, Paris, France|Centre Eugene Marquis, Rennes Cedex, France|Institut Univ Cancer Toulouse, Toulouse, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Kyoto, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom"		https://ClinicalTrials.gov/show/NCT02667587
1011	NCT00436436	O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy		Terminated	Has Results	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: temozolomide	Confirmed Best Objective Tumor Response Rate (Complete or Partial Response) in Patients With Methylguanine Methyltransferase (MGMT)-Positive Tumors as Assessed by Immunohistochemistry (IHC)|Objective Tumor Response Rate in Patients With Methylguanine Methyltransferase (MGMT)-Negative Tumors as Assessed by Immunohistochemistry (IHC)|Toxicity as Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v 3)|Best Overall Response|Progression-free Survival|Overall Survival	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	12	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	070052|NCI-07-C-0052|AOI-NCI-07-C-0052|CDR0000529875	13-Nov-06	15-Mar-10	14-Apr-10	19-Feb-07	28-Mar-17	28-Mar-17	"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00436436
1012	NCT00014677	NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: interleukin-4 PE38KDEL cytotoxin|Procedure: conventional surgery		Neurocrine Biosciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Industry	Interventional	Primary Purpose: Treatment	NBI-3001-0001|CDR0000068586|NBI-BB-IND-7004|SLUMC-11350	Mar-01	Sep-02	Jul-08	13-Nov-03		18-Jul-13	"UCSD Thornton Hospital, La Jolla, California, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Charlotte Neurosurgical Associates, Charlotte, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00014677
1013	NCT03717142	Feasibility of the LUM Imaging System for Detection of Cancer to the Brain		"Active, not recruiting"	No Results Available	Low Grade Glioma of Brain|Glioblastoma|Metastasis to Brain	Combination Product: LUM Imaging System	Correlation of fluorescence levels in normal and tumor tissue by dose of LUM015|Number of reported safety events	"Lumicell, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other	CL0004	3-May-19	Jun-22	Sep-22	24-Oct-18		13-Sep-21	"Brigham and Women's Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT03717142
1014	NCT00584883	A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain Tumor	Drug: ABT 510	All patients enrolled in this study will be statistically characterized for baseline and disease characteristics using descriptive statistics for continuous measures.	University of Alabama at Birmingham	All	"19 Years and older   (Adult, Older Adult)"	Phase 1	24	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UAB 0327|ABT510	Aug-03	Jul-08	Jul-08	2-Jan-08		5-Dec-19	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT00584883
1015	NCT00998010	"Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma"		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: bortezomib + temozolomide+ radiation therapy	Overall Survival|Toxicity Assessed According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.|Time to Progression|Survival at 1 Year|Tumor Progression as Assessed by Magnetic Resonance Imaging (MRI) and Neurologic Exam	"Jonsson Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	24	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-002222|UCLA-X05303|CDR0000657015|MILLENNIUM-UCLA-X05303|09-03-084	3-Oct-11	29-Mar-16	20-Apr-18	20-Oct-09	17-Jul-20	28-Aug-20	"University of California Los Angeles, Los Angeles, California, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/10/NCT00998010/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT00998010/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT00998010
1016	NCT01491893	PVSRIPO for Recurrent Glioblastoma (GBM)	PVSRIPO	"Active, not recruiting"	Has Results	GBM|Glioblastoma|Glioma|Malignant Glioma	Biological: Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)	Maximum Tolerated Dose (MTD)|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)|Recommended Phase 2 Dose (RP2D)|Median Overall Survival (OS)|Median Progression-free Survival (PFS)	"Istari Oncology, Inc.|National Cancer Institute (NCI)|Brain Tumor Research Charity Grant|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	61	Industry|NIH|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00031169|NS20023	25-Apr-12	27-Jun-17	Dec-21	14-Dec-11	28-Sep-18	25-Oct-21	"Duke University Medical Center, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/93/NCT01491893/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01491893
1017	NCT05084430	Study of Pembrolizumab and M032 (NSC 733972)		Not yet recruiting	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Gliosarcoma	Drug: M032|Drug: Pembrolizumab	Overall Survival at 12 and 24 months|Progression Free Survival at 6 months (PFS-6)|Overall Survival (OS)|Progression Free Survival (PFS)	University of Alabama at Birmingham|Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	28	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-300007756	20-Dec-21	20-Dec-23	20-Dec-24	19-Oct-21		8-Dec-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT05084430
1018	NCT02617589	"An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)"	CheckMate 498	"Active, not recruiting"	Has Results	Brain Cancer	Drug: Nivolumab|Drug: Temozolomide|Radiation: Radiotherapy	Overall Survival (OS)|Progression Free Survival (PFS)|OS at 24 Months|OS in Tumor Mutational Burden (TMB) High Population|PFS in Tumor Mutational Burden (TMB) High Population	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	560	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-498|2015-003739-37	1-Mar-16	17-Jan-19	31-Aug-21	1-Dec-15	3-Feb-21	3-Feb-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph Hospital And Medical Center, Phoenix, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|Sutter Institute For Medical Research, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|The University Of Chicago, Chicago, Illinois, United States|University Of Kansas Medical Center, Westwood, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School OF Medicine-Siteman Cancer Center, Saint Louis, Missouri, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Kepler Universitaetsklinikum, Linz, Austria|Medical University Of Vienna, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Uz Leuven, Leuven, Belgium|BC Cancer - Vancouver, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Odense, Denmark|Hopital Neurologique Pierre Wertheimer, Bron Cedex, France|Local Institution, Lille Cedex, France|Hopital La Timone, Marseille, France|Hopital Central, Nancy, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, France|Local Institution, Paris, France|Centre Eugene Marquis, Rennes Cedex, France|Institut Univ Cancer Toulouse, Toulouse, France|Universitaetsklinikum Bonn, Bonn, Germany|Uniklinik Erlangen, Erlangen, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt am Main, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Universitasklinikum Tubingen, Tuebingen, Germany|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Rozzano (milano), Italy|Local Institution, Siena, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Mitaka-shi, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|NKI AVL, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Erasmus Mc, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Oslo, Norway|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Lund, Sweden|Local Institution, Solna, Sweden|University Hospital Geneva, Geneve, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitaetsspital Zuerich, Zuerich, Switzerland|University College Hospital, London, Greater London, United Kingdom|Christie Hospital Nhs Found. Trust, Manchester, Greater Manchester, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Beaston West of Scotland Cancer Centre, Glasgow, United Kingdom"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/89/NCT02617589/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02617589/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02617589
1019	NCT00047294	"Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: celecoxib|Drug: temozolomide|Drug: thalidomide|Procedure: adjuvant therapy		Dana-Farber Cancer Institute|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	00302|P30CA006516|CDR0000257587|NCI-G02-2118|CELGENE-2000-P-002521/1	Apr-01	Mar-05	Sep-07	27-Jan-03		11-Jul-17	"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Cancer Center at the University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00047294
1020	NCT00458601	Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme	ACT III	Completed	No Results Available	Malignant Glioma	Drug: CDX-110 with GM-CSF|Drug: Temozolomide	"Progression-free survival status|Safety and tolerability characterized by adverse events (term, grade, frequency).|Safety and tolerability characterized by physical examinations.|Safety and tolerability characterized by hematologic and metabolic panel (including CBC with differential, electrolytes, BUN, Cr, liver associated enzymes).|Safety and tolerability characterized by urinalysis.|Safety and tolerability characterized by vital signs.|Immune response; T-cell response to vaccine.|Immune response; antibody response to vaccine.|Immune response; HLA typing.|Overall survival."	Celldex Therapeutics	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	82	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDX110-003	Aug-07	Nov-10	May-16	11-Apr-07		16-Jan-18	"Celldex Investigational Site, Orange, California, United States|Celldex Investigational Site, San Francisco, California, United States|Celldex Investigational Site, San Francisco, California, United States|Celldex Investigational Site, Stanford, California, United States|Celldex Investigational Site, Stanford, California, United States|Celldex Investigational Site, New Haven, Connecticut, United States|Celldex Investigational Site, New Haven, Connecticut, United States|Celldex Investigational Site, New Haven, Connecticut, United States|Celldex Investigational Site, Gainesville, Florida, United States|Celldex Investigational Site, Chicago, Illinois, United States|Celldex Investigational Site, Evanston, Illinois, United States|Celldex Investigational Site, Boston, Massachusetts, United States|Celldex Investigational Site, Lansing, Michigan, United States|Celldex Investigational Site, Saginaw, Michigan, United States|Celldex Investigational Site, Saginaw, Michigan, United States|Celldex Investigational Site, Hackensack, New Jersey, United States|Celldex Investigational Site, Amherst, New York, United States|Celldex Investigational Site, New York, New York, United States|Celldex Investigational Site, New York, New York, United States|Celldex Investigational Site, Durham, North Carolina, United States|Celldex Investigational Site, Cincinnati, Ohio, United States|Celldex Investigational Site, Cincinnati, Ohio, United States|Celldex Investigational Site, Cincinnati, Ohio, United States|Celldex Investigational Site, Cleveland, Ohio, United States|Celldex Investigational Site, Cleveland, Ohio, United States|Celldex Investigational Site, Orange Village, Ohio, United States|Celldex Investigational Site, West Chester, Ohio, United States|Celldex Investigational Site, Westlake, Ohio, United States|Celldex Investigational Site, Philadelphia, Pennsylvania, United States|Celldex Investigational Site, Houston, Texas, United States|Celldex Investigational Site, San Antonio, Texas, United States|Celldex Investigational Site, Salt Lake City, Utah, United States|Celldex Investigational Site, Charlottesville, Virginia, United States|Celldex Investigational Site, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00458601
1021	NCT01013285	"Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma"		Completed	Has Results	Brain and Central Nervous System Tumors	Biological: bevacizumab|Drug: temozolomide|Radiation: external beam radiation therapy	Overall Survival|Time to Disease Progression|Progression-free Survival at 6 Months|Radiographic Response (When Evaluable)|Median Overall Survival (OS) Based on the MGMT Promoter Methylation Status	Jonsson Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	70	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-000558|UCLA-0604016|AVF3770s|CDR0000628787|GENENTECH-UCLA-0604016	Jun-06	Oct-13	Aug-15	13-Nov-09	21-Sep-20	21-Sep-20	"Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT01013285
1022	NCT00304031	Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: Concurrent temozolomide|Radiation: Concurrent radiation therapy|Drug: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Drug: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle	Median Overall Survival Time|Median Progression-free Survival (PFS) Time|Median Overall Survival Time by MGMT Status|Median Progression-free Survival Time by MGMT Status|Best Treatment Response by MGMT Status|Distribution of Highest Grade AE Reported as Possibly/Probably/Definitely Related to Protocol Treatment|Overall Survival Status by Progression Status at 6 Months|Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy|Mean Neurocognitive Function (NCF) Composite Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy|Mean EORTC QLQ-C30 Global Health Status Score at Cycle 10 for Participants Without Progression After 6 Months of Adjuvant Therapy|Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 1|Mean Change From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Mid-cyle for Cycle 4|Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 1|Mean Change From Baseline in EORTC QLQ-C30 Global Health Status Score at Mid-cyle for Cycle 4|Change From Baseline in Mean EORTC QLQ-C30 Global Health Status|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score at Cycle 4|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Interference Score at Cycle 4|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 1|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 4|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score and EORTC QLQ-C30 Global Health Status Score (GHS) at Cycle 10|Mean MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Symptom Severity Score Over Time|Determination of Impactful Baseline Instruments on Overall Survival|Mean Neurocognitive Function (NCF) Composite Score Over Time|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition Score at Cycle 1|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 4|Number of Participants With Deterioration From Baseline in MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) Cognitive Score and Hopkins Verbal Learning Test - Revised (HVLT-R) Delayed Recognition (DR) Score at Cycle 10	Radiation Therapy Oncology Group|National Cancer Institute (NCI)|European Organisation for Research and Treatment of Cancer - EORTC|NRG Oncology	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 3	1173	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-0525|CDR0000465183|EORTC-26052|EORTC-22053|NCI-2009-00731	Jan-06	Feb-11	Dec-16	17-Mar-06	30-Apr-14	9-Jun-20	"Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital, Fairbanks, Alaska, United States|Arizona Oncology Services Foundation, Phoenix, Arizona, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Arizona Oncology - Tucson, Tucson, Arizona, United States|Auburn Radiation Oncology, Auburn, California, United States|Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States|Radiation Oncology Centers - Cameron Park, Cameron Park, California, United States|Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Kaiser Permanente Medical Center - Los Angeles, Los Angeles, California, United States|Radiation Oncology Center - Roseville, Roseville, California, United States|Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States|Mercy General Hospital, Sacramento, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Solano Radiation Oncology Center, Vacaville, California, United States|Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States|Poudre Valley Radiation Oncology, Fort Collins, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus, Boca Raton, Florida, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Integrated Community Oncology Network, Jacksonville Beach, Florida, United States|Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States|Integrated Community Oncology Network at Southside Cancer Center, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Baptist-South Miami Regional Cancer Program, Miami, Florida, United States|Integrated Community Oncology Network - Orange Park, Orange Park, Florida, United States|Florida Cancer Center - Palatka, Palatka, Florida, United States|Flagler Cancer Center, Saint Augustine, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Northwest Community Hospital, Arlington Heights, Illinois, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|InterCommunity Cancer Center of Western Illinois, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Valley Cancer Center, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Radiation Oncology Associates Southwest, Fort Wayne, Indiana, United States|Parkview Regional Cancer Center at Parkview Health, Fort Wayne, Indiana, United States|Central Indiana Cancer Centers - East, Indianapolis, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Saint Joseph Regional Medical Center, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Kansas City Cancer Centers - Southwest, Overland Park, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|DeCesaris Cancer Institute at Anne Arundel Medical Center, Annapolis, Maryland, United States|St. Agnes Hospital Cancer Center, Baltimore, Maryland, United States|Union Hospital Cancer Program at Union Hospital, Elkton, Maryland, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Haematology-Oncology Associates of Ohio and Michigan, PC, Lambertville, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Alexandria, Minnesota, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Independence Regional Health Center, Independence, Missouri, United States|St. John's Regional Medical Center, Joplin, Missouri, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|St. Joseph Medical Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Parvin Radiation Oncology, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Kansas City Cancer Centers - South, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Dartmouth - Hitchcock Concord, Concord, New Hampshire, United States|Kingsbury Center for Cancer Care at Cheshire Medical Center, Keene, New Hampshire, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|St. Barnabas Medical Center Cancer Center, Livingston, New Jersey, United States|Frederick R. and Betty M. Smith Cancer Treatment Center, Sparta, New Jersey, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|New York Methodist Hospital, Brooklyn, New York, United States|Monter Cancer Center of the North Shore-LIJ Health System, Lake Success, New York, United States|CCOP - North Shore University Hospital, Manhasset, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hudson Valley Oncology Associates, Poughkeepsie, New York, United States|Lipson Cancer and Blood Center at Rochester General Hospital, Rochester, New York, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Wayne Radiation Oncology, Goldsboro, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Wilmed Radiation Oncology Services, Wilson, North Carolina, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Cleveland Clinic Cancer Center, Independence, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Luke's Hospital, Maumee, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford, Salem, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Cancer Treatment Center, Wooster, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Willamette Valley Cancer Center - Eugene, Eugene, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Legacy Good Samaritan Hospital & Comprehensive Cancer Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|Adventist Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center and Children's Hospital, Portland, Oregon, United States|Salem Hospital Regional Cancer Care Services, Salem, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Rosenfeld Cancer Center at Abington Memorial Hospital, Abington, Pennsylvania, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Northeast Radiation Oncology Center, Dunmore, Pennsylvania, United States|Dale and Frances Hughes Cancer Center at Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Riddle Memorial Hospital Cancer Center, Media, Pennsylvania, United States|Upper Delaware Valley Cancer Center, Milford, Pennsylvania, United States|Intercommunity Cancer Center, Monroeville, Pennsylvania, United States|Alle-Kiski Medical Center, Natrona Heights, Pennsylvania, United States|Cancer Center of Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|Frankford Hospital Cancer Center - Torresdale Campus, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Somerset Oncology Center, Somerset, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|CCOP - Main Line Health, Wynnewood, Pennsylvania, United States|Lankenau Cancer Center at Lankenau Hospital, Wynnewood, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center West, Knoxville, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Thompson Cancer Survival Center at Methodist, Oak Ridge, Tennessee, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Texas Oncology, PA at Texas Cancer Center Dallas Southwest, Dallas, Texas, United States|Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital, Fort Worth, Texas, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Texas Oncology, PA at Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas, United States|American Fork Hospital, American Fork, Utah, United States|Sandra L. Maxwell Cancer Center, Cedar City, Utah, United States|Jon and Karen Huntsman Cancer Center at Intermountain Medical Center, Murray, Utah, United States|Val and Ann Browning Cancer Center at McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center - Provo, Provo, Utah, United States|Dixie Regional Medical Center - East Campus, Saint George, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|Norris Cotton Cancer Center - North, Saint Johnsbury, Vermont, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Sentara Cancer Institute at Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Cascade Cancer Center at Evergreen Hospital Medical Center, Kirkland, Washington, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|North Star Lodge Cancer Center at Yakima Valley Memorial Hospital, Yakima, Washington, United States|Theda Care Cancer Institute, Appleton, Wisconsin, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Community Memorial Hospital Cancer Care Center, Menomonee Falls, Wisconsin, United States|Regional Cancer Center at Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Door County Cancer Center at Door County Memorial Hospital, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Waukesha Memorial Hospital Regional Cancer Center, Waukesha, Wisconsin, United States|Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada|Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada|Cancer Care Program at Thunder Bay Regional Health Sciences, Thunder Bay, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|McGill Cancer Centre at McGill University, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00304031
1023	NCT00919737	Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme		Completed	No Results Available	Malignant Glioma	Drug: NPC-08	Overall survival to 12 months|Progression-free survival	Nobelpharma	All	18 Years to 64 Years   (Adult)	Phase 1|Phase 2	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NPC-08-1	Jun-09	Apr-11	Apr-11	12-Jun-09		30-Oct-13	"The Tazuke Kofukai Foundation Medical Research Kitano Hospital, Osaka, Japan"		https://ClinicalTrials.gov/show/NCT00919737
1024	NCT03176160	LITT Palliative Treatment for Patients With Malignant Gliomas		Withdrawn	No Results Available	Malignant Glioma of Brain|Glioblastoma	Other: Palliative regimen consisting of LITT	Change in NCCN distress thermometer score|Median overall survival|Change in Karnofsky Performance Status (KPS)	Duke University|Monteris Medical	All	"18 Years and older   (Adult, Older Adult)"		0	Other|Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	Pro00079623	Jun-19	Jun-20	Jun-22	5-Jun-17		27-Feb-19	"The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03176160
1025	NCT00001148	Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor		Completed	No Results Available	Astrocytoma|Glioblastoma|Glioma			National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	"Child, Adult, Older Adult"		25	NIH	Observational		000009|00-N-0009	Oct-99		Jan-05	4-Nov-99		4-Mar-08	"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00001148
1026	NCT02758366	Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma		Terminated	No Results Available	"Glioblastoma (GBM)|DIPG|Brainstem Glioma, Pediatric|Diffuse Spinal Glioma|Bilateral Thalamic Glioma|Gliomatosis Cerebri|Anaplastic Astrocytoma|Midline Diffuse Glioma"	Drug: Doxorubicin	Time to early discontinuation of the study drug (doxorubicin)|Number of participants with treatment-related serious adverse events (SAE) as assessed by CTCAE v4.0|Number of patients who died for SAE as assessed by CTCAE v4.0|Number of patients who undergone to withdrawal of doxorubicin|Event free survival|Overall survival|Progression free survival|Rate of treatment response	Meyer Children's Hospital	All	"3 Years to 30 Years   (Child, Adult)"	Phase 2	21	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GBMTMZ/DOX2015|2015-002307-28	Feb-16	16-Jan-20	16-Jan-20	2-May-16		9-Feb-21	"Meyer Children's Hospital, Florence, Italy"		https://ClinicalTrials.gov/show/NCT02758366
1027	NCT00504660	"6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients"		Completed	Has Results	Anaplastic Glioma of Brain|Glioblastoma Multiforme|Brain Cancer	Drug: Capecitabine|Drug: Celecoxib (Celebrex)|Drug: Temozolomide|Drug: Lomustine|Drug: 6-Thioguanine	12 Month-progression-free Survival for Participants With Anaplastic Tumors|6 Month Progression-free Survival for Participants With Glioblastoma	M.D. Anderson Cancer Center	All	"12 Years and older   (Child, Adult, Older Adult)"	Phase 2	75	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2003-0600	Sep-03	Aug-10	Aug-10	20-Jul-07	11-Jan-12	11-Jan-12	"UT MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00504660
1028	NCT05023551	Study of DSP-0390 in Patients With Recurrent High-Grade Glioma		Recruiting	No Results Available	High Grade Glioma|Glioblastoma Multiforme	Drug: DSP-0390	Dose Escalation: Assess safety of DSP-0390 by Incidence of TEAEs and SAEs in adult patients with recurrent high-grade glioma|Dose Escalation: Assess safety of DSP-0390 by severity of TEAEs and SAEs in adult patients with recurrent high-grade glioma|Dose Escalation: Determine the MTD and/or RDE of DSP-0390|Dose Expansion: Evaluate the change in Baseline tumor activity of DSP-0390 using radiologic assessments.|Dose Expansion: Evaluate the safety of the Recommended Phase 2 Dose of DSP-0390 by assessment of incidence of TEAEs and SAEs|Dose Expansion: Evaluate the safety of the Recommended Phase 2 Dose by assessment of severity of TEAEs and SAEs|Dose Escalation: Characterize the PK profile for AUC|Dose Escalation: Characterize the PK profile for Cmax|Dose Escalation: Characterize the PK profile for tmax|Dose Escalation: Characterize the PK profile for t1/2|Dose Escalation: Characterize the PK profile for Racc	"Sumitomo Dainippon Pharma Oncology, Inc"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	70	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DSP-0390-101	8-Sep-21	Nov-24	1-Mar-25	26-Aug-21		3-Dec-21	"Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States|Kyoto University Hospital, Kyoto, Sakyo-ku, Japan|National Cancer Center Hospital, Chuo Ku, Tokyo, Japan"		https://ClinicalTrials.gov/show/NCT05023551
1029	NCT00017147	S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma		Completed	No Results Available	"Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System"	Drug: carmustine|Radiation: radiation therapy|Drug: O6-Benzylguanine	Survival|Progression-free survival|Time to treatment failure|Toxicity	Southwest Oncology Group|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	183	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000068656|S0001|U10CA032102	Sep-01	May-06	Nov-12	27-Jan-03		30-Jan-13	"Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|CCOP - Western Regional, Arizona, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Banner Thunderbird Medical Center, Phoenix, Arizona, United States|North Bay Cancer Center, Fairfield, California, United States|Memorial Hospital Cancer Center, Colorado Springs, Colorado, United States|St. Anthony Central Hospital, Denver, Colorado, United States|University of Colorado Cancer Center at University of Colorado Health Sciences Center, Denver, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|St. Anthony North Hospital, Westminster, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|West Florida Cancer Institute at West Florida Hospital - Pensacola, Pensacola, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Hematology Oncology Associates of Eastern Idaho, Idaho Falls, Idaho, United States|Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States|University of Illinois at Chicago Cancer Center, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago Westside Hospital, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Good Samaritan Regional Health Center, Mt. Vernon, Illinois, United States|Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, United States|St. Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Genesis Regional Cancer Center at Genesis Medical Center, Davenport, Iowa, United States|Genesis Medical Center - West Campus, Davenport, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, P.A. - El Dorado, El Dorado, Kansas, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Kansas, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Cancer Center of Kansas - Kingman, Kingman, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas, P.A. - Parsons, Parsons, Kansas, United States|Pratt Cancer Center of Kansas, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Salina Regional Health Center, Salina, Kansas, United States|Stormont-Vail Cancer Center, Topeka, Kansas, United States|St. Francis Comprehensive Cancer Center, Topeka, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates in Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas, P.A., Wichita, Kansas, United States|Cancer Center of Kansas, P.A. - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Baton Rouge General Regional Cancer Center, Baton Rouge, Louisiana, United States|Mary Bird Perkins Cancer Center - Baton Rouge, Baton Rouge, Louisiana, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|Medical Center of Louisiana - New Orleans, New Orleans, Louisiana, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County General Hospital, Big Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Mercy Medical Center, Grand Rapids, Michigan, United States|Spectrum Health Cancer Care - Butterworth Campus, Grand Rapids, Michigan, United States|Metropolitan Hospital, Grand Rapids, Michigan, United States|Holland Community Hospital, Holland, Michigan, United States|Hackley Hospital, Muskegon, Michigan, United States|Northern Michigan Hospital, Petoskey, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|St. Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital, Gape Girardeau, Missouri, United States|Freeman Cancer Institute at Freeman Health System, Joplin, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - St. Louis-Cape Girardeau, St. Louis, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, St. Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Deaconess Billings Clinic - Downtown, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare, Billings, Montana, United States|Deaconess Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Internal Medicine Associates of Bozeman, Bozeman, Montana, United States|St. James Community Hospital, Butte, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Sletten Regional Cancer Institute, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Eastern Montana Cancer Center, Miles City, Montana, United States|Community Medical Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Good Samaritan Health Systems, Kearney, Nebraska, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Riverside Cancer Services, Columbus, Ohio, United States|Mount Carmel West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Community Oncology Group - Independence, Independence, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Middletown Regional Hospital, Middletown, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Mercy Medical Center Oncology Unit, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital, Westerville, Ohio, United States|Cleveland Clinic - Wooster, Wooster, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Legacy Mount Hood Medical Center, Glesham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Institute of Oncology at Vilnius University, Portland, Oregon, United States|Salem Hospital Regional Cancer Center, Salem, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center, Kingsport, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Wilford Hall Medical Center, Lackland AFB, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States|Danville Regional Medical Center, Danville, Virginia, United States|St. Joseph Hospital Community Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mt. Vernon, Washington, United States|Capital Medical Center, Olympia, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|North Puget Oncology at United General Hospital, Sedro-Wooley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Allenmore Hospital, Tacoma, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|St. Clare Hospital, Tacoma, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Central Washington Hospital, Wenatchee, Washington, United States|Wenatchee Valley Clinic, Wenatchee, Washington, United States|Welch Cancer Center, Sheridan, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT00017147
1030	NCT01986348	Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas	KING	Terminated	Has Results	Glioblastoma|Glioma	Drug: Selinexor	6-Month Progression-Free Survival (PFS) Rate|Overall Response Rate (ORR)|Overall Survival (OS)|Progression-free Survival (PFS)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	Karyopharm Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	76	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KCP-330-004	3-Mar-14	23-Jan-20	23-Jan-20	18-Nov-13	2-Aug-21	2-Aug-21	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Center for Neuro-Oncology, Boston, Massachusetts, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|The Phase I Unit, Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark|University of Groningen Faculty of Medical Sciences, Medical Oncology, Groningen, Netherlands|Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit, Rotterdam, Netherlands"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/48/NCT01986348/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/48/NCT01986348/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT01986348
1031	NCT04444427	Evaluation of GLR2007 for Advanced Solid Tumors		"Active, not recruiting"	No Results Available	Non-small Cell Lung Cancer|Glioblastoma Multiforme	Drug: GLR2007	"Dose Escalation: Dose-limiting Toxicities|Dose Escalation: Incidence And Severity Of Adverse Events, Including The Incidence Of Dose-limiting Toxicities Within The First Cycle|Dose Expansion: Incidence And Severity Of Adverse Events|Dose Escalation: Objective Response Rate|Dose Expansion: Objective Response Rate|Dose Escalation And Expansion: Maximum Observed Plasma Concentration After Single And Multiple Oral Dose Administrations|Dose Escalation And Expansion: Time At Which Maximum Plasma Concentration Is Observed And Apparent Half-life After Single And Multiple Oral Dose Administrations|Dose Escalation And Expansion: Area Under The Plasma Concentration-time Curve From 0 To Last Measurable Concentration And From 0 To Infinity After Single And Multiple Oral Dose Administrations|Dose Escalation And Expansion: Accumulation Ratio After Single And Multiple Oral Dose Administrations|Dose Escalation And Expansion: Steady-state Volume Of Distribution After Single And Multiple Oral Dose Administrations|Dose Escalation And Expansion: Clearance After Single And Multiple Oral Dose Administrations"	"Gan and Lee Pharmaceuticals, USA"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	66	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GLP-CDK-1009	15-Jul-20	Sep-22	Sep-22	23-Jun-20		16-Dec-21	"USA002, Lafayette, Indiana, United States|USA005, Omaha, Nebraska, United States|USA001, Philadelphia, Pennsylvania, United States|USA004, Dallas, Texas, United States"		https://ClinicalTrials.gov/show/NCT04444427
1032	NCT01026493	Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: temozolomide 60 mg x 21 days|Drug: temozolomide 75 mg x 21 days|Drug: ABT-888 20 mg x 21 days|Drug: ABT-888 40 mg x 21 days|Drug: Temozolomide 150 mg x 5 days|Drug: ABT-888 40 mg x 5 days	Phase 1: Maximum Tolerated Dose (MTD)|Phase II: 6-month Progression-free Survival (PFS) Rate for Patients With Measurable Disease After Surgery|Phase II: Objective Response (Partial and Complete Response) Rate for Patients With Measurable Disease After Surgery|Phase II: Overall Survival (OS)	Radiation Therapy Oncology Group|National Cancer Institute (NCI)|NRG Oncology	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	257	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG-0929|CDR0000660545	Jul-10	May-14	Dec-16	4-Dec-09	2-Jul-17	2-Jul-17	"Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Leeward Radiation Oncology, 'Ewa Beach, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Hawaii Medical Center - East, Honolulu, Hawaii, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Kansas City, Prairie Village, Kansas, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Louisville Oncology at Norton Cancer Institute - Louisville, Louisville, Kentucky, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Renown Institute for Cancer at Renown Regional Medical Center, Reno, Nevada, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Highland Hospital of Rochester, Rochester, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Legacy Good Samaritan Hospital & Comprehensive Cancer Center, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT01026493
1033	NCT00615927	Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Imatinib Mesylate & Hydroxyurea	12-month Progression Free Survival (PFS)|Median Progression-free Survival|Median Overall Survival (OS)|Objective Response Rate|Safety and Tolerability of Gleevec + Hydroxyurea in Patients With Low-grade Gliomas	Duke University|Novartis Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	64	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00008799	Feb-06	Apr-09	Jun-12	14-Feb-08	15-Mar-13	15-Mar-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00615927
1034	NCT03633552	Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma		Unknown status	No Results Available	Glioblastoma Multiforme of Brain|Anaplastic Astrocytoma of Brain	Drug: Temozolomide	Overall survival|Progression-free survival|Anemia|Neutropenia|Presence of alopecia|Presence of nausea|Presence of vomiting	Mashhad University of Medical Sciences	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	62	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	960021|IRCT20160706028815N3	3-Mar-18	3-Mar-21	3-Apr-21	16-Aug-18		16-Aug-18	"Radiation ward of Emam Reza Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of|Omid Hospital, Mashhad, Razavi Khorasan, Iran, Islamic Republic of"		https://ClinicalTrials.gov/show/NCT03633552
1035	NCT00915694	"Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme"		Terminated	No Results Available	Brain and Central Nervous System Tumors	Drug: nelfinavir mesylate|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy	Maximum tolerated dose of nelfinavir mesylate|Dose-limiting toxicities as assessed by NCI CTC v3.0|Progression-free survival|Overall survival	Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	15	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000644278|UPCC-01309|IRB#809463	Apr-09	Jul-11	Dec-15	8-Jun-09		23-Apr-19	"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00915694
1036	NCT02330562	Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab		Completed	No Results Available	Malignant Glioma|Glioblastoma	Drug: MRZ|Drug: BEV	"Part 1 (Phase 1): Maximum Tolerated Dose (MTD) / Maximum Administered Dose (MAD)|Part 1 (Phase 1): Recommended Phase 2 Dose (RP2D)|Part 2 (Phase 2): MRZ single agent tumor activity|Part 3 (Phase 2): activity of MRZ + BEV with intra-patient dose escalation|Part 4 (Phase 1): Maximum Tolerated Dose (MTD) of enterally administered MRZ|Part 5 (Phase 1): repeat-dose pharmacokinetics of MRZ administered IV|Parts 1 & 5 (Phase 1): Tumor activity|Part 1 (Phase 1): Tumor activity|Parts 1, 2, 3, 4 & 5 (Phase 1 and Phase 2): Assess safety and tolerance|Part 1, 4 & 5 (Phase 1): MRZ pharmacokinetics|Parts 1 & 4 (Phase 1): Proteasome Activity in Packed Whole Blood (PWB) and peripheral blood mononuclear cells (PBMCs)|Parts 1, 2 & 3 (Phase 1 and Phase 2): Neurological Coordination Assessment|Parts 1, 2 & 3 (Phase 1 and Phase 2): Quality of Life Assessment"	Celgene|Triphase	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	121	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MRZ-108	15-Apr-15	2-Jun-21	2-Jun-21	5-Jan-15		2-Nov-21	"University of Californai, Irvine, Orange, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Weill Cornell Medical College, New York, New York, United States|Duke Univ Medical Center, Durham, North Carolina, United States|Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT02330562
1037	NCT00613132	Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG		Completed	No Results Available	Glioblastoma|Gliosarcoma	"Drug: Gleevec, RAD001, and Hydroxyurea"	To determine MTD & DLT & Imatinib mesylate & RAD001 when combined w Hydroxyurea among pt w GBM|To further evaluate safety & tolerability & Imatinib mesylate in combo w RAD001 & Hydroxyurea|To evaluate PK on Imatinib mesylate when administered w RAD001 among GBM pt who are on & not on EIAEDs	Annick Desjardins|Novartis Pharmaceuticals|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	78	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00005875|7020-07-32	May-05	Aug-08	Jan-13	12-Feb-08		20-Feb-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00613132
1038	NCT00613028	Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Temo + Avastin|Drug: VP-16 + Avastin	"The Primary Outcome Measure is 6 Month Progression-free Survival.|Radiographic Response|Median Progression-free Survival (PFS)|Median Overall Survival (OS)|Grade 3 or Greater, Treatment Related, Non-hematologic Toxicities."	"Duke University|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	23	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00003768	Apr-08	Oct-09	Jan-11	12-Feb-08	4-Feb-13	16-Jul-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00613028
1039	NCT00612430	Ph II Bevacizumab + Etoposide for Pts w Recurrent MG		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Bevacizumab and Etoposide	6 Month Progression-Free Survival (PFS)|Objective Response Rate|Safety of Study Treatment Regimen|Median Progression-Free Survival|Median Overall Survival (OS)	"Duke University|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	59	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000379	Mar-07	Sep-08	Sep-11	11-Feb-08	26-Jul-13	12-Aug-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00612430
1040	NCT03150862	A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: Pamiparib|Drug: TMZ|Radiation: Radiation	"Phase 1b: Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE|Phase 1b: Incidence, nature and severity of adverse events as assessed by CTCAE|Phase 1b: Number of treatment cycles (Arm C only), dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment|Phase 2 Arm A [Pamiparib + RT] and Arm B [Pamiparib + RT + TMZ]: Modified disease control rate (mDCR) using modified Response Assessment in Neuro-oncology (mRANO)|Phase 2 Arm C [Pamiparib + TMZ]: Objective response rate (ORR) using mRANO|Pharmacokinetic (PK) parameters of Pamiparib of steady state Ctrough|Disease control rate|Objective response rate (ORR)|Clinical benefit rate (CBR)|Duration of response (DOR)|Progression free survival (PFS).|Overall survival (OS)|Incidence, nature and severity of adverse events as assessed by CTCAE|Length of treatment, dose intensity of components of each treatment , and changes in vital signs and clinical laboratory tests during and following treatment|PK parameter of Pamiparib of steady state Ctrough|Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment"	"BeiGene USA, Inc.|BeiGene"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	116	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BGB-290-104|2017-001554-33	1-Aug-17	17-Mar-21	17-Mar-21	12-May-17		19-Apr-21	"Center for Neurosciences, Tucson, Arizona, United States|UCLA Neuro-Oncology, Los Angeles, California, United States|University of California at San Francisco, San Francisco, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Massachusetts General Hospital Pappas Center for Neuro-Oncology, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Health Midwest Ventures Group, LLC, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center (Stephenson Cancer Center), Oklahoma City, Oklahoma, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|SCRI / Tennessee Oncology, Nashville, Tennessee, United States|Huntsman Cancer Center, Salt Lake City, Utah, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|Institut Gustave Roussy, Villejuif, France|Erasmus University Medical Center, Rotterdam, Netherlands|Universitätsspital Zuerich - Klinik fur Neurologie, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT03150862
1041	NCT00409214	Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma		Completed	No Results Available	Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: LS11 (talaporfin sodium)|Device: Light source (interstitial light emitting diodes)|Procedure: Intraoperative placement of device in glioma	To demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma	Light Sciences Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LSO-OL007	Nov-06	Feb-08		8-Dec-06		16-Nov-12	"Institute of Neurosurgery, Clinical Centre Serbia, Belgrade, Serbia"		https://ClinicalTrials.gov/show/NCT00409214
1042	NCT00074646	Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas		Completed	No Results Available	Glioblastoma|Malignant Gliomas	Drug: CC-8490		Celgene Corporation|Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Industry	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	CC-8490-GLIO-001	Dec-03		Jun-05	19-Dec-03		4-Jan-07	"Neuro Oncology BranchNational Cancer Institute, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00074646
1043	NCT00756106	MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma		Terminated	Has Results	Brain and Central Nervous System Tumors	Drug: temozolomide|Other: Imaging biomarker analysis|Radiation: Photon Radiation Therapy	"Relative Cerebral Blood Volume as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy|Relative Cerebral Blood Flow as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy|Vessel Diameter as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy|Mean Transit Time as Measured by Perfusion-weighted MRI Before, During, and After Chemoradiotherapy|Permeability-surface Area Product Before, During, and After Chemoradiotherapy|Apparent Diffusion Coefficient Before, During, and After Chemoradiotherapy|Tensor Fractional Anisotropy Before, During, and After Chemoradiotherapy|Relative Regional Concentrations of Choline, N-acetyl-asparate, and Myoinositol as Measured by Magnetic Resonance Spectroscopy Before, During, and After Chemoradiotherapy to Interrogate Cell Membrane Turnover, Neuronal Integrity, and Glial Reactions|Affects of a Short Period of 100% Oxygen Inhalation on Imaging of Tumor and Surrounding Tissue Regions of Interest, Specifically Cerebral Blood Volume Changes in Each Area as Compared to Room Air"	Massachusetts General Hospital|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	15	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	07-292	Jul-08	Feb-12	Feb-12	19-Sep-08	21-Apr-20	13-May-20	"Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00756106
1044	NCT00553150	"Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma"		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: everolimus|Drug: temozolomide|Radiation: radiation	"Maximum Tolerated Dose (MTD) of Everolimus (RAD001) in Combination With Temozolomide (TMZ) and 3D-conformal Radiotherapy (RT) or Intensity-modulated Radiotherapy (IMRT) Followed by Adjuvant TMZ With or Without RAD001 (Phase I)|Overall Survival at 12 Months (Phase II)|Response Rate, as Measured in Patients Receiving FLT-PET Imaging (Phase II)|Time to Progression (Phase II)|Progression-free-survival at 6 Months (Phase II)|Overall Survival Time"	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	122	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCCTG-N057K|NCI-2009-00654|CDR0000573917	Mar-09	Jan-12	15-Nov-19	4-Nov-07	11-Jan-17	13-Feb-20	"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Bettendorf, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Mercy Clinic Cancer and Hematology - Rolla, Rolla, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|MeritCare Broadway, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Roger Maris Cancer Center at MeritCare Hospital, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Precision Radiotherapy at University Pointe, West Chester, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT00553150
1045	NCT04776980	Multimodality MRI and Liquid Biopsy in GBM		Enrolling by invitation	No Results Available	"Glioblastoma Multiforme|Brain Tumor, Adult: Glioblastoma|Brain Tumor, Recurrent|Brain Tumor, Primary"	Diagnostic Test: Post Feraheme Infusion MRI	Macrophage quantification status|Cell free tumor DNA (ctDNA)	Abramson Cancer Center of the University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	843601	Jan-22	Mar-23	Dec-23	2-Mar-21		22-Dec-21	"University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04776980
1046	NCT03951142	Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study	ImPRESS	Recruiting	No Results Available	Glioblastoma|Brain Metastases	Drug: Losartan	Relative cerebral blood flow by MRI|Relative solid stress by MRI|Relative cerebral blood volume by MRI|Mean transit time by MRI|Contrast agent extravasation by MRI|Relative vessel size index by MRI|Relative mean vessel density by MRI|Relative mean vessel caliber by MRI|Apparent diffusion coefficient by MRI|Fractional anisotropy by MRI|Relative shear modulus by MRI|Relative stiffness by MRI|Relative viscosity by MRI|Relative strain tensor by MRI|Drug tolerance|Neurologic performance by KPS|Neurologic performance by ECOG|Neurologic performance by NANO|RANO|Steroid dosage|Quality of life (QoL)|Progression free survival (PFS)|Overall survival (OS)	Kyrre Eeg Emblem|Oslo University Hospital	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	165	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ImPRESS|2018-003229-27	1-Oct-19	1-Oct-23	31-Dec-23	15-May-19		23-Sep-20	"Oslo University Hospital, Oslo, Norway"		https://ClinicalTrials.gov/show/NCT03951142
1047	NCT00609999	Ph I Dasatinib + Erlotinib in Recurrent MG		Completed	No Results Available	Glioblastoma|Gliosarcoma	Drug: Erlotinib and Dasatinib	To determine MTD & DLT of Dasatinib when combined w Erlotinib among pts w Recurrent MG|To further evaluate safety & tolerability of Dasatinib + Erlotinib|To evaluate the PK of Dasatinib when administered w Erlotinib among Recurrent MG pts who are on & not on EIAEDs|To evaluate for anti-tumor activity w this regimen in this pt population	"Duke University|Bristol-Myers Squibb|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	47	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00002272	Jan-08	Jul-10	Jul-10	7-Feb-08		16-Jul-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00609999
1048	NCT04998864	Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients		Recruiting	No Results Available	"Glioma, Malignant|Glioblastoma"	Device: Magnetic Resonance guided Focused ultrasound (MRgFUS)	Device and procedure related adverse events|Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging	InSightec	All	"18 Years to 80 Years   (Adult, Older Adult)"		5	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	BT008E	25-Aug-21	30-Dec-22	30-Dec-23	10-Aug-21		6-Jan-22	"Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy|CINAC-Hospital HM Puerta del Sur, Móstoles, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT04998864
1049	NCT00431561	Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma		Completed	No Results Available	Glioblastoma|Anaplastic Astrocytoma	Drug: AP 12009 10 µM|Drug: AP 12009 80 µM|Drug: temozolomide or PCV|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System	Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans|Overall survival|Response rates|Progression-free survival|Time to progression|Time to response|Best of all response rates assessed by survival status and variation of tumor size on brain MRI|Change of quality of life and Karnofsky Performance Status (KPS)|Best of all response rates|Safety and tolerability	Isarna Therapeutics GmbH	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	141	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AP 12009-G004	Apr-03	Mar-09	Mar-09	6-Feb-07		3-Dec-13	"Universitätsklinik Innsbruck; Abteilung für Neurochirurgie, Innsbruck, Austria|Landes-Nervenklinik Wagner-Jauregg, Linz, Austria|Kaiser Franz Josef Spital, Abteilung für Neurologie, Wien, Austria|Sarajishvili Institute of Clinical Neurology and Neurosurgery, Tbilisi, Georgia|Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin, Germany|Klinik und Poliklinik für Neurologie, Cottbus, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany|Universitätsklinikum Gießen, Neurochirurgische Universitätsklinik, Gießen, Germany|Universitätsklinikum Kiel, Klinik für Neurochirurgie, Kiel, Germany|Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Germany|Universitätsklinik Magdeburg, Klinik für Neurochirurgie, Magdeburg, Germany|Universitätskliniken Mainz, Neurochirurgische Klinik und Poliklinik, Mainz, Germany|Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie, Münster, Germany|Klinikum und Poliklinik für Neurologie, Universität Regensburg, Regensburg, Germany|Klinikum Saarbrücken, Neurochirurgie, Saarbrücken, Germany|Neurologische Universitätsklinik Tübingen, Tübingen, Germany|Department of Neurosurgery, Amrita Institute of Medical Sciences & Research Centre, Cochin, Kerala, India|Sree Chitra Tirunal Institute for Medical Sciences & Technology, Department of Neurosurgery, Trivandrum, Kerala, India|Manipal Hospital; Manipal Institute for Neurological Disorders, Bangalore, India|Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, India|Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, India|Department of Neurosurgery, LTMG Hospital & LTM Medical College, Mumbai, India|Department of Neurosurgery, Neurosciences Center, New Dehli, India|Department of Neurological Sciences, Christian Medical College & Hospital, Vellore, India|Soroka Medical Center, Neurosurgery Department, Beer Sheva, Israel|Rambam Medical Center, Neurosurgery Department, Haifa, Israel|Rabin Medical Center, Neurosurgery Department, Petach Tikva, Israel|Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation|Republican Clinical Hospital of Ministry of Health of Tatarstan Republic, Kazan, Russian Federation|Burdenko Neurosurgery Research Institute, Moscow, Russian Federation|Omsk State Medical Academy; State Educational Institution of Higher Professional Education, Omsk, Russian Federation|State Institution of Healthcare, Samara Regional Clinical Hospital in the name of M.I. Kalinin, Samara, Russian Federation|Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation|Military Medical Academy named after I.S.M. Kirov, Neurosurgery Department, St. Petersburg, Russian Federation|Medical Center ""XXI century"", St. Petersburg, Russian Federation|Tcheliabinsk Regional Clinical Hospital; State Medical Institution for Prophylaxis and Treatment, Tcheliabinsk, Russian Federation"		https://ClinicalTrials.gov/show/NCT00431561
1050	NCT04903795	Bispecific T Cell Engager BRiTE for Patients With Grade IV Malignant Glioma	BRiTE	Not yet recruiting	No Results Available	Malignant Glioma|Glioblastoma	Drug: hEGFRvIII-CD3 (BRiTE)|Biological: Activated Cell Therapy	Dose-limiting toxicity (DLT)|Objective response rate (ORR)|Pharmacokinetic (PK) of BRiTe observed during the first injection of BRiTE as measured by time (in minutes)|Pharmacokinetic (PK) of BRiTe administered with ACT as measured by time (in minutes)	Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00108079	May-22	Dec-22	Dec-22	27-May-21		23-Nov-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04903795
1051	NCT01648348	Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Neoplasm	Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment	Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose Limiting Toxicities|Progression-free Survival (PFS) (Phase II)|Overall Toxicity Rate for Grade 3 or Higher Adverse Events Considered at Least Possibly Related to Treatment (Phase II)|Overall Survival (Phase II)|Progression Free Survival at 6 Months (PFS6) (Phase II) as Measured by the Percentage of Participants With Progression Free Survival at 6 Months|Quality of Life (QOL) as Assessed by the EORTC QLQ-C15-PAL Questionnaire [Item 15: Global Health Status/Quality of Life] (Phase II)|QOL Assessed by EORTC-QLQ-BN20 Patient Questionnaire [Items 1-20] (Phase II)|QOL Assessed by WIWI Questionnaire (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	116	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01989|CDR0000737109|N1174|NCCTG-N1174|U10CA180821|U10CA025224	Nov-12	11-May-16	15-Apr-17	24-Jul-12	23-May-18	23-May-18	"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Saint Jude Medical Center, Fullerton, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Sharp Memorial Hospital, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Gynecologic Oncology LLC, Newark, Delaware, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Nanticoke Memorial Hospital, Seaford, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|NorthShore Hematology Oncology-Libertyville, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States|Spector, David MD (UIA Investigator), Moline, Illinois, United States|Trinity Medical Center, Moline, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Michiana Hematology Oncology PC-Crown Point, Crown Point, Indiana, United States|Elkhart Clinic, Elkhart, Indiana, United States|Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Community Howard Regional Health, Kokomo, Indiana, United States|IU Health La Porte Hospital, La Porte, Indiana, United States|Memorial Regional Cancer Center Day Road, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States|Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States|Reid Health, Richmond, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States|Mary Greeley Medical Center, Ames, Iowa, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Constantinou, Costas L MD (UIA Investigator), Bettendorf, Iowa, United States|McFarland Clinic PC-Boone, Boone, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|McFarland Clinic PC-Trinity Cancer Center, Fort Dodge, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|McFarland Clinic PC-Jefferson, Jefferson, Iowa, United States|McFarland Clinic PC-Marshalltown, Marshalltown, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wichita NCI Community Oncology Research Program, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Baptist Health Corbin, Corbin, Kentucky, United States|Oncology Hematology Care Inc-Crestview, Crestview Hills, Kentucky, United States|Hardin Memorial Hospital, Elizabethtown, Kentucky, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Baptist Health Madisonville/Merle Mahr Cancer Center, Madisonville, Kentucky, United States|Baptist Health Paducah, Paducah, Kentucky, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Beaumont Hospital-Dearborn, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Community Hospital, Niles, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Ann Arbor Hematology -Oncology Associates, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Saint Luke's Hospital of Duluth, Duluth, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|LRGHealthcare-Lakes Region General Hospital, Laconia, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|MD Anderson Cancer Center at Cooper-Voorhees, Voorhees, New Jersey, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Mount Sinai Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio, United States|Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio, United States|Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OneHealth Marion General Hospital, Marion, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|PinnacleHealth Cancer Center-Community Campus, Harrisburg, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Andrews, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|University Medical Center Brackenridge, Austin, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Community Memorial Hospital, Menomonee Falls, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Big Horn Basin Cancer Center, Cody, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT01648348
1052	NCT00002619	Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation		NYU Langone Health	All	"6 Years to 59 Years   (Child, Adult)"	Phase 2	60	Other	Interventional	Primary Purpose: Treatment	CDR0000063964|NYU-97-8|MSKCC-94101|NCI-V94-0594	Sep-94	Apr-00		11-Aug-04		9-Nov-12	"Kaplan Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00002619
1053	NCT02903069	Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer		Completed	No Results Available	Glioblastoma|Malignant Glioma	Drug: MRZ|Drug: TMZ|Radiation: RT|Device: Optune	"Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ)|To assess adverse events during the adjuvant treatment|To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients|Assess adverse events during concomitant and adjuvant treatment|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT|MRZ pharmacokinetics - Maximum Serum Concentration (Cmax)|MRZ pharmacokinetics - Elimination Half-Life (t1/2)|MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t, AUC0-inf)|MRZ pharmacokinetics - Clearance (CL)|MRZ pharmacokinetics - Volume of Distribution (Vd)|TMZ serum concentration|Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)|Evaluate the activity (overall survival [OS]) of MRZ + TMZ + Optune|Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + Optune"	Celgene|Triphase	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	66	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MRZ-112	17-Aug-16	25-Jan-21	25-Jan-21	16-Sep-16		19-Apr-21	"University of California San Diego Medical Center, La Jolla, California, United States|UC Irvine, Orange, California, United States|John Wayne Cancer Center Outpatient Clinic, Santa Monica, California, United States|Northwestern Center For Clinical Research, Chicago, Illinois, United States|Duke Cancer Center, Durham, North Carolina, United States|Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|University of Zurich Hospital, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT02903069
1054	NCT02833701	Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma		Terminated	No Results Available	Glioblastoma|Glioma	Dietary Supplement: Ascorbic Acid|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment	Frequency of occurrence of overall toxicity|Incidence of dose limiting toxicities (DLT)|Incidence rates of adverse events|Maximum tolerated dose of ascorbic acid in combination with bevacizumab defined as the highest dose tested which results in DLT in no more than 1 of 6 evaluable patients|Changes in serum levels of ascorbic acid using HPLC with coulometric electrochemical detection|Disease status by radiologic assessment|Progression free survival|QOL using EORTC QLQ-C30|Survival	University of Nebraska|National Cancer Institute (NCI)	All	"19 Years and older   (Adult, Older Adult)"	Phase 1	9	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	769-15|NCI-2016-00239|769-15-FB|P30CA036727	Mar-16	Mar-19	Mar-19	14-Jul-16		26-Jul-19	"University of Nebraska Medical Center, Omaha, Nebraska, United States"		https://ClinicalTrials.gov/show/NCT02833701
1055	NCT03877861	Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms		Completed	No Results Available	Glioma|Glioblastoma	Device: Readiband Sleep Tracking	"Correlation between sleep patterns and disease progression/recurrence|Correlation between SAFTE fatigue predictions and self-reported fatigue levels|Sleep pattern differences between healthy controls and brain tumor patients|Correlation between fatigue and sleep patterns and treatment tolerance/success|Change in Sleep, Activity, Fatigue, and Task Effectiveness (SAFTE) score"	Allina Health System	All	"22 Years to 70 Years   (Adult, Older Adult)"		7	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NSJT-1701	15-Mar-18	1-May-21	1-May-21	18-Mar-19		9-Jun-21	"Abbott Northwestern Hospital, Minneapolis, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT03877861
1056	NCT02664363	EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma	ExCeL	Terminated	Has Results	Glioblastoma|Gliosarcoma	Biological: EGFRvIII CAR T cells	Maximally Tolerated Dose|Number of Patients Who Experienced a Dose-limiting Toxicity (DLT)	Gary Archer Ph.D.|Duke University	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	3	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00069444	1-Feb-17	25-Sep-18	12-Sep-19	27-Jan-16	24-Jul-20	24-Jul-20	"The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/63/NCT02664363/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02664363
1057	NCT03868943	Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma	JAZZ	Recruiting	No Results Available	Glioma|Glioblastoma	Drug: Soliramfetol	Proportion of Adverse Events|Epworth Sleepiness Scale|Pittsburgh Sleep Quality Index (PSQI)|Neurocognitive Battery Record|Cancer Fatigue Scale (CFS)|Beck's Depression Inventory (BDI)|FACT-Brain module (FACT-Br)|7 day Actigraphy|7-day Patient-Reported Sleep Diary	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB00056700|NCI-2019-01299|P30CA012197|CCCWFU 98418	27-Jan-21	Aug-22	30-Jan-23	11-Mar-19		5-Feb-21	"Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03868943
1058	NCT00548938	"Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM"		Terminated	No Results Available	Glioblastoma Multiforme|High-Grade Glioma	Drug: Gliadel wafer|Drug: Temozolomide|Radiation: External Beam Radiation Therapy	"To determine the efficacy of Gliadel wafer + radiation + temozolomide in patients with newly diagnosed high grade glioma undergoing surgery as determined by time to disease progression.|Median, one year and overall survival rate."	Methodist Healthcare	All	"18 Years to 72 Years   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MHIRB #2007-040	Oct-07	Oct-09	Oct-10	24-Oct-07		18-Sep-09	"Methodist University Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00548938
1059	NCT02490930	A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma		Completed	No Results Available	Glioblastoma|Anaplastic Astrocytoma	Drug: Fingolimod	Incidence of severe infection attributable to fingolimod-induced lymphopenia|Total lymphocyte counts (TLC)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	J14168|IRB00055036	Jul-15	Sep-17	Sep-17	7-Jul-15		13-Sep-17	"The Johns Hopkins University, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT02490930
1060	NCT03551249	Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption		Recruiting	No Results Available	Glioma|Glioblastoma	Device: Focused ultrasound (FUS)	Device and procedure related adverse events|Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging	InSightec	All	"18 Years to 80 Years   (Adult, Older Adult)"	Not Applicable	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT008	26-Mar-19	Mar-22	Dec-24	11-Jun-18		28-Jun-21	"University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Virginia, Charlottesville, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States"		https://ClinicalTrials.gov/show/NCT03551249
1061	NCT03532295	INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas		Recruiting	No Results Available	Glioma|Glioblastoma	Drug: Epacadostat|Drug: Bevacizumab|Radiation: Radiation therapy|Procedure: Peripheral blood draw	Overall survival|Progression-free survival (PFS)|Neurologic functions as measured by the NANO scale|Safety and toxicity of regimen as measured by adverse events experienced by participant	Washington University School of Medicine|Incyte Corporation	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	55	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202003050	20-Apr-20	31-Jan-23	30-Apr-26	22-May-18		29-Oct-21	"Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03532295
1062	NCT04869449	Neuro-pharmacological Study of Ketoconazole for High-grade Gliomas		Not yet recruiting	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain|Glioblastoma Multiforme, Adult"	Drug: Ketoconazole	"Establish drug concentration versus time profile yielding maximum plasma concentration (Cmax)|Establish drug concentration versus time profile yielding half-life pharmacodynamics|Frequency and severity of treatment-emergent adverse events as assessed by CTCAE v 5.0|Hexokinase activity assay- measured as a proportion of hexokinase enzyme activity in relation to positive control|Concentration of lactate measured using mass spectrometry in resected tumor tissue|Concentration of pyruvate, measured using mass spectrometry in resected tumor tissue|Evaluate ketoconazole's effect on tumor proliferation in tumor tissue|Evaluate ketoconazole's effect on cell death in tumor tissue|Evaluate ketoconazole's effect on angiogenesis in tumor tissue|Correlation of concentration versus time profile of ketoconazole , compared to that of lactate - measured using mass spectrometry over 24 hours|Correlation of concentration versus time profile of ketoconazole, compared to that of pyruvate - measured using mass spectrometry over 24 hours"	Milton S. Hershey Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00014115	Jan-22	May-23	May-23	3-May-21		10-Nov-21	"Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04869449
1063	NCT04825275	Neuro-pharmacological Study of Posaconazole for High-grade Gliomas: A Phase 0 Clinical Trial		Not yet recruiting	No Results Available	"Glioblastoma|Glioblastoma Multiforme|Glioblastoma Multiforme of Brain|Glioblastoma Multiforme, Adult"	Drug: Posaconazole Pill	"Establish the neuro-pharmacokinetic profile of posaconazole, using microdialysis catheters|Evaluate tolerability of preoperative steady-state dosing of Posaconazole|Evaluate posaconazole effect on Hexokinase 2 activity within tumor tissue|Evaluate posaconazole on tumor proliferation in tumor tissue|Evaluate posaconazole on cell death in tumor tissue|Evaluate posaconazole angiogenesis in tumor tissue|Correlation of posaconazole pharmacokinetic profile with that of lactate using MDC|Correlation of posaconazole pharmacokinetic profile with that of pyruvate using MDC"	Milton S. Hershey Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STUDY00015948	Jan-22	May-23	May-23	1-Apr-21		10-Nov-21	"Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT04825275
1064	NCT00503204	Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour		Completed	No Results Available	Recurrent Glioblastoma|Brain Tumor	Drug: Cediranib|Drug: Lomustine	"Assess the safety and tolerability of cediranib in combination with oral lomustine and to confirm a dose for further studies with this combination.|Compare the pharmacokinetics of cediranib alone versus when in combination with lomustine as measured by minimum steady state plasma concentration (Css,min) steady-state plasma concentration"	AstraZeneca	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D8480C00057|EuDract 2007-000909-30	Sep-07	Dec-08	Dec-08	18-Jul-07		25-Nov-09	"Research Site, Boston, Massachusetts, United States|Research Site, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT00503204
1065	NCT02006563	Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors		Completed	No Results Available	Brain Tumor|Glioblastoma Multiforme		Difference between Metabolic Tumor Volumes and Clinical Tumor Volumes in Patients with Brain Tumors	University of Miami	All	"18 Years and older   (Adult, Older Adult)"		22	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	20100809	8-Jun-11	Jan-16	Jul-17	10-Dec-13		24-Oct-17	"University of Miami, Miami, Florida, United States"		https://ClinicalTrials.gov/show/NCT02006563
1066	NCT01238237	Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA		Completed	No Results Available	Glioblastoma Multiforme (GBM)|ANAPLASTIC ASTROCYTOMA (AOA)|GBM|Anaplastic Astrocytoma	Drug: Superselective Intraarterial Cerebral Infusion of Cetuximab	The maximum tolerated dose (MTD) of superselective intracerebral intraarterial Cetuximab.|descriptive frequency of subjects experiencing toxicities .|Composite overall response rate|Six-month progression-free survival (PFS) and overall survival (OS).	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-712	Dec-09	Jan-16	Jan-16	10-Nov-10		1-Feb-17	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01238237
1067	NCT01516905	PET/CT Imaging of Malignant Brain Tumors With 124I-NM404		Completed	No Results Available	Glioblastoma|Brain Metastases	Drug: NM404	tumor to background ratios	"University of Wisconsin, Madison|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"		19	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	RO11310|1R01CA158800-01|NCI-2012-02042|2011-0452|A539300|SMPH\RADIOLOGY\RADIOLOGY	Dec-11	17-May-16	17-May-16	25-Jan-12		15-Nov-19	"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01516905
1068	NCT01502241	Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly	Methusalem	Completed	No Results Available	Glioblastoma|Anaplastic Astrocytoma	Drug: Temozolomide|Radiation: Radiotherapy of the partial brain.	Overall survival|Event-free survival|Best response|Molecular prognostic or predictive biomarkers	Heidelberg University	All	65 Years and older   (Older Adult)	Phase 3	412	Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NOA-08|05-01	Jan-05	Nov-10	Nov-11	30-Dec-11		30-Dec-11	"University of Heidelberg, Heidelberg, Baden-Württemberg, Germany|University of Frankfurt, Frankfurt, Hessen, Germany|Charite Berlin, Berlin, Germany|University of Bochum, Bochum, Germany|University of Bonn, Bonn, Germany|University of Dresden, Dresden, Germany|University of Düsseldorf, Düsseldorf, Germany|University of Erlangen, Erlangen, Germany|University of Essen, Essen, Germany|University of Freiburg, Freiburg, Germany|University of Hamburg, Hamburg, Germany|University of Hannover II, Hannover, Germany|University of Hannover, Hannover, Germany|University of Homburg, Homburg, Germany|University of Kiel, Kiel, Germany|University of Leipzig, Leipzig, Germany|University of Mainz, Mainz, Germany|University of Heidelberg, Mannheim, Germany|University of Marburg, Marburg, Germany|University of Regensburg, Regensburg, Germany|University of Tübingen, Tübingen, Germany|University of Ulm, Ulm, Germany|University of Zurich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT01502241
1069	NCT04780009	Loupe-Based Intraoperative Fluorescence Imaging		Recruiting	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma		Positive Predictive Value (PPV)|Negative Predictive Value (NPV)|Residual Tumor	Guoqiang Yu|Bioptics Technology LLC|National Cancer Institute (NCI)|Kentucky Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR)|University of Kentucky	All	"18 Years to 90 Years   (Adult, Older Adult)"		20	Other|NIH	Observational	Observational Model: Case-Only|Time Perspective: Prospective	MCC-17-0605-F1V|R41CA243600-01	17-Nov-17	31-Jul-22	31-Jul-22	3-Mar-21		3-Mar-21	"University of Kentucky, Lexington, Kentucky, United States"		https://ClinicalTrials.gov/show/NCT04780009
1070	NCT02025231	Image Guided Reirradiation of High-grade Glioma		Terminated	No Results Available	Malignant Glioma|Glioblastoma	Radiation: External beam radiotherapy	Toxicity|Diagnostic precision of 18F-FET-PET imaging in recurrent high-grade glioma|Time to neurocognitive decline|Time to progression|Value of 18F-FET-PET in reirradiation of high-grade glioma|Objective response rate	"Rigshospitalet, Denmark|Danish Center for Interventional Research in Radiation Oncology (CIRRO)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	31	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RH ReRT 2011|H-2-2011-092	Dec-11	Apr-15	Apr-15	31-Dec-13		8-Feb-17	"Department of Radiation Oncology, Rigshospitalet, Copenhagen, Denmark|Skånes universitetssjukhus, Lund, Sweden"		https://ClinicalTrials.gov/show/NCT02025231
1071	NCT03615404	"Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma"	ATTAC-P	Completed	Has Results	"Glioblastoma|Malignant Glioma|Medulloblastoma Recurrent|Pediatric Glioblastoma Multiforme|Pediatric Brain Tumor, Recurrent|Pediatric Brain Tumor"	Biological: CMV-DCs with GM-CSF|Biological: Td (tetanus toxoid)	Percentage of Patients for Whom 3 or More Vaccines Can be Made|Percentage of Patients Who Experience Unacceptable Toxicity	Gary Archer Ph.D.|Duke University	All	"up to 35 Years   (Child, Adult)"	Phase 1	11	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00092868	5-Oct-18	19-Nov-19	2-Jul-20	3-Aug-18	28-Jan-21	28-Jan-21	"Duke University Medical Center, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/04/NCT03615404/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT03615404
1072	NCT03834740	A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection		Recruiting	No Results Available	Glioblastoma Multiforme|Glioma of Brain	Drug: Ribociclib|Drug: Everolimus	"Pharmacokinetic analysis -Total and Unbound Ribociclib and Everolimus AUC (0-24)|Pharmacokinetic analysis - Total and Unbound Ribociclib and Everolimus Median concentration Cmax (0-24)|Pharmacokinetic analysis -Median concentration of Total Ribociclib and Everolimus Tmax|Pharmacokinetic analysis - Total Ribociclib and Everolimus T1/2 (0-24)|Pharmacokinetic analysis - Total and Unbound Ribociclib and Everolimus CL/F (0-24)|Median concentration of ribociclib and everolimus for all patients for unbound plasma, CSF, Unbound NE, Unbound enhancing (2-24H post last dose)|The percentage of pRB positive cells will be quantified in resected post-treatment recurrent tumor tissue compared to baseline (archival primary GBM tumor)|The percentage of pS6 positive cells will be quantified in resected post-treatment recurrent tumor tissue compared to baseline (archival primary GBM tumor)|MTD: highest dose of drug that did not cause a DLT in > 33% of participants|Median progression-free survival (PFS) from time of surgery to date of recurrence in Phase 2 patients|Median Overall Survival (OS) from time of surgery to date of recurrence in Phase 2 patients|Number of Adverse Events|Median concentration of trough plasma concentrations of Total Ribociclib and Total Everolimus in Phase 2"	"St. Joseph's Hospital and Medical Center, Phoenix|Ivy Brain Tumor Center|Barrow Neurological Institute"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	24	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-500-311-70-38	21-Dec-18	30-Jun-21	31-Jul-22	8-Feb-19		22-Mar-21	"Chandler Regional Medical Center, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States"		https://ClinicalTrials.gov/show/NCT03834740
1073	NCT00613093	Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Glioma	Drug: Temodar and O6-Benzylguanine (BG)	Radiographic evidence of tumor response|6 month progression-free survival|Relationship between tumor AGT at original diagnosis & response to Temozolomide + O6-BG	"Duke University|Keryx / AOI Pharmaceuticals, Inc.|National Institutes of Health (NIH)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	67	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4260	Oct-02	Mar-06	Aug-08	12-Feb-08		9-Jul-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00613093
1074	NCT01905228	A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm		Completed	No Results Available	Solid Tumors|Glioblastoma	Drug: CBL0137	Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)	Incuron	All	"15 Years and older   (Child, Adult, Older Adult)"	Phase 1	83	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I137-101	Jul-13	May-19	Jun-19	23-Jul-13		10-Dec-20	"Roswell Park Cancer Institute, Buffalo, New York, United States|University Hospital of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|CTRC at The University of Texas Healh Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT01905228
1075	NCT03401866	Multi-site Validation and Application of a Consensus DSC-MRI Protocol		Unknown status	No Results Available	Glioblastoma Multiforme|Gliosarcoma	Diagnostic Test: DSC-MRI	Histologic measures of tumor fraction|Determine the repeatability of rCBV measured with the consensus DSC-MRI protocol.|Determine overall survival (OS) in recurrent GBM patients.	"St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	80	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	17-DSC-MRI-Quarles	Feb-18	Jan-21	Jul-21	17-Jan-18		17-Jan-18	"Mayo Clinic, Scottsdale, Arizona, United States|Brown University, Providence, Rhode Island, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03401866
1076	NCT00039572	Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain		Completed	No Results Available	Brain and Central Nervous System Tumors|Melanoma (Skin)|Metastatic Cancer	Drug: boronophenylalanine-fructose complex		Beth Israel Deaconess Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	BIDMC-E-010284FB|CDR0000069398|NEDH-E-010284FB|NCI-V02-1702	May-02		Jan-05	27-Jan-03		26-Jun-13	"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Massachusetts Institute of Technology, Cambridge, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00039572
1077	NCT02933736	Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients		Recruiting	No Results Available	Glioblastoma Multiforme|Meningioma	Drug: Ribociclib	Plasma Exposure|CSF Penetration|Brain Accumulation of Ribociclib	"Nader Sanai|Novartis|Ivy Brain Tumor Center|Barrow Neurological Institute|St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	48	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PHX-16-0116-80-12	Oct-16	Jun-22	Nov-22	14-Oct-16		11-Oct-21	"Barrow Brain and Spine, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT02933736
1078	NCT03865355	Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients		Recruiting	No Results Available	Glioma|Glioblastoma Multiforme	Other: Non- interventional	Metabolic phenotype of glioma patients|Overall survival (OS)|Progression free survival (PFS)	"Novosibirsk State University|FSBI ""Federal Neurosurgical Center"" Novosibirsk, Russia|FSBI ""Novosibirsk Research Institute of Traumatology and Orthopedics named after Ya. L. Tsiviyan"", Russia"	All	"18 Years and older   (Adult, Older Adult)"		50	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	MetGlio/19	13-Mar-19	11-Apr-24	11-Apr-29	6-Mar-19		17-Sep-20	"Novosibirsk State University, Novosibirsk, Novosibirskaya Oblast', Russian Federation"		https://ClinicalTrials.gov/show/NCT03865355
1079	NCT00939991	"Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas"		Completed	Has Results	Brain Tumor|Glioblastoma	Drug: Vorinostst/Bevacizumab/Temozolomide	"Phase I: Determination of the Maximum Tolerated Dose (MTD)|Phase II: 6-month Progression-free Survival (PFS)|Phase II: Radiographic Response.|Phase II: Median Progression-free Survival (PFS)|Phase II: Median Overall Survival (OS)|Phase II: Number of Patients With Grade 2 or Greater, Treatment-related Toxicities"	"Katy Peters|Genentech, Inc.|Merck Sharp & Dohme Corp.|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	48	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00016446	Oct-09	Jan-12	Apr-13	15-Jul-09	24-Jun-13	24-Jun-13	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00939991
1080	NCT02142803	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors		"Active, not recruiting"	No Results Available	Adult Glioblastoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Serous Adenocarcinoma|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Cancer|Solid Neoplasm|Stage IIIA Fallopian Tube Cancer AJCC v7|Stage IIIA Ovarian Cancer AJCC v6 and v7|Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIB Fallopian Tube Cancer AJCC v7|Stage IIIB Ovarian Cancer AJCC v6 and v7|Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIC Fallopian Tube Cancer AJCC v7|Stage IIIC Ovarian Cancer AJCC v6 and v7|Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7	Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib	"MTD/RP2D of TORC1/2 inhibitor MLN0128, determined according to incidence of dose-limiting toxicity, as graded using the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events, graded according to NCI CTCAE version 4.0|PFS|Objective RR, defined as a complete or partial response, as determined by investigator assessment using RECIST or RANO|OS|Frequency of toxicities leading to missed doses or delays|Percentage of courses given or not within 7 days of their scheduled times|Percentage of actual planned dosage administration|Percentage of patients that discontinue study drugs due to treatment related toxicity"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	50	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-01118|14-079|9552|P30CA006516|U01CA062490|U01CA076576|UM1CA186709|UM1CA186712	20-May-14	31-Dec-20		20-May-14		18-Nov-21	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02142803
1081	NCT03149575	VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM	STAR-3	Terminated	No Results Available	Glioblastoma Multiforme|Glioblastoma|Glioma|GBM|Brain Cancer	"Drug: VAL-083, Dianhydrogalactitol|Drug: Physician's Choice of Salvage Therapy - temozolomide|Drug: Physician's Choice of Salvage Therapy - lomustine|Drug: Physician's Choice of Salvage Therapy - carboplatin"	Overall Survival|Progression Free Survival|Duration of Response|Incidence of Treatment-Emergent Adverse Events (Overall Safety and Toxicity)|Cmax|Tmax|AUClast|AUCinf|CL/F|Mean Residence Time|Vz|Lambda z|T 1/2|Quality of Life	"DelMar Pharmaceuticals, Inc.|Kintara Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	2	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DLM-16-002	27-Oct-17	31-May-19	31-Aug-19	11-May-17		14-Nov-19	"Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|University of California, San Francisco - Division of Neuro-Oncology, San Francisco, California, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Atlantic Neuroscience Institute - Brain Tumor Center of NJ, Summit, New Jersey, United States|Dent Neurosciences Research Center, Amherst, New York, United States"		https://ClinicalTrials.gov/show/NCT03149575
1082	NCT03283631	Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM	INTERCEPT	Terminated	No Results Available	Recurrent Glioblastoma|Recurrent Gliosarcoma	Biological: EGFRvIII-CARs	Determination of Maximum Tolerated Dose (MTD)|Assessment of T Cell trafficking within the brain tumor|Assessment of T cell trafficking systemically|Median survival|Median progression-free survival	Gary Archer Ph.D.|National Cancer Institute (NCI)|Duke Cancer Institute|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	2	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00083828|5P50CA190991-03	30-May-18	19-Sep-19	30-Jun-20	14-Sep-17		5-Apr-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03283631
1083	NCT00870181	ADV-TK Improves Outcome of Recurrent High-Grade Glioma	HGG-01	Completed	No Results Available	Malignant Glioma of Brain|Glioblastoma	Biological: ADV-TK/GCV|Procedure: Surgery|Drug: systemic chemotherapy	The primary end point was 6-month progression-free survival rate (PFS-6)|progression-free survival (PFS)|overall survival (OS)|safety|clinical benefit	Huazhong University of Science and Technology|Beijing Tiantan Hospital|Beijing Chao Yang Hospital|Beijing Friendship Hospital	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	47	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009HGG-01	Jan-08	Dec-11	Dec-12	27-Mar-09		25-Jun-13	"Beijing YouAn Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT00870181
1084	NCT00780819	Borderzone Sampling	BZS	Completed	No Results Available	High Grade Glioma|Glioblastoma	Device: PoleStar N20 intraoperative MRI	"The relation between the shape and size of contrast enhancement on intraoperative MRI at the resection cavity border, and the presence of residual tumor tissue.|The relation between possible contrast enhancement and contrast enhancing tissue volume on the last intraoperative MRI scan and the early diagnostic MRI scan|Postoperative clinical condition (WHO Performance Scale)|Survival (Kaplan Meier)"	Maastricht University Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MEC 07-2-039|ABR-17679	Oct-08	Jul-09	Dec-12	28-Oct-08		14-May-13	"Maastricht University Medical Center, Maastricht, Limburg, Netherlands"		https://ClinicalTrials.gov/show/NCT00780819
1085	NCT04267978	Study of Recombinant Human Endostatin Combined With Temozolomide and Irinotecan in Recurrent Gliomas		Recruiting	No Results Available	"Glioblastoma, Recurrent|Lower Grade Glioma, Recurrent"	"Drug: recombinant human endostatin,temozolomide,irinotecan"	progression-free survival rate at 6 months|objective response rate|Progression-free survival|Overall survival|Safety data	Beijing Sanbo Brain Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	109	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SBNK-YJ-2019-006-02	13-Feb-20	28-Feb-23	30-Nov-23	13-Feb-20		3-Dec-20	"Beijing Sanbo Brain Hospital, Beijing, China"		https://ClinicalTrials.gov/show/NCT04267978
1086	NCT03607643	"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies"		Unknown status	No Results Available	"Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer, Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme"	Drug: Cannabidiol|Drug: Bortezomib|Drug: Leucovorin|Drug: 5-FU|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Irinotecan|Drug: Gemcitabine|Drug: Temozolomide	Response rate|Time to progression (TTP) in patients using lab results and radiographic data.|Progression-free survival (PFS) in patients using lab results and radiographic data.|Quality-of-life assessment in patients using patient-reported outcomes (PRO) data.|Quality-of-life assessment in patients using clinician-reported outcomes (ClinRO) data.	Leaf Vertical Inc.	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1|Phase 2	160	Industry	Interventional	"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	Olympian	15-Jan-19	30-Jun-20	15-Dec-20	31-Jul-18		31-Jul-18	"Southwest Cancer Center, Orlando, Florida, United States"		https://ClinicalTrials.gov/show/NCT03607643
1087	NCT02781792	Temozolomide Chronotherapy for High Grade Glioma		"Active, not recruiting"	No Results Available	Glioma|Glioblastoma Multiforme	Drug: Temozolomide|Other: Functional Assessment of Cancer Therapy - Brain|Other: ActTrust Condor Instrument Watch	"Feasibility of patient treatment compliance as measured by at least 80% compliance with assigned administration time|Duration of response|Number of patients experiencing grade 3 or 4 lymphopenia, thrombocytopenia, neutropenia and anemia in each group as measured by standard blood draws|Quality of life as measured by FACT-Br score|Progression-free survival (PFS)|Overall survival|Comparison of the level of sleep disruption in sleep-wake cycles of participants receiving temozolomide in the morning versus participants receiving temozolomide in the evening"	Washington University School of Medicine	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	42	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201605081	11-Aug-16	28-Feb-22	30-Nov-22	24-May-16		17-Aug-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT02781792
1088	NCT01540513	PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404		Completed	Has Results	Glioblastoma Multiforme|Brain Metastases	Drug: NM404	Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake|Tumor to Background Ratios (TBR) Post-imaging for Confirmed Malignant Tumors|Tumor to Blood Pool Ratios Post-imaging for All Lesions With PET Uptake|Tumor to Blood Pool Ratios Post-imaging for Confirmed Malignant Tumors	"University of Wisconsin, Madison"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	RO11360|2011-0830|NCI-2012-02080|A539300|SMPH\RADIOLOGY\RADIOLOGY	Mar-12	Oct-14	Oct-14	28-Feb-12	11-Dec-17	2-Dec-19	"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01540513
1089	NCT02794883	Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma		Unknown status	No Results Available	Malignant Glioma|Recurrent Glioblastoma	Biological: Durvalumab|Other: Laboratory Biomarker Analysis|Procedure: Surgical Procedure|Biological: Tremelimumab	T-cell (immunologic) changes in blood|MRI changes|Incidence of Adverse Events|Overall survival|Time to progression	Northwestern University|AstraZeneca|MedImmune LLC|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 15C03|STU00202283|P30CA060553|NCI-2016-00665	Sep-16	Dec-19	Jun-20	9-Jun-16		5-Apr-19	"Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT02794883
1090	NCT01124461	BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor	CONDR	Completed	No Results Available	GLIOBLASTOMA MULTIFORME|Brain Neoplasm			Washington University School of Medicine|National Institute of Neurological Disorders and Stroke (NINDS)	All	"18 Years to 70 Years   (Adult, Older Adult)"		112	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	09-1625|1R01NS066905-01	Jan-10	Nov-17	Nov-17	17-May-10		11-May-18	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01124461
1091	NCT01811992	Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma		Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme	Biological: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L	Maximum Tolerated Dose (MTD)|Number of Patients Alive at 12 and 24 Months	University of Michigan Rogel Cancer Center|Phase One Foundation	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	19	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2015.024|HUM00057130	Apr-14	Feb-19	Jan-21	15-Mar-13		31-Aug-21	"University of Michigan Health System Department of Neurosurgery, Ann Arbor, Michigan, United States"		https://ClinicalTrials.gov/show/NCT01811992
1092	NCT00611325	Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Avastin|Drug: Bortezomib	"6-month Progression-free Survival (PFS)|Median Progression Free Survival (PFS)|Median Overall Survival (OS)|Radiographic Response Rate|Number of Patients With Grade 3 or Greater, Treatment-related, Non-hematologic Toxicities"	"Duke University|Millennium Pharmaceuticals, Inc.|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	56	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00003596	May-08	Sep-09	Oct-13	8-Feb-08	4-Feb-14	12-Mar-14	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00611325
1093	NCT00671970	Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Bevacizumab and Erlotinib	6 Month Progression-free Survival|Radiographic Response|Pharmacokinetics of Erlotinib: Cmax|Pharmacokinetics of Erlotinib: AUC|Association of Biomarkers and One-year Survival - Epidermal Growth Factor (EGFR)|Association of Biomarkers and One-year Survival - EGFR vIII|Association of Biomarkers and One-year Survival - Phosphatase and Tensin Homologue (PTEN)|Association of Biomarkers and One-year Survival - Phosphorylated Protein Kinase B (pAKT)|Association of Biomarkers and One-year Survival - Phosphorylated Mitogen-activated Protein Kinase (pMAPK)|Association of Biomarkers and One-year Survival - Vascular Endothelial Growth Factor (VEGF)|Association of Biomarkers and One-year Survival - VEGFR-2	"Duke University|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	57	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000220	Feb-07	Nov-08	Apr-10	6-May-08	13-May-13	13-May-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00671970
1094	NCT00672243	Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: Erlotinib + sirolimus	"6-month Progression-free Survival (PFS)|Median Progression Free Survival (PFS)|Median Overall Survival (OS)|Best Radiographic Response|Number of Participants Experiencing a ≥ Grade 3, Treatment-related, Non-hematologic Toxicity."	"Duke University|Genentech, Inc.|OSI Pharmaceuticals"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	32	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000345	Apr-07	Sep-08	Dec-09	6-May-08	4-Apr-13	7-Aug-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00672243
1095	NCT00085566	Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer		Completed	Has Results	Brain and Central Nervous System Tumors|Prostate Cancer	Drug: everolimus|Drug: gefitinib	Overall Objective Response	Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	Male	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	61	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	04-010|MSKCC-04010	Mar-04	Feb-08	Feb-08	11-Jun-04	20-Jan-16	20-Jan-16	"Memorial Sloan Kettering Cancer Center, New York, New York, United States|Vall d'Hebron University Hospital, Barcelona, Spain"		https://ClinicalTrials.gov/show/NCT00085566
1096	NCT04091503	Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma		Unknown status	No Results Available	"Glioma, Malignant|Gliosarcoma|Astrocytoma of Brain"	Drug: Intranasal Modified Temozolomide	The randomized study to determine the safety of Intranasal Administration of modified Temozolomide.|The maximum tolerated therapeutic dose (MTD) of modified Temozolomide for intranasal administration	Center Trials & Treatment Europe	All	"21 Years to 70 Years   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	7SQZ309D4W	10-Dec-19	15-Sep-20	15-Nov-20	16-Sep-19		17-Sep-19	"Central Contact, Banja Luka, Bosnia and Herzegovina|Central Contact, Plovdiv,, Bulgaria|Central Contact, Tbilisi, Georgia"		https://ClinicalTrials.gov/show/NCT04091503
1097	NCT01582152	Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma		Terminated	Has Results	Brain Neoplasms|Central Nervous System Neoplasms	Drug: TPI287|Drug: Bevacizumab	Progression Free Survival (PFS)|Objective Response Rate (ORR)	"M.D. Anderson Cancer Center|Cortice Biosciences, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	12	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0705|NCI-2012-00846	Jul-12	Mar-16	Mar-16	20-Apr-12	5-Jun-19	5-Jun-19	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01582152
1098	NCT00613054	Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma		Completed	No Results Available	Glioblastoma|Gliosarcoma	"Drug: Zactima, Gleevec, Hydroxyurea"	To determine MTD & dose-limiting toxicity (DLT) & Zactima when combo w Imatinib mesylate & Hydroxyurea among pt w Recurrent MG|To further assess safety & tolerability of Zactima & Imatinib mesylate & Hydroxyurea	Annick Desjardins|Novartis Pharmaceuticals|AstraZeneca|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000393	Nov-07	Mar-09	Apr-09	12-Feb-08		5-Dec-12	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00613054
1099	NCT04489420	Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM	CYNK001GBM01	"Active, not recruiting"	No Results Available	"Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme|Cyclophosphamide|Immunosuppressive Agents|Immunologic Factors|Physiological Effects of Drugs|Molecular Mechanisms of Pharmacological Action|Antiviral Agents|Anti-infective Agents|Analgesics, Non-narcotic|Analgesics|Sensory System Agents|Peripheral Nervous System Agents"	Biological: CYNK001-IV|Biological: CYNK001-IT	Number of Participants who experienced a Dose-Limiting Toxicity (DLT)|Adverse Events (AEs)|Overall Response Rate|Duration of Response Rate|Progression-free survival|Time to porgression|Overall Survival	Celularity Incorporated	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CYNK001-GBM-001	1-Oct-20	1-Sep-23	1-Feb-24	28-Jul-20		14-Jul-21	"The Univeristy of Texas MD ANderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04489420
1100	NCT03332355	Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2		Suspended	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma	Drug: PAC-1 Compound	Maximum Tolerated Dose (MTD)|Adverse Effects|Disease Response	"Vanquish Oncology, Inc.|University of Illinois at Chicago"	All	"18 Years to 85 Years   (Adult, Older Adult)"	Phase 1	9	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0058	1-Oct-17	31-Dec-21	30-Jun-22	6-Nov-17		22-Sep-20	"University of Illinois at Chicago, Chicago, Illinois, United States|Johns Hopkins Cancer Center, Baltimore, Maryland, United States|Regions Hospital, Saint Paul, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT03332355
1101	NCT00354913	Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma		Completed	Has Results	Glioblastoma|Gliosarcoma	Drug: hydroxyurea|Drug: imatinib mesylate	Progression-free Survival at 6 Months|Median Progression-free Survival (PFS)|Median Overall Survival (OS)|Objective Response Rate	Duke University|National Cancer Institute (NCI)|Novartis Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	21	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00006768|DUMC-7082-05-4R0|NOVARTIS-DUMC-7082-05-4R0	May-05	Mar-09	Oct-10	20-Jul-06	14-Jan-13	18-Jan-13	"Duke Cancer Institute, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00354913
1102	NCT00613223	Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas		Completed	No Results Available	Gliosarcoma|Glioblastoma	Drug: Vandetanib and Etoposide	"Safety, tolerability, biologic activity, & pharmacokinetic profile of vandetanib when used in combo w etoposide"	Annick Desjardins|AstraZeneca|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	49	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00001919	Feb-08	Oct-10	May-11	12-Feb-08		20-Feb-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00613223
1103	NCT02750891	A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas		Completed	No Results Available	Glioblastoma|Diffuse Intrinsic Pontine Glioma	Drug: DSP-7888	DLT (dose-limiting toxicity)|Overall Survival （OS）|Overall Response Rate（ORR）|Progression-free survival (PFS)|adverse events (AEs)|serious adverse events (SAEs)|DTH （delayed-type hypersensitivity）|WT1 peptide-specific CTL-induction activity|expression of WT1 in biopsy tissues|expression of HLA in biopsy tissues|expression of PD-L1 in biopsy tissues	"Sumitomo Dainippon Pharma Co., Ltd."	All	"up to 19 Years   (Child, Adult)"	Phase 1|Phase 2	18	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DB601001|JapicCTI-163216	Apr-16	Jan-20	Jan-20	26-Apr-16		9-Jun-20	"National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan|Osaka University Hospital, Suita, Osaka, Japan|National Center for Child Health and Development, Setagaya, Tokyo, Japan|Hiroshima University Hospital, Hiroshima, Japan|Osaka City General Hospital, Osaka, Japan"		https://ClinicalTrials.gov/show/NCT02750891
1104	NCT03900689	Social Determinants of Health in Glioblastoma Population		Recruiting	No Results Available	Glioma|Astrocytoma|Oligodendroglioma|Ependymoma|Ganglioglioma|Pleomorphic Xanthoastrocytoma	Other: Part 1 Survey Group|Other: Part 2 Focus Group	PRAPARE Instrument Questionnaire|Accountable Health Communities Health-Related Social Needs Screening Tool|Social Determinants of Health Supplementary Questionnaire|Proportion of Social Determinants Based on Two Communities|Social Determinants of Health in Participants|Social Determinants of Health in Participants' Communities|Comparisons of Treatment Timelines Among Low Income and High Income Communities|Number of Low Income to High Income Community Participants	Wake Forest University Health Sciences	All	"18 Years and older   (Adult, Older Adult)"		115	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	WFBCCC 03119|IRB00057185|NCI-2019-02214	22-May-19	Jan-22	May-22	3-Apr-19		11-Oct-21	"Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03900689
1105	NCT02431572	A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy		Completed	Has Results	Intracranial Tumors|Glioblastoma|Melanoma	Other: PBR PET|Biological: Cancer Immunotherapy|Radiation: Radiation and chemotherapy	Change in PBR Uptake (Changes in PBR Uptake by PET)|Median PBR Uptake	Massachusetts General Hospital	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	11	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	14-421	May-15	Feb-19	Feb-19	1-May-15	28-Apr-20	28-Apr-20	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/72/NCT02431572/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02431572
1106	NCT01068782	Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse		Completed	No Results Available	Astrocytic Tumors	Drug: XL184	"In the Randomized Phase, to evaluate the preliminary efficacy and tolerability of multiple regimens of XL184|In the Expansion Phase, to evaluate the efficacy of XL184 treatment|To further evaluate the safety and tolerability of XL184 treatment during the entire treatment period|To further characterize the pharmacokinetic and pharmacodynamic parameters of XL184"	Exelixis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	19	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XL184-205	Apr-10	May-11	Oct-13	15-Feb-10		30-Jul-14	"Birmingham, Alabama, United States|Encinitas, California, United States|Pleasant Hill, California, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Amhearst, New York, United States|Rochester, New York, United States|Cleveland, Ohio, United States|Hershey, Pennsylvania, United States|Dallas, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Seattle, Washington, United States|Calgary, Alberta, Canada|Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT01068782
1107	NCT01113398	AMG 102 and Avastin for Recurrent Malignant Glioma		Completed	Has Results	Glioblastoma Multiforme|Gliosarcoma	Drug: AMG 102|Drug: Avastin	Radiographic Response|Median Overall Survival (OS)|Six-month Progression-free Survival (PFS6)|Percentage of Participants Who Experience Treatment-related Grade 2 or Greater CNS Hemorrhage or Grade 4 or Greater Non-hematologic Toxicities	Katy Peters|Amgen|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	36	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00022491	Aug-10	Nov-14	Sep-15	29-Apr-10	10-Dec-15	10-Dec-15	"The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01113398
1108	NCT00479765	A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma		Terminated	Has Results	Glioblastoma Multiforme|Brain Neoplasms	Drug: OncoGel (ReGel/Paclitaxel)	Occurence of Dose-limiting Toxicities (DLTs)	BTG International Inc.	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	4	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PR016-CLN-pro002|OGL-109	Mar-07	Oct-09	Oct-09	28-May-07	15-May-14	15-May-14	"The University of Chicago Brain Tumor Center, Chicago, Illinois, United States|The Johns Hopkins University, Baltimore, Maryland, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00479765
1109	NCT03213002	Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	CAPTEM	Recruiting	No Results Available	"Glioblastoma Multiforme (GBM)|Glioblastoma|Glioma of Brain|Glioblastoma, Adult|Brain Tumor|Brain Tumor, Primary|Brain Tumor Adult|Cancer|Brain Cancer"	Drug: Capecitabine|Drug: Temozolomide	Progression-free survival (PFS)|Overall Survival (OS)|Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)|Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03.	Northwell Health	All	"18 Years to 74 Years   (Adult, Older Adult)"	Phase 1|Phase 2	67	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-0312	13-Jun-17	Jun-24	Jun-24	11-Jul-17		31-Aug-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03213002
1110	NCT00669669	O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas		Completed	Has Results	Glioblastoma|Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Biological: Filgrastim|Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: O6-Benzylguanine|Drug: Plerixafor|Radiation: Proton Beam Radiation Therapy|Drug: Temozolomide	Number of Participants Dose-limiting Toxicity (DLT)|Number of Participants With Retrovirus or Leukemia|Response Rate|Duration of Response|Number of Participants That Survived|Time to Progression|Gene Transfer Efficiency and in Vivo Selection|Number of Participants With Chemoprotection	Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	12	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000.00|NCI-2013-00701|8357|P30CA015704|RG1709046	25-Feb-09	6-Jul-18	20-Jan-21	30-Apr-08	28-Dec-18	16-Jun-21	"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/69/NCT00669669/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT00669669
1111	NCT00612638	Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas		Completed	No Results Available	Glioblastoma|Gliosarcoma	"Drug: Temodar, O6-BG, and Irinotecan"	Incidence of toxicities|Response rate & progression-free survival	"Duke University|Keryx / AOI Pharmaceuticals, Inc.|Pharmacia"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	96	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00007681	Jan-05	Jan-07	Jul-08	12-Feb-08		19-Jun-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00612638
1112	NCT03623347	Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment	TEMOBEVA	Completed	No Results Available	Chemoradiotherapy	Other: TMZ and BEV induction before chemoradiotherapy	Optimal chemoradiotherapy after upfront TMZ and BEV treatment.	"Centre Hospitalier Universitaire, Amiens"	All	"18 Years and older   (Adult, Older Adult)"		70	Other	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	PI2011_843_0001	1-Jan-11	12-May-17	12-May-17	9-Aug-18		9-Aug-18			https://ClinicalTrials.gov/show/NCT03623347
1113	NCT00052624	Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Biological: transferrin-CRM107		Xenova Biomedix|National Cancer Institute (NCI)	All	"5 Years to 18 Years   (Child, Adult)"	Phase 1		Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	MUSC-10550|KSB-311P/CI/001|CDR0000258574	Jul-02			27-Jan-03		15-May-18	"Children's Hospital of Orange County, Orange, California, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT00052624
1114	NCT05062772	Brain Tumor Intraoperative Ultrasound Database	BraTioUS-DB	Not yet recruiting	No Results Available	Brain Tumor|Brain Neoplasms|Brain Cancer|Glioma|Glioblastoma	Diagnostic Test: Ultrasound	Overall survival	Hospital del Río Hortega	All	"15 Years and older   (Child, Adult, Older Adult)"		100	Other	Observational	Observational Model: Cohort|Time Perspective: Other	21-PI085	1-Nov-21	30-Apr-22	30-Nov-22	30-Sep-21		8-Oct-21	"University Hospital Rio Hortega, Valladolid, Spain"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/72/NCT05062772/Prot_000.pdf"	https://ClinicalTrials.gov/show/NCT05062772
1115	NCT00272870	Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy		Terminated	No Results Available	Glioblastoma Multiforme (WHO Grade IV)|Anaplastic Astrocytoma (WHO Grade III)	Drug: 06Benzylguanine|Genetic: MGMT P140K|Device: Meltenyi CliniMacs	"To assess the safety and feasibility of infusing autologous PBSC transduced with MSCV-MGMTP140K construct, using the fibronectin component CH-296 to assist gene transfer.|Assess the efficiency of gene transfer and durability of transgene expression in this clinical setting.|Assess the degree of chemotherapy resistance in transduced cells, and the ability to enrich the population of transduced stem cells with subsequent courses of chemotherapy."	"Children's Hospital Medical Center, Cincinnati"	All	"5 Years to 55 Years   (Child, Adult)"	Phase 1	1	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CCHMCEH003	Dec-05	Dec-08	Aug-12	9-Jan-06		29-Aug-12	"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00272870
1116	NCT03311542	Expanded Access for Pembrolizumab (MK-3475)		No longer available	No Results Available	Melanoma (Skin)|Melanoma Recurrent|Glioblastoma Multiforme|Glioblastoma by Gene Expression Profile|Glioma of Brain	Biological: pembrolizumab		Center Trials & Treatment	All	"18 Years to 80 Years   (Adult, Older Adult)"			Other	Expanded Access:Individual Patients		PST-2-B				17-Oct-17		10-Jan-18	"N.N. Alexandrov National Cancer Centre, Minsk, Belarus|The Hong Kong Cancer Institute, Hong Kong, Hong Kong|""Cancer Research Center"" of the Ministry of Health of the Republic of Tajikistan, Dushanbe, Tajikistan|Republican Cancer Research Center of the Ministry of Health of the Republic of Uzbekistan (RENTC MH RUz), Tashkent, Uzbekistan"		https://ClinicalTrials.gov/show/NCT03311542
1117	NCT01317888	Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas		Unknown status	No Results Available	Glioblastoma Multiforme|Astrocytoma Anaplastic Foci	Drug: MAB-425 radiolabeled with I-125	Prevention of disease progression	Drexel University	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	11	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18508|1043323	Jan-10	Jan-14		17-Mar-11		17-Mar-11			https://ClinicalTrials.gov/show/NCT01317888
1118	NCT03673787	A Trial of Ipatasertib in Combination With Atezolizumab	IceCAP	Recruiting	No Results Available	Solid Tumor|Glioblastoma Multiforme|Prostate Cancer Metastatic	Drug: ipatasertib|Drug: Atezolizumab	"To identify a maximum tolerated dose in Phase I|To determine the number and type of treatment-related adverse events of the two drug combination as assessed by CTCAE v4.0|Determination of changes in immune-cell population in blood and plasma, using Fluorescence-Activated Cell Sorting (FACS)|To assess the tumour microenvironment by immunophenotyping"	"Institute of Cancer Research, United Kingdom|Hoffmann-La Roche"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	87	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	CCR4720	13-Aug-18	Jul-22	Nov-22	17-Sep-18		18-Jun-21	"Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom"		https://ClinicalTrials.gov/show/NCT03673787
1119	NCT02525692	"Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma"		Recruiting	No Results Available	Glioblastoma|Diffuse Midline Glioma|H3 K27M Glioma|Thalamic Glioma|Infratentorial Glioma|Basal Ganglia Glioma	Drug: ONC201	Progression-free survival	Chimerix	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 2	140	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONC006	Jan-16	Dec-21	Dec-21	17-Aug-15		2-Dec-21	"University of California, Los Angeles, Los Angeles, California, United States|Miami Cancer Institute, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT02525692
1120	NCT01020292	A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma		Completed	No Results Available	Glioma	Drug: Nelfinavir	"To determine the safety, dose-limiting toxicities, and maximally tolerated dose of NFV concurrently with radiation and temozolomide.|To determine the progression free survival (PFS) and overall survival (OS) with an exploratory analysis to compare the observed median value obtained in this study to the historical median values of 6.9 months and 14.6 months respectively."	Abramson Cancer Center of the University of Pennsylvania	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	31	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UPCC 01309	Apr-09	Dec-17	Dec-17	24-Nov-09		12-Apr-19	"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT01020292
1121	NCT01122888	Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme		Terminated	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Solid Neoplasm|Recurrent Adult Brain Neoplasm	Drug: Cilengitide|Other: Clinical Observation|Other: Laboratory Biomarker Analysis	"Change in serum VEGFR2|Comparison of the change in serum VEGFR2 in courses 1 and 2|Progression-free survival|Response rate evaluated using RECIST criteria|Serum type I collagen c-telopeptide crosslink measurements|Toxicity rates, graded using the NCI CTCAE version 4.0"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	41	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-01455|CDR0000659080|UCCRC-09-259-A|09-259-A|8313|P30CA014599|U01CA069852	Dec-09	Sep-12	Apr-15	13-May-10		28-Apr-15	"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT01122888
1122	NCT04446416	Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients		Recruiting	No Results Available	"Glioblastoma Multiforme|Glioblastoma|Glioma|Brain Tumor|Neoplasms|Neoplasms, Nerve Tissue"	Device: NaviFUS System|Drug: Bevacizumab	Adverse Event|Progression-free survival at 6 months (PFS-6)|Tumor shrinkage|Objective response rate (ORR)|PET uptake|Overall survival (OS)|Degree of the BBB opening|Corticosteroid consumption|Quality of life (QoL) assessment with the EORTC QLQ-C30|Quality of life (QoL) assessment with the EORTC QLQ-BN20	NaviFUS Corporation|Chang Gung Memorial Hospital	All	"20 Years and older   (Adult, Older Adult)"	Not Applicable	10	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NF-2019-01	21-Jul-20	Dec-22	Dec-22	24-Jun-20		4-Aug-21	"Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan"		https://ClinicalTrials.gov/show/NCT04446416
1123	NCT01290692	Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma		Completed	No Results Available	Grade IV Glioma|Grade IV Astrocytoma|Glioblastoma Multiforme	Biological: TVI-Brain-1	Progression Free Survival|Overall Survival|Quality of life|Toxicity|Time to progression|Objective response rate|Cancer immunogenicity	TVAX Biomedical	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	86	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TVI-AST-005	Jun-11	Dec-13	Feb-14	7-Feb-11		24-Oct-16	"Saint Luke's Hospital, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Baylor University Medical Center, Dallas, Texas, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01290692
1124	NCT03722355	Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma		Completed	No Results Available	Glioma|Glioblastoma Multiforme|Astrocytoma	Radiation: Conventional RT|Radiation: Hyperfractionated RT|Drug: Carmustine	Overall Survival	Radiation Therapy Oncology Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	712	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTOG 9006	9-Nov-90	15-Mar-94	18-Oct-02	26-Oct-18		12-Nov-19			https://ClinicalTrials.gov/show/NCT03722355
1125	NCT00923117	Sunitinib to Treat Recurrent Brain Cancer		Terminated	Has Results	Glioblastoma Multiforme|Malignant Gliomas|Anaplastic Gliomas	Drug: Sutent (sunitinib)	6-month Progression-free Survival.|Number of Participants With Adverse Events	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	87	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	080168|08-C-0168	Jun-08	Jun-12	Jun-12	18-Jun-09	25-Jun-13	30-Sep-15	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00923117
1126	NCT04630379	Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers		Completed	No Results Available	Glioblastoma|Malignant Glioma|WHO Grade III Glioma	Other: Palliative Therapy|Other: Quality-of-Life Assessment|Other: Supportive Care|Other: Survey Administration	"Change in feasibility of using the Beacon Patient Reported Outcomes Quality of Life Scale (PROQOL)|Change in feasibility of using a single question to assess prognostic understanding in patients, caregivers, and clinicians|Quality of life of patients and caregivers|Discordance in prognostic understanding over time"	Mayo Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	16	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	17-011342|NCI-2020-07998|P30CA015083	13-Jun-18	13-Jun-19	31-Aug-20	16-Nov-20		27-Nov-20	"Mayo Clinic in Arizona, Scottsdale, Arizona, United States"		https://ClinicalTrials.gov/show/NCT04630379
1127	NCT04479696	Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors		Recruiting	No Results Available	Glioblastoma|WHO Grade II Glioma|WHO Grade III Glioma	Other: Educational Intervention|Other: Questionnaire Administration|Other: Survey Administration|Other: Video	Changes in patient S-Anxiety subscale score of the State-Trait Anxiety Inventory (STAI)|Changes in caregiver S-Anxiety subscale score of the STAI and Distress Thermometer score|Change in patient and caregiver S-Anxiety subscale score of the STAI and Distress Thermometer scores|Changes in patient Distress Thermometer score and FACT-Br score|Patient survey	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	102	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2018-0097|NCI-2020-03698	5-Jun-19	30-Jun-22	30-Jun-22	21-Jul-20		22-Sep-20	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04479696
1128	NCT02661282	Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma		"Active, not recruiting"	No Results Available	Cytomegalovirus Positive|Glioblastoma|Gliosarcoma|Malignant Glioma|Recurrent Brain Neoplasm|Recurrent Glioblastoma	Biological: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery	Maximum feasible dose (MFD) or maximum tolerated dose (MTD) (recurrent glioblastoma cohort)|Immunological effects in tumor tissue (recurrent glioblastoma cohort)|Progression free survival (PFS) (recurrent glioblastoma cohort)|Overall survival (OS) (newly diagnosed glioblastoma cohort)|Time to progression (recurrent glioblastoma cohort)|Objective response rate (ORR) (newly diagnosed glioblastoma cohort)|Median duration of response (newly diagnosed glioblastoma cohort)|Progression free survival (PFS) (newly diagnosed glioblastoma cohort)|Incidence of toxicity (newly diagnosed glioblastoma cohort)	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	65	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0899|NCI-2016-00183	1-Jun-16	1-Jun-22	1-Jun-22	22-Jan-16		8-Oct-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02661282
1129	NCT04424966	Infigratinib in Recurrent High-Grade Glioma Patients		Recruiting	No Results Available	Glioma|Glioblastoma|GBM	Drug: Infigratinib	Phase 0: Concentration of infigratinib in enhancing and non-enhancing tumor tissue|Phase 0: Concentration of infigratinib in plasma (0-24H)|Phase 0: Concentration of infigratinib in CSF|Expansion Cohort: 6-month Progression-free survival|Phase 0: PD Analysis|Number of Adverse Events|Incidence of drug-related toxicity|Incidence of treatment-emergent adverse events|Number of Deaths|Number of clinical laboratory abnormalities per CTCAE	"Nader Sanai|Ivy Brain Tumor Center|Barrow Neurological Institute|QED Therapeutics|St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2020-08|20-500-092-34-38	21-Jul-20	31-Dec-22	29-Jul-23	11-Jun-20		31-Dec-20	"Chandler Regional Medical Center, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|HonorHealth Scottsdale Osborn Medical Center, Scottsdale, Arizona, United States"		https://ClinicalTrials.gov/show/NCT04424966
1130	NCT03251027	Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma		Recruiting	No Results Available	Glioblastoma|WHO Grade II Glioma|WHO Grade III Glioma	Radiation: Intensity-Modulated Radiation Therapy|Other: Quality-of-Life	Incidence of wound infection or wound dehiscence|Incidence of titanium implants|Incidence of hair loss|Incidence of recovery rate|Quality of life using European Quality of Life Five Dimension Five Level Scale Questionnaire	Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	125	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17D.074	17-Jul-17	1-Jan-23	1-Jan-24	16-Aug-17		7-Jun-21	"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03251027
1131	NCT02666066	Radiomics for Prediction of Survival in GBM	Radiomics	Completed	No Results Available	Glioblastoma|Glioma|Astrocytoma		Sensitive value of 6 months survival after radiotherapy with radiomics|Sensitive value of 12 months survival after radiotherapy with radiomics|Specificity value of 6 months survival after radiotherapy with radiomics|Specificity value of 12 months survival after radiotherapy with radiomics	Maastricht Radiation Oncology	All	"Child, Adult, Older Adult"		289	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	15-43-05/08-intern	Jan-16	Jan-18	Jul-18	28-Jan-16		17-Aug-18	"Maastricht Radiation Oncology (MAASTRO clinic), Maastricht, Limburg, Netherlands"		https://ClinicalTrials.gov/show/NCT02666066
1132	NCT01233492	Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme		Terminated	No Results Available	Brain and Central Nervous System Tumors	Drug: boron phenylalanine|Drug: mannitol|Other: biologic sample preservation procedure|Radiation: radiation therapy treatment planning/simulation	"Optimal dose of boron phenylalanine (BPA)|Causality of each adverse event to BPA and grading severity according to NCI CTCAE Version 3.0|Pharmacokinetic (PK) parameters used to construct a PK model with the aim of being able to predict boron up-take by tumor and normal brain tissue|Change in mean dose to the planning target volume of greater than 15%, for a constant maximum and mean dose to normal tissue in any treatment cohort of the study|Change in the intra-nuclear percentage of 10B atoms in any cohort of the study of greater than 20%|Establishment of a repository of samples including serum and tumor tissue for future studies using techniques such as proteomics and DNA array"	Cancer Research UK	All	"45 Years to 75 Years   (Adult, Older Adult)"	Phase 1	36	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000687653|CRUK-PH1/093|EUDRACT-2004-002413-37	Oct-07	Sep-13	Sep-13	3-Nov-10		8-Oct-13	"Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom|Cancer Research UK Clinical Trials Unit - Birmingham, Birmingham, England, United Kingdom"		https://ClinicalTrials.gov/show/NCT01233492
1133	NCT00045565	Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma		Completed	No Results Available	Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma	Drug: arsenic trioxide|Radiation: radiation therapy	Maximum tolerated dose of ATO in conjunction with radiotherapy and optimum ATO dose for radiosensitization determined by dose-limiting toxicities|Proportion of patients with serious or life-threatening toxicities using the grading scale of Adverse Events Criteria|Duration of survival with this treatment regimen|Overall event rates (hazards rates)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03162|NABTT-2115|JHOC-NABTT-2115|U01CA062475	Oct-02	Nov-08		27-Jan-03		9-Apr-13	"New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00045565
1134	NCT00643097	Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	ACTIVATe	Completed	Has Results	Malignant Neoplasms of Brain	Biological: PEP-3 vaccine|Biological: sargramostim|Drug: Temozolomide	"Humoral and Cellular Immune Response|Clinical Efficacy of Vaccination, in Terms of Progression-free Survival (PFS)|Response to Vaccination|Toxicity to PEP-3 Vaccine Immunization"	John Sampson|National Institute of Neurological Disorders and Stroke (NINDS)|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00004040|P50NS020023|CDR0000589632|DUMC-5421	Sep-07	Jan-12	Nov-16	26-Mar-08	17-Feb-14	1-Feb-17	"Duke University Medical Center, Durham, North Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00643097
1135	NCT01434602	Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas		Completed	No Results Available	Brain Tumor|Glioblastoma|Anaplastic Glioma	Drug: everolimus|Drug: sorafenib	Maximum tolerated dose and safety of everolimus in combination with sorafenib for patients with recurrent malignant gliomas|Median Rate of subject survival without disease progression after treatment for glioblastoma patients with no prior bevacizumab exposure|Median Rate of subject survival without disease progression after treatment for glioblastoma patients with prior bevacizumab exposure|Median Rate of subject survival without disease progression after treatment for AG patients with no prior bevacizumab exposure|Median amount of time subject survives without disease progression and the median amount of time a subject survives after therapy|Proportion of subject with tumor size reduction|Rate of patient's symptom severity and interference with function	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	86	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	160011|16-C-0011	11-Apr-16	19-Oct-20	13-Jul-21	15-Sep-11		21-Jul-21	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01434602
1136	NCT00820963	"Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Radiation: hypofractionated radiation therapy|Radiation: radiation therapy	Duration of survival	Centre Leon Berard|National Cancer Institute (NCI)	All	"60 Years and older   (Adult, Older Adult)"	Phase 3	70	Other	Interventional	Allocation: Randomized|Primary Purpose: Treatment	CDR0000626713|LEONB-ET2005-006|LEONB-Nordic Glioma Adulte|INCA-RECF0031|EUDRACT-2006-003606-25|SPRI-LEONB-ET2005-006	Jul-06	May-11		12-Jan-09		12-May-11	"Centre Leon Berard, Lyon, France"		https://ClinicalTrials.gov/show/NCT00820963
1137	NCT00897663	Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies		Completed	No Results Available	Brain and Central Nervous System Tumors	Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: protein expression analysis|Other: diagnostic laboratory biomarker analysis|Other: immunohistochemistry staining method	Molecular characteristics that predict for overall survival and progression-free survival	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"		56	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	N0477|NCCTG-N0477|CDR0000527337|NCI-2009-00645	Nov-06	Jan-18	Jan-18	12-May-09		24-Jan-18	"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States"		https://ClinicalTrials.gov/show/NCT00897663
1138	NCT03370926	FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy	IMAGG	Unknown status	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Radiotherapy		"Target volumes contoured on standard MRI and planning CT, FET-PET and multiparametric MRI images|Treatment failure pattern in respect to the target volume based on standard MRI, multiparametric MRI and FET-PET.|Sites of failures with composite and standard MRI based RT planning|Progression-free Survival"	"University Hospital, Brest"	All	"18 Years and older   (Adult, Older Adult)"		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	IMAGG	31-Oct-16	31-Oct-19	31-Oct-19	13-Dec-17		13-Dec-17	"CHRU de Brest, Brest, France"		https://ClinicalTrials.gov/show/NCT03370926
1139	NCT00723827	Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)		Completed	Has Results	Glioblastoma|Glioma|Astrocytoma	Drug: Temozolomide|Radiation: Radiotherapy	"Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Experiencing Unexpected Adverse Drug Reactions (ADRs)|Number of Temozolomide Misuse or Abuse Events|Number of Temozolomide Drug Interactions|Efficacy: Number of Participants Experiencing Complete Response (CR), Partial Response (PR), or Stable Disease(SD)"	Merck Sharp & Dohme Corp.	All	"Child, Adult, Older Adult"		682	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	P05557	Mar-08	Sep-11	Sep-11	29-Jul-08	8-Jan-13	30-Jan-15			https://ClinicalTrials.gov/show/NCT00723827
1140	NCT00128700	Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Drug: vatalanib|Procedure: adjuvant therapy|Radiation: radiation therapy	"Dose-limiting toxicity and maximum tolerated dose of vatalanib as determined by CTCAE v3.0 during phase I|Progression-free survival at 6 months during phase II|Severe toxic events as assessed by CTCAE v3.0 at weeks 3 and 6 (concomitant treatment), weeks 2 and 4 after radiotherapy, before each course of adjuvant treatment, monthly during maintenance treatment, and every 3 months during follow-up in phase II|Overall survival at 1 year during phase II|Correlation of angiogenesis and hypoxia markers expression and O-6-methylguanine DNA methyltransferase (MGMT) methylation status with clinical outcome during phase II"	European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years to 69 Years   (Adult, Older Adult)"	Phase 1|Phase 2	20	Other	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26041-22041|EORTC-26041|EORTC-22041|EUDRACT-2004-003896-35	Jun-05	Nov-07		10-Aug-05		24-Sep-12	"U.Z. Gasthuisberg, Leuven, Belgium|Klinikum der Universitaet Regensburg, Regensburg, Germany|Azienda Ospedaliera di Padova, Padova, Italy|Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00128700
1141	NCT00238277	Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme		Terminated	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Procedure: adjuvant therapy|Procedure: chemotherapy|Procedure: radiation therapy	Death	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	15	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	J0498|P30CA006973|CDR0000445270|04-12-16-03	15-Feb-05	11-Dec-07	11-Dec-07	13-Oct-05		27-Jun-18	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00238277
1142	NCT01609790	Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors		"Active, not recruiting"	Has Results	Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Oligodendroglioma|Recurrent Brain Neoplasm|Recurrent Glioblastoma	Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo Administration|Biological: Trebananib	"Number of Patients Experiencing of Dose-limiting Toxicity (Cohort 1)|Six-month Progression-free Survival (Cohort 2)|Incidence of Grade 3+ Treatment-related Toxicity, Measured by CTCAE v. 4 (Cohort 2)|Overall Survival (Cohort 2)|Progression-free Survival (Cohort 2)|Radiographic Response Rate (Cohort 2)|Percentage of Patients Requiring Dose Reduction/Interruption or Discontinuation in the First 2 and Subsequent Courses (Cohort 1)"	National Cancer Institute (NCI)|NRG Oncology	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	137	NIH|Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	NCI-2012-01969|S13-00759|CDR0000734205|RTOG-1122|U10CA180868|U10CA021661	4-Jun-12	2-Oct-15		1-Jun-12	27-Feb-17	22-Dec-21	"Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Arizona Oncology-Deer Valley Center, Phoenix, Arizona, United States|Arizona Oncology Services Foundation, Scottsdale, Arizona, United States|Arizona Oncology Associates-West Orange Grove, Tucson, Arizona, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Sutter Cancer Research Consortium, Novato, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|California Pacific Medical Center-Pacific Campus, San Francisco, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|William Backus Hospital, Norwich, Connecticut, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Heartland Cancer Research NCORP, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Carle Cancer Institute Normal, Normal, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Kansas City NCI Community Oncology Research Program, Prairie Village, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Green Bay Oncology - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Lake Huron Medical Center, Port Huron, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Singing River Hospital, Pascagoula, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital Joplin, Joplin, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Heartland Hematology and Oncology Associates Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Mercy Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology Inc, Saint Joseph, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Cancer Research for the Ozarks NCORP, Springfield, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|New York Oncology Hematology PC - Albany, Albany, New York, United States|New York Oncology Hematology PC - Albany Medical Center, Albany, New York, United States|Hematology Oncology Associates of Central New York-Auburn, Auburn, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse, New York, United States|Hematology Oncology Associates of Central New York-Liverpool, Liverpool, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Hematology Oncology Associates of Central New York-Rome, Rome, New York, United States|Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Mountain Radiation Oncology PA, Asheville, North Carolina, United States|AdventHealth Infusion Center Asheville, Asheville, North Carolina, United States|Messino Cancer Centers, Asheville, North Carolina, United States|AdventHealth Hendersonville, Hendersonville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Southeast Clinical Oncology Research Consortium NCORP, Winston-Salem, North Carolina, United States|Summa Health System - Akron Campus, Akron, Ohio, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|Summa Health System - Barberton Campus, Barberton, Ohio, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Delaware Radiation Oncology, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lancaster Radiation Oncology, Lancaster, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|Summa Health Medina Medical Center, Medina, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, United States|Springfield Regional Medical Center, Springfield, Ohio, United States|University of Cincinnati Cancer Center-West Chester, West Chester, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Warren Clinic Oncology-Tulsa, Tulsa, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|UPMC-Heritage Valley Health System Beaver, Beaver, Pennsylvania, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|UPMC Cancer Center at UPMC Horizon, Farrell, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|UPMC Cancer Centers - Arnold Palmer Pavilion, Greensburg, Pennsylvania, United States|Cherry Tree Cancer Center, Hanover, Pennsylvania, United States|UPMC-Johnstown/John P. Murtha Regional Cancer Center, Johnstown, Pennsylvania, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|UPMC Cancer Center at UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC Cancer Center-Natrona Heights, Natrona Heights, Pennsylvania, United States|UPMC Jameson, New Castle, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC-Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Margaret, Pittsburgh, Pennsylvania, United States|UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States|UPMC Jefferson Regional Radiation Oncology, Pittsburgh, Pennsylvania, United States|UPMC-Passavant Hospital, Pittsburgh, Pennsylvania, United States|UPMC-Saint Clair Hospital Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Cancer Center at UPMC Northwest, Seneca, Pennsylvania, United States|UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States|UPMC Washington Hospital Radiation Oncology, Washington, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Main Line Health NCORP, Wynnewood, Pennsylvania, United States|WellSpan Health-York Hospital, York, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology - Central Austin Cancer Center, Austin, Texas, United States|Texas Oncology - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology Bedford, Bedford, Texas, United States|Texas Oncology at Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States|Texas Oncology-Grapevine, Grapevine, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology-Seton Williamson, Round Rock, Texas, United States|Texas Oncology - Round Rock Cancer Center, Round Rock, Texas, United States|Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Sandra L Maxwell Cancer Center, Cedar City, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Utah Cancer Specialists-Salt Lake City, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Cancer Care Northwest-North Spokane, Spokane, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Compass Oncology Vancouver, Vancouver, Washington, United States|Langlade Hospital and Cancer Center, Antigo, Wisconsin, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|ProHealth D N Greenwald Center, Mukwonago, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls, Wisconsin, United States|Saint Vincent Hospital Cancer Center at Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Green Bay Oncology - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States|Aspirus Regional Cancer Center, Wausau, Wisconsin, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT01609790
1143	NCT01967810	ANG1005 in Patients With Recurrent High-Grade Glioma		Completed	No Results Available	"Glioma|Glioblastoma|Brain Tumor, Recurrent"	Drug: ANG1005|Drug: Bevacizumab	"Objective Response Rate (ORR) (Arms 1 and 3)|PFS3 (Arm 2)|ORR in Arm 2|PFS at 3, 6 and 12 months|Median PFS|Duration of response|Overall survival|Safety and tolerability|Plasma Pharmacokinetics of ANG1005 (Half-life [T1/2], Maximum Concentration [Cmax], Area Under the Curve [AUC])"	Angiochem Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	73	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANG1005-CLN-03	Oct-13	Feb-16	Sep-17	23-Oct-13		25-Feb-20	"Moores UC San Diego Cancer Center, La Jolla, California, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Cleveland Clinic, Cleveland, Ohio, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Univeristy of Texas Health Science Center in San Antonio, San Antonio, Texas, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01967810
1144	NCT04327011	A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511		Terminated	No Results Available	"Glioblastoma Multiforme|Astrocytoma|Gliomas, Malignant"	Biological: Toca 511 vector|Drug: Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine	Long term safety follow up|Overall survival in days from the initial Toca 511 administration on parent study to the date of death.	Tocagen Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	65	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Tg 511-09-01	Feb-11	Dec-19	Dec-19	30-Mar-20		30-Mar-20	"University of California, Los Angeles, Los Angeles, California, United States|UCSD, San Diego, California, United States|UCSF, San Francisco, California, United States|Henry Ford Health System, Detroit, Michigan, United States|JFK Medical Center Neuroscience Institute, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University, Hackensack, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Swedish Neuroscience Institute, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT04327011
1145	NCT04181684	LITT Followed by Hypofractionated RT for Recurrent Gliomas	GCCC 19140	Recruiting	No Results Available	Glioblastoma|Brain Tumor|Glioma|Neoplasms	Device: Procedure: LITT|Radiation: Hypo-Fractionated Radiation Therapy	"Adverse Events|Progression-free survival at 6 months|Median progression-free survival|Median overall survival|1-year overall survival|Overall response rate|Quality of Life before, during, and after treatment"	"University of Maryland, Baltimore|Keep Punching Foundation"	All	"22 Years and older   (Adult, Older Adult)"	Not Applicable	32	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00088569	8-Jan-20	Feb-23	Feb-23	29-Nov-19		22-Jul-21	"University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|UCH Kaufman Cancer Center, Bel Air, Maryland, United States|Central Maryland Radiation Oncology, Columbia, Maryland, United States|Baltimore Washington Medical Center, Glen Burnie, Maryland, United States"		https://ClinicalTrials.gov/show/NCT04181684
1146	NCT01294735	Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)		Completed	No Results Available	Recurrence of Solid Tumor|Glioblastoma Multiforme|Melanoma	Drug: MK-4827|Drug: Temozolomide	Number of participants with DLTs|Number of participants with an objective response rate of partial or complete response|Number of participants with 6-month progression-free survival|Progression-Free Survival (PFS)	Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4827-014	Feb-11	Apr-12	May-12	11-Feb-11		15-Aug-12			https://ClinicalTrials.gov/show/NCT01294735
1147	NCT00045968	Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer	GBM	Unknown status	No Results Available	Glioblastoma Multiforme|Glioblastoma|GBM|Grade IV Astrocytoma|Glioma|Brain Cancer|Brain Tumor	Drug: Dendritic cell immunotherapy	The primary objective of this study is to compare progression free survival from time of randomization between patients treated with DCVax-L and control patients.|The secondary objective is to compare overall survival and time to disease progression between DCVax-L treated and control patients.	Northwest Biotherapeutics	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	348	Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	20221	Dec-06	Nov-16		19-Sep-02		14-Oct-16	"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Sutter East Bay Neuroscience Institute-Eden Medical Center, Castro Valley, California, United States|City of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente - Los Angeles, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Kaiser Permanente - Redwood City, Redwood City, California, United States|Sutter Institute for Medical Research, Sacramento, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Mount Sinai Community Clinical Oncology Program, Miami Beach, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Cadence Cancer Center, Warrenville, Illinois, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Markey Cancer Center/University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|John Nasseff Neuroscience Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|St. Luke's Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|The Brain Tumor Center at JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|Capital Health Regional Medical Center, Trenton, New Jersey, United States|Long Island Brain Tumor Center at Neurological Surgery, P.C., Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|New York University Clinical Cancer Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook Medicine, Stony Brook, New York, United States|Brain and Spine Surgeons of New York and Northern Westchester Hospital, White Plains, New York, United States|University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|OhioHealth, Columbus, Ohio, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Hospitals and Clinics, Charleston, South Carolina, United States|Saint Thomas Research Institute, Nashville, Tennessee, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|The Methodist Hospital, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Cancer Therapy & Research at University of Texas Health Science Center San Antonio, San Antonio, Texas, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States|Swedish Hospital Neuroscience Research, Seattle, Washington, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada|CHUS - Hôpital Fleurimont, Sherbrooke, Quebec, Canada|Universitätsklinikum Heidelberg Neurochirurgische Klinik, Heidelberg, Baden-Württemberg, Germany|Katharinenhospital, Stuttgart, Baden-Württemberg, Germany|Universitätsklinikum FrankfurtKlinik und Poliklinik für Neurochirurgie, Frankfurt, Hesse, Germany|Universitätsklinikum Bonn Nervenklinik (Zentrum), Klinik und Poliklinik für Neurochirurgie, Bonn, North Rhine-Westphalia, Germany|Universitätsklinikum Klinik für allgemeine Neurochirurgie, Köln, North Rhine-Westphalia, Germany|BG-Kliniken Bergmannstrost, Klinik für Neurochirurgie, Halle, Saxony-Anhalt, Germany|Klinik für Neurochirurgie, Klinikum Chemnitz gGmbH, Chemnitz, Saxony, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Saxony, Germany|Neurochirurgische Klinik, Hamburg, Germany|Addenbrookes NHS Trust, Cambridge, Cambridgeshire, East Anglia, United Kingdom|Kings College Hosital NHS Foundation Trust, London, Greater London, United Kingdom|University College Hospital London, London, Greater London, United Kingdom|University Hospital of Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom"		https://ClinicalTrials.gov/show/NCT00045968
1148	NCT04982926	A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer		Recruiting	No Results Available	Solid Tumor|Glioblastoma|Non-small Cell Lung Cancer|Breast Cancer	Drug: TAS2940	Dose Escalation:Maximum Tolerated Dose (MTD)|Dose Expansion:Overall Response Rate|Dose Escalation: Overall Response Rate (ORR)|Dose Escalation:Pharmacokinetic (PK) Profile|Dose Expansion:Incidence of treatment-emergent Adverse Events (Safety and tolerability)|Dose Expansion:Duration of Response (DOR)|Dose Expansion:Disease Control Rate (DCR)|Dose Expansion:Progression Free Survival (PFS)|Dose Expansion:Pharmacokinetic profile of TAS2940	"Taiho Oncology, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	42	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TAS2940-101|2021-002189-41	16-Sep-21	May-25	Jun-25	29-Jul-21		16-Dec-21	"Tennessee Oncology, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CLCC Gustave Roussy, Villejuif, Cedex, France"		https://ClinicalTrials.gov/show/NCT04982926
1149	NCT02795364	Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas		Unknown status	No Results Available	Glioma|Anaplastic Oligoastrocytoma|Glioblastomas (GBM)	Procedure: Structural Image Guidance|Procedure: Metabolic Image Guidance	Overall survival|Progression free survival (PFS)|Karnofsky performance status (KPS)	Huashan Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	50	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	KY2016-232	Jun-16	May-17	May-18	10-Jun-16		10-Jun-16			https://ClinicalTrials.gov/show/NCT02795364
1150	NCT00473408	The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas	Gliomstudien	Terminated	No Results Available	Anaplastic Astrocytoma|Glioblastoma Multiforme|Tumor Angiogenesis	Device: Functional MRI (DCE-MRI)|Procedure: Blood sample|Procedure: Tumor sample		Haukeland University Hospital|University of Bergen	All	"18 Years and older   (Adult, Older Adult)"		1	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	15437|REK ID: 202.06	Mar-07	May-07	Nov-11	15-May-07		6-Dec-16	"Dept. of Oncology & Dept. of Radiology, Haukeland University Hospital, Bergen, Norway, Hordaland, Norway"		https://ClinicalTrials.gov/show/NCT00473408
1151	NCT00704080	A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas		Completed	No Results Available	Mixed Gliomas|Malignant Gliomas|Glioblastoma Multiforme	Drug: XL765 (SAR245409)|Drug: Temozolomide	"Safety, tolerability, and maximum tolerated dose of XL765 administered in combination with temozolomide in subjects with anaplastic gliomas or glioblastoma currently stable on a maintenance temozolomide dose|To evaluate plasma pharmacokinetics and pharmacodynamic effects of XL765 and temozolomide when administered in combination|To evaluate preliminary efficacy of XL765 in combination with temozolomide in adults with anaplastic gliomas or glioblastoma"	Sanofi	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	54	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TED11441|XL765-002	Aug-08	Feb-12	Feb-13	24-Jun-08		10-Apr-13	"Investigational Site Number, Birmingham, Alabama, United States|Investigational Site Number, Los Angeles, California, United States|Investigational Site Number, Boston, Massachusetts, United States|Investigational Site Number, New York, New York, United States|Investigational Site Number, Rochester, New York, United States|Investigational Site Number, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00704080
1152	NCT04197934	"WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases"		Recruiting	No Results Available	"Anaplastic Astrocytoma, IDH-Wildtype|Glioblastoma, IDH-Wildtype|Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Central Nervous System|Metastatic Malignant Neoplasm in the Leptomeninges"	Drug: EGFR/EGFRvIII Inhibitor WSD0922-FU|Procedure: Therapeutic Conventional Surgery	Recommended phase 2 dose|Incidence of adverse events|Overall response rate|Duration of response (DOR)|Progression Free Survival (PFS)	"Mayo Clinic|National Cancer Institute (NCI)|FDA Office of Orphan Products Development|Wayshine Biopharm, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	72	Other|NIH|U.S. Fed|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1914|NCI-2019-07825|P30CA015083	20-Dec-19	20-Dec-22	20-Dec-22	13-Dec-19		8-Nov-21	"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT04197934
1153	NCT00004129	Phosphorus 32 in Treating Patients With Glioblastoma Multiforme		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Radiation: brachytherapy|Radiation: phosphorus P32		Center for Molecular Medicine|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other	Interventional	Primary Purpose: Treatment	CDR0000067357|CMM-2|NCI-V99-1575	Sep-99			27-Jan-03		17-Sep-13	"Center for Molecular Medicine, Garden City, New York, United States"		https://ClinicalTrials.gov/show/NCT00004129
1154	NCT00626015	"Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery"	ZAP IT	Completed	No Results Available	Malignant Neoplasms of Brain	Biological: PEP-3-KLH conjugate vaccine|Biological: daclizumab|Drug: temozolomide|Other: placebo|Biological: PEP-3-KLH	Functional suppressive capacity of CD4+CD25+CD127- T-regulatory cells|Comparison of proliferative T-cell response to phytohemagglutinin (PHA) among treatment groups (with versus without daclizumab/basiliximab)	John Sampson|National Cancer Institute (NCI)|Duke University	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	16	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00000947|R21CA132891|CDR0000579573	Mar-07	Feb-13	Feb-13	29-Feb-08		21-Jan-16	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00626015
1155	NCT04289155	Individual Patient Compassionate Use of GX-I7		Available	No Results Available	Glioblastoma|High Grade Glioma|Recurrent Glioblastoma|Melanoma|Advanced Cancer	Drug: GX-I7		"Genexine, Inc."		"Child, Adult, Older Adult"			Industry	Expanded Access:Individual Patients		GX-I7_TP				28-Feb-20		28-Feb-20	"Kangnam St. Mary's Hospital, Seoul, Korea, Republic of"		https://ClinicalTrials.gov/show/NCT04289155
1156	NCT04314674	Comparison of Hypertonic Saline and Mannitol on Brain Relaxation During Supratentorial Tumors Resection		Not yet recruiting	No Results Available	"Brain Tumor - Metastatic|Brain Tumor, Adult: Glioblastoma"	Drug: %3 HS bolus|Drug: %3 HS infusion 20 ml/h|Drug: 20% mannitol	Brain relaxation score|Sodium level|Potassium level	Istanbul University	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	90	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	Neuroanesthesia Cerrahpasa	Apr-20	Apr-22	Dec-22	19-Mar-20		19-Mar-20			https://ClinicalTrials.gov/show/NCT04314674
1157	NCT00624728	Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)	GLIO-TEP	Completed	No Results Available	High-grade Glioma|Astrocytoma|Glioblastoma	Radiation: 18F Fluorothymidine PET CT	"Predictive positive value of PET uptake for detection of malignant tissue (defined with Ki-67 proliferation index >15% in PET+ volumes)|Comparison of volumes defined by PET and MRI|Description of a quantitative PET proliferation index (""standardized uptake value"")"	"University Hospital, Bordeaux"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	21	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	9420-04|2004-033	Feb-08	Nov-11	Nov-11	27-Feb-08		4-May-12	"Hôpital St André, CHU de Bordeaux, Bordeaux, France|Hôpital Pellegrin-tripode , CHU de Bordeaux, Bordeaux, France"		https://ClinicalTrials.gov/show/NCT00624728
1158	NCT01383135	Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2		Suspended	No Results Available	Breast Cancer|Non-Small-Cell Lung Cancer|Glioblastoma|Other Cancers	Drug: FPPRGD2	"Response of primary tumor to treatment after six weeks, based on each of 1. change in PET uptake from baseline 2. change in CT tumor size from baseline 3. PET EORTC response criteria 4. CT RECIST response criteria"	Sanjiv Sam Gambhir|Stanford University	All	"18 Years and older   (Adult, Older Adult)"		46	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	VAR0047|SU-09022010-6791	Oct-10	Aug-15	Dec-15	28-Jun-11		17-Nov-15	"Stanford University School of Medicine, Stanford, California, United States"		https://ClinicalTrials.gov/show/NCT01383135
1159	NCT01711580	Re-irradiation of High Grade Gliomas: a Quality of Life Study		Withdrawn	No Results Available	Anaplastic Astrocytoma|Glioblastoma Multiforme|Anaplastic Oligoastrocytoma	Other: EORTC QLQ-C30|Other: EORTC QLQ-BN20|Other: Hopkins Verbal Learning Test-Revised (HVLT-R)|Other: Stroop color-word test|Other: Controlled oral word association test (COWA)|Other: Jamar hand dynamometer|Other: EORTC QLQ- FA13|Other: Trail Making Test (TMT)	"Change from baseline in the palliative effect of re-irradiation in patients with a high grade glioma, defined by quality-of-life parameters|Overall survival of patients with glioblastoma and anaplastic glioma after re-irradiation|Progression free survival of patients with glioblastoma and anaplastic glioma after re-irradiation"	Maastricht Radiation Oncology	All	"18 Years and older   (Adult, Older Adult)"		0	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	12-01-25/01-intern-6810	Mar-13	Mar-15	Sep-15	22-Oct-12		12-May-15	"Maastricht Radiation Oncology, Maastricht, Netherlands"		https://ClinicalTrials.gov/show/NCT01711580
1160	NCT00686387	Establishment of a Brain and Spinal Tumor Tissue Bank		Unknown status	No Results Available	Glioblastoma Multiforme|Glioma|Neuroectodermal Tumors		"Collect, annotate, and store fresh frozen specimens of normal tissue, tumors, and pre-malignant lesions for biological investigation.|Collect, process, and store serum, plasma and isolate lymphocytes from blood drawn from patients with Brain and Spinal Tumor|Establish a database to link materials acquisition, pathologic, and clinical information on patients who participate in the protocol|To utilize the clinical database to perform clinical and pathological correlation with the results of current and future scientific studies|To evaluate various NAT2, EGFR and MGMT for evidence of genomic and biochemical activation|To test the effect of small molecule inhibitors on the activation of wild-type and mutant NAT2, EGFR, MGMT and/or other potential molecular targets|To correlate tumor genotype and signaling abnormalities with clinical response to NAT2, EGFR, MGMT and/or other potential molecular targets inhibitors|Analysis of laboratory findings in relationship to patient demographics and clinical course"	Taipei Medical University WanFang Hospital	All	"20 Years and older   (Adult, Older Adult)"		70	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	2008WFCRC-01	May-08	May-13	May-13	29-May-08		12-Apr-11	"Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan"		https://ClinicalTrials.gov/show/NCT00686387
1161	NCT00890032	Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme		Completed	No Results Available	Recurrent Central Nervous System Neoplasm	Biological: BTSC mRNA-loaded DCs	Feasibility and safety|Humoral and cellular immune responses	John Sampson|National Cancer Institute (NCI)|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00006677|R01CA135272|P30CA014236|CDR0000630701	Sep-09	Oct-14	Feb-16	29-Apr-09		17-Oct-16	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00890032
1162	NCT00973557	The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function		Completed	No Results Available	Colorectal Cancer|Lung Cancer|Breast Cancer|Glioblastoma		"To determine whether the drug, Bevacizumab (a monoclonal anti VEGF-A antibody), which is approved to treat patients with metastatic colon cancer induces hyperprolactinemia (increased prolactin secretion) in humans with intact pituitary function."	Cedars-Sinai Medical Center	All	"18 Years and older   (Adult, Older Adult)"		6	Other	Observational	Observational Model: Cohort|Time Perspective: Cross-Sectional	Pro00019830	Sep-09	Sep-11	Jan-12	9-Sep-09		7-Feb-12	"Cedars-Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00973557
1163	NCT05099068	Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)	PLANET	Recruiting	No Results Available	Advanced / Metastic Solid Tumors|Glioblastoma|Chronic Leukemia Lymphocytic	Biological: Blood and tumor samples	Number of patients with meaningful molecular genetic alterations on tumor sample|Number of patients with meaningful molecular genetic alterations on circulating tumour DNA (ctDNA)|Number of patients with meaningful immunological features|Objective Response Rate (ORR) as per RECIST V1.1 and according to central review|Progression-Free Survival (PFS)|Objective Response Rate (ORR) according to iwCLL criteria|Correlation between disease evolution and molecular and/or immunological biomarkers|Evaluation of circulating-tumor DNA (ctDNA; liquid biopsy) yields similar genomic profile as the tumor sample.|Number of patients with recommended therapy according to biological data (liquid versus tumor biopsy)|Tumor characteristics using a radiomic approach and detailed analyses of imaging.|FACT-G questionnaire|HADS questionnaire|PRO questionnaire|Correlation between patient's understanding and experiences of precision medicine clinical trial|Correlation between socio-spatial inequalities in access to the PLANET program and the impact on the quality of life of patients|TKI pharmacokinetics	Centre Leon Berard	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	500	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Plasticity Longitudinal cANcer	16-Nov-21	15-Sep-25	15-Sep-25	29-Oct-21		18-Nov-21	"HOPITAL Pierre WERTHEIMER - HCL, Bron, France|Centre Léon Bérard, Lyon, France"		https://ClinicalTrials.gov/show/NCT05099068
1164	NCT04699773	LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)		Recruiting	No Results Available	Glioma|Glioblastoma|Brain Tumor	Procedure: LITT|Radiation: Hypofractionated Radiation Therapy	Adverse Events|Progression-free survival at 6 months|Median progression-free survival|Median overall survival|1-year overall survival|Overall response rate|Quality of Life assessed by M.D. Anderson Symptom Inventory	"University of Maryland, Baltimore|Keep Punching Foundation"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	32	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00094285	20-Feb-21	Feb-23	Dec-25	7-Jan-21		2-Apr-21	"Maryland Proton Treatment Center, Baltimore, Maryland, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|UCH Kaufman Cancer Center, Bel Air, Maryland, United States|Central Maryland Radiation Oncology, Columbia, Maryland, United States|Baltimore Washington Medical Center, Glen Burnie, Maryland, United States"		https://ClinicalTrials.gov/show/NCT04699773
1165	NCT03657576	Trial of C134 in Patients With Recurrent GBM	C134-HSV-1	Recruiting	No Results Available	Glioblastoma Multiforme of Brain|Anaplastic Astrocytoma of Brain|Gliosarcoma of Brain	Biological: C134	Measure of Treatment-Emergent Adverse Events [Safety and Tolerability]|Measure of Progression Free Survival|Measure Overall Survival|Measurement of HSV titer|Composition of the white blood cells|Measure interferon levels	University of Alabama at Birmingham|Gateway for Cancer Research|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-3000000571|R01CA222903	23-Sep-19	Sep-22	Sep-24	5-Sep-18		4-Jun-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT03657576
1166	NCT02658981	Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)		"Active, not recruiting"	No Results Available	Glioblastoma|Gliosarcoma|Recurrent Brain Neoplasm	Biological: Anti-LAG-3 Monoclonal Antibody BMS 986016|Biological: Anti-PD-1|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis|Biological: Anti-CD137	"Maximum tolerated dose (MTD) of anti-LAG-3 monoclonal antibody BMS-986016 as monotherapy as determined by frequency of toxicity|Maximum tolerated dose (MTD) of anti-CD137 as monotherapy as determined by frequency of toxicity|MTD of Anti-LAG-3 + Anti-PD-1 as determined by frequency of toxicity|MTD of Anti-CD137 + Anti-PD-1 as determined by frequency of toxicity|Overall Survival|Progression-free survival rate|Overall Response, assessed by RANO and iRANO|Overall Response to anti-LAG-3 monoclonal antibody BMS-98601, assessed by RANO and iRANO|Overall Response to anti-CD137 as monotherapy, assessed by RANO and iRANO|Overall Response to Anti-LAG-3 + Anti-PD-1, assessed by RANO and iRANO"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	63	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC 1501|IRB00095527|UM1CA137443	24-Aug-16	5-Mar-21	Feb-22	20-Jan-16		10-Sep-21	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02658981
1167	NCT03581292	"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations"		"Active, not recruiting"	No Results Available	Anaplastic Astrocytoma|Glioblastoma|Malignant Glioma	Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Veliparib	Event free survival (EFS)|Objective response|Overall survival (OS)	National Cancer Institute (NCI)	All	"3 Years to 25 Years   (Child, Adult)"	Phase 2	115	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2018-01361|ACNS1721|U10CA180886	31-Oct-18	30-Sep-24	30-Sep-24	10-Jul-18		29-Oct-21	"Children's Hospital of Alabama, Birmingham, Alabama, United States|USA Health Strada Patient Care Center, Mobile, Alabama, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|UCSF Benioff Children's Hospital Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Beaumont Children's Hospital-Royal Oak, Royal Oak, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Renown Regional Medical Center, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|John Hunter Children's Hospital, Hunter Regional Mail Centre, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia|Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Janeway Child Health Centre, Saint John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec, Canada|Starship Children's Hospital, Grafton, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico"		https://ClinicalTrials.gov/show/NCT03581292
1168	NCT01475006	AMG 595 First-in-Human in Recurrent Gliomas		Completed	No Results Available	Advanced Malignant Glioma|Anaplastic Astrocytomas|Glioblastoma Multiforme	Drug: AMG 595	"Clinically significant or > or = to Grade 3 CTCAE changes in safety laboratory tests, physical exams, ECGs or vital signs|PK Parameters: Cmax, Cmin, and if feasible half life - 8 time points up to 6 weeks|Objective response in GBM tumors as assessed by Macdonald criteria|Dose limiting toxicity used to estimate the MTD|Clinical benefit rate|Progressive free survival|Overall survival|Anti-AMG 595 antibody formation"	Amgen	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	32	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20090505	Feb-12	Apr-16	Apr-16	21-Nov-11		15-Apr-16	"Research Site, Los Angeles, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Parkville, Victoria, Australia"		https://ClinicalTrials.gov/show/NCT01475006
1169	NCT01081223	Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma		Completed	No Results Available	Glioma|High Grade Astrocytoma|Glioblastoma Multiforme	"Biological: Cancer vaccine plus immune adjuvant, plus activated white blood cells"	Relative toxicity|Progression free survival|Immunogenicity|Overall survival	TVAX Biomedical	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	14	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TVI-AST-002	Apr-10	Mar-11	Mar-11	5-Mar-10		6-Jun-13	"Saint Luke's Hospital, Kansas City, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01081223
1170	NCT00089427	"IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma"		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Oligoastrocytoma	Drug: IL13-PE38QQR|Procedure: Surgery for placement|Procedure: Radiation therapy|Drug: Temozolomide with radiation therapy		INSYS Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IL13PEI-106-R01	Jul-04	Jul-07		6-Aug-04		4-Jul-11	"University of California San Francisco - Dept. of Neurological Surgery, San Francisco, California, United States|Carolina Neurosurgery & Spine Assoc., Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation Department of Neurological Surgery, Cleveland, Ohio, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|University of Virginia Health Systems - Department of Neurological Surgery, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00089427
1171	NCT01738646	Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients		Completed	Has Results	Recurrent Glioblastoma Multiforme|Malignant Glioma|Adult Brain Tumor	Drug: Vorinostat|Drug: Bevacizumab	"Six-month Progression-free Survival (PFS6)|Radiographic Response|Percentage of Participants Who Experience Grade 3 or Greater, Treatment Related, Non-hematologic Toxicities.|Median Progression-free Survival (PFS)|Median Overall Survival (OS)"	"Duke University|Genentech, Inc.|Merck Sharp & Dohme Corp."	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	48	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00024983	Jan-13	Dec-14	Feb-16	30-Nov-12	29-Oct-15	6-Mar-17	"Duke Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01738646
1172	NCT01579253	Combined O-(2-[18F]Fluoroethyl)-L-tyrosine (FET) Positron Emission Tomography (PET) and Simultaneous Magnetic Resonance Imaging (MRI) Follow-up in Re-irradiated Recurrent Glioblastoma Patients		Unknown status	No Results Available	"Glioblastoma|Nervous System Neoplasms|Central Nervous System Neoplasms|Astrocytoma|Glioma|Neoplasms, Neuroepithelial|Neuroectodermal Tumors|Neoplasms by Histologic Type|Neoplasms, Nerve Tissue"			Ludwig-Maximilians - University of Munich	All	"18 Years to 75 Years   (Adult, Older Adult)"		10	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	361-11	Apr-12			17-Apr-12		18-Dec-12	"University of Munich, Dep. of Radiation Oncology, Munich, Bavaria, Germany"		https://ClinicalTrials.gov/show/NCT01579253
1173	NCT02655601	"Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001"	BMX-HGG	"Active, not recruiting"	No Results Available	"High Grade Glioma|Astrocytoma, Grade III|Glioblastoma"	Drug: BMX-001|Radiation: Radiation Therapy|Drug: Temozolomide	Phase 2 - Overall survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Progression-free survival|Protection/improvement of cognition|Radiographic response to tumor.|Protection of Bone Marrow against Chemotherapy-Induced Thrombocytopenia	"BioMimetix JV, LLC|Duke Cancer Institute|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	160	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BMX-HGG-001	25-Sep-18	Apr-22	Oct-22	14-Jan-16		25-May-21	"University of Alabama- Birmingham, Birmingham, Alabama, United States|University of California San Francisco, San Francisco, California, United States|University of Kentucky, Lexington, Kentucky, United States|St. Luke's Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke Cancer Institute, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT02655601
1174	NCT02629757	A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas	β-elemene	Recruiting	No Results Available	Anaplastic Oligoastrocytoma|Anaplastic Astrocytoma|Glioblastoma	Drug: β-elemene	Over-all survival|Quality of life	Sun Yat-sen University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 3	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSNO2015001	Apr-15	Apr-20	May-23	14-Dec-15		23-Feb-18	"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT02629757
1175	NCT02529072	Nivolumab With DC Vaccines for Recurrent Brain Tumors	AVERT	Completed	Has Results	Malignant Glioma|Astrocytoma|Glioblastoma	Drug: nivolumab|Biological: DC	The Safety of Administering DC Vaccines With Nivolumab|Overall Survival|Progression Free Survival (PFS)	Gary Archer Ph.D.|Bristol-Myers Squibb|Duke Cancer Institute|Duke University	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	6	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00065241	Jan-16	15-Sep-17	30-Dec-19	19-Aug-15	26-Mar-20	26-Mar-20	"Duke University Medical Center, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/72/NCT02529072/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02529072
1176	NCT01765088	A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas		Unknown status	No Results Available	Anaplastic Oligoastrocytoma|Anaplastic Astrocytoma|Glioblastoma	Drug: Temozolomide|Drug: α-IFN	Over-all survival|Quality of life	Sun Yat-sen University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 3	300	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSNO2012001	Sep-12	Dec-17	Dec-19	10-Jan-13		23-Feb-18	"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT01765088
1177	NCT00823797	Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm	Drug: Bendamustine Hydrochloride|Other: Quality-of-Life Assessment	PFS-6|PFS|Toxic Death|Overall Survival	University of Washington|National Cancer Institute (NCI)|National Comprehensive Cancer Network	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	45	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6803|NCI-2010-00714|P30CA015704	Oct-08	Dec-15	Apr-17	16-Jan-09	19-May-17	7-Jul-17	"Northwestern University, Chicago, Illinois, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00823797
1178	NCT00650923	"Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma"		Completed	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Tumor	Drug: ziv-aflibercept|Procedure: radiation therapy|Drug: temozolomide|Procedure: pharmacological study|Procedure: laboratory biomarker analysis	"Maximum tolerated dose of aflibercept defined as the dose at which fewer than one-third of patients experience DLT based on the CTC severity grading|Efficacy in terms of antitumor activity based on clinical, radiographic, and biologic assessments|Plasma aflibercept (VEGF Trap) concentrations and PK parameters such as Cmax, Tmax, area under the plasma concentration-time curve (AUCo-t and AUC), clearance (CL), apparent volume of distribution at steady state (Vdss), and terminal half-life (t1/2)"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	61	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00678|CDR0000590174|NABTC-07-01|NABTC07-01|U01CA137443	Jul-08	Jun-13	Dec-13	2-Apr-08		30-May-14	"University of California at Los Angeles (UCLA ), Los Angeles, California, United States|UCSF-Mount Zion, San Francisco, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Adult Brain Tumor Consortium, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Charlestown, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00650923
1179	NCT00087451	Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)		Completed	No Results Available	Malignant Glioma|Glioblastoma|Gliosarcoma	Drug: AP23573		Merck Sharp & Dohme Corp.|Ariad Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	11	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8669-023|AP23573-04-103	Jul-04	Nov-05	Nov-05	13-Jul-04		19-Aug-15	"Center For Neuro-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States|The Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States|Brain Tumor Institute, The Cleveland Clinic, Cleveland, Ohio, United States|M.D. Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00087451
1180	NCT00610571	Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas		Completed	No Results Available	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma	Drug: Oral Topotecan and Temodar	maximum tolerated dose|Safety & efficacy	Katy Peters|GlaxoSmithKline|Schering-Plough|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	62	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00003970|5487	Apr-04	Sep-09	Apr-12	8-Feb-08		25-Oct-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00610571
1181	NCT03020602	BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab		Completed	No Results Available	Gliosarcoma|Recurrent Glioblastoma|Astrocytoma of Brain|Glioblastoma	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Ubidecarenone Injectable Nanosuspension	"Percentage of patients with dose-limiting toxicities defined as thrombocytopenia >= grade 3, hemorrhage >= grade 3, and INR elevation >= grade 2 assessed by CTCAE v4.03|Incidence of adverse events graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) version (v)4.03"	Seema Nagpal|Stanford University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-38514|NCI-2016-01973|BRN0035	4-Jan-17	4-Apr-19	26-Jun-21	13-Jan-17		10-Aug-21	"Stanford University, School of Medicine, Palo Alto, California, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/02/NCT03020602/ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT03020602
1182	NCT00751270	Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas	BrTK01	Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma	Biological: AdV-tk|Drug: Valacyclovir	Safety of the intervention will be evaluated based on laboratory and clinical parameters graded using CTCAEver3.|Tumor Response|Progression-free Survival|Overall Survival|Quality of Life (QOL)	"Candel Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrTK01	Nov-05	Jan-10	Jan-11	11-Sep-08		4-Mar-16	"The Ohio State University Medical Center, Dept Neurosurgery, Columbus, Ohio, United States|The Methodist Hosptial, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00751270
1183	NCT00028158	"Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer"		Completed	No Results Available	Glioma|Astrocytoma|Glioblastoma	"Drug: G207, an oncolytic virus"		MediGene	All	"19 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	65	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NG1-003	Dec-01		Oct-03	18-Dec-01		24-Jun-05			https://ClinicalTrials.gov/show/NCT00028158
1184	NCT00589875	Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)	BrTK02	Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma	Biological: AdV-tk|Drug: Valacyclovir	Expand the safety evaluation at the maximum dose of AdV-tk evaluated in a completed phase Ib study|Overall survival|Progression free survival|Quality of life	"Candel Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	52	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrTK02	Mar-07	Dec-15	Aug-16	10-Jan-08		11-Apr-17	"City of Hope Medical Center, Duarte, California, United States|The University of Chicago, Chicago, Illinois, United States|The Ohio State University Medical Center, Dept. Neurological Surgery, Columbus, Ohio, United States|The Methodist Hospital Neurological Institute, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00589875
1185	NCT00612651	PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas		Completed	No Results Available	Gliosarcoma|Glioblastoma|Anaplastic Astrocytoma	Drug: Temodar and SCH 66336	Dose-limiting toxicity|Progression-free survival	Duke University|Schering-Plough	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	37	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00005027|7009/Pro00005027	Oct-05	Jan-09	Jun-11	12-Feb-08		20-Feb-13	"Duke University Health System, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00612651
1186	NCT03975959	Memory Perception Assessment in Central/Non-central Nervous System Cancers	PROMESSE	Recruiting	No Results Available	Glioblastoma|Glioma|Breast Cancer|Healthy	Other: QMRP questionnaire	the nature of subjective memory complaints|the significant psychopathological correlates of the subjective PM and RM complaints|the significant correlates between the subjective PM and RM complaints and the subjective fatigues|the significant correlates between the subjective PM and RM complaints|the effect of disease on the subjective PM and RM complaints|the effect of cancer on the subjective PM and RM complaints	Institut du Cancer de Montpellier - Val d'Aurelle	All	"18 Years to 80 Years   (Adult, Older Adult)"	Not Applicable	420	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	PROICM 2018-07 BPR	10-May-19	30-Jun-23	30-Oct-23	5-Jun-19		21-Dec-21	"Icm Val D'Aurelle, Montpellier, Herault, France|CHU D'amiens, Amiens, Nord, France|UFR de Psychologie Université de Lille, Villeneuve-d'Ascq, Nord, France|Hôpital d'Instruction des Armées, Clamart, France|Hopital saint Louis, Paris, France|CHU Lyon, Saint-Genis-Laval, France"		https://ClinicalTrials.gov/show/NCT03975959
1187	NCT02800486	"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA"		Recruiting	No Results Available	"Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Glioma|Brain Neoplasm|Brain Cancer|Brain Tumor|Brain Tumor, Recurrent|Brain Neoplasm, Malignant"	Drug: Intra-arterial Cetuximab|Drug: Intra-arterial Mannitol|Radiation: Hypofractionated re-irradiation	Progression Free Survival (PFS)|Overall Survival (OS)|Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)|Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	37	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HS16-0181	May-16	May-24	May-25	15-Jun-16		31-Aug-21	"Lenox Hill Brain Tumor Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02800486
1188	NCT02540135	Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma		Withdrawn	No Results Available	High Grade Malignant Neoplasm|Glioblastoma Multiforme|Anaplastic Astrocytoma	Other: fluorescein|Other: intraoperative MRI	Extent of resection|Surgical time difference	"University of Colorado, Denver"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	0	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other	15-1313	1-Mar-15	18-Jul-18	18-Jul-18	3-Sep-15		20-Jul-18	"University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States"		https://ClinicalTrials.gov/show/NCT02540135
1189	NCT00430911	Radiotherapy for Malignant Astrocytomas in the Elderly		Completed	No Results Available	Primary Brain Tumor|Anaplastic Astrocytoma|Glioblastoma Multiforme	Drug: Radiotherapy	Survival|Progression free survival|Quality of life|Cognitive functions	Assistance Publique - Hôpitaux de Paris	All	70 Years and older   (Older Adult)	Phase 3		Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	"PHRC, P000502 AOM 98071"	Feb-01			2-Feb-07		2-Feb-07	"Hôpital de la Salpêtrière, Paris, Ile de France, France"		https://ClinicalTrials.gov/show/NCT00430911
1190	NCT01663012	Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma		Completed	Has Results	Anaplastic Astrocytomas|Anaplastic Oligodendrogliomas|Glioblastomas (GBM)	Drug: Etirinotecan pegol	"Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria|Survival From the Time of First NKTR-102 Dose for Patients With BEV-resistant Glioma Receiving NKTR-102 to Date of Death|Overall Survival From Time of Diagnosis"	Lawrence Recht|Nektar Therapeutics|Stanford University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-24833|SU-06212012-10228|NCI-2012-01288|BRN0021	Jul-12	Feb-15	Feb-15	13-Aug-12	11-Jun-15	24-Feb-16	"Stanford University School of Medicine, Palo Alto, California, United States"		https://ClinicalTrials.gov/show/NCT01663012
1191	NCT03392545	Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)	InSituVac1	Unknown status	No Results Available	"High Grade Glioma|Glioblastoma|Glioma of Brainstem|Glioma, Malignant"	Combination Product: Combined immune adjuvants and radiation	Incidence of Treatment-related Adverse Events|Progression-free Survival|Overall Survival	Beijing Tiantan Hospital|Duke University	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B0011	1-Apr-18	1-Apr-20	1-Jun-20	8-Jan-18		11-Jul-19	"Beijing Tiantan Hospital, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT03392545
1192	NCT03649464	Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants		Not yet recruiting	No Results Available	Glioblastoma|Astrocytoma|Oligodendroglioma	Drug: OKN-007	Number of Participants with DLTs (Dose Limiting Toxicities) and AEs (Adverse Events)|Number of Participants with Best Overall Response Rate in the brain|Proportion of Participants as Assessed by 6-month Progression-Free Survival (PFS)|Proportion of Participants as Assessed by Overall Survival (OS)|The Cmax of OKN-007 in plasma|The Tmax (time to maximum concentration) of OKN-007 in plasma|AUC (area under the time curve) of OKN-007 in plasma|Plasma concentration of OKN-007|OKN-007 plasma levels over time for food-effect study	"Oblato, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OKN-007-OL-RMG-201	Aug-22	Apr-25	Aug-25	28-Aug-18		28-Sep-21			https://ClinicalTrials.gov/show/NCT03649464
1193	NCT05054400	Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR		Not yet recruiting	No Results Available	Brain Metastases|Cancer|Gliomas|Glioblastoma	Drug: F18 Fluciclovine|Other: Standard of Care	To establish the relationship between brain malignancy volume as defined by post-contrast T1 weighted and F18 Fluciclovine before and following LITT.	M.D. Anderson Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	20	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-1030	30-Nov-21	30-Nov-22	30-Nov-22	23-Sep-21		24-Sep-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT05054400
1194	NCT01598597	"An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)"		Completed	No Results Available	Breast Cancer|Colorectal Cancer|Non-Small Cell Lung Cancer|Glioblastoma|Renal Cell Cancer		"Percentage of subjects who complete the survey and who provide evaluable genetic information (DNA)|Clinical characteristics (current disease status/previous treatments) of subjects participating in this study|Demographic distribution (age, sex) of subjects participating in this study"	"Genentech, Inc.|23andMe, Inc."	All	"18 Years and older   (Adult, Older Adult)"		276	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GO28289	Mar-12	Nov-14	Nov-14	15-May-12		8-May-15	"Many locations, Alabama, United States|Many locations, Alaska, United States|Many locations, Arizona, United States|Many locations, Arkansas, United States|Many locations, California, United States|Many locations, Colorado, United States|Many locations, Connecticut, United States|Many locations, Delaware, United States|Many locations, Florida, United States|Many locations, Georgia, United States|Many locations, Hawaii, United States|Many locations, Idaho, United States|Many locations, Illinois, United States|Many locations, Indiana, United States|Many locations, Iowa, United States|Many locations, Kansas, United States|Many locations, Kentucky, United States|Many locations, Louisiana, United States|Many locations, Maine, United States|Many locations, Maryland, United States|Many locations, Massachusetts, United States|Many locations, Michigan, United States|Many locations, Minnesota, United States|Many locations, Mississippi, United States|Many locations, Missouri, United States|Many locations, Montana, United States|Many locations, Nebraska, United States|Many locations, Nevada, United States|Many locations, New Hampshire, United States|Many locations, New Jersey, United States|Many locations, New Mexico, United States|Many locations, New York, United States|Many locations, North Carolina, United States|Many locations, North Dakota, United States|Many locations, Ohio, United States|Many locations, Oklahoma, United States|Many locations, Oregon, United States|Many locations, Pennsylvania, United States|Many locations, Rhode Island, United States|Many locations, South Carolina, United States|Many locations, South Dakota, United States|Many locations, Tennessee, United States|Many locations, Texas, United States|Many locations, Utah, United States|Many locations, Vermont, United States|Many locations, Virginia, United States|Many locations, Washington, United States|Many locations, West Virginia, United States|Many locations, Wisconsin, United States|Many locations, Wyoming, United States"		https://ClinicalTrials.gov/show/NCT01598597
1195	NCT00004017	Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Procedure: conventional surgery|Radiation: iodine I 131 monoclonal antibody TNT-1/B		Peregrine Pharmaceuticals|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Industry	Interventional	Primary Purpose: Treatment	CDR0000067235|PEREGRINE-TNT9802|MUSC-7993|PEREGRINE-BB-IND-7344|TCLONE-BB-IND-7344|TCLONE-TNT9802|NCI-G99-1560	Feb-00			27-Jan-03		9-Feb-09	"Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina, United States|Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT00004017
1196	NCT03561207	3D Prediction of Patient-Specific Response	3D-PREDICT	Recruiting	No Results Available	Advanced Cancer|Ovarian Cancer|Glioblastoma Multiforme|Anaplastic Astrocytoma	Diagnostic Test: EV3D Assay	Establish correlation of Assay results with patient outcomes|Evaluate the use of Assay results and the effects on medical decision-making and patient outcomes|Compare clinical response (progression free survival or time to progression) in patients who receive treatment aligned with Assay results of response versus patients who are not treated aligned with Assay results of response|Compare clinical response (progression free survival or time to progression) in patients who receive treatment aligned with Assay results of response versus historical response rates|Compare clinical outcomes (event free survival and overall survival) in patients who are treated aligned with Assay results versus historical response rates|Define Assay success across histologic subtypes and classes of anti-cancer compounds	KIYATEC	All	"18 Years and older   (Adult, Older Adult)"		570	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	KIY-REG-001	11-Jun-18	Jun-24	Dec-24	19-Jun-18		7-Oct-21	"University of Arkansas for Medical Sciences, Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States|University of California, San Francisco, San Francisco, California, United States|Capital Health Institute for Neurosciences, Trenton, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Veterans Administration Portland Health Care System, Portland, Oregon, United States|Penn State Health, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Prisma Health, Greenville, South Carolina, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States"		https://ClinicalTrials.gov/show/NCT03561207
1197	NCT00243022	"Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme"		Terminated	Has Results	Brain and Central Nervous System Tumors|Cerebral Edema	Drug: Boswellia serrata extract|Dietary Supplement: cyanocobalamin	Change From Pooled Baseline in Peritumoral Brain Edema|Change From Baseline in Peritumoral Brain Edema|Quality of Life at 6 Months|Time-to-tumor-progression: Percentage of Patients With Tumor Progression at 6 Months|Time-to-tumor-progression: Percentage of Patients With Tumor Progression at 1 Year|Overall Survival: Percentage of Patients That Were Alive at 1 Year	Ali Altunkaya|National Cancer Institute (NCI)|Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	12	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE1304|CCF-7348|NCI-2010-01384|R21CA107277-01	Sep-04	Mar-10	Mar-11	21-Oct-05	30-Jul-13	30-Apr-19	"Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00243022
1198	NCT02038699	A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer		Withdrawn	No Results Available	Advanced Glioblastoma|Advanced Colorectal Cancer|Advanced Triple-negative Breast Cancer|Advanced Non-small Cell Lung Cancer	Drug: ONC201	"In Phase I, to determine the recommended phase II doses of ONC201.|In phase II, Progression-free survival of patients treated with ONC201."	Chimerix	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1	Jan-14	Dec-15	Dec-16	16-Jan-14		30-Apr-21	"Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT02038699
1199	NCT01441388	A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.		Withdrawn	No Results Available	"Carcinoma, Renal Cell|Glioblastoma|Carcinoma, Hepatocellular"	Drug: Crizotinib plus VEGF inhibitor combinations|Drug: Crizotinib plus axitinib|Drug: Crizotinib plus sunitinib|Drug: Crizotinib plus bevacizumab|Drug: Crizotinib plus sorafenib	"Dose Limiting Toxicities (DLTs).|Duration of Response (DR)|Progression free survival (PFS)|Area under the plasma concentration versus time curve (AUC) of crizotinib and each VEGF inhibitor|Best overall response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 or , in the case of GBM (glioblastoma multiforme , RANO (Response Assessment in Neuro-Oncology) criteria.|Overall survival (OS) up to 12 months|Pre- and post-dose levels of soluble peripheral blood biomarkers.|Tumor tissue biomarkers.|6-month progression free survival proportion (PFS6) for glioblastoma patients|Peak plasma concentration (Cmax) of crizotinib and each VEGF inhibitor"	Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A8081030	Dec-11	Nov-13	Nov-13	27-Sep-11		20-Dec-11			https://ClinicalTrials.gov/show/NCT01441388
1200	NCT01351519	A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors		Terminated	No Results Available	Malignant Glioma|Glioma|Glioblastoma|Glioblastoma Multiforme|Astrocytoma	Drug: Aminolevulinic Acid	Time to disease progression after initial surgery.|Complete Resection|Determine the number of subjects with adverse events due to ALA in this dosage and indication.|Overall Survival	MultiCare Health System Research Institute	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ALA 11.07	May-11	Jan-15	Jan-15	11-May-11		17-Mar-16	"MultiCare Health System Research Institute, Tacoma, Washington, United States"		https://ClinicalTrials.gov/show/NCT01351519
1201	NCT04782609	Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma	Glio	Not yet recruiting	No Results Available	"1st, 2nd or 3rd Recurrence of IDH Wild Type Glioblastoma Multiforme (GBM)|Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma With Molecular Features of Glioblastoma Multiforme (GBM)|Grade 3 or 4, Isocitrate Dehydrogenase (IDH) Mutant Astrocytoma|Glioblastoma Surgery"	Drug: Icapamespib	Incidence and severity of adverse events|Maximum Tolerated Dose (MTD)/Coverage with evidence development (CED)/recommended phase 2 dose (RP2D) (Part 1 Only|Icapamespib Plasma Concentration at Time of Surgery	"Samus Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	48	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PU-AD-SD-0104	Nov-21	Apr-22	Aug-22	4-Mar-21		22-Sep-21			https://ClinicalTrials.gov/show/NCT04782609
1202	NCT01740258	Bevacizumab Beyond Progression (BBP)	BBP	Completed	Has Results	Malignant Glioma|Grade 4 Malignant Glioma|Glioblastoma|Gliosarcoma	Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Bevacizumab	Overall Survival|Toxicity: Percentage of Subjects With Unacceptable Toxicities|Progression-free Survival (PFS)	"Duke University|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	68	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00038098	Jan-13	14-Nov-19	14-Nov-19	4-Dec-12	2-Dec-20	26-Jan-21	"Duke Cancer Center, Durham, North Carolina, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/58/NCT01740258/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01740258
1203	NCT00498927	Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: temozolomide|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique	Progression-free Survival (PFS) Rate at 6 Months|Overall Survival	Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Weill Medical College of Cornell University|Schering-Plough	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	47	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-064|P30CA008748|MSKCC-07064|SPRI-PO5096	Jun-07	Dec-13	Dec-13	11-Jul-07	29-Feb-16	29-Feb-16	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00498927
1204	NCT03050736	Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression		"Active, not recruiting"	No Results Available	Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer	Drug: VAL-083 (Dianhydrogalactitol)	"Efficacy evaluation of tumor response in patients, as measured by magnetic resonance imaging|Safety evaluation of VAL-083 in combination with a standard radiation therapy, as determined by incidence of patient adverse events and changes in laboratory results, ECG and vital signs|Ctrough|Cmax|Tmax|AUClast|AUCinf|CL/F|Mean Residence Time|Vz|Lambda z|T½|Pharmacokinetic profile and dose-exposure relationship of VAL-083 in Cerebral Spinal Fluid (CSF)"	"Kintara Therapeutics, Inc.|Sun Yat-sen University"	All	"18 Years to 69 Years   (Adult, Older Adult)"	Phase 2	30	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DLM-14-001	17-Dec-17	Jun-21	Aug-21	13-Feb-17		8-Jun-21	"Sun Yat-Sen University Cancer Center, Guangzhou, China"		https://ClinicalTrials.gov/show/NCT03050736
1205	NCT03956706	Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas		Recruiting	No Results Available	"Glioblastoma|Astrocytoma, Grade III|Astrocytoma, Grade IV|Malignant Glioma"	Radiation: Stereotactic Radiosurgery	Toxicity of Therapy|Progression-free survival	Northwell Health	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	36	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18-0794	24-Dec-18	Jun-21	Dec-21	21-May-19		5-Jan-21	"Northwell Health Brain Tumor Center, Lake Success, New York, United States"		https://ClinicalTrials.gov/show/NCT03956706
1206	NCT04608812	Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection		Recruiting	No Results Available	"Glioma, Malignant|High Grade Glioma|Glioblastoma|Glioblastoma Multiforme|Anaplastic Astrocytoma"	Drug: OS2966|Drug: Gadoteridol|Device: Infuseon Cleveland Multiport Catheter	Number of qualifying treatment emergent adverse events or dose limiting toxicities|Optimal Biological Dose|Spatial Distribution of OS2966 when delivered via the ICMC|Tumor Response Rate|Time to Progression	"OncoSynergy, Inc.|Infuseon Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OS2966CED-001	2-Mar-21	Jul-22	Jul-23	29-Oct-20		10-Aug-21	"Moffitt Cancer Center, Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT04608812
1207	NCT01985256	Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma	Biological: Toca 511|Drug: Toca FC	"Maximum feasible, safe, and tolerated dose of Toca 511 as measured by dose limiting toxicities.|Measure Toca 511 deposition in tumor at the time of resection by QT-PCR|Measure how long Toca 511 stays in blood after IV administration by serum QT-PCR|Safety and tolerability of Toca FC given at various doses and schedules as measured by dose limiting toxicities.|Evaluate preliminary efficacy of Toca 511 and Toca FC by assessing overall survival, and tumor response rates.|Evaluate preliminary efficacy by assessing landmark PFS [6 months]"	Tocagen Inc.	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	17	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Tg 511-13-01	Feb-14	3-Mar-16	3-Mar-16	15-Nov-13		21-May-18	"UC Irivine, Irvine, California, United States|UCLA, Los Angeles, California, United States|UC San Diego, Moores Cancer Center, San Diego, California, United States|Henry Ford Hospital, Detroit, Michigan, United States|JFK Medical Center New Jersery, Edison, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01985256
1208	NCT01977677	Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma		Completed	Has Results	Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Oligodendroglial Tumors|Adult Pineoblastoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)	Radiation: radiation therapy|Drug: temozolomide|Drug: plerixafor|Other: laboratory biomarker analysis|Other: pharmacological study	Dose-limiting Toxicity|Participants Alive and Without Disease Progression At 6 Months After the Start of the Irradiation	Lawrence Recht|National Cancer Institute (NCI)|Stanford University	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	30	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BRN0023|NCI-2013-02012|P30CA124435	Nov-14	Nov-17	Sep-18	7-Nov-13	3-Jul-18	23-Oct-18	"Stanford University, School of Medicine, Stanford, California, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/77/NCT01977677/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01977677
1209	NCT02039778	Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma	STRONG	Terminated	Has Results	Glioblastoma|Malignant Glioma|Brain Tumors|Anaplastic Astrocytoma	Radiation: Stem Cell Radiotherapy (ScRT) and Temozolomide	Overall Survival|Progression-free Survival|Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Neurocognition|Quality of Life	Beth Israel Medical Center|St. Luke's-Roosevelt Hospital Center	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	4	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-0151	Dec-13	Dec-15	Dec-15	20-Jan-14	5-Jun-17	5-Jun-17	"Roosevelt Hospital, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02039778
1210	NCT01470794	Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma	Biological: Toca 511 vector|Drug: Toca FC	Dose Limiting Toxicities|Overall Survival of Subjects|Progression Free Survival (PFS) of Subjects	Tocagen Inc.	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	58	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Tg 511-11-01	Feb-12	12-Apr-16	12-Apr-16	11-Nov-11		21-May-18	"UCLA, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|Henry Ford Hospital, Detroit, Michigan, United States|JFK Medical Center, Edison, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Swedish Neuroscience Institute, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01470794
1211	NCT01478178	Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma		Completed	No Results Available	Glioma|Glioblastoma|Glioblastoma Multiforme|GBM|Brain Cancer	Drug: VAL-083 (Dianhydrogalactitol)	Determination of maximum tolerated dose (MTD)|Evaluate tumor response in patients with recurrent malignant glioma|Characterization of Cycle 1 plasma pharmacokinetics	"DelMar Pharmaceuticals, Inc.|Kintara Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	55	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DLM-10-001	Oct-11	Dec-15	Oct-16	23-Nov-11		20-Jan-17	"University of California, San Francisco, Division of Neuro-Oncology, San Francisco, California, United States|Sarah Cannon Research Institute, Denver, Colorado, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT01478178
1212	NCT04712721	Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.		Recruiting	No Results Available	Glioblastoma Multiforme|Brain Neoplasms|Gastroesophageal Adenocarcinoma|Pancreatic Ductal Adenocarcinoma	Drug: 68Ga-FF58	"Non-decay corrected tissue time-activity curves (TACs) from 68Ga-FF58 PET/CT images|Number of lesions detected by [68Ga]-FF58|Number of Participants with Lesions detected by [68Ga]-FF58 per Location|Standard Uptake Value (SUV) mean and max in lesions detected by PET scans|Tumor to Background Ratio (TBR) of lesions detected by PET scans|Number of Participants with Treatment Emergent Adverse Events|Percentage of lesions detected by conventional scans, PET scans, or both modalities|Lesion-level analyses of diagnostics by [68Ga]-FF58 compared with conventional imaging|Dosimetry Group: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of 68Ga-FF58|Dosimetry Group: Time of maximum observed drug concentration occurrence (Tmax) of 68Ga-FF58|Dosimetry Group: Observed maximum plasma concentration (Cmax) of 68Ga-FF58|Dosimetry Group: Terminal elimination half-life (T^1/2) of 68Ga-FF58|Dosimetry Group: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) of 68Ga-FF58|Dosimetry Group: Total systemic clearance for intravenous administration (CL) of 68Ga-FF58|Dosimetry Group: Volume of distribution during the terminal phase following intravenous elimination (Vz) of 68Ga-FF58|Dosimetry Group: Urinary excretion of radioactivity expressed as a percentage of injected activity (%IA)|Dosimetry Group: Absorbed dose of 68Ga- FF58|Dosimetry Group: Effective whole-body dose of 68Ga- FF58"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	80	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	CAAA504A12101|2020-004038-39	14-Oct-21	13-Dec-22	27-Dec-22	15-Jan-21		23-Dec-21	"Novartis Investigative Site, Lyon Cedex, France"		https://ClinicalTrials.gov/show/NCT04712721
1213	NCT04740190	Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd	TAC-GReD	Recruiting	No Results Available	Recurrent Glioma|Recurrent Glioblastoma|Poly ADP Ribose Polymerase (PARP) Inhibitor|PTEN Gene Inactivation|IDH Mutation	Drug: Talazoparib	Progression free survival in 6 months|Overall survival|Objective response rate|Duration of response	The University of Hong Kong	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	33	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UW-20396	1-Jan-21	31-Dec-22	31-Dec-23	5-Feb-21		20-Aug-21	"Department of Clinical Oncology, Hong Kong, Hong Kong"		https://ClinicalTrials.gov/show/NCT04740190
1214	NCT02052648	Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors		Completed	No Results Available	Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor	Drug: Indoximod|Drug: Temozolomide|Drug: Bevacizumab|Radiation: Stereotactic Radiation	Phase 1: Determine Phase 2 Dosing|Phase 2: Efficacy|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Dose of Temozolomide Delivered Versus Historical Control|Serum concentrations (Cmax/Steady State) of indoximod HLC|Overall response rate	NewLink Genetics Corporation|Lumos Pharma	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 1|Phase 2	160	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NLG2102	Mar-14	18-Apr-18	20-Jun-19	3-Feb-14		28-May-20	"Eden Medical Center, Castro Valley, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kentucy, Lexington, Kentucky, United States|John Nasseff Neuroscience Institute, Minneapolis, Minnesota, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Texas Oncology, Austin, Texas, United States|Huntsman Cancer Center, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02052648
1215	NCT05131763	NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors		Recruiting	No Results Available	Hepatocellular Carcinoma|Glioblastoma|Medulloblastoma|Colon Cancer	Biological: NKG2D-based CAR T-cells	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Detailed adverse events post NKG2D-based CAR-T therapy.|overall survival (OS)|Progress Free Survival (PFS)|Partial response rate	Fudan University|KAEDI	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	3	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Fudan-Changchun	1-Mar-21	1-Dec-22	1-Dec-23	23-Nov-21		23-Nov-21	"Xunyang Changchun Shihua Hospital, Jiujiang, Jiangxi, China"		https://ClinicalTrials.gov/show/NCT05131763
1216	NCT02798406	Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects	CAPTIVE	Completed	No Results Available	"Brain Cancer|Brain Neoplasm|Glioma|Glioblastoma|Gliosarcoma|Malignant Brain Tumor|Neoplasm, Neuroepithelial|Neuroectodermal Tumors|Neoplasm by Histologic Type|Neoplasm, Nerve Tissue|Nervous System Diseases"	Biological: DNX-2401|Biological: pembrolizumab	Objective response rate (ORR)|Overall survival (OS)|Time to tumor response|Duration of response	"DNAtrix, Inc.|Merck Sharp & Dohme Corp."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	49	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2401BT-002P	6-Oct-16	17-Mar-21	30-Jun-21	14-Jun-16		15-Jul-21	"University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|University of Minnesota Neurosurgery, Minneapolis, Minnesota, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill-Cornell Medicine New York-Presbyterian, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University James Cancer Center, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Texas Oncology Austin-Midtown, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Health Network, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT02798406
1217	NCT04270461	NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors		Withdrawn	No Results Available	Hepatocellular Carcinoma|Glioblastoma|Medulloblastoma|Colon Cancer	Biological: NKG2D-based CAR T-cells	"Number of Participants with severe cytokine release syndrome(CRS) as a Measure of Safety and Tolerability.|Copies numbers of CAR|overall survival (OS)|Progress Free Survival (PFS)|Duration of response, (DoR)"	Jiujiang University Affiliated Hospital|KAEDI	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JiujiangUH	17-Mar-20	17-Oct-20	17-Oct-20	17-Feb-20		22-Oct-20	"Affiliated hospital of jiujiang university, Jiujiang, Jiangxi, China"		https://ClinicalTrials.gov/show/NCT04270461
1218	NCT01817751	"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma"		"Active, not recruiting"	Has Results	Glioblastoma|Recurrent Adult Brain Neoplasm|Malignant Glioma|WHO Grade III Glioma	Drug: sorafenib tosylate|Drug: valproic acid|Drug: sildenafil citrate	"Number of Participants With 6-Month Progression Free Survival (PFS)|Number of Participants Whose Tumors Express PDGFRa With and Without 6-Month PFS.|Number of Participants With Best Response of CR Plus Number of Participants With Best Response of PR.|Number of Participants Whose Tumors Express PDGFRa With Best Response of CR Plus Number of Participants Whose Tumor Expresses PDGFRa With Best Response of PR.|Number of Participants With 12-Month Progression Free Survival (PFS).|Number of Participants Whose Tumors Express PDGFRa With and Without 12-Month PFS.|Evaluation of Safety and Toxicity of Sorafenib, Valproic Acid, and Sildenafil"	Virginia Commonwealth University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	47	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-14816|HM14816|NCI-2013-00705|P30CA016059	11-Apr-13	27-Aug-20	30-Oct-27	25-Mar-13	28-Oct-21	28-Oct-21	"Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/51/NCT01817751/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT01817751/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT01817751
1219	NCT04734444	SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue		Recruiting	No Results Available	Brain Tumour|High Grade Glioma|Low-grade Glioma|Glioblastoma	Device: SonoClear ACF	Contrast-to-Noise Ratio (CNR) to quantify the reduction in noise|Surgeons Image Rating (SIR) to assess the image quality|Adverse events up to 30 days post procedure	SonoClear AS	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	20	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ACF-03	1-Sep-21	1-Mar-22	1-Mar-22	2-Feb-21		17-Nov-21	"University Hospital Bratislava, Bratislava, Slovakia"		https://ClinicalTrials.gov/show/NCT04734444
1220	NCT04102436	Non-Viral TCR Gene Therapy		Suspended	No Results Available	Glioblastoma|Non-Small Cell Lung Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancer|Ovarian Cancer	Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Biological: Sleeping Beauty Transposed PBL	Response rate|Phenotypic and functional characteristics of PBL|Safety and tolerance|Immune monitoring	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	210	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	190143|19-C-0143	7-Dec-21	31-Dec-28	31-Dec-29	25-Sep-19		20-Oct-21	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT04102436
1221	NCT04757662	Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma		Recruiting	No Results Available	"Grade III Astrocytoma|Grade IV Astrocytoma|Astrocytoma, Grade IV|Astrocytoma, Grade III"	Drug: Tadalafil	Relative change of MDSCs in peripheral blood|Frequency of adverse events as measured by CTCAE v5.0|Rate of severe lymphopenia|Progression-free survival (PFS)|Overall survival (OS)|Number of imaging changes on heterogeneity diffusion imaging (HDI)	Washington University School of Medicine|The Curtis L. Brown Glioblastoma Research Fund	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	202103257	14-May-21	31-Jul-23	31-Jul-23	17-Feb-21		8-Sep-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT04757662
1222	NCT04323046	Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults		Recruiting	No Results Available	Glioblastoma|Malignant Glioma|Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent Grade III Glioma|Grade III Glioma	Biological: Ipilimumab|Biological: Nivolumab|Drug: Placebo Administration|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	Percentage change in cell cycle-related genetic signature|Proportion of participants with treatment-related adverse events|Overall survival|Progression-free survival (PFS)	"Sabine Mueller, MD, PhD|Bristol-Myers Squibb|Pacific Pediatric Neuro-Oncology Consortium|University of California, San Francisco"	All	"6 Months to 22 Years   (Child, Adult)"	Phase 1	45	Other|Industry	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment"	190815|NCI-2020-01502|PNOC 0019	2-Oct-20	1-Mar-22	1-Mar-25	26-Mar-20		21-Dec-21	"Children's Hospital of Los Angeles, Los Angeles, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Perth Children's' Hospital, Perth, Western Australia, Australia|Sheba Medical Center, Ramat Gan, Israel|The University Children's Hospital in Zurich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT04323046
1223	NCT03389230	Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma		Recruiting	No Results Available	Glioblastoma|Malignant Glioma|Recurrent Glioma|Refractory Glioma|WHO Grade III Glioma	Biological: HER2(EQ)BBζ/CD19t+ T cells|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis	"Incidence of grade 3 adverse events|Dose limiting toxicities (DLT)|Incidence of adverse events|Chimeric antigen receptor (CAR) T cells detected in tumor cyst fluid, peripheral blood, and cerebrospinal fluid (CSF)|Tumor cyst fluid, peripheral blood, and cerebrospinal fluid (CSF) cytokine levels|Progression free survival|Overall Survival (OS)|Disease response|Chimeric antigen receptor (CAR) T cells detected in tumor tissue|HER2 antigen expression levels in tumor tissue"	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	42	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16064|NCI-2017-01755|P30CA033572	14-Aug-18	15-Dec-23	15-Dec-23	3-Jan-18		12-Aug-21	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT03389230
1224	NCT03593993	A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas		Recruiting	No Results Available	Glioma|BRAF V600E|Pleomorphic Xantho-Astrocytoma|Glioblastoma	Procedure: Surgical Cohort	Concentration of dabrafenib in brain tumor|Concentration of trametinib in brain tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Musella Foundation	All	"6 Weeks and older   (Child, Adult, Older Adult)"		8	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	J1801|IRB00158788	19-May-18	19-May-22	19-May-22	20-Jul-18		10-Sep-21	"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusettes General Hospital, Boston, Massachusetts, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03593993
1225	NCT01156584	A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma		Completed	No Results Available	Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma	Biological: Toca 511 vector|Drug: Toca FC	"Maximum Feasible, Safe and Well Tolerated Dose of Toca 511|Safety and tolerability of repeated treatment with Toca FC following administration of Toca 511|Overall survival of Subjects|Evaluate progression free survival (PFS) at 6 months"	Tocagen Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	54	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Tg 511-08-01	Jul-10	18-Aug-16	18-Aug-16	5-Jul-10		21-May-18	"City of Hope, Duarte, California, United States|UCLA, Los Angeles, California, United States|UCSD, San Diego, California, United States|UCSF, San Francisco, California, United States|Henry Ford Hospital, Detroit, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The Methodist Hospital Research Institute, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01156584
1226	NCT00905060	HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM	HeatShock	Completed	Has Results	Brain and Central Nervous System Tumors	Biological: HSPPC-96|Drug: Temozolomide|Procedure: Standard Surgical Resection	Number of Participants With Treatment-Related Adverse Events of Any Grade|Median Overall Survival|Median Progression Free Survival (PFS)|Median PD-L1 Positivity in Circulating Myeloid Cells	"University of California, San Francisco|Agenus Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	70	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	081010|C-100-37|NCI-2015-01229	29-Jun-09	3-Jun-14	3-Jun-14	20-May-09	24-Mar-21	24-Mar-21	"University of California, San Francisco, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|The Valley Hospital, Paramus, New Jersey, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Columbia University, New York, New York, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00905060
1227	NCT03718767	Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype		Recruiting	No Results Available	Glioma|Glioblastoma|High Grage Glioma|Low Grade Glioma|Malignant Glioma	Drug: Nivolumab	6-month progression free survival rate|Median amount of time subject survives after therapy and Proportion of patients that have progressive disease after 12 months|Correlation between neoantigen burden of tumor and proportion of subjects that survive after 6 and 12 months|Proportion of patients that have improvement in quality of life	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	95	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	190006|19-C-0006	27-Mar-19	28-Feb-25	27-Feb-26	24-Oct-18		6-Jan-22	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03718767
1228	NCT02327078	"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)"		Completed	No Results Available	B-cell Malignancies|Colorectal Cancer (CRC)|Head and Neck Cancer|Lung Cancer|Lymphoma|Melanoma|Ovarian Cancer|Glioblastoma	Drug: Nivolumab (Phase 1)|Drug: Epacadostat (Phase 1)|Drug: Chemotherapy (Phase 1)|Drug: Nivolumab (Phase 2)|Drug: Epacadostat (Phase 2)	"Phase 1, Part 1: Safety and tolerability of epacadostat and nivolumab assessed by number of subjects with dose limiting toxicities (DLTs)|Phase 1, Part 2: Safety and tolerability of epacadostat administered in combination with nivolumab and chemotherapy regimen assessed by number of subjects with DLTs|Phase 1, Part 1 and 2: Safety assessed by the frequency of adverse events, serious adverse events, and deaths|Phase 2: Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for subjects with solid tumors and per Cheson criteria for subjects with DLBCL|Phase 2: Progression free survival (PFS)|Phase 2: Overall survival (OS) for subjects with Glioblatoma|Phase 1, Part 1: ORR per RECIST v1.1 and mRECIST for subjects with solid tumors; per Cheson and mCheson criteria for subjects with B-cell NHL; and per RANO and mRANO criteria for subjects with GBM|Phase 1, Part 2: ORR per RECIST v1.1 and modified RECIST for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: Duration of response (DOR) for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 1, Part 2: PFS for subjects with advanced or metastatic SCCHN and advanced or metastatic NSCLC|Phase 2: Duration of response (DOR)|Phase 2: Duration of disease control, defined as CR, PR, and stable disease (SD)|Phase 2: Safety and tolerability measured by the frequency of adverse events (AEs), serious adverse events (SAEs), and deaths"	Incyte Corporation|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	307	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INCB 24360-204 / ECHO-204	26-Nov-14	10-Jul-20	10-Jul-20	30-Dec-14		28-Aug-20	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCSF - University of California San Francisco, San Francisco, California, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|The University of Kansas Clinical Research Center, Fairway, Kansas, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|NYU Cancer Center, New York, New York, United States|Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Research, Fargo, North Dakota, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|Sanford Research, North Sioux City, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology Research, Austin, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/78/NCT02327078/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02327078/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02327078
1229	NCT03914742	BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations		Recruiting	No Results Available	IDH1 Mutation|IDH2 Mutation|Recurrent Glioblastoma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma	Drug: PARP Inhibitor BGB-290|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery	Phase I: Maximum tolerated dose (MTD)|Phase I: Percentage of participants with adverse events|Phase II: Tumor radiographic response|Phase II: Progression-free survival (PFS)|Phase II: Overall survival (OS)|Duration of response|Percentage of participants with serious or life-threatening adverse events	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|BeiGene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	100	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC-1801|UM1CA137443	3-Jan-20	Apr-22	Jul-23	16-Apr-19		10-Sep-21	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|University of California, Los Angeles, Los Angeles, California, United States|Yale University, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|University Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT03914742
1230	NCT01454596	CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII		Completed	Has Results	Malignant Glioma|Glioblastoma|Brain Cancer|Gliosarcoma	Biological: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide	Number of Treatment Related Adverse Events|Progression Free Survival|Number of Patients With an Objective Response|Circulating Chimeric Antigen Receptor (CAR+) Cells in Peripheral Blood at 1 Month Post Treatment|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	18	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	110266|11-C-0266	16-May-12	1-Nov-18	17-Jan-19	19-Oct-11	21-Aug-19	21-Aug-19	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/96/NCT01454596/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/96/NCT01454596/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT01454596
1231	NCT00734682	A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas		Completed	No Results Available	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma	Drug: Nanoliposomal CPT-11	To assess the safety and pharmacokinetics of NL CPT-11 in patients with recurrent malignant glioma stratified based on UGT1A1 genotyping.|To determine the maximum tolerated dose of NL CPT-11 in these patient populations.	"University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	34	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8103	Aug-08	Dec-14	Dec-14	14-Aug-08		7-Jan-15	"University of California, San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00734682
1232	NCT00062504	Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas		Terminated	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Oligoastrocytoma	Drug: Talampanel		"Teva Branded Pharmaceutical Products R&D, Inc.|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Industry|NIH	Interventional	Intervention Model: Parallel Assignment|Primary Purpose: Treatment	IXR-205-21-189	Jul-03	Jan-06	Apr-06	12-Jun-03		23-May-11			https://ClinicalTrials.gov/show/NCT00062504
1233	NCT04678648	A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies		Recruiting	No Results Available	Advanced Malignant Solid Neoplasm|RAS Mutation|Lung Cancer|Colon Cancer|Glioblastoma|Pancreatic Cancer	Drug: RSC-1255 Dose Escalation|Drug: RSC-1255 Dose Expansion	Maximum Tolerated Dose (MTD) for RSC-1255 as monotherapy|Recommended Phase 2 Dose (RP2D) for RSC-1255 as monotherapy|Adverse event profile of RSC-1255|Overall Survival (OS)	"RasCal Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	134	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RSC-101	16-Feb-21	16-Jan-24	5-Mar-24	22-Dec-20		5-Jan-22	"University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Anschutz Cancer Pavilion - University of Colorado Hospital, Aurora, Colorado, United States|Sarah Cannon Research Institute - Health One, Denver, Colorado, United States|Sidney Kimmel Cancer Center - Thomas Jefferson Hospital, Philadelphia, Pennsylvania, United States|Sarah Cannon Tennessee Oncology, Nashville, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT04678648
1234	NCT00099060	Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: lapatinib ditosylate	Toxicity for phase I assessed by CTCAE v.3.0 MacDonald criteria|Response for phase II|Correlative studies on archival tissue|Pharmacokinetics	National Cancer Institute (NCI)|NCIC Clinical Trials Group	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	24	NIH|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I170|CAN-NCIC-IND170|CDR0000389155	Dec-04	Nov-07	Nov-07	9-Dec-04		27-Jan-14	"Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada|British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00099060
1235	NCT01967758	Phase I Study of Safety and Immunogenicity of ADU-623		Completed	No Results Available	Astrocytic Tumors|Glioblastoma Multiforme|Anaplastic Astrocytoma|Brain Tumor	Biological: Cohort 1|Biological: Cohort 2|Biological: Cohort 3|Drug: Antibiotics	Maximum Tolerated Dose|Tumor response based on magnetic resonance imaging (MRI) exam|Immune Response	"Providence Health & Services|Aduro Biotech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	11	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-012A	8-Jan-14	18-Jun-18	15-Aug-18	23-Oct-13		17-Aug-18	"Providence Cancer Center, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT01967758
1236	NCT00041587	Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma		Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Mixed Oligoastrocytoma	Drug: IL13-PE38QQR|Procedure: targeted fusion protein therapy|Procedure: surgery		INSYS Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	80	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IL13PEI-103	Jul-02	Jun-06	Jul-07	12-Jul-02		6-Jun-11	"University of Colorado Health Sciences Center, Denver, Colorado, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Hospital Eppendorf, Hamburg, Germany|University Hospital Kiel, Department of Neurosurgery, Kiel, Germany|Sourasky Medical Center, Tel Aviv, Israel|Chaim Sheba Medical Center, Tel Hashomer, Israel"		https://ClinicalTrials.gov/show/NCT00041587
1237	NCT00024570	Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma		Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Mixed Oligoastrocytoma	Drug: IL13-PE38QQR|Procedure: targeted fusion protein therapy|Procedure: surgery		INSYS Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IL13PEI-001|NCI-NABTT-9903|JHU-NABTT-9903	Nov-00	Jul-07	Jul-07	21-Sep-01		14-Nov-14	"University of Alabama at Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Henry Ford Health Systems, Detroit, Michigan, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00024570
1238	NCT03749187	BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas	PNOC017	Recruiting	No Results Available	Glioblastoma|IDH1 Gene Mutation|IDH2 Gene Mutation|Low Grade Glioma|Malignant Glioma|Recurrent Glioblastoma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma|WHO Grade II Glioma|WHO Grade III Glioma	Drug: PARP Inhibitor BGB-290|Drug: Temozolomide	Proportion of participants with Dose Limiting Toxicities (DLTs)	"University of California, San Francisco|BeiGene USA, Inc.|Pacific Pediatric Neuro-Oncology Consortium"	All	"13 Years to 39 Years   (Child, Adult)"	Phase 1	78	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18083|NCI-2018-02345|PNOC017	3-Apr-19	30-Jun-22	30-Jul-27	21-Nov-18		26-Nov-21	"Children's Hospital Los Angeles, Los Angeles, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT03749187
1239	NCT01174121	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer		Suspended	No Results Available	Metastatic Colorectal Cancer|Progressive Glioblastoma|Metastatic Pancreatic Cancer|Metastatic Ovarian Cancer|Metastatic Breast Carcinoma	Biological: Young TIL|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Pembrolizumab (Keytruda)	Response rate|Frequency and severity of treatment-related to adverse events|Safety and efficacy of pembrolizumab following TIL therapy	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	93	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	100166|10-C-0166	26-Aug-10	29-Dec-23	27-Dec-24	3-Aug-10		20-Dec-21	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01174121
1240	NCT00068770	Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT		Terminated	Has Results	Brain and Central Nervous System Tumors	Radiation: radiation therapy|Drug: Celecoxib	"Effects of Hepatic Enzyme Inducing Drugs Such as Anticonvulsants, on the PK of Celecoxib|Overall Survival"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	35	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTT-2100 CDR0000328117|U01CA062475|NABTT-2100|JHOC-NABTT-2100	Oct-03	May-05	May-06	11-Sep-03	18-Mar-15	18-Mar-15	"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00068770
1241	NCT00045708	A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: ixabepilone|Other: pharmacological study|Drug: Anticonvulsant	Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma|Group A (P450) Estimated MTD and Group B (nonP450) Estimated MTD of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma|Measure Pharmacokinetic Parameters Using Estimation of Half-lives Related to BMS-247550 and Anticonvulsants|Measure Pharmacokinetic Parameters Using Clearance as Related to BMS-247550 and Anticonvulsant Measurements|Measure Pharmacokinetic Parameters Using Volume of Distribution at Steady State as Related to BMS-247550 and Anticonvulsants|Response Rate of Patients at the MTD|Grade 3 and 4 Toxicity (NCI Common Terminology Criteria for Adverse Events Associated With BMS-247550 Treatment in at Least 5% of Patients|Duration of Overall Survival|The Duration of Progression Free Survival (Phase 2)|Percent of Subjects With 6M Progression Free Survival at the Phase 2 Arm of Study	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	57	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03016|NABTT 2111|CDR257118|U01CA062475	Oct-02	May-10	May-10	27-Jan-03	9-May-17	18-Oct-17	"Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00045708
1242	NCT02208362	Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma		Recruiting	No Results Available	Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma|Refractory Glioblastoma|Refractory Malignant Glioma|Refractory WHO Grade II Glioma|Refractory WHO Grade III Glioma	Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Other: Laboratory Biomarker Analysis|Procedure: Magnetic Resonance Imaging|Procedure: Magnetic Resonance Spectroscopic Imaging|Other: Quality-of-Life Assessment	"Incidence of grade 3 toxicity|Incidence of dose limiting toxicity (DLT), graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0|Incidence of toxicities, graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0 as well as the modified neurological grading system|Changes in largest length of tumor|Changes in cytokine levels|Changes in chimeric antigen receptor (CAR) T levels|Progression free survival (PFS)|Disease response by the Response Assessment in Neuro-Oncology criteria|Disease response (stratum 1 and 2)|CAR T cell detection (stratum 1 and 2)|Endogenous immune cell detection (stratum 1 and 2)|Cytokine and post progression therapy(ies) (stratum 1 and 2)|Overall survival (OS)|Changes in quality of life|T cell detection in tumor|IL13Ra2 antigen expression levels"	City of Hope Medical Center|National Cancer Institute (NCI)|Food and Drug Administration (FDA)	All	"12 Years to 75 Years   (Child, Adult, Older Adult)"	Phase 1	92	Other|NIH|U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13384|NCI-2014-01488|P30CA033572|R01FD005129	18-May-15	18-Jan-22	18-Jan-22	5-Aug-14		11-Feb-21	"City of Hope Comprehensive Cancer Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT02208362
1243	NCT04049669	Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG		Recruiting	No Results Available	Glioblastoma|Medulloblastoma|Ependymoma|Diffuse Intrinsic Pontine Glioma	Drug: Indoximod|Radiation: Partial Radiation|Radiation: Full-dose Radiation|Drug: Temozolomide|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Lomustine	"8-month iRANO-PFS (Progression-Free Survival, defined by immune-adapted iRANO criteria)|12-month Overall Survival (OS)|Overall Survival (OS)|iRANO-PFS (Progression-Free Survival, defined by immune-adapted iRANO criteria)|Time to Regimen Failure (TTRF)"	Theodore S. Johnson|National Cancer Institute (NCI)|Augusta University|Emory University	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	140	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCC1949|R01CA229646	2-Oct-19	2-Oct-24	2-Oct-26	8-Aug-19		14-Jun-21	"Augusta University, Georgia Cancer Center, Augusta, Georgia, United States|Emory University, Children's Heathcare of Atlanta, Druid Hills, Georgia, United States"		https://ClinicalTrials.gov/show/NCT04049669
1244	NCT03971734	Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas		Recruiting	No Results Available	High Grade Glioma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Glioblastoma	Drug: Regadenoson 0.05mg|Drug: Regadensoson 0.1mg|Drug: Regadensoson 0.2mg|Drug: Regadensoson 0.4mg|Drug: Regadensoson 0.7mg|Drug: Regadensoson 1.0mg|Drug: Regadensoson 1.4mg	Dose of regadenoson	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	18 Years to 45 Years   (Adult)	Phase 1	45	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC 1804|UM1CA137443	6-Dec-19	Mar-22	Mar-22	3-Jun-19		10-Sep-21	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03971734
1245	NCT00575887	Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma		Completed	Has Results	"Glioblastoma|Astrocytoma|Oligodendroglioma|Brain Tumor, Recurrent"	Drug: Temozolomide	Progression-free Survival at 6-months	Marmara University|Schering-Plough	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	25	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MU-RO-2005-1	Aug-06	Mar-09	Mar-09	18-Dec-07	20-Dec-13	20-Dec-13	"Marmara University Hospital, Istanbul, Turkey"		https://ClinicalTrials.gov/show/NCT00575887
1246	NCT00001171	Evaluation of Factors in Human Brain Tumors		Completed	No Results Available	Brain Neoplasm|Glioblastoma|Glioma|Pituitary Neoplasm			National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	"Child, Adult, Older Adult"		800	NIH	Observational		790089|79-N-0089	Jul-79		Sep-05	4-Nov-99		4-Mar-08	"National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00001171
1247	NCT00132158	ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors		Completed	No Results Available	Glioblastoma|Rhabdomyosarcomas|Neuroblastoma|Osteosarcoma	"Drug: Irinotecan (Camptosar), Gefitinib (Iressa)"	To estimate the maximum tolerated dose (MTD) of the intravenous formulation of irinotecan given orally in combination with a fixed dose of oral gefitinib.	St. Jude Children's Research Hospital|AstraZeneca	All	"up to 21 Years   (Child, Adult)"	Phase 1	19	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	POCPZD|IRUSIRES0181	Sep-05	Oct-11	Oct-11	19-Aug-05		17-Apr-12	"St. Jude Children's Research Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00132158
1248	NCT01902771	Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors		Terminated	No Results Available	Glioma|Brain Cancer|Brain Tumor|Glioblastoma Multiforme|High Grade Glioma	Biological: Dendritic Cell Vaccine|Biological: Tumor Lysate|Other: Imiquimod|Procedure: Leukapheresis	Rate of Toxicity in Study Participants Receiving Protocol Therapy|Rate of Feasibility of Protocol Therapy in Study Participants|Rate of Prolonged Survival or Prolonged Progression-Free Survival in Study Participants|Rate of Measurable Immune Response in Subjects Receiving Protocol Therapy.|Comparison of clinical parameters of study participants versus associated outcomes for patients on other DC/Imiquimod studies.|Estimation of the Proportion of Subjects with Recurrent Pediatric Brian Tumors who are able to complete DC Vaccine therapy and DC Vaccine + Lysate Therapy.|Identification of Parameters Associated with Poorer Activity of the Vaccine in Study Participants	Edward Ziga|University of Miami	All	"1 Year to 29 Years   (Child, Adult)"	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20130136	3-Sep-13	24-Oct-16	26-Jan-17	18-Jul-13		10-Mar-17	"University of Miami, Miami, Florida, United States"		https://ClinicalTrials.gov/show/NCT01902771
1249	NCT01656980	Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma		Unknown status	No Results Available	Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma	Drug: Carmustine|Procedure: tumor resection surgery	Overall Survival|Progress Free Survival|Overall Survival Rate at 12 months|Karnofsky Performance Status(KPS)|Quality of Life(QOL)|Safety of intracranially implanted carmustine after maximal tumor resection	"Shandong Lanjin Pharmaceuticals Co.,Ltd"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 3	236	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LJ-Glioma 3. 3.0 Version	Aug-12	Aug-14	Dec-14	3-Aug-12		3-Aug-12	"Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China"		https://ClinicalTrials.gov/show/NCT01656980
1250	NCT01637753	Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma		Unknown status	No Results Available	Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma	Drug: Carmustine(BCNU)|Procedure: Surgery	Overall Survival|Overall Survival Rate|Progress Free Survival Rate at 6 months|Tumor response rate|KPS Score|QOL Score|Safety of intracranially implanted carmustine after maximal tumor resection	"Shandong Lanjin Pharmaceuticals Co.,Ltd"	All	"18 Years to 70 Years   (Adult, Older Adult)"	Not Applicable	212	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LJ-Glioma 3.1.0 Version	Jun-12	Jun-13	Dec-13	11-Jul-12		11-Jul-12	"Sun Yat-Sen University Cancer Center, Guangzhou, Guangzhou, China"		https://ClinicalTrials.gov/show/NCT01637753
1251	NCT01204684	Dendritic Cell Vaccine for Patients With Brain Tumors		"Active, not recruiting"	No Results Available	Glioma|Anaplastic Astrocytoma|Anaplastic Astro-oligodendroglioma|Glioblastoma	Biological: autologous tumor lysate-pulsed DC vaccination|Biological: Tumor lysate-pulsed DC vaccination+0.2% resiquimod|Biological: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC	Most effective combination of DC vaccine components|Time to tumor progression and overall survival	Jonsson Comprehensive Cancer Center	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	60	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-000202	8-Oct-10	31-Jan-22	31-Jan-23	17-Sep-10		5-Mar-21	"University of Los Angeles, California, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT01204684
1252	NCT02465528	Ceritinib Rare Indications Study in ALK+ Tumors		Terminated	Has Results	Tumors With Aberrations in ALK|Anaplastic Large Cell Lymphoma|Inflammatory Myofibroblastic Tumor|Glioblastoma	Drug: Ceritinib (LDK378)	Disease Control Rate (DCR) Based on Investigator Assessments for Participants With at Least 16 Weeks of Treatment|Overall Response Rate (ORR) Per Investigator Assessment|Duration of Response (DOR) Per Investigator Assessment|Time to Response (TTR) Per Investigator Assessment|Progression Free Survival (PFS) Per Investigator Assessments|Percent of Participant Deaths During Treatment and Follow-up	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	22	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLDK378A2407	6-May-16	20-Aug-18	20-Aug-18	8-Jun-15	21-Oct-19	27-Dec-19	"Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/28/NCT02465528/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02465528/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02465528
1253	NCT00392171	The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)		Completed	Has Results	Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma	Drug: Temozolomide	Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.	Merck Sharp & Dohme Corp.	All	"19 Years to 70 Years   (Adult, Older Adult)"	Phase 2	120	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P04601	9-Jun-06	15-Sep-09	15-Sep-09	25-Oct-06	17-May-10	7-Jun-17			https://ClinicalTrials.gov/show/NCT00392171
1254	NCT00747253	Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors		Completed	No Results Available	"Brain Tumor|Brain Tumor, Recurrent|Brain Neoplasm|Brain Cancer|Glioblastoma Multiforme|Recurrent Glioblastoma Multiforme"	Device: AutoLITT system	"Primary endpoint is safety, as determined by absence of severe clinical toxicity or procedure-related neurological deficits"	Monteris Medical	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AutoLITT™ FIM	Aug-08	Oct-09	Apr-10	5-Sep-08		24-Aug-21	"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00747253
1255	NCT00006358	Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Drug: thalidomide		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	44	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment	NABTC-9904|CDR0000068227	13-Jun-00	23-Jan-03	20-Jul-06	26-May-04		26-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00006358
1256	NCT05039346	Quality of Life and Patient Needs in Advanced High Grade Gliomas		"Active, not recruiting"	No Results Available	Quality of Life|Brain Tumor|Glioblastoma|Glioma|Anaplastic Astrocytoma	Other: Phone interviews	Quality of life and end of life symptoms in brain tumor patients|Examination	Henry Ford Health System	All	"18 Years and older   (Adult, Older Adult)"		75	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	IRB 14537	11-Feb-12	26-Sep-17	31-Dec-21	9-Sep-21		9-Sep-21			https://ClinicalTrials.gov/show/NCT05039346
1257	NCT00031083	Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas		Completed	No Results Available	"Glioblastoma Multiforme|Anaplastic Astrocytoma|Oligoastrocytoma, Mixed|Gliosarcoma"	Genetic: Interferon-beta		Biogen	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C-1502|0101-453	2-Apr-02		10-Oct-03	22-Feb-02		17-Nov-20	"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona at Tucson, Tucson, Arizona, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00031083
1258	NCT03973918	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG	BRAF	Recruiting	No Results Available	High Grade Glioma|BRAF V600E|BRAF V600K|Anaplastic Astrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Gliosarcoma|Glioblastoma	Drug: Encorafenib|Drug: Binimetinib|Biological: Research Bloods|Biological: Tumor Tissue	Tumor radiographic response per RANO for 3 treatment cohorts|Progression free survival for 3 treatment cohorts|Overall Survival|Duration of response|Number of participants with adverse events as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	62	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC 1802|UM1CA137443	29-Jul-19	Jul-25	Jul-27	4-Jun-19		10-Sep-21	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03973918
1259	NCT02722512	Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine		Terminated	No Results Available	"Glioblastoma Multiforme|Astrocytoma, Grade III|Anaplastic Ependymoma|Clear Cell Ependymoma|Ependymoma"	Biological: Heat Shock Protein Peptide Complex-96 (HSPPC-96)|Procedure: Tumor Resection|Radiation: Radiation	The rolling 6 statistical design will be utilized to establish the MTD and RP2D of HSPCC autologous vaccine in children with newly diagnosed high grade glioma (HGG) following focal radiation therapy and in recurrent HGG and ependymoma given alone.|To estimate the progression-free survival distribution in children with recurrent and resectable HGG treated with HSPPC-96 vaccine therapy alone (Arm B).|To estimate the progression-free survival distribution in children with recurrent and resectable ependymoma treated with HSPPC-96 vaccine therapy alone (Arm B).|To evaluate patient immune responses as measured by immune correlates in the above patient groups.	Ann & Robert H Lurie Children's Hospital of Chicago|Northwestern University	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	10	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-362	Jul-16	13-Nov-19	13-Nov-19	30-Mar-16		28-Jul-20	"Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT02722512
1260	NCT00028795	"Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy	Improved outcome|Toxicity as assessed by NCI CTCAE v. 2.0	Children's Oncology Group|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	170	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACNS0126|COG-ACNS0126|CDR0000069135	Dec-02	Sep-07	Mar-12	27-Jan-03		21-Feb-14	"Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States|University of South Alabama Cancer Research Institute, Mobile, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Sutter Cancer Center, Sacramento, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center - Sacramento, Sacramento, California, United States|Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California, United States|Children's Hospital and Health Center - San Diego, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Kaiser Permanente Medical Center - Santa Clara Kiely Campus, Santa Clara, California, United States|General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California, United States|Children's Hospital Cancer Center, Denver, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital at Memorial, Hollywood, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Baptist-South Miami Regional Cancer Program, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Nemours Children's Clinic-Orlando, Orlando, Florida, United States|Sacred Heart Children's Hospital, Pensacola, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|St. Joseph's Children's Hospital of Tampa, Tampa, Florida, United States|Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States|MBCCOP-Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Medical Center, Chicago, Illinois, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Advocate Hope Children's Hospital, Oak Lawn, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States|St. Vincent Hospitals and Health Care Centers, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Wesley Medical Center, Wichita, Kansas, United States|Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Pediatric Specialty Clinic at Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Walter Reed Army Medical Center, Silver Spring, Maryland, United States|Floating Hospital for Children, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Regional Cancer Program at D'Amour Center for Cancer Care, Springfield, Massachusetts, United States|UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|DeVos Children's Hospital, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|St. Mary's - Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Children's Hospitals and Clinics - Minneapolis/St. Paul, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri - Columbia, Columbia, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Valerie Fund Children's Center at Atlantic Health, Summit, New Jersey, United States|University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Children's Hospital at Albany Medical Center, Albany, New York, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Comprehensive Cancer Center at Maimonides Medical Center, Brooklyn, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New York Weill Cornell Cancer Center at Cornell University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Long Island Cancer Center at Stony Brook University Hospital, Stony Brook, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital, Greenville, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Dakota Cancer Institute at Innovis Health - Dakota Clinic, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Columbus Children's Hospital, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Toledo Children's Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Tod Children's Hospital - Forum Health, Youngstown, Ohio, United States|Children's Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, United States|Doernbecher Children's Hospital at Oregon Health & Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, United States|Children's Hospital of Greenville Hospital System, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|East Tennessee State University Cancer Center at Johnson City Medical Center, Johnson City, Tennessee, United States|East Tennessee Children's Hospital, Knoxville, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, United States|Children's Hospital of Austin, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|MBCCOP - South Texas Pediatrics, San Antonio, Texas, United States|Methodist Cancer Center at Methodist Specialty and Transplant Hospital, San Antonio, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Center for Cancer Prevention and Care at Scott and White Clinic, Temple, Texas, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States|Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|INOVA Fairfax Hospital, Falls Church, Virginia, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Medical Center for Children at Roanoke Community Hospital, Roanoke, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center - Tacoma, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division, Charleston, West Virginia, United States|Cabell Huntington Hospital, Huntington, West Virginia, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|Cross Cancer Institute at University of Alberta, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|University Medical Center Groningen, Groningen, Netherlands|Starship Children's Health, Auckland, New Zealand|Puerto Rico Cancer Center at University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico|San Jorge Children's Hospital, Santurce, Puerto Rico|Swiss Pediatric Oncology Group Bern, Bern, Switzerland|Swiss Pediatric Oncology Group Geneva, Geneva, Switzerland|Swiss Pediatric Oncology Group Lausanne, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00028795
1261	NCT02498665	A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies		Completed	No Results Available	Acute Myeloid Leukemia|Myelodysplastic Syndromes|Glioblastoma Multiforme|Melanoma|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Sarcoma|Renal Cell Carcinoma	Drug: DSP-7888 Dosing Emulsion	Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing dose-limiting toxicities (DLTs)|Determination of the safety and tolerability of DSP-7888 Dosing Emulsion by assessing duration of study treatment|Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)|Assessment of the preliminary anti-tumor activity by assessing Progression-Free Survival (solid tumors and acute myeloid leukemia (AML))|Overall Survival|Pharmacodynamic activity of DSP-7888 Dosing Emulsion as assessed by biomarker analysis	"Sumitomo Dainippon Pharma Oncology, Inc"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BBI-DSP7888-101	Nov-15	Aug-18	Sep-18	15-Jul-15		1-Aug-19	"USOR - Rocky Mountain Cancer Center, Denver, Colorado, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Horizon Oncology Research, Lafayette, Indiana, United States|USOR - TX Oncology Austin, Austin, Texas, United States|USOR -TX Oncology Dallas, Dallas, Texas, United States|USOR - TX Oncology Tyler, Tyler, Texas, United States|USOR - VA Cancer Specialists, Fairfax, Virginia, United States|USOR - VA Oncology Associates, Norfolk, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02498665
1262	NCT01478321	Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas		Terminated	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma	Drug: Temozolomide|Radiation: hypofractionated radiation therapy|Biological: bevacizumab|Other: questionnaire administration	"Overall Survival (OS) for Patients With Recurrent High Grade Malignant Gliomas Treated With Concurrent Radiation, Temozolomide, and Bevacizumab Followed by Adjuvant Temozolomide and Bevacizumab.|Patient Reported Quality of Life (QOL)|Safety Profile for Patients With Recurrent High Grade Malignant Gliomas Treated With Concurrent Radiation, Temozolomide, and Bevacizumab Followed by Adjuvant Temozolomide and Bevacizumab|Percentage of Patients With Progression Free Survival (PFS) at 6 Months and 12 Months"	Northwestern University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	54	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 11C02|STU00053636|NCI CTRP#	14-Dec-11	12-Sep-18	12-Sep-18	23-Nov-11	12-Mar-20	12-Mar-20	"Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Central Dupage Hospital, Warrenville, Illinois, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/21/NCT01478321/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01478321
1263	NCT05106296	Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer		Not yet recruiting	No Results Available	Ependymoma|Medulloblastoma|Glioblastoma|Primitive Neuroectodermal Tumor (PNET)	Drug: Ibrutinib|Drug: Indoximod|Drug: Cyclophosphamide|Drug: Etoposide	Incidence of regimen-limiting toxicity (RLT)|Objective Response Rate (ORR)|Adverse events (AEs)|Frequency of cycle delays for toxicity|Frequency of dose-reductions of the chemotherapy regimen|Complete Response Rate (CRR)|Partial Response Rate (PRR)|Modified Objective Response Rate (mORR)|iRANO-PFS|Overall Survival (OS)	Theodore S. Johnson|Augusta University	All	"12 Years to 25 Years   (Child, Adult)"	Phase 1	37	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCC2020	Feb-22	Mar-25	Apr-25	3-Nov-21		3-Nov-21	"Augusta University, Georgia Cancer Center, Augusta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT05106296
1264	NCT00667394	Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors		Completed	Has Results	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Oligoastrocytoma	Biological: Bevacizumab|Drug: MLN-518 (Tandutinib)|Procedure: Quality-of-life assessment	Progression-free Survival at 6 Months|Number of Participants With Adverse Events	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	42	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	080101|08-C-0101	Apr-08	Jul-11	Jul-11	28-Apr-08	31-Aug-12	5-Nov-15	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00667394
1265	NCT01798771	Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery	IMAGER	Unknown status	No Results Available	Primary Malignant Neoplasm of Nervous System|Glioma|Glioblastoma|Metastasis	Procedure: Interventional arm|Procedure: Control arm	Extent of Resection|Volumetric extent of resection|PFS 6|PFS 12|Quality of life	Johann Wolfgang Goethe University Hospital	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	108	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	JohannWGUH_IMAGER|206/12	Mar-13	Feb-15	Feb-16	26-Feb-13		26-Feb-13	"Klinik für Neurochirurgie Johann Wolfgang Goethe University, Frankfurt am Main, Hessen, Germany"		https://ClinicalTrials.gov/show/NCT01798771
1266	NCT00002814	Combination Chemotherapy for Patients With Brain Cancer		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: filgrastim|Drug: paclitaxel|Drug: topotecan hydrochloride		Dartmouth-Hitchcock Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D9607|NCI-V96-0955	Aug-96	Apr-01	Dec-01	6-Apr-04		27-Oct-11	"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States"		https://ClinicalTrials.gov/show/NCT00002814
1267	NCT00024557	Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients		Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Mixed Oligoastrocytoma|Malignant Astrocytoma	Drug: IL13-PE38QQR|Procedure: targeted fusion protein therapy|Procedure: surgery		INSYS Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IL13PEI-002	Jun-01	Jun-06	Jul-07	21-Sep-01		6-Jun-11	"University of California San Francisco, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00024557
1268	NCT01861990	Valproic Acid in Childhood Progressive Brain Tumors		Withdrawn	No Results Available	Pediatric Brain Tumor|Glioma|Anaplastic Astrocytoma|Medulloblastoma|Glioblastoma	Drug: Valproic Acid	Completion of protocol|Time to progression	Medical University of South Carolina	All	"1 Year and older   (Child, Adult, Older Adult)"	Phase 1	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VA2013|IRG-97-219-14	May-13	Dec-13	Dec-13	24-May-13		22-May-15	"Medical University of South Carolina, Charleston, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT01861990
1269	NCT01316809	AZD8055 for Adults With Recurrent Gliomas		Completed	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Malignant Glioma|Brainstem Glioma	Drug: AZD8055	To establish the maximum tolerated dose (MTD) of AZD8055 on a continuous once daily schedule in patients with recurrent gliomas not on enzyme-inducing anti-epileptic drugs (EIAED).|Generate pharmacokinetic data of AZD8055 on a continuous once daily schedule|To obtain exploratory information about the antitumor activity of AZD8055.	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 1	22	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	110122|11-C-0122	4-Mar-11	14-Apr-14	4-Apr-16	16-Mar-11		12-Dec-19	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01316809
1270	NCT03600467	Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma	START	Terminated	No Results Available	Solid Tumor|Androgen Receptor Gene Overexpression	Drug: SEVI-D (Seviteronel in combination with dexamthasone)	Objective tumour response or the ratio of time-to-progression over the preceding period|Overall survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.|Change in quality of life measurements during treatment|Change in pain score measurements during treatment	"St Vincent's Hospital, Sydney"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	4	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	START	13-Aug-18	28-Feb-21	28-Feb-21	26-Jul-18		5-Mar-21	"St Vincent's Hospital, Darlinghurst, New South Wales, Australia"		https://ClinicalTrials.gov/show/NCT03600467
1271	NCT01281982	(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas		Terminated	No Results Available	Low Grade Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Oligoastrocytoma			National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 99 Years   (Adult, Older Adult)"		2	NIH	Observational	Time Perspective: Prospective	110081|11-C-0081	13-Jan-11		24-Sep-12	24-Jan-11		5-Jul-18	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01281982
1272	NCT00720564	"Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: arsenic trioxide|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: intensity-modulated radiation therapy|Radiation: radiation therapy	Maximum tolerated dose of arsenic trioxide|Dose-limiting toxicities as measured by CTCAE version 3.0	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000600335|P30CA033572|CHNMC-07058|CEPHALON-CHNMC-07058	Apr-08	Feb-09	Feb-09	22-Jul-08		11-Aug-10	"City of Hope Comprehensive Cancer Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT00720564
1273	NCT00683761	A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma		Unknown status	No Results Available	Malignant Glioma|Glioblastoma Multiforme|GBM|Astrocytoma|Oligodendroglioma	Drug: 131I-TM601	"The safety and tolerability of multiple doses of intravenously (IV) administered 131I-TM601 in adult patients with progressive and/or recurrent malignant glioma with measurable disease.|The therapeutic efficacy of multiple doses of IV-administered 131I-TM601, as assessed by clinical response, time-to-progression, 6 month progression-free survival and overall survival in adult patients with progressive and/or recurrent malignant glioma.|Radiation absorbed dose to tumor and normal organs from IV administered 131I-TM601 in a subset of study patients."	TransMolecular	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	64	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TM601-008	Aug-08	Feb-10	Apr-10	23-May-08		17-Jul-09	"University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|St. Mary's Health Care, Grand Rapids, Michigan, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00683761
1274	NCT00591058	Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma		Unknown status	No Results Available	Malignant Glioma|Glioblastoma Multiforme|GBM|Astrocytoma|Oligodendroglioma	Drug: TM-601	"To determine the safety profile/tolerability of TM-601 in this patient population, based on adverse event incidence, severity, duration, causality, seriousness and type as well as by physical examination, vital signs and clinical laboratory assessments.|A primary objective of this study is to evaluate the biologically active dose of TM-601 in this population of patients based on changes in perfusion MRI parameters."	TransMolecular	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TM601-007	Feb-08	Feb-10	Feb-10	11-Jan-08		17-Jul-09	"University of Alabama, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|Washington University, St. Louis, Missouri, United States|Columbia University, New York, New York, United States|Wake Forest University, Winston-Salem, North Carolina, United States|University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00591058
1275	NCT00009035	Natural History of Patients With Brain and Spinal Cord Tumors		Completed	No Results Available	Astrocytoma|Oligodendroglioma|Glioblastoma|Glioma|Anaplastic Glioma		To evaluate patients with tumors of the central nervous system (CNS) who are probable future candidates for NCI Phase I and II protocols.	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"1 Year to 100 Years   (Child, Adult, Older Adult)"		3050	NIH	Observational	Observational Model: Case-Only|Time Perspective: Prospective	010070|01-C-0070	22-Jan-01		11-Sep-18	24-Jan-01		12-Dec-19	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00009035
1276	NCT04482933	HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma		Not yet recruiting	No Results Available	Neoplasms|High Grade Glioma|Glioblastoma Multiforme|Malignant Glioma of Brain|Anaplastic Astrocytoma of Brain|High-grade Glioma|Anaplastic Glioma|Giant Cell Glioblastoma	Drug: Biological G207	Efficacy (overall survival)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Virologic Shedding	"University of Alabama at Birmingham|Treovir, LLC"	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XUAB 2045	1-Dec-21	1-Oct-24	1-Oct-25	23-Jul-20		8-Jul-21	"Children's of Alabama, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT04482933
1277	NCT01117155	A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas		Withdrawn	No Results Available	Ependymoma|Brainstem Glioma|Astrocytoma|Glioblastoma Multiforme|PNET			National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	1 Year to 17 Years   (Child)		0	NIH	Observational	Time Perspective: Prospective	100105|10-C-0105	23-Apr-10		22-Oct-12	5-May-10		12-Dec-19			https://ClinicalTrials.gov/show/NCT01117155
1278	NCT04188535	Serial MRI Scans During Radiation Therapy	RELAY	Recruiting	No Results Available	Glioblastoma|Esophageal Cancer|Radiotherapy|Magnetic Resonance Imaging|MRI|Prostate Cancer|Vulvar Cancer|Pediatric Glioblastoma Multiforme	Diagnostic Test: MRI IMAGING	Feasibility of acquiring serial MRI scans on an MRI simulator during treatment with radiation therapy|Ability to measure disease control (for imaging expansion cohort)|Dosimetric Change	Dana-Farber Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	166	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other	19-573	15-Jan-20	31-Jul-25	31-Jul-25	6-Dec-19		10-Aug-21	"Brigham and Women Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT04188535
1279	NCT00959946	Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer		Terminated	Has Results	Advanced Breast Cancer (Parts 1 and 2)|Advanced Pancreatic Cancer (Part 1)|Advanced Colorectal Cancer (Part 1)|Advanced Cholangiocarcinoma (Part 1)|Advanced Glioblastoma Multiforme (Part 1)	Drug: Bosutinib|Drug: Capecitabine	Maximum Tolerated Dose (MTD) - Part 1|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) - Part 1|Percentage of Participants With Objective Response - Part 2|Best Overall Response - Part 1|Progression Free Survival (PFS) - Part 2|Clinical Benefit Rate - Part 2|Duration of Response (DR) - Part 2|Maximum Observed Plasma Concentration (Cmax) - Part 2|Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 2|Apparent Volume of Distribution (Vz/F) - Part 2|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] - Part 2|Apparent Oral Clearance (CL/F) - Part 2|Terminal-Phase Disposition Rate Constant (λz) - Part 2|Plasma Decay Half-Life (t1/2) - Part 2	Pfizer	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	32	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	3160A6-2208|B1871011	Sep-09	Mar-11	Mar-11	17-Aug-09	22-Feb-13	22-Feb-13	"Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Saint Herblain, France|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT00959946
1280	NCT01657734	Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy		Unknown status	No Results Available	Malignant Gliomas	Other: MR imaging		Universitaire Ziekenhuizen Leuven	All	"18 Years and older   (Adult, Older Adult)"		30	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	S53303	Sep-11			6-Aug-12		6-Aug-12	"University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium|University Hospitals of Leuven, Leuven, Vlaams-Brabant, Belgium"		https://ClinicalTrials.gov/show/NCT01657734
1281	NCT02885324	Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children		Recruiting	No Results Available	Glioblastoma Multiforme|Anaplastic Astrocytoma|Malignant Brain Tumor|High Grade Glioma	Drug: Cabozantinib	Disease response	Indiana University	All	"2 Years to 21 Years   (Child, Adult)"	Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IUSCC-0601	18-May-17	Jul-23	Jan-24	31-Aug-16		25-Aug-21	"Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States"		https://ClinicalTrials.gov/show/NCT02885324
1282	NCT03244995	Mind-Body Intervention in Glioma Couples		Completed	No Results Available	Glioblastoma|Low Grade Glioma|Malignant Glioma|Metastatic Malignant Neoplasm in the Brain|Partner|WHO Grade III Glioma	Procedure: Mind-Body Intervention Procedure|Other: Quality-of-Life Assessment|Other: Questionnaire Administration	Feasibility of couple-based mind-body program (CBMB) as determined by overall accrual|Feasibility of CBMB program as determined by attrition|Feasibility of CBMB program as determined by adherence|Feasibility of CBMB program as determined by acceptability|CBMB program efficacy	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	74	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2017-0290|NCI-2018-01099	6-Aug-17	31-Oct-19	31-Oct-19	10-Aug-17		10-Nov-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03244995
1283	NCT03538587	Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers		Recruiting	No Results Available	Glioblastomas|Sarcoma|Astrocytoma|Brain Cancer|Leukemia	Behavioral: Enhanced Mindfulness Intervention|Behavioral: Psychoeducation	Feasibility	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"5 Years and older   (Child, Adult, Older Adult)"	Not Applicable	40	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	180080|18-C-0080	29-Jan-19	1-Sep-22	31-Dec-22	29-May-18		4-Jan-22	"National Institutes of Health Clinical Center, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03538587
1284	NCT00025675	Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: gefitinib	Progression-free survival at 6 months	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	105	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTC-0001 CDR0000068984|U01CA062399|ABTC-0001|NABTC-0001	9-Oct-01	5-Jul-06	2-Jan-10	27-Jan-03		26-Jun-18	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00025675
1285	NCT05099003	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma and H3 K27M-Mutant High-Grade Glioma		Not yet recruiting	No Results Available	"Anaplastic Astrocytoma|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-Mutant|Glioblastoma|Malignant Glioma"	Radiation: Radiation Therapy|Drug: Selinexor	Maximum tolerated dose|Event free survival (EFS)|Overall Survival (OS)|Overall response rate (ORR)	National Cancer Institute (NCI)	All	"12 Months to 21 Years   (Child, Adult)"	Phase 1|Phase 2	36	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2021-11337|ACNS1821|U10CA180886	4-Feb-22	30-Jun-24	30-Jun-24	29-Oct-21		17-Dec-21			https://ClinicalTrials.gov/show/NCT05099003
1286	NCT01849952	Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas		Recruiting	No Results Available	Astrocytoma|Oligodendroglioma|Oligoastrocytoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma|Brain Tumors|Brain Cancer		Overall Survival|Progression-Free Survival	Dartmouth-Hitchcock Medical Center	All	"18 Years and older   (Adult, Older Adult)"		200	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	D12160	May-13	May-22	May-22	9-May-13		2-Jun-21	"Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of Vermont, Burlington, Vermont, United States"		https://ClinicalTrials.gov/show/NCT01849952
1287	NCT01380782	BIBF 1120 for Recurrent High-Grade Gliomas		Completed	Has Results	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma	Drug: BIBF 1120	6-Month Progression Free Survival|3-Month Progression Free Survival|Proportion of Participants Experiencing Stable Disease (SD) as Their Best Radiographic Response|Overall Survival|Time-to-tumor Progression|Safety Profile as Summarized With Descriptive Statistics (Using Toxicity Data Gathered on Trial)	"Patrick Y. Wen, MD|Boehringer Ingelheim|Wake Forest University Health Sciences|University of Virginia|Massachusetts General Hospital|The Cleveland Clinic|Dana-Farber Cancer Institute"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	37	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-055|BIBF 1199.94	May-12	Jul-13	Jul-14	27-Jun-11	18-Aug-14	18-Aug-14	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT01380782
1288	NCT00458731	"Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma"		Completed	No Results Available	"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia"	Biological: bevacizumab|Drug: cediranib maleate	Safety and toxicity profile of combination bevacizumab and cediranib maleate|Pharmacokinetic profile of oral cediranib maleate in combination with bevacizumab	National Cancer Institute (NCI)	All	"15 Years and older   (Child, Adult, Older Adult)"	Phase 1	57	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00184|MDACC 2005-0910|CDR0000538277|7534|P30CA016672|U01CA062461	May-07	Dec-13		11-Apr-07		19-Feb-14	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00458731
1289	NCT02238496	Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas		"Active, not recruiting"	No Results Available	"Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma"	Procedure: Cytoreductive surgery|Drug: Perifosine|Drug: Temsirolimus	Clinical Benefit Rate|Median Overall Survival Rate	"Andrew B Lassman, MD|Pfizer|AEterna Zentaris|Columbia University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAM3801	8-Dec-14	27-Oct-17	Aug-22	12-Sep-14		7-Jan-21	"Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02238496
1290	NCT03152318	A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2	rQNestin	Recruiting	No Results Available	Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic/Pylomyxoid Astrocytoma|Brain Tumor|Glioma|Brain Cancer|Glioblastoma|Glioblastoma Multiforme	Drug: rQNestin|Drug: Cyclophosphamide|Procedure: Stereotactic biopsy	Maximum Tolerated Dose|MRI Changes in Permeability|MRI Changes in Volume|MRI Changes in Flow|Viral Shedding in Saliva|HSV1 Viremia|HSV1 Antibody Response	"Dana-Farber Cancer Institute|National Institutes of Health (NIH)|Candel Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	56	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-557	18-Jul-17	Dec-22	Dec-23	15-May-17		11-Aug-21	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT03152318
1291	NCT00008008	Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation	Response rate|Disease-free interval|Overall survival|Toxicity|Pharmacokinetics|Presence of high-dose thiotepa in the cerebrospinal fluid	Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"Child, Adult, Older Adult"	Phase 2	40	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000068362|CPMC-IRB-8017|CPMC-CAMP-013|NCI-G00-1883	Sep-97	Jun-05	May-08	27-Jan-03		4-Feb-13	"St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00008008
1292	NCT02168270	Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma		Terminated	Has Results	Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma|Gliosarcoma	Dietary Supplement: ascorbic acid|Drug: temozolomide|Other: quality-of-life assessment|Other: laboratory biomarker analysis	"Maximum Tolerated Dose of Ascorbic Acid in Combination With Temozolomide, Defined as the Highest Dose Tested Which Results in Dose Limiting Toxicity (DLT) in no More Than One of Six Evaluable Patients|Incidence Rates of Adverse Events, Graded According to the NCI Common Toxicity Criteria for Adverse Events Version 4.0|Changes in Serum Levels of Ascorbic Acid (Using HPLC With Coulometric Electrochemical Detection)|Using Radiologic Measurements for Tumor Response"	University of Nebraska|National Cancer Institute (NCI)	All	"19 Years and older   (Adult, Older Adult)"	Phase 1	4	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	735-13|NCI-2014-01061|P30CA036727	Jun-14	Aug-15	Aug-15	20-Jun-14	23-Feb-18	23-Feb-18	"University of Nebraska Medical Center, Omaha, Nebraska, United States"		https://ClinicalTrials.gov/show/NCT02168270
1293	NCT00884416	Sorafenib in Newly Diagnosed High Grade Glioma		Completed	No Results Available	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma	Drug: Sorafenib dose escalation	Safety and tolerability of sorafenib in combination with radiation and temozolomide chemotherapy|Maximum Observed Plasma Concentration (Cmax) and Area under the curve (AUC) of sorafenib and temozolomide|Response rate|Time to treatment failure|6 month progression-free survival|Event free survival|Overall survival	"University Hospital, Geneva|Bayer"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	17	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-122|2009DR1029|13031	Mar-09	Dec-11	Mar-12	20-Apr-09		4-Nov-14	"Geneva University Hospital (Hopitaux Universitaires de Geneve), Department of Oncology, Geneva, GE, Switzerland"		https://ClinicalTrials.gov/show/NCT00884416
1294	NCT03896568	Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma		Recruiting	No Results Available	IDH1 wt Allele|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma	Biological: Oncolytic Adenovirus Ad5-DNX-2401|Procedure: Therapeutic Conventional Surgery	Maximum-tolerated dose (MTD)|Incidence of adverse events (AEs)|Tumor response|Time to progression|Virus replication in tumor|Virus shedding|Immunogenicity based on adenoviral (AdV) antibodies	"M.D. Anderson Cancer Center|DNAtrix, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015-0953|NCI-2019-01195	12-Feb-19	31-May-22	31-May-22	1-Apr-19		28-Apr-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03896568
1295	NCT04044937	Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors		Recruiting	No Results Available	Intracranial Neoplasm|Low Grade Glioma|Recurrent Glioblastoma|Recurrent World Health Organization (WHO) Grade II Glioma|Recurrent WHO Grade III Glioma	Drug: F-18 Fluoroethyltyrosine (FET)|Procedure: Positron Emission Tomography (PET)	Misclassification rate for either having recurrent disease or not having recurrent disease for patients previously treated for glial and metastatic disease (Population 1)|Misclassification rate for either high grade or low grade in patients with suspected neoplasms (Population 2)|Binary characterization of follow-up imaging as positive/negative for tumor recurrence|Misclassification rate for FET PET in the evaluation of recurrent low-grade gliomas (Population 1)	"Thomas Hope|University of California, San Francisco"	All	"3 Years and older   (Child, Adult, Older Adult)"	Phase 2	199	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	171022|NCI-2018-01875	29-Oct-18	1-Aug-22	1-Aug-22	5-Aug-19		30-Aug-21	"University of California, San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT04044937
1296	NCT00179803	Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors		Completed	No Results Available	Glioblastoma|Astrocytoma|Pineoblastoma|Rhabdoid Tumor|Supratentorial Neoplasms	Procedure: Stem Cell Transplant	"To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors|The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation.|To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy.|Determine the long term neurocognitive, endocrinologic, cardiopulmonary, and hematologic sequelae of sequential myeloablative chemotherapy and stem cell rescues in patients treated for high risk CNS and recurrent CNS tumors.|Determine the feasibility and utility of the myeloablative preparatory regimen of Carboplatinum, VP-16 and Thiotepa administered in an outpatient setting, and to determine the cost savings obtained via this strategy."	Ann & Robert H Lurie Children's Hospital of Chicago	All	"18 Months to 25 Years   (Child, Adult)"	Phase 2	24	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BMT 0398	Mar-98	Jan-08	Sep-09	16-Sep-05		5-Aug-20	"Children's Memorial Hospital, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00179803
1297	NCT03243461	International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)	HIT-HGG-2013	Recruiting	No Results Available	Glioblastoma WHO Grade IV|Diffuse Midline Glioma Histone 3 K27M WHO Grade IV|Anaplastic Astrocytoma WHO Grade III|Diffuse Intrinsic Pontine Glioma|Gliomatosis Cerebri	Drug: Temozolomide + Valproic Acid	Comparison of effects of valproine acid with respect to historical control group.	University of Göttingen|Deutsche Kinderkrebsstiftung|Hannover Medical School	All	3 Years to 17 Years   (Child)	Phase 3	167	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	01153|2013-004187-56	17-Jul-18	31-Dec-23	31-Dec-23	9-Aug-17		15-Jan-21	"Universitätsklinik RWTH Aachen, Aachen, Germany|Klinikum Augsburg, Augsburg, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|HELIOS Klinikum Berlin Buch, Berlin, Germany|Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany|Universitätsklinikum Bonn, Bonn, Germany|Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Klinikum Bremen-Mitte gGmbH, Bremen, Germany|Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Sana Kliniken Duisburg GmbH - Wedau Kliniken, Duisburg, Germany|HELIOS Klinikum Erfurt GmbH, Erfurt, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Universitätsklinikum Halle, Halle, Germany|Universitätsklinikum Hamburg, Hamburg, Germany|Angelika-Lautenschläger-Klinik, Heidelberg, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Gemeinschaftskrankenhaus Herdecke, Herdecke, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Universitätsklinikum Jena, Jena, Germany|Städtisches Klinikum Karlsruhe, Karlsruhe, Germany|Gesundheit Nordhessen - Klinikum Kassel, Kassel, Germany|UKSH Kiel, Kiel, Germany|Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz, Germany|HELIOS Klinikum Krefeld, Krefeld, Germany|Kliniken der Stadt KölngGmbH, Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|UKSH Campus Lübeck, Lübeck, Germany|Universitätsklinikum Magdeburg A. ö. R., Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|UMM Universitätsmedizin Mannheim, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Technische Universität München / Klinikum Schwabing, München, Germany|Universitätsklinikum Münster, Münster, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Universitäts-Kinder- und Jugendklinik Rostock, Rostock, Germany|ASKLEPIOS Klinik St. Augustin, Sankt Augustin, Germany|Klinikum Stuttgart - Olgahospital, Stuttgart, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Universitätsklinikum Ulm, Ulm, Germany|Universitätsklinik Würzburg, Würzburg, Germany"		https://ClinicalTrials.gov/show/NCT03243461
1298	NCT02055196	Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas		Withdrawn	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Biological: carboxylesterase-expressing allogeneic neural stem cells|Drug: irinotecan hydrochloride|Other: laboratory biomarker analysis	"Incidence of dose-limiting toxicity (DLT), graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of all attributable toxicities, graded according to NCI CTCAE version 4.0|Biologic activity of the hCE1m6-NSCs through Cmax and AUC of irinotecan and SN-38 in dialysate and plasma|Incidence of immunogenicity measured by the development of T cell responses and antibodies against the NSCs using TcR Vβ spectratyping, CD 107 degranulation assays, and flow cytometry|NSC biodistribution in the brain via Feraheme-labeling of NSCs and MR imaging|Clinical benefit measured by tumor response|NSC persistence at autopsy"	City of Hope Medical Center|National Cancer Institute (NCI)	All	18 Years to 64 Years   (Adult)	Phase 1	0	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13455|NCI-2014-00117|P30CA033572		May-14		5-Feb-14		2-Jun-14	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT02055196
1299	NCT00080054	A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas		Completed	No Results Available	Glioma|Glioblastoma|Astrocytoma|Oligodendroglioma|Brain Neoplasm	Drug: Motexafin Gadolinium Injection		Pharmacyclics LLC.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCYC-0218				23-Mar-04		3-Apr-09	"Barrow Neurological Institute, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT00080054
1300	NCT00995007	A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas		Completed	Has Results	Glioblastoma Multiforme|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Oligoastrocytoma	Drug: ZD6474 (Vandetanib)|Drug: Carboplatin	Progression Free Survival at 6 Months|Overall Survival|Number of Participants With Adverse Events	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 100 Years   (Adult, Older Adult)"	Phase 2	112	NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	090222|09-C-0222	Sep-09	Jun-15	Dec-15	14-Oct-09	29-Mar-16	29-Mar-16	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00995007
1301	NCT00734864	Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma		Withdrawn	No Results Available	Glioblastoma Multiforme|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Glioma	Drug: enzyme-inducing anti-epileptic drugs	Toxicity assessed using CTCAE v.3.0|Progression free and overall survival|Radiographic response (modified MacDonald Criteria)	Annick Desjardins|Bristol-Myers Squibb|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	0	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00007909|BMS Protocol #CA180-108	Jun-09	Jun-10	Jun-12	14-Aug-08		21-Nov-12	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00734864
1302	NCT03660761	Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors		Completed	No Results Available	Efficacy and Safety	Drug: apatinib|Drug: temodar	Response to treatment|Median non-progress survival (PFS)	Rongjie Tao|Shandong Cancer Hospital and Institute	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ShandongCHI005	3-Mar-16	3-Jan-17	6-Jan-18	7-Sep-18		16-Apr-19	"Neurosurgery, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"		https://ClinicalTrials.gov/show/NCT03660761
1303	NCT00064779	Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma		Completed	No Results Available	Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Oligoastrocytoma	Drug: IL13-PE38QQR|Procedure: targeted fusion protein therapy|Procedure: surgery		INSYS Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IL13PEI-105	Jul-03	Jun-06	Jul-07	15-Jul-03		6-Jun-11	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00064779
1304	NCT03160599	Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors		Unknown status	No Results Available	Malignant Tumors	Other: ketogenic diet	Adverse events of patients on high-fat diet	Second Affiliated Hospital of Guangzhou Medical University	All	18 Years to 60 Years   (Adult)	Not Applicable	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCYY	1-Mar-18	1-Dec-19	1-Dec-20	19-May-17		5-Sep-18	"the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China"		https://ClinicalTrials.gov/show/NCT03160599
1305	NCT00031538	Genetic Analysis of Brain Tumors		Terminated	No Results Available	Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Oligodendroglioma|Astrocytoma		To generate a large publicly accessible molecular and genetic data base with prospective corollary clinical data for 1000 gliomas	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"1 Year to 99 Years   (Child, Adult, Older Adult)"		674	NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	020140|02-C-0140	1-Mar-02		29-Apr-15	7-Mar-02		9-Dec-19	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Columbia University, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00031538
1306	NCT01514201	"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas"		Completed	Has Results	Anaplastic Astrocytoma|Brain Stem Glioma|Childhood Mixed Glioma|Fibrillary Astrocytoma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliosarcoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Veliparib	Maximum-tolerated Dose of Veliparib Defined as Highest Dose Level With Fewer Than 2 Dose Limiting Toxicities in 6 Patients as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Phase I)|Percentage of Participants Observed to Have Unacceptable Toxicity During the Intra-patient Dose Escalation of Temozolomide During Maintenance Therapy (Feasibility Analysis Population)|Overall Survival|Number of Phase I Patients Who Experienced Dose Limiting Toxicities (DLTs)|Progression-free Survival (PFS)|Percentage of Patients With Pseudo Progression|Maximum Concentration of Veliparib (Cmax) on Days 1 and 4 (Measured in ng/mL) [Pharmacokinetic Parameter]|Mean Apparent Clearance (CL/F) for Veliparib [Pharmacokinetic Parameter]|Maximum Concentration of Veliparib (Cmax) on Day 1 (Measured in μM) [Pharmacokinetic Parameter]|Apparent Volume of Distribution (Vd/F) for Veliparib [Pharmacokinetic Parameter]|Terminal Half-life (t1/2) for Veliparib [Pharmacokinetic Parameter]|Trough for Veliparib [Pharmacokinetic Parameter]	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1|Phase 2	66	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-00082|PBTC-033|12-C-0213|CDR0000717423|P12978|U01CA081457|UM1CA081457	1-Feb-12	28-Mar-18	28-Mar-18	23-Jan-12	13-Aug-19	13-Aug-19	"Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/01/NCT01514201/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01514201
1307	NCT03797326	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)		"Active, not recruiting"	No Results Available	Advanced Solid Tumors|Triple Negative Breast Cancer|Ovarian Cancer|Gastric Cancer|Colorectal Cancer|Glioblastoma|Biliary Tract Cancers|Pancreatic Cancer	Biological: Pembrolizumab|Drug: Lenvatinib	Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria for Glioblastoma (GBM) by Investigator Assessment in Initial Cohorts|ORR per RECIST 1.1 or RANO (GBM) by Blinded Independent Central Review (BICR) in Expanded Cohorts (Combined with Initial Cohorts)|Percentage of Participants Receiving Pembrolizumab Plus Lenvatinib who Experience an Adverse Event (AE)|Percentage of Participants Receiving Pembrolizumab Plus Lenvatinib who Discontinue Study Treatment Due to an AE|Percentage of Participants Receiving Lenvatinib Monotherapy who Experience an AE|Percentage of Participants Receiving Lenvatinib Monotherapy who Discontinue Study Treatment Due to an Adverse Event (AE)|Disease Control Rate (DCR) per RECIST 1.1 by Investigator Assessment in Initial Cohorts|Duration of Response (DOR) per RECIST 1.1 or RANO (GBM) by Investigator Assessment in Initial Cohorts|Progression Free Survival (PFS) per RECIST 1.1 or RANO (GBM) by Investigator Assessment in Initial Cohorts|Overall Survival (OS) in Initial Cohorts|DCR per RECIST 1.1 by BICR in Expanded Cohorts (Combined with Initial Cohorts)|DOR per RECIST 1.1 or RANO (GBM) by BICR in Expanded Cohorts (Combined with Initial Cohorts)|PFS per RECIST 1.1 or RANO (GBM) by BICR in Expanded Cohorts (Combined with Initial Cohorts)|OS in Expanded Cohorts (Combined with Initial Cohorts)|ORR per RECIST 1.1 by BICR in Lenvatinib Monotherapy Arm|DCR per RECIST 1.1 by BICR in Lenvatinib Monotherapy Arm|DOR per RECIST 1.1 by BICR in Lenvatinib Monotherapy Arm|PFS per RECIST 1.1 by BICR in Lenvatinib Monotherapy Arm|OS in Lenvatinib Monotherapy Arm|Plasma Concentration of Lenvatinib	Merck Sharp & Dohme Corp.|Eisai Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	590	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7902-005|2018-003747-37|MK-7902-005|E7080-G000-224|LEAP-005	12-Feb-19	22-Dec-23	22-Dec-23	9-Jan-19		12-Nov-21	"City of Hope ( Site 0002), Duarte, California, United States|Cedars Sinai Medical Center ( Site 0003), Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center ( Site 0005), Sacramento, California, United States|University of Colorado, Anschutz Cancer Pavilion ( Site 0007), Aurora, Colorado, United States|University of Florida-Health Cancer Center-Orlando ( Site 0015), Orlando, Florida, United States|Rutgers Cancer Institute of New Jersey ( Site 0009), New Brunswick, New Jersey, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0023), New York, New York, United States|Sanford Fargo Medical Center ( Site 0059), Fargo, North Dakota, United States|Lehigh Valley Hospital- Cedar Crest ( Site 0047), Allentown, Pennsylvania, United States|Sanford Cancer Center ( Site 0058), Sioux Falls, South Dakota, United States|West Cancer Center - East Campus ( Site 0018), Germantown, Tennessee, United States|Mary Crowley Cancer Research Centers - Medical City Hospital ( Site 0049), Dallas, Texas, United States|Swedish Medical Center ( Site 0021), Seattle, Washington, United States|University of Wisconsin Carbone Cancer Center ( Site 0017), Madison, Wisconsin, United States|Fundacion Favaloro para la Docencia e Investigacion Medica ( Site 2106), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Aleman ( Site 2100), Buenos Aires, Caba, Argentina|Hospital Britanico de Buenos Aires ( Site 2109), Ciudad de Buenos Aires, Caba, Argentina|Instituto de Oncologia de Rosario ( Site 2105), Rosario, Santa Fe, Argentina|CEMIC ( Site 2104), Buenos Aires, Argentina|IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2101), Caba, Argentina|Royal Brisbane and Women s Hospital ( Site 0901), Herston, Queensland, Australia|Alfred Health ( Site 0902), Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital ( Site 0903), Nedlands, Western Australia, Australia|BC Cancer - Abbotsford ( Site 0200), Abbotsford, British Columbia, Canada|CancerCare Manitoba ( Site 0201), Winnipeg, Manitoba, Canada|Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0208), Hamilton, Ontario, Canada|Sunnybrook Research Institute ( Site 0207), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, Canada|Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0210), Montreal, Quebec, Canada|CHU de Quebec Universite de Laval ( Site 0206), Quebec, Canada|Centro Investigación del Cáncer James Lind ( Site 1203), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez ( Site 1201), Santiago, Region M. De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 1202), Santiago, Region M. De Santiago, Chile|Hospital Clinico Universidad de Chile ( Site 1200), Santiago, Region M. De Santiago, Chile|Fundacion Colombiana de Cancerologia Clinica Vida ( Site 1105), Medellin, Antioquia, Colombia|Instituto Nacional de Cancerologia E.S.E ( Site 1102), Bogota, Distrito Capital De Bogota, Colombia|Oncologos del Occidente S.A. ( Site 1106), Pereira, Risaralda, Colombia|Fundacion Valle del Lili ( Site 1101), Cali, Valle Del Cauca, Colombia|Centre Antoine Lacassagne ( Site 0404), Nice, Alpes-Maritimes, France|Centre Leon Berard ( Site 0405), Lyon, Auvergne, France|Institut Claudius Regaud IUCT Oncopole ( Site 0403), Toulouse, Haute-Garonne, France|Centre Oscar Lambret ( Site 0401), Lille, Nord, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0402), Saint-Herblain, Val-de-Marne, France|Institut Gustave Roussy ( Site 0400), Villejuif, Val-de-Marne, France|Robert Bosch GmbH ( Site 0307), Stuttgart, Baden-Wurttemberg, Germany|Universitaetsklinikum Regensburg ( Site 0304), Regensburg, Bayern, Germany|Universitaetsklinikum Frankfurt ( Site 0306), Frankfurt am Main, Hessen, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0301), Wiesbaden, Hessen, Germany|SRH Wald-Klinikum Gera GmbH ( Site 0309), Gera, Thuringen, Germany|Universitaetsklinikum Jena ( Site 0302), Jena, Thuringen, Germany|Soroka Medical Center ( Site 0601), Beer Sheva, Israel|Rambam Medical Center ( Site 0602), Haifa, Israel|Hadassah Ein Kerem Medical Center ( Site 0604), Jerusalem, Israel|Chaim Sheba Medical Center ( Site 0600), Ramat Gan, Israel|Sourasky Medical Center ( Site 0603), Tel Aviv, Israel|Istituto Clinico Humanitas Research Hospital ( Site 1402), Rozzano, Milano, Italy|Policlinico Le Scotte - A.O. Senese ( Site 1401), Siena, Toscana, Italy|Istituto Nazionale Tumori Fondazione Pascale ( Site 1400), Napoli, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 1403), Roma, Italy|Asan Medical Center ( Site 1002), Songpagu, Seoul, Korea, Republic of|Seoul National University Hospital ( Site 1000), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 1001), Seoul, Korea, Republic of|Arkhangelsk Clinical Oncological Dispensary ( Site 1600), Arkhangelsk, Arkhangel Skaya Oblast, Russian Federation|Russian Oncological Research Center n.a. N.N. Blokhin ( Site 1604), Moscow, Moskva, Russian Federation|Leningrad Regional Oncology Center ( Site 1609), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1610), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City Clinical Oncology Center ( Site 1608), Saint-Petersburg, Sankt-Peterburg, Russian Federation|Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1603), Kazan, Tatarstan, Respublika, Russian Federation|Hospital Clinic i Provincial ( Site 0703), Barcelona, Spain|Hospital Universitario Gregorio Maranon ( Site 0701), Madrid, Spain|Clinica Universitaria de Navarra ( Site 0704), Madrid, Spain|Hospital Ramon y Cajal ( Site 0702), Madrid, Spain|Inselspital Universitaetsspital Bern ( Site 1705), Bern, Berne, Switzerland|Kantonsspital Graubuenden ( Site 1704), Chur, Grisons, Switzerland|Kantonsspital St. Gallen ( Site 1702), St. Gallen, Sankt Gallen, Switzerland|Ospedale Regionale di Bellinzona e Valli ( Site 1703), Bellinzona, Ticino, Switzerland|Hopitaux Universitaires de Geneve HUG ( Site 1701), Geneve, Switzerland|Universitaetsspital Zurich ( Site 1700), Zurich, Switzerland|National Cheng Kung University Hospital ( Site 3003), Tainan, Taiwan|National Taiwan University Hospital ( Site 3000), Taipei, Taiwan|Chulalongkorn University ( Site 5001), Bangkok, Krung Thep Maha Nakhon, Thailand|Ramathibodi Hospital. ( Site 5002), Bangkok, Krung Thep Maha Nakhon, Thailand|Siriraj Hospital ( Site 5003), Bangkok, Krung Thep Maha Nakhon, Thailand|Cambridge University Hospitals NHS Trust ( Site 0803), Cambridge, Cambridgeshire, United Kingdom|Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 0804), Leicester, Leicestershire, United Kingdom|Guy's Hospital ( Site 0806), London, London, City Of, United Kingdom|Royal Marsden Hospital (Sutton) ( Site 0800), London, Surrey, United Kingdom|Christie NHS Foundation Trust ( Site 0805), Manchester, United Kingdom"		https://ClinicalTrials.gov/show/NCT03797326
1308	NCT03739372	Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma	PNOC008	Recruiting	No Results Available	Glioma|Glioma of Brain|Cancer|Pediatric Cancer|Pediatric Brain Tumor|Astrocytoma|Glioblastoma|Hemispheric	Other: Specialized tumor board recommendation	12 month Progression Free Survival (PFS) for Stratum A|12 month Overall Survival (OS) for Stratum B|Frequency of Adverse Events|Frequency of Serious Adverse Events	"University of California, San Francisco|Pacific Pediatric Neuro-Oncology Consortium|The V Foundation for Cancer Research"	All	"up to 21 Years   (Child, Adult)"	Not Applicable	44	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	170827|PNOC008	28-Nov-18	1-Jan-25	1-Jan-27	13-Nov-18		20-Dec-21	"University of California, San Diego Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Children's Hospitals and Clinics of Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT03739372
1309	NCT00006773	Bortezomib in Treating Patients With Recurrent Glioma		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: bortezomib	"Maximum tolerated dose of bortezomib defined as the dose level below that at which > 1 of 3-6 patients experience DLT|Biological effectiveness estimated using 20S proteosome activity|Frequency of toxicity, graded using the CTC version 2.0"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	42	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02367|NABTT-9910|U01CA062475|CDR0000068326	May-01	Jun-07		27-Jan-03		24-Jan-13	"New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00006773
1310	NCT02374255	Improving Goals of Care Discussion in Advanced Cancer Patients		Completed	Has Results	Primary Stage IV Hepatobiliary|Esophageal|Colorectal Cancer|Glioblastoma|Cancer of Stomach|Cancer of Pancreas|Melanoma|Head or Neck Cancer|Stage III|Stage IV|Lung Cancers|Pancreatic Cancers	Behavioral: GoC intervention	Number of Participants Who Perceived Increased Goals of Care Discussions|Number of Patients Perception of Improved Goals of Care Discussions|Communication Skills Training	Icahn School of Medicine at Mount Sinai|Patient-Centered Outcomes Research Institute	All	"21 Years and older   (Adult, Older Adult)"	Not Applicable	265	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	GCO 14-0082	15-Mar-16	16-May-18	16-May-18	27-Feb-15	1-Oct-19	1-Oct-19	"Smilow Cancer Hospital, Yale Cancer Center, Yale University, New Haven, Connecticut, United States|Mount Sinai Beth Israel, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Kings County Hospital Center, New York, New York, United States"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/55/NCT02374255/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02374255/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT02374255
1311	NCT03011671	Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma		Recruiting	No Results Available	Malignant Glioma of Brain	Drug: Acetazolamide|Drug: Temozolomide	Number of participants with adverse events|Measure objective response rate (ORR); change in tumor size|Time until progression free survival (PFS)|Time until overall survival (OS)|Analysis of formalin fixed paraffin embedded surgical specimens.|To determine feasibility of cooperative interaction between multiple sites	University of Chicago	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	60	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB16-0767	3-Oct-18	Feb-22	Mar-22	5-Jan-17		15-Jun-21	"University of Chicago Medical Center, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT03011671
1312	NCT00727506	BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma		Completed	Has Results	Glioma	Drug: BIBW 2992|Drug: TMZ|Drug: BIBW 2992 plus TMZ	"Number of Participants With DLT- Phase I|Progression-free Survival (PFS-6) at Six Months - Phase II|Objective Tumor Response in Phase I|Objective Tumor Response in Phase II|Progression-free Survival (PFS)- Phase II Part|AUCτ,ss for Afatinib|Cmax,ss for Afatinib|Tmax,ss for Afatinib|AUC (0-8) for Temozolomide|Cmax for Temozolomide|Tmax for Temozolomide|t1/2 for Temozolomide|Phase II - Trough Plasma Concentration of Afatinib|Number of Participants With EGFRvIII Assessed by IHC Test.|Number of Participants With MGMT Marker Assessed by IHC Test.|Number of Participants With EGFR Marker Assessed by IHC Test.|Number of Participants With PTEN Marker Assessed by IHC Test.|Number of Participants With PAKT Marker Assessed by IHC Test.|Number of Participants With EGFR Assessed by FISH|Number of Participants With PTEN Assessed by FISH|Number of Participants With Chromosomes (CEP7) Assessed by FISH|Number of Participants With Chromosomes (CEP10) Assessed by FISH|Number of Participants With Investigator Defined Drug-Related AEs, AEs Leading to Discontinuation of Trial Drug, All Serious Adverse Events (AE) and Other Significant AEs - Phase I|Number of Participants With Adverse Events (AEs) Based on Intensity and Incidence of AE's - Phase I|Number of Participants With Adverse Events, Graded According CTCAE - Phase I|Causes of Death - Phase I|Number of Participants With Investigator Defined Drug-Related AEs, AE Leading to Dose Reduction, AEs Leading to Discontinuation of Trial Drug and All SAE- Phase II|Number of Participants With Adverse Events (AEs) Based on Intensity and Incidence of AE's - Phase II|Number of Participants With Adverse Events, Graded According CTCAE - Phase II|Causes of Death - Phase II|Number of Participants With Clinically Relevant Abnormalities for Decreased Cardiac Left Ventricular Function - Phase II"	Boehringer Ingelheim	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	151	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1200.36	14-Jul-08	12-May-11	25-May-16	4-Aug-08	24-Jan-14	15-Aug-17	"1200.36.0016 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States|1200.36.0012 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States|1200.36.0005 Boehringer Ingelheim Investigational Site, Duarte, California, United States|1200.36.0014 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1200.36.0019 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States|1200.36.0023 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States|1200.36.0008 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States|1200.36.0002 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.36.0003 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|1200.36.0009 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.36.0001 Boehringer Ingelheim Investigational Site, Durham, North Carolina, United States|1200.36.0007 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States|1200.36.0020 Boehringer Ingelheim Investigational Site, Memphis, Tennessee, United States|1200.36.0017 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1200.36.0010 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1200.36.0011 Boehringer Ingelheim Investigational Site, Charlottesville, Virginia, United States|1200.36.0022 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|1200.36.1005 Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada|1200.36.1010 Boehringer Ingelheim Investigational Site, Winnipeg, Manitoba, Canada|1200.36.1009 Boehringer Ingelheim Investigational Site, Moncton, New Brunswick, Canada|1200.36.1011 Boehringer Ingelheim Investigational Site, Halifax, Nova Scotia, Canada|1200.36.1008 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1200.36.1001 Boehringer Ingelheim Investigational Site, Kingston, Ontario, Canada|1200.36.1003 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1200.36.1004 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1200.36.1007 Boehringer Ingelheim Investigational Site, Fleurimont, Quebec, Canada|1200.36.1002 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.36.1006 Boehringer Ingelheim Investigational Site, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00727506
1313	NCT04547621	HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM	HSCK-010	"Active, not recruiting"	No Results Available	"Glioma, Malignant"	Device: Radiation|Drug: Temozolomide	Overall survival (OS)|Progression-free survival (PFS)|Objective response rate (ORR)|Quality of Life score (QoL)|Cognitive function|Toxicity rate	Huashan Hospital	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1|Phase 2	50	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KY2020-791	1-Sep-20	1-Jan-23	1-Jan-24	14-Sep-20		14-Sep-20	"CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai, Shanghai, China"		https://ClinicalTrials.gov/show/NCT04547621
1314	NCT00004688	"Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms"		Completed	No Results Available	Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Gliomas|Glioblastoma Multiforme|Recurrent Brain Tumor	Drug: carmustine|Drug: mercaptopurine|Drug: streptozocin		Emory University|FDA Office of Orphan Products Development	All	"Child, Adult, Older Adult"	Phase 2	35	Other	Interventional	Primary Purpose: Treatment	199/13310|EUSM-FDR001274	Aug-96		Jul-98	25-Feb-00		25-Mar-15			https://ClinicalTrials.gov/show/NCT00004688
1315	NCT02335918	A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors		Completed	No Results Available	Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Ovarian Carcinoma-Enrollment Completed|Colorectal Cancer (CRC)-Enrollment Completed|Renal Cell Carcinoma (RCC) (Phase ll Only)|Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed	Drug: Combination of varlilumab and nivolumab	"Phase I: Number of participants with treatment-related adverse events as determined by CTCAE v4.0, dose-limiting toxicities, and laboratory abnormalities.|Phase II: Preliminary antitumor activity of the combination of varlilumab and nivolumab as measured by objective response rate (ORR) in patients with CRC, ovarian cancer, RCC and SCCHN and Overall Survival-12 months in GBM."	Celldex Therapeutics|Bristol-Myers Squibb	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	175	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDX1127-02	Jan-15	12-Dec-18	12-Dec-18	12-Jan-15		9-Dec-19	"University of Arizona Cancer Center, Tucson, Arizona, United States|The Stanford Center for Clinical and Translational Education and Research, Palo Alto, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Medical Center, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Northwest Georgia Oncology Centers PC, Marietta, Georgia, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Laura and Isaac Perlmutter Cancer Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Health & Services, Portland, Oregon, United States|Inova Schar Cancer Institute Research, Fairfax, Virginia, United States"		https://ClinicalTrials.gov/show/NCT02335918
1316	NCT00085540	FR901228 in Treating Patients With Recurrent High-Grade Gliomas		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: depsipeptide	Number of Participants With Dose-limiting Toxicities Due to Romidepsin Graded According to the NCI Common Toxicity Criteria (CTCAE Version 3.0) (Phase I)|6 Months Progression-free Survival (Phase II)|Response Rate Associated With Depsipeptide Therapy (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	50	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02596|NABTC-0303|U01CA062399|CDR0000370817	Jan-05	Dec-08	Mar-09	11-Jun-04	15-Nov-16	2-Jan-17	"University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00085540
1317	NCT00107003	GW572016 to Treat Recurrent Malignant Brain Tumors		Completed	No Results Available	Glioma|Brain Tumor|Glioblastoma Multiforme|GBM|Gliosarcoma|GS	Drug: lapatinib ditosylate|Procedure: Adjuvant therapy|Procedure: Conventional surgery|Procedure: Neoadjuvant therapy	Determine 6-month progression-free survival of patients undergoing surgery for recurrent progressive glioblastoma multiforme or gliosarcoma treated with lapatinib.	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	9	NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	050134|05-C-0134	30-Mar-05	5-Dec-07	30-Nov-12	4-Apr-05		5-Jul-18	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00107003
1318	NCT04889495	A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer		Not yet recruiting	No Results Available	Non-small Cell Lung Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer|Metastatic Kidney Cancer|Cervical Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer	Drug: Zirabev	Safety profile|Efficacy profile	Pfizer	All	"19 Years and older   (Adult, Older Adult)"		400	Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	B7391012	31-May-23	1-Aug-24	16-Aug-25	17-May-21		13-Oct-21			https://ClinicalTrials.gov/show/NCT04889495
1319	NCT00875433	Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours		Completed	Has Results	Neoplasms	Drug: BIBW 2992	"Objective Response (OR)|Average Time-matched QT Corrected by the Fridericia Formula (QTcF) Change From Baseline to Day 14|Progression-free Survival (PFS)|Overall Survival (OS)|Disease Control|Duration of Disease Control (DC)|Patients With Notable Findings in QTcF on Day 14|Patients With Clinically Relevant Findings in ECG on Day 14|Time-matched QTcF Changes From Baseline to Day 14 at Each Time-point|Average Time-matched QT Change From Baseline to Day 14|Patients With Notable Findings in QT on Day 14|Average Time-matched Heart Rate Change From Baseline to Day 14.|Highest CTC Grade for Adverse Events|Area Under Curve 0-24 Hours (AUC0-24) on Day 1|Maximum Concentration (Cmax)|Time From Dosing to the Maximum Concentration (Tmax)|Area Under Curve of Afatinib Over a Uniform Dosing Interval Tau at Steady State (AUCtau,ss)|Maximum Concentration of Afatinib in Plasma at Steady State (Cmax,ss)|Time From Dosing to the Maximum Concentration of Afatinib in Plasma at Steady State (Tmax,ss)|Accumulation Ratio of AUC Values (R_A,AUC)|Accumulation Ratio of AUC Values (R_A,Cmax)|Percentage Peak Trough Fluctuation (PTF)"	Boehringer Ingelheim	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1200.24|2008-006288-36	Mar-09	Apr-11		3-Apr-09	13-Nov-13	30-Dec-13	"1200.24.4403 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom|1200.24.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.24.4404 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.24.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT00875433
1320	NCT01171469	Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor		Completed	No Results Available	Brain Tumor|Glioblastoma|Medulloblastoma|Ependymoma|Anaplastic Astrocytoma	Biological: Dendritic Cells|Drug: Imiquimod	Maximum Tolerated Dose|Time to Tumor Progression	"Masonic Cancer Center, University of Minnesota"	All	"Child, Adult, Older Adult"	Phase 1	8	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008LS053|0809M48641	Sep-10	May-12	Jun-12	28-Jul-10		2-Dec-17	"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT01171469
1321	NCT02015819	"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas"		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor|Anaplastic Oligoastrocytoma	Biological: E. coli CD-expressing genetically modified neural stem cells|Drug: flucytosine|Drug: leucovorin calcium|Other: pharmacological study|Other: laboratory biomarker analysis	Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)|Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham|Number of Participants Developing Antibodies Against NSCs|Average Steady State Levels of 5-FC and 5-FU in the Brain|Average Steady State Levels of 5-FC Concentrations in Plasma|Comparison of 5-FC in the Brain to 5-FC in the Plasma|Summary of Tumor Response Using the Response Assessment in Neuro-Oncology (RANO) Criteria	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	16	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13401|NCI-2013-02346|FD-R-004816	7-Oct-14	7-Oct-17	7-Oct-17	19-Dec-13	29-Sep-21	20-Oct-21	"City of Hope Medical Center, Duarte, California, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/19/NCT02015819/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02015819
1322	NCT00323076	"[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours"		Terminated	No Results Available	Renal Cell Carcinoma|Neuroendocrine Tumours	Drug: 18F-FAZA PET Imaging	Phase I: demonstrate the safety of 18F-FAZA manufactured at the Edmonton Radiopharmaceutical Centre/Edmonton PET Centre. Phase II: determine the general biodistribution pattern of18F-FAZA.|Determine the relative tumour uptake of 18F-FAZA|Confirm the safety of 18F-FAZA manufactured at the Edmonton Radiopharmaceutical Centre/Edmonton PET Centre	AHS Cancer Control Alberta	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 1|Phase 2	92	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	DX-FAZ-001	12-Sep-06	4-Feb-19	4-Feb-19	9-May-06		26-Aug-19	"Cross Cancer Institute, Edmonton, Alberta, Canada"		https://ClinicalTrials.gov/show/NCT00323076
1323	NCT00526812	A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas		Completed	No Results Available	Glioma	Drug: RTA 744|Drug: RTA 744 injection	To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of RTA 744 Injection in the patient population studied and to determine the qualitative and quantitative toxic effects of RTA 744 Injection.|To characterize the multiple-dose pharmacokinetics of RTA 744 and to document any potential antitumor activity of RTA 744 in those patients with measurable disease.	"Reata Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	54	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RTA 744-C-0401	Nov-05	Dec-08		10-Sep-07		7-Nov-14	"UCLA School of Medicine, Department of Neurology, Los Angeles, California, United States|Baylor University Medical Center: Neuro-Oncology Associates, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00526812
1324	NCT03893487	Fimepinostat in Treating Brain Tumors in Children and Young Adults	PNOC016	Recruiting	No Results Available	Diffuse Intrinsic Pontine Glioma|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent Medulloblastoma	Drug: Fimepinostat|Procedure: Therapeutic Conventional Surgery	Penetration of fimepinostat across the blood brain barrier (BBB)	"Sabine Mueller, MD, PhD|Pacific Pediatric Neuro-Oncology Consortium|Cannonball Kids' Cancer Foundation|Curis, Inc.|University of California, San Francisco"	All	"3 Years to 39 Years   (Child, Adult)"	Early Phase 1	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18086|NCI-2019-00144|PNOC016	7-Aug-19	1-Jun-22	1-Jun-27	28-Mar-19		5-Jan-22	"Rady Children's Hospital, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|Children's Minnesota Research Institute, Minneapolis, Minnesota, United States|Washington University in St Louis, Saint Louis, Missouri, United States|Nationwide Children's, Columbus, Ohio, United States|Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|University of Utah, Children's Primary, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|The University Children's Hospital in Zurich, Zürich, Zurich, Switzerland"		https://ClinicalTrials.gov/show/NCT03893487
1325	NCT01445691	More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery		Withdrawn	No Results Available	"Benign Neoplasms, Brain|Brain Cancer|Brain Neoplasms, Benign|Brain Neoplasms, Malignant|Brain Tumor, Primary|Brain Tumor, Recurrent|Brain Tumors|Intracranial Neoplasms|Neoplasms, Brain|Neoplasms, Intracranial|Primary Brain Neoplasms|Primary Malignant Brain Neoplasms|Primary Malignant Brain Tumors|Gliomas|Glioblastoma"	Drug: 5-ALA (Gliolan)	Radicality of Brain Tumor Resection|Progression-free survival every 3 months after surgery	Constantinos Hadjipanayis|NX PharmaGen|National Cancer Institute (NCI)|Icahn School of Medicine at Mount Sinai	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 2	0	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 15-2034|WCI1999-11|R01CA176659|R21CA186169|IRB00051663	Nov-15	Sep-16	Sep-16	4-Oct-11		17-May-16	"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01445691
1326	NCT04295759	INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas		Recruiting	No Results Available	"Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|DIPG|High-grade Astrocytoma NOS|CNS Primary Tumor, NOS (Malignant Glioma)"	Drug: INCB7839	To evaluate the incidence of INCB7839 treatment-emergent adverse events in children with recurrent/progressive High-Grade Gliomas.|Maximum tolerated dose (MTD) and/or recommend Phase II dose (RP2D) of INCB7839.|To characterize the area under the plasma concentration versus time curve (AUC) of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.|To characterize the maximum concentration [CMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.|To characterize the apparent oral clearance [CL/F] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.|To characterize the time to reach CMAX [TMAX] of INCB7839 administered on this schedule in children with recurrent/progressive high-grade glioma.|To make a preliminary assessment of progression-free survival in children with recurrent/progressive high-grade glioma.|To make a preliminary assessment of overall survival in children with recurrent/progressive high-grade glioma.|To make a preliminary assessment of duration of response in children with recurrent/progressive high-grade glioma.	Pediatric Brain Tumor Consortium	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	28	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-056	27-May-20	31-Mar-22	31-Dec-23	4-Mar-20		22-Sep-21	"Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Lurie Childrens Hospital-Chicago, Chicago, Illinois, United States|National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04295759
1327	NCT03919071	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma		Suspended	No Results Available	Anaplastic Astrocytoma|Anaplastic Ganglioglioma|Anaplastic Pleomorphic Xanthoastrocytoma|Glioblastoma|Malignant Glioma|WHO Grade III Glioma	Drug: Dabrafenib Mesylate|Radiation: Radiation Therapy|Drug: Trametinib Dimethyl Sulfoxide	"Event-free survival (EFS) for stratum 1|Overall survival (OS) for stratum 1, stratum 2, and stratum 3|Event-free survival (EFS) for stratum 2 and stratum 3|Incidence of adverse events"	National Cancer Institute (NCI)	All	"3 Years to 25 Years   (Child, Adult)"	Phase 2	58	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2019-02289|ACNS1723|U10CA180886	2-Oct-19	30-Sep-24	30-Sep-24	18-Apr-19		23-Dec-21	"Children's Hospital of Alabama, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Beaumont Children's Hospital-Royal Oak, Royal Oak, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Morristown Medical Center, Morristown, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Broadway Medical Center, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|HIMA San Pablo Oncologic Hospital, Caguas, Puerto Rico"		https://ClinicalTrials.gov/show/NCT03919071
1328	NCT00679354	Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy		Completed	Has Results	Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: cilengitide|Other: laboratory biomarker analysis|Other: pharmacological study	"Objective Response to Cilengitide|Time to Tumor Progression (TTP)|Time to Treatment Failure (TTF)|Time to Death (TTD)|Rate of Toxicity, Especially That of Symptomatic Intratumoral Hemorrhage (ITH) Assessed by Common Terminology Criteria for Adverse Events Version 4.0|Pharmacokinetic Parameter of Cilengitide in Plasma: Volume of Central Compartment (Vc)|Pharmacokinetic Parameter of Cilengitide in Plasma: Elimination Rate Constant (Ke)|Pharmacokinetic Parameter of Cilengitide in Plasma: Half-life (t1/2)|Pharmacokinetic Parameter of Cilengitide in Plasma: Systemic Clearance (Cl)|Pharmacogenetic Polymorphism in Drug Transporter Gene ABCB1 and Relate to Cilengitide Disposition as Measured by AUC|Pharmacogenetic Polymorphism in Drug Transporter Gene ABCB1 and Relate to Cilengitide Disposition as Measured by Systemic Clearance|Pharmacogenetic Polymorphism in Drug Transporter Gene ABCG2 and Relate to Cilengitide Disposition as Measured by AUC|Pharmacogenetic Polymorphism in Drug Transporter Gene ABCG2 and Relate to Cilengitide Disposition as Measured by Systemic Clearance"	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 2	30	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00339|COG-ACNS0621|CDR0000595623|ACNS0621|U10CA098543	Jun-08	Oct-10	Jul-11	16-May-08	20-Feb-14	1-Aug-18	"Kaiser Permanente-Oakland, Oakland, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|New York University Langone Medical Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Palmetto Health Richland, Columbia, South Carolina, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Seattle Children's Hospital, Seattle, Washington, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada"		https://ClinicalTrials.gov/show/NCT00679354
1329	NCT01721577	Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas	AXL1717	Unknown status	No Results Available	Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Anaplastic Ependymoma	Drug: AXL1717	Phase I - Determine recommended Phase II dose.|Phase II - Determine Antitumor effect|Phase I - Maximum Tolerated Dose (MTD)|Phase I - Molecular markers of optimum response|Phase I - Molecular Markers of IGF (insulin like growth factor)-1R pathway|Phase II - Time-To-Progression (TTP) and Overall Survival (OS)|Phase II - Overall Response Rate|Phase II - Imaging Evidence of Response.	Rush University Medical Center|Axelar AB	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	30	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11090804|VABC; GCR	Dec-12	Dec-15	Dec-15	4-Nov-12		12-Jan-15	"Rush University Medical Center, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT01721577
1330	NCT00243490	Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors		Withdrawn	No Results Available	Malignant Intracranial Tumors|Glioblastoma Multiforme|Anaplastic Astrocytomas|Anaplastic Oligodendrogliomas|Anaplastic Ependymoma	Procedure: Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M	The addition of photodynamic therapy to standard brain tumor treatments will result in a significant prolongation of time to recurrence and survival in newly diagnosed malignant intracranial tumors.	National Taiwan University Hospital	All	"20 Years to 75 Years   (Adult, Older Adult)"	Phase 2	5	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	33MD01			Jan-09	24-Oct-05		12-Jan-10	"National Taiwan University Hospital, Taipei, Taiwan"		https://ClinicalTrials.gov/show/NCT00243490
1331	NCT02365662	A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor		Terminated	No Results Available	Head and Neck Squamous Cell Carcinoma|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Carcinoma|Glioblastoma Multiforme	Drug: ABBV-221	Number of participants with adverse events|Maximum Plasma Concentration (Cmax) of ABBV-221|Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221|Maximum tolerated dose of ABBV-221|Area Under the Plasma Concentration-time Curve of ABBV-221|Recommended Phase 2 dose of ABBV-221|Assess the effect of systemic ABBV-221 administration on QT prolongation|Objective Response Rate (ORR)	AbbVie	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 1	46	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M14-429|2014-003557-34	9-Jan-15	15-Mar-18	15-Mar-18	19-Feb-15		30-Mar-18	"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Fundacion Jimenez Diaz, Madrid, Spain|Hosp Univ Madrid Sanchinarro, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT02365662
1332	NCT01189240	RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma		Terminated	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Biological: bevacizumab|Other: laboratory biomarker analysis|Other: pharmacological study	Maximum-tolerated Dose and the Recommended Phase II Dose of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab Determined by Dose-limiting Toxicity Rate (Phase I)|Toxicity Description (Dose Limiting Toxicity-DLT) of Gamma-secretase Inhibitor RO4929097 in Combination With Bevacizumab|Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1|Measurement of Cmax to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15|Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 1|Measurement of AUC24 to Determine the Effect of Bevacizumab on the Plasma Pharmacokinetics of RO4929097 Day 15	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	13	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-02509|CDR0000683099|ABTC-1002|U01CA137443	Dec-10	Jan-13	Feb-15	26-Aug-10	14-Jul-15	14-Dec-15	"University of California at Los Angeles (UCLA ), Los Angeles, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01189240
1333	NCT01904123	STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain		"Active, not recruiting"	No Results Available	Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Recurrent Brain Neoplasm|Recurrent Glioblastoma|Recurrent Malignant Glioma	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: STAT3 Inhibitor WP1066	"Maximum tolerated dose (MTD) of JAK2 inhibitor WP1066, defined as the dose level at which 0/6 or 1/6 patients experience a dose limiting toxicity (DLT) with at least 2 patients experiencing DLT at the next higher dose level|Incidence of adverse events assessed using NCI CTC|Pharmacokinetic analysis of the in vivo bioavailability of JAK2 inhibitor WP1066|Proportion of patients reaching complete response or partial response|Duration of response|Overall survival|Progression free survival|The proportion of patients who develop additional melanoma metastatic lesions|Change in regulatory T cell numbers|Change in the number of peripheral blood mononuclear cells expressing phosphorylated STAT3"	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	8	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2012-0358|NCI-2015-00163|P50CA127001|P50CA093459	13-Jul-18	31-Jul-22	31-Jul-22	22-Jul-13		30-Jul-21	"M D Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01904123
1334	NCT01999270	Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors		Completed	No Results Available	"Astrocytoma, Oligoastrocytoma, Mixed|Ganglioneuroma|Glioma|Ganglioglioma|Glioblastoma Multiforme Glioma"	Drug: Irinotecan|Drug: Bevacizumab|Device: FDOPA-PET/MRI imaging	FDOPA-PET/MRI imaging	Washington University School of Medicine	All	"up to 21 Years   (Child, Adult)"	Phase 1	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201303069	Apr-13	May-16	May-16	3-Dec-13		21-Oct-16	"Washington University School of Medicine, St. Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT01999270
1335	NCT00114309	131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma		Unknown status	No Results Available	Malignant Glioma|Glioblastoma Multiforme|GBM|Anaplastic Astrocytoma|Oligo-Astrocytoma|Gliosarcoma	Drug: 131-I-TM-601|Drug: 131I-TM601	Determine Maximum Tolerated Dose (MTD) of 131-I-TM-601 administered intracavitary to patients with recurrent high-grade glioma|Determine the toxicity of a three (3) and six (6) dose cycle of 131-I-TM-601 administrations into the tumor resection site of patients with recurrent high-grade glioma|Evaluate the 6 and 12-month rate of progression and survival of patients with recurrent high-grade glioma treated with a three (3) or six (6) dose cycle of 131-I-TM-601|Evaluate the overall time to progression and death of patients with recurrent high-grade glioma treated with either a three (3) or six (6) dose cycle of 131-I-TM-601|Evaluate if either a three (3) or six (6) dose cycle of 131-I-TM-601 affects Quality of Life	TransMolecular	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	66	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TM-601-002	Nov-04	Mar-09	Aug-09	14-Jun-05		3-Apr-09	"University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Tufts-New England Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Lacks Cancer Center at St. Mary's Health Care, Grand Rapids, Michigan, United States|St. Louis Hospital, St. Louis, Missouri, United States|Washington University Medical Center, St. Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Carolina Neurosurgery and Spine, Charlotte, North Carolina, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00114309
1336	NCT01339039	Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma		Terminated	No Results Available	High Grade Glioma: Glioblastoma (GBM)|High Grade Glioma: Gliosarcoma|Anaplastic Astrocytoma (AA)|Anaplastic Oligodendroglioma (AO)|Mixed Anaplastic Oligoastrocytoma (AOA)	Drug: Plerixafor|Drug: Bevacizumab|Procedure: Surgery	Determination of Maximum Tolerated Dose (MTD)|Safety Evaluation (3 weeks on / 1 week off) - Assessment of the proportion of subjects with different grades of toxicities|Safety and Tolerability (daily plerixafor) - Assessment of the proportion of subjects with different grades of toxicities|Determination of Plasma PK Parameters|Exploratory Objective #1 - Preliminary data assessment on anti-tumor efficacy|Exploratory Objective #2 - Investigation of cerebrospinal fluid (CSF) penetration of plerixafor|Exploratory Objective #3 - Investigation of tumor tissue penetration of plerixafor|Exploratory Objective #4 - Investigation of the correlation of treatment response with laboratory correlates including circulating biomarkers	"Patrick Y. Wen, MD|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|Genzyme, a Sanofi Company"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	26	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-329|MAMO0909-6	Dec-11	Apr-14	8-Apr-17	20-Apr-11		17-Nov-17	"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01339039
1337	NCT03911388	HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors		Recruiting	No Results Available	"Neoplasms, Brain|Glioblastoma Multiforme|Glioblastoma of Cerebellum|Neoplasms|Astrocytoma|Astrocytoma, Cerebellar|Neuroectodermal Tumors|Neuroectodermal Tumors, Primitive|Cerebellar PNET, Childhood|Cerebellar Neoplasms|Cerebellar Neoplasms, Primary|Cerebellar Neoplasm, Malignant|Cerebellar Neoplasm Malignant Primary|Neoplasm Metastases|Neoplasm Malignant|Neoplasms, Neuroepithelial|Neoplasms, Germ Cell and Embryonal|Neoplasms by Histologic Type|Neoplasms, Glandular and Epithelial|Neoplasms, Nerve Tissue|Central Nervous System Neoplasms, Primary|Central Nervous System Neoplasms, Malignant|Nervous System Neoplasms|Neoplasms by Site|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Medulloblastoma Recurrent|HSV|Virus|Pediatric Brain Tumor|Nervous System Cancer|Primitive Neuroectodermal Tumor (PNET) of Cerebellum"	Biological: G207	Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events|Immunologic Response|Virologic Shedding|Progression Free Survival|Overall Survival|Change in Performance (Ability to Perform Normal Activities)|Quality of Life (optional)	University of Alabama at Birmingham	All	"3 Years to 18 Years   (Child, Adult)"	Phase 1	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UAB 18113|R01FD006368	12-Sep-19	1-Sep-23	1-Sep-24	11-Apr-19		8-Jul-21	"Children's of Alabama, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT03911388
1338	NCT00369590	VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Biological: ziv-aflibercept|Other: pharmacological study|Other: laboratory biomarker analysis	Progression-free Survival (PFS) at 6 Months|Safety Profile - Toxicities|Safety Profile - Events That Discontinued Treatment|Response Rate Associated With VEGF Trap Therapy Defined as Proportions of Patients Experiencing Complete or Partial Response|Progression Free Survival (PFS) Rate for Subjects With Radiographic Response|Overall Survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	58	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00677|CDR0000495275|NABTC06-01|NABTC-06-01|U01CA062399	Aug-06	Dec-11	Oct-12	29-Aug-06	2-Oct-15	2-Oct-15	"University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00369590
1339	NCT01144247	Cellular Immunotherapy Study for Brain Cancer	alloCTL	Completed	No Results Available	Gliomas|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Glioma|Glioblastoma Multiforme|Malignant Meningioma	Drug: alloreactive CTL	Number of patients with adverse events as a measure of safety and tolerability|Maximum tolerated dose	Jonsson Comprehensive Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCLA 07-09-008|R01CA125244	Jul-10	Jul-15	Jul-15	15-Jun-10		27-May-16	"University of California, Los Angeles, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT01144247
1340	NCT00093613	Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma		Completed	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Drug: sorafenib tosylate|Other: pharmacological study	"Maximum tolerated dose (MTD) of sorafenib tosylate in patients with recurrent or progressive malignant glioma, receiving (group A) or not receiving (group B) anticonvulsants known to be metabolized by the P450 hepatic enzyme complex|Frequency of the toxicities associated with sorafenib tosylate treatment between patients with recurrent or progressive malignant glioma, receiving or not receiving anticonvulsants|Effect of taking enzyme inducing anticonvulsant drugs on the pharmacokinetics and metabolism of sorafenib tosylate|Magnitude of variability in the steady-state pharmacokinetics of the drug both within and between patients|Overall survival"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	47	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03102|NABTT-0401|ABTC-0401|NABTT 0401|U01CA062475	Dec-04	Oct-10	Dec-11	8-Oct-04		30-May-14	"University of Alabama at Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Adult Brain Tumor Consortium, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00093613
1341	NCT04732065	"ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023)"		Recruiting	No Results Available	Diffuse Midline Glioma (DMG)|Malignant Brain Tumors|Glioblastoma|Recurrent Ependymoma|Recurrent Malignant Brain Neoplasm|Spinal Cord Glioma|WHO Grade III Glioma	Drug: ONC206|Radiation: Standard of Care Radiation Therapy	Proportion of participants with dose-limiting toxicities (DLT)|Maximum tolerated dose (MTD) of ONC206|Mean maximum concentration (Cmax) of ONC206|Mean corresponding time (Tmax) of ONC206|Area under the curve (AUC) of ONC206|Elimination half-life (t1/2) of ONC206|Mean Total body clearance (CL) for ONC206|Mean Volume of Distribution (Vd) for ONC206	"Sabine Mueller, MD, PhD|Chimerix|Mithil Prasad Foundation|Storm the Heavens Fund|The ChadTough Defeat DIPG Foundation|University of California, San Francisco"	All	"2 Years to 21 Years   (Child, Adult)"	Phase 1	256	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	200814|NCI-2021-00046	23-Aug-21	31-Jan-24	31-Dec-25	1-Feb-21		16-Dec-21	"University of California, San Francisco, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT04732065
1342	NCT04427384	Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)		Recruiting	No Results Available	"Brain Tumor, Recurrent|Brain Tumor|Brain Tumor, Primary|Brain Tumor - Metastatic|Brain Tumor, Adult: Glioblastoma|Brain Tumor, Adult Meningioma"	Device: GammaTile	Surgical Bed-Recurrence Free Survival in Metastatic Tumor Subjects|Surgical Bed-Recurrence Free Survival in Meningioma Tumor Subjects|Overall Survival in High Grade Glioma Subjects	"GT Medical Technologies, Inc."	All	"Child, Adult, Older Adult"		600	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GTM-101	11-Sep-20	31-Oct-28	31-Dec-28	11-Jun-20		16-Jul-21	"HonorHealth Research Institute, Phoenix, Arizona, United States|Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of North Carolina Health, Chapel Hill, North Carolina, United States|Vidant, Greenville, North Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Univertity of Texas Healthy Science Center of San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT04427384
1343	NCT03212274	"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations"		Recruiting	No Results Available	Advanced Malignant Solid Neoplasm|Glioblastoma|Recurrent Cholangiocarcinoma|Recurrent Glioma|Recurrent Malignant Solid Neoplasm|WHO Grade II Glioma|WHO Grade III Glioma	Drug: Olaparib	Overall response rate|Progression-free survival|Incidence of adverse events	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	145	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2017-01182|2000023083|10129|UM1CA186689	30-Mar-18	31-Jul-22	31-Jul-22	11-Jul-17		10-Nov-21	"UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|University of Kansas Cancer Center - North, Kansas City, Missouri, United States|University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States|University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|Vanderbilt Breast Center at One Hundred Oaks, Nashville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT03212274
1344	NCT01095094	Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma		Terminated	Has Results	Brain Tumor|Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Oligodendroglioma|Brain Stem Glioma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Mixed Glioma	Drug: ritonavir|Drug: lopinavir	Progression-free Survival|Grade 3-5 Toxicity as Assessed by NCI CTC v3.0	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	19	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE2307|NCI-2009-01288	Jan-09	Jun-10	Nov-11	29-Mar-10	10-Jun-13	10-Jun-13	"Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01095094
1345	NCT01082926	"Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2"		Completed	No Results Available	Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Brain Stem Glioma|Ependymoblastoma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Grade III Meningioma|Meningeal Hemangiopericytoma|Mixed Glioma|Pineal Gland Astrocytoma|Brain Tumor	Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Other: laboratory biomarker analysis|Procedure: positron emission tomography	Safety of GRm13Z40-2 CTL CNS loco-regional cellular immunotherapy|Safety of convection enhanced delivery (CED) of recombinant human Interleukin-2 (rhuIL-2) used in conjunction with GRm13Z40-2 CTL adoptive transfer|Toxicity as assessed by NCI CTCAE version 4.0|Ability of 9-(4-fluoro-3-hydroxy-methyl-butyl) guanine (18FHBG) positron emission tomography PET to image GRm13Z40-2 CTLs|Impact of concurrent dexamethasone on the tempo and magnitude of T cell allograft rejection responses by tracking the frequency of anti-GRm13Z40-2 immune responses in serially acquired peripheral blood samples|Evaluation of ganciclovir administration for ablating transferred GRm13Z40-2 in vivo should significant graft-mediated toxicities be encountered	City of Hope Medical Center	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	6	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07082|NCI-2010-00303	May-10	Sep-13	Sep-13	9-Mar-10		8-Jun-15	"City of Hope, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT01082926
1346	NCT03355794	A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)		"Active, not recruiting"	No Results Available	Diffuse Intrinsic Pontine Glioma|Malignant Glioma of Brain|High Grade Glioma|Bithalamic High Grade Glioma|Brainstem Glioma|Glioblastoma|Anaplastic Astrocytoma	Drug: ribociclib|Drug: Everolimus	Number of adverse events|Estimate the maximum tolerated dose and/or recommended phase 2 dose of ribociclib combined with everolimus|Pharmacokinetics of combination of ribociclib and everolimus|Time from diagnosis to death - overall survival|Number of patients with observed pseudoprogression|Whole exome sequencing to explore biology of DIPG and HGG tumors	"Children's Hospital Medical Center, Cincinnati|Novartis"	All	"12 Months to 30 Years   (Child, Adult)"	Phase 1	24	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CONNECT1701_LEE/RAD17T-MD-1604	14-Nov-17	31-Jul-20	31-Jul-22	28-Nov-17		27-Aug-21	"Children's National Medical Center, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT03355794
1347	NCT04566393	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies		Available	No Results Available	Pancreatic Cancer|Small Bowel Cancer|Colorectal Cancer|Melanoma|Non Small Cell Lung Cancer|Thyroid Cancer|Bladder Cancer|Head and Neck Cancer|Gastric Cancer|Esophageal Cancer|Cholangiocarcinoma|Ovarian Cancer|Hepatocellular Carcinoma|Glioblastoma|MAPK Gene Mutation|KRAS Activating Mutation|BRAF Gene Mutation|NRAS Gene Mutation|HRAS Gene Mutation|MEK Mutation|ERK Mutation	Drug: Ulixertinib (BVD-523)		xCures|Cancer Commons	All	"12 Years and older   (Child, Adult, Older Adult)"			Industry|Other	Expanded Access:Intermediate-size Population		ULI-EAP-100				28-Sep-20		2-Sep-21	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|xCures Inc., San Francisco, California, United States|Providence Saint John's Health Center, Santa Monica, California, United States|University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Franciscan Health, Indianapolis, Indiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Cancer and Leukemia Center, Sterling Heights, Michigan, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Duke Health, Durham, North Carolina, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Texas Oncology - Denton, Denton, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT04566393
1348	NCT02031965	Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery		Terminated	No Results Available	Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma	Biological: oncolytic HSV-1716|Drug: dexamethasone|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis	"MTD of oncolytic HSV-1716, defined as the highest dose level at which 0 out of 3 or at most one out of 6 patients have been treated experiencing a dose limiting toxicity and the next higher dose level has been determined to be too toxic|Antiviral immune responses|Systemic viremia and viral shedding|Progression free survival|Overall survival|Changes in MR parameters (including diffusion and perfusion studies) (optional)|Changes in MRS and PET parameters (including diffusion and perfusion studies) (optional)|Anti-tumor cellular responses|Humoral immune responses"	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"12 Years to 21 Years   (Child, Adult)"	Phase 1	2	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-037|NCI-2013-00526|U01CA081457	Dec-13	May-16	May-16	9-Jan-14		30-May-16	"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02031965
1349	NCT01151670	Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors		Completed	No Results Available	"Brain Neoplasms, Malignant|Brain Neoplasms, Benign|Malignant Meningioma|Glioblastoma Multiforme|Anaplastic Astrocytoma"	Drug: pioglitazone|Drug: Pioglitazone	Best tolerated dose of 2 different doses of orally administered pioglitazone|Toxicities associated with both dose levels|To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.	Wake Forest University Health Sciences	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB00014528|NCI-2009-01452|CCCWFU 97409	Aug-10	Aug-14	Aug-14	28-Jun-10		1-Aug-18	"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01151670
1350	NCT04135807	Implantable Microdevice In Primary Brain Tumors		Recruiting	No Results Available	Grade II Glioma|Grade III Glioma|Grade IV Glioma|Astrocytoma|Oligodendroglioma of Brain|Anaplastic Astrocytoma of Brain|Anaplastic Oligodendroglioma|Glioblastoma	Combination Product: Microdevice	Success Rate of Microdevice Retrieval|Number of Participants with Microdevice Related Adverse Events as Assessed by CTCAE Volume 5.0|Measure Local Intratumor Response to Different Agents|Correlate Tissue Genetic Features with Drug Response	Oliver Jonas|Dana-Farber Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18-623	3-Mar-20	21-Sep-21	1-Feb-22	23-Oct-19		23-Feb-21	"Brigham and Women's Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT04135807
1351	NCT03072134	Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma		"Active, not recruiting"	No Results Available	"Glioma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Oligoastrocytoma|Glioblastoma Multiforme|Astrocytoma, Grade III|Astrocytoma, Grade IV|Brain Cancer"	Biological: Neural stem cells loaded with an oncolytic adenovirus	Determine the maximum number of neural stem cells loaded with the oncolytic adenovirus.|Assessment of tumor response or progression to treatment on MRI.	Northwestern University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	13	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STU00203933	24-Apr-17	6-Apr-20	31-Dec-21	7-Mar-17		14-Oct-20	"City of Hope, Duarte, California, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT03072134
1352	NCT01996527	3T MRI Biomarkers of Glioma Treatment Response		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor	Device: 3-Tesla magnetic resonance imaging|Device: CEST-MRI|Device: DW-MRI|Device: DCE-MRI|Device: DSC-MRI|Drug: IV administration of gadolinium-containing contrast agent	Best Response|Progression Free Survival (PFS)	Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	7	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	VICC NEU 1268|NCI-2013-02195|P30CA068485	May-12	23-Nov-15	1-Jan-16	27-Nov-13		17-Apr-17	"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT01996527
1353	NCT01269411	RO4929097 in Treating Patients With Recurrent Invasive Gliomas		Terminated	No Results Available	Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Tumor	Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Procedure: therapeutic conventional surgery|Other: pharmacological study|Other: laboratory biomarker analysis	"Maximum-tolerated dose (MTD) defined as the dose level in which less than or equal to 1 out of 6 patients experience dose limiting toxicity (DLT) assessed using NCI CTCAE version 4.0|Pharmacokinetic (PK) profile of RO4909297|Progression-free survival following treatment with R04929097|Inhibition of p75NTR cleavage and processing|Establishment and growth of BTIC cultures in neurosphere growth conditions, effects on proliferation, ability to self-renewal, and ability to differentiate along lineage-specific pathways|Inhibition of Notch signaling, by assessing downstream target activation"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	22	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-02565|PHL-075|N01CM00032|CDR0000691784	Jul-11	Feb-12		4-Jan-11		7-Feb-13	"University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT01269411
1354	NCT03175224	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	SPARTA	Recruiting	No Results Available	Solid Tumor|Advanced Cancer|Renal Cancer|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma|NSCLC|Lung Cancer|Brain Tumor|Glioblastoma Multiforme	Drug: APL-101 Oral Capsules	"Estimate the maximum tolerated dose (MTD) and the incidence of DLTs in Phase 1|Objective response rate (ORR = CR + PR) per blinded independent review committee (BIRC) based on RECIST v1.1 (or relevant criteria per tumor type)|Median duration of response (DOR) per BIRC.|ORR per investigator assessment based on RECIST v1.1.|Median DOR per investigator assessment.|Antitumor activity by clinical benefit rate (CR + PR + SD ≥ 4 cycles) based on RECIST v1.1 Median time to progression (TTP).|Median time to progression (TTP).|Progression Free Survival (PFS) and overall survival (OS) at 6, 12, 18 and 24 months"	Apollomics Inc.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	201	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APL-101-01	27-Sep-17	30-Dec-22	30-Dec-22	5-Jun-17		26-Nov-21	"Banner MD Anderson, Gilbert, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|University of California, Los Angeles (UCLA) Ronald Reagan Medical Center, Los Angeles, California, United States|Kaiser Permanente - CA, Riverside, California, United States|St. Joseph Health, Santa Rosa, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Christiana Hospital, Newark, Delaware, United States|Florida Cancer Specialists - South, Fort Myers, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists - North, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Moffitt, Tampa, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Maryland Oncology Hematology, Silver Spring, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Institute - Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University (OSU), Columbus, Ohio, United States|Kettering Health Network, Kettering, Ohio, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|St. Francis Cancer Center, Greenville, South Carolina, United States|Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States|The Don & Sybil Harrington Cancer Center, Amarillo, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Health System, Tacoma, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Flinders Medical Centre, Bedford Park, South Australia, Australia|Border Medical Oncology, Albury, Australia|St Vincents Hospital Melbourne, Melbourne, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Calvary Central Districts Hospita, North Adelaide, Australia|Lady Davis Institute for Medical Research Jewish General Hospital, Montreal, Quebec, Canada|Cross Cancer Institute, Edmonton, Canada|McGill University Health Center - Research Institute, Montréal, Canada|Princess Margaret Hospital, Toronto, Canada|Cancer Care Manitoba, Winnipeg, Canada|Helsinki University Central Hospita, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|CHRU de Brest - Hôpital Morvan, Brest, France|CHRU de Lille, Lille, France|Centre Leon Berard, Lyon, France|Hopital Bichat - Claude Bernard - AP-HP, Paris, France|CHU Rennes - Hopital Pontchaillou, Rennes, France|Gustave Roussy, Villejuif, France|Szent Borbala Korhaz, Tatabanya, Hungary|Torokbalinti Tudogyogyintezet, Torokbalint, Hungary|Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico, Catania, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|IRCCS Ospedale San Raffaele, Milan, Italy|PanOncology Trials, LLC, Rio Piedras, Puerto Rico|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russian Federation|Private Medical Institution Euromedservice, Saint Petersburg, Russian Federation|Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology), Saint Petersburg, Russian Federation|Ogarev Mordovia State University, Saransk, Russian Federation|JSC Current Medical Technologies, St. Petersburg, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russian Federation|National Cancer Centre Singapore, Singapore, Singapore|Oncocare Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Donostia, San Sebastián, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan|Chi-Mei Hospital - Liouying Branch, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital (CGMHLK), Taoyuan City, Taiwan|City Hematology Center of Municipal Non-Profit Enterprise ""City Clinical Hospital #4"" DCC, Dnipropetrovs'k, Ukraine|Communal Non-commercial Enterprise of Kharkiv Regional Council Regional Clinical Specialized Dispensary of Radiation Protection of Population, Department of Surger, Kharkiv, Ukraine|State Institution V.T.Zaitsev Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine, Department of Purulent Surgery, Kharkiv, Ukraine|Kyiv Municipal Clinical Oncology Center, Kyiv, Ukraine|Imperial College Healthcare NHS Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Surrey Quays, United Kingdom"		https://ClinicalTrials.gov/show/NCT03175224
1355	NCT01723020	A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma		Completed	No Results Available	Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors|Glioblastoma|Multiple Myeloma	Drug: AMG 232	Safety of AMG 232|Objective Tumor Response	"Kartos Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	107	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20120106	27-Dec-12	15-Mar-17	25-Sep-17	7-Nov-12		2-Sep-21	"Research Site, Santa Monica, California, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Greenville Hospital System, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Lyon CEDEX 08, France|Research Site, Villejuif, France|Research Site, Amsterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands"		https://ClinicalTrials.gov/show/NCT01723020
1356	NCT01103375	Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Tumor	Drug: erlotinib hydrochloride|Drug: isotretinoin|Other: laboratory biomarker analysis|Genetic: protein expression analysis	"Recommended phase II doses of erlotinib hydrochloride and isotretinoin|Toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0|Progression-free survival|Overall survival|Response rates (complete or partial response)|EGFRvIII, PTEN, cyclin D1, cyclin E, and RARbeta1 expression in tumor samples"	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	5	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00012306|NCI-2010-00132|CCCWFU 91209	May-10	Jan-13	Mar-13	14-Apr-10		1-Aug-18	"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01103375
1357	NCT00499473	Sunitinib in Treating Patients With Recurrent Malignant Gliomas		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Pineal Gland Astrocytoma	Drug: sunitinib malate|Other: pharmacological study	Progression-free Survival at 6 Months (Stratum 1)|Maximum Tolerable Dose Based on Dose-limiting Toxicity of Sunitinib in Patients Receiving EIAC (Stratum 2)|Dose Resulting in Steady-state Trough|Confirmed Objective Response (Complete Response[CR] or Partial Response [PR])|Percentage of Patients Progression Free at 12 Months|Overall Survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	31	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00215|OSU-IRB-2006C0098|CDR0000554443|OSU-06060|OSU 06060|7745|N01CM62207|N01CM62203|P30CA016058|N01CM62206	Jun-07	Jun-09	Oct-14	11-Jul-07	29-Feb-16	29-Feb-16	"Ohio State University Medical Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00499473
1358	NCT02974738	"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)"		"Active, not recruiting"	No Results Available	"Advanced Solid Tumors|Solid Tumor|Solid Carcinoma|Solid Tumor, Adult|ccRCC|RCC, Clear Cell Adenocarcinoma|RCC|Kidney Cancer|Clear Cell Renal Cell Carcinoma|Renal Cell Carcinoma, Metastatic|Renal Cell Carcinoma Recurrent|Renal Cell Carcinoma, Clear Cell Adenocarcinoma|Glioblastoma|Glioblastoma, Adult|GBM|Glioblastoma Multiforme"	Drug: Belzutifan	maximum tolerated dose (MTD)	"Peloton Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	123	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6482-001|PT2977-101|MK-6482-001	7-Dec-16	14-Apr-23	14-Apr-23	28-Nov-16		8-Sep-21			https://ClinicalTrials.gov/show/NCT02974738
1359	NCT04541082	Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms		Recruiting	No Results Available	"Central Nervous System Neoplasms|Glioblastoma|Gliosarcoma, Adult|Anaplastic Oligodendroglioma|Anaplastic Astrocytoma|Pilocytic Astrocytoma|Oligodendroglioma|Gliomatosis Cerebri|Pleomorphic Xanthoastrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Diffuse Midline Glioma, H3 K27M-Mutant|Ependymoma|Ependymoma, Anaplastic|Medulloblastoma|Teratoid Rhabdoid Tumor|Neuroectodermal Tumors, Primitive|Neuroectodermal Tumors|Anaplastic Meningioma|Atypical Meningioma|Choroid Plexus Neoplasms|Pineal Tumor|Diffuse Astrocytoma|Glial Tumor"	Drug: ONC206	Maximum Tolerated Dose	Chimerix|National Institutes of Health (NIH)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	102	Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONC206-01|NIH 20C0069	26-Oct-20	Sep-24	Feb-25	9-Sep-20		15-Apr-21	"National Institutes of Health, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT04541082
1360	NCT01291420	Dendritic Cell Vaccination for Patients With Solid Tumors		Unknown status	No Results Available	Glioblastoma|Renal Cell Carcinoma|Sarcomas|Breast Cancers|Malignant Mesothelioma|Colorectal Tumors	Biological: autologous dendritic cell vaccination	Immunogenicity of intradermal DC vaccination	"University Hospital, Antwerp"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCRG 11-001	Feb-11	Feb-14		8-Feb-11		12-Jul-13	"Antwerp University Hospital, Center for Cellular Therapy and Regenerative Medicine, Edegem, Antwerp, Belgium"		https://ClinicalTrials.gov/show/NCT01291420
1361	NCT01421524	"Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma"		"Active, not recruiting"	No Results Available	"Multiple Myeloma|Lymphoma, Large B-Cell, Diffuse|Pleiotropic Pathway Modifier|Glioblastoma|Lymphoma|Primary Central Nervous System Lymphoma"	Drug: CC-122	Dose-Limiting Toxicity (DLT)|Pharmacokinetics- Cmax|Pharmacokinetics- AUC|Pharmacokinetics- tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Non-tolerated dose (NTD)|Maximum Tolerated Dose (MTD)|Response Rate|Tissue concentration of CC-122|6-month progression free survival (PFS) rate for GBM chort	Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	271	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-122-ST-001|U1111-1203-5132	12-Sep-11	1-Aug-22	1-Aug-22	23-Aug-11		29-Sep-21	"City of Hope Cancer Center, Duarte, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Rutgers Cancer Institute of New Jersey University, New Brunswick, New Jersey, United States|Mount Sinai Hospital, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|MUSC Rheumatology and Immunology Dept., Charleston, South Carolina, United States|Greenville Hospital System, Greenville, South Carolina, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Texas Oncology, PA - Dallas 75246, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States|Yakima Valley Memorial Hospital/ North Star Lodge, Yakima, Washington, United States|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|CU CHU Clemenceau, Caen Cedex, France|Paoli CalmettesHematology, Marseille le Cedex, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Institut universitaire du cancer de Toulouse (IUCT) - Oncopole, Toulouse CEDEX 9, France|Institut Gustave Roussy, Villejuif Cedex, France|A.O.U. di Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy|U.O.C. Ospedale Bellaria, Bologna, Italy|Istituto Nazionale Tumori, Milan, Italy|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Istituto Nazionale Tumori Regina Elena, Struttura Complessa Ematologia ed Unita di Cellule Staminali, Roma, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain|Hospital del Mar, Barcelona, Spain|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Universitario Clinico de Valencia, Valencia, Spain"		https://ClinicalTrials.gov/show/NCT01421524
1362	NCT00112736	Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Recurrent Adult Brain Tumor	Drug: erlotinib|Drug: temsirolimus|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis|Other: pharmacological study	Maximum Tolerated Dose (Phase I)|Safety/Dose Limiting Toxities Phase I|Efficacy - Response Phase 1|Pharmacokinetics (Phase I)|Progression-free Survival at 6 Months (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	69	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02921|CDR0000429553|NABTC04-02|NABTC-04-02|U01CA062399	Apr-05	Apr-10	Apr-14	3-Jun-05	15-Jun-15	15-Jun-15	"University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00112736
1363	NCT03734913	A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors		Recruiting	No Results Available	Basal Cell Carcinoma|Medulloblastoma|Adenocarcinoma of Esophagogastric Junction|Small Cell Lung Cancer|Neuroendocrine Neoplasm|Glioblastoma	Drug: ZSP1602	Dose-limiting Toxicity (DLT)|Maximum tolerated dose (MTD)|Time to progression (TTP)|Over all response (ORR)|Cmax of ZSP1602|Tmax of ZSP1602|Cmin of ZSP1602|AUC0-t of ZSP1602|T1/2 of ZSP1602|Cl/F of ZSP1602	"Guangdong Zhongsheng Pharmaceutical Co., Ltd."	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	65	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ZSP1602-16-01	25-Jan-19	31-Jul-21	31-Jul-21	8-Nov-18		22-Jul-20	"Jilin Cancer Hospital, Chang Chun, Jilin, China"		https://ClinicalTrials.gov/show/NCT03734913
1364	NCT01922076	Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas		"Active, not recruiting"	No Results Available	"Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Diffuse Intrinsic Pontine Glioma|Diffuse Midline Glioma, H3 K27M-Mutant|Glioblastoma|Gliosarcoma"	Drug: Adavosertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Radiation Therapy	Maximum tolerated dose (MTD)|Incidence and grade of adverse events	National Cancer Institute (NCI)	All	"37 Months to 21 Years   (Child, Adult)"	Phase 1	46	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2013-01602|COG-ADVL1217|ADVL1217|UM1CA097452	3-Sep-13	31-Dec-20		14-Aug-13		1-Dec-21	"Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT01922076
1365	NCT02644291	Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors		Recruiting	No Results Available	"Medulloblastoma|Astrocytoma, Grade III|Glioblastoma|Anaplastic Astrocytoma|Brain Stem Neoplasms, Malignant|Oligodendroblastoma|Anaplastic Oligodendroglioma|Malignant Glioma"	Drug: Mebendazole	Adverse events attributed to mebendazole for patients enrolled in this study|Overall survival for patients enrolled in this study	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	21	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J15211|IRB00072999	May-16	Jun-24	Jun-25	31-Dec-15		21-Sep-21	"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT02644291
1366	NCT02175745	18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas		Terminated	Has Results	Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Recurrent Adult Brain Tumor|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Diffuse Astrocytoma|Recurrent Childhood Fibrillary Astrocytoma|Recurrent Childhood Gemistocytic Astrocytoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma|Recurrent Childhood Oligoastrocytoma|Recurrent Childhood Oligodendroglioma|Recurrent Childhood Pilomyxoid Astrocytoma|Recurrent Childhood Protoplasmic Astrocytoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Anaplastic Oligoastrocytoma|Untreated Childhood Anaplastic Oligodendroglioma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Cerebellar Astrocytoma|Untreated Childhood Cerebral Astrocytoma|Untreated Childhood Diffuse Astrocytoma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Gemistocytic Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliomatosis Cerebri|Untreated Childhood Gliosarcoma|Untreated Childhood Oligoastrocytoma|Untreated Childhood Oligodendroglioma|Untreated Childhood Pilomyxoid Astrocytoma|Untreated Childhood Protoplasmic Astrocytoma|Untreated Childhood Subependymal Giant Cell Astrocytoma|Untreated Childhood Visual Pathway and Hypothalamic Glioma|Untreated Childhood Visual Pathway Glioma	Drug: 18F-fluoro-dihydroxyphenylalanine|Procedure: Positron emission tomography (PET)|Procedure: Computed tomography (CT)|Procedure: Magnetic resonance imaging	Number of Suspicious Lesions Identified by 18F FDOPA PET|Percent Agreement of 18F FDOPA PET With Pathology	Erik Mittra|National Cancer Institute (NCI)|Stanford University	All	"16 Years and older   (Child, Adult, Older Adult)"	Not Applicable	2	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IRB-29364|NCI-2014-01289|BRN0024|P30CA124435	Dec-14	Aug-15	Dec-15	26-Jun-14	20-Mar-17	20-Mar-17	"Stanford University Hospitals and Clinics, Stanford, California, United States"		https://ClinicalTrials.gov/show/NCT02175745
1367	NCT02194452	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors		Withdrawn	No Results Available	Acoustic Schwannoma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Meningioma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Choroid Plexus Tumor|Adult Craniopharyngioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Meningeal Hemangiopericytoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Supratentorial Ependymoma|Meningeal Melanocytoma|Newly Diagnosed Childhood Ependymoma|Recurrent Adult Brain Tumor|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Diffuse Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Fibrillary Astrocytoma|Recurrent Childhood Gemistocytic Astrocytoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Oligoastrocytoma|Recurrent Childhood Oligodendroglioma|Recurrent Childhood Pilocytic Astrocytoma|Recurrent Childhood Pilomyxoid Astrocytoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Pleomorphic Xanthoastrocytoma|Recurrent Childhood Protoplasmic Astrocytoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Anaplastic Oligodendroglioma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Cerebellar Astrocytoma|Untreated Childhood Cerebral Astrocytoma|Untreated Childhood Diffuse Astrocytoma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Gemistocytic Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliomatosis Cerebri|Untreated Childhood Gliosarcoma|Untreated Childhood Medulloblastoma|Untreated Childhood Oligoastrocytoma|Untreated Childhood Oligodendroglioma|Untreated Childhood Pilocytic Astrocytoma|Untreated Childhood Pilomyxoid Astrocytoma|Untreated Childhood Pineoblastoma|Untreated Childhood Pleomorphic Xanthoastrocytoma|Untreated Childhood Protoplasmic Astrocytoma|Untreated Childhood Subependymal Giant Cell Astrocytoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor|Untreated Childhood Visual Pathway and Hypothalamic Glioma|Untreated Childhood Visual Pathway Glioma	Radiation: gallium Ga 68-edotreotide|Procedure: positron emission tomography|Procedure: computed tomography|Other: laboratory biomarker analysis	Change in standardized uptake value (SUV) uptake after gallium Ga 68-edotreotide|Proportion of discordance and concordance between gallium Ga 68-edotreotide and biopsy	Sue O'Dorisio|National Cancer Institute (NCI)|Ride for Kids|University of Iowa	All	"6 Months to 29 Years   (Child, Adult)"	Not Applicable	0	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	201302711|P30CA086862	Sep-13	Mar-17	Mar-17	18-Jul-14		28-Apr-17	"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States"		https://ClinicalTrials.gov/show/NCT02194452
1368	NCT03434262	SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors		Recruiting	No Results Available	"Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Pleomorphic Xanthoastrocytoma, Anaplastic|Atypical Teratoid/Rhabdoid Tumor|Brain Cancer|Brain Tumor|Central Nervous System Neoplasms|Choroid Plexus Carcinoma|CNS Embryonal Tumor With Rhabdoid Features|Ganglioneuroblastoma of Central Nervous System|CNS Tumor|Embryonal Tumor of CNS|Ependymoma|Glioblastoma|Glioma|Glioma, Malignant|Medulloblastoma|Medulloblastoma; Unspecified Site|Medulloepithelioma|Neuroepithelial Tumor|Neoplasms|Neoplasms, Neuroepithelial|Papillary Tumor of the Pineal Region (High-grade Only)|Pediatric Brain Tumor|Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)|Pineoblastoma|Primitive Neuroectodermal Tumor|Recurrent Medulloblastoma|Refractory Brain Tumor|Neuroblastoma. CNS|Glioblastoma, IDH-mutant|Glioblastoma, IDH-wildtype|Medulloblastoma, Group 3|Medulloblastoma, Group 4|Glioma, High Grade|Neuroepithelial Tumor, High Grade|Medulloblastoma, SHH-activated and TP53 Mutant|Medulloblastoma, SHH-activated and TP53 Wildtype|Medulloblastoma, Chromosome 9q Loss|Medulloblastoma, Non-WNT Non-SHH, NOS|Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, PTCH1 Mutation|Medulloblastoma, WNT-activated|Ependymoma, Recurrent|Glioma, Recurrent High Grade|Glioma, Recurrent Malignant|Embryonal Tumor, NOS|Glioma, Diffuse Midline, H3K27M-mutant|Embryonal Tumor With Multilayered Rosettes (ETMR)|Ependymoma, NOS, WHO Grade III|Ependymoma, NOS, WHO Grade II|Medulloblastoma, G3/G4|Ependymoma, RELA Fusion Positive"	Drug: Gemcitabine|Drug: ribociclib|Drug: sonidegib|Drug: trametinib|Biological: filgrastim	Estimate the Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of each doublet by stratum|Pharmacokinetics of combination treatment: Stratum A|Pharmacokinetics of combination treatment: Stratum B|Pharmacokinetics of combination treatment: Stratum C|Response rate by stratum|Duration of objective response by stratum	St. Jude Children's Research Hospital|Novartis Pharmaceuticals	All	"1 Year to 39 Years   (Child, Adult)"	Phase 1	108	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SJDAWN|NCI-2018-00284	5-Mar-18	Feb-25	Mar-25	15-Feb-18		25-Aug-21	"St. Jude Children's Research Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT03434262
1369	NCT01576666	"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors"		Completed	No Results Available	"Dose Escalation|Safety|Preliminary Efficacy|Advanced Solid Tumors|Metastatic Breast Cancer|Advanced Pancreatic Adenocarcinoma|Metastatic Colorectal Cancer|Recurrent Glioblastoma Multiforme|Gastric Cancer|Gastroesophageal Junction Cancer|Triple Negative Metastatic Breast Cancer|Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer"	Drug: LDE225|Drug: BKM120	Dose Limiting Toxicities|Number of Patients with Adverse Events and Serious Adverse Events|Objective response rate (ORR)|Early progression rate (EPR)|Plasma pharmacokinetics (PK) parameters	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	120	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CLDE225X2114|2011-005016-28	Jul-12	Apr-15	Apr-15	12-Apr-12		19-Dec-20	"Cedars Sinai Medical Center SC, Los Angeles, California, United States|University of California San Francisco UCSF (SC), San Francisco, California, United States|H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa, Florida, United States|Dana Farber Cancer Institute Dana SC, Boston, Massachusetts, United States|Mayo Clinic - Rochester Division of Hematology, Rochester, Minnesota, United States|Duke University Medical Center Duke - Baker, Durham, North Carolina, United States|Willamette Valley Clinical Studies Williamette Valley Cancer, Eugene, Oregon, United States|Northwest Cancer Specialists Northwest Cancer, Portland, Oregon, United States|Fox Chase Cancer Center FCCC, Philadelphia, Pennsylvania, United States|Texas Oncology Midtown Texas Oncology, Dallas, Texas, United States|Sammons Cancer Center - Texas Oncology SC-2, Dallas, Texas, United States|University of Texas/MD Anderson Cancer Center SC-3, Houston, Texas, United States|University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT01576666
1370	NCT01836549	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors		Terminated	Has Results	"Anaplastic Astrocytoma|Anaplastic Ependymoma|Astrocytoma, Grade II|Ependymoma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Oligodendroglioma|Brainstem Tumors"	Drug: imetelstat sodium	Numver of Patients With Telomerase-positive Archival Tumors Who Demonstrate at Least 50% Reduction|Phase II: Stratum-specific Objective Response (CR+PR) Rate|Number of Participants With Telomerase Inhibition|Stratum-specific Progression-free Survival (PFS) (Phase II)|Number of Patients With Telomerase Expression Data by Detection of hTERT mRNA and TERC RNA Levels by qRT-PCR and Telomerase Activity by TRAP in Archival Tumor Tissue and to Explore Association of Telomerase Positivity With Objective Response and PFS|Quantitative MRI Parameters of Tumors Prior to and After Treatment With Imetelstat (Molecular Biology and Phase II Studies)	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"12 Months to 21 Years   (Child, Adult)"	Phase 2	43	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-036|NCI-2013-00482|U01CA081457	Mar-13	Apr-16	Apr-16	22-Apr-13	20-Jul-18	20-Jul-18	"Childrens Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital- Chicago, Chicago, Illinois, United States|NCI - Pediatric Oncology Branch, Bethesda, Maryland, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01836549
1371	NCT01250470	Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma		Completed	No Results Available	Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Mixed Glioma|Recurrent Brain Neoplasm	Other: Laboratory Biomarker Analysis|Drug: Montanide ISA-51/Survivin Peptide Vaccine|Biological: Sargramostim	"Incidence of toxicity, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Immune response, defined as a patient who has responded in either interferon gamma enzyme-linked immunosorbent spot (ELISPOT) or multimer assays"	Roswell Park Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	9	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 171010|NCI-2010-02042|P30CA016056	5-Sep-12	29-May-14	29-May-14	30-Nov-10		27-Feb-17	"Roswell Park Cancer Institute, Buffalo, New York, United States"		https://ClinicalTrials.gov/show/NCT01250470
1372	NCT05139277	Evaluation of the CONVIVO System		Not yet recruiting	No Results Available	Glioblastoma|Glial Tumor|Brain Metastases|Meningioma|Schwannoma|Pituitary Tumor	Diagnostic Test: CONVIVO system|Other: Conventional histologic evaluation	"Diagnostic performance of CONVIVO in discriminating between normal and abnormal tissue|Degree of concordance with histologic diagnosis|Sensitivity and Specificity of CONVIVO system|Rate of uninterpretable or non-diagnostic imaging with the CONVIVO system.|Correlation between intra-operative confocal microscopy and co-registered MRI points.|Correlation between visible yellow-light fluorescence (560 nm filter) and intraoperative confocal microscopy.|Correlation between visible blue-light fluorescence and quantitative fluorescence measurements|Extent of tumor resection|Adverse events related to the administration of fluorescein|Time to interpretation of imaging and histology|Ability to discriminate between viable tumor and pseudoprogression or ""treatment effect"" using the CONVIVO system."	"Dartmouth-Hitchcock Medical Center|Carl Zeiss Meditec, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	D20056	Dec-21	Oct-22	Nov-22	1-Dec-21		1-Dec-21			https://ClinicalTrials.gov/show/NCT05139277
1373	NCT01378481	High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Neoplasm	Drug: Vorinostat|Radiation: Stereotactic Radiosurgery|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Procedure: Therapeutic Conventional Surgery	"Maximal tolerated dose (MTD), defined as one level below at which 2 of 6 patients experience a dose-limiting toxicity (DLT)|Dose limiting toxicities (grade 3 or higher) defined by Common Toxicity Criteria (CTC) version 4.0|Overall survival (OS)|Progression free survival (PFS)|Response rate defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01139|11D.101|9018|P30CA056036	Jun-12	Aug-13	Aug-13	22-Jun-11		23-Dec-14	"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT01378481
1374	NCT01148966	Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Tumor	Drug: aminolevulinic acid|Other: laboratory biomarker analysis|Procedure: therapeutic conventional surgery	Establishment of a safe dose for oral ALA administration|Determination of which of 3 ALA doses provide optimal discrimination between normal and malignant tissue intraoperatively|Comparison of time-to-progression (TTP) and survival to that in comparable cases performed without the aid of ALA	University of Washington|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	6	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	7140|NCI-2010-00946	Jun-10	Apr-12		23-Jun-10		15-Feb-17	"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT01148966
1375	NCT03684811	A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation		"Active, not recruiting"	No Results Available	"Cohort 1a and 1b: Glioma|Cohort 1a and 1b: Glioblastoma Multiforme|Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)|Cohort 3a and 3b: Chondrosarcoma|Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma|Cohort 5a: Other Solid Tumors With IDH1 Mutations"	Drug: FT-2102|Drug: Azacitidine|Biological: Nivolumab|Drug: Gemcitabine and Cisplatin	"Number of participants with a Dose Limiting Toxicity (DLT) [Phase 1]|Doses recommended for future studies [Phase 1]|Objective response [CR+PR +MR (glioma only)] rate of FT-2102 single agent or in combination with azacitidine (glioma and chondrosarcoma), nivolumab (hepatobiliary tumors) and gemcitabine/cisplatin (intrahepatic cholangiocarcinoma) [Phase 2]|Area under the plasma concentration versus time curve (AUC) [Phase 1 and Phase 2]|Peak Plasma Concentration (Cmax) [Phase 1 and Phase 2]|Time of peak plasma concentration Tmax [Phase 1 and Phase 2]|Time for half of the drug to be absent in blood stream following dose (T 1/2) [Phase 1 and Phase 2]|Rate at which drug is removed from blood stream (CL/F) [Phase 1 and Phase 2]|Rate of drug distribution within the blood stream (Vd/F) [Phase 1 and Phase 2]|Drug level within CSF (Glioma only) [Phase 1 and Phase 2]|Overall response rate of FT-2102 as a single-agent or in combination with azacitidine or nivolumab or gemcitabine/cisplatin [Phase 1]|Incidence and severity of adverse events as assessed by CTCAE v4.0 as a single-agent or in combination with azacitidine or nivolumab or gemcitabine/cisplatin [Phase 1and 2]|Progression-Free Survival (PFS) [Phase 1b and 2]|Time to Progression (TTP) [Phase 1b and 2]|Duration of Response (DOR) [Phase 1b and 2]|Overall Survival (OS) [Phase 1b and 2]|Time to Response (TTR) [Phase 1b and 2]"	"Forma Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2102-ONC-102	1-Nov-18	1-Sep-21	1-Apr-22	26-Sep-18		29-Mar-21	"Banner MD Anderson, Gilbert, Arizona, United States|University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Northwestern University, Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Univerity of Iowa, Holden Comprehesive Cancer Institute, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Baylor Scott and White Medical Center, Temple, Texas, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Medical College of Wisconsin, Froedtert Hospital, Milwaukee, Wisconsin, United States|Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|Centre de Lutte Contre Cancre (CLCC) - Institute Bergonie, Bordeaux, France|Centre de Lutte Cancre (CLCC) - Lyon, Lyon, France|Hospital de la Timone, Marseille, France|Institut Gustave Roussy Cancer Campus, Villejuif, France|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Vall D'Hebron University Hospital, Barcelona, Spain|Cancer Research Beatson Institute, Glasgow, United Kingdom|The Royal Marsden Hospital, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT03684811
1376	NCT00042991	Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas		Completed	Has Results	Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Anaplastic Oligodendroglioma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliomatosis Cerebri|Untreated Childhood Gliosarcoma|Untreated Childhood Oligodendroglioma	Drug: gefitinib|Radiation: radiation therapy|Other: pharmacological study|Other: laboratory biomarker analysis	Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy|Median Progression-free Survival in Newly Diagnosed Brain Stem Gliomas|Median Survival in Newly Diagnosed Brain Stem Gliomas|Change in Tumor Volume Measured on Fluid Attenuated Inversion Recovery (FLAIR) Imaging at Before the Protocol Therapy Started and at Two Weeks After Completion of Radiation|Change From Baseline in Volume Enhancing at Two Weeks After Completion of Radiation|Change From Baseline in Diffusion Ratio at Two Weeks After Completion of Radiation|Change From Baseline in Perfusion Ratio at Two Weeks After Completion of Radiation|Mean Tumor to Gray Matter Ratio Measured at Baseline|Mean Tumor to White Matter Ratio Measured at Baseline|Peak Serum Concentration of Gefitinib (Cmax)|Elimination Half Life of Gefitinib (t1/2)|Clearance of Gefitinib (Cl)|Time of Maximum Clearance of Gefitinib (Tmax)|Gefitinib Area Under the Concentration Curve From 0-24 Hours (AUC)|Number of Patients With Epidermal Growth Factor Receptor (EGFR) Amplification	National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1|Phase 2	69	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03022|PBTC-007|U01CA081457	Jul-02	Feb-10	Mar-10	27-Jan-03	11-Jul-11	28-May-14	"Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00042991
1377	NCT02186509	Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Recurrent Adult Brain Tumor	Radiation: Hyperfractionated radiation therapy|Radiation: Stereotactic radiosurgery|Drug: Alisertib|Procedure: Quality-of-life assessment	Maximum Tolerated Dose (MTD) of Alisertib|Number of Participants With Complete or Partial Response|Number of Participants With Progression Free Survival at 6 Months|Number of Participants With Overall Survival at 6 Months	"Sidney Kimmel Cancer Center at Thomas Jefferson University|Millennium Pharmaceuticals, Inc.|Thomas Jefferson University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	17	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13P.528|2013-12	30-Jan-15	31-Mar-17	31-Dec-18	10-Jul-14	9-Sep-19	9-Sep-19	"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/09/NCT02186509/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02186509
1378	NCT04913337	Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies		Recruiting	No Results Available	Mesothelioma|Glioblastoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Melanoma|Pancreatic Ductal Adenocarcinoma|Gastric Cancer|Squamous Cell Carcinoma of Head and Neck|Cholangiocarcinoma|Breast Cancer|Ovarian Cancer|Cervical Cancer|Endocervical Cancer|Colorectal Cancer|Esophageal Cancer	Drug: NGM707|Drug: NGM707 plus pembrolizumab	Number of Patients with Dose-limiting Toxicities|Incidence of Adverse Events|Number of Patients with Clinically Significant Laboratory Abnormalities|Number of Patients in Expansion Cohorts with Objective Responses|Duration of Response for Patients in Expansion Cohorts|Progression-free Survival for Patients in Expansion Cohorts|Overall Survival for Patients in Combination Dose Expansion Cohorts|Observed Plasma Concentration of NGM707 (Including Cmax)|Area Under the Curve (AUC) of Plasma NGM707|Plasma Half-life (t1/2) of NGM707|Anti-drug Antibodies (ADA) Against NGM707	"NGM Biopharmaceuticals, Inc"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	179	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	707-IO-101	9-Jun-21	Feb-25	Jul-25	4-Jun-21		27-Dec-21	"Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States|START Midwest, LLC, Grand Rapids, Michigan, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|MD Anderson Cancer Center, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT04913337
1379	NCT04970615	Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models	IMAGE-3D	Recruiting	No Results Available	"Brain Tumor|Glioma|Glioblastoma|Astrocytoma|Neoplasm, Brain|Oligodendroglioma|Patient Education as Topic|Decision Making, Shared"	Device: Three-dimensional printed model	Immediate information recall|Delayed information recall|Patient experiences|Inclusion rate of patients meeting the inclusion criteria|Number of patients with completed follow-up at 1 week|Time between pre-operative consultation and immediate information recall questionnaire|Time between pre-operative consultation and delayed information recall questionnaire|Educational level|Cognitive functioning	Sümeyye Sezer|Radboud University	All	"18 Years to 100 Years   (Adult, Older Adult)"		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	2021-7292	15-May-21	15-Sep-22	15-Dec-23	21-Jul-21		21-Jul-21	"Radboud University Medical Center, Nijmegen, Gelderland, Netherlands"		https://ClinicalTrials.gov/show/NCT04970615
1380	NCT01051557	Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm	Other: Laboratory Biomarker Analysis|Drug: Perifosine|Drug: Temsirolimus|Procedure: Therapeutic Conventional Surgery	Maximum Tolerated Dose of Temsirolimus|Determine the Efficacy of Temsirolimus in Combination With Perifosine in Patients With Recurrent/Progressive Glioblastomas (GBMs) Not Taking EIAEDs as Measured by 6 Month Progression-free Survival (6mPFS) and Radiographic Response Rates. (Phase II)	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	36	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-01409|09-058|MSKCC-09058|CDR0000663573|8249|P30CA008748|U01CA069856	27-Jan-10	16-Nov-18	30-Sep-20	18-Jan-10	18-Apr-16	19-Jul-21	"Memorial Sloan Kettering Cancer Center, New York, New York, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/57/NCT01051557/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01051557
1381	NCT02502708	"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors"		Completed	No Results Available	Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma|Diffuse Intrinsic Pontine Glioma|Primary CNS Tumor	Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation|Drug: Cyclophosphamide|Drug: Etoposide	"Incidence of regimen limiting toxicities (RLTs)|Objective Response Rate|Safety and tolerability assessed by development of AEs and laboratory parameters of indoximod in combination with cyclophosphamide and etoposide.|Pharmacokinetics: Serum concentrations (Cmax/Steady State)|Safety and Tolerability of Indoximod combined with Temozolomide as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.|Progression Free Survival (PFS)|Time to Progression|Overall Survival|Safety and Feasibility of Indoximod combined with conformal radiation as assessed by incidence and severity of adverse events, dose interruptions and dose reductions."	NewLink Genetics Corporation|Lumos Pharma	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	81	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NLG2105	Oct-15	12-Dec-19	28-Feb-20	20-Jul-15		4-Jun-20	"Children's Hospital Colorado, Aurora, Colorado, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Children's Heathcare of Atlanta, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT02502708
1382	NCT01172964	A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas		Completed	No Results Available	Adult Anaplastic Astrocytoma|Recurrent Grade III Glioma|Recurrent Grade IV Glioma|Adult Anaplastic Oligodendroglioma|Adult Brain Tumor|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Tumor|Adult Anaplastic Oligoastrocytoma|Recurrent High Grade Glioma	Drug: flucytosine|Other: polymerase chain reaction|Other: immunohistochemistry staining method|Biological: gene therapy|Other: pharmacological study|Other: 3-Tesla magnetic resonance imaging|Other: laboratory biomarker analysis|Procedure: therapeutic conventional surgery|Biological: E. coli CD-expressing genetically modified neural stem cells	Determination of the safety and feasibility of intracerebral administration of genetically-modified neural stem cells (NSCs) in combination with oral 5-fluorocytosine.|Relationship between intracerebral and systemic concentrations of 5-FC and 5-FU with increasing NSC dose level|Presence of 5-FU in the brain using 19F-MRS|Assessment of development of immunogenicity against NSCs|Obtain preliminary imaging data regarding perfusion permeability parameters and imaging characteristics as shown on magnetic resonance imaging (MRI) studies due to the presence of NSCs in the brain.|Assessment of the fate of NSCs at autopsy when feasible|Assess the intracerebral distribution of NSCs using iron-labeling as a cellular tracker.	City of Hope Medical Center	All	"13 Years and older   (Child, Adult, Older Adult)"	Phase 1	15	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08002|NCI-2010-01388	Aug-10	11-Feb-15	11-Feb-15	30-Jul-10		9-Nov-17	"City of Hope, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT01172964
1383	NCT00268385	Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas		"Active, not recruiting"	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Neoplasm	Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Drug: Vorinostat	"MTD of vorinostat with temozolomide defined as the dose at which less than one-third of patients experience dose-limiting toxicity based on the CTC severity grading (Part I)|Efficacy in terms of anti-tumor activity based on clinical, radiographic, and biologic assessments (Part II)|Plasma pharmacokinetic parameters of vorinostat"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	83	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2009-00675|NABTC 04-03|CDR0000450762|NABTC04-03|NABTC-04-03|U01CA137443|U01CA062399	16-Dec-05	15-Oct-11		22-Dec-05		1-Dec-21	"University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00268385
1384	NCT02255461	"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors"		Terminated	Has Results	Childhood Choroid Plexus Tumor|Childhood Ependymoblastoma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor	Drug: palbociclib isethionate|Other: pharmacological study|Other: laboratory biomarker analysis	Maximum Tolerated Dose (MTD) of Palbociclib in Stratum I|Maximum Tolerated Dose (MTD) of Palbociclib in Stratum II|Number of Patients Who Experienced Dose Limiting Toxicities (DLTs)|Single Dose Apparent Volume of Central Compartment (Vc/F)|Single Dose Elimination Rate Constant (Ke)|Single Dose Half-life (t1/2)|Single Dose Apparent Oral Clearance (CL/F)|Single Dose Area Under the Plasma Concentration Time Curve (AUC)|Steady State Apparent Volume of Central Compartment (Vc/F)|Steady State Elimination Rate Constant (Ke)|Steady State Half-life (t1/2)|Steady State Apparent Oral Clearance (CL/F)|Steady State Area Under the Plasma Concentration Time Curve (AUC)|Number of Subjects With Objective Responses|Association Between Neutropenia and Single Dose Palbociclib AUC|Association Between Lymphopenia and Single Dose Palbociclib AUC|Association Between Leukopenia and Single Dose Palbociclib AUC	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"4 Years to 21 Years   (Child, Adult)"	Phase 1	35	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-042|U01CA081457	8-Dec-14	25-Feb-19	25-Feb-19	2-Oct-14	8-Apr-20	2-Mar-21	"Childrens Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Lurie Childrens Hospital-Chicago, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children Research Hospital, Memphis, Tennessee, United States|Texas Childrens Hospital, Houston, Texas, United States|Seattle Children Hospital, Seattle, Washington, United States"	"Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/61/NCT02255461/ICF_001.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT02255461/Prot_SAP_002.pdf"	https://ClinicalTrials.gov/show/NCT02255461
1385	NCT00045110	Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma		Completed	Has Results	Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Grade III Meningioma|Recurrent Adult Brain Tumor	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis|Other: pharmacological study	Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I|Define Maximum Tolerated Dose (MTD) of Erlotinib by Phase 1 Cohorts|6 Months Progression-free Survival in Recurrent Malignant Gliomas (Phase II)|Percent of Participants With a Grade 3 or 4 Adverse Events Phase 1|1 Year Survival - Phase II Newly Diagnosed GBM Post RT|Overall Survival Newly Diagnosed GBM Post RT|Response Rate (Complete or Partial Response) Graded Using Modified RECIST Criteria Phase II|Percent of Patients With One or More Grade 3-5 Toxicity Described Based on the CTC Severity Grading Phase II|Time of Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -|Peak Plasma Concentration Per Dose Level Phase I (on Anticonvulsants) -|Estimation of the Area Under the Curve Per Dose Level Phase I (on Anticonvulsants) -|Trough Level Per Dose Level Phase I (on Anticonvulsants) -|Peak Plasma Concentration Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -|Time to Peak Plasma Concentration for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -|Estimation of Area Under the Curve for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg-|Trough Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs - Phase 2 - Dose 150mg -|Pharmacokinetics (Plasma) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs|Pharmacokinetics (Tissue) Level for Recurrent Patients Not on Enzyme-inducing Antiepileptic Drugs	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	136	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-02490|NCI-03-C-0114|CDR0000256358|NABTC-01-03|U01CA062399	Aug-02	Dec-10	Dec-10	27-Jan-03	13-Jul-17	17-Aug-17	"University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|National Cancer Institute Neuro-Oncology Branch, Bethesda, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00045110
1386	NCT01837862	A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas		Recruiting	No Results Available	"Pilomyxoid Astrocytoma|Pilocytic Astrocytoma|Glioma, Astrocytic|Optic Nerve Glioma|Pleomorphic Xanthoastrocytoma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Gliosarcoma|Diffuse Intrinsic Pontine Glioma|DIPG|Low-grade Glioma|Brainstem Glioma"	Drug: Mebendazole|Drug: Vincristine|Drug: Carboplatin|Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan	"Maximally tolerated dose of mebendazole in combination with vincristine, carboplatin, and temozolomide|Maximally tolerated dose of mebendazole in combination with bevacizumab and irinotecan.|Survival of patients with low-grade gliomas|Survival of patients with high-grade gliomas|Frequency of cerebrospinal fluid (CSF) dissemination in pilomyxoid astrocytoma|Partial or complete response rate on MRI of patients with high-grade gliomas/pontine gliomas|Partial or complete response rate on MRI of patients with low-grade gliomas"	Julie Krystal|Janssen Pharmaceuticals|Northwell Health	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1|Phase 2	36	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCMC1411	22-Oct-13	Apr-22	Apr-23	23-Apr-13		5-Mar-21	"Cohen Children's Medical Center of New York, New Hyde Park, New York, United States"		https://ClinicalTrials.gov/show/NCT01837862
1387	NCT03787056	Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients	ONCOPRO	Recruiting	No Results Available	Cancer|Breast Cancer|Gastric Cancer|Renal Cancer|Prostate Cancer|Melanoma|Lung Cancer|Hepatocellular Cancer|Colorectal Cancer|Head and Neck Cancer|Pancreatic Cancer|Ovarian Cancer|Glioblastoma|Endometrial Cancer|Bladder Cancer|Esophageal Cancer|B-cell Lymphoma	Other: Blood draws	"ROC curve AUC regarding diagnostic accuracy of progastrin levels at baseline in cancer patients compared to non-cancer controls|Longitudinal kinetic of progastrin values during treatments, assessed by modeled kinetic parameters of interest|Nycthemeral and weekly and post-operative progastrin variations|Determinants of progastrin serum values: hepatic function|Determinants of progastrin serum values: renal function|Determinants of progastrin serum values: age|Determinants of progastrin serum values: gender|Overall survival|recurrence free survival|progression free survival|The tumor size at cancer diagnosis|Complete surgery|time to recurrence (for patients enrolled in curative intent cohorts).|time to progression (for patients enrolled in non-curative intent cohorts)|time to death (whenever it occurred)|Comparison of the initial values and of the kinetics of other serum tumor markers (CA15-3, CA 19-9, CA125, CEA, PSA, AFP) with those of progastrin"	Hospices Civils de Lyon	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	410	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	69HCL18_0369	4-Dec-18	4-Jan-28	4-Jan-28	26-Dec-18		16-Jul-21	"Service de NEURO-ONCOLOGIE du Groupement Hospitalier EST, Bron, France|Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'hôpital de la Croix-Rousse, Lyon, France|Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE de l'Hôpital E. Herriot, Lyon, France|Service d'Oto-Rhino-Laryngologie de l'Hôpital de la Croix-Rousse, Lyon, France|Service d'Urologie de l'Hôpital E. Herriot, Lyon, France|Service de Gynécologie de l'hôpital de la Croix-Rousse, Lyon, France|Service de Gynécologie du Groupement Hospitalier Est, Lyon, France|Service de Pneumologie de l'hôpital de la Croix-Rousse, Lyon, France|Service de Pneumologie du Groupement Hospitalier Est, Lyon, France|Service d'Hématologie de l'Hôpital Lyon Sud, Pierre-Bénite, France|Service d'ONCOLOGIE DIGESTIVE et HEPATOLOGIE du Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Service d'Oncologie médicale du Centre hospitalier Lyon Sud, Pierre-Bénite, France|Service d'Urologie de l'hôpital Lyon Sud, Pierre-Bénite, France|Service de Chirurgie de l'hôpital Lyon Sud, Pierre-Bénite, France|Service de Dermatologie de l'hôpital Lyon Sud, Pierre-Bénite, France|Service de Gynécologie de l'hôpital Lyon Sud, Pierre-Bénite, France|Service de Pneumologie de l'Hôpital Lyon Sud, Pierre-Bénite, France"		https://ClinicalTrials.gov/show/NCT03787056
1388	NCT02372409	Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors		Recruiting	No Results Available	Glioma|Pilocytic Astrocytoma|Anaplastic Astrocytoma|Glioblastoma|Mixed Oligoastrocytoma|Mixed Glioma|Oligodendroglioma|Optic Glioma|Astrocytoma	Device: MRI-guided laser ablation|Drug: Doxorubicin|Drug: Etoposide|Device: Dynamic contrast-enhanced (DCE) MRI|Device: Dynamic susceptibility contrast (DSC) MRI	Arm A only: Progression-free survival (PFS)|Arm A only: Overall survival (OS)|Arm B only: Progression-free survival (PFS)|Arm B only: Quality of life (QOL)|Correlation of MR imaging with peritumoral BBB disruption|Serum biomarkers of peritumoral BBB disruption|Predictive value of the peritumoral permeability score for patient outcome as measured by PFS	Washington University School of Medicine	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	12	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201502062	14-Aug-15	31-Aug-28	31-Aug-28	26-Feb-15		15-Mar-21	"Washington University School of Medicine, Saint Louis, Missouri, United States"		https://ClinicalTrials.gov/show/NCT02372409
1389	NCT03389802	Phase I Study of APX005M in Pediatric CNS Tumors		Recruiting	No Results Available	"Glioblastoma Multiforme|High-grade Astrocytoma NOS|CNS Primary Tumor, Nos|Ependymoma, NOS|Diffuse Intrinsic Pontine Gliomas (DIPG)|Medulloblastoma"	Biological: APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|Biological: APX005M treatment for newly diagnosed DIPG patients	The incidence of APX005M treatment-emergent adverse events in children with central nervous system tumors.|The maximum tolerated dose and/or the recommended phase II dose of APX005M.|The pharmacokinetics of APX005M.|The overall response rate.|The duration of response.|The progression-free survival.|The overall survival for DIPG patients.	"Pediatric Brain Tumor Consortium|St. Jude Children's Research Hospital|American Lebanese Syrian Associated Charities|The Cancer Therapy Evaluation Program of the National Cancer Institute|Apexigen, Inc.|Solving Kids' Cancer|Ty Louis Campbell Foundation|A Kids' Brain Tumor Cure Foundation"	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	45	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-051	2-Feb-18	31-Mar-22	30-Sep-22	4-Jan-18		22-Sep-21	"Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children Hospital Stanford University, Palo Alto, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Lurie Childrens Hospital-Chicago, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children Hospital Medical Center, Cincinnati, Ohio, United States|Children Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT03389802
1390	NCT02709889	Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors		Terminated	Has Results	Malignant Melanoma|Medullary Thyroid Cancer|Glioblastoma|Large-Cell Neuroendocrine Carcinoma|Neuroendocrine Prostate Cancer|High Grade Gastroenteropancreatic Neuroendocrine Carcinoma|Other Neuroendocrine Carcinoma|Other Solid Tumors	Drug: Rovalpituzumab tesirine|Drug: Dexamethasone	"Summary of Treatment-Emergent Adverse Events (TEAEs), by Dose and Neuroendocrine (NEC) or Non-NEC Disease Groups|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS)|Serum Concentrations of Rovalpituzumab Tesirine Over Time|Number of Participants With Anti-therapeutic Antibodies (ATA)"	AbbVie	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 1|Phase 2	200	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRX001-006	23-Sep-16	27-Aug-19	27-Aug-19	16-Mar-16	19-Oct-20	19-Oct-20	"Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert, Arizona, United States|Mayo Clinic - Scottsdale /ID# 155419, Scottsdale, Arizona, United States|University of California, Los Angeles /ID# 155429, Los Angeles, California, United States|Univ California, San Francisco /ID# 155409, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 155428, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 155415, Aurora, Colorado, United States|Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420, Denver, Colorado, United States|University of Florida - Archer /ID# 155414, Gainesville, Florida, United States|Moffitt Cancer Center /ID# 170220, Tampa, Florida, United States|Emory University Hospital /ID# 155417, Atlanta, Georgia, United States|University of Kentucky Chandler Medical Center /ID# 155423, Lexington, Kentucky, United States|Johns Hopkins University /ID# 155412, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 155411, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 171044, Boston, Massachusetts, United States|Mayo Clinic - Rochester /ID# 155416, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 155425, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick, New Jersey, United States|University of New Mexico /ID# 205054, Albuquerque, New Mexico, United States|Roswell Park Comprehensive Cancer Center /ID# 162015, Buffalo, New York, United States|Weill Cornell Medical College /ID# 155418, New York, New York, United States|Duke University Medical Center /ID# 155421, Durham, North Carolina, United States|Univ Hosp Cleveland /ID# 155410, Cleveland, Ohio, United States|Oregon Health and Science University /ID# 162011, Portland, Oregon, United States|Greenville Hospital System /ID# 155427, Greenville, South Carolina, United States|Mary Crowley Cancer Research /ID# 162014, Dallas, Texas, United States|Texas Oncology - Forth Worth /ID# 162045, Fort Worth, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 155413, Houston, Texas, United States|University of Utah /ID# 155426, Salt Lake City, Utah, United States|Virginia Cancer Specialists /ID# 162006, Fairfax, Virginia, United States|Northwest Cancer Specialists, P.C. /ID# 155431, Vancouver, Washington, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/89/NCT02709889/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT02709889
1391	NCT01392209	Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma		Completed	No Results Available	Brain Cancer|MALIGNANT GLIOMA|Glioblastoma|Anaplastic Astrocytoma (AA)|Anaplastic Oligodendroglioma (AO)|Anaplastic Oligo-astrocytoma (AOA)|Anaplastic Mixed Gliomas|Malignant Glioma NOS	Other: Bevacizumab & Stereotactic Radiotherapy	To establish the maximum tolerated dose (MTD)|Response rate|Median progression free survival|6 month progression-free survival rate|Median overall survival|Use of tractography to predict routes of progression in gliomas (MSKCC only)|Correlation of VEGF and VEGFR IHC and related pathways (MSKCC only) and MGMT promoter methylation with efficacy	"Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University|University of California, San Francisco"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-057	8-Jul-11	15-Nov-19	15-Nov-19	12-Jul-11		22-Nov-19	"University of California San Francisco, San Francisco, California, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01392209
1392	NCT01884740	Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22		Recruiting	No Results Available	Glioblastoma Multiforme|Fibrillary Astrocytoma of Brain|Glioma of Brainstem|Anaplastic Astrocytoma|Pilomyxoid Astrocytoma|Mixed Oligodendroglioma-Astrocytoma|Brain Stem Glioma|Diffuse Intrinsic Pontine Glioma	Drug: SIACI of Erbitux and Bevacizumab	Composite Overall Response Rate (CORR)|Number of treatment emergent adverse events|Median Progression-free survival (PFS)|Median Overall Survival (OS)	Weill Medical College of Cornell University	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1|Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1202012214	Jun-13	Jan-25	Jan-25	24-Jun-13		20-Apr-21	"Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01884740
1393	NCT02457845	HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors		"Active, not recruiting"	No Results Available	"Supratentorial Neoplasms, Malignant|Malignant Glioma|Glioblastoma|Anaplastic Astrocytoma|PNET|Cerebral Primitive Neuroectodermal Tumor|Embryonal Tumor"	Biological: G207	Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events|Immunologic Response|Virologic Shedding|Progression Free Survival|Overall Survival|Change in Performance (Ability to Perform Normal Activities)|Quality of Life (optional)	University of Alabama at Birmingham	All	"3 Years to 18 Years   (Child, Adult)"	Phase 1	12	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UAB 1472|R01FD005379	May-16	Jun-20	Mar-22	29-May-15		8-Jul-21	"Children's of Alabama, Birmingham, Alabama, United States|Nationwide Children's Hospital, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02457845
1394	NCT05139056	Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas		Not yet recruiting	No Results Available	Recurrent Anaplastic Astrocytoma|Recurrent Anaplastic Oligoastrocytoma|Recurrent Anaplastic Oligodendroglioma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma|Recurrent WHO Grade II Glioma|Recurrent WHO Grade III Glioma	Biological: Neural Stem Cells-expressing CRAd-S-pk7|Procedure: Resection	Incidence of adverse events|Neural Stem Cells-expressing CRAd-S-pk7 (NSC-CRAd-S-pk7) immunogenicity|NSC-CRAd-S-pk7 migration within the brain|NSC-CRAd-S-pk7 migration outside the brain|Disease response|Progression-free survival (PFS)|Overall survival (OS)|Changes in HSPG and survivin expression|Changes in immune cell populations|Changes in tumor growth	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	19498|NCI-2021-05885|P30CA033572	17-Dec-21	30-Jun-23	30-Jun-23	1-Dec-21		1-Dec-21	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT05139056
1395	NCT01975116	p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors		Completed	No Results Available	"Teratoid Tumor, Atypical|Choroid Plexus Neoplasms|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Brainstem Tumors|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Medulloblastoma|Neuroectodermal Tumor, Primitive"	Drug: azurin-derived cell-penetrating peptide p28	Number of patients experiencing dose-limiting toxicities (DLT) defined as any adverse event or grade 3 or 4 toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Percentage of patients whose tumors are p53 positive (greater than or equal to 10% of tumor cells staining for p53)|Type and frequency of p53 mutations present in the tumor specimens analyzed|Change in tumor size	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	18	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC-041|NCI-2013-01710|U01CA081457	Aug-13	Apr-15	Apr-15	3-Nov-13		7-Aug-17	"Children's Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01975116
1396	NCT01806675	18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy		Completed	Has Results	"Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Male Breast Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Hypopharyngeal Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Laryngeal Cancer|Recurrent Lip and Oral Cavity Cancer|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Nasopharyngeal Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Oropharyngeal Cancer|Recurrent Pancreatic Cancer|Recurrent Paranasal Sinus and Nasal Cavity Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVA Salivary Gland Cancer|Stage IVB Colon Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer|Tongue Cancer|Unspecified Adult Solid Tumor, Protocol Specific"	Drug: 18F-fludeoxyglucose (18F-FDG)|Drug: 18F-FPPRGD2	Change From Baseline in Maximum Standard Uptake Values (SUVmax)|Response Assessment by RANO Criteria|Change in Tumor Size|Tumor Response Rate by EORTC Criteria|Progression-free Survival (PFS)	Sanjiv Sam Gambhir|National Cancer Institute (NCI)|Stanford University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	25	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IRB-25970|NCI-2013-00535|VARIMG0002	4-Mar-13	7-Dec-16	Apr-19	7-Mar-13	6-Sep-19	3-Oct-19	"Stanford University, School of Medicine, Stanford, California, United States"		https://ClinicalTrials.gov/show/NCT01806675
1397	NCT00095940	Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors		Completed	Has Results	Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Ependymoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliosarcoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Oligodendroglioma	Drug: lapatinib ditosylate|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: positron emission tomography|Procedure: magnetic resonance imaging	Relative Phosphorylation of ERBB2 (Molecular Biology Objective)|Number of Participants With a Sustained Objective Response (Complete or Partial Response) (Phase II Objective)|Tumor to Plasma Lapatinib Concentration (Molecular Biology Objective)|Maximum Concentration of Lapatinib in Plasma (Phase II Objective)|Number of Participants With Tumors Expressing Total ERBB2|Number of Participants With Tumors Expressing Phosphorylated ERBB2 (Phase II Objective)	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1|Phase 2	52	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03007|PBTC-016|U01CA081457	Oct-04	Jul-10	Jul-10	9-Nov-04	6-Feb-12	23-May-14	"Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00095940
1398	NCT02192359	Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas		Recruiting	No Results Available	Recurrent Anaplastic Astrocytoma|Recurrent Anaplastic Oligoastrocytoma|Recurrent Anaplastic Oligodendroglioma|Recurrent Glioblastoma|Recurrent Gliosarcoma|Recurrent Malignant Glioma|Recurrent WHO Grade III Glioma	Biological: Carboxylesterase-expressing Allogeneic Neural Stem Cells|Drug: Irinotecan|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study	"Incidence of dose limiting toxicities (DLTs) graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of all attributable toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Pharmacokinetics parameters, including maximum concentration and area under the curve of irinotecan and SN-38 in dialysate and plasma|Development of neural stem cells (NSC) immunogenicity after first and repeat exposures|Clinical benefit, defined by tumor response based on magnetic resonance imaging (MRI) results|Fate of the neural stem cells (NSCs), defined by NSC persistence"	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years to 69 Years   (Adult, Older Adult)"	Phase 1	53	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14108|NCI-2014-01463|P30CA033572|R01CA198076	7-Mar-16	31-Dec-21	31-Dec-21	16-Jul-14		16-Dec-21	"City of Hope Medical Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT02192359
1399	NCT02967380	"Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases"		Terminated	No Results Available	Adult Anaplastic (Malignant) Meningioma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Choroid Plexus Neoplasm|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Primary Melanocytic Lesion of Meninges|Adult Supratentorial Primitive Neuroectodermal Tumor|Malignant Adult Intracranial Hemangiopericytoma|Metastatic Malignant Neoplasm in the Brain|Multiple Sclerosis|Recurrent Adult Brain Neoplasm	Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Drug: Gadobenate Dimeglumine|Drug: Gadobutrol|Radiation: Gadopentetate Dimeglumine	Agreement of using Magnevist® or Multihance versus Gadavist® on glioma grading	University of Southern California|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	14	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	0S-11-6|NCI-2014-01852|D1 2010-10|HS-11-00363|P30CA014089	14-Dec-11	14-Oct-14	14-Oct-15	18-Nov-16		27-Mar-17	"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT02967380
1400	NCT01234740	Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases		Completed	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Recurrent Adult Brain Tumor|Tumors Metastatic to Brain|Adult Anaplastic Oligoastrocytoma	Drug: bafetinib|Procedure: microdialysis|Other: pharmacological study|Other: liquid chromatography|Other: mass spectrometry|Other: laboratory biomarker analysis|Genetic: protein expression analysis|Genetic: western blotting|Other: immunohistochemistry staining method|Procedure: therapeutic conventional surgery	Area-under-the-concentration-time-curve (AUC) of bafetinib in dialysate|Peak concentration (Cmax) of bafetinib in dialysate|AUC of bafetinib in plasma|Cmax of bafetinib in plasma|Determination of adverse events associated with bafetinib in patient with recurrent malignant brain tumors|Response rate in patients with malignant brain tumors treated with bafetinib|Progression-free survival in patients with malignant brain tumors treated with bafetinib|Overall survival in patients with malignant brain tumors treated with bafetinib|Assessment for expression of Lyn and Fyn kinases and phosphorylation status in pre-treatment tumor samples.	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	7	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10134|NCI-2010-01963	Dec-10	Mar-13	Mar-13	4-Nov-10		17-Apr-18	"City of Hope Medical Center, Duarte, California, United States|South Pasadena Cancer Center, South Pasadena, California, United States"		https://ClinicalTrials.gov/show/NCT01234740
1401	NCT01165632	Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma		"Active, not recruiting"	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma	Procedure: biopsy|Procedure: computed tomography|Procedure: therapeutic conventional surgery|Radiation: radiation therapy treatment planning/simulation|Radiation: radiation therapy|Procedure: magnetic resonance imaging|Procedure: positron emission tomography|Drug: fluorine F 18 fluorodopa	"18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies|18F- FDOPA-PET metabolic imaging information|Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies|With and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information|18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies"	Mayo Clinic|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Early Phase 1	24	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MC1078|NCI-2010-01607|10-001904	26-Jul-10	1-Nov-13	30-Dec-21	20-Jul-10		8-Apr-21	"Mayo Clinic, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT01165632
1402	NCT01119599	"RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma"		Completed	No Results Available	Acoustic Schwannoma|Adult Anaplastic (Malignant) Meningioma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Brain Stem Glioma|Adult Choroid Plexus Neoplasm|Adult Craniopharyngioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Primary Melanocytic Lesion of Meninges|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma|Adult Supratentorial Primitive Neuroectodermal Tumor|Malignant Adult Intracranial Hemangiopericytoma	Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Gamma-Secretase Inhibitor RO4929097|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Temozolomide|Procedure: Therapeutic Conventional Surgery	Maximum-tolerated dose defined as the highest dose studied for which the incidence of dose limiting toxicity is less than 33% using National Cancer Institute Common Toxicity Criteria|Changes in MRI parameters|Percent changes in serum YKL-40 levels and hair follicle HES1 levels|Pharmacokinetic (PK) parameters of gamma-secretase/Notch signalling pathway inhibitor RO4929097	National Cancer Institute (NCI)	All	"19 Years and older   (Adult, Older Adult)"	Phase 1	22	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-01410|CDR0000672641|09-177|8556|P30CA008748|U01CA069856	May-10	Jun-13		7-May-10		29-Sep-15	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT01119599
1403	NCT01234805	Yoga Therapy in Treating Patients With Malignant Brain Tumors		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Meningioma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Choroid Plexus Tumor|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Meningeal Hemangiopericytoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Recurrent Adult Brain Tumor	Procedure: yoga therapy|Other: questionnaire administration|Procedure: quality-of-life assessment	"Estimate the participation rate, accrual, adherence, and retention to a yoga trial in patients with malignant brain tumors|Self-reported fatigue|Depressive symptoms|Distress|Health-related quality of life|Preliminary estimates of the efficacy of a yoga intervention in patients with malignant brain tumors on the outcomes of fatigue, distress, and cognitive function|Standardize the cancer-specific yoga protocol for use with brain tumor patients"	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	9	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB00015038|NCI-2010-02044|CCCWFU 98410	Dec-10	Sep-12	Sep-12	4-Nov-10		3-Jul-18	"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01234805
1404	NCT00430079	Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymoma	Drug: etanidazole|Procedure: conventional surgery|Other: pharmacological study|Other: laboratory biomarker analysis	"Time to local recurrence|Time to death|Presence and pattern of EF5 binding in newly diagnosed brain masses by IHC analyses|Levels of EF5 binding within histological subtypes of SMG|Relationship between hypoxia and clinical outcomes (i.e., time to local recurrence and survival)|Association between EF5 binding and Eppendorf needle electrode measurements in brain masses"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	48	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NCI-2012-02419|UPCC# 1301|R21CA093007|CDR0000068962	Jul-01	Sep-07		1-Feb-07		16-Jan-13	"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00430079
1405	NCT01131234	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors		Completed	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Solid Neoplasm|Male Breast Carcinoma|Recurrent Adult Brain Neoplasm|Recurrent Breast Carcinoma|Recurrent Colon Carcinoma|Recurrent Melanoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Carcinoma|Recurrent Rectal Carcinoma|Recurrent Renal Cell Carcinoma|Stage III Pancreatic Cancer|Stage III Renal Cell Cancer|Stage IIIA Colon Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Ovarian Germ Cell Tumor|Stage IIIA Rectal Cancer|Stage IIIA Skin Melanoma|Stage IIIB Breast Cancer|Stage IIIB Colon Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Ovarian Germ Cell Tumor|Stage IIIB Rectal Cancer|Stage IIIB Skin Melanoma|Stage IIIC Breast Cancer|Stage IIIC Colon Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Ovarian Germ Cell Tumor|Stage IIIC Rectal Cancer|Stage IIIC Skin Melanoma|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer	Drug: Gamma-Secretase Inhibitor RO4929097|Drug: Cediranib Maleate|Other: Pharmacological Study|Other: Laboratory Biomarker Analysis	Recommended phase II dose of gamma-secretase inhibitor RO4929097 defined as the dose level at which < 1/6 patients experience dose-limiting toxicity as graded by the National Cancer Institute (NCI) CTCAE version 4.0|Incidence of adverse events as graded by the NCI CTCAE version 4.0|PK profiles for both drugs|PD effects of gamma-secretase inhibitor RO4929097 when administered alone and in combined with cediranib maleate|Preliminary antitumor efficacy	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-01428|CDR0000673867|PJC-004|8503|U01CA132123	May-10	Sep-14	Sep-14	26-May-10		23-Dec-14	"Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT01131234
1406	NCT00110032	Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors		Terminated	No Results Available	Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Central Nervous System Germ Cell Tumor|Adult Choroid Plexus Tumor|Adult Craniopharyngioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Grade III Meningioma|Adult Medulloblastoma|Adult Meningeal Hemangiopericytoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Subependymoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Meningeal Melanocytoma	Drug: EF5|Procedure: conventional surgery|Procedure: positron emission tomography|Radiation: fluorine F 18 EF5|Other: pharmacological study	"Safety of F-18-EF5 based on the NCI CTCAE version 3.0|Pharmacokinetics of radioactively labeled [F-18]-EF5|Extent of hypoxia, determined by [F-18]-EF5 PET imaging|IHC analysis of cold EF5|Progression-free survival"	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	46	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NCI-2012-02651|UPCC 01304|CDR0000423313	Jun-05	Jan-07		4-May-05		16-Jan-13	"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00110032
1407	NCT02223052	Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies		Completed	No Results Available	Hematological Neoplasms|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndromes|Neoplasms|Melanoma|Breast Cancer|Metastatic Breast Cancer|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Renal Cell Carcinoma|Glioblastoma Multiforme|Osteosarcoma|Sarcoma|Thyroid Cancer|Genitourinary	Drug: CC-486|Drug: Vidaza	Pharmacokinetics Cmax - Stage I (Bioequivalence)|Pharmacokinetics Tmax - Stage I (Bioequivalence)|Pharmacokinetics AUC-t - Stage I (Bioequivalence)|Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)|Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)|Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)|Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)|Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)|Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)|Adverse Events (AEs)	Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	89	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-486-CAGEN-001	27-Oct-14	11-Jun-18	18-Dec-18	22-Aug-14		12-May-20	"Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of Iowa, Iowa City, Iowa, United States|Henry Ford Health System, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States|The Methodist Hospital Research Institute l, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02223052
1408	NCT00030498	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction		Completed	No Results Available	"Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Primary Hepatocellular Carcinoma|Adult Subependymoma|Advanced Adult Primary Liver Cancer|Advanced Malignant Mesothelioma|Male Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Bladder Cancer|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Malignant Mesothelioma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage II Esophageal Cancer|Stage II Pancreatic Cancer|Stage III Esophageal Cancer|Stage III Pancreatic Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Bladder Cancer|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary"	Drug: erlotinib hydrochloride|Other: laboratory biomarker analysis	Maximum tolerated dose (MTD) of OSI-774 determined by dose-limiting toxicities	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	75	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01868|CALGB-60101|U10CA031946|CDR0000069170	Dec-01	Jul-07		27-Jan-03		16-Jan-13	"Cancer and Leukemia Group B, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00030498
1409	NCT03958240	Deciphering Mechanisms Underlying Cancer Immunogenicity	DECIDE	Recruiting	No Results Available	Head and Neck Cancer|Ovarian Cancer|Cervical Cancer|Cervical Intraepithelial Neoplasia 3|Glioblastoma Multiforme of Brain Stem|Non Small Cell Lung Cancer|Anal Cancer	"Other: Blood samples, tumor biopsy specimens and ascites samples will be collected."	Percentage of CD4 and CD8 T cells expressing PD-1|Rate of patients presenting a high Trm (Tissue resident memory) infiltrate in tumor samples	Institut Claudius Regaud	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	900	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	19 GENE 13	17-Jan-20	Sep-29	Sep-29	21-May-19		9-Dec-21	"Hopital Larrey, Toulouse, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France"		https://ClinicalTrials.gov/show/NCT03958240
1410	NCT01353625	"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies."		Completed	No Results Available	Glioblastoma Multiforme|Squamous Cell Carcinoma of Head and Neck|Prostate Cancer|Ewing's Osteosarcoma|Chronic Lymphocytic Leukemia|Neoplasm Metastasis	Drug: CC-115	Dose-Limiting Toxicity|Non-Tolerated Dose|Maximum Tolerated Dose|Maximum Observed Concentration in Plasma of CC-115|Area Under the Concentration-Time Curve for CC-115|Time to Maximum Concentration of CC-115|Terminal Half-Life for CC-115|Apparent Total Body Clearance of CC-115|Apparent Volume of Distribution of CC-115|Accumulation Index of CC-115|Pharmacodynamics|Anti-Tumor Efficacy	Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	118	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-115-ST-001	25-Apr-11	12-Mar-21	12-Mar-21	13-May-11		5-Oct-21	"Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center - New Center One, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Gustave Roussy, Villejuif Cedex, France|Uniklinik Koln, Koeln, Germany|Universitatsklinikum Wurzburg, Würzburg, Germany|Hospital Val d'Hebron, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital de Donosti, San Sebastián (Guipuzcoa), Spain|Hospital Virgen del Rocio, Sevilla, Spain"		https://ClinicalTrials.gov/show/NCT01353625
1411	NCT04604158	Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients		Recruiting	No Results Available	Cancer|Cancer Metastatic|Neoplasms|Breast Cancer|Lung Cancer|Glioblastoma|Prostate Cancer|Gynecologic Cancer|Colorectal Cancer|Sarcoma|Kidney Cancer|Bladder Cancer|Lymphoma|Leukemia|Head and Neck Cancer|Pancreas Cancer|Multiple Myeloma|Anxiety|Social Isolation|Stress|Loneliness|Melanoma|Uterine Cancer	Behavioral: Elly Mobile Phone Application	Absolute change in patient-reported anxiety scores at Day 30 compared with baseline.|Absolute change in patient-reported anxiety scores at Day 14 compared with baseline.|Absolute change in patient-reported anxiety scores at Day 60 compared with baseline.|Absolute change in patient-reported anxiety scores at Day 90 compared with baseline.|Absolute change in patient-reported anxiety scores at Day 120 compared with baseline.|Absolute change in patient-reported anxiety scores at Day 150 compared with baseline.|Absolute change in patient-reported anxiety scores at Day 180 compared with baseline.|Absolute change in patient-reported depression scores at Day 30 compared with baseline.|Absolute change in patient-reported depression scores at Day 60 compared with baseline.|Absolute change in patient-reported depression scores at Day 90 compared with baseline.|Absolute change in patient-reported depression scores at Day 120 compared with baseline.|Absolute change in patient-reported depression scores at Day 150 compared with baseline.|Absolute change in patient-reported depression scores at Day 180 compared with baseline.|Absolute change in patient-reported loneliness scores at Day 30 compared with baseline.|Absolute change in patient-reported loneliness scores at Day 60 compared with baseline.|Absolute change in patient-reported loneliness scores at Day 90 compared with baseline.|Absolute change in patient-reported loneliness scores at Day 120 compared with baseline.|Absolute change in patient-reported loneliness scores at Day 150 compared with baseline.|Absolute change in patient-reported loneliness scores at Day 180 compared with baseline.|Absolute change in patient-reported social isolation scores at Day 30 compared with baseline.|Absolute change in patient-reported social isolation scores at Day 60 compared with baseline.|Absolute change in patient-reported social isolation scores at Day 90 compared with baseline.|Absolute change in patient-reported social isolation scores at Day 120 compared with baseline.|Absolute change in patient-reported social isolation scores at Day 150 compared with baseline.|Absolute change in patient-reported social isolation scores at Day 180 compared with baseline.|Frequency of Elly app use|Elly app login amount|Duration of Elly app use|Participant's experience with Elly app at Day 14-30.|Participant's experience with Elly app at Day 180-360.	Gillian Gresham|Cedars-Sinai Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	100	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IIT2020-13-GRESHAM-ELLY	2-Dec-20	8-Jul-22	8-Jul-22	27-Oct-20		9-Dec-21	"Cedars Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT04604158
1412	NCT01392352	HYPAZ: Hypertension Induced by Pazopanib	HYPAZ	Terminated	No Results Available	Renal Cell Carcinoma|Soft Tissue Sarcoma|Glioblastoma|Ovarian Cancer|Cervical Cancer|Breast Cancer|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Pancreatic Cancer|Melanoma|Gastrointestinal Cancer	Drug: Pazopanib	Change in endothelial dependent function|Change in endothelial independent function	Cambridge University Hospitals NHS Foundation Trust|University of Cambridge	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	31	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	A091962|2010-021613-23	Apr-11	Sep-14	Sep-15	12-Jul-11		13-Feb-20	"Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom"		https://ClinicalTrials.gov/show/NCT01392352
1413	NCT00879437	"Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma"		Completed	Has Results	Glial Cell Tumors|Malignant Gliomas|Glioblastoma Multiforme|Anaplastic Astrocytoma|Gliomatosis Cerebri|Gliosarcoma|Brainstem Glioma|Diffuse Intrinsic Pontine Glioma	Drug: Valproic acid|Drug: Bevacizumab|Radiation: Radiation therapy	"1-year Event Free Survival (EFS)|Percentage of Participants With Grade 3 Thrombocytopenia Assessed by CTCAE v3.0 During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Neutropenia Assessed by CTCAE v3.0 During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Lymphopenia Assessed by CTCAE v3.0 During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Leukopenia, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 Somnolence, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 Fatigue, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Weight Gain, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 Weight Gain, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 Hypoglycemia, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Lipase and Amylase Elevation, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 Pancreatitis, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Dehydration, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 4 Radiation Necrosis, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 Abdominal Pain, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 2 AST Elevation, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 1 Cystitis, Assessed by CTCAE v3.0, During Concurrent Valproic Acid and Radiation Treatment|Percentage of Participants With Grade 3 Thrombocytopenia, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Neutropenia, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Lymphopenia, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Intratumoral/Intracranial Hemorrhage, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Fatigue, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Fatigue, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Somonolence, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Somonolence, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Weight Gain, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Weight Gain, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Hypertension, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Grade 2 Hypertension, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Hypoglycemia, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Subacute Bone Infarction, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 3 Cellulitis, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Proteinuria, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 4 Deep Vein Thrombosis, Pulmonary Embolism, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Ocular Keratitis, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage Participants With Grade 2 Urinary Tract Infection, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Cough, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Anorexia, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Hypoalbuminemia, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Percentage of Participants With Grade 2 Abdominal Pain, Assessed by CTCAE v3.0, During Maintenance Therapy of Valproic Acid and Bevacizumab|Median Event Free Survival (EFS)|Median Overall Survival (OS)|Partial Response in Diffuse Intrinsic Pontine Glioma|Partial Response in High-grade Gliomas|Complete Response in High-grade Gliomas"	"Baylor College of Medicine|Cook Children's Medical Center|University of Oklahoma|University of Texas, Southwestern Medical Center at Dallas|The University of Texas Health Science Center at San Antonio|M.D. Anderson Cancer Center"	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	38	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	24549	1-Sep-09	30-Aug-15	2-Oct-17	10-Apr-09	21-Jul-21	21-Jul-21	"University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Children's Medical Center Dallas, Center for Cancer and Blood Disorders, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States"	"Study Protocol, Statistical Analysis Plan, and Informed Consent Form, https://ClinicalTrials.gov/ProvidedDocs/37/NCT00879437/Prot_SAP_ICF_000.pdf"	https://ClinicalTrials.gov/show/NCT00879437
1414	NCT04388033	Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients.		Recruiting	No Results Available	"Glioblastoma|Glioma|Neoplasms, Neuroepithelial|Neuroectodermal Tumors|Neoplasms|Neoplasms, Nerve Tissue|Vaccines|Immunologic Factors"	Biological: Dendritic Cell/Tumor Fusion Vaccine|Drug: Interleukin-12|Drug: Temozolomide	Adverse Events (AE) / Serious Adverse Events (SAE)|Progression free survival (PFS) at 6 months|Immunological Assays|Overall survival (OS) time	"Second Affiliated Hospital, School of Medicine, Zhejiang University|Hangzhou Medical Biotechnology Co., Ltd|CyTIX.Inc"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDKZJU-DCf12-2019408	Dec-20	Dec-22	Dec-23	14-May-20		9-Jun-20	"The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China"		https://ClinicalTrials.gov/show/NCT04388033
1415	NCT02576665	"A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)"		Terminated	No Results Available	Colorectal Cancer|Triple Negative Breast Cancer|Pancreatic Cancer|Non-Small Cell Lung Cancer|Head and Neck Cancer|Ovarian Cancer|Lymphoma|Sarcoma|Bladder Cancer|Melanoma|IDH1 Mutated Solid Tumors|IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)	Biological: Toca 511|Drug: Toca FC	Changes from baseline in immune activity in tumor and peripheral blood	Tocagen Inc.	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1	21	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Tg 511-15-02	Jul-16	May-19	20-Dec-19	15-Oct-15		7-Feb-20	"Sarah Cannon Research Institute, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02576665
1416	NCT04978727	"A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma"		Not yet recruiting	No Results Available	Medulloblastoma|Glioblastoma Multiforme|Anaplastic Astrocytoma|High-grade Astrocytoma NOS|Anaplastic Oligodendroglioma|Anaplastic Ependymoma|Ependymoma|Diffuse Intrinsic Pontine Glioma	"Biological: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years|Biological: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years|Biological: SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years"	Percentage of Subjects with Regimen-Limiting Toxicity (RLT)|Percentage of Subjects with Pseudoprogression Related Regimen-Limiting Toxicity|Differences in MR permeability and MR perfusion parameters for patients with true progression vs. pseudoprogression	Pediatric Brain Tumor Consortium|Roswell Park Cancer Institute	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	35	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PBTC 060	1-Jan-22	1-Jul-25	1-Jan-28	27-Jul-21		6-Aug-21			https://ClinicalTrials.gov/show/NCT04978727
1417	NCT02611024	Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors		Recruiting	No Results Available	Advanced Solid Tumors|Glioblastoma|Soft Tissue Sarcoma (Excluding GIST)|Endometrial Carcinoma|Epithelial Ovarian Carcinoma|Mesothelioma|Gastroenteropancreatic Neuroendocrine Tumor|SCLC|Gastric Carcinoma|Pancreatic Adenocarcinoma|Colorectal Carcinoma|Neuroendocrine Tumors	Drug: Lurbinectedin|Drug: Irinotecan	Maximum Tolerated Dose (MTD)|Recommended Dose (RD)|Response Rate|Safety evaluation|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Volume of distribution based on the terminal half-life (Vz)|Volume of distribution at steady state (Vss)|Clearance (CL)|Half-life (t1/2)|Duration of response|Progression-free Survival|Overall Survival	PharmaMar	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	320	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PM1183-A-014-15	6-May-16	Nov-23	Nov-23	20-Nov-15		2-Dec-21	"Massachusetts General Hospital -, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Virgen Del Rocio, Sevilla, Spain"		https://ClinicalTrials.gov/show/NCT02611024
1418	NCT03975829	Pediatric Long-Term Follow-up and Rollover Study		Recruiting	No Results Available	"Diffuse Astrocytoma|Anaplastic Astrocytoma|Astrocytoma|Oligodendroglioma, Childhood|Anaplastic Oligodendroglioma|Glioblastoma|Pilocytic Astrocytoma|Giant Cell Astrocytoma|Pleomorphic Xanthoastrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Angiocentric Glioma|Chordoid Glioma of Third Ventricle|Gangliocytoma|Ganglioglioma|Anaplastic Ganglioglioma|Dysplastic Gangliocytoma of Cerebrellum|Desmoplastic Infantile Astrocytoma and Ganglioglioma|Papillary Glioneuronal Tumor|Rosette-forming Glioneurona Tumor|Central Neurocytoma|Extraventricular Neurocytoma|Cerebellar Liponeurocytoma|Neurofibromatosis Type 1"	Drug: dabrafenib|Drug: trametinib	Number of participants with Adverse Events and Serious Adverse Events (SAEs)|Percentage of participants with height (measured by cm or in) changes over time|Percentage of participants with weight (measured by kg or lb) changes over time|Percentage of participants with skeletal maturation (measured by bone age on x-ray or MRI) changes over time|Percentage of participants with sexual maturation (measured by tanner staging criteria) changes over time|Percentage of participants with cardiac function (measured by ECG) changes over time|Clinical Benefit (measured by CT/MRI)	Novartis Pharmaceuticals|Novartis	All	"1 Year and older   (Child, Adult, Older Adult)"	Phase 4	250	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDRB436G2401|2018-004459-19	4-Nov-19	29-May-26	29-May-26	5-Jun-19		19-Apr-21	"Phoenix Childrens Hospital, Phoenix, Arizona, United States|Children s National Hospital CQTI571A2306, Washington, District of Columbia, United States|Johns Hopkins University IDS Pharmacy, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Rennes, Bretagne, France|Novartis Investigative Site, Marseille Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT03975829
1419	NCT03043391	Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children		"Active, not recruiting"	No Results Available	Malignant Glioma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Glioblastoma|Gliosarcoma|Atypical Teratoid/Rhabdoid Tumor of Brain|Medulloblastoma|Ependymoma|Pleomorphic Xanthoastrocytoma of Brain|Embryonal Tumor of Brain	Biological: Polio/Rhinovirus Recombinant (PVSRIPO)	Percentage of participants with unacceptable toxicity|24-month overall survival	"Istari Oncology, Inc.|Solving Kids' Cancer|The Andrew McDonough B+ Foundation|Duke University"	All	"12 Years to 21 Years   (Child, Adult)"	Phase 1	12	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00071228	5-Dec-17	30-Dec-21	1-Mar-22	6-Feb-17		13-Jul-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT03043391
1420	NCT05131815	The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors		Not yet recruiting	No Results Available	"Cancer|Cancer Metastatic|Neoplasms|Breast Cancer|Lung Cancer|Thyroid Cancer|Lymphoma|Lymphoma, Non-Hodgkin|Hodgkin Lymphoma|Leukemia|Sarcoma|Skin Cancer|Bone Cancer|Gynecologic Cancer|Pancreas Cancer|Multiple Myeloma|Colorectal Cancer|Gastrointestinal Cancer|Prostate Cancer|Glioblastoma|Brain Cancer|Head and Neck Cancer"	Behavioral: Virtual group based physical activity (BurnAlong) and Social Media Discussion Board	Feasibility of BurnAlong|Resting Heart Rate|Sleep Duration|Sleep Quality|Patient-Reported Outcomes Measurement Information System (PROMIS)-29|Post-Traumatic Growth Inventory (PTGI)|Health Action Process Approach Inventory (HAPA Inventory)|Patient-Reported Outcomes Measurement Information System (PROMIS) Social Support|Adolescent and Young Adult Psycho-Oncology Screening Tool (AYA-POST)	Cedars-Sinai Medical Center|Walter Reed National Military Medical Center	All	"15 Years to 25 Years   (Child, Adult)"	Not Applicable	20	Other|U.S. Fed	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IIT2020-24-SHIRAZIP-BURN	11-Jan-22	10-Jan-23	9-Jan-24	23-Nov-21		23-Nov-21			https://ClinicalTrials.gov/show/NCT05131815
1421	NCT03576612	"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas"	GMCI	"Active, not recruiting"	No Results Available	"Glioma, Malignant"	Biological: AdV-tk|Drug: Valacyclovir|Radiation: Radiation|Drug: Temozolomide|Biological: Nivolumab|Other: Laboratory Biomarker Analysis	Incidence of adverse events|Overall survival (death)|Progression-free survival (progression)|Immune profiling - Tumor Tissue|Tumor mutation - Tumor Tissue|Peripheral blood mononuclear cells (PBMCs) in serum samples|Immune characterization as determined by Cytokines|Immune characterization as determined by Extracellular vesicles (EVs) proteins	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Candel Therapeutics, Inc.|National Cancer Institute (NCI)|Bristol-Myers Squibb"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	36	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC-1603|IRB00172749|UM1CA137443	27-Feb-18	22-Feb-22	28-Oct-22	3-Jul-18		10-Sep-21	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abrams Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT03576612
1422	NCT00763750	"PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors"		Completed	Has Results	Brain Tumor	Drug: PPX +TMZ+XRT	Number of Patients Assessed for Toxicity According to CTC Version 3.0	howard safran|Rhode Island Hospital|MaineHealth|Brown University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	25	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrUOG-Brain-223	Oct-08	Jun-11	Jul-12	1-Oct-08	16-Dec-13	17-Feb-20	"Lifespan Hospitals, Providence, Rhode Island, United States"		https://ClinicalTrials.gov/show/NCT00763750
1423	NCT02684058	Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG		"Active, not recruiting"	No Results Available	"Diffuse Astrocytoma|Anaplastic Astrocytoma|Astrocytoma|Oligodendroglioma, Childhood|Anaplastic Oligodendroglioma|Glioblastoma|Pilocytic Astrocytoma|Giant Cell Astrocytoma|Pleomorphic Xanthoastrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Angiocentric Glioma|Chordoid Glioma of Third Ventricle|Gangliocytoma|Ganglioglioma|Anaplastic Ganglioglioma|Dysplastic Gangliocytoma of Cerebrellum|Desmoplastic Infantile Astrocytoma and Ganglioglioma|Papillary Glioneuronal Tumor|Rosette-forming Glioneurona Tumor|Central Neurocytoma|Extraventricular Neurocytoma|Cerebellar Iponeurocytoma"	Drug: dabrafenib|Drug: trametinib|Drug: Carboplatin with vincristine	HGG cohort: Overall response rate (ORR)|LGG cohort: Overall response rate (ORR)|HGG and LGG cohorts: Duration of response (DOR)|HGG and LGG cohorts: Time to response (TTR)|HGG and LGG cohorts: Overall survival (OS)|HGG and LGG cohorts: Progression free survival (PFS)|Patients on DRB+TMT: Area under the curve (AUClast)|Patients on DRB+TMT: Area under the curve (AUCtau)|Patients on DRB+TMT: Maximum Plasma Concentration (Cmax)|Patients on DRB+TMT: Time to reach maximum concentration (Tmax)|Patients on DRB+TMT: Elimination half-life (T1/2)|Patients on DRB+TMT: Predose plasma concentration (Ctrough)|HGG and LGG cohorts: Adverse events|HGG and LGG cohorts: Vital signs|HGG and LGG cohorts: Abnormal lab values|HGG and LGG cohorts: Changes in Electrocardiogram (ECG)|HGG and LGG cohorts: ECHO|HGG and LGG cohort: Palatability of pediatric formulations|LGG cohort: PROMIS Parent Proxy scale|HGG and LGG Cohorts: Clinical benefit rate (CBR)|LGG cohort: 2 year Overall survival (OS)	Novartis Pharmaceuticals|Novartis	All	12 Months to 17 Years   (Child)	Phase 2	150	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDRB436G2201|2015-004015-20	28-Dec-17	23-Aug-21	30-May-23	17-Feb-16		6-Dec-21	"Children's Hospital of Orange County, Orange, California, United States|Children s National Hospital, Washington, District of Columbia, United States|Nicklaus Childrens Hospital, Miami, Florida, United States|Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Johns Hopkins University IDS Pharmacy John Hopkins Hospital, Baltimore, Maryland, United States|Washington University School of Medicine SC, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center Cancer & Blood Disease Inst., Cincinnati, Ohio, United States|St Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children s Hospital Baylor College of Medicine, Houston, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Vancouver, British Colombia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Villejuif Cedex, Villejuif, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Petach-Tikva, Israel|Novartis Investigative Site, Tel-Hashomer, Israel|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Setagaya-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Utrecht, CS, Netherlands|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT02684058
1424	NCT03452774	SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry		Recruiting	No Results Available	"Cancer, Metastatic|Cancer|Cancer of Pancreas|Cancer of Liver|Cancer of Stomach|Cancer Liver|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Cervix|Cancer of Colon|Cancer of Larynx|Cancer, Lung|Cancer, Breast|Cancer, Advanced|Cancer Prostate|Cancer of Neck|Cancer of Skin|Neuroendocrine Tumors|Carcinoma|Mismatch Repair Deficiency|BRCA Gene Rearrangement|Non Hodgkin Lymphoma|Leukemia|Non Small Cell Lung Cancer|Cholangiocarcinoma|Glioblastoma|Central Nervous System Tumor|Melanoma|Urothelial Carcinoma|Bladder Cancer|Ovarian Cancer|Endometrial Cancer|Testicular Cancer|Breast Cancer|COVID|Myelofibrosis|Myeloproliferative Neoplasm|Myeloproliferative Disorders|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndromes"	Other: Clinical Trial Matching	"Proportion of patients Eligible for CTE versus Actual CTE|Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis|Identification of Barriers to CTE|Real World Data Analytics|Virtual Tumor Board Utilization|Time from Intervention to Actual CTE (months)"	"Massive Bio, Inc."	All	"Child, Adult, Older Adult"		5000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	SYNERGY-AI	1-Jan-18	Jun-22	Dec-22	2-Mar-18		25-May-21	"Massive Bio, Inc, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT03452774
1425	NCT04028479	The Registry of Oncology Outcomes Associated With Testing and Treatment	ROOT	Recruiting	No Results Available	"Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma"	Diagnostic Test: Biomarker Testing (L)|Drug: Systemic Treatment (T)|Other: Patient Reported Outcomes (P)	Best overall response (BOR) - 1st line of therapy|Best overall response (BOR) - 2nd line of therapy|Best overall response (BOR) - 3rd line of therapy|Best overall response (BOR) - 4th line of therapy|Best overall response (BOR) - 5th line of therapy|Progression-free survival (PFS) - 1st line of therapy|Progression-free survival (PFS) - 2nd line of therapy|Progression-free survival (PFS) - 3rd line of therapy|Progression-free survival (PFS) - 4th line of therapy|Progression-free survival (PFS) - 5th line of therapy|Overall survival (OS)	Taproot Health	All	"18 Years and older   (Adult, Older Adult)"		100000	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	ROOT	5-May-21	1-Oct-29	1-Oct-31	22-Jul-19		11-Oct-21	"Teton Cancer Institute, Idaho Falls, Idaho, United States"		https://ClinicalTrials.gov/show/NCT04028479
1426	NCT03154190	Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer		"Active, not recruiting"	No Results Available	Acute Myeloid Leukemia|Brain Glioblastoma|Estrogen Receptor Negative|Extensive Stage Small Cell Lung Carcinoma|Head and Neck Carcinoma|HER2/Neu Negative|Hormone-Resistant Prostate Cancer|Limited Stage Small Cell Lung Carcinoma|Myelodysplastic Syndrome|Progesterone Receptor Negative|Progressive Disease|Recurrent Carcinoma|Stage II Pancreatic Cancer|Stage II Rectal Cancer|Stage IIA Pancreatic Cancer|Stage IIA Rectal Cancer|Stage IIB Pancreatic Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage III Colon Cancer|Stage III Esophageal Cancer|Stage III Gastric Cancer|Stage III Non-Small Cell Lung Cancer|Stage III Ovarian Cancer|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Skin Melanoma|Stage IIIA Colon Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Gastric Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Rectal Cancer|Stage IIIA Skin Melanoma|Stage IIIB Colon Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Gastric Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Rectal Cancer|Stage IIIB Skin Melanoma|Stage IIIC Colon Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Rectal Cancer|Stage IIIC Skin Melanoma|Stage IV Bladder Cancer|Stage IV Bone Sarcoma|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IV Soft Tissue Sarcoma|Stage IVA Bone Sarcoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Bone Sarcoma|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Triple-Negative Breast Carcinoma	Other: Best Practice|Other: Laboratory Biomarker Analysis|Procedure: Supportive Care|Other: Survey Administration	Emergency Department Visit (Chart Review)|Hospitalization Visits (Chart Review)|Change in patient satisfaction with care and decision making among patients undergoing health care coach support as assessed by Consumer Assessment of Healthcare Providers and Systems-G and Patient Satisfaction with Decision Scale|Change in patient satisfaction with care among patients undergoing health care coach support as assessed by Consumer Assessment of Healthcare Providers and Systems-G.|Hospice Consult (Chart Review)|Palliative Care Consult (Chart Review)|Total Costs of Care	Stanford University	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	128	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	VAR0134	15-Dec-16	30-Nov-21	30-Nov-21	16-May-17		1-Dec-21	"Virginia K Crosson Cancer Center, Fullerton, California, United States"		https://ClinicalTrials.gov/show/NCT03154190
1427	NCT02966509	Engagement of Patients With Advanced Cancer	EPAC	Completed	Has Results	End of Life|Advanced Cancer|Lung Neoplasm|Gastric Cancer|Colon Cancer|Glioblastoma Multiforme|Head and Neck Neoplasms|Rectum Cancer|Melanoma|Kidney Cancer|Prostate Cancer|Testicular Neoplasms|Liver Cancer|Cancer of Unknown Origin	Behavioral: EPAC	Number of Participants With Completed Goals of Care Documentation. We Will Evaluate if 75% of Patients in the Intervention Arm Have a Documented Goals of Care Titled Medical Note Within 6 Months of Patient Enrollment in the Study.|Emergency Department Visit (Chart Review)|Hospitalization Visits (Chart Review)|Hospice Referral (Chart Review)|Palliative Care Referral (Chart Review)|Change in Patient Satisfaction With Care Using the Consumer Assessment of Health Care Providers and Systems -General Survey|Patient Satisfaction With Decision-Making Using the Satisfaction With Decision Survey	Stanford University|VA Palo Alto Health Care System	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	213	Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research	EPAC1	Aug-13	Dec-16	Dec-16	17-Nov-16	18-Dec-17	31-Oct-18			https://ClinicalTrials.gov/show/NCT02966509
1428	NCT01522820	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors		Completed	No Results Available	Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Estrogen Receptor Negative|Estrogen Receptor Positive|Glioblastoma|Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Metastatic Renal Cell Cancer|Recurrent Adult Brain Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Lung Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Uterine Corpus Carcinoma|Resectable Hepatocellular Carcinoma|Sarcoma|Stage IA Breast Cancer|Stage IA Ovarian Cancer|Stage IA Uterine Corpus Cancer|Stage IB Breast Cancer|Stage IB Ovarian Cancer|Stage IB Uterine Corpus Cancer|Stage IC Ovarian Cancer|Stage II Uterine Corpus Cancer|Stage IIA Breast Cancer|Stage IIA Lung Carcinoma|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Esophageal Cancer|Stage IIB Lung Carcinoma|Stage IIB Ovarian Cancer|Stage IIB Skin Melanoma|Stage IIC Ovarian Cancer|Stage IIC Skin Melanoma|Stage IIIA Breast Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Lung Carcinoma|Stage IIIA Ovarian Cancer|Stage IIIA Skin Melanoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Breast Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Skin Melanoma|Stage IIIB Uterine Corpus Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Skin Melanoma|Stage IIIC Uterine Corpus Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Esophageal Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Skin Melanoma|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer	Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sirolimus	"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0|NY-ESO-1 specific cellular immunity|NY-ESO-1 specific humoral immunity"	Roswell Park Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 191511|NCI-2011-03568|071614|P30CA016056|R01CA158318	Mar-12	Jul-16	Jul-16	1-Feb-12		4-Oct-16	"Roswell Park Cancer Institute, Buffalo, New York, United States"		https://ClinicalTrials.gov/show/NCT01522820
1429	NCT03896958	The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)	PIONEER	Recruiting	No Results Available	"Cancer, All Types|Cancer of Liver|Cancer of Stomach|Cancer of Head and Neck|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Colon|Cancer Skin|Cancer of Cervix|Cancer, Metastatic|Cancer of Larynx|Cancer of Neck|Cancer of Lung|Cancer of Brain and Nervous System|Cancer of Vulva, Disseminated|Cancer of Pancreas|Sarcoma|GIST|Small-cell Lung Cancer|Adenocarcinoma Lung|Cancer of Prostate|Cancer, Advanced|Adrenal Cancer|Testicular Cancer|Uterine Cancer|Bronchoalveolar Cell Lung Cancer|Cancer Unknown Primary|Glioblastoma Multiforme|Oligodendroglioma|Breast Cancer|Renal Cell Carcinoma|Hepatocellular Carcinoma|Cholangiocarcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Cancer, Other|Cancer, Anal|Melanoma|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancers Cell Neuroendocrine|Cancer Differentiated Poorly|Cancer, Anaplastic Thyroid"		Return of research information|Assessment of benefit of return of research results|Assessment of benefit of return of research results by SpeciCare Outcome Monitor Board	SpeciCare|Georgia Institute of Technology|Predictive Oncology|University of Washington|Netnoids|Northeast Georgia Hospital System	All	"1 Month to 99 Years   (Child, Adult, Older Adult)"		1000	Industry|Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	MYCT001	21-Mar-19	12-Mar-24	12-Mar-24	1-Apr-19		4-Dec-20	"Specicare, Gainesville, Georgia, United States"		https://ClinicalTrials.gov/show/NCT03896958
1430	NCT02101905	Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma		"Active, not recruiting"	No Results Available	Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Oligodendroglioma|Gliosarcoma|Mixed Glioma|Recurrent Adult Brain Neoplasm|Recurrent Glioblastoma	Other: Laboratory Biomarker Analysis|Drug: Lapatinib|Drug: Lapatinib Ditosylate|Other: Pharmacological Study|Procedure: Therapeutic Conventional Surgery	Lapatinib ditosylate intratumoral concentration (pharmacokinetics)|Ratio of phosphorylated (p)EGFR/total EGFR (PD) in tumor tissue|Incidence of adverse events (AEs)|Inhibition of tumor cell proliferation (KI-67)|Ex-vivo sensitivity of tumor sphere cultures to lapatinib ditosylate|Objective response rate|Overall survival|Progression-free survival	National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	29	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-00634|ABTC-1302|U01CA137443|UM1CA137443	13-Mar-14	19-Oct-21	19-Oct-22	2-Apr-14		21-Oct-21	"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT02101905
1431	NCT01929720	"Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors"	FOCUS	Completed	No Results Available	"Anxiety Disorder|Worry|Uncertainty|Sleep Disorders|Insomnia|Fatigue|Pain|Depression|Cognitive-behavioral Therapy|Psychological Intervention|Esophageal Cancer|Pancreatic Cancer|Leukemia|Lung Cancer|Multiple Myeloma|Ovarian Neoplasm|Stage III or IV Cervical or Uterine Cancer|Stage IIIB, IIIC, or IV Breast Cancer|Glioblastoma Multiforme|Relapsed Lymphoma|Stage III or IV Colorectal Cancer|Stage IIIC or IV Melanoma"	"Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia"	Changes in worry on the Penn State Worry Questionnaire|Changes in sleep efficiency on the Insomnia Severity Index|Changes in intolerance of uncertainty on the Intolerance of Uncertainty Scale|Levels of cortisol|Levels of pro and anti-inflammatory cytokines|Levels of myeloid-derived suppressor cells (MDSC)	"Ohio State University Comprehensive Cancer Center|American Cancer Society, Inc.|Lance Armstrong Foundation"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	33	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	OSU-09096|NCI-2012-02879	Aug-11	Sep-14	Sep-14	28-Aug-13		5-Apr-17	"Wexner Medical Center at The Ohio State University Department of Psychiatry, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01929720
1432	NCT01177397	"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma"		Completed	No Results Available	Multiple Myeloma|Diffuse Large B-Cell Lymphoma|Glioblastoma Multiforme|Hepatocellular Carcinoma|Non-Small Cell Lung Cancer|Neuroendocrine Tumors of Non-Pancreatic Origin|Hormone Receptor-Positive Breast Cancer	Drug: CC-223	Safety|Pharmacokinetics|Pharmacodynamics|Efficacy	Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	173	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC-223-ST-001	20-Jul-10	15-Nov-16	9-Dec-16	9-Aug-10		14-Nov-17	"Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Mayo Clinic Cancer Clinical Studies Unit, Rochester, Minnesota, United States|Billings Clinic, Billings, Montana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|NYU Cancer Institute - Bellevue Hospital, New York, New York, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Institut Claudius Regaud, Toulouse Cedex, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif, France|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Sarah Cannon Research Institute UK, London, United Kingdom|UCL Cancer Institute, London, United Kingdom"		https://ClinicalTrials.gov/show/NCT01177397
1433	NCT00561873	Nimotuzumab in Children With HGG		Completed	No Results Available	High Grade Glioma		"Response rate according to RECIST criteria|Progress free interval, Toxicity according to CTC criteria, Symptom control"	"Oncoscience AG|Children's Medical Hospital, University of Bonn, Germany|University of Wuerzburg|University of Bonn|Dept. of Statistics, University of Dortmund, Germany|CRM Biometrics GmbH|Heinrich-Heine University, Duesseldorf|University Hospital Augsburg|Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany|Children's Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany|Children's Medical Hospital, Medical School Hannover, Hannover, Germany|Children's Medical Hospital, University of Essen, Essen, Germany|Dept. of Neuropediatrics and Muscle Disorders, University of Freiburg, Germany|University of Cologne|Universitätsklinikum Hamburg-Eppendorf|University of Regensburg"	All	"3 Years to 20 Years   (Child, Adult)"		45	Industry|Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	BN001-PED04	Jun-04		Feb-07	21-Nov-07		21-Nov-07	"University Bonn, Children's Medical Hospital, Bonn, Germany"		https://ClinicalTrials.gov/show/NCT00561873
1434	NCT01631552	Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer		Completed	Has Results	Gastric Adenocarcinoma|Esophageal Cancer|Hepatocellular Carcinoma|Non-small Cell Lung Cancer|Small Cell Lung Cancer|Ovarian Epithelial Cancer|Carcinoma Breast Stage IV|Hormone-refractory Prostate Cancer|Head and Neck Cancers- Squamous Cell|Renal Cell Cancer|Urinary Bladder Neoplasms|Cervical Cancer|Endometrial Cancer|Glioblastoma Multiforme|Triple Negative Breast Cancer|Pancreatic Cancer	Drug: Sacituzumab Govitecan-hziy (SG)	"Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events|Percentage of Participants Who Permanently Discontinued Sacituzumab Govitecan-hziy (SG) Due to Any Adverse Events, Excluding Adverse Events Leading to Death|Percentage of Participants Who Required Dose Interruption Due to Any Adverse Events|Objective Response Rate (ORR) by Independent Central Review (ICR)|Objective Response Rate by Local Assessment|Duration of Response by ICR|Duration of Response by Local Assessment|Time to Response by ICR|Time to Response by Local Assessments|Clinical Benefit Rate (CBR) by Local Assessment|Progression Free Survival (PFS) by Local Assessment|Overall Survival by Local Assessment|Pharmacokinetic (PK) Parameter: T1/2 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38|PK Parameter: AUC0-24 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38|PK Parameter: AUC0-168 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38|PK Parameter: AUC0-inf of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38|PK Parameter: Cmax of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38"	Gilead Sciences	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	515	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IMMU-132-01	17-Dec-12	1-Mar-19	13-Aug-20	29-Jun-12	6-Apr-21	12-Aug-21	"University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Helen F. Graham Cancer Center, Newark, Delaware, United States|MD Anderson Cancer Center Orlando (UF Health Cancer Center), Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|IU Health Goshen Cancer Center, Goshen, Indiana, United States|Massachusettes General Hospital, Boston, Massachusetts, United States|Weill Cornell/New York Presbyterian Hospital, New York, New York, United States|Columbia University Herbert Irving Cancer Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Virginia Mason Cancer Center, Seattle, Washington, United States"	"Study Protocol, https://ClinicalTrials.gov/ProvidedDocs/52/NCT01631552/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01631552/SAP_001.pdf"	https://ClinicalTrials.gov/show/NCT01631552
1435	NCT00003535	Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma		Terminated	Has Results	High Grade Glioma	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"6 Months to 18 Years   (Child, Adult)"	Phase 2	9	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066582|BC-BT-06	Apr-94	Jan-98	Jan-98	27-Jan-03	13-Dec-17	21-Mar-18	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003535
1436	NCT01246869	"Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water"		Recruiting	No Results Available	Brain Cancer		Determination of multi-tracer update times as related to overall survival and time to progression	University of Utah	All	"18 Years and older   (Adult, Older Adult)"		30	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	HCI44704	27-Mar-13	Nov-21	Dec-21	23-Nov-10		22-Sep-21	"Huntsman Cancer Institute, Salt Lake City, Utah, United States"		https://ClinicalTrials.gov/show/NCT01246869
1437	NCT02323880	Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas		Recruiting	No Results Available	Malignant Glioma|Recurrent Brain Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Glioblastoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Primary Central Nervous System Neoplasm|WHO Grade III Glioma	Other: Pharmacological Study|Drug: Selinexor	Frequency of dose limiting toxicities of selinexor|Frequency of adverse events of selinexor|Area under the drug concentration curve of selinexor|Half-life of selinexor|Maximum serum concentration of selinexor|Minimum serum concentration of selinexor|Clearance of selinexor|Antitumor effect of selinexor|Pharmacodynamics of selinexor|Pharmacodynamics of selinexor in high-grade glioma (HGG) patients|Radiographic response of selinexor in HGG patients|Progression-free survival of selinexor in HGG patients	Children's Oncology Group|National Cancer Institute (NCI)	All	"12 Months to 21 Years   (Child, Adult)"	Phase 1	68	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADVL1414|NCI-2014-02410|UM1CA097452	5-Oct-15	31-Mar-22		24-Dec-14		22-Jul-21	"Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT02323880
1438	NCT02444546	Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors		"Active, not recruiting"	No Results Available	Childhood Astrocytoma|Childhood Atypical Teratoid/Rhabdoid Tumor|Diffuse Intrinsic Pontine Glioma|Glioma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Neoplasm|Recurrent Childhood Glioblastoma|Recurrent Childhood Medulloblastoma|Recurrent Primitive Neuroectodermal Tumor|Refractory Brain Neoplasm	Other: Laboratory Biomarker Analysis|Biological: Sargramostim|Biological: Wild-type Reovirus	"MTD, based on the incidence of dose-limiting toxicity (DLT) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0|Adverse event profile|Objective responses|Overall survival|Time to progression|Time to treatment failure|Time until any treatment-related toxicity|Time until treatment-related grade 3+ toxicity|Toxicity profile, assessed by CTCAE v4.0"	Mayo Clinic|National Cancer Institute (NCI)	All	"10 Years to 21 Years   (Child, Adult)"	Phase 1	6	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MC1472|NCI-2015-00665|P30CA015083	21-Jun-15	13-Jul-18	1-Jan-25	14-May-15		18-Aug-21	"Mayo Clinic, Rochester, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT02444546
1439	NCT01743950	A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab		Recruiting	No Results Available	Glioma	Drug: Bevacizumab|Radiation: PRDR	Overall survival|Incidence of Adverse Events|Incidence of Late Toxicities|progression free survival|Change in Mini Mental State Exam (MMSE) Score|Change in Participant Reported FACT-BR Score|Change in Participant Reported FACIT-F Score|Change in Karnofsky Performance Status	"University of Wisconsin, Madison|Genentech, Inc.|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	80	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CO11374|NCI-2012-02775|2012-0648|2017-0683|A533300|SMPH\HUMAN ONCOLOGY\HUMAN ONCO|Protocol Version 10/14/2020	3-Dec-12	Dec-22	Dec-22	6-Dec-12		21-Sep-21	"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01743950
1440	NCT01220271	A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma		Completed	No Results Available	Glioma	Drug: LY2157299|Drug: Radiation|Drug: Temozolomide	Phase 1: Recommended dose for Phase 2 portion|Phase 2: Relationship of change in response biomarker to clinical benefit|Phase 1: Pharmacokinetics - Concentration Maximum|Phase 1: Number of patients with a tumor response|Phase 2: Overall Survival at 12 Months|Phase 2: Overall Survival|Phase 2: Progression Free Survival|Phase 2: Proportion of patients achieving an objective response (Response Rate)|Phase 2: Duration of tumor Response|Phase 2: Time to Treatment Failure|Phase 1: Pharmacokinetics - Time to Concentration Maximum|Phase 1: Pharmacokinetics - Area under the Curve|Phase 2: Change from baseline in MD Anderson Symptom Inventory - Brain Tumor	Eli Lilly and Company	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	75	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11585|H9H-MC-JBAI	Apr-11	Aug-15	Nov-16	13-Oct-10		16-Feb-17	"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain"		https://ClinicalTrials.gov/show/NCT01220271
1441	NCT02300532	Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)		Completed	No Results Available	Malignant Glioma	Other: No intervention	Number of Adverse Events/Serious Adverse Events|Survival rate	"Eisai Co., Ltd.|Eisai Inc."	All	"Child, Adult, Older Adult"		561	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GLI01S	10-Jan-13	10-Jul-14	24-Mar-15	25-Nov-14		27-Feb-17	"Osaka, Japan|Tokyo, Japan"		https://ClinicalTrials.gov/show/NCT02300532
1442	NCT02300506	Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma		Completed	No Results Available	Malignant Glioma	Other: No intervention	Survival rate	"Eisai Co., Ltd.|Eisai Inc."	All	"Child, Adult, Older Adult"		507	Industry	Observational	Observational Model: Cohort|Time Perspective: Prospective	GLI02T	10-Jan-14	10-Jul-16	10-Jul-16	25-Nov-14		5-Nov-18	"Osaka, Japan|Tokyo, Japan"		https://ClinicalTrials.gov/show/NCT02300506
1443	NCT00293423	GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma		Completed	Has Results	Brain and Central Nervous System Tumors	Biological: HSPPC-96|Procedure: Standard Surgical Resection	"Maximum Tolerated Dose (MTD) (Phase 1)|Frequency of gp96 Heat Shock Protein-peptide Complex Vaccine (Phase 1)|Number of Participants With Dose Limiting Toxicities (Phase 1)|Median Progression-free Survival at 6 Months (Phase 2)|Percentage of Participants With Progression-free Survival at 12 Months (Phase 2)|Number of Patients With an Immunological Response (Phase 1)|Number of Patients With an Immunological Response (Phase 2)|Number of Participants With Grade 3 or Higher, Vaccine Treatment-Related Adverse Events by Toxicity (Phase 2)|Median Overall Survival (Phase 2)|Percentage of Participants Surviving at 6 Months (Phase 2)|Percentage of Participants Surviving at 12 Months (Phase 2)"	"University of California, San Francisco|National Cancer Institute (NCI)|Agenus Inc.|American Brain Tumor Association"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	96	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05103|UCSF-H41995-27311-01|NCI-2011-01231|P50CA097257-06|R01CA164714-02	18-Nov-05	12-Jan-13	12-Jan-13	17-Feb-06	13-May-21	13-May-21	"University of California, San Francisco, San Francisco, California, United States|Columbia University, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00293423
1444	NCT00070525	"Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma"		Completed	No Results Available	Childhood High-grade Cerebral Astrocytoma|Childhood Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: tipifarnib	"Best objective tumor response rates (complete and partial response), based on MRIs|Time to tumor progression (TTP)|Time to treatment failure (TTF)|Time to death (TTD)|Incidence of adverse events graded according to NCI CTCAE version 3.0"	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 2	90	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01806|CDR0000334862|COG-ACNS0226|ACNS0226|U10CA098543	Nov-03	Sep-06		7-Oct-03		8-Oct-13	"Children's Oncology Group, Arcadia, California, United States"		https://ClinicalTrials.gov/show/NCT00070525
1445	NCT00006024	Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma		Completed	No Results Available	Brain Tumor|Central Nervous System Tumor	Drug: lomustine|Drug: temozolomide	Progression Free Survival	Children's Oncology Group|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	32	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADVL0011|COG-ADVL0011|CCG-ADVL0011|CCG-A0993|CDR0000068036	Nov-00	Jan-05	Sep-06	27-Jan-03		13-Feb-14	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|University of South Alabama Medical Center, Mobile, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Jonathan Jaques Children's Cancer Center, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital of Oakland, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States|Sutter Cancer Center, Sacramento, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California, United States|Children's Hospital San Diego, San Diego, California, United States|Kaiser Permanente Medical Center - San Francisco Geary Campus, San Francisco, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|Children's Hospital of Denver, Denver, Colorado, United States|Childhood Hematology/Oncology Associates, Denver, Colorado, United States|Presbyterian-St Luke's Medical Center, Denver, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|Alfred I. Dupont Institute, Wilmington, Delaware, United States|Lombardi Cancer Center, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital at Memorial, Hollywood, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami-Jackson Memorial Hospital, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Nemours Children's Clinic-Orlando, Orlando, Florida, United States|Sacred Heart Children's Hospital, Pensacola, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|Tampa Children's Hospital, Tampa, Florida, United States|St. Mary's Hospital, West Palm Beach, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia, United States|Medical College of Georgia Comprehensive Cancer Center, Augusta, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Memorial Health University Medical Center, Inc., Savannah, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Mountain States Tumor Institute, Boise, Idaho, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Hope Children's Hospital, Oak Lawn, Illinois, United States|Lutheran General Hospital, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Raymond Blank Memorial Hospital for Children, Des Moines, Iowa, United States|John Stoddard Cancer Center, Des Moines, Iowa, United States|Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Wesley Medical Center, Wichita, Kansas, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Floating Hospital for Children, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. John Hospital and Medical Center, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Children's Hospitals and Clinics - Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|State University of New York Health Science Center at Brooklyn College of Medicine, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia Presbyterian Hospital, New York, New York, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Saint Joseph's Health System, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Healthcare, Charlotte, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Dakota Cancer Institute, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Toledo Children's Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Forum Health-Tod Childrens Hospital, Youngstown, Ohio, United States|Children's Hospital of Oklahoma, Oklahoma City, Oklahoma, United States|CCOP - Oklahoma, Tulsa, Oklahoma, United States|Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|Doernbecher Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, United States|Children's Hospital of Greenville Hospital System, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sioux Valley Hospital, Sioux Falls, South Dakota, United States|East Tennessee State University Cancer Center at JCMC, Johnson City, Tennessee, United States|East Tennessee Children's Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, United States|Children's Hospital of Austin, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Methodist Health Care System, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Vermont Cancer Center, Burlington, Vermont, United States|Cancer Center at the University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States|Massey Cancer Center, Richmond, Virginia, United States|Carilion Medical Center for Children, Roanoke, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Cooperative, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Mary Bridge Children's Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University - Charleston, Charleston, West Virginia, United States|Cabell-Huntington Hospital, Inc, Huntington, West Virginia, United States|West Virginia University Hospitals, Morgantown, West Virginia, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|Children's Hospital, Hamilton, Ontario, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Center - Montreal Children's Hospital, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Centre Hospitalier de L'Universite Laval, Sainte Foy, Quebec, Canada|Laval University Medical Center, Sainte-Foy, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Academisch Ziekenhuis Groningen, Groningen, Netherlands|Starship Children's Hospital, Auckland, New Zealand|University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Puerto Rico|San Jorge Childrens Hospital, Santurce, Puerto Rico|Swiss Pediatric Oncology Group Bern, Bern, Switzerland|Swiss Pediatric Oncology Group Geneva, Geneva, Switzerland|Swiss Pediatric Oncology Group Lausanne, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00006024
1446	NCT01076530	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors		Completed	No Results Available	Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Embryonal Tumor|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Extra-adrenal Paraganglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Central Nervous System Embryonal Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Spinal Cord Neoplasm|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: vorinostat|Drug: temozolomide|Other: diagnostic laboratory biomarker analysis|Other: pharmacological study	Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT using NCI CTCAE version 4.0|Pharmacokinetic parameters of vorinostat in combination with temozolomide|Response assessed according to RECIST criteria	National Cancer Institute (NCI)	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	27	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2011-02011|ADVL0819|CDR0000664388|COG-ADVL0819|U01CA097452	Feb-10	Oct-12		26-Feb-10		3-May-13	"Childrens Memorial Hospital, Chicago, Illinois, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT01076530
1447	NCT00003410	Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: motexafin gadolinium|Procedure: magnetic resonance imaging|Procedure: surgical procedure		Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Diagnostic	UCLA-HSPC-970904303|CDR0000066422|UCLA-HSPC-970904301|UCLA-HSPC-970904302|NCI-T97-0107	Jul-98		Jun-04	9-Jun-04		26-Jun-13	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00003410
1448	NCT00946335	ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors		Completed	No Results Available	Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Spinal Cord Neoplasm|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: veliparib|Drug: temozolomide|Other: pharmacological study|Other: laboratory biomarker analysis	"MTD or recommended phase II dose of veliparib|Acute toxicities|Chronic toxicities|Plasma drug concentrations and pharmacokinetic parameters, including volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)"	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1	31	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03177|CDR649727|PBTC-027|U01CA081457	Jul-09	Oct-11	Jun-14	27-Jul-09		9-Jul-14	"Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00946335
1449	NCT00363272	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma		Completed	No Results Available	"Childhood Burkitt Lymphoma|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Spinal Cord Neoplasm|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: ispinesib|Other: laboratory biomarker analysis|Other: pharmacological study	"Maximum tolerated dose, defined as the maximum dose at which fewer than one-third of patients experience DLT, graded according to NCI CTCAE version 3.0"	National Cancer Institute (NCI)	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	30	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01828|ADVL0517|U01CA097452|CDR0000491407	Jun-06	Oct-08		15-Aug-06		16-Jan-13	"Children's Oncology Group, Arcadia, California, United States"		https://ClinicalTrials.gov/show/NCT00363272
1450	NCT00091182	Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment		Completed	No Results Available	Childhood Central Nervous System Germ Cell Tumor|Childhood Extragonadal Germ Cell Tumor|Childhood Hepatoblastoma|Childhood Hepatocellular Carcinoma|Childhood High-grade Cerebral Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Malignant Ovarian Germ Cell Tumor|Childhood Malignant Testicular Germ Cell Tumor|Childhood Teratoma|Recurrent Adrenocortical Carcinoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Colon Cancer|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Nasopharyngeal Cancer|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer	Drug: oxaliplatin	Response rate	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 2	180	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01815|ADVL0421|COG-ADVL0421|CDR0000384560|U10CA098543	Oct-04	Feb-06		9-Sep-04		5-Jun-13	"Children's Oncology Group, Arcadia, California, United States"		https://ClinicalTrials.gov/show/NCT00091182
1451	NCT00100880	"Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors"		Completed	No Results Available	Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: lenalidomide|Procedure: perfusion-weighted magnetic resonance imaging|Procedure: diffusion-weighted magnetic resonance imaging|Other: laboratory biomarker analysis	"MTD, estimated using the modified Continual Reassessment Method (CRM)|Plasma drug concentrations and pharmacokinetic parameters, including volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)"	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1	45	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03176|CDR653734|PBTC-018|U01CA081457	Nov-04	Nov-10		7-Jan-05		30-Sep-13	"Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00100880
1452	NCT00063973	Cilengitide in Treating Children With Refractory Primary Brain Tumors		Completed	No Results Available	Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: cilengitide|Other: laboratory biomarker analysis	MTD of cilengitide|Response	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1	24	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03175|CDR653715|PBTC-012|U01CA081457	Jul-03	Mar-08		9-Jul-03		30-Sep-13	"Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00063973
1453	NCT00053963	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia		Completed	No Results Available	"Blastic Phase Chronic Myelogenous Leukemia|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Chronic Myelogenous Leukemia|Childhood Craniopharyngioma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Spinal Cord Neoplasm|Childhood Supratentorial Ependymoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: romidepsin	"MTD, defined as that dose at which fewer than one-third of patients experience DLT, graded according to the NCI CTC version 2.0"	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1	30	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01803|ADVL0212|U01CA097452|CDR0000269671	Sep-02	Feb-06		6-Feb-03		16-Jan-13	"Children's Oncology Group, Arcadia, California, United States"		https://ClinicalTrials.gov/show/NCT00053963
1454	NCT00052780	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors		Completed	No Results Available	Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma	Drug: O6-benzylguanine|Drug: temozolomide|Biological: filgrastim|Other: pharmacological study|Other: laboratory biomarker analysis	MTD of temozolomide|Pharmacokinetic parameters|Acute toxicities|Chronic toxicities|Histological response|Duration of disease control|Survival	National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1	72	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03174|CDR653709|PBTC-005|U01CA081457	Oct-02	Nov-07		27-Jan-03		30-Sep-13	"Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00052780
1455	NCT03793088	A Patient-Centric Platform Trial for Precision Oncology	XCELSIOR	Recruiting	No Results Available	Oncology		Progression Free Survival (PFS)|Overall Survival (OS)	"xCures|Cancer Commons|Musella Foundation for Brain Tumor Research and Information, Inc.|Pediatric Oncology Experimental Therapeutics Investigators Consortium"	All	"Child, Adult, Older Adult"		10000	Industry|Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	XC3-GCTA-2018	7-Feb-19	Jan-24	Jan-26	4-Jan-19		12-Apr-21	"Cancer Commons, Los Altos, California, United States"		https://ClinicalTrials.gov/show/NCT03793088
1456	NCT04404569	Continued Treatment for Participants Enrolled in Studies of BXQ-350	ETERNITI	Enrolling by invitation	No Results Available	Neoplasms	Drug: BXQ-350	Percentage of subjects with clinical benefit|Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v5.0|Time to Disease Progression|Overall Survival	"Bexion Pharmaceuticals, Inc.|CTI Clinical Trial and Consulting Services"	All	"1 Year and older   (Child, Adult, Older Adult)"	Phase 1	50	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BXQ-350.AE	8-Jun-20	May-22	Jul-22	27-May-20		22-Jul-21	"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|University of Cincinnati Barrett Center, Cincinnati, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT04404569
1457	NCT01729260	Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide	Mebendazole	Completed	No Results Available	Newly Diagnosed High-Grade Glioma	Drug: Mebendazole	maximum tolerated dose (MTD) of mebendazole|Overall Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Accelerate Brain Cancer Cure	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1194|NA_00049848	4-Apr-13	Sep-16	16-Apr-21	20-Nov-12		7-May-21	"The Johs Hopkins Hospital, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT01729260
1458	NCT03189420	Glioma Microenvironment an Exploratory Study		"Active, not recruiting"	No Results Available	Glioma of Brain	Procedure: Tumor resection	gene expression changes|cytokines expression	Hospital Sirio-Libanes	All	"18 Years to 65 Years   (Adult, Older Adult)"		30	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	CAAE 58310716.6.0000.5461	Oct-16	Oct-20	Dec-21	16-Jun-17		29-Jul-20	"Hospital Sirio Libanes, São Paulo, Sao, Brazil"		https://ClinicalTrials.gov/show/NCT03189420
1459	NCT02859857	Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors		Completed	No Results Available	Neoplasms	Drug: BXQ-350	Part 1-MTD|Part 2-RECIST|Part 2-RANO|Part 3 - RECIST|Part 2- Area under Curve (AUC)|Part 2-Cmax|Part 2-half life|Part 2-CL|Part 2-Progression-free survival (PFS-6)|Part 2-time to response|Part 2-duration of response	"Bexion Pharmaceuticals, Inc.|CTI Clinical Trial and Consulting Services"	All	"18 Years to 80 Years   (Adult, Older Adult)"	Phase 1	86	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BXQ-350.AA	1-Sep-16	17-Jun-19	15-Jun-20	9-Aug-16		22-Jul-21	"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|University of Cincinnati Barrett Center, Cincinnati, Ohio, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02859857
1460	NCT01240161	Personalized Translational Platform for Biomarker Discovery in Brain Tumors		Completed	No Results Available	High Grade Glioma	Drug: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT	Overall Survival|Progression free Survival	"Marcelo F. Di Carli, MD, FACC|Society of Nuclear Medicine and Molecular Imaging|General Electric|Brigham and Women's Hospital"	All	"18 Years to 85 Years   (Adult, Older Adult)"		37	Other|Industry	Observational	Observational Model: Case-Only|Time Perspective: Prospective	2008P000554	Dec-09	Mar-16	Mar-16	15-Nov-10		29-Aug-17	"University of California at San Diego, San Diego, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT01240161
1461	NCT00539344	"A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma"		Completed	No Results Available	Recurrent or Progressive Malignant Glioma	Drug: ANG1005	To characterize the safety and tolerability of intravenously administered ANG1005 in patients with malignant glioma.|To identify the maximum tolerated dose (MTD) of ANG1005 in patients with malignant glioma.|To examine the pharmacokinetics (PK) of ANG1005.|To confirm the safety and tolerability of ANG1005 at the MTD.|To assess the immunogenicity of ANG1005.|To obtain preliminary information about the antitumor activity of ANG1005 in patients with malignant glioma.|To obtain preliminary information about whether or not ANG1005 crosses the blood- brain barrier into malignant glioma tumors (Sub-study).	Angiochem Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	63	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)	ANG1005-CLN-01|FDA	Oct-07	Mar-10	Mar-10	4-Oct-07		31-Jul-14	"Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|UT Health Science Center at the Cancer Therapy and Research Center (CTRC), San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00539344
1462	NCT00100802	"Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas"		Completed	Has Results	Brain Tumors|Central Nervous System Tumors	Drug: lomustine|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy	One Year Overall Survival|Occurrence of Death Attributable to Complications of Protocol Therapy	Children's Oncology Group|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	118	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACNS0423|CDR0000407744|COG-ACNS0423|NCI-2012-02645|U10CA098543	Jul-05	1-Sep-12	30-Jun-17	7-Jan-05	13-Jan-17	7-Aug-19	"Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital & Research Center Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Sutter Cancer Center, Sacramento, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States|Children's Hospital and Health Center - San Diego, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States|Children's Hospital Cancer Center, Denver, Colorado, United States|Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Broward General Medical Center Cancer Center, Fort Lauderdale, Florida, United States|Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States|Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Advocate Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, United States|CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States|Maine Children's Cancer Program at Barbara Bush Children's Hospital, Scarborough, Maine, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Spectrum Health Hospital - Butterworth Campus, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Children's Hospital, Omaha, Nebraska, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Norris Cotton Cancer Center at Dartmouth - Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Overlook Hospital, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Albany Medical Center Hospital, Albany, New York, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Columbus Children's Hospital, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|Tod Children's Hospital, Youngstown, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|East Tennessee Children's Hospital, Knoxville, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas, United States|Children's Hospital of Austin, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|INOVA Fairfax Hospital, Fairfax, Virginia, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Carilion Cancer Center of Western Virginia, Roanoke, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Providence Cancer Center at Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States|Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|John Hunter Hospital, Newcastle, New South Wales, Australia|Westmead Institute for Cancer Research at Westmead Hospital, Westmead, New South Wales, Australia|Royal Children's Hospital, Herston, Brisbane, Queensland, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|CHUS-Hopital Fleurimont, Sherbrooke, Alberta, Canada|Children's & Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada|Centre Hospitalier Universitaire de Quebec, Quebec, Canada|Starship Children's Health, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Wellington Children's Hospital, Wellington, New Zealand|San Jorge Children's Hospital, Santurce, Puerto Rico|Swiss Pediatric Oncology Group Geneva, Geneva, Switzerland"		https://ClinicalTrials.gov/show/NCT00100802
1463	NCT00313521	Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: thiotepa|Procedure: adjuvant therapy|Radiation: radiation therapy	Degree of surgical resection by surgical and radiological assessments|Tumor response to chemotherapy by imaging	Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)	All	"3 Years to 20 Years   (Child, Adult)"	Phase 2	30	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000454503|CCLG-9405|EU-20575|CCLG-CNS-1995-01	Jun-95	Nov-97		12-Apr-06		20-Sep-13			https://ClinicalTrials.gov/show/NCT00313521
1464	NCT00095771	Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: arsenic trioxide|Radiation: radiation therapy	Maximum tolerated dose as assessed by NCI CTCAE v. 3.0 following study completion|Safety as assessed by NCI CTCAE v. 3.0 following study completion	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	36	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000393829|P30CA006973|JHOC-J0423|JHOC-04041906	Nov-04	Jan-11	Jan-11	9-Nov-04		22-Apr-11	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00095771
1465	NCT00003475	Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors		Completed	Has Results	Malignant Brain Tumors	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066512|BC-BT-21	Feb-96	May-11	May-11	27-Jan-03	19-Dec-16	24-Aug-17	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003475
1466	NCT00752323	Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: aminolevulinic acid|Procedure: Surgical Resection	"Assess 2 doses of 5-ALA|Correlation between intensity of in vivo fluorescence and the pathologist's quantification of tumor in biopsy specimens (e.g., percentage of tumor present) as measured by PpIX concentration and intra-operative fluorescence intensity|Correlation between the amount and location of residual tumor detected intraoperatively by fluorescence imaging and frameless stereotaxy after maximal resection and the post-operative image enhancement on CT scan and/or MRI"	"Andrew Sloan, MD|Case Comprehensive Cancer Center"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	73	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	CASE1305	8-Dec-09	15-Sep-18	14-Oct-18	15-Sep-08		17-Sep-21	"University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/23/NCT00752323/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT00752323/ICF_001.pdf"	https://ClinicalTrials.gov/show/NCT00752323
1467	NCT00019071	Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: chemotherapy|Drug: cladribine|Radiation: radiation therapy		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000064153|NCI-95-C-0092A|NCI-95-C-0092	Mar-95			5-Apr-04		29-Apr-15	"Radiation Oncology Branch, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00019071
1468	NCT00003916	Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Radiation: radiation therapy|Radiation: stereotactic radiosurgery		European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years to 65 Years   (Adult, Older Adult)"	Phase 3	25	Other	Interventional	Allocation: Randomized|Primary Purpose: Treatment	EORTC-22972-26991|EORTC-22972|EORTC-26991|MRC-BR10	Apr-99	Dec-01		16-Feb-04		24-Sep-12	"Alfred Hospital, Melbourne, Victoria, Australia|Centre Antoine Lacassagne, Nice, France|Medizinische Klinik I, Dresden, Germany|Universitaet Wuerzburg/Hautkrankheiten, Wuerzburg, Germany|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Institut Catala d'Oncologia - Hospital Duran i Reynals, Barcelona, Spain|Universitaetsspital, Zurich, Switzerland|Royal Marsden Hospital, Sutton, England, United Kingdom"		https://ClinicalTrials.gov/show/NCT00003916
1469	NCT00005859	Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: tipifarnib		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	136	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTC-9901|CDR0000067888|U01CA062455	16-May-00	1-Jul-05	1-Aug-06	27-Jan-03		26-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00005859
1470	NCT00492687	"Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas"		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: carboplatin|Drug: tamoxifen citrate|Drug: temozolomide|Procedure: adjuvant therapy|Radiation: radiation therapy	Progression-free survival|Overall survival|Toxicity|Tumor response	San Diego Pacific Oncology & Hematology Associates|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	80	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000551555|POHA-0601	Dec-06	Jul-09		27-Jun-07		10-Jan-14	"San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States"		https://ClinicalTrials.gov/show/NCT00492687
1471	NCT03185780	Complementary/Integrative Medicine for Brain Cancer Patients		Withdrawn	No Results Available	Quality of Life|Chemotherapeutic Toxicity|Radiation Toxicity	Other: Acupuncture	"Measure Yourself Concerns and Wellbeing (MYCAW) study tool|Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br) questionnaire|Edmonton Symptom Assessment Scale (ESAS)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30)|Adverse effects attributed to the complementary/integrative medicine treatments|RDI - relative dose intensity"	The Chaim Sheba Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	ChaimShebaMC	1-Jul-18	31-Dec-19	31-Dec-19	14-Jun-17		28-Nov-18			https://ClinicalTrials.gov/show/NCT03185780
1472	NCT04114786	3D Printed Mask for GBM and Brain Mets		Recruiting	No Results Available	Brain Cancer	Device: 3D-printed mask|Device: Thermoplastic mask	Treatment planning time|3D-mask confection time|Inter- and intra-fraction motion|Patient reported adverse events and tolerability of mask|Gamma values and histograms for MRI-based plans	"University Health Network, Toronto"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	50	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18-5753	26-Sep-19	Apr-22	Apr-22	3-Oct-19		6-Oct-21	"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT04114786
1473	NCT00107185	Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: therapeutic autologous dendritic cells	Dose-limiting toxicity of adjuvant vaccination with autologous tumor lysate-pulsed dendritic cells after surgical resection in pediatric patients with malignant glioma.|survival	Jonsson Comprehensive Cancer Center	All	"1 Year to 18 Years   (Child, Adult)"	Phase 1	7	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000420930|UCLA-0410044-01	Jan-05	Oct-09	Mar-10	6-Apr-05		5-Aug-20	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00107185
1474	NCT00078988	High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas		Completed	No Results Available	Brain Tumor|Central Nervous System Tumor	Biological: filgrastim|Drug: carboplatin|Drug: etoposide|Drug: isotretinoin|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation	Event-free survival|Toxic death attributable to complications of treatment in the absence of tumor progression as assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0|Overall survival (OS)	Children's Oncology Group|National Cancer Institute (NCI)	All	"up to 20 Years   (Child, Adult)"	Phase 3	1	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACNS0231|COG-ACNS0231|CDR0000353207|NCI-2012-02578|U10CA098543	Oct-04	Sep-06	Sep-06	9-Mar-04		7-May-15	"Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Children's Hospital and Research Center - Oakland, Oakland, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Children's Hospital and Health Center - San Diego, San Diego, California, United States|Children's Hospital Cancer Center, Denver, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States|Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States|Floating Hospital for Children at Tufts - New England Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Spectrum Health Cancer Care - Butterworth Campus, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, St. Louis, Missouri, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Columbus Children's Hospital, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|INOVA Fairfax Hospital, Fairfax, Virginia, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Children's & Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Ste-Foy, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00078988
1475	NCT00357253	"Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: capecitabine|Radiation: radiation therapy	"Maximum tolerated dose of capecitabine rapidly disintegrating tablets (RDT) in combination with radiotherapy|Dose-limiting toxicity|Pharmacokinetics of capecitabine RDT measured periodically during course 1|Tumor response|Survival|Radiographic changes in gliomas as measured by MRI, magnetic resonance spectroscopy (MRS), perfusion and diffusion MRI"	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	24	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000484429|U01CA081457|PBTC-021	Jan-06	Mar-10	Mar-10	27-Jul-06		10-Jan-13	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00357253
1476	NCT00253487	Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: busulfan|Drug: temozolomide|Procedure: adjuvant therapy|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy		"Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI)"	All	"5 Years to 55 Years   (Child, Adult)"	Not Applicable		Other|NIH	Interventional	Primary Purpose: Treatment	CCHMC-04660|CDR0000446082|NCI-7036	Aug-05	Aug-12	Aug-12	15-Nov-05		6-Jan-14			https://ClinicalTrials.gov/show/NCT00253487
1477	NCT00350727	Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma	VEG102857	Completed	Has Results	Glioma	Drug: pazopanib|Drug: lapatinib	"Number of Participants With the Indicated Change From Baseline to Study Completion in Systolic Blood Pressure|Number of Participants With the Indicated Change From Baseline to Study Completion in Diastolic Blood Pressure|Number of Participants With the Indicated Change From Baseline to Study Completion in Heart Rate|Mean Change From Baseline to Maximum Value in Phase II of the Study for Albumin|Mean Change From Baseline to Maximum Value in Phase II of the Study for Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase|Mean Change From Baseline to Maximum Value in Phase II of the Study for Amylase and Lipase|Mean Change From Baseline to Maximum Value in Phase II of the Study for Total Bilirubin and Creatinine|Mean Change From Baseline to Maximum Value in Phase II of the Study for Calcium, Glucose, Potassium, Magnesium, Inorganic Phosphorus, Sodium, and Urea|Mean Change From Baseline to Maximum Value in Phase II of the Study for Thyroxine and Free T3 (Triiodothyronine)|Mean Change From Baseline to Maximum Value in Phase II of the Study for Thyroid Stimulating Hormone|Mean Change From Baseline to Maximum Value in Phase II of the Study for Total T3|Mean Change From Baseline to Maximum Value in Phase II of the Study for Hemoglobin|Mean Change From Baseline to Maximum Value in Phase II of the Study for Hematocrit|Mean Change From Baseline to Maximum Value in Phase II of the Study for Lymphocytes, Neutrophils, Platelet Count, and White Blood Count|Mean Change From Baseline to Maximum Value in Phase II of the Study for International Normalized Ratio (Prothrombin Time)|Mean Change From Baseline to Maximum Value in Phase II of the Study for Partial Thromboplastin Time and Prothrombin Time|Mean Change From Baseline to Maximum Value in Phase I of the Study for Albumin|Mean Change From Baseline to Maximum Value in Phase I of the Study for Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase|Mean Change From Baseline to Maximum Value in Phase I of the Study for Amylase and Lipase|Mean Change From Baseline to Maximum Value in Phase I of the Study for Total Bilirubin and Creatinine|Mean Change From Baseline to Maximum Value in Phase I of the Study for Calcium, Glucose, Potassium, Magnesium, Inorganic Phosphorus, Sodium, and Urea|Mean Change From Baseline to Maximum Value in Phase I of the Study for Thyroxine|Mean Change From Baseline to Maximum Value in Phase I of the Study for Free T3 (Triiodothyronine)|Mean Change From Baseline to Maximum Value in Phase I of the Study for Thyroid Stimulating Hormone|Mean Change From Baseline to Maximum Value in Phase I of the Study for Total T3|Mean Change From Baseline to Maximum Value in Phase I of the Study for Hemoglobin|Mean Change From Baseline to Maximum Value in Phase I of the Study for Hematocrit|Mean Change From Baseline to Maximum Value in the Study for Lymphocytes, Neutrophils, Platelet Count, and White Blood Count|Mean Change From Baseline to Maximum Value in Phase I of the Study for International Normalized Ratio (Prothrombin Time)|Mean Change From Baseline to Maximum Value in Phase I of the Study for Partial Thromboplastin Time and Prothrombin Time|Number of Participants Experiencing a Dose-limiting Toxicity at the Indicated Dose|Overall Response (OR) in Phase II Based GlaxoSmithKline's Evaluation|Overall Response (OR) in Phase II Based on the Investigator-assigned Response|Overall Response (OR) in Phase II Based on an Independent Radiologist's Review|Progression-free Survival at 6 Months|Phase I: Pharmacokinetic Parameters Including AUC(0-24), [AUC(0-12) for Patients on Twice Daily Administration], Cmax, the Time to Maximum Observed Concentration (Tmax) and C24 of Pazopanib and Lapatinib When Administered in Combination With EIAC.|Phase II: Pharmacokinetic Parameters Including AUC(0-24), [AUC(0-12) for Patients on Twice Daily Administration], Cmax, Tmax, and C24 of Pazopanib and Lapatinib, as Appropriate, When Administered Together in Combination With Non-EIAC.|Phase II: Plasma Concentrations of the Circulating Biomarkers VEGF, sVEGFR-1, and sVEGFR-2.|Progression-free Survival|Time to Disease Progression or Death Due to Any Cause"	GlaxoSmithKline	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	75	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VEG102857	Dec-06	Dec-09	Dec-09	11-Jul-06	20-Jun-11	19-Apr-13			https://ClinicalTrials.gov/show/NCT00350727
1478	NCT01303835	Low Dose Naltrexone for Glioma Patients		Completed	Has Results	Malignant Glioma	Drug: LDN|Drug: Placebo	Effects of Low-dose Naltrexone Versus Placebo on Change in Quality of Life (QoL) in High-grade Glioma Patients Undergoing Standard Chemoradiation From Baseline|Effects of Low-dose Naltrexone Versus Placebo on Change in Functional Capacity From Baseline|Effects of Low-dose Naltrexone Versus Placebo on Change in Neurocognitive Function From Baseline	Katy Peters|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	110	Other	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment"	Pro00027661	May-11	Jun-14	May-15	25-Feb-11	26-Jun-15	17-Jul-15	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01303835
1479	NCT03234595	A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma		Recruiting	No Results Available	Recurrent High Grade Glioma	Drug: Cerebraca wafer	Determination of the DLT/MTD of Cerebraca Wafer with TMZ (Temozolomide) in patients with recurrent high grade glioma.|Evaluation of the efficacy/safety profile of Cerebraca Wafer with TMZ (Temozolomide) in patients with recurrent high grade glioma.	"Everfront Biotech Co., Ltd."	All	"20 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	36	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	EFBPOLZ20141120	1-Nov-17	30-Dec-21	31-Dec-22	31-Jul-17		30-Mar-21	"Hualien Tzu Chi Hospital, Hualien City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-Service General Hospital, Taipei, Taiwan"		https://ClinicalTrials.gov/show/NCT03234595
1480	NCT00337207	Bevacizumab in Treating Patients With Recurrent or Progressive Glioma		Completed	Has Results	Brain and Central Nervous System Tumors	Biological: bevacizumab	Safety of Treatment|Progression-free Survival at 6 Months|Tumoral Blood Flow Changes	Northwestern University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	55	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 05C3|NU-05C3|STU00005237	Mar-06	Nov-08	May-09	15-Jun-06	19-Nov-12	7-Feb-20	"Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00337207
1481	NCT00052455	"Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: lomustine|Drug: procarbazine hydrochloride|Drug: temozolomide|Drug: vincristine sulfate	Overall survival|Progression-free survival at 12 weeks (Arm II)|Toxicity|Quality of life as measured by EORTC QLQ-C30 and BTM|Cost effectiveness	"Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	500	Other	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000258428|MRC-BR12|EU-20114|ISRCTN83176944	Oct-02		Sep-10	27-Jan-03		18-Dec-13	"Medical Research Council Clinical Trials Unit, London, England, United Kingdom"		https://ClinicalTrials.gov/show/NCT00052455
1482	NCT00003842	IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Biological: interleukin-4 PE38KDEL cytotoxin|Drug: isolated perfusion|Procedure: surgical procedure		Barrett Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Primary Purpose: Treatment	CDR0000067001|UCMC-981061|NBI-3001-9802|NCI-V99-1536	Mar-99			14-Sep-04		18-Dec-13	"University of Southern California, Healthcare Consultation Center, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Neuro-Oncology Service, San Francisco, California, United States|John Wayne Cancer Institute, Santa Monica, California, United States|Laboratory of Molecular Biology, Bethesda, Maryland, United States|Food and Drug Administration, Rockville, Maryland, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Charlotte Neurosurgical Associates, Charlotte, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00003842
1483	NCT00003348	Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: carmustine		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	56	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000066327|DUMC-1094-99-6R5|DUMC-929-97-6R3|DUMC-980-98-6R4|NCI-T94-0080	May-98	Aug-00	Aug-00	16-Aug-04		20-Feb-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00003348
1484	NCT00002824	Gene Therapy in Treating Patients With Primary Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: gene therapy|Drug: chemotherapy|Drug: ganciclovir|Procedure: conventional surgery		Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000065004|UPCC-3394|NCI-H96-0976	Feb-96			29-Jul-04		13-Mar-19	"University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00002824
1485	NCT00003301	Irinotecan in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irinotecan hydrochloride		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000066241|NABTT-9711|JHOC-NABTT-9711	Jul-98		Apr-04	9-Apr-04		21-Jun-13	"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003301
1486	NCT00022360	Taurolidine in Treating Patients With Recurrent or Progressive Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: taurolidine		Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	MSKCC-01057|CDR0000068808|WALLACE-393|NCI-G01-2000	May-01	Oct-01	Oct-01	19-Mar-04		18-Jun-13	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00022360
1487	NCT00036660	SarCNU in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: SarCNU		NCIC Clinical Trials Group|Canadian Cancer Trials Group	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I142|CAN-NCIC-IND142|CDR0000068652	10-Jan-02	15-Apr-03	22-Sep-08	8-Jul-03		6-Apr-20	"Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada|Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00036660
1488	NCT00002971	O(6)-Benzylguanine in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	NABTC-9702|CDR0000065479|NCI-T96-0103	19-Jun-97	20-Feb-03	1-Jan-09	5-May-03		27-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00002971
1489	NCT00014443	Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: thalidomide|Drug: topotecan hydrochloride		Rush University Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	20	Other	Interventional	Primary Purpose: Treatment	CDR0000068544|RUSH-G101|NCI-V01-1651	Aug-00			27-Jan-03		24-Jul-08	"Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00014443
1490	NCT00003788	"Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas"		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: lomustine|Drug: porfimer sodium|Drug: procarbazine hydrochloride|Procedure: neoadjuvant therapy|Procedure: surgical procedure|Radiation: radiation therapy		Colorado Health Foundation|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	270	Other	Interventional	Allocation: Randomized|Primary Purpose: Treatment	CDR0000066927|HEALTHONE-43892|HEALTHONE-1A|HEALTHONE-CA43892|RPCI-DS-9802|NCI-V99-1525	Apr-98			27-Jan-03		6-Nov-13	"Rocky Mountain Neurological Associates, Englewood, Colorado, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|St. Michael's Hospital-Annex, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT00003788
1491	NCT01004887	Study of Tissue and Blood Samples From Patients With High-Grade Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Other: diagnostic laboratory biomarker analysis	time to progression|survival	Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"		631	Other|NIH	Observational	Observational Model: Case-Only|Time Perspective: Retrospective	NCCTG-94-72-52|NCCTG-947252|CDR0000406625|NCI-2009-00688	Nov-95	Dec-14	15-Jan-19	30-Oct-09		17-Jan-19	"Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|Bettendorf, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|Mount Sinai Medical Center, New York, New York, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Roger Maris Cancer Center at MeritCare Hospital, Fargo, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center Cancer Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States"		https://ClinicalTrials.gov/show/NCT01004887
1492	NCT03630861	Establishment of a Signature of Circulating microRNA as a Tool to Aid Diagnosis of Primary Brain Tumors in Adults	MIRNA	Completed	No Results Available	Brain Tumors		QR (relative amount)|QR value of each microRNA for all groups|Genetic abnormalities|Main imaging and anatomopathology characteristics	Assistance Publique - Hôpitaux de Paris	All	"50 Years to 75 Years   (Adult, Older Adult)"		160	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NI 14007|2015-A00503-46	10-Jan-16	5-Oct-17	Nov-17	15-Aug-18		15-Aug-18	"Groupe Hospitalier Pitié-Salpêtrière, Paris, France"		https://ClinicalTrials.gov/show/NCT03630861
1493	NCT03330197	A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG		Terminated	No Results Available	Pediatric Brain Tumor|Diffuse Intrinsic Pontine Glioma	Biological: Ad-RTS-hIL-12|Drug: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)|Drug: Oral Veledimex - Arm 2 (DIPG)	The safety and tolerability of intratumoral Ad-RTS-hIL-12 and veledimex as measured by dose limiting toxicities and compliance.|To measure the veledimex in blood and brain tumor by using the LC-MS method|Evaluate preliminary efficacy of Ad-RTS-hIL-12 and veledimex by assessing survival and tumor response rates|Measure immune response of Ad-RTS-hIL-12 and veledimex by a quantitative multiplex immunoassay for determination of IL-12 and IFNg levels|Subjects with Ad-RTS-hIL-12 and veledimex related adverse events will be assessed for safety by CTCAE v5.0	Ziopharm	All	"up to 21 Years   (Child, Adult)"	Phase 1|Phase 2	6	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATI001-103	26-Sep-17	10-Sep-21	10-Sep-21	6-Nov-17		11-Nov-21	"University of California San Francisco, Benioff Children's Hospital, San Francisco, California, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Dana- Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT03330197
1494	NCT01048008	Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer	DM-CHOC-PEN	Completed	No Results Available	Advanced Cancer|Brain Involvement	Drug: DM-CHOC-PEN	Document maximum tolerated dose (MTD) & SLT|Document a toxicity profile for the drug	"DEKK-TEC, Inc.|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	22	Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DTI-021|5R43CA132257-02	Sep-10	Jul-13	Nov-13	13-Jan-10		4-Aug-20	"Tulane University Medical School, New Orleans, Louisiana, United States"		https://ClinicalTrials.gov/show/NCT01048008
1495	NCT00278278	Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: cisplatin|Drug: etoposide|Drug: ifosfamide|Drug: lomustine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate	"Overall survival (OS) rate at 5.5 years|Comparison of OS, progression-free survival, and event-free survival with historical control annually|Long-term sequelae annually|Tumor response|Progression-free survival|Event-free survival|Health status"	Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)	All	"3 Years to 18 Years   (Child, Adult)"	Phase 3	150	Other	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000454723|GPOH-HIT-GBM-D|EU-205100	Sep-03	Mar-10		18-Jan-06		19-Dec-13	"M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00278278
1496	NCT01508104	Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors		Terminated	No Results Available	Cancer	Drug: BEZ235|Drug: Everolimus	Dose limiting toxicity	University of Cincinnati|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CBEZ235ZUS08T	Jan-12	Feb-14	Dec-14	11-Jan-12		23-Aug-17	"University of Cincinnati, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT01508104
1497	NCT00516282	VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma		Terminated	No Results Available	Brain and Central Nervous System Tumors	Drug: CLORETAZINE|Drug: temozolomide	MTD of CLORETAZINE|Progression-free survival rate|Toxicities of CLORETAZINE when administered with Temodar®.|MGMT Methylation Status|Determine overall survival|Response rate to CLORETAZINE after Temodar® in patients with malignant gliomas in first or second relapse|Record the toxicities of CLORETAZINE when administered after Temodar|Measure the level of AGT expression|CSF penetration of CLORETAZINE	Northwestern University|Vion Pharmaceuticals	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	14	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 07C1	Aug-07	Oct-09	Oct-09	15-Aug-07		26-Aug-11	"Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00516282
1498	NCT01966809	Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas		Terminated	Has Results	"Brain Tumor, Recurrent"	Drug: Photofrin photodynamic therapy.	Six Month Relapse-free Survival (RFS).|Remission Rate.|Progression-free Survival and Overall Survival.|Tumor Response.	"Harry T Whelan, MD|Pinnacle Biologics Inc.|Medical College of Wisconsin"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	1	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO00023580	Jun-15	19-Dec-17	19-Dec-17	22-Oct-13	8-Aug-19	20-Aug-19	"Medical College of Wisconsin/ Froedtert Hospital, Milwaukee, Wisconsin, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/09/NCT01966809/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT01966809
1499	NCT00285324	Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis		Completed	No Results Available	Glioma Tumor Recurrence|Radiation Necrosis|Primary Brain Tumor			National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	"21 Years and older   (Adult, Older Adult)"		29	NIH	Observational		060085|06-N-0085	27-Jan-06		20-Aug-13	1-Feb-06		6-Oct-17	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00285324
1500	NCT00068510	Vaccine Therapy in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: therapeutic autologous dendritic cells	"Dose Limiting Toxicity|Time to tumor progression, overall survival and cellular immune responses in brain tumor patients injected with tumor lysate pulsed dendritic cells"	Jonsson Comprehensive Cancer Center|National Institutes of Health (NIH)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	28	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000327711|UCLA-0304053	Jun-03	Sep-12	Sep-12	11-Sep-03		3-Aug-20	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00068510
1501	NCT00005855	Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: efaproxiral	Safety and tolerability|Maximum tolerated dose|Pharmacokinetic profile|Efficacy	New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	48	Other|NIH	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000067881|NABTT-9806|JHOC-NABTT-9806	Jul-00		Oct-06	27-Jan-03		21-Jun-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00005855
1502	NCT00004080	Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: recombinant adenovirus-p53 SCH-58500|Procedure: conventional surgery		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000067291|NABTT-9703|JHOC-NABTT-9703	Dec-99			5-Aug-04		9-Feb-09			https://ClinicalTrials.gov/show/NCT00004080
1503	NCT00003574	Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Procedure: surgical procedure|Radiation: brachytherapy|Radiation: intraoperative radiation therapy|Radiation: iodine I 125		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000066641|NABTT-9801|JHOC-NABTT-9801	Apr-99		Jun-04	16-Jun-04		21-Jun-13	"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003574
1504	NCT00005081	Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: carmustine		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	0059|DUMC-0059-00-1|DUMC-T98-0059|NCI-T98-0059|CDR0000067688	Aug-00	Apr-01	Apr-01	3-May-04		21-Aug-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00005081
1505	NCT00003176	Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: temozolomide		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	82	Other|NIH	Interventional	Primary Purpose: Treatment	NABTC-9701|CDR0000065986|NCI-T96-0082	25-Mar-98	3-Dec-01	6-Jan-04	7-Apr-04		27-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00003176
1506	NCT00004004	Procarbazine in Treating Patients With Recurrent Brain Tumor		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: procarbazine hydrochloride		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000067214|NABTT-9901|JHOC-NABTT-9901	Jul-99		Aug-03	20-Aug-03		21-Jun-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004004
1507	NCT00743353	"Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5"	K5	Completed	No Results Available	Sarcoma|Melanoma|Lung Cancer|Breast Cancer|High Grade Gliomas	Drug: F-18 RGD-K5	To collect bio-distribution data to calculate dosimetry values in normals and obtain and evaluate PET images in cancer subjects for resolution of [F-18]RGD-K5	Siemens Molecular Imaging	All	"Child, Adult, Older Adult"	Early Phase 1	16	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	K5-100	Aug-08	Jan-09	Jan-09	28-Aug-08		2-Feb-09	"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00743353
1508	NCT00036972	Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: cintredekin besudotox|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy		Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	NEOPHARM-IL13PEI-002-R01|MSKCC-01141|CDR0000069345|NCI-G02-2066	Nov-01	Jan-05	Dec-09	27-Jan-03		26-Jun-13	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00036972
1509	NCT00017264	Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: atrasentan hydrochloride		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000068668|NABTT-2008|JHOC-NABTT-2008	Jun-02			27-Jan-03		13-Jan-09	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00017264
1510	NCT00014521	Karenitecin in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: karenitecin		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000068552|NABTT-2006|JHOC-NABTT-2006	Jan-02			27-Jan-03		24-Jul-08	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00014521
1511	NCT00012038	Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irofulven		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068474|NABTT-2005|JHOC-NABTT-2005	Jul-01		Oct-03	27-Jan-03		24-Jun-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00012038
1512	NCT00006268	Immunotoxin Therapy in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: cintredekin besudotox|Drug: isolated perfusion|Procedure: conventional surgery		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068211|NABTT-9903|JHOC-NABTT-9903|NEOPHARM-TS-G1-TI4|NEOPHARM-IL13PEI-001-R03	Oct-00		Mar-05	27-Jan-03		24-Jun-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00006268
1513	NCT00006093	EMD 121974 in Treating Patients With Progressive or Recurrent Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: cilengitide		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068098|NABTT-9911|JHOC-NABTT-9911	Sep-00		Oct-06	27-Jan-03		24-Jun-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00006093
1514	NCT00004147	COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: incyclinide		New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000067379|NABTT-9809|JHOC-NABTT-9809	Jul-00		Nov-06	27-Jan-03		21-Jun-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004147
1515	NCT00003067	Biological Therapy in Treating Patients With Primary or Advanced Glioma		Suspended	No Results Available	Brain and Central Nervous System Tumors	Biological: aldesleukin|Biological: lymphokine-activated killer cells		Weill Medical College of Cornell University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other	Interventional	Primary Purpose: Treatment	CDR0000065739|NYWCCC-0902499|NYWCCC-IMMUNE-0902499|SIUH-RP-96-004|NCI-V97-1326	Jul-97			27-Jan-03		9-Feb-09	"Staten Island University Hospital, Staten Island, New York, United States"		https://ClinicalTrials.gov/show/NCT00003067
1516	NCT00463008	Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: methotrexate|Other: pharmacological study	Comparison of methotrexate levels in the brain extracelluar fluid vs in the serum|Safety and efficacy of the microdialysis catheter	New Approaches to Brain Tumor Therapy Consortium|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	12	Other|NIH	Interventional	Allocation: Non-Randomized|Primary Purpose: Treatment	CDR0000346432|NABTT-0302|JHOC-NABTT-0302	May-04		Apr-07	19-Apr-07		24-Jun-13			https://ClinicalTrials.gov/show/NCT00463008
1517	NCT00897611	Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma		Completed	No Results Available	High Grade Glioma	Procedure: DNA methylation analysis|Procedure: polymerase chain reaction|Procedure: computed tomography|Procedure: magnetic resonance imaging	Total plasma glioma-specific DNA concentration|Tumor size	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|North American Brain Tumor Consortium	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	42	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)	NABTT-0402 CDR0000462562|U01CA062475|NABTT-0402	Apr-05	Aug-09		12-May-09		30-Nov-12			https://ClinicalTrials.gov/show/NCT00897611
1518	NCT01906385	"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)"		Recruiting	No Results Available	Glioma	Drug: Rhenium Liposome Treatment	Maximum Tolerated Dose|Dose Distribution|Response rate|Survival	Plus Therapeutics|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	55	Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTRC 12-02|14-450X|20141749|1R01CA235800-01A1	3-Jun-15	Jan-25	Jan-25	24-Jul-13		5-Nov-21	"UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|The Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT01906385
1519	NCT00268359	Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: bevacizumab|Drug: irinotecan hydrochloride	Safety|Activity in terms of progression-free survival	Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	68	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	Pro00004091|DUMC-6771-05-1R0|GENENTECH-AVF3311s|CDR0000450832	May-05	Aug-06	Oct-09	22-Dec-05		21-Jul-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00268359
1520	NCT00433472	MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Device: magnetic resonance imaging (MRI)	Measurable effect of efaproxiral on the brain as measured by T2 and/or T2* MRI|Predicted oxygenation changes based on observed T2 MRI changes|Effects of efaproxiral on T2 and T2* MRI relaxation times of normal areas of the brain|Baseline oxygen extraction ratios in tumors|New tumor- or non-tumor-related abnormalities on T2 and T2* MRI	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	0	Other|NIH	Interventional	Primary Purpose: Diagnostic	NABTT-2002 CDR0000274785|U01CA062475|P30CA006973|NABTT-2002|JHOC-NABTT-2002|ALLOS-RSR13CT-001i				12-Feb-07		29-Jul-15			https://ClinicalTrials.gov/show/NCT00433472
1521	NCT00087061	Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: gimatecan		Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	SIGMATAU-ST-01-402|UCLA-0403029-01	May-04		Jun-05	12-Jul-04		18-Jul-13	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00087061
1522	NCT00075894	Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: L-alanosine		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000349473|NABTT-0303	Mar-04			13-Jan-04		13-Jan-09	"H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00075894
1523	NCT00631137	Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma		Terminated	Has Results	Brain and Central Nervous System Tumors|Musculoskeletal Complications	Drug: testosterone gel applied to skin|Dietary Supplement: whey powder protein	"Time to Event, Defined as ≥ 50% Loss of Strength in the Hip Flexors as Assessed by Dynamometry Peak Force Measures at Baseline and at 1, 3, 5, and 7 Months|Muscle Strength Testing in Other Proximal Muscles (i.e., Knee Extensors, Knee Flexors, Arm Abductors, Elbow Extensors and Flexors, and Neck Flexors) as Assessed by Dynamometry at Baseline and at 1, 3, 5, and 7 Months|Performance on Timed Functional Tests (TFT) as Assessed at Baseline and at 1, 3, 5, and 7 Months|Leg Muscle Mass as Assessed by CT Scan at Baseline and at 3 and 7 Months|Activities of Daily Living as Assessed by the Health Assessment Questionnaire-Disability Index at Baseline and at 1, 3, 5, and 7 Months|Side Effects of Testosterone Gel as Assessed by Frequency of Adverse Events, Including Laboratory Abnormalities|Serum Total Testosterone Levels as Assessed at Baseline and at 1, 3, and 7 Months"	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	Male	"18 Years to 120 Years   (Adult, Older Adult)"	Not Applicable	1	Other|NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care"	J0634|P30CA006973|JHOC-J0634|NA_00003125|CDR0000584274	Jan-08	Sep-08	Sep-08	7-Mar-08	27-Aug-18	27-Aug-18	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00631137
1524	NCT00404248	Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: terameprocol|Other: pharmacological study	Maximum Tolerated Dose (Phase I)|Maximum Tolerated Dose (Phase I) - Dose Limiting Toxicity (DLT)|Pharmacokinetics - Total Body Clearance|Pharmacokinetics - Steady-State Apparent Volume Distribution|Pharmacokinetics - Terminal Phase Half-life|Efficacy - Best Overall Response|Survival	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	35	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NABTT-0503 CDR0000515952|U01CA062475|NABTT-0503	Jan-07	Jun-09	Feb-12	28-Nov-06	11-Aug-15	6-Mar-19	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00404248
1525	NCT00045474	Brachytherapy in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Procedure: adjuvant therapy|Radiation: iodine I 125		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000256587|NABTT-2106|JHOC-NABTT-2106	Oct-02			27-Jan-03		9-Feb-09	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00045474
1526	NCT00253669	Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors|Thromboembolism	Other: laboratory biomarker analysis|Other: physiologic testing|Procedure: management of therapy complications	Thrombosis-free survival as assessed by objectively documented deep vein thrombosis or pulmonary embolism|ABO blood group association with venous thromboembolism (VTE) factor VIII activity and VTE as assessed by laboratory test result at study entry	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|North American Brain Tumor Consortium	All	"18 Years to 120 Years   (Adult, Older Adult)"		110	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NABTT-0307|U01CA062475|CDR0000441111|JHOC-NABTT-0307	Apr-05	Aug-09	Aug-09	15-Nov-05		28-Jun-18	"Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00253669
1527	NCT00445965	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer		"Active, not recruiting"	No Results Available	Brain and Central Nervous System Tumors|Intraocular Melanoma|Lung Cancer|Melanoma (Skin)|Metastatic Cancer|Neuroblastoma|Ovarian Cancer|Retinoblastoma|Sarcoma|Small Intestine Cancer	Genetic: DNA analysis|Other: immunologic technique|Other: pharmacological study|Radiation: iodine I 131 monoclonal antibody 3F8|Radiation: 131I-3F8	Six-month overall survival|response rate|cumulative toxicities	Memorial Sloan Kettering Cancer Center	All	"Child, Adult, Older Adult"	Phase 2	78	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-122|MSKCC-05122	Jan-06	Jan-23	Jan-23	9-Mar-07		1-Nov-21	"Memorial Sloan Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00445965
1528	NCT00002647	Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors		Unknown status	No Results Available	Brain and Central Nervous System Tumors|Metastatic Cancer	Drug: verteporfin|Procedure: conventional surgery		Medical College of Wisconsin|National Cancer Institute (NCI)	All	"3 Years to 70 Years   (Child, Adult, Older Adult)"	Phase 1	24	Other	Interventional	Primary Purpose: Treatment	CDR0000064165|MCW-7594|MCW-CHW-511|MCW-CHW-9411|NCI-V95-0652	May-94			27-Jan-03		20-Sep-13	"Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States|Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00002647
1529	NCT00118222	High Light and Low Light Dose PDT in Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: porfimer sodium|Procedure: adjuvant therapy|Procedure: conventional surgery	Time to progression and survival measured	Case Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	1	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CWRU4303|P30CA043703|CASE-4303|CWRU-00003937|CWRU-4303	Mar-05	Mar-06	Mar-06	11-Jul-05		11-Jun-10	"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00118222
1530	NCT01132547	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer		Terminated	Has Results	Cancer	Drug: cyproheptadine hydrochloride|Other: placebo	Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline|Severity of Weight Loss|Pattern of Weight in the Study Population	University of South Florida|National Cancer Institute (NCI)	All	"2 Years to 21 Years   (Child, Adult)"	Phase 3	22	Other|NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care"	SCUSF 0703|SCUSF-0703|5U10CA081920-11	Jun-10	Jan-14	Jan-14	28-May-10	2-Jul-15	2-Jul-15	"Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States"		https://ClinicalTrials.gov/show/NCT01132547
1531	NCT00069940	Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor		Completed	No Results Available	Brain and Central Nervous System Tumors|Gastrointestinal Stromal Tumor|Sarcoma	Biological: sargramostim|Biological: telomerase: 540-548 peptide vaccine		Dana-Farber Cancer Institute|National Cancer Institute (NCI)	All	"2 Years and older   (Child, Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	03-365|P30CA006516	Dec-00	Aug-06	Aug-08	7-Oct-03		28-Dec-10	"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00069940
1532	NCT00002754	Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors|Melanoma (Skin)|Metastatic Cancer	Biological: monoclonal antibody Me1-14 F(ab')2		Duke University|National Cancer Institute (NCI)	All	"3 Years and older   (Child, Adult, Older Adult)"	Phase 1	6	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000064690|DUMC-0334-99-2R6|DUMC-219-96-2R3|DUMC-302-97-2R4|DUMC-308-98-2R5|NCI-V96-1071	Feb-93	Apr-01	Apr-01	29-Jul-04		20-Feb-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00002754
1533	NCT00006263	"Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma"		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Biological: filgrastim|Drug: carboplatin|Drug: temozolomide		NYU Langone Health|National Cancer Institute (NCI)	All	"up to 64 Years   (Child, Adult)"	Phase 2	0	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068203|NYU-0004H|NYU-0029H|NCI-G00-1856	Nov-97			27-Jan-03		5-Aug-15	"NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00006263
1534	NCT00124657	Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma		Completed	Has Results	Brain and Central Nervous System Tumors	Drug: Erlotinib hydrochloride	"Number of Participants With Dose-limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD) of Erlotinib|Progression Free Survival (PFS)|Cmax of Erlotinib and Its Metabolite OSI-420|Erlotinib Tmax|AUC Time 0-infinite (AUCinf) of Erlotinib and Its Metabolite OSI-420|Number of Positive Mutations of EGFR and Downstream Pathways|Ability of Erlotinib to Inhibit EGFR Signaling|Correlation Between Standard Magnetic Resonance Imaging and Investigational Radiologic Techniques in Assessing Tumor Response to This Treatment|To Prospectively Investigate the Technical Factors Involved in Planning and Administering Conformal Fractionated RT as Outlined in This Study, and to Correlate RT Dosimetry With Patterns of Failure, Standard and Investigational Imaging and Toxicity|Plasma and CSF Levels of VEGF, bFGF, and SDF1|Number of Participants Experiencing Grade 3 or 4 Toxicity Events"	"St. Jude Children's Research Hospital|Rady Children's Hospital, San Diego|Duke University"	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1|Phase 2	62	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SJHG04	Mar-05	Jul-12	Sep-14	28-Jul-05	29-Apr-14	4-Dec-15	"University of California San Diego, San Diego, California, United States|Duke Children's Hospital and Health Center, Durham, North Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00124657
1535	NCT00003476	Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors		Terminated	Has Results	Childhood Brain Tumor	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"6 Months to 18 Years   (Child, Adult)"	Phase 2	8	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066513|BC-BT-22	Mar-96	Jan-12	Jan-12	27-Jan-03	10-Apr-17	24-Aug-17	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003476
1536	NCT04430842	"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S"		Recruiting	No Results Available	Astrocytoma|Brain Cancer|Brain Metastases|Bladder Cancer|Breast Cancer|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophagus Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Liver Cancer|Lung Cancer|Melanoma|Ovarian Cancer|Pancreatic Cancer|Pleural Mesothelioma|Prostate Cancer|Sarcoma|Tongue Cancer|Thymic Carcinoma|Urinary Tract Cancer	Drug: QBS10072S	Determination of maximum tolerated dose (MTD)|Safety and tolerability assessed by adverse events and serious adverse events|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC) of QBS10072S|Half-life of QBS10072S in plasma (t1/2)|Time to maximum concentration of QBS10072S in plasma (Tmax)	"Quadriga Biosciences, Inc.|Novotech (Australia) Pty Limited"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	50	Industry	Interventional	Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QBS-72S-1001	20-Jul-20	Sep-21	Dec-21	12-Jun-20		9-Mar-21	"St George Private Hospital, Kogarah, New South Wales, Australia|Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia"		https://ClinicalTrials.gov/show/NCT04430842
1537	NCT00005796	Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors		Completed	No Results Available	Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ	Procedure: filgrastim|Biological: gene therapy|Drug: lomustine|Drug: procarbazine hydrochloride|Drug: vincristine sulfate|Procedure: in vitro-treated peripheral blood stem cell transplantation	Determine the toxicity (detection of replication competent retrovirus) associated with CD34+ cells transduced with a retroviral vector expressing human O6-methylguanine DNA methyltransferase in adult and pediatric patients with poor prognosis CNS tumors.	Indiana University|Indiana University Melvin and Bren Simon Cancer Center	All	"5 Years and older   (Child, Adult, Older Adult)"	Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	9607-22|IUMC-9607-22|NCI-H00-0049	Feb-00	Jun-03	Dec-11	28-Apr-04		25-Mar-15	"Indiana University Cancer Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00005796
1538	NCT00002752	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers		Completed	No Results Available	Brain and Central Nervous System Tumors|Metastatic Cancer	Radiation: iodine I 131 monoclonal antibody 81C6		Duke University	All	"3 Years and older   (Child, Adult, Older Adult)"	Phase 1|Phase 2		Other	Interventional	Primary Purpose: Treatment	Pro00004635|DUMC-2426-01-2R8|DUMC-000223-00-2R7|DUMC-0328-99-2R6|DUMC-221-96-2R3|DUMC-307-97-2R4|DUMC-307-98-2R5|NCI-H96-0009|CDR0000064688	Feb-93	Jan-03	Mar-10	8-Jul-03		16-Jul-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00002752
1539	NCT00014573	Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation		Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)	All	"up to 65 Years   (Child, Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000068559|P30CA022453|WSU-D-1654|WSU-07-92-98-P04-FB|NCI-G01-1937	Aug-98	Oct-04	Oct-04	5-Apr-04		8-Apr-13	"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States"		https://ClinicalTrials.gov/show/NCT00014573
1540	NCT01403311	A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain	ALA	Unknown status	No Results Available	Glioma	Drug: 5-Aminolevuline Acid	Establish a safe dose to provide optimal discrimination between normal and malignant tissue for oral ALA administration intraoperatively|Compare time-to-progression and survival to that in comparable cases performed without the aid of ALA	"Legacy Health System|DUSA Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	18	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	5-ALA-01	Oct-10	Dec-11	Mar-15	27-Jul-11		26-Mar-14	"Legacy Health System, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT01403311
1541	NCT00002608	Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors		Completed	No Results Available	Adrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma	Drug: cisplatin|Drug: doxorubicin hydrochloride|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy		Ottawa Regional Cancer Centre|National Cancer Institute (NCI)	All	"up to 65 Years   (Child, Adult, Older Adult)"	Phase 2	30	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CAN-OTT-9401|CDR0000063892|NCI-V94-0566	May-94		Apr-05	27-Jan-03		10-Jul-13	"Ottawa Regional Cancer Centre at Ottawa Hospital - General Campus, Ottawa, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT00002608
1542	NCT01480050	Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide|Other: 3'-deoxy-3'-[18F]fluorothymidine|Other: pharmacological study|Drug: Mibefradil	Maximum-tolerated dose of mibefradil dihydrochloride|Dose-limiting toxicity|Toxicity and adverse events according to CTCAE v. 4.0|Biological activity of treatment determined by radiographic response|Pharmacokinetics of mibefradil dihydrochloride as measured by the steady-state maximum plasma concentration (Cmax)|Potential effect of mibefradil dihydrochloride on tumor metabolism as determined by [F-18]FLT PET scans in the dose-expansion cohort	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Jazz Pharmaceuticals	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	28	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABTC-1101 CDR0000716313|NA_00068561|M1 CA137443	31-May-12	Aug-15	1-Jun-17	28-Nov-11		22-May-19	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT01480050
1543	NCT00302159	Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors		Completed	Has Results	High Grade Gliomas|Brain Tumors	Procedure: adjuvant therapy|Drug: Temozolomide|Drug: Valproic Acid|Radiation: Radiation therapy	"Median Progression Free Survival.|Percentage of Participants With Progression Free Survival at 6, 12, and 24 Months|Number of Participants With Best Response|Median Overall Survival|Percentage of Participants With Overall Survival at 6, 12, and 24 Months|Number of Participants With Adverse Events"	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	"18 Years to 90 Years   (Adult, Older Adult)"	Phase 2	43	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	060112|06-C-0112	Mar-06	Jun-13	Nov-14	13-Mar-06	24-Jun-14	18-Aug-16	"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Virginia Commonwealth University, Richmond, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00302159
1544	NCT00544284	Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment		Completed	No Results Available	"Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific"	Drug: bortezomib|Drug: temozolomide|Other: pharmacological study	Dose-limiting toxicity and maximum tolerated dose|Pharmacokinetics|Confirmed complete or partial response|Percentage of patients with 6-month progression-free survival	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	25	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	04032|P30CA033572|CHNMC-04032|CDR0000570245	Jan-05	Jan-12	Jan-12	16-Oct-07		15-Feb-13	"City of Hope Comprehensive Cancer Center, Duarte, California, United States|City of Hope Medical Group, Pasadena, California, United States"		https://ClinicalTrials.gov/show/NCT00544284
1545	NCT01273090	Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma		Completed	No Results Available	"Brain and Central Nervous System Tumors|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: imetelstat sodium|Other: laboratory biomarker analysis|Other: pharmacological study	Maximum-tolerated dose and/or recommended phase II dose of imetelstat sodium in children with refractory or recurrent solid tumors or lymphoma|Toxicities of imetelstat sodium	Children's Oncology Group|National Cancer Institute (NCI)	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	34	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADVL1112|COG-ADVL1112	May-11	Sep-13	Oct-13	10-Jan-11		30-Jan-14	"UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Riley's Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St. Louis, Missouri, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT01273090
1546	NCT00612001	Vaccine Therapy in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine	Dose-limiting toxicity and maximum tolerated dose of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides|Survival|Tumor progression	Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	8	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000585166|R01CA112358|UCLA-06-01-052	May-06	Jan-11	Oct-12	11-Feb-08		5-Oct-15	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00612001
1547	NCT00795665	Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma		Completed	Has Results	Glioma	Drug: bevacizumab|Drug: carmustine	Progression-free Survival|Radiographic Response to Therapy|Differentiate a Radiographic Response Due to Tumor Shrinkage From a Radiographic Response Due to Decreased Vasogenic Edema|Safety and Toxicity|Overall Survival	"University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	7	Other|NIH|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	224865|UCDCC#208|P30CA093373	Jun-08	Dec-15	Dec-15	21-Nov-08	12-May-20	12-May-20	"University of California Davis Cancer Center, Sacramento, California, United States"		https://ClinicalTrials.gov/show/NCT00795665
1548	NCT00005083	Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Procedure: conventional surgery|Procedure: magnetic resonance imaging|Procedure: magnetic resonance spectroscopic imaging		Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	18 Years to 55 Years   (Adult)	Phase 2	0	Other|NIH	Interventional	Primary Purpose: Diagnostic	CDR0000067692|UCLA-9712069|NCI-G00-1726	Mar-98			16-Dec-03		4-Oct-12			https://ClinicalTrials.gov/show/NCT00005083
1549	NCT00005637	Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: temozolomide		Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000067793|MSKCC-99114|NCI-G00-1765	Dec-99	Jun-03	Dec-09	27-Jan-03		4-Apr-13	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00005637
1550	NCT00967200	Study of Tissue Samples From Patients With Glioma or Other Brain Tumors		Completed	No Results Available	Central Nervous System Lymphoma	Other: laboratory biomarker analysis|Other: pharmacogenomic studies	Pathophysiology of gliomas|Identification of molecular	"University Hospital, Montpellier"	All	"18 Years to 120 Years   (Adult, Older Adult)"		180	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	7745	Nov-03	Jul-09	Nov-15	27-Aug-09		24-Nov-15	"CHU Montpellier, Montpellier, France|Clinique Gui de Chauliac, Montpellier, France"		https://ClinicalTrials.gov/show/NCT00967200
1551	NCT00009854	Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm		Unknown status	No Results Available	Brain and Central Nervous System Tumors|Metastatic Cancer	Drug: carmustine in ethanol|Procedure: conventional surgery		Direct Therapeutics|National Cancer Institute (NCI)	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 1|Phase 2		Industry	Interventional	Primary Purpose: Treatment	CDR0000068416|DTI-0002|UCSF-H7858-17520-01|NCI-V00-1642	Jun-00			27-Jan-03		6-Nov-13	"UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Massey Cancer Center, Richmond, Virginia, United States"		https://ClinicalTrials.gov/show/NCT00009854
1552	NCT00387933	"Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: hydroxyurea|Drug: imatinib mesylate|Drug: vatalanib	Maximum tolerated dose and dose-limiting toxicity of imatinib mesylate and vatalanib when administered with hydroxyurea|Safety|Tolerability|Pharmacokinetic|Antiangiogenic effects	Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	37	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00006014|DUMC-7019-06-3R1|NOVARTIS-DUMC-7019-06-3R1	Jul-05	Jan-09		13-Oct-06		14-Oct-15	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00387933
1553	NCT01032200	Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors		Completed	Has Results	Brain Tumors|Nervous System Tumors|Cognition Disorders|Fatigue	Drug: Armodafinil|Other: placebo	Retention|Adherence|Fatigue|Sleepiness|HVLT-IR	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	54	Other|NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"	IRB00012856|U10CA081851|REBACCCWFU97509	1-Aug-10	8-Jan-13	8-Jan-13	15-Dec-09	13-Feb-17	28-Sep-21	"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01032200
1554	NCT00003564	Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Drug: Isotretinoin|Drug: Procarbazine Hydrochloride	Time to Progression for Procarbazine alone or with Isotretinoin	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	"16 Years and older   (Child, Adult, Older Adult)"	Phase 3	0	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DM97-050|P30CA016672|MDA-DM-97050|NCI-T97-0078|CDR0000066630				13-Sep-04		22-Feb-12			https://ClinicalTrials.gov/show/NCT00003564
1555	NCT00002572	Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: aldesleukin|Biological: muromonab-CD3|Biological: therapeutic tumor infiltrating lymphocytes|Procedure: conventional surgery		"University of Colorado, Denver|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	10	Other|NIH	Interventional	Primary Purpose: Treatment	93-0426.cc|UCHSC-COMIRB-93426|NCI-T94-0065O	Nov-94	Dec-99	Dec-99	29-Jul-04		30-May-13	"Children's Health Center, Denver, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|University of Colorado Cancer Center, Denver, Colorado, United States"		https://ClinicalTrials.gov/show/NCT00002572
1556	NCT00004041	Gene Therapy in Treating Patients With Recurrent Malignant Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: Ad5CMV-p53 gene|Procedure: conventional surgery		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	NABTC-9703|CDR0000066871	25-Feb-99	22-Jul-02	1-Jul-03	19-Jul-04		27-Jun-18	"UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00004041
1557	NCT00002639	Suramin in Treating Patients With Recurrent Primary Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: chemotherapy|Drug: suramin		Emory University|National Cancer Institute (NCI)	All	"15 Years and older   (Child, Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000064118|EUC-DON-9420|NCI-T94-0033O	Jul-95		May-04	26-May-04		21-Jun-13	"Department of Neurosurgery - Emory, Atlanta, Georgia, United States"		https://ClinicalTrials.gov/show/NCT00002639
1558	NCT00004113	Temozolomide in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temozolomide		Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	99-019|CDR0000067337|NCI-G99-1602	Jun-99	Oct-01	Oct-01	21-May-04		19-Jun-13	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00004113
1559	NCT00005082	Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Procedure: biopsy|Procedure: magnetic resonance imaging		Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	1	Other|NIH	Interventional	Primary Purpose: Diagnostic	CDR0000067691|UCLA-9808001|NCI-G00-1725	Nov-98	Nov-00		23-Apr-04		8-Jan-13	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00005082
1560	NCT00274755	Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: chemotherapy|Procedure: conventional surgery|Procedure: magnetic resonance imaging|Procedure: magnetic resonance spectroscopic imaging|Radiation: radiation therapy	Survival|Time to clinical progression	"University of California, San Francisco|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	250	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Diagnostic	CDR0000441015|UCSF-05106	Nov-03	Apr-07		11-Jan-06		20-May-14	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00274755
1561	NCT00027625	Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: gefitinib|Drug: temozolomide		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	NABTC-0102|CDR0000069049	28-Jan-02	17-Mar-05	1-Nov-05	27-Jan-03		27-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00027625
1562	NCT00022724	CCI-779 in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: temsirolimus		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	49	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Primary Purpose: Treatment	NABTC-0101|CDR0000068848	27-Aug-01	4-May-06	15-Dec-07	27-Jan-03		26-Jun-18	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00022724
1563	NCT00006025	Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irinotecan hydrochloride|Drug: temozolomide		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment	NABTC-9907|CDR0000068037|UCLA-0006095|NCI-2012-02353	5-Jan-01	10-Jan-05	1-Dec-07	27-Jan-03		27-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00006025
1564	NCT00005951	Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irinotecan hydrochloride|Drug: temozolomide		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	1087|DUMC-1087-02-6R3|DUMC-001087-006R1|DUMC-1067-99-6|NCI-G00-1795|DUMC-001087-01-6R2|CDR0000067931	Aug-00	Apr-06	Apr-06	27-Jan-03		22-Aug-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00005951
1565	NCT00039364	Imatinib Mesylate in Treating Patients With Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: imatinib mesylate		European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	112	Other	Interventional	Primary Purpose: Treatment	EORTC-16011-26013|EORTC-16011|EORTC-26013	Mar-02	Aug-04		27-Jan-03		24-Jul-12	"Kaiser Franz Josef Hospital, Vienna, Austria|U.Z. Gasthuisberg, Leuven, Belgium|Centre de Lutte Contre le Cancer, Georges-Francois Leclerc, Dijon, France|CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France|Centre Antoine Lacassagne, Nice, France|Institut Gustave Roussy, Villejuif, France|Azienda Ospedaliera di Padova, Padova, Italy|Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Beatson Oncology Centre, Glasgow, Scotland, United Kingdom"		https://ClinicalTrials.gov/show/NCT00039364
1566	NCT00036894	CC-5013 in Treating Patients With Recurrent Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: lenalidomide		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000069338|NCI-02-C-0145	Mar-02			27-Jan-03		30-Apr-15	"Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00036894
1567	NCT00006474	"Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: temozolomide|Procedure: conventional surgery		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	1388|DUMC-1388-02-8R2|DUMC-1388-00-8|NCI-490|DUMC-1388-01-8R1|CDR0000068301	Mar-01	Aug-04	Aug-04	27-Jan-03		20-Jun-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00006474
1568	NCT00005976	Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carboplatin|Drug: pyrazoloacridine		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01850|NCCTG-987254|CDR0000067963	May-00	Dec-06	Apr-07	27-Jan-03		3-Jun-13	"CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ochsner, New Orleans, Louisiana, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Health Plaza, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Medcenter One Health System, Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00005976
1569	NCT00004028	Carmustine in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Procedure: conventional surgery		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000065129|NABTT-101-9601|JHOC-NABTT-101-9601|NCI-T96-0052H	Sep-96			27-Jan-03		9-Feb-09	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004028
1570	NCT00004024	Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: muromonab-CD3|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Procedure: surgical procedure|Radiation: radiation therapy		Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000067243|P30CA022453|WSU-C-1403-BT|NCI-G99-1567	Jun-97	Jan-04	Jan-04	27-Jan-03		5-Apr-13	"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States"		https://ClinicalTrials.gov/show/NCT00004024
1571	NCT00498979	"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers"		Completed	No Results Available	Stage IV Melanoma	Biological: recombinant interferon alfa-2b|Drug: cisplatin|Drug: sodium stibogluconate|Drug: dacarbazine|Drug: vinblastine	Safety of the combination of sodium stibogluconate and interferon alfa-2b with chemotherapy|Effects of sodium stibogluconate on interferon alfa-2b induced gene modulation and signal transduction pathways by measuring the serum soluble gene product|Effectiveness of sodium stibogluconate in inhibiting the protein tyrosine phosphatases SHP-1 and SHP-2 assayed from peripheral blood leukocytes|Pharmacokinetics of sodium stibogluconate in serum at escalating doses|Clinical response to the combination of sodium stibogluconate and interferon alfa-2b as priming for combination chemotherapy	Case Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	22	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE3Y06	May-07	May-10	Jan-12	11-Jul-07		24-Jul-20	"Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00498979
1572	NCT00509431	Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: Erlotinib + Sirolimus	To determine maximum tolerated dose and dose limiting toxicity of escalating doses of erlotinib in combination with sirolimus|To characterize the single-dose pharmacokinetic (PK) profile of erlotinib (in serum) and sirolimus (in whole blood) combination therapy in these patient populations|To characterize repeated-dose pharmacokinetic (PK) profile of erlotinib (in serum) and sirolimus (in whole blood) combination therapy in these patient populations	Jonsson Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	19	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000557423|UCLA-0604104	Aug-06	Dec-11	Sep-12	31-Jul-07		31-Jul-20	"Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT00509431
1573	NCT03322813	ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma		"Active, not recruiting"	No Results Available	Glioma	Device: ExAblate 4000 - Type 2	Device and procedure related adverse events|Feasibility of BBB disruption	InSightec	All	"21 Years to 85 Years   (Adult, Older Adult)"	Not Applicable	15	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT004	18-Oct-18	Jun-21	Dec-21	26-Oct-17		23-Jun-21	"University of Maryland Medical System, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT03322813
1574	NCT00003876	Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: polifeprosan 20 with carmustine implant|Procedure: surgical procedure|Radiation: iodine I 125		Barrett Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other	Interventional	Primary Purpose: Treatment	UCMC-98724|CDR0000067042|UCMC-55853|NCI-V99-1543	Apr-99		May-04	20-May-04		26-Jun-13	"Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00003876
1575	NCT00003463	Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: carmustine|Drug: irinotecan hydrochloride|Drug: polifeprosan 20 with carmustine implant|Procedure: surgical procedure		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	0901|DUMC-0901-02-5R4|DUMC-0901-02-5R2|DUMC-000901-00-5R2|DUMC-000901-01-5R3|DUMC-0797-99-5RI|DUMC-796-98-5|DUMC-98065|UCLA-9812060|NCI-G98-1464|DUMC-0901-01-5R3|CDR0000066497	Jul-98	Jul-02	Jul-02	25-Sep-03		18-Feb-13	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00003463
1576	NCT00074243	CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: CC-8490		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000343702|NCI-04-C-0035	Dec-03			11-Dec-03		30-Apr-15	"Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00074243
1577	NCT00064363	Talampanel in Treating Patients With Recurrent High-Grade Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: talampanel	Progression at 6 months	National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2		NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	030207|03-C-0207|CDR0000315425	Jun-03		Feb-07	9-Jul-03		8-Mar-12	"Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00064363
1578	NCT00999622	Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma		Completed	No Results Available	Brain and Central Nervous System Tumors|Infection	Other: laboratory biomarker analysis|Other: questionnaire administration	Frequency and severity of decreases in CD4 counts|Determination of decrease in CD4 counts as significant predictor of infections or adverse outcomes	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|North American Brain Tumor Consortium	All	"18 Years and older   (Adult, Older Adult)"		104	Other|NIH	Observational	Observational Model: Case-Control|Time Perspective: Prospective	NABTT-0305 CDR0000363636|U01CA062475|NABTT-0305	Jul-04	Aug-09		22-Oct-09		28-May-12			https://ClinicalTrials.gov/show/NCT00999622
1579	NCT00004868	SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: semaxanib		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	NABTC-9902|CDR0000067527|MSKCC-01045|NCI-00-C-0173	24-Mar-00	15-Sep-04	15-Sep-05	23-May-03		27-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Neuro-Oncology Branch, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00004868
1580	NCT00047281	"Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: celecoxib|Drug: cyclophosphamide|Drug: etoposide|Drug: thalidomide		Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Schering-Plough|Celgene	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2		Other|NIH|Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	01-278|P30CA006516|CDR0000257584|NCI-G02-2117|CELGENE-2001-P-001757/3	Mar-04	Aug-05	Feb-06	27-Jan-03		11-Jul-17	"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00047281
1581	NCT00010049	Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: imatinib mesylate		Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1|Phase 2	105	Other|NIH	Interventional	Intervention Model: Parallel Assignment|Primary Purpose: Treatment	NABTC-9908|CDR0000068437|NCI-01-C-0243|UCLA-0101024	27-Feb-01	17-Mar-05	15-Aug-06	27-Jan-03		27-Jun-18	"Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00010049
1582	NCT01164189	Bevacizumab in Recurrent Grade II and III Glioma	TAVAREC	Completed	No Results Available	Central Nervous System Tumors	Biological: Bevacizumab|Drug: Temozolomide	Probability of survival at 1 year|Objective response rate and duration of response|Progression-free survival|Overall survival and survival at 24 months|Safety|Clinical/neurological deterioration-free survival|Steroid use|Quality of life of patients and caregivers/relatives|Cognitive deterioration	European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	155	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26091|2009-017422-39	Feb-11	19-Jan-17	24-Sep-17	16-Jul-10		28-Feb-19	"Landesnervenklinik Wagner Jauregg, Linz, Austria|Medical University Vienna - General Hospital AKH, Vienna, Austria|Universitair Ziekenhuis Brussel, Brussel, Belgium|U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium|CHRU de Lille, Lille, France|CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Lyon, France|Assistance Publique - Hôpitaux de Marseille - Hôpital de La Timone, Marseille, France|CHU de Nice - Hopital Pasteur, Nice, France|CHU Pitie-Salpetriere, Paris, France|Institut Gustave Roussy, Paris, France|Centre Eugene Marquis, Rennes, France|Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau, Saint - Herblain, France|Centre Paul Strauss, Strasbourg, France|Universitaetsklinikum Bonn, Bonn, Germany|Universitaetsklinikum - Essen, Essen, Germany|Klinikum Der J.W. Goethe Universitaet, Frankfurt am Main, Germany|Universitaetsklinikum Heidelberg - UniversitaetsKlinikum Heidelberg - Head Hospital, Heidelberg, Germany|Universitaetskliniken Regensburg, Regensburg, Germany|Ospedale Bellaria, Bologna, Italy|Medisch Centrum Haaglanden - Westeinde, Den Haag, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam, Netherlands|Universitair Medisch Centrum - Academisch Ziekenhuis, Utrecht, Netherlands|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|UniversitaetsSpital Zurich - Division of Oncology, Zurich, Switzerland|University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre, Bristol, United Kingdom|University Of Dundee - Ninewells Hospital, Dundee, United Kingdom|NHS Lothian - Western General Hospital, Edinburgh, United Kingdom|NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital, Glasgow, United Kingdom|Leeds Teaching Hospitals NHS Trust - St. James's University Hospital, Leeds, United Kingdom|Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, Northern Centre For Cancer Care, Newcastle upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust - City Hospital, Nottingham, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital, Sheffield, United Kingdom|Royal Marsden Hospital - Sutton, Surrey, Sutton, United Kingdom"		https://ClinicalTrials.gov/show/NCT01164189
1583	NCT00354068	Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: imatinib mesylate|Drug: temozolomide|Other: pharmacological study	Maximum tolerated dose|Dose-limiting toxicity|Safety and tolerability|Pharmacokinetics|Anti-tumor activity	Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	65	Other|NIH	Interventional	Primary Purpose: Treatment	Pro00004364|DUMC-5514-06-1R2|NOVARTIS-DUMC-5514-06-1R2|CDR0000483760	Jul-04	Nov-08	Nov-08	20-Jul-06		28-Mar-13	"Duke Cancer Institute, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00354068
1584	NCT00629889	Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors|Seizure	Drug: levetiracetam|Drug: pregabalin	"Survival without occurrence of status epilepticus, 2 seizures with consciousness impairment, need to add a second antiepileptic drug (AED) (except transitory benzodiazepine), and need to discontinue study drug for lack of efficacy or adverse events|Adverse events|Anxiety|Need to add a second AED|Study drug discontinuation|Occurrence of consciousness-impairing seizures or status epilepticus|Mortality"	Dr Andrea Rossetti|Centre Hospitalier Universitaire Vaudois	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	52	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CDR0000586523|CHUV-Neurology-CePO-LEV-PGB|EU-20807	Feb-08	May-12	May-13	6-Mar-08		22-May-13	"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|USZ, Zürich, Switzerland"		https://ClinicalTrials.gov/show/NCT00629889
1585	NCT00352521	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: bevacizumab|Drug: irinotecan|Procedure: dynamic contrast-enhanced magnetic resonance imaging	Correlation of the acute permeability and blood flow response (24-48 hours) with progression-free survival (PFS)|Overall Survival and Tumor Response|Incidence and severity of central nervous system (CNS) hemorrhage and systemic hemorrhage	Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	20	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00012387|DUMC-8053-05-12R0|CDR0000481476	Apr-06	Dec-06	Jul-09	14-Jul-06		22-Jul-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00352521
1586	NCT00516607	Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: enzastaurin hydrochloride|Drug: temozolomide|Other: pharmacological study	Recommended phase II dose|Dose-limiting toxicity|Response rate|Progression-free survival|Overall survival|Pharmacokinetics of enzastaurin hydrochloride alone and in combination with temozolomide	European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	28	Other	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-26054	Jul-07	Nov-08		15-Aug-07		10-Feb-15	"Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom"		https://ClinicalTrials.gov/show/NCT00516607
1587	NCT01009307	Study of Blood and Cheek Cell Samples From Patients With Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: medical chart review	Factors related to glioma survival	"University of California, San Francisco|National Cancer Institute (NCI)"	All	"18 Years to 120 Years   (Adult, Older Adult)"		1709	Other|NIH	Observational		CDR0000437072|UCSF-H6539-04956-13A	Oct-01	Jul-06		6-Nov-09		22-Jul-19	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT01009307
1588	NCT00002753	Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Radiation: iodine I 131 monoclonal antibody 81C6		Duke University	All	"3 Years and older   (Child, Adult, Older Adult)"	Phase 1	6	Other	Interventional	Primary Purpose: Treatment	CDR0000064689|DUMC-1965-98-12R7|DUMC-1752-96-12R5|DUMC-1775-95-12R4|DUMC-1860-97-12R6|NCI-H96-0008	Nov-91	Apr-01	Apr-01	29-Jul-04		18-Feb-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00002753
1589	NCT00079092	Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: procarbazine hydrochloride|Drug: thalidomide	"Response rate by CT scan and MRI at baseline, pre-odd cycles, and study completion|Progression-free survival by CT scan, MRI, and follow up form at baseline, pre-odd cycles, and study completion|Overall survival by follow-up form at study completion|Quality of life by FACT-Br, FACIT-F and Karnofsky performance status (PS) at baseline, pre-odd cycles, and study completion|Toxicity by evaluation form at baseline, pre-odd cycles, and study completion"	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	18	Other|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	REBACDR0000354204|CCCWFU-91202|NCI-6358	1-Jan-04	21-Mar-06	21-Mar-06	9-Mar-04		9-Sep-21	"CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT00079092
1590	NCT00004892	O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: O6-benzylguanine|Drug: polifeprosan 20 with carmustine implant|Procedure: conventional surgery		National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		NIH	Interventional	Primary Purpose: Treatment	CDR0000067569|NABTT-9803|JHOC-NABTT-9803	Apr-00			3-May-04		9-Feb-09	"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004892
1591	NCT00301873	Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma		Completed	Has Results	Brain Tumors|Osteoporosis|Central Nervous System(CNS)Malignancies	Drug: IV Zometa	Percent of Patients With Change in Combined Bone Mass Density T-score <= -0.5.|Skeletal-related Complications|Mean Change in Bone Mass Density (BMD)	Duke University|Novartis|National Institute of Neurological Disorders and Stroke (NINDS)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00010125|P50NS020023	May-06	Feb-11	Sep-12	13-Mar-06	16-Jan-13	18-Feb-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00301873
1592	NCT00276770	Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas		Completed	No Results Available	Brain and Central Nervous System Tumors	Other: fluorine F 18 fluorothymidine|Procedure: positron emission tomography		University of Washington|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Not Applicable	12	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	27318|UW-6230|NCI-7223	Feb-06	May-07		13-Jan-06		27-Feb-19	"University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00276770
1593	NCT00730613	Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: therapeutic autologous lymphocytes|Genetic: gene expression analysis|Other: laboratory biomarker analysis	Feasibility|Safety|Anti-tumor activity of adoptively transferred clones|Anti-IL 13 zetakine and anti-HyTK immune response in patients|Efficacy of ganciclovir for clone ablation (in the event of toxicity)	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	3	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	01020|P30CA033572|CHNMC-01020|CDR0000590506	Feb-02	Aug-11	Aug-11	8-Aug-08		9-Oct-17			https://ClinicalTrials.gov/show/NCT00730613
1594	NCT00275067	"Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery"		"Active, not recruiting"	No Results Available	Brain and Central Nervous System Tumors	Drug: arsenic trioxide|Drug: temozolomide|Radiation: radiation therapy	Maximum tolerated dose of arsenic trioxide and temozolomide in combination with radiotherapy|Collect data on the toxicity of arsenic and temozolomide during radiation therapy|Assess serum biomarkers and correlate with tumor tissue|Determine progression free survival at 6 and 12 months|Determine time to disease progression|To determine overall survival|To determine radiographic response to study regimen|To collect safety data during the radiation therapy phase|To evaluate a potential surrogate marker for outcomes	Northwestern University|Cephalon|CTI BioPharma	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	50	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 04C1|CDR0000456504|STU00007792	May-05	May-21	May-21	11-Jan-06		25-Feb-20	"Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00275067
1595	NCT00401024	Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: imatinib mesylate|Other: pharmacological study|Procedure: conventional surgery	Tumor:plasma concentration ratio of imatinib mesylate	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 1	3	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J0623|P30CA006973|CDR0000510133|NA_00001201	12-Oct-06	4-Feb-08	11-Nov-08	17-Nov-06		28-Jun-18	"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00401024
1596	NCT00471653	Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy		Terminated	No Results Available	Brain and Central Nervous System Tumors|Thrombocytopenia	Drug: temozolomide|Genetic: comparative genomic hybridization|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: pharmacological study|Radiation: radiation therapy	Pharmacokinetics (PK) of temozolomide (TMZ) in patients with severe thrombocytopenia after standard first-line therapy as measured by Area Under the Curve (AUC)|Pharmacokinetics (PK) of temozolomide (TMZ) in patients with severe thrombocytopenia after standard first-line therapy as measured by maximum drug concentration (Cmax)|Pharmacokinetic (PK) profile of temozolomide (TMZ) in patients without severe thrombocytopenia after standard first-line therapy as measured by AUC|Pharmacokinetic (PK) profile of temozolomide (TMZ) in patients without severe thrombocytopenia after standard first-line therapy as measured by Cmax|Presence of single nucleotide polymorphisms in the O6-methylguanine-DNA methyltransferase gene.	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"		10	Other|NIH	Observational	Observational Model: Other|Time Perspective: Prospective	J0684|P30CA006973|CDR0000543866|NA_00004964	11-Nov-06	12-Nov-08	18-Aug-09	10-May-07		9-Jul-18	"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00471653
1597	NCT00538850	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain		Completed	Has Results	Cancer	Drug: Fentanyl sublingual spray|Drug: Placebo	"Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)|Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing|Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing|Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing"	INSYS Therapeutics Inc|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	130	Industry|NIH	Interventional	"Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment"	INS-05-001|CDR0000581128	Oct-07	Feb-10	Oct-10	3-Oct-07	5-Mar-14	5-Mar-14	"InSys Therapeutics, Incorporated, Chandler, Arizona, United States"		https://ClinicalTrials.gov/show/NCT00538850
1598	NCT00025558	Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer		Completed	No Results Available	Brain and Central Nervous System Tumors	Biological: filgrastim|Drug: carboplatin|Drug: temozolomide|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation		NYU Langone Health|National Cancer Institute (NCI)	All	"1 Year to 49 Years   (Child, Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068973|P30CA016087|NYU-0006H|NCI-G01-2022	Oct-00	May-07		27-Jan-03		28-Mar-11	"NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Columbus Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia"		https://ClinicalTrials.gov/show/NCT00025558
1599	NCT00003478	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Procedure: conventional surgery|Radiation: iodine I 131 monoclonal antibody 81C6|Radiation: radiation therapy		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	10	Other|NIH	Interventional	Allocation: Randomized|Primary Purpose: Treatment	1529|DUMC-1529-01-8R4|DUMC-1363-97-9|DUMC-1409-98-9R1|DUMC-1529-00-8R3|DUMC-1630-99-9R2|DUMC-97112|NCI-5950NS20023|NCI-G98-1471|CDR0000066515	Oct-97	Jul-07	Jul-07	27-Jan-03		20-Feb-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00003478
1600	NCT00477919	E-MOSAIC Electronic Tool to Monitor Symptoms		Completed	No Results Available	Cancer		Determine the effect of an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC) and a Longitudinal Monitoring Sheet (LoMoS) on global quality of life (G-QOL)|Determine if this tool affects communication between these patients and their treating physicians.|Determine if this tool affects the symptoms and syndromes reported by these patients|Determine if this tool impacts symptom management performance	Swiss Group for Clinical Cancer Research	All	"18 Years and older   (Adult, Older Adult)"		264	Other	Observational	Observational Model: Other|Time Perspective: Other	SAKK 95/06|EU-20711	Feb-07	Jan-12	Jan-12	24-May-07		15-May-19	"Universitaetsspital-Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Spital Buelach, Bulach, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Kantonsspital Freiburg, Freiburg, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland"		https://ClinicalTrials.gov/show/NCT00477919
1601	NCT00276783	"Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases"		"Active, not recruiting"	No Results Available	Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer	Drug: pemetrexed	Progression free survival at 6 months and time to disease progression|Radiographic response|Collect safety data|Overall survival|Compare blood and tissue methylation patterns and correlate with response.	Northwestern University|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	31	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 05C2|P30CA060553|NU-05C2|STU00007255	Nov-05	Dec-22	Dec-22	13-Jan-06		5-Mar-20	"Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States"		https://ClinicalTrials.gov/show/NCT00276783
1602	NCT00376818	Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers		Completed	No Results Available	Brain and Central Nervous System Tumors|Psychosocial Effects of Cancer and Its Treatment	Behavioral: exercise intervention|Other: educational intervention|Other: physiologic testing|Other: management of therapy complications|Behavioral: mind-body intervention procedure|Procedure: Measurement of stress-related hormones	Quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items (EORTC QLQ-C30) and Brain Cancer Module-20|Decrease in perception of stress and anxiety in patients and their primary family caregivers as measured by the Perceived Stress Scale and Beck Anxiety Inventory questionnaires|Decrease in stress- and inflammation-related hormones in patients and their primary family caregivers as measured by saliva samples	Case Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	4	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CASE2306|P30CA043703	Jun-06	Apr-08	Apr-08	15-Sep-06		4-Jun-12	"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00376818
1603	NCT00352313	ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: ATN-161|Drug: carboplatin	Safety|Maximum tolerated dose (phase I)|Progression-free survival at 6 months|Response rate (phase I)|Overall survival|Efficacy|Response rate (phase II)	National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	82	NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	060170|06-C-0170|NCI-P6790|ATN-161-002|CDR0000487605	May-06	Jan-07	Jan-08	14-Jul-06		2-May-12	"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00352313
1604	NCT00083096	Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: lonafarnib|Drug: temozolomide	Dose-limiting toxicity and maximum tolerated dose of lonafarnib determined by CTCAE v3.0|Response (complete [CR] or partial response [PR]) measured by McDonald's criteria at least 4 weeks after first documented response and every 8 weeks until disease progression or until start of another treatment	European Organisation for Research and Treatment of Cancer - EORTC	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	EORTC-16027-26023|EORTC-16027|EORTC-26023|SPRI-P03174	Mar-04	Jun-09		17-May-04		10-Feb-15	"Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France|Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00083096
1605	NCT00369785	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors		Completed	Has Results	Brain Tumors|Metastatic Disease	Drug: donepezil hydrochloride|Drug: Placebo	Memory as Quantified by HVLT-immediate Recall|Memory as Quantified by the HVLT-discrimination	Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 3	198	Other|NIH	Interventional	"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care"	IRB00000551|U10CA081851|REBACCCWFU 91105	Feb-08	1-Jul-12	1-Jul-12	29-Aug-06	9-Mar-17	20-Oct-21	"Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Central Maine Comprehensive Cancer Center at Central Maine Medical Center, Lewiston, Maine, United States|New Hampshire Oncology - Hematology, PA - Hooksett, Hooksett, New Hampshire, United States|Lakes Region General Hospital, Laconia, New Hampshire, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Trinity CancerCare Center, Minot, North Dakota, United States|Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio, United States|MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States|United States Air Force Medical Center - Wright-Patterson, Wright-Patterson Air Force Base, Ohio, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT00369785
1606	NCT00255671	Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders		Completed	No Results Available	Brain and Central Nervous System Tumors|Metastatic Cancer|Radiation Toxicity	Other: Questionnaire	Short-term adverse effects as assessed by a questionnaire	Case Comprehensive Cancer Center	All	"18 Years and older   (Adult, Older Adult)"		76	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CASE4Z05	May-05	Apr-08	May-12	21-Nov-05		27-Jul-20	"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00255671
1607	NCT00005790	Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors		Withdrawn	No Results Available	Brain and Central Nervous System Tumors	Other: laboratory biomarker analysis|Procedure: biopsy|Procedure: magnetic resonance imaging|Radiation: gadopentetate dimeglumine		Northwestern University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	0	Other|NIH	Interventional	Primary Purpose: Diagnostic	NU 95C1|NU-95C1|NCI-G00-1738	Apr-96	May-99	May-99	9-Jun-04		11-Jun-12			https://ClinicalTrials.gov/show/NCT00005790
1608	NCT00008086	Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors		Completed	No Results Available	"Brain and Central Nervous System Tumors|Unspecified Adult Solid Tumor, Protocol Specific"	Dietary Supplement: calcitriol|Drug: carboplatin		University of Pittsburgh|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	97-004|CDR0000068374|PCI-IRB-970532|NCI-G00-1885	Jan-96	Sep-04	Sep-04	4-Sep-03		19-Dec-13	"University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00008086
1609	NCT00006368	Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer		Completed	No Results Available	Brain and Central Nervous System Tumors|Breast Cancer|Gastrointestinal Carcinoid Tumor|Islet Cell Tumor|Lung Cancer|Lymphoma|Melanoma (Skin)|Neoplastic Syndrome	Radiation: yttrium Y 90-edotreotide		Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	60	Industry	Interventional	Primary Purpose: Treatment	NOVARTIS-SMT-B151|MCC-12275|MCC-IRB-5473|CDR0000068241|NCI-G00-1857	Jan-98	Nov-03	Nov-03	2-Apr-04		1-May-13	"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States"		https://ClinicalTrials.gov/show/NCT00006368
1610	NCT00003484	Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors|Neuroblastoma	Drug: carmustine|Drug: irinotecan hydrochloride|Procedure: surgical procedure|Radiation: iodine I 131 monoclonal antibody 81C6		"Darell D. Bigner, MD, PhD|National Cancer Institute (NCI)|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	21	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00008915|DUMC-1533-02-8R5ER|DUMC-1533-01-8R4|DUMC-1373-97-9|DUMC-1408-98-9R1|DUMC-1533-00-8R3|DUMC-1570-99-9R2|DUMC-97107|5P0NS20023|NCI-G98-1472|CDR0000066522	Sep-97	Nov-03	Mar-10	30-Apr-03		23-Apr-15	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00003484
1611	NCT00073944	BCX-1777 in Treating Patients With Refractory Cancer		Completed	No Results Available	Cancer	Drug: forodesine hydrochloride		BioCryst Pharmaceuticals|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1		Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	BIOCRYST-1777BC-101|CDR0000341332|CCF-5909	Apr-03	Jan-05		11-Dec-03		30-May-13	"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00073944
1612	NCT00070161	Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor		Completed	No Results Available	Brain and Central Nervous System Tumors|Radiation Toxicity	Dietary Supplement: EGb761|Drug: donepezil hydrochloride|Procedure: cognitive assessment		Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 2	68	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Supportive Care	REBACCCWFU-97100|U10CA081851	1-Jul-01	1-May-05	1-Aug-12	7-Oct-03		9-Sep-21	"CCOP - Western Regional, Arizona, Phoenix, Arizona, United States|Regional Radiation Oncology Center at Rome, Rome, Georgia, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT00070161
1613	NCT00049296	Thalidomide and Docetaxel in Treating Patients With Advanced Cancer		Completed	No Results Available	Cancer	Drug: docetaxel|Drug: thalidomide	"Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma."	Case Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	26	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CWRU4Y01|P30CA043703|CWRU-4Y01|NCI-G02-2123	Jul-02	Dec-04	Jan-06	27-Jan-03		11-Jun-10	"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00049296
1614	NCT00031798	Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors		Terminated	No Results Available	Brain and Central Nervous System Tumors|Cognitive/Functional Effects|Depression|Fatigue|Quality of Life	Drug: methylphenidate hydrochloride|Procedure: quality-of-life assessment|Radiation: radiation therapy		Wake Forest University Health Sciences|National Cancer Institute (NCI)	All	"18 Years to 120 Years   (Adult, Older Adult)"	Phase 3		Other|NIH	Interventional	Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care	REBACDR0000069227|CCCWFU-97600|NCI-P02-0211	1-Apr-02	1-Mar-05	1-May-06	27-Jan-03		9-Sep-21	"CCOP - Western Regional, Arizona, Phoenix, Arizona, United States|CCOP - Central Illinois, Decatur, Illinois, United States|MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, United States|CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|CCOP - Columbus, Columbus, Ohio, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States"		https://ClinicalTrials.gov/show/NCT00031798
1615	NCT00019019	Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas		Completed	No Results Available	"Brain and Central Nervous System Tumors|Breast Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Melanoma (Skin)|Ovarian Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific"	Drug: carboxyamidotriazole|Drug: paclitaxel		National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	70	NIH	Interventional	Primary Purpose: Treatment	950015|95-C-0015|NCI-CPB-334|NCI-T94-0006N|CDR0000063881	Oct-94	Jul-06	Jul-06	27-Jan-03		15-Mar-12	"Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Medical Oncology Clinical Research Unit, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00019019
1616	NCT00003567	Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma		Terminated	No Results Available	"Brain and Central Nervous System Tumors|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific"	Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: O6-benzylguanine|Drug: carmustine|Drug: temozolomide|Procedure: in vitro-treated peripheral blood stem cell transplantation	Gene transfer expression	Case Comprehensive Cancer Center|National Cancer Institute (NCI)	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 1	8	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CWRU2Y97|R21CA076192|P30CA043703|CASE-CWRU-2Y97|NCI-T97-0060|CASE-2Y97	May-99	Jan-07	Feb-07	27-Jan-03		11-Jun-10	"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00003567
1617	NCT00003461	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors|Metastatic Cancer|Neuroblastoma	Procedure: surgical procedure|Radiation: astatine At 211 monoclonal antibody 81C6		Duke University|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	2237|DUMC-2237-01-12R4|DUMC-0013-00-1R2|DUMC-0036-99-1R1|DUMC-060-98-1|DUMC-2237-00-12R3|DUMC-98007|NCI-5P50NS20023|NCI-G98-1462|CDR0000066493	Feb-98	Feb-05	Feb-05	27-Jan-03		21-Aug-14	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00003461
1618	NCT00003022	Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer		Completed	No Results Available	Brain and Central Nervous System Tumors|Intraocular Melanoma|Lung Cancer|Melanoma (Skin)|Neuroblastoma|Retinoblastoma|Sarcoma	Radiation: iodine I 131 monoclonal antibody 3F8		Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)	All	"3 Years and older   (Child, Adult, Older Adult)"	Phase 1		Other|NIH	Interventional	Primary Purpose: Treatment	97-021|CDR0000065607|NCI-G97-1267	Apr-97	Jan-05	Jan-05	27-Jan-03		3-Jul-13	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT00003022
1619	NCT03128047	HUMC 1612: Optune NovoTTF-200A System		Recruiting	No Results Available	High Grade Glioma|Ependymoma	Device: Optune NovoTTF-200A System	Safety of the Optune NovoTTF-200A System when used alone in pediatric patients with recurrent high-grade gliomas.|Tolerability of the Optune NovoTTF-200A System when used alone in pediatric patients with recurrent high-grade gliomas.|Assess the progression free of patients treated on this study protocol to aid in the future development of pediatric phase II/III studies using the Optune NovoTTF-200A System.|Assess the overall survival of patients treated on this study protocol to aid in the future development of pediatric phase II/III studies using the Optune NovoTTF-200A System.	Hackensack Meridian Health|NovoCure Ltd.	All	"5 Years to 21 Years   (Child, Adult)"	Phase 1	6	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro2016-0583	6-Apr-17	Sep-23	Sep-23	25-Apr-17		16-Aug-21	"Arnold Palmer Hospital for Children, Orlando, Florida, United States|Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States"		https://ClinicalTrials.gov/show/NCT03128047
1620	NCT01257594	EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas		Completed	No Results Available	Brain Cancer	Drug: erlotinib|Procedure: Cytoreductive Surgery	Clinical Benefit Rate (either radiographic response or at least 6 months of progression-free survival)	"Andrew B Lassman, MD|Genentech, Inc.|OSI Pharmaceuticals|Columbia University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	22	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAJ7500	7-Jan-11	22-Nov-16	31-Dec-18	9-Dec-10		7-Jan-21	"Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT01257594
1621	NCT00619112	Temozolomide in Treating Patients With Recurrent High-Grade Glioma		Completed	Has Results	Recurrent Central Nervous System Neoplasm	Drug: temozolomide	6 Month Progression-free Survival|Progression-free Survival (PFS) Based on Tumor MGMT (O(6)-Methylguanine-DNA Methyltransferase) Promoter Methylation Status.|Overall Survival|Patients With Tumors With Functional Alterations of the Mismatch Repair (MMR) System|Patients Progressing After Two First-line Adjuvant Courses of Temozolomide|Patients Progressing Within 6 Months After 6th Adjuvant Course of Temozolomide|Patients Progressing 6 Months After Temozolomide is Voluntarily Discontinued	"University of California, San Francisco|National Cancer Institute (NCI)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	60	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCSF-07107|SPRI-UCSF-H44867-31182-01	Oct-07	Dec-11	Sep-12	20-Feb-08	29-Oct-13	31-Jan-18	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States"		https://ClinicalTrials.gov/show/NCT00619112
1622	NCT00004068	Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: irinotecan hydrochloride|Drug: temozolomide|Procedure: conventional surgery|Radiation: radiation therapy		St. Jude Children's Research Hospital|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 2	53	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000067271|P30CA021765|SJCRH: SJHG98|SPRI-P-00112|NCI-G99-1577	Mar-99	Apr-03	Apr-03	8-May-03		4-Oct-11	"Saint Jude Children's Research Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT00004068
1623	NCT00634231	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors		Completed	No Results Available	Malignant Glioma|Recurrent Ependymoma	Biological: AdV-tk|Drug: valacyclovir|Radiation: Radiation	Safety based on standard laboratory and clinical adverse event monitoring|Overall survival|Progression-free survival|Objective tumor response|Immunologic function	"Candel Therapeutics, Inc.|Boston Children's Hospital"	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	8	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-098	Oct-10	Dec-15	Jun-21	12-Mar-08		2-Nov-21	"Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital), Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States"		https://ClinicalTrials.gov/show/NCT00634231
1624	NCT00021229	Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma		Terminated	Has Results	Brain and Central Nervous System Tumors	Drug: imatinib mesylate|Radiation: local irradiation therapy	Number of Participants in Phase I Stratum I With Dose Limiting Toxicities (DLT) Observed During First 8 Weeks (Courses 1 and 2) of Imatinib Therapy|Number of Participants in Phase I Stratum II With Dose Limiting Toxicities (DLT) Observed During First 8 Weeks (Courses 1 and 2) of Imatinib Therapy|Median Progression-free Survival (PFS)|Change From Baseline in Volume FLAIR at Two Weeks After Completion of Radiation|Peak Concentration (Cmax)|Median Overall Survival|Pre-treatment Basic Fibroblast Growth Factor Values From Urine|Pre-treatment Basic Fibroblast Growth Factor Values From Plasma|Pre-treatment Vascular Endothelial Growth Factor From Urine|Pre-treatment Vascular Endothelial Growth Factor Values From Plasma	National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1|Phase 2	85	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-03019|PBTC-006|U01CA081457|CDR0000068761	May-01	Aug-08	Aug-08	27-Jan-03	9-Apr-10	31-Jul-14	"UCSF Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00021229
1625	NCT01295632	Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)		Completed	No Results Available	Advanced Cancer	Drug: ridaforolimus|Drug: MK-0752|Drug: MK-2206	Number of participants receiving ridaforolimus + MK-2206 who experience dose-limiting toxicities (DLTs).|Number of participants receiving ridaforolimus + MK-0752 who experience DLTs.|Number of participants whose best response is partial response (PR) or complete response (CR).|Area under the plasma concentration curve (AUC) for ridaforolimus.|AUC for the ridaforolimus + MK-0752 doublet	Merck Sharp & Dohme Corp.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	65	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	8669-049	Feb-11	Dec-13	Aug-15	14-Feb-11		27-Aug-15			https://ClinicalTrials.gov/show/NCT01295632
1626	NCT02986178	PVSRIPO in Recurrent Malignant Glioma		"Active, not recruiting"	No Results Available	Malignant Glioma	Biological: PVSRIPO	"Objective Radiographic Response Rate|Duration of Objective Radiographic Response|Overall Survival|Landmark Survival|Disease Control Rate Following PVSRIPO Infusion|Safety of PVSRIPO: proportion of patients who experience grade 3, 4, or 5 AEs"	"Istari Oncology, Inc.|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	122	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00077024	1-Jun-17	Aug-23	Dec-23	8-Dec-16		22-Jun-21	"UCSF Neurological Surgery, San Francisco, California, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"		https://ClinicalTrials.gov/show/NCT02986178
1627	NCT02423525	Safety Study of Afatinib for Brain Cancer		"Active, not recruiting"	No Results Available	Brain Cancer	Drug: Afatinib	Rate of dose limiting toxicities of pulsatile afatinib|Maximum tolerated dose (MTD) of pulsatile afatinib|Treatment-emergent adverse events|Afatinib levels in cerebrospinal fluid (CSF) and blood|Objective response rate as assessed by the RANO criteria|Best overall response rate|Progression free survival|Overall Survival	Santosh Kesari|Boehringer Ingelheim|John Wayne Cancer Institute	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	24	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1200.229|20161975	Dec-16	Dec-21	Dec-22	22-Apr-15		12-Feb-21	"John Wayne Cancer Institute, Santa Monica, California, United States"		https://ClinicalTrials.gov/show/NCT02423525
1628	NCT01961934	"C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression"		Withdrawn	No Results Available	Gliomas	Drug: Sodium Acetate C11 PET/CT Imaging	Biopsy Correlation|SUV (Standardized Uptake Value)	Phoenix Molecular Imaging	All	"18 Years to 70 Years   (Adult, Older Adult)"	Phase 2|Phase 3	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AMIC-AC-003	May-14	May-16	May-18	14-Oct-13		28-Sep-16	"Phoenix Molecular Imaging, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT01961934
1629	NCT04547777	Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma		Recruiting	No Results Available	"Glioma, Malignant"	Drug: D2C7-IT|Drug: 2141-V11	Proportion of patients with dose-limiting toxicity (DLT) within each dose level	Darell Bigner|Rockefeller University|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00104852	9-Jul-21	Dec-23	Dec-25	14-Sep-20		20-Jul-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04547777
1630	NCT04190628	Safety of ABM-1310 in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Advanced Solid Tumor|BRAF V600 Mutation	Drug: ABM-1310|Drug: Cobimetinib	Determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Number of participants with abnormal laboratory values|Area under the concentration time curve (AUC)|Maximum plasma concentration (Cmax)|Steady-state concentration (Css)|Time to maximum plasma concentration (Tmax)|Half-life (T1/2)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall Survival (OS)|Time to Response (TTR)	"ABM Therapeutics, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	48	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABM1310X1101	16-Jun-20	Dec-21	Dec-21	9-Dec-19		18-Jun-21	"Henry Ford Cancer Institute, Detroit, Michigan, United States|Comprehensive Cancer Centers of Nevada (CCCN), Las Vegas, Nevada, United States|MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT04190628
1631	NCT03973879	Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma		Withdrawn	No Results Available	Malignant Glioma	Biological: PVSRIPO|Drug: Atezolizumab	Number of unacceptable adverse events|Proportion of patients alive	"Darell Bigner|Istari Oncology, Inc.|Genentech, Inc.|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00100677	Feb-20	Jan-24	Jan-24	4-Jun-19		11-Feb-20			https://ClinicalTrials.gov/show/NCT03973879
1632	NCT03478462	"Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma"	CLOVER-2	Recruiting	No Results Available	Pediatric Solid Tumor|Pediatric Lymphoma|Pediatric Brain Tumor|DIPG|Neuroblastoma|Ewing Sarcoma|Rhabdomyosarcoma|Osteosarcoma	Drug: CLR 131	"Number of participants with dose limiting toxicities (DLT)|Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults|Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults|Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults|Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults|Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults|Determine dosimetry of CLR 131 in children, adolescents, and young adults"	"Cellectar Biosciences, Inc."	All	"2 Years to 25 Years   (Child, Adult)"	Phase 1	30	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DCL-17-001	30-Apr-19	Sep-22	Dec-24	27-Mar-18		2-Dec-21	"Lucile Packard Children's Hospital, Palo Alto, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Hospital for Sick Children, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT03478462
1633	NCT01654497	Dexanabinol in Patients With Brain Cancer		Completed	No Results Available	Brain Cancer	Drug: Dexanabinol	Rate of dose limiting toxicities and the maximum tolerated dose (MTD) of weekly dexanabinol|Treatment-emergent adverse events|Objective response rate and best overall response rate over time as assessed by the RANO criteria|Progression free survival|Overall Survival	"Santosh Kesari, M.D., Ph.D.|e-Therapeutics PLC|University of California, San Diego"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	26	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	111827	Jun-12	Sep-15	Jul-17	31-Jul-12		14-Nov-19	"Moores UCSD Cancer Center, La Jolla, California, United States"		https://ClinicalTrials.gov/show/NCT01654497
1634	NCT04160494	D2C7-IT With Atezolizumab for Recurrent Gliomas		Recruiting	No Results Available	Malignant Glioma	Drug: D2C7-IT (6920 ng/mL via convection-enhanced delivery)|Drug: Atezolizumab (1200 mg every three weeks)|Drug: D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)	Proportion of patients with an unacceptable adverse event	"Darell Bigner|Istari Oncology, Inc.|National Cancer Institute (NCI)|Genentech, Inc.|Duke University"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00101898|FOR0003	20-Mar-20	Jan-22	Jan-26	13-Nov-19		11-May-21	"Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT04160494
1635	NCT04808245	A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas	INTERCEPT-H3	Not yet recruiting	No Results Available	Newly Diagnosed H3-mutated Glioma	Drug: Tecentriq 1200 MG in 20 ML Injection|Biological: H3K27M peptide vaccine|Other: Imiquimod (5%)	Assessment of safety of repeated fixed dose vaccinations with the H3K27M peptide vaccine administered with radiotherapy and Atezolizumab in patients with H3K27M-mutant gliomas. Primary safety endpoint is the Regime Limiting Toxicity (RLT).|Assessment of immunogenicity of repeated fixed dose vaccinations with the H3K27M peptide vaccine administered with radiotherapy and Atezolizumab in patients with H3K27M-mutant gliomas.|Progression-free survival (PFS)|Overall response rate (ORR)|Analyze the association between immunogenicity and the clinical outcome parameters ORR|Analyze the association between immunogenicity and the clinical outcome parameters PFS	"German Cancer Research Center|Johannes Gutenberg University Mainz|Charite University, Berlin, Germany|Roche Pharma AG|German Cancer Aid"	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	15	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCT-2018-576	6-Dec-21	Mar-24	Mar-24	22-Mar-21		30-Jul-21	"Department of Neurology University Hospital, Mannheim, Bade-Württemberg, Germany|Department of Neurology and Polyclinic, Universitiy Clinic Heidelberg, Heidelberg, Baden-Württemberg, Germany|Neurological Clinic, Department of Neurology with an interdisciplinary focus on neurooncology, Neurological University Clinic Tübingen, Tübingen, Baden-Württemberg, Germany|Dr. Senckenberg Institute for Neurooncology, University Hospital Frankfurt, Frankfurt am Main, Hessen, Germany|Clinical Neuro-Oncology Section, University Hospital Bonn (UKB), Bonn, Nordrhein-Westfalen, Germany|Neurooncology Department, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany|Clinic and Polyclinic for Neurosurgery, University Hospital Carl Gustav Carus Dresden, Dresden, Sachsen, Germany|Department of Neurosurgery with Pediatric Neurosurgery, Berlin, Germany"		https://ClinicalTrials.gov/show/NCT04808245
1636	NCT04521686	Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations		Recruiting	No Results Available	Cholangiocarcinoma|Chondrosarcoma|Glioma|Any Solid Tumor	Drug: LY3410738	Recommended Phase 2 dose (RP2D)|Objective Response Rate|Assess the safety and tolerability of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine.|To assess the preliminary anti-tumor activity of LY3410738 monotherapy and in combination with cisplatin plus gemcitabine|Characterize PK properties of LY3410738 when administered alone or in combination with cisplatin plus gemcitabine.|To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma.	"Eli Lilly and Company|Loxo Oncology, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	180	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LOXO-IDH-20002|2020-002863-77|I9Y-OX-JDHC	16-Oct-20	Feb-23	Sep-23	20-Aug-20		14-Dec-21	"Mayo Clinic of Scottsdale, Phoenix, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|USC Norris Cancer Hospital, Los Angeles, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|The John Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France|Gustave Roussy, Villejuif Cedex, France|Prince of Wales Hospital, Hong Kong, Shatin, New Territories, Hong Kong|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Osaka University Hospital, Suita-shi, Osaka, Japan|Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|China Medical University Hospital, Taichung City, Taiwan|National Cheng-Kung Uni. Hosp., Tainan, Taiwan"		https://ClinicalTrials.gov/show/NCT04521686
1637	NCT04743310	Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System		Recruiting	No Results Available	Central Nervous System Tumor	Drug: tozuleristide|Device: Canvas imaging system|Procedure: Surgical resection of tumor	"Percentage of patients with fluorescence-positive primary tumor biopsy|True positive rate of fluorescence, defined as the percentage of tumor-positive and fluorescence-positive tissue biopsies among all tumor-positive tissue biopsies|True negative rate of fluorescence, defined as the percentage of tumor-negative and fluorescence-negative tissue biopsies among all tumor-negative tissue biopsies|Positive predictive value of fluorescence, defined as the percentage of tumor-positive and fluorescence-positive tissue biopsies among all fluorescence-positive tissue biopsies|Negative predictive value of fluorescence, defined as the percentage of tumor-negative and fluorescence-negative tissue biopsies among all fluorescence-negative tissue biopsies|Extent of residual tumor measured on post-operative magnetic resonance imaging scans among all patients with evidence of residual fluorescence at the time of surgery"	John Yu|Blaze Bioscience Inc.|Cedars-Sinai Medical Center	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	39	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIT2020-09-Yu-BBIST001	30-Sep-21	Sep-23	Sep-23	8-Feb-21		30-Nov-21	"Cedars-Sinai Medical Center, Los Angeles, California, United States"		https://ClinicalTrials.gov/show/NCT04743310
1638	NCT04238819	A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors		Recruiting	No Results Available	Relapsed Solid Tumor|Refractory Solid Tumor	Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide	"Number or Participants with Dose Limiting Toxicities (DLTs)|Pharmacokinetics (PK): Mean Steady State Concentrations of Abemaciclib|PK: Mean Steady State Concentrations of Irinotecan|PK: Mean Steady State Concentrations of Temozolomide|Overall Response Rate (ORR): Percentage of Participants with Best Response of Complete Response (CR) or Partial Response (PR)|Duration of Response (DoR)|Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR or SD With a Duration of At Least 6 Months|Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease (SD)|Acceptability Questionnaire"	Eli Lilly and Company	All	"up to 18 Years   (Child, Adult)"	Phase 1	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16950|I3Y-MC-JPCS|2019-002931-27	9-Nov-20	30-Sep-22	21-Dec-23	23-Jan-20		17-Dec-21	"Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UZ-Gent, Gent, Belgium|Centre Leon Berard, Lyon, Rhône, France|Institut Curie, Paris, France|Gustave Roussy, Villejuif Cedex, France|Charité Campus Virchow-Klinikum, Berlin, Germany|Universtitätsklinikum Essen AöR, Essen, Germany|Hopp-Kindertumorzentrum Heidelberg (KiTZ), Heidelberg, Germany|Policlinico Gemelli - Università Cattolica del Sacro Cuore, Roma, Italy|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain"		https://ClinicalTrials.gov/show/NCT04238819
1639	NCT04094610	"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations"		Recruiting	No Results Available	Locally Advanced Solid Tumors|Metastatic Solid Tumors|Lymphoma|Primary CNS Tumors	Drug: Oral repotrectinib (TPX-0005)	Dose limiting toxicities (DLTs) (Phase 1)|Pediatric Recommended Phase 2 Dose (RP2D) (Phase 1)|Overall Response Rate (ORR) (Phase 2)|Overall Response Rate (ORR) (Phase 1)|Clinical Benefit Rate (CBR) (Phase 1 and Phase 2)|Time to response (TTR) (Phase 1 and Phase 2)|Duration of response (DOR) (Phase 1 and Phase 2)|Intracranial objective response rate (IC-ORR) (Phase 1 and Phase 2)|Central Nervous System Progression-Free Survival (CNS-PFS) (Phase 2)|Progression-free survival (PFS) (Phase 2)|Overall survival (OS) (Phase 2)|Maximum concentration of repotrectinib in plasma (Cmax)|Area under the concentration versus time curve of repotrectinib in plasma (AUC)	"Turning Point Therapeutics, Inc."	All	"up to 25 Years   (Child, Adult)"	Phase 1|Phase 2	75	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TPX-0005-07	20-Mar-20	Dec-22	Dec-23	19-Sep-19		4-Nov-21	"Children's Hospital Los Angeles, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Penn State Children's Hospital at Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The University of Texas Southwestern Medical Center, Children's Medical Center of Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Sydney Children's Hospital, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia|Perth Children's Hospital, Nedlands, Western Australia, Australia|Stollery Children's Hospital, Edmonton, Alberta, Canada|Seoul National University Hospital, Seoul, Korea, Republic of|Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan"		https://ClinicalTrials.gov/show/NCT04094610
1640	NCT03696355	Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas		"Active, not recruiting"	No Results Available	Brain and Central Nervous System Tumors	Drug: GDC-0084|Radiation: radiation therapy	Estimate the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of GDC-0084 after standard-of-care radiation therapy (RT)|Incidence of adverse events at least possibly associated with GDC-0084 after RT by stratum|Pharmacokinetics of GDC-0084 by stratum|Rate of best overall response by stratum|Duration of best overall response by stratum|Progression-free survival for patients treated with GDC-0084 after RT|Overall survival for patients treated with GDC-0084 after RT	St. Jude Children's Research Hospital|Kazia Therapeutics Limited	All	"2 Years to 21 Years   (Child, Adult)"	Phase 1	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SJPI3K|NCI-2018-02268	19-Nov-18	2-Apr-21	Jun-24	4-Oct-18		13-Apr-21	"St. Jude Children's Research Hospital, Memphis, Tennessee, United States"		https://ClinicalTrials.gov/show/NCT03696355
1641	NCT02119338	5-ALA in Recurrent Glioma		Unknown status	No Results Available	Glioma	Drug: 5-ala	Presence of fluorescence in tumor tissue compared to tissue with treatment effect.|Extent of resection|Progression-free survival rate at 6 months|Overall survival	"St. Joseph's Hospital and Medical Center, Phoenix"	All	"18 Years and older   (Adult, Older Adult)"	Not Applicable	60	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	11BN092	Feb-14	Jun-17	Sep-17	21-Apr-14		6-Jan-17	"Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States"		https://ClinicalTrials.gov/show/NCT02119338
1642	NCT02381886	A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations		"Active, not recruiting"	No Results Available	Advanced Malignancies That Harbor IDHR132 Mutations	Drug: IDH305	"Incident rate of dose limiting toxicities (DLTs)|Incidence of adverse events (AEs)|Plasma PK parameters (AUC, Cmax, Tmax)|Changes of 2-hydroxyglutarate concentration in patient specimens|Overall response rate (ORR)|Incidence of serious adverse events (SAE)"	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	166	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CIDH305X2101	6-Jan-15	7-Dec-16	25-Oct-24	6-Mar-15		10-Dec-21	"Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States|Columbia University Medical Center- New York Presbyterian Onc Dept., New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Jena, Germany|ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55, Rotterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain"		https://ClinicalTrials.gov/show/NCT02381886
1643	NCT01868906	FMISO-PET in Brain Tumors and SCS Effect	FMISOPETSCS	Terminated	No Results Available	Malignant Glioma	Drug: 18F-FMISO|Procedure: PET without SCS|Device: SCS|Procedure: PET without/with SCS|Radiation: Radiotherapy|Drug: Temozolomide	Tumor hypoxia measurement using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio). Baseline measurement.|Change from baseline tumor hypoxia using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio) during SCS.|Correlation between 18F-FMISO-PET values and pathological tumor parameters|Correlation with Karnofsky scale.|Correlation with the ECOG (Eastern Cooperative Oncology Group) performance status scale|Correlation with the Quality of Life Questionnaire QLQ-C30 (EORTC)|Overall survival.|Radiological response to treatment|Radiological location of tumor relapse or progression	"Bernardino Clavo, MD, PhD|Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid|Instituto de Salud Carlos III|Grupo de Investigación Clínica en Oncología Radioterapia|Instituto Canario de Investigación del Cáncer|RSbiomed|Fundación DISA, Canary Islands, Spain|Dr. Negrin University Hospital"	All	"18 Years to 75 Years   (Adult, Older Adult)"	Phase 2	6	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	"TC-FMISO-PET-06-1413|2009-015852-11|PI 06/1413, PI 12/02940"	Jun-13	17-Sep-17	17-Sep-17	5-Jun-13		24-Aug-18	"Dr. Negrin University Hospital, Las Palmas, Spain|Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid, Madrid, Spain"		https://ClinicalTrials.gov/show/NCT01868906
1644	NCT02149459	Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy	SMC 0712-13	Unknown status	No Results Available	Brain Neoplasms	Radiation: Partial brain re-irradiation.|Drug: Metformin|Behavioral: low carbohydrate diet	Number of patients with adverse events.|Number of patients completing the trial.|Number of patients whose brain tumors respond on imaging.|Number of patients who demonstrate changes in systemic energy metabolism.	Sheba Medical Center|European Union	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SHEBA-13-0712-YL-CTIL	Jun-14	Jul-18	Jul-18	29-May-14		27-Oct-17	"Sheba Medical Center, Ramat Gan, Israel"		https://ClinicalTrials.gov/show/NCT02149459
1645	NCT01682746	Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors		Completed	No Results Available	"Brain Tumor, Recurrent"	Drug: Photofrin (porfimer sodium) & photodynamic therapy.	Maximum tolerable dose (MTD) of Photofrin® in pediatric subjects|Brain tumor response	"Harry T Whelan, MD|Pinnacle Biologics Inc.|Medical College of Wisconsin"	All	"6 Months to 18 Years   (Child, Adult)"	Phase 1	5	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	163588-1	Mar-13	29-Jun-18	29-Jun-18	11-Sep-12		25-Feb-19	"Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States"		https://ClinicalTrials.gov/show/NCT01682746
1646	NCT00848523	Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors		Terminated	No Results Available	Recurrent Malignant Gliomas	Drug: Panobinostat	To generate preliminary data of anti-tumor efficacy of LBH589 in adults with recurrent malignant gliomas.|To determine primary efficacy endpoint PFS-6|To determine objective response (CR + PR) Rate	"Neurological Surgery, P.C."	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	6	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)	LIBTC-2008-1	Nov-08	Apr-09	Apr-09	20-Feb-09		16-Jul-10	"Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates, Commack, New York, United States|Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates, Great Neck, New York, United States"		https://ClinicalTrials.gov/show/NCT00848523
1647	NCT01517776	Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents	HGG-CilMetro	Terminated	No Results Available	Gliomas	Drug: Cilengitide|Drug: Temozolomide	"Efficacy of a combined treatment with cilengitide and temozolomide as measured by 6 months overall survival after diagnosis of relapsed or refractory high grade glioma or diffuse intrinsic pontine glioma in children and adolescents|Safety and toxicity of the study treatment|Response rates (RR) at 6 months, progression-free survival (PFS) at 6 months, and RR, overall survival (OS), and PFS at 12 months after relapse diagnosis or diagnosis of tumor progression|Peak plasma levels of cilengitide [ng/ml] on day 1 of week 1 and day 4 of week 6"	"Martin-Luther-Universität Halle-Wittenberg|Merck KGaA, Darmstadt, Germany"	All	3 Years to 17 Years   (Child)	Phase 2	28	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIT-HGG-CilMetro|2009-011898-33	Jan-12	Mar-14	Apr-14	25-Jan-12		21-Jul-15	"University Children´s Hospital, Halle, Saxonia-Anhalt, Germany"		https://ClinicalTrials.gov/show/NCT01517776
1648	NCT01128218	A Study of the Specificity and Sensitivity of 5- Aminolevulinic Acid (ALA) Fluorescence in Malignant Brain Tumors		Completed	No Results Available	Brain Neoplasms	Drug: Tumor fluorescence	Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Tumor fluorescence intra-operative assessment by neurosurgeon|Tumor density determined by post-operative imaging	"Southern Illinois University|DUSA Pharmaceuticals, Inc."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	35	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COZ-SIU 10-002-1	Mar-11	Feb-21	Feb-21	21-May-10		6-Apr-21	"Southern Illinois University School of Medicine, Springfield, Illinois, United States"		https://ClinicalTrials.gov/show/NCT01128218
1649	NCT00977795	A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors		Withdrawn	No Results Available	Brain Neoplasms	Drug: 5-aminolevulinic acid	Establish a safe dose for oral 5-ALA administration.|Determine the sensitivity and specificity of 5-ALA mediated fluorescence for malignant glioma tissue in the brain|Compare the neurosurgeon's intra-operative estimate of the extent of malignant glioma resection (as guided by tumor fluorescence) with the actual extent of resection determined by post-operative imaging|Compare time-to-progression and survival to that in comparable cases performed without the aid of 5-ALA	NorthShore University HealthSystem	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EH09-377	Sep-09	Jan-10	Jan-10	16-Sep-09		10-Sep-19			https://ClinicalTrials.gov/show/NCT00977795
1650	NCT04365647	Intra-operative Variation in Size of Brain Tumors After Craniotomy		Completed	No Results Available	"Brain Tumor, Primary"		Tumor dimension change|Tumor distance from dural surface|Relationship of tumor size change with other characteristics	Sheri Kashmir Institute of Medical Sciences	All	"15 Years to 75 Years   (Child, Adult, Older Adult)"		51	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	"SKIMS, Soura"	1-Mar-18	1-Nov-19	31-Mar-20	28-Apr-20		28-Apr-20	"Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu And Kashmir, India"		https://ClinicalTrials.gov/show/NCT04365647
1651	NCT01183663	"Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)"		Completed	No Results Available	Advanced Cancers	Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil	"Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)|Tumor Response"	M.D. Anderson Cancer Center|Celgene	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	180	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2010-0108|NCI-2012-01790	Aug-10	May-16	May-16	17-Aug-10		3-Jun-16	"University of Texas MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT01183663
1652	NCT00782756	"Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma"		Completed	Has Results	Brain Cancer|Malignant Glioma	Other: radiotherapy (RT) in combination with temozolomide and bevacizumab	Number of Participants With Adverse Events|Progression Free Survival|Neurocognitive Outcome	"Memorial Sloan Kettering Cancer Center|Genentech, Inc.|National Institutes of Health (NIH)"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	40	Other|Industry|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-126	28-Oct-08	23-Mar-17	23-Mar-17	31-Oct-08	6-Feb-18	6-Feb-18	"Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States"	"Study Protocol and Statistical Analysis Plan, https://ClinicalTrials.gov/ProvidedDocs/56/NCT00782756/Prot_SAP_000.pdf"	https://ClinicalTrials.gov/show/NCT00782756
1653	NCT00979173	Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma		Completed	No Results Available	Glioma	Drug: AC480	Intratumoral and plasma pharmacokinetics of AC480 will be obtained on surgical tissue specimens from 5 patients treated pre-operatively with AC480.|Anti-proliferative effect of AC480 by FDG-PET|Intratumoral and plasma pharmacodynamics of AC480|6-month progression-free survival (PFS)|Radiographic response|Adverse event and toxicity monitoring	Annick Desjardins|Ambit Biosciences Corporation|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	5	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00018751	Nov-09	Oct-10	Jun-12	17-Sep-09		29-Jan-14	"The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00979173
1654	NCT01699269	Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging	TeDi-C2	Completed	No Results Available	High Grade Brain Tumor	Other: peritumoral glial cell infiltration	DTI-MRI|Biopsy|count cell|datas co-registration	"University Hospital, Clermont-Ferrand"	All	"18 Years to 85 Years   (Adult, Older Adult)"	Not Applicable	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Screening	CHU-0125|2011-A0159-40	Apr-12	Aug-13	Aug-13	3-Oct-12		8-Jul-14	"CHU Clermont-Ferrand, Clermont-Ferrand, France"		https://ClinicalTrials.gov/show/NCT01699269
1655	NCT01740570	Phase I/II Cabazitaxel for Recurrent Malignant Glioma		Withdrawn	No Results Available	Brain Cancer	Drug: Cabazitaxel	Maximum Tolerated Dose (MTD)|Progression Free Survival (PFS)	M.D. Anderson Cancer Center|Sanofi	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2012-0228	Apr-13	Apr-17		4-Dec-12		19-Jan-18			https://ClinicalTrials.gov/show/NCT01740570
1656	NCT00314925	Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features		Unknown status	No Results Available	Carcinoid|Neuroendocrine	Drug: Seneca Valley Virus (biological agent)	"Incidence of dose-limiting toxicity and determination of phase II dose|Number of responses according to RECIST criteria|Limited pharmacokinetics, biodistribution and elimination|Limited evaluation of occurrence of neutralizing antibody"	Neotropix	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N05-10564	Apr-06	Dec-08	Dec-08	17-Apr-06		25-Feb-10	"Cancer Centers of Florida, Ocoee, Florida, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|New York Oncology Hematology P.C., Albany, New York, United States|Dayton Oncology & Hematology, P.A ., Kettering, Ohio, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Mary Crowley Research Center, Dallas, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Northwest Cancer Specialists - Vancouver Cancer Center, Vancouver, Washington, United States"		https://ClinicalTrials.gov/show/NCT00314925
1657	NCT00157703	G207 Followed by Radiation Therapy in Malignant Glioma		Completed	No Results Available	Malignant Glioma	Drug: G207	Adverse events|Radiographic response|Performance scale|Overall survival|Immune response|Presence of G207 in blood and saliva	MediGene|National Cancer Institute (NCI)	All	"19 Years and older   (Adult, Older Adult)"	Phase 1	9	Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CT2001	May-05	Oct-08	Dec-08	12-Sep-05		16-Dec-08	"University of Alabama at Birmingham, Birmingham, Alabama, United States"		https://ClinicalTrials.gov/show/NCT00157703
1658	NCT01607905	Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer		Completed	Has Results	Solid Tumor	Drug: Selinexor|Drug: Acetaminophen	"Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Participants With Treatment-related Treatment-emergent Adverse Events|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03|Number of Participants Who Experienced Dose Limiting Toxicity (DLT)|Recommended Phase 2 Dose (RP2D)|Maximum Observed Plasma Concentration (Cmax) of Selinexor|Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor|Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor|Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor|Elimination Half-Life (t1/2) of Selinexor|Apparent Total Body Clearance (CL/F) of Selinexor|Apparent Volume of Distribution of Selinexor (Vd/F)|Number of Participants With Best Overall Response (BOR)|Percentage of Participants With Objective Response|Duration of Stable Disease (SD)|Progression-free Survival (PFS)|Overall Survival (OS)"	Karyopharm Therapeutics Inc	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	192	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KCP-330-002	18-Jun-12	15-Mar-16	15-Mar-16	30-May-12	30-Apr-21	30-Apr-21	"Moffitt Cancer Center, Tampa, Florida, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Rigshospitalet, Copenhagen, Denmark"		https://ClinicalTrials.gov/show/NCT01607905
1659	NCT01324479	Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors		Completed	No Results Available	Solid Tumors	Drug: INC280	Incidence rate of dose-limiting toxicities and adverse events|Objective response by local investigator assessment	Novartis Pharmaceuticals|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	131	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CINC280X2102|2010-024101-12	29-Feb-12	4-Jul-17	4-Jul-17	29-Mar-11		19-Dec-20	"Highlands Oncology Group, Fayetteville, Arkansas, United States|University of Chicago SC, Chicago, Illinois, United States|Karmanos Cancer Institute Wayne St Karmanos, Detroit, Michigan, United States|Sarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States|University of Texas/MD Anderson Cancer Center Dept of Onc, Houston, Texas, United States|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, La Tronche, France|Novartis Investigative Site, LILLE Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Seoul, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Utrecht, The Netherlands, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand"		https://ClinicalTrials.gov/show/NCT01324479
1660	NCT02038218	Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors	DM-CHOC-PEN	Completed	Has Results	Primary Brain Tumors|Metastatic Malignant Neoplasm to Brain	Drug: 4-Demethyl-4-cholestryloxycarbonylpenclomedine	Tumor Diameter|Overall Survival	"DEKK-TEC, Inc.|Tulane University Medical Center, New Orleans, LA|Icahn School of Medicine at Mount Sinai|Detroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MI|National Cancer Institute (NCI)|Ochsner Health System|The University of Texas Health Science Center, Houston"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	29	Industry|Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DTI-022|R44CA125871-03	Sep-13	May-16	Aug-20	16-Jan-14	16-Sep-20	16-Sep-20	"Tulane University Medical Center, New Orleans, Louisiana, United States|Detroit Clinical Research Centers, Lansing, Michigan, United States|The University of Texas Health Science Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT02038218
1661	NCT00528684	Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas		Completed	No Results Available	Malignant Glioma	Biological: REOLYSIN®	determine the maximum tolerated dose|and response rate of treated tumors|determine the dose limiting toxicity|Determine the patient survival|functional status using the Karnofsky Performance Status scale and Clinical Neurological Assessment|time to progression for the treated tumor	Oncolytics Biotech	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	18	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	REO 007	Jul-06	Apr-10	Jun-10	12-Sep-07		2-Oct-14	"University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center, Columbus, Ohio, United States"		https://ClinicalTrials.gov/show/NCT00528684
1662	NCT00717197	Study of Capecitabine to Treat Recurrent High Grade Gliomas		Completed	Has Results	Malignant Glioma	Drug: Capecitabine	Percentage of Participants With Progression-free Survival.	University of Florida	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HGG-001	Jul-08	Mar-12	May-13	17-Jul-08	25-Mar-13	2-Jul-13	"University of Florida, Gainesville, Florida, United States"		https://ClinicalTrials.gov/show/NCT00717197
1663	NCT02977689	Trial of IDH305 in IDH1 Mutant Grade II or III Glioma		Withdrawn	No Results Available	Glioma	Drug: IDH305	Radiographic response rate|Safety (adverse events) of the protocol therapy|Volumetric radiographic response rate|Median duration of response|Median progression-free survival (PFS)|Progression-free survival at 6 months (PFS6)|2-year overall survival (OS)	NYU Langone Health|Novartis	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	0	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-00589	Apr-18	Apr-20	Apr-20	30-Nov-16		20-Dec-17	"Laura & Isaac Perlmutter Cancer Center & NYU Langone Medical Center, New York, New York, United States"		https://ClinicalTrials.gov/show/NCT02977689
1664	NCT01017653	Panitumumab and Irinotecan for Malignant Gliomas		Terminated	Has Results	Malignant Glioma of Brain	Drug: Irinotecan|Drug: Panitumumab	6-month Progression-free Survival (PFS)|One-Year Overall Survival|Safety of Panitumumab in Combination With Irinotecan|Effect of Panitumumab in Combination With Irinotecan on Corticosteroid Dose|Relationship Between Epidermal Growth Factor Receptor (EGF-R) Mutational Analysis and Efficacy or Toxicity|Objective Response Rate|Median Overall Survival (OS)	Annick Desjardins|Amgen|Duke University	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	16	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00015447	Feb-10	Oct-11	Oct-11	20-Nov-09	4-Sep-13	4-Sep-13	"The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT01017653
1665	NCT03234712	"A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)"		Completed	No Results Available	Advanced Solid Tumors Cancer	Drug: ABBV-321	AUCt for ABBV-321|AUC∞ for ABBV-321|Tmax of ABBV-321|Terminal phase elimination rate constant (β) for ABBV-321|Cmax of ABBV-321|Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for ABBV-321|t1/2 for ABBV-321|Dose Escalation Phase: Maximum tolerated dose (MTD) of ABBV-321|Progression-Free Survival (PFS)|Duration of Response (DOR)|Disease Control Rate (DCR)|Time to progression (TTP)|Change from Baseline in QTcF|Overall Survival (OS)|Objective response rate (ORR)	AbbVie	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	62	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16-438	10-Oct-17	14-Apr-21	14-Apr-21	31-Jul-17		6-May-21	"Highlands Oncology Group /ID# 166132, Springdale, Arkansas, United States|The Angeles Clinic and Researc /ID# 166133, Los Angeles, California, United States|University of California, Davis Comprehensive Cancer Center /ID# 215012, Sacramento, California, United States|Northwestern University Feinberg School of Medicine /ID# 165191, Chicago, Illinois, United States|University of Chicago /ID# 166064, Chicago, Illinois, United States|Northshore University Health System Dermatology Clinical Trials Unit /ID# 201095, Skokie, Illinois, United States|University of Kentucky Markey Cancer Center /ID# 217665, Lexington, Kentucky, United States|Dana-Farber Cancer Institute /ID# 212920, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 214955, Saint Louis, Missouri, United States|Columbia Univ Medical Center /ID# 167184, New York, New York, United States|Stony Brook University Hospital /ID# 216976, Stony Brook, New York, United States|Duke University Medical Center /ID# 166135, Durham, North Carolina, United States|Lifespan Cancer Institute at Rhode Island Hospital /ID# 168600, Providence, Rhode Island, United States|South Texas Accelerated Research Therapeutics /ID# 166134, San Antonio, Texas, United States|Northern Cancer Institute /ID# 166138, St Leonards, New South Wales, Australia|Monash Health /ID# 217435, Clayton, Victoria, Australia|Austin Hospital /ID# 166137, Heidelberg, Victoria, Australia|Sheba Medical Center /ID# 166398, Ramat Gan, Israel"		https://ClinicalTrials.gov/show/NCT03234712
1666	NCT00120939	Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer		Completed	No Results Available	Breast Neoplasms|Ovarian Neoplasms|Prostatic Neoplasms|Lung Neoplasms|Gastrointestinal Neoplasms	Drug: Motexafin Gadolinium	"Determine the Dose Limiting Toxicity at 8 weeks (2 cycles), and the Maximum Tolerated Dose at 24 weeks.|Tumor response rate 8, 16 and 24 weeks, and common PK parameters at 24 weeks"	Pharmacyclics LLC.	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	25	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCYC-0212				19-Jul-05		3-Apr-09	"University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00120939
1667	NCT00003457	Antineoplaston Therapy in Treating Patients With Brain Tumors		Completed	Has Results	Refractory Brain Tumors	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"18 Years to 99 Years   (Adult, Older Adult)"	Phase 2	40	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066489|BC-BT-9	Jul-96	Feb-12	Feb-12	27-Jan-03	16-Dec-16	22-Aug-17	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003457
1668	NCT04704154	A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors		Recruiting	No Results Available	Solid Tumors	"Drug: Regorafenib, (Stivarga, BAY73-4506)|Drug: Nivolumab (Opdivo)"	Overall response rate (ORR)|Duration of response (DOR)|Disease control rate (DCR)|Progression free survival (PFS)|6 months PFS|Overall survival (OS)|1 year OS|Severity of AEs (adverse events) per CTCAE v 5.0|Number of participants with adverse events	"Bayer|Bristol Myers Squibb Co. and Ono Pharmaceutical Co., Ltd"	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	200	Industry|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	21136|2020-003359-13	3-Feb-21	13-Jul-23	21-Dec-24	11-Jan-21		18-Nov-21	"City of Hope National Medical Center, Duarte, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Oncology Associates of Oregon, Eugene, Oregon, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Baylor Charles A. Sammons Cancer Center at Dallas, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Hôpital Erasme/Erasmus Ziekenhuis, Bruxelles - Brussel, Belgium|UZ Antwerpen, Edegem, Belgium|CHU de Liège, Liege, Belgium|Institut Bergonié - Unicancer Nouvelle Aquitaine, Bordeaux Cedex, France|Centre Léon Bérard, Lyon Cedex, France|Hôpital de la Pitié-Salpétrière, Paris, France|Institut de Cancérologie de l'Ouest - Saint Herblain, Saint Herblain, France|Institut Claudius Regaud - iUCT Oncopole, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif Cedex, France|AUSL di Bologna - IRCCS Istituto Scienze Neurologiche, Bologna, Emilia-Romagna, Italy|Istituto Clinico Humanitas - Humanitas Mirasole S.p.A., Milano, Lombardia, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|Istituto Oncologico Veneto IRCCS (IOV), Padova, Veneto, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Saitama Cancer Center, Kita-Adachigun, Saitama, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|China Medical University Hospital, Taichung, Taiwan|Chi-Mei Medical Center, Liouyine, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Royal Marsden NHS Trust (Surrey), Sutton, Surrey, United Kingdom|University Hospitals Coventry and Warwickshire NHS Trust, Coventry, West Midlands, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Marsden Hospital (London), London, United Kingdom"		https://ClinicalTrials.gov/show/NCT04704154
1669	NCT00003458	Antineoplaston Therapy in Treating Children With Brain Tumors		Completed	Has Results	Childhood Brain Tumors	Drug: Antineoplaston therapy (Atengenal + Astugenal)	Number of Participants With Objective Response|Percentage of Participants Who Survived	Burzynski Research Institute	All	"6 Months to 18 Years   (Child, Adult)"	Phase 2	34	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000066490|BC-BT-10	Sep-96	Sep-14	Sep-14	27-Jan-03	19-Jan-17	5-Feb-18	"Burzynski Clinic, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003458
1670	NCT01621542	Clinical Study of WT2725 in Patients With Advanced Malignancies		Completed	Has Results	Cancer	Biological: WT2725	Occurrence of Dose-limiting Toxicities and Adverse Events|Maximum Tolerated Dose (MTD) of WT2725 Based on the Evaluation of Dose-limiting Toxicity (DLT)|Antitumor Responses to WT2725 Based on the Immune-related Response Criteria (irRC)|Immune Response to WT2725	"Sunovion|Sumitomo Dainippon Pharma Co., Ltd."	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	64	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D8350004	31-Jul-12	17-May-17	17-May-17	18-Jun-12	5-Apr-19	17-Jul-19	"The University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States"	"Study Protocol: Final Protocol, https://ClinicalTrials.gov/ProvidedDocs/42/NCT01621542/Prot_000.pdf|""Study Protocol: Amendment history"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01621542/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT01621542/SAP_002.pdf"	https://ClinicalTrials.gov/show/NCT01621542
1671	NCT02711137	Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies		Terminated	No Results Available	Solid Tumors	Drug: INCB057643|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Rucaparib|Drug: Abiraterone|Drug: Ruxolitinib|Drug: Azacitidine	"Safety and tolerability of INCB057643 as monotherapy and in combination with standard of care (SOC) agents in patients with advanced malignancies; assessed by clinical laboratory assessments, physical examinations, 12 lead ECGs, and adverse events (AEs)|Pharmacokinetics of INCB057643 as monotherapy in the fasted state and in the fed state (food effect; Part 2 only) and when administered in combination with Standard of Care (SOC) agents in the fasted state assessed by plasma and urine concentrations|Measurement of cellular myc protein concentrations before and after administration of INCB057643 when administered as monotherapy|Efficacy of INCB057643 when administered as monotherapy and in combination with SOC agents based on the investigator assessment of response using criteria appropriate for each disease in subjects with advanced malignancies criteria"	Incyte Corporation	All	"18 Years and older   (Adult, Older Adult)"	Phase 1|Phase 2	136	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INCB 57643-101	18-May-16	13-Feb-19	13-Feb-19	17-Mar-16		17-Feb-20	"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France"		https://ClinicalTrials.gov/show/NCT02711137
1672	NCT00074334	TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma		Terminated	No Results Available	Brain and Central Nervous System Tumors	Biological: TGFa-PE38 immunotoxin|Procedure: conventional surgery	"Maximum safe volume rate of TP-38 infused through three catheters (Stratum A) or through two catheters (Stratum B).|Maximum tolerated infusion concentration of TP-38 infused through three catheters (Stratum A) or through two catheters (Stratum B).|Toxicities of TP-38|Post-infusion survival (phase II)|EGFR expression and phosphorylation (activity)|Correlation of EGFR expression with tumor histology, tumor grade, tumor response (phase I and phase II) and survival and progression-free survival (phase II).|Post-infusion progression-free survival (phase II)|Objective response (phase II)"	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1|Phase 2	3	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000344416|PBTC-013	May-04	Jun-06	Jun-06	11-Dec-03		21-Oct-09	"Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00074334
1673	NCT00541138	"Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors"		Completed	No Results Available	"Brain and Central Nervous System Tumors|Metastatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific"	Drug: carboplatin|Drug: tamoxifen citrate|Drug: topotecan hydrochloride|Other: pharmacological study	Toxicity profile as assessed by NCI CTC v2.0|Response rate in patients with recurrent glial tumors as assessed by RECIST criteria|Response rate in patients with epithelial CNS metastases as assessed by RECIST criteria|Reason for going off-study|Progression|Survival	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 2	50	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	02191|P30CA033572|CHNMC-02191|CDR0000570253	May-03	Oct-07	Oct-07	8-Oct-07		21-Sep-11	"City of Hope Comprehensive Cancer Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT00541138
1674	NCT00499798	"Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors"		Completed	No Results Available	Brain and Central Nervous System Tumors|Chemotherapeutic Agent Toxicity|Infertility		assess any changes in standard semen/sperm analysis parameters	Wake Forest University Health Sciences|National Cancer Institute (NCI)	Male	18 Years to 60 Years   (Adult)		16	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	CDR0000553297|CCCWFU-97404|CCCWFU-BG04-308	Aug-04	Jun-09	Sep-14	11-Jul-07		30-May-17	"Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00499798
1675	NCT00784914	"A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors"		Completed	No Results Available	Brain and Central Nervous System Tumors|Metastatic Cancer	Drug: temsirolimus|Other: pharmacological study|Other: cytokine levels	"Feasibility of using a microdialysis catheter to assess the neuropharmacodynamics (nPD) of temsirolimus|Changes in intracerebral levels of vascular endothelial growth factor (VEGF), interleukin-1ß (IL-1ß), and other cytokines|Relationship between temsirolimus dose and changes in intracerebral levels of VEGF, IL-1ß, and other cytokines|Relationship between the degree of microvascular proliferation and the tensin homologue deleted on chromosome 10 (PTEN) status in tumor tissue|Relationship between changes in intracerebral cytokine levels after treatment with temsirolimus|Compare changes in intracerebral cytokine levels to changes in systemic cytokine levels."	City of Hope Medical Center|National Cancer Institute (NCI)	All	"18 Years and older   (Adult, Older Adult)"	Phase 1	12	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07064|P30CA033572|CHNMC-07064|CDR0000617019	Jun-08	Nov-10	Nov-10	4-Nov-08		17-Apr-18	"City of Hope Comprehensive Cancer Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT00784914
1676	NCT00281905	Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors		Unknown status	No Results Available	Brain and Central Nervous System Tumors|Neuroblastoma	Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: methotrexate|Drug: vincristine sulfate|Radiation: radiation therapy	Response rate|Event-free survival|Local recurrence or occurrence of CNS metastases|Quality of survival|Tolerance|Long-term toxicity|Proportion of patients requiring radiotherapy|Prognosis of children who receive both chemotherapy and radiotherapy|Nature and behavior of brain tumors	Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)	All	up to 3 Years   (Child)	Phase 2	50	Other	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000454575|CCLG-CNS-9204|EU-20574|CCLG-CNS-1992-04	Jun-92			25-Jan-06		20-Sep-13	"Our Lady's Hospital for Sick Children, Dublin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Institute of Child Health at University of Bristol, Bristol, England, United Kingdom|Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom|Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, England, United Kingdom|Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom|Childrens Hospital for Wales, Cardiff, Wales, United Kingdom"		https://ClinicalTrials.gov/show/NCT00281905
1677	NCT00003241	Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: phenylacetate		Texas Children's Cancer Center|National Cancer Institute (NCI)	All	"2 Years to 21 Years   (Child, Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	TCCC-H-5057|CDR0000066116|NCI-98-C-0107D|NCI-T96-0070	May-98		Sep-04	10-Sep-04		26-Jun-13	"Children's Hospital Los Angeles, Los Angeles, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Pediatric Oncology Branch, Bethesda, Maryland, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Texas Children's Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00003241
1678	NCT00360945	Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: cisplatin|Drug: temozolomide|Genetic: fluorescence in situ hybridization|Genetic: loss of heterozygosity analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Radiation: radiation therapy	Response rate after 2 courses|Relapse-free survival|Best response in patients receiving more than 2 courses|Rate of progression at 6 months and 1 and 2 years|Overall survival	Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)	All	"4 Years to 20 Years   (Child, Adult)"	Phase 2	87	Other	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000482280|CCLG-CNS-2004-02|EU-20622	Apr-04			7-Aug-06		17-Sep-13	"Institut Gustave Roussy, Villejuif, France|Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Institute of Child Health at University of Bristol, Bristol, England, United Kingdom|Bristol Royal Hospital for Children, Bristol, England, United Kingdom|Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Middlesex Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children NHS Trust, London, England, United Kingdom|Central Manchester and Manchester Children's University Hospitals NHS Trust, Manchester, England, United Kingdom|Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton University Hospital NHS Trust, Southampton, England, United Kingdom|Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom|Childrens Hospital for Wales, Cardiff, Wales, United Kingdom"		https://ClinicalTrials.gov/show/NCT00360945
1679	NCT01346267	Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy	SCUSF1202	Completed	Has Results	"Central Nervous System Tumor, Pediatric|Chemotherapy-induced Nausea and Vomiting|Unspecified Childhood Solid Tumor, Protocol Specific"	Procedure: Real Acupressure Band|Procedure: Placebo Acupressure Band	Efficacy of Treatment on CIN During Acute Phase of Chemotherapy|Efficacy of Treatment on CIN During Delayed Phase of Chemotherapy|Comparison of Control of CIV During the Acute and Delayed Phase of Chemotherapy	University of South Florida|National Cancer Institute (NCI)	All	"4 Years to 18 Years   (Child, Adult)"	Not Applicable	187	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	SCUSF 1202|SCUSF-1202|Previously COG-ACCL1032|5U10CA081920	May-11	May-16	May-16	2-May-11	25-Jun-21	18-Aug-21	"Miller Children's Hospital, Long Beach, California, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A I duPont Hospital for Children, Wilmington, Delaware, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Palms West Hospital, Loxahatchee Groves, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Kapiolani Medical for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation New Orleans, New Orleans, Louisiana, United States|Dana Farber Cancer Institute at Boston Children's Hospital, Boston, Massachusetts, United States|Columbia University Medical Center, New York, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Mercy Children's Hospital, Toledo, Ohio, United States|Randall Children's Hospital at Legacy Emanuel, Portland, Oregon, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Methodist Healthcare System of San Antonio, San Antonio, Texas, United States|Scott & White Pediatrics, Temple, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Hospital for Sick Children, Toronto, Ontario, Canada"		https://ClinicalTrials.gov/show/NCT01346267
1680	NCT00572182	MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer		Terminated	No Results Available	Brain and Central Nervous System Tumors	Drug: MK-0752	Maximum tolerated dose|MK0752 systemic exposure|Pharmacokinetics|Toxicity|Objective response rate	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	33	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000578114|U01CA081457|PBTC-024|NCI-09-C-0112	Jul-08	Feb-11	Feb-11	12-Dec-07		6-Mar-12	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|NCI - Pediatric Oncology Branch, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00572182
1681	NCT00897858	Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors		Withdrawn	No Results Available	Brain and Central Nervous System Tumors		Number of IRB approvals of the study|Number of patients with proteomic data received at the Operations and Biostatistics Center|Number of differentially expressed biomarker proteins	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"		0	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	CDR0000481330|PBTC-N08	Aug-06	Jan-14		12-May-09		19-Apr-13	"Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00897858
1682	NCT00788125	"Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors"		"Active, not recruiting"	No Results Available	"Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: carboplatin|Drug: dasatinib|Drug: etoposide phosphate|Drug: ifosfamide|Genetic: microarray analysis|Genetic: western blotting|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: therapeutic conventional surgery|Radiation: radiation therapy	"Maximum tolerated dose of dasatinib (Phase I)|Toxicity as measured by NCI CTCAE v3.0 (Phase I)|Overall survival at 1 year in patients with relapsed sarcoma (Phase II, Stratum A)|Response rate prior to consolidation therapy as measured by RECIST criteria (Phase II)|Progression-free survival (Phase II)|Exploratory correlative studies"	City of Hope Medical Center|National Cancer Institute (NCI)	All	"1 Year to 25 Years   (Child, Adult)"	Phase 1|Phase 2	143	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07053|P30CA033572|CHNMC-07053|CA180 121|CDR0000617760	3-Sep-08	24-Aug-10	31-Dec-21	10-Nov-08		10-Mar-21	"City of Hope Comprehensive Cancer Center, Duarte, California, United States"		https://ClinicalTrials.gov/show/NCT00788125
1683	NCT00623077	MT2004-30: Tomotherapy for Solid Tumors		Terminated	No Results Available	Brain and Central Nervous System Tumors|Kidney Cancer|Liver Cancer|Retinoblastoma|Sarcoma	Biological: filgrastim|Drug: busulfan|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: thiotepa|Procedure: stem cell transplantation|Radiation: tomotherapy|Radiation: total marrow irradiation|Drug: Mesna|Radiation: Whole lung radiation	"Maximum tolerated dose of tomotherapy up to 12 Gy|Percent of patients who had PET scans and ""spot radiation"" to PET-positive lesions after transplantation|Change in bone mineral density|Rate of Treatment Related Mortality in Non-TMI Treated Patients|Rate of Primary Neutrophil Engraftment|Overall Survival|Disease-Free Survival"	"Masonic Cancer Center, University of Minnesota"	All	"up to 70 Years   (Child, Adult, Older Adult)"	Phase 1	23	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2005LS023|UMN-MT2004-30|0504M69306	Aug-05	Jul-12	Oct-16	25-Feb-08		5-Dec-17	"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States"		https://ClinicalTrials.gov/show/NCT00623077
1684	NCT00392886	Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors		Unknown status	No Results Available	Brain and Central Nervous System Tumors	Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy	"Time to tumor progression, disease recurrence, or death of any cause|Event-free survival at 2 years|Toxicity|Response to induction as assessed by one-time tumor measurements at baseline and after completion of induction chemotherapy|Time to death|Overall survival"	Children's Hospital Los Angeles|National Cancer Institute (NCI)	All	up to 10 Years   (Child)	Phase 3	120	Other	Interventional	Primary Purpose: Treatment	CDR0000503990|CHLA-HEAD-START-III|CHLA-HSIII|CHLA-2004-020|CHLA-04.020|UMN-MT2004-06	Mar-04	Dec-10		26-Oct-06		18-Dec-13	"Phoenix Children's Hospital Outpatient Center, Phoenix, Arizona, United States|Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital at UCLA, Los Angeles, California, United States|Children's Hospital and Research Center Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|University of Chicago Comer Children's Hospital, Chicago, Illinois, United States|Riley's Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Tomorrows Children's Institute at Hackensack University Medical Center, Hackensack, New Jersey, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Toledo Children's Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Children's & Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Christchurch Hospital, Christchurch, New Zealand|Wellington Children's Hospital, Wellington, New Zealand|Swiss Pediatric Oncology Group Bern, Bern, Switzerland|Universitaets Kinderklinik, Bern, Switzerland"		https://ClinicalTrials.gov/show/NCT00392886
1685	NCT00002463	Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: MOPP Regimen|Drug: Leucovorin Calcium|Drug: Mechlorethamine Hydrochloride|Drug: Methotrexate|Drug: Prednisone|Drug: Procarbazine Hydrochloride|Drug: Vincristine Sulfate|Procedure: Conventional Surgery	Number of Patient with Overall Response	M.D. Anderson Cancer Center|National Cancer Institute (NCI)	All	up to 3 Years   (Child)	Phase 2	4	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P88-006|P30CA016672|MDA-P-88006|NCI-V89-0125|CDR0000075917	Feb-89	Jan-07	Jan-08	22-Apr-04		18-Feb-13	"University of Texas - MD Anderson Cancer Center, Houston, Texas, United States"		https://ClinicalTrials.gov/show/NCT00002463
1686	NCT00303940	Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors		Completed	No Results Available	"Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: carboplatin|Drug: talabostat mesylate|Drug: temozolomide|Other: pharmacological study		National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)	All	"2 Years to 18 Years   (Child, Adult)"	Phase 1	26	NIH	Interventional	Primary Purpose: Treatment	050239|05-C-0239|NCI-P6672|CDR0000462620	Dec-05		Feb-10	17-Mar-06		15-Mar-12	"Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States"		https://ClinicalTrials.gov/show/NCT00303940
1687	NCT00238173	"Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors"		Terminated	No Results Available	Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Long-term Effects Secondary to Cancer Therapy in Children	Biological: filgrastim|Drug: acetylcysteine|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide phosphate|Drug: mannitol|Drug: sodium thiosulfate	"To assess toxicity and the maximally tolerated dose of N-acetylcysteine administered in conjunction with carboplatin, cyclophosphamide and etoposide phosphate BBBD, and delayed high dose sodium thiosulfate, in children with malignant brain tumors."	OHSU Knight Cancer Institute|National Cancer Institute (NCI)	All	"1 Year to 18 Years   (Child, Adult)"	Phase 1	2	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00002050|OHSU-8522|OHSU-SOL-04085-L|OHSU-IRB-2050	Dec-04	17-Feb-06	17-Feb-06	13-Oct-05		21-Apr-17	"OHSU Knight Cancer Institute, Portland, Oregon, United States"		https://ClinicalTrials.gov/show/NCT00238173
1688	NCT00138216	"Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors"		Completed	No Results Available	"Brain and Central Nervous System Tumors|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: irinotecan hydrochloride|Drug: temozolomide|Drug: vincristine sulfate	Determine maximum tolerated dose (MTD) of oral irinotecan|To preliminarily define the antitumor activity	Children's Oncology Group|National Cancer Institute (NCI)	All	"1 Year to 21 Years   (Child, Adult)"	Phase 1	42	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ADVL0414|COG-ADVL0414|CDR0000440069	Oct-05	Jun-09	Jan-11	30-Aug-05		20-Feb-14	"Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|Children's Hospital of Orange County, Orange, California, United States|Stanford Cancer Center, Stanford, California, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University Cancer Institute, Portland, Oregon, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00138216
1689	NCT00112619	"Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors"		Terminated	No Results Available	"Brain and Central Nervous System Tumors|Carcinoma of Unknown Primary|Leukemia|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: topotecan hydrochloride	Estimate the maximum tolerated dose of intraventricular topotecan on this schedule|Number of patients with dose-limiting toxicity|Estimate the dose of intraventricular topotecan that will result in cerebrospinal fluid lactone concentrations exceeding 1 ng/mL for at least 8 hours after an intrathecal injection|Number of patients with objective documentation of tumor response to intraventricular topotecan|Pharmacokinetics|Correlation of imaging parameters with tumor response	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	19	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000430504|U01CA081457|PBTC-019	Aug-05	Aug-10		3-Jun-05		30-Jun-11	"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00112619
1690	NCT00107458	Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors		Completed	No Results Available	"Brain and Central Nervous System Tumors|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: valproic acid	Efficacy of oral etoposide at 50 mg/m2/day given concurrently with radiotherapy	Children's Oncology Group|National Cancer Institute (NCI)	All	"2 Years to 21 Years   (Child, Adult)"	Phase 1	26	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	ADVL0419|COG-ADVL0419|NCI-05-C-0235|NCI-P6631|CDR0000417845	May-05	Oct-07	Mar-12	6-Apr-05		7-Aug-14	"Children's Hospital of Orange County, Orange, California, United States|Stanford Comprehensive Cancer Center - Stanford, Stanford, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University Cancer Institute, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada"		https://ClinicalTrials.gov/show/NCT00107458
1691	NCT00098761	"VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors"		Completed	No Results Available	Brain and Central Nervous System Tumors	Drug: laromustine	Estimate the maximum tolerated dose|Number of participants with dose limiting toxicities|Pharmacokinetics|Tumor response to VNP40101M	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 1	42	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000396779|PBTC-017|VION-VNP40101M	Feb-05	Oct-06	Feb-08	9-Dec-04		30-Jun-11	"UCSF Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00098761
1692	NCT00003141	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors		Completed	No Results Available	Brain Tumors|Central Nervous System Tumors|Neuroblastoma|Sarcoma	Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation	"Feasibility|Maximal tolerated dose of thiotepa for consolidation therapy|Overall rates of significant toxicities including grade IV ototoxicity, electrolytic wasting (grade IV), and hemorrhagic cystitis (grade IV)|Event Free Survival"	Children's Oncology Group|National Cancer Institute (NCI)	All	up to 2 Years   (Child)	Phase 1	94	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	99703|COG-99703|CCG-99703|CDR0000065924	Mar-98	Dec-07	Oct-11	6-Nov-03		28-Mar-14	"City of Hope Comprehensive Cancer Center, Duarte, California, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's Hospital Center for Cancer and Blood Disorders, Aurora, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States|MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Kalamazoo, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Children's Hospitals and Clinics of Minnesota - St. Paul, St. Paul, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States|Overlook Hospital, Morristown, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Beth Israel Medical Center - Petrie Division, New York, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Akron Children's Hospital, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's - Dayton, Dayton, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Texas Tech University Health Sciences Center School of Medicine - Amarillo, Amarillo, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center - Tacoma, Tacoma, Washington, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Children's & Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada"		https://ClinicalTrials.gov/show/NCT00003141
1693	NCT00066248	Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment		Completed	No Results Available	"Brain Tumor|Central Nervous System Tumors|Cachexia|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: cyproheptadine hydrochloride|Drug: megestrol acetate	"Efficacy of study agents as measured by changes in weight at baseline, and 4 weeks after the beginning of study treatment|Effect of study agents on protein and fat levels as measured by pre-albumin and lipid profile at baseline, and 4 weeks after the beginning of study treatment"	University of South Florida|National Cancer Institute (NCI)	All	"2 Years to 20 Years   (Child, Adult)"	Phase 2	70	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	SCUSF 0205|HLMCC-0205|U10CA081920	Jun-03	Aug-07	Aug-07	7-Aug-03		3-Feb-14	"CCOP - Bay Area Tumor Institute, Oakland, California, United States|Children's Hospital & Research Center Oakland, Oakland, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Sacred Heart Cancer Center at Sacred Heart Hospital, Pensacola, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|St. Joseph's Children's Hospital of Tampa, Tampa, Florida, United States|CCOP - Florida Pediatric, Tampa, Florida, United States|Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States|MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Floating Hospital for Children at Tufts - New England Medical Center, Boston, Massachusetts, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Detroit, Michigan, United States|DeVos Children's Hospital, Grand Rapids, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Saint Paul, Minnesota, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Tomorrows Children's Institute at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Columbus Children's Hospital, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Tod Children's Hospital, Youngstown, Ohio, United States|Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|MBCCOP - South Texas Pediatrics, San Antonio, Texas, United States|Methodist Cancer Center at Methodist Specialty and Transplant Hospital, San Antonio, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|San Jorge Children's Hospital, Santurce, Puerto Rico"		https://ClinicalTrials.gov/show/NCT00066248
1694	NCT00006342	Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor		Completed	No Results Available	Brain and Central Nervous System Tumors|Lymphoma	Genetic: chromosomal translocation analysis|Genetic: gene rearrangement analysis|Genetic: mutation analysis		Duke University|National Cancer Institute (NCI)	All	"Child, Adult, Older Adult"		19	Other|NIH	Observational	Observational Model: Case-Only|Time Perspective: Prospective	CDR0000067681|DUMC-0113-99-1R2|DUMC-IRB-086-97-1|NCI-G00-1840	Jan-97	Sep-00	Jan-01	4-May-04		15-Oct-15	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00006342
1695	NCT00002485	Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer		Completed	No Results Available	"Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Leukemia|Liver Cancer|Lymphoma|Neuroblastoma|Ovarian Cancer|Psychosocial Effects of Cancer and Its Treatment|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific"	Procedure: psychosocial assessment and care	Determine why eligible patients are not enrolled on available Pediatric Oncology Group therapeutic clinical trials.	Children's Oncology Group|National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"		359	Other|NIH	Observational		9284|POG-9284/9285|NCI-P92-0003|CDR0000077305	Feb-92	Jul-03	Sep-05	26-Apr-04		14-Feb-14	"University of California Davis Medical Center, Sacramento, California, United States|Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|CCOP - Florida Pediatric, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|CCOP - Wichita, Wichita, Kansas, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Tomorrows Children's Institute, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Mission Hospital, Asheville, North Carolina, United States|Presbyterian Healthcare, Charlotte, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Oklahoma Memorial Hospital, Oklahoma City, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Vermont Cancer Center, Burlington, Vermont, United States|West Virginia University - Charleston Division, Charleston, West Virginia, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Montreal Children's Hospital, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Puerto Rico|Clinique de Pediatrie, Geneva, Switzerland"		https://ClinicalTrials.gov/show/NCT00002485
1696	NCT00036959	ABT-751 in Treating Young Patients With Refractory Solid Tumors		Completed	No Results Available	"Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: ABT-751		National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)	All	"up to 18 Years   (Child, Adult)"	Phase 1	90	NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	020141|02-C-0141|ABBOTT-M01-357|CDR0000069344	Mar-02	Feb-10	Feb-10	27-Jan-03		15-Mar-12	"Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States"		https://ClinicalTrials.gov/show/NCT00036959
1697	NCT00006246	Busulfan in Treating Children and Adolescents With Refractory CNS Cancer		Completed	No Results Available	Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Leukemia|Lymphoma|Metastatic Cancer|Retinoblastoma|Sarcoma	Drug: busulfan	Toxicities of IT administered busulfan in children and adolescents with refractory CNS malignancies|Maximum tolerated dose of IT administered busulfan|Serum and CSF pharmacokinetics of IT administered busulfan	Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)	All	"3 Years to 21 Years   (Child, Adult)"	Phase 1	28	Other|NIH	Interventional	Primary Purpose: Treatment	CDR0000068178|PBTC-004	Nov-00	May-03		27-Jan-03		7-Oct-09	"UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States"		https://ClinicalTrials.gov/show/NCT00006246
1698	NCT00006102	Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma		Completed	No Results Available	"Brain and Central Nervous System Tumors|Lymphoma|Neuroblastoma|Retinoblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific"	Drug: becatecarin		National Cancer Institute (NCI)	All	"up to 21 Years   (Child, Adult)"	Phase 2	200	NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2012-01851|COG-P9963|CDR0000068111	Jul-00	Jun-06		27-Jan-03		5-Feb-13	"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|University of South Alabama Medical Center, Mobile, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital of Oakland, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States|Sutter Cancer Center, Sacramento, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California, United States|Children's Hospital San Diego, San Diego, California, United States|Kaiser Permanente Medical Center - San Francisco Geary Campus, San Francisco, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|Children's Hospital of Denver, Denver, Colorado, United States|Presbyterian-St Luke's Medical Center, Denver, Colorado, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Yale Comprehensive Cancer Center, New Haven, Connecticut, United States|Alfred I. Dupont Institute, Wilmington, Delaware, United States|Lombardi Cancer Center, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital at Memorial, Hollywood, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami-Jackson Memorial Hospital, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Walt Disney Memorial Cancer Institute at Florida Hospital, Orlando, Florida, United States|Nemours Children's Clinic-Orlando, Orlando, Florida, United States|Sacred Heart Children's Hospital, Pensacola, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|Tampa Children's Hospital, Tampa, Florida, United States|St. Mary's Hospital, West Palm Beach, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Children's Healthcare of Atlanta - Scottish Rite, Atlanta, Georgia, United States|Medical College of Georgia Comprehensive Cancer Center, Augusta, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Mountain States Tumor Institute, Boise, Idaho, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Advocate Hope Children's Hospital, Oak Lawn, Illinois, United States|Lutheran General Hospital, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Raymond Blank Memorial Hospital for Children, Des Moines, Iowa, United States|Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Wesley Medical Center, Wichita, Kansas, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Floating Hospital for Children, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts Memorial Medical Center - University Campus, Worcester, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|St. John Hospital and Medical Center, Detroit, Michigan, United States|Michigan State University, East Lansing, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|St. Mary's/Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Children's Hospitals and Clinics - Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Children's Hospitals and Clinics - Minnesota, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri-Columbia Hospital and Clinics, Columbia, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|St. Barnabas Medical Center, Livingston, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Atlantic Health System, Summit, New Jersey, United States|University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|Albert Einstein Clinical Cancer Center, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|State University of New York Health Science Center at Brooklyn College of Medicine, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|New York Presbyterian Hospital - Cornell Campus, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|State University of New York - Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission St. Joseph's Health System, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Healthcare, Charlotte, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|East Carolina University School of Medicine, Greenville, North Carolina, United States|Dakota Cancer Institute, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Toledo Children's Hospital, Toledo, Ohio, United States|Forum Health-Tod Childrens Hospital, Youngstown, Ohio, United States|Children's Hospital of Oklahoma, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|Doernbecher Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, United States|Children's Hospital of Greenville Hospital System, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sioux Valley Hospital, Sioux Falls, South Dakota, United States|East Tennessee State University Cancer Center at JCMC, Johnson City, Tennessee, United States|East Tennessee Children's Hospital, Knoxville, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Methodist Health Care System, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Vermont Cancer Center, Burlington, Vermont, United States|Cancer Center at the University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States|Massey Cancer Center, Richmond, Virginia, United States|Carilion Medical Center for Children, Roanoke, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Cooperative, Seattle, Washington, United States|Deaconess Medical Center, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University - Charleston, Charleston, West Virginia, United States|Cabell-Huntington Hospital, Inc, Huntington, West Virginia, United States|West Virginia University Hospitals, Morgantown, West Virginia, United States|Bellin Memorial Hospital, Green Bay, Wisconsin, United States|CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Medical College of Ohio Hospital, Madison, Wisconsin, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|Children's Hospital, Hamilton, Ontario, Canada|Children's Hospital of Western Ontario, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|McGill University Health Center - Montreal Children's Hospital, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Laval University Medical Center, Sainte-Foy, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Academisch Ziekenhuis Groningen, Groningen, Netherlands|Starship Children's Hospital, Auckland, New Zealand|University of Puerto Rico School of Medicine Medical Sciences Campus, San Juan, Puerto Rico|San Jorge Childrens Hospital, Santurce, Puerto Rico|Swiss Pediatric Oncology Group Bern, Bern, Switzerland|Swiss Pediatric Oncology Group Geneva, Geneva, Switzerland|Swiss Pediatric Oncology Group Lausanne, Lausanne, Switzerland"		https://ClinicalTrials.gov/show/NCT00006102
1699	NCT00005955	Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors|Neuroblastoma	Drug: temozolomide		Duke University|National Cancer Institute (NCI)	All	"4 Years to 21 Years   (Child, Adult)"	Phase 2		Other|NIH	Interventional	Primary Purpose: Treatment	0931|DUMC-0931-02-6R3|DUMC-000931-00-5R1|DUMC-0831-99-5|NCI-G00-1799|DUMC-000931-01-6R1|CDR0000067936	Aug-00		Sep-02	27-Jan-03		20-Jun-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00005955
1700	NCT00005952	Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors		Completed	No Results Available	Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Head and Neck Cancer|Kidney Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor	Biological: filgrastim|Drug: temozolomide|Procedure: peripheral blood stem cell transplantation	Overall response at 12 months|Disease-free survival at 12 months|Toxicity by NCI Common Toxicity Criteria v. 3.0 at 12 months|Engraftment related to autologous marrow or peripheral blood stem cell transplantation at 12 months	Duke University|National Cancer Institute (NCI)	All	"up to 18 Years   (Child, Adult)"	Phase 1|Phase 2	30	Other|NIH	Interventional	Primary Purpose: Treatment	1735|DUMC-1735-04-9R5|DUMC-1735-02-9R3|DUMC-1735-01-9R2|DUMC-1833-99-10|NCI-G00-1796|CDR0000067932	Aug-00	Nov-05	Nov-05	27-Jan-03		20-Jun-13	"Duke Comprehensive Cancer Center, Durham, North Carolina, United States"		https://ClinicalTrials.gov/show/NCT00005952
1701	NCT00004212	DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas		Completed	No Results Available	"Brain and Central Nervous System Tumors|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific"	Biological: filgrastim|Drug: exatecan mesylate		"Daiichi Sankyo, Inc."	All	"up to 21 Years   (Child, Adult)"	Phase 1		Industry	Interventional	Primary Purpose: Treatment	CDR0000067330|DAIICHI-8951A-PRT013|MSKCC-99071|UTHSC-9895011445|NCI-V99-1573	Sep-99	Apr-04	Apr-04	27-Jan-03		16-May-12	"Memorial Sloan-Kettering Cancer Center, New York, New York, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Children's Medical Center of Dallas, Dallas, Texas, United States|Institute for Drug Development, San Antonio, Texas, United States"		https://ClinicalTrials.gov/show/NCT00004212